<SEC-DOCUMENT>0001558370-24-015155.txt : 20241112
<SEC-HEADER>0001558370-24-015155.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112072028
ACCESSION NUMBER:		0001558370-24-015155
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scholar Rock Holding Corp
		CENTRAL INDEX KEY:			0001727196
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				823750435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38501
		FILM NUMBER:		241443265

	BUSINESS ADDRESS:	
		STREET 1:		301 BINNEY STREET
		STREET 2:		3RD FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		857-259-3860

	MAIL ADDRESS:	
		STREET 1:		301 BINNEY STREET
		STREET 2:		3RD FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>srrk-20240930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.8.0.95 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 11/11/2024 2:39:23 PM -->
<!-- iXBRL Library version: 1.0.9027.2259 -->
<!-- iXBRL Service Job ID: 43420ee2-c3da-4d51-84f4-7a2206dd8ada -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srrk="http://www.scholarrock.com/20240930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" xs:nil="true" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_DwG3LGD1-kC2bTEkgK0sLg"/><ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" xs:nil="true" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_vL2eRir2PkqR1Vd-7r0w4A"/><ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" xs:nil="true" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" name="us-gaap:PreferredStockValue" id="Hidden_fK1O5Hk2KUGhAObC0ROnWw"/><ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" xs:nil="true" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" name="us-gaap:PreferredStockValue" id="Hidden_K0-1HCmOakWX3iXS5vAj_A"/><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityCentralIndexKey" id="Tc_pkRxhkUuDU-AvpoQMW6jKg_1_1">0001727196</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:CurrentFiscalYearEndDate" id="Tc_Yfe7Iq_0rk6X8BjkKOdNHg_2_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:DocumentFiscalYearFocus" id="Tc_lb3IwqGri0CWIzYrVwe2ng_3_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_MnSQMR3yXkSAf9hSWVR0IA_4_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:AmendmentFlag" id="Tc_yWYjNBPfG0yrxk6VBiEv6Q_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_5YCHwVa3eUWYGBrG00S36Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_yNMlVyLhgkev8fVrqOwLKQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_LyQTJMKS5kuj9s5A7zJITA">80081535</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_SUTORcMu20ytkQS8A1M_tQ">75979495</ix:nonFraction><ix:nonNumeric contextRef="Duration_11_10_2022_To_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_rTABVC0FK0WrPzEHVwYh_g" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Hidden_VBPAhXNcSkCfo6QuLvnBlg">http://fasb.org/us-gaap/2024#PrimeRateMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="srrk-20240930.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_10_1_2024_To_10_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EKUEbTHr-Ea-uOCZ6iVjdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pFHBf0hY5UW0FWY703uxbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0wakrHVLCE2j3KU_Wo3X-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_10_2024_To_10_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DS-yvkHxka87ldWHUSkvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-10</xbrli:startDate><xbrli:endDate>2024-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_8_2024_To_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_tVRY0dVzb0i50FyP8rdL6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-08</xbrli:startDate><xbrli:endDate>2024-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_7FmVsKFVF0aJhLlDxLXyug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oFzCQeJoUUSgYwvWF5ktNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7Zh84n4-Ykq6WGOpfdZ02g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MuQ8eux8ckqYO9qz-3WyHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9xzkVt4VMU2Z76J7CR-7zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g5MOsQI7QkGSEfP3mEn_Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cYBDTrhv5k6-VEbdQ5UWiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dKD3wJCHqEuE8Jri1puoRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ORLJCxuY40S9_SNp0cm9Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_55LwgvBeAEWVjIhgYoVZ_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bEpiyEGiwkG49eAV_JtQTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_wqwnwDf4JkGc0MFSynknLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZjASu7KTjUmyEQ3U5sdd6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2nNWjMEjVEeMAdYk2gMIZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_nozla3sC4EiSz8NaIUpFgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rI2SWZIWcUGpK_a1C6sCUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LyOvZrAbr0mYiQTtryH6Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_WyRIrmBEzU25Yii5LaCicA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mdZ4Vf_v90mj5UjPiNSTZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sEwTkPlLLkSbqd_LCKEveg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iGIZ5dBRVkeElrLQcBXYfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_Fxn6BbkW0Um942NziX600Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8rb9ujm1066sXa5nb2vXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CDkUieplhE6Jbi_MfC9KFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DSycY3vZYkmsf4sXbaV2Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_Ck3LkULZgUu4IahGYkThNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j0Tq9iEgI0WxB3qMug6fdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fq5xFmnwbE6Bb4giq5tdsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6oRTpQ0UIkSjNufZC8jLZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UaO3_RTxqUKoz5-Yyidv_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BUGwTFWlqE6W4huRO8juSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kviCKzjbT0OnEPOSUwBMvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Jl5WhaKOMEWbPOAHelRptA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JqYd9nXR30C5hBt7QuvWkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8SSCuIUnHEa3XtfgIHQmTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Upyc56e-ZUuXeiJ1EZGbkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q6t-2V68bkiFrfajlGSBeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_8_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_kidvJgGpG0maEoeyfhtn0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_8_2024_us-gaap_StatementEquityComponentsAxis_srrk_PreFundedWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_5SGDYfs7OECckL2UaG60KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_75tkU34fOUy3WI_eCj09wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q7G20lfZrEGGf9s5KiiN4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qeLfTKYhf0WUaB1ixSydRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_btXk1iwRBEitcM4l_d0v9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_StatementScenarioAxis_srrk_AggregateMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_ya99nBLVs0yCCbyZ5u51EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:AggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_0F_1Zc84bky0_5lT0wv1fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hohbrgalOEmxhqwnpMP8fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KI1BGZUe6kqHi_LI40MMew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rkA0oDL87kCoKZIqo1taMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uw72zZDY0ka7tF4uwvAQKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NipCJOW77ECvOR_obikyPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JwQxc0pT8kKm0ykun0RF7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QKxAZY5g4UK604mpOKeFxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AvRWZZzhQUSBZgDTGob30Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__bNeEJWJfkecGakhaXbnYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tkrpxbJb_Eq1PgDgb69BVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fk_SSWQDLU6gbCA2Hoe86w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_19bHARrGm0mAeIg-yhN-Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_17_2024_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_Hgg07AAyG02T4Jv5fZE-FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_17_2024_srt_StatementScenarioAxis_srrk_TrancheThreeMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_u2DvbaL6ckmuYfubdLSQiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_17_2024_srt_StatementScenarioAxis_srrk_TrancheFourMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_NKmevx8gPUq3cZ8kssDJNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:TrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2022_srt_StatementScenarioAxis_srrk_TrancheTwoMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_CDA1wcxtM0OOvFBfiQ1ZIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2022_srt_StatementScenarioAxis_srrk_TrancheOneMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_1o4-ToeAa0Ws6_A2nhaIWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_A2Z61BQQoEaOUGpduwOO4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_JtpKqHohmUCTdUXoThTIWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_srt_StatementScenarioAxis_srrk_UponExpirationOfFirstExtensionTermMember_WYDXdjdOlEim9o-T7lrtyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">srrk:BinneyStCambridgeMaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:UponExpirationOfFirstExtensionTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_V7tZSLwfkEiSdTEO0LipJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_10_2022_To_11_10_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_CK6FHGQq20Km9jMf98wKZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_10_2022_To_11_10_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_EPztZdder02zre_iKLe24Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_74qePC5v6kCjrygaeq4KKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2024_5P3UGITXB0-czc9H0PmBtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_n9DGS8M0kE24zj_oklD1kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_6NJQiQ1vPEGInMGw0DCVKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:CommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_iFj3QnQzOU-8kQacFHjl3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_PTkW0Ae7q0-gfeY7Vb1FxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2020_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_WrTjGUDWz0OGm3OPxFpVKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_-E3ijiIBr06-jKD1_9WN-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:CommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_xn5zGRExdEqV3w6EYHlpYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hWuMG1NhkkW9bHAcUgbYxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EGRmdupzaUKG_rn7xck0fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lH_pD1wqKE-js0Bu3cDiQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_GRQncXuqCk6pkM25ZxfA6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Q37l2topEU2AU5wm5NYCjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XZbR-apKpk2fl7Q5s_WQGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-T623QZuKkiWEpLOpPmaJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_kZda-3Zt-kGSsr8DQ7g3kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_UlyEzRV6tEm11MvO7uPFnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yUXtseVKLEmLijTO5Hn_0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hZuVKm_vv0uSY2YRXuVk-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bwusGcH5nkSqDzdmdcCglA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BRNbuA-xdUWVSanmpZGNKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_BYs8SrAKnkyWg65xLBo1ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_srrk_CommonWarrantMember_5ObJ1CZ65E21VrAjZyMJVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">srrk:CommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_WcKh_paNQEO1eHbYGf_3nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_leFkp74BkEGzez-zOjF2mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_srrk_CommonWarrantMember_gCi3mjIZR0W0dKa1gLVEAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">srrk:CommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_sX3h_3P7vU628onpj2CP_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_33ZytFP8IkiHsYntj3TCwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0rdTgvAQZ0SGGGDzlLKrng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ephi9PPE4Em6WeJ6Tatiiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WYPheoLxHESQikinAnOQbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZscaUP5tbkyTvjREC97cOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_EyntDTnzGkKhLJiLcViJlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3cefOggcskeAM_epSw3VaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ERzFFMLhQkOjWn1JX4pSxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5mmOYnBYhECqu2JZBuf-nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_n1BJNZBWIkiQKIcb1a5qjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rC1XfV1TjE6F-U0p2kSCCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dN42DahesES9T_h8Jy0MRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CE-n08KE9kym4zuTU2o9Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_StatementScenarioAxis_srrk_AggregateMember_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_vHhfARkPrEeM6UAWteancQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:AggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_SZALhDjjmEyPmtlfB7lZaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_UUZbJLH39kSS8xaTMnAraA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:CommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4gsxBsTIOUKDdJU0qMOv6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ePsDgOB7_0WDZ--l8zx3Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_ijSq6JdiwE60YiJXwFSdRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_ZLcu95SjEEyxu4lbKeIrfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_16_2020_To_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_gUd46vYiWE6S_1qXC2sVKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-16</xbrli:startDate><xbrli:endDate>2020-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_BxOz9tF8aU6Z0utpswOoRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_17_2024_To_5_17_2024_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_qdKJj99R-UKWV1diKEhPMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-17</xbrli:startDate><xbrli:endDate>2024-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_M1v0aqRvFEaEli6XZP3iLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">srrk:BinneyStCambridgeMaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_GTqAgMQoLEKmU-Yg4Ni_LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">srrk:BinneyStCambridgeMaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_10_2022_To_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_rTABVC0FK0WrPzEHVwYh_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2024_To_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_gi0LiBrpuUGw7o_sZbKeZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">srrk:BinneyStCambridgeMaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2019_To_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_CdJUVb4pFUiKpg6aL0QLLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">srrk:BinneyStCambridgeMaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_7_2024_7kr9rNMD5kGfUtrmu_jUDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_security_rO9x9MuL10eAmA3nIFOJ7w"><xbrli:measure>srrk:security</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_abc83fff_e823_49f7_afb9_10b9b0b27d0d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:50.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:DocumentType" id="Narr_KaBU4eUJ2ESlJjtfwllaXQ"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:50.0%;border:none;margin:0 auto;"><a id="_970ef6c1_7bb5_4bc8_aa9d_0e2a1623e655"></a><a id="Tc_V4L1pD70OESyoisfsQ9Q4w_1_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:2.72%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:97.27%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:2.72%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:DocumentQuarterlyReport" id="Tc_4n5iJhh-q0af6uw7R2b_3g_1_0"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:97.27%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">FOR THE QUARTERLY PERIOD ENDED </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:DocumentPeriodEndDate" id="Narr_6dbZRkvnY0SM4CKM46s0Xw"><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:DocumentPeriodEndDate" id="Narr_GP6Ws5VysEeU6eiwg_GbRA"><b style="font-size:9pt;font-weight:bold;">September 30, 2024</b></ix:nonNumeric></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_acd7c4b6_a341_4bab_a329_7a6e8cb15f0e"></a><a id="Tc_dUZ7OqGyWUKOE-YZ1brT-Q_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.44%;"><tr style="height:1pt;"><td style="vertical-align:top;width:2.4%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:97.59%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:2.4%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:DocumentTransitionReport" id="Tc_79rHxA1tIUC9PQPSlDbIrQ_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:97.59%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">FOR THE TRANSITION PERIOD FROM _ TO _</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">COMMISSION FILE NUMBER </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityFileNumber" id="Narr_Plf6lOESSU6laklVpJJ7-g"><b style="font-size:9pt;font-weight:bold;">001-38501</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">______________________________________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityRegistrantName" id="Narr_OjXa02mo_0aJGXx_Skj2BQ"><b style="font-weight:bold;">SCHOLAR ROCK HOLDING CORP</b></ix:nonNumeric><b style="font-weight:bold;">ORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:50.0%;border:none;margin:0 auto;"><a id="_6d8e38d2_f3d9_409b_9605_1d5384bfbe9c"></a><a id="Tc_TwsMpIVwmk-GZCoveGpuRg_2_0"></a><a id="Tc_xybIvRy2LEmzOyS1bTCzaQ_2_1"></a><a id="Tc_pupdndUzGUO4kFXGY5irfQ_4_0"></a><a id="Tc_vyM3TsVJy0WbDLOErQ_UZQ_5_0"></a><a id="Tc_kZo1JfUvOU2LsFHIiuAbng_5_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_fgSXGQbqUEurY71KAASCuA_1_0"><span style="font-size:9pt;">Delaware</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityTaxIdentificationNumber" id="Tc_MMFvoa8TSkSv0TcpLYm7kQ_1_1"><span style="font-size:9pt;">82-3750435</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.85pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityAddressAddressLine1" id="Narr_rSnbSFlNuE2UV1eAo4pg4w"><span style="font-size:9pt;">301 Binney Street, 3rd Floor</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityAddressCityOrTown" id="Narr__7sw6nl1vEyST50X_dWNiw"><span style="font-size:9pt;">Cambridge</span></ix:nonNumeric><span style="font-size:9pt;">, </span><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityAddressStateOrProvince" id="Narr_3Ws3sOuZXUeZ8btKpro1wA"><span style="font-size:9pt;">Massachusetts</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityAddressPostalZipCode" id="Tc_9sxlIlimQESwr_V25AFpcA_4_1"><span style="font-size:9pt;">02142</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">(</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:CityAreaCode" id="Narr_WxrYVpDZNk-NQeJphGiOgQ"><span style="font-size:9pt;">857</span></ix:nonNumeric><span style="font-size:9pt;">) </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:LocalPhoneNumber" id="Narr_uzqlmKGaW0yM18l_Zjh-QA"><span style="font-size:9pt;">259 3860</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Securities registered pursuant to Section 12(b) of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_e0ceecec_2b59_461c_bc66_4141b8245ed7"></a><a id="Tc_fkinylaH7U2BponefHB_aw_1_0"></a><a id="Tc_i2P2goM-gE-hPTcTZz50bw_1_1"></a><a id="Tc_LXzzyyk0cEigNNAdzvCmTQ_1_2"></a><a id="Tc_6LB6D0E8v0yh4LazJ8UNbA_2_0"></a><a id="Tc_xSvm3EItA0aahX8jl8Vi-g_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:38.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.52%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.12%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:38.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:22.52%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading symbol(s)</b></p></td><td style="vertical-align:top;width:39.12%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:38.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:Security12bTitle" id="Narr_-FoeURyHk0a_hP6_4hoNjg">Common Stock</ix:nonNumeric>, par value $0.001 per share</p></td><td style="vertical-align:top;width:22.52%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:TradingSymbol" id="Tc_eHnpg9FLjUOia-RTG2ACug_2_1">SRRK</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.12%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The <ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:SecurityExchangeName" id="Narr_1XMTYNSSdEmbh2seFA2l0Q">Nasdaq</ix:nonNumeric> Global Select Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityCurrentReportingStatus" id="Narr_zO9wnqtHZU23nazKZfkHNg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityInteractiveDataCurrent" id="Narr_b-jM4lv3Y0OKnMH5EWvldg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_d087e034_e410_4d29_a6e8_46957eea91bf"></a><a id="Tc_XW-JP8fBNUGS1ISp1gxxOw_1_0"></a><a id="Tc_6uElF62DlU2hh60SkJbsZA_1_1"></a><a id="Tc_LXga_9oLHk6lpH52XdOk2A_1_2"></a><a id="Tc_9DbjADrNI026eX6dBExmIA_1_3"></a><a id="Tc_bTCTcGOU30-BRXUaHVT9lQ_3_1"></a><a id="Tc_MYniDDrdTUaCLkmNUvW5SA_3_2"></a><a id="Tc_Dx9v40tGm0mTmoOvB1Zs-A_5_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.44%;"><tr style="height:1pt;"><td style="vertical-align:top;width:21.98%;margin:0pt;padding:1.5pt;"/><td style="vertical-align:bottom;width:47.59%;margin:0pt;padding:1.5pt;"/><td style="vertical-align:top;width:26.63%;margin:0pt;padding:1.5pt;"/><td style="vertical-align:bottom;width:3.78%;margin:0pt;padding:1.5pt;"/></tr><tr><td style="vertical-align:top;width:21.98%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:47.59%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:26.63%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:3.78%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr style="height:3pt;"><td style="vertical-align:bottom;width:21.98%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.59%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.63%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.78%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:21.98%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityFilerCategory" id="Tc_Jyyg30schU-90TFZvhn4FQ_3_0"><span style="font-size:9pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:47.59%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:26.63%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;width:3.78%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntitySmallBusiness" id="Tc_MmxYrdAIYU6jd731DIiQhA_3_3"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p></td></tr><tr style="height:4.8pt;"><td style="vertical-align:bottom;width:21.98%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.59%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.63%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.78%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:21.98%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.59%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:26.63%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:3.78%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityEmergingGrowthCompany" id="Tc_i7w4hUTT6E2h8a6z4uPQ1g_5_3"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="dei:EntityShellCompany" id="Narr_46xfoJ8SIUiAl0tiXJAxgA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 10pt 0pt;">The number of outstanding shares of the Registrant&#8217;s Common Stock as of November 7, 2024 was <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_7_2024_7kr9rNMD5kGfUtrmu_jUDQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_9LCSwsrZE0yKqw2Rvi5-KA">93,614,951</ix:nonFraction>.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e3ae244d_778d_445b_b819_7c7427d27e7b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">This Quarterly Report on Form&#160;10-Q (&#8220;Quarterly Report&#8221;), including the documents incorporated by reference, contains forward-looking statements within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of complying with those safe harbor provisions. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements include, among others, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success, cost and timing of clinical trials for apitegromab (such as our Phase 2 EMBRAZE clinical trial) and SRK-181, including the progress, completion, timing of results, and actual results of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, scope, or likelihood of our ability to obtain and maintain regulatory approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;), the European Commission (&#8220;EC&#8221;) and other regulatory authorities for apitegromab following completion of our Phase 3 SAPPHIRE clinical trial, and any related restrictions, limitations or warnings in the label of any approval for apitegromab;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our success in identifying and executing a development program for our preclinical product candidates, including SRK-439, and identifying additional product candidates from our preclinical programs and research pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our success in identifying and executing development programs for additional indications for apitegromab and SRK-181;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical utility of our product candidates and their potential advantages over other therapeutic options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain, generally or on terms acceptable to us, funding for our operations, including funding necessary to complete further development and, upon successful development, if approved, commercialization of apitegromab, SRK-181, SRK-439 or any of our future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to retain our executives and highly skilled technical and managerial personnel, which could be affected due to any transition in management, or if we fail to recruit additional highly skilled personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and the duration of such protection and our ability to operate our business without infringing on the intellectual property rights of others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability, through third party manufacturers, to successfully manufacture our product candidates for clinical trials and for commercial use, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully build a commercial infrastructure to launch and market apitegromab, or otherwise provide access to apitegromab, if and when it is approved or receives pricing or reimbursement approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish or maintain collaborations or strategic relationships; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations relating to the potential of our proprietary platform technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in combination with others;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of new laws and regulations or amendments to existing laws and regulations in the United States and foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks associated with the impact of global economic and political developments on our business, including rising inflation and capital market disruptions, economic sanctions and economic slowdowns or recessions or public health pandemics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments and projections relating to our competitors and our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates and expectations regarding cash, cash reserves, and expense levels, future revenues, capital requirements and needs for additional financing, including our expected use of proceeds from our public offerings, and liquidity sources; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the period during which we qualify as a &#8220;smaller reporting company&#8221; as defined by Rule 12b-2 of the Exchange Act; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risks and uncertainties, including those listed under the caption Part&#160;II, Item&#160;1A &#8220;Risk Factors&#8221;.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The risks set forth above are not exhaustive. Other sections of this report may include additional factors that could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all risk factors, nor can we assess the impact of all risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Investors should also refer to our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q for future periods and Current Reports on Form 8-K as we file them with the SEC, and to other materials we may furnish to the public from time to time through Current Reports on Form 8-K or otherwise, for a discussion of risks and uncertainties that may cause actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements. We expressly disclaim any responsibility to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events, or otherwise, and you should not rely upon these forward-looking statements after the date of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry data, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a1dfbc70_7773_4d81_b3c2_55069e59fc0a"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">SCHOLAR ROCK HOLDING CORPORATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Page</span></p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_833603"><span style="font-style:normal;font-weight:normal;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1_885442"><span style="font-style:normal;font-weight:normal;">Item&#160;1. Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.7pt;"><a href="#Item1ConsolidatedBalanceSheets"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.7pt;"><a href="#Item1ConsolidatedStatementofOperations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023</span></a> </p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.7pt;"><a href="#EquityStatement"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity for the Nine Months Ended September 30, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.7pt;"><a href="#Item1ConsolidatedStatementsofCashFlows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 29.7pt;"><a href="#Item1NotestoConsolidatedFinancialStatem"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2_MDA"><span style="font-style:normal;font-weight:normal;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">20</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"><span style="font-style:normal;font-weight:normal;">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4CONTROLSANDPROCEDURES_891868"><span style="font-style:normal;font-weight:normal;">Item&#160;4. Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PartII"><span style="font-style:normal;font-weight:normal;">PART&#160;II. OTHER INFORMATION</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_714803"><span style="font-style:normal;font-weight:normal;">Item&#160;1. Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_725058"><span style="font-style:normal;font-weight:normal;">Item&#160;1A. Risk Factors</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:bottom;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_371711"><span style="font-style:normal;font-weight:normal;">Item&#160;3. Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_809103"><span style="font-style:normal;font-weight:normal;">Item&#160;4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_154003"><span style="font-style:normal;font-weight:normal;">Item&#160;5. Other Information</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_14170"><span style="font-style:normal;font-weight:normal;">Item&#160;6. Exhibits</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td></tr><tr><td style="vertical-align:top;width:92.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_251590"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:7.96%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">87</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_9fb51dbc_36bb_4cf9_b73f_79a9a63ea3d9"></a><a id="PARTIFINANCIALINFORMATION_833603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PART I. FINANCIAL INFORMATION</b></p><a id="Item1_885442"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 1</b><b style="font-weight:bold;">. Financial Statements</b></p><a id="Item1ConsolidatedBalanceSheets"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">SCHOLAR ROCK HOLDING CORPORATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">(In thousands, except share and per share data)</p><a id="_39bf5ecb_0676_4e3e_ae34_175a17125e11"></a><a id="Tc_VL2BY9kRO0OSPh7u0YeRLA_1_2"></a><a id="Tc_KwG4CnfeJECOnLLKjWaZSw_1_5"></a><a id="Tc_sZq_G3r800eTCmQvpLTALg_2_2"></a><a id="Tc_Z3kJNPs3Y0qo8aIXpPYMeQ_2_5"></a><a id="Tc_EsgQa0X0RUW_ESq7qY9DrQ_3_0"></a><a id="Tc_NGSO8ym2pEuvFt6bi7Fhiw_4_0"></a><a id="Tc_ci_6Vfk-t0uitE2dTdSbtw_5_0"></a><a id="Tc_iNIwUpYbqEqE8m_LBuL43w_5_2"></a><a id="Tc_64NB8KDq3U2XSDG04rTtDg_5_5"></a><a id="Tc_csaTtpix7025Sn2sHUqYCg_6_0"></a><a id="Tc_IevwGyN-Uki66Apa7uA4qg_7_0"></a><a id="Tc_RU2zY8MOTE-TNGlpGtuh0Q_8_0"></a><a id="Tc_dQIb-HNnLEa57rTk5ej_KA_9_0"></a><a id="Tc_vy53FudyEUSb1IW7UPxTIA_10_0"></a><a id="Tc_sSkOHPbk7kq93XZAP82UoQ_11_0"></a><a id="Tc_fSi-dAZrqUijfMpC5Te7wg_12_0"></a><a id="Tc_Xis13ecRQka-EzycD6AW6g_13_0"></a><a id="Tc_LWu1WuQvBU6Ss_bNsRvq8Q_13_2"></a><a id="Tc_LENCYWe4jk-gLaL-hVIcWQ_13_5"></a><a id="Tc_MBebyQkjPk6dqpcoe7jYpw_14_0"></a><a id="Tc_YGO12aeGH0ykzHEGq-ji_Q_15_0"></a><a id="Tc_r_c8yQHSbUGGFd6DkW8GCA_16_0"></a><a id="Tc_k5jLlJV8fEu--39aBhfukA_16_2"></a><a id="Tc_jfrtzcb8y02aiEoD3YPxhg_16_5"></a><a id="Tc_rplCKLbGSESJXhZeTTjwAg_17_0"></a><a id="Tc_Qril6WXxUkSMHiB0FgRjFw_18_0"></a><a id="Tc_7HQlXcuoPUOxntOYtMw58Q_19_0"></a><a id="Tc_Z9bRk3u2S0CKwMlaOHFaHA_19_3"></a><a id="Tc_ShewQi5rsUONWSyfdcpR3Q_20_0"></a><a id="Tc_SnWoDaXP5E2fGICbO_Qutg_20_3"></a><a id="Tc_lPr3Y6a6gU-HF7I11ddfKA_21_0"></a><a id="Tc_g0fcVzGJlkWsALaHhFr6tQ_22_0"></a><a id="Tc_uY6LlDCUOk6gUdsLrlI0QQ_23_0"></a><a id="Tc_NC96KeU15USiZz0zL6DueA_24_0"></a><a id="Tc_4K8309CPsUeDEh-BF98Fyw_25_0"></a><a id="Tc_xEaxZ7ni6UGuNpqU_R2qEg_26_0"></a><a id="Tc__qe-Xp9RXUa_y180BNaKhA_27_0"></a><a id="_d478156d_620e_4ea0_8fcc_0bb543fa0f87"></a><a id="_d478156d_620e_4ea0_8fcc_0bb543fa0f87_2"></a><a id="_d478156d_620e_4ea0_8fcc_0bb543fa0f87_3"></a><a id="Tc_seCBsaUlFkamQI9nu0rz_g_28_0"></a><a id="Tc_F3wSbYi66kOzL2TxEzONCw_29_0"></a><a id="Tc_LlNGZnkYck-wBnGzEnKQQA_30_0"></a><a id="Tc_qvKVaV1j-kCkxQq74wOhmQ_31_0"></a><a id="Tc__4AeQWaL1kGr0Qoh6E2Fvg_32_0"></a><a id="Tc_VUoQLbkQC0C0toT07G_UJg_33_0"></a><a id="Tc_YUDNyBJ1rEa84Qh7QZF9hQ_33_2"></a><a id="Tc_KZ13EkIwjES07Qc0ua6NSQ_33_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_aCcRkB5vDUWxLLtU--jI-w_5_3">76,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_qJYKIZKqZEioRC2PD45SGg_5_6">101,855</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_ItEMBhr5AUiafXdyHJ-UeA_6_3">62,674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_FBg-zPTC8E6tb16N4U4-kw_6_6">178,083</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_NhOnfY8lEke8Wf3Hw5Zocg_7_3">13,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_gm6_7XrfyEabNA5MIupDxg_7_6">8,256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_1w45VSSJsUqi7PHUeCF9rw_8_3">152,927</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_30q_kjUamkSQyZCbS_MP5Q_8_6">288,194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_eMTDVg-7F0Cq9A43cTDQmA_9_3">3,156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_aChqpk5HdU6vS9aq2XXf7w_9_6">4,600</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_sKQFWPde7kSCtPsO2X62ZA_10_3">16,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_9epHfdBN2kyQsY_EYwOLVQ_10_6">11,417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_pnLub_GHqEWg3LHDTep5uw_11_3">2,407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_WKlyP3FTkU-zMYoSWZmSWA_11_6">2,407</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_K305BkPpxEGODdUOFYw7Lg_12_3">3,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_YGlbk3j_KU-3f0X615AmNA_12_6">4,417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_-61ooKn3mk6L0r4hDSoMXA_13_3">179,133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_KwEwEyeBl0O81mtBsTntTw_13_6">311,035</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_VuZU-VByOk2G-Dx90LHnyA_16_3">4,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_PoUJYNKlLkK7JbqVQscjtw_16_6">3,465</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_GHjeBYprt02LKZokCc1qow_17_3">29,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_HCSsmY11UkOt8WSLH68g9w_17_6">20,449</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_AJWIV8kwAEGzf8SebLq9Tg_18_3">6,041</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_CivlNMgDsUiKZ82qgLmvqg_18_6">7,408</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Short-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="3" id="Tc_PKbpphgNlk2yWo64RY_yGg_19_6">1,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_5JqAsEOTiU21aOSR-L88_A_20_6">85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_QcKdvixKiEyNoTnMdbpCWw_21_3">39,372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_gkRsz8KGzk2uh2VkALsHBw_21_6">32,741</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_3biJYh1LV0S-rDKSkejdMg_22_3">10,466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_3hwCvLFPr0OJI-bJyqpxfQ_22_6">4,392</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_ci2slnzOfECLqUg0LjAhBg_23_3">50,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_CCy7x68ytEyY8wtY4itwiQ_23_6">48,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_R5kGVsaAZk-FhDO07qLkfQ_24_3">99,937</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_8f1ROaW-2EyAHp5AN8CQgQ_24_6">85,817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note&#160;9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_cfqCJ8XAjECqVh0_TBYfpQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Si5IlHBX_Emz67vmQv2ZMA">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_5LuIdYHy8ECuk_cdTdRn8Q"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_L1SCZHYbYEqo0yl05zQPWg">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_yTr11GPocU-25bykpYG3sA"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_qWIoQsDjX0KD7_2F8ewXoA">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30,&#160;2024 and December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_fK1O5Hk2KUGhAObC0ROnWw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_K0-1HCmOakWX3iXS5vAj_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_K66krIiX70CfPUQHZ7dmYA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ueId3rW2MkCJEqXUrKjPSg">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_rF3QnXEUM0uHP0qOxtG-CQ"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_5ZTVfV7gSUu_z6ES7Y-UNQ">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_ahRA9xdO3U2DsDvkxquW6w">80,081,535</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_T1GMwkcs-Eqe_cjoqaGYQw">75,979,495</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_LyQTJMKS5kuj9s5A7zJITA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_SUTORcMu20ytkQS8A1M_tQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of September 30,&#160;2024 and December&#160;31,&#160;2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_NVwC5RziF0CPl0si4HiL-w_28_3">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_6kB10_KVIUm4vYGyoLcBQQ_28_6">76</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_3BebXkDa5USohV3DPwQeSg_29_3">935,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_e1quhkHPuEKQrxQKxbn_8g_29_6">901,471</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_A5F7zkTx_kSEn213nFJdWA_30_3">128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_B7fUyjLvjUKs0s9P64k0vA_30_6">92</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_MWr2fL-tQUCrJ_RLwC7ntw_31_3">856,261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_JqQl6v4pxkydVUh9yPoUqg_31_6">676,421</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_i3HrZfkumka0Q-GD9__X2Q_32_3">79,196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6GfUINMvRUOmSS_WiA9YKA_32_6">225,218</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_3FWUM7ARLU6uRP4WzFF5gg_33_3">179,133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_PwWB44u_4Eqh0D62URAWFw_33_6">311,035</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c5bf37e0_f93a_4adc_9bb5_07689cdfbba1"></a><a id="Item1ConsolidatedStatementofOperations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">SCHOLAR ROCK HOLDING CORPORATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(In thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e9c34ce0_c45f_4e9f_bad6_352e462b8150"></a><a id="_3fa86955_b1ad_4610_a45f_44390f597aa0"></a><a id="Tc_752fPHnW2kmIiFqNuZHCrg_1_2"></a><a id="Tc_XuhH0MHS1U6kLO18FkQp6Q_1_8"></a><a id="Tc_5GgQNYNLQ0eyZFAs9aVS0w_2_2"></a><a id="Tc_mOkilfCgZ0WkIEePfZWOJg_2_5"></a><a id="Tc_GYKUmG7b4EK8vBleIqyj_w_2_8"></a><a id="Tc_0xn0tsOoAkuHvlfdXoQIAA_2_11"></a><a id="Tc_5x6qJSSaOE23qD0xBvjVKA_3_0"></a><a id="Tc_bIkbi8fET0mRjYEm6OKjdA_4_0"></a><a id="Tc_lQjFjuJpakGDTBCLIvkN5g_4_2"></a><a id="Tc_5jEE9CE-uk2SCv09FApvYw_4_5"></a><a id="Tc_ZrxBk39oT0GnlQy48z6tzQ_4_8"></a><a id="Tc_USZ_TV56i0qefAioFyzknQ_4_11"></a><a id="Tc_0E2tI1wyLk2p4bchPkBUaQ_5_0"></a><a id="Tc_cw09X0KSVU2LkF7NfaIndQ_6_0"></a><a id="Tc_UYZNVsfmyEygPspZctsTmQ_7_0"></a><a id="Tc_mrk-T9Qb3kanH-aSXuGAYg_8_0"></a><a id="Tc_9zWwGhRtMEqLM5Y8UoPpgw_9_0"></a><a id="Tc_h-bxbxDu_0CfD8BPzOtHpg_9_2"></a><a id="Tc__Z4qkxgTd0Saug19H2qvfw_9_5"></a><a id="Tc_RJRI-4XmY06ky_0PtcSp1Q_9_8"></a><a id="Tc_56GcJLQAM0eFPET7GwC1DA_9_11"></a><a id="Tc_UH280NMUZkmBdD4tvlLrKA_10_0"></a><a id="Tc_VDnWyJV4skWfwlKsDd73VA_10_2"></a><a id="Tc_uHeV5lfRW0Wd4KYHSfZ1Fg_10_5"></a><a id="Tc_dXA__SDakE-NTnge92MG2w_10_8"></a><a id="Tc_XElKBCsH2EC9WlvSOQU-5Q_10_11"></a><a id="Tc_b23tsjWxuEWfJdIQ5eJTRg_11_0"></a><a id="Tc_ekFdpzga90CLEB622WM-oQ_13_0"></a><a id="Tc_8Cfec8VlYkGo7L10WOw8UA_14_0"></a><a id="Tc_b2l3mJ4Vn0OVtya0NA-vIQ_14_2"></a><a id="Tc_nHHUB-TJNE-OdN5O-MkzQg_14_5"></a><a id="Tc_4OMChgvOh0O2WmiuTIjlpw_14_8"></a><a id="Tc_ys3RtgQHekOj6aToAtSAuA_14_11"></a><a id="Tc_VIiEvyG63E-55Udn9HW2uA_15_0"></a><a id="Tc_Y5vWvVY-NkqJ6n_K0h5CsQ_16_0"></a><a id="Tc_TDYHjhZMkE27HVFVEEW9Pw_17_0"></a><a id="Tc_PIFx_4d_okGdZboVOJNduw_18_0"></a><a id="Tc_845FU8jDq02Xi6Dqg1HOpQ_18_2"></a><a id="Tc_8O0r1s843EOH1Oqk19GIuw_18_5"></a><a id="Tc_GYDA-tbIkkWQbeAQT-B8pA_18_8"></a><a id="Tc_tYKIVqR_WESky86GOF2Q2Q_18_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_PuP0elZT1kKBWvD_cXxr-A_4_3">48,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_UO_YJyOAjEqGU6WVS8g00Q_4_6">30,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_IE5ZnwP6_EG4X18eeP6Nxg_4_9">134,185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_v085U3mqzUqy0p64_FgMoQ_4_12">86,939</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_j2ha1kBd6ESIAnFykGZ4EA_5_3">16,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_vKEf7ekhaUuh1LEpJSFvZg_5_6">13,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_K6_EfJHvw0ai4roDqci6KA_5_9">48,512</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_SIEwQJJVC0ui1dqyEuGO6Q_5_12">36,324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_LlR4TC2tr0OiuhSVLOKgiA_6_3">64,780</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_8QyeonHO0EGJMOINTt5egg_6_6">43,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_IyBQ3TcSQEKge9YC0h8wmQ_6_9">182,697</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_PKjp6Ksa90mJgWavmN807g_6_12">123,263</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_boUs8BJelE6fqzogxlHOdg_7_3">64,780</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_7oEGdhl4s0mRb7S3ZQGlRg_7_6">43,672</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_k2IbCQYshUiSh7PTkHq0aw_7_9">182,697</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_yl_QiCvhaUOahPaBH-XOkA_7_12">123,263</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_kMVR0KkdQkCiFF-JOikNHw_8_3">301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_SxUirkKVAEex8l88RTol5w_8_6">1,313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_FHxhFe7QfkKgK5SJ9IQFmA_8_9">2,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_KtMksrprjkakxgXpRmi85A_8_12">3,600</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_cG0DfJOoy0aZmzgzpdMF9w_9_3">64,479</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GBg8h5tOl0CWyzgOIc_KOA_9_6">42,359</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_PBeZzRj0u0yvfS02NVSXgw_9_9">179,840</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1esIPTnOL0mQpOGFzOqmnA_9_12">119,663</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_zRuNCfFjvEOE-9JFQ1atFg_10_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_zRuNCfFjvEOE-9JFQ1atFg_10_3_2">0.66</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_C4PpbHm5_UqLPdC8GI0sSw_10_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_C4PpbHm5_UqLPdC8GI0sSw_10_6_2">0.53</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_4XVAnMhOSkS-YSsg5OK9uQ_10_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_4XVAnMhOSkS-YSsg5OK9uQ_10_9_2">1.86</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Pyjy4KvkiUip3OZ7mZtL_A_10_12"><ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Pyjy4KvkiUip3OZ7mZtL_A_10_12_2">1.49</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_MYOhjT0ktUiEAOPUO9CDIg_11_3"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_MYOhjT0ktUiEAOPUO9CDIg_11_3_2">97,050,637</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_t9mKdCnxvUyCRpS-rTgO9w_11_6"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_t9mKdCnxvUyCRpS-rTgO9w_11_6_2">80,606,438</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_nhJPy4U_dkaMdmPokXTj2g_11_9"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_nhJPy4U_dkaMdmPokXTj2g_11_9_2">96,587,149</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_w1-2YDG7KkyW-GIlxWFPfg_11_12"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_w1-2YDG7KkyW-GIlxWFPfg_11_12_2">80,115,143</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3aI9iCN0306n128T6EuAEw_14_3">64,479</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ziBK0-qg-EqJ-U5sMPtDpA_14_6">42,359</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_u8fi5OSgMUittCAMiBNtNA_14_9">179,840</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_UFQpK7ghK0Gk-tqe-0-a8A_14_12">119,663</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_h2SZRqVNZEeTbhm9XeGHjw_16_3">182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_xXf19hrjhEeHGHopBOWZgQ_16_6">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_0tNpsyFYbUeSRTgXnCqM4Q_16_9">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_H62FkandYEGKWHZO_kDIXw_16_12">861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_12SAWdlPO0eBBLirlP6Vsg_17_3">182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_GS4MC20DqkuX--i9Alzg6Q_17_6">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_xBfIHMizCkuJBOykjNp4tA_17_9">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_AMRd_nkA3EqNvsqYqzummw_17_12">861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_3z1GBnB9x0uMJPUaHkI3Gw_18_3">64,297</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc__k_3LNa-I0yHS8dN3idJUw_18_6">42,319</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_l4fRPLGYvE6VLuULvAUCIQ_18_9">179,804</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_KhqCsUv2E0qvqrinllflgQ_18_12">118,802</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Content</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6a134ab3_39fa_4363_bf66_47c4655e767a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:10pt;text-align:center;margin:0pt;">SCHOLAR ROCK HOLDING CORPORATION</p><a id="EquityStatement"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:10pt;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:10pt;text-align:center;margin:0pt;">(In thousands, except share data)</p><a id="_a0e667ab_8eec_4d07_a723_e2dbe59462dc"></a><a id="Tc_hbtDMEKUk0-dLprpkq9D1w_1_10"></a><a id="Tc_FKMVv29A50ytm2d4wY7dSg_2_7"></a><a id="Tc_-XZmsxFznk684ITBI5PvMQ_2_10"></a><a id="Tc_z-A6PPaDuUqU745LLX9bRg_2_16"></a><a id="Tc_1zFfoJwI9UGhhuwPEQXFeg_3_2"></a><a id="Tc_58mMTxgVBE-YPPR_8jAsjw_3_7"></a><a id="Tc_6WXjgtgrPUiaLQ2r20quuw_3_10"></a><a id="Tc_4eVYSGJAIUCfxPv7XrNPIg_3_13"></a><a id="Tc_3edyzHHp70iCKzzeqXT2xA_3_16"></a><a id="Tc_pwOQgXgbQ0qHuE6rgdYOUA_4_2"></a><a id="Tc_LhsWPNaDkkGApZJNLTDlzg_4_4"></a><a id="Tc_Evg_BTYCZkW3ctVsVt3hrw_4_7"></a><a id="Tc_CXSeYadzlUeKLtRAkrvUfw_4_10"></a><a id="Tc_loYzvVSNvk2uvETsO1pLXw_4_13"></a><a id="Tc_aB6rEDTmUECSP8i8skGWAA_4_16"></a><a id="Tc_SrEe-vjMt0OJxfoToyktTA_5_0"></a><a id="Tc_NNgh5_UIZk2OuwGStVaM9Q_5_4"></a><a id="Tc_w9ilZxeVKUeVZbrqXhJSyg_5_7"></a><a id="Tc_oE3_8bUZ0UuelSuSfY2NHQ_5_10"></a><a id="Tc_aqDsc0Oz602iEkWpyYD72g_5_13"></a><a id="Tc_dHXKwi3nnkyFyhXEfR6_9Q_5_16"></a><a id="Tc_3JyXC3__mk-_RWDjNqVF-Q_6_0"></a><a id="Tc__200DUK4RE-bXsn8bSkR_g_6_2"></a><a id="Tc_-dmwA_M9x0-5JIjYC0lQ3g_6_5"></a><a id="Tc_CVb7HFuBCka3XjP2blXMDg_6_8"></a><a id="Tc_JJymwCej2E2X4ETyqTmoPw_6_14"></a><a id="Tc_Nto-i4l3BECrI84R8agRUg_7_0"></a><a id="Tc_GAYAZ_K-8kmh91fn3UBY6Q_7_5"></a><a id="Tc_5-L_u_wIB0uwPPuhg62mHg_7_11"></a><a id="Tc_Ls2Kam2aJ0eKGuK7Fo9N6g_7_14"></a><a id="Tc_0khu0H_c4k2yo-4tjXbuxg_8_0"></a><a id="Tc_TaJ20mM-A0uAhYP-3Mab_A_8_5"></a><a id="Tc_CiAtMasqGEOrhvMdJd5OBg_8_8"></a><a id="Tc_X2tsTYHL90-cJEMUXvRfSw_8_11"></a><a id="Tc_5ULSvFjBJEahtpdHJX2DXA_8_14"></a><a id="Tc__LliYb_9pEurk0or_7Q-LQ_8_17"></a><a id="Tc_PCN5htCLv0uo0EcLZHyjLg_9_0"></a><a id="Tc_gDmT60dAhUeV1sZfOZvJDQ_9_11"></a><a id="Tc_y0Yfbk1DqEWYYD4yjL5reQ_9_14"></a><a id="Tc_nILCwcCGxEixUUPIXwnxBA_10_0"></a><a id="Tc_qmciepU5R0erLJNUfXmQFQ_10_2"></a><a id="Tc_mP9UU14E4kiip_axjrQQiw_10_5"></a><a id="Tc_rAQlfrl23E2_x4NESbrSXw_10_11"></a><a id="Tc_Kx13_npA-k-l0P_ythA6ew_10_14"></a><a id="Tc_bgdOeFghfUGK3lw3nb1wUQ_11_0"></a><a id="Tc_FeiO_8Rkekat7yiJYEbDdQ_11_2"></a><a id="Tc_K-JuIcptF0Cf5PAqwhuQDA_11_5"></a><a id="Tc_AGBZFDJd_0St_IlEZaJWvA_11_8"></a><a id="Tc_XY6yNxAYsEKwy7Upf-f42A_11_11"></a><a id="Tc_6-kyfTvEjESeXrAjXNQeSw_12_0"></a><a id="Tc_gnv-i1FW1UuR6QbmAyZvcA_12_4"></a><a id="Tc_mJn3jFwel060RXvhxekbXQ_12_7"></a><a id="Tc_3hajJfZIukCY9mdisNBoBg_12_10"></a><a id="Tc_KBY2YRb5dUqyOWjHEPlTFQ_12_13"></a><a id="Tc_cMGDsOdJY0aGmSVOOKvS6g_12_16"></a><a id="Tc_310RGfL2jkqZ6zrZJRuogQ_13_0"></a><a id="Tc_rjTHSWvQu0SFSDWphEzXJQ_13_2"></a><a id="Tc_3yh3PNoihECMzR76YJ5CNQ_13_5"></a><a id="Tc_I1xI_aQ6_k-2XnIslowP_g_13_8"></a><a id="Tc_mExe4da47EC5zUfXsxW_ng_13_14"></a><a id="Tc_VpjT1huNP0eEqk__74QinQ_14_0"></a><a id="Tc_GajtDTOttkCLD7OZ2zzFDA_14_5"></a><a id="Tc_DlKTlfb1kk28LI7uhRSNjg_14_11"></a><a id="Tc_AzRi0VPNYUO-wMcaXum9QA_14_14"></a><a id="Tc_uog82YRwc0GB4ra0ps0bag_15_0"></a><a id="Tc_tDZXzYaCSkulcFHfA-OTJw_15_5"></a><a id="Tc_NpAvxuQ6KkKdErc9bowTPQ_15_8"></a><a id="Tc_ybAGs8gsXECBSDI_EpcR_g_15_11"></a><a id="Tc_l7DUCpXiF0aw3M_B4ioSuA_15_14"></a><a id="Tc_RGqiU7Lt0UGGcQ00VizwXA_15_17"></a><a id="Tc_4XkkWPV5dUa10wC10b2mqA_16_0"></a><a id="Tc_dPZWNz2iukSCG400f1CH3w_16_2"></a><a id="Tc_I5UW2dCbfUancmynG3FXhw_16_5"></a><a id="Tc_wHlIG-ORDEeT7jox14bdSA_16_11"></a><a id="Tc_iKm3ZO3vJk2jf-iMu5j0OQ_16_14"></a><a id="Tc_yoWHkY0mX0qZBDoRcQw1Qg_17_0"></a><a id="Tc_MhPnMu9S6EWg5InMfzwLJw_17_2"></a><a id="Tc_D7MggiorYECd21WXhewkLQ_17_5"></a><a id="Tc_Jg2PMVJ4VU-6mZ2uvWbCWw_17_8"></a><a id="Tc_8-h35U4um063YdYeIkfceg_17_11"></a><a id="Tc_1NX5Iv4d0UCG1sNel6_VEA_18_0"></a><a id="Tc_b1bbCLcMqEy0bk9yakiSmw_18_4"></a><a id="Tc_UUPWtXftAE-sF8SZoAHDMw_18_7"></a><a id="Tc_iSx6-3Lv1ESBHxIcULMVlg_18_10"></a><a id="Tc_GzEsuaX3dUCDjadraEv-ew_18_13"></a><a id="Tc_eVy06XZXUUq9m5RMF0iLfA_18_16"></a><a id="Tc_WcY8T6yawUGvkVCWPCxuXA_19_0"></a><a id="Tc_hhBpRw2iCkuCivWmiJLsgQ_19_2"></a><a id="Tc_Z65cb8Isr0ytQlzX0ozYRg_19_5"></a><a id="Tc_RKW-2pP4jkqCUQUzOkM-lg_19_8"></a><a id="Tc_e_seJbCTH0aDs77bJprglw_19_14"></a><a id="Tc_XIlp-Q8RQ02XGrjXQ9OhgA_20_0"></a><a id="Tc_3vZwEyCYE0C0b8X2JELz0g_20_5"></a><a id="Tc_eXL7BWwO4Eu_yHCvW88JUw_20_11"></a><a id="Tc_cOZIGOB4Z0GZP2ioSkRo-A_20_14"></a><a id="Tc_xPZxm9vSo0ykzAuaGGH7iQ_21_0"></a><a id="Tc_NRLTWcvv6k-5nmlv5_R_yA_21_5"></a><a id="Tc_cFTl3FA-lEeidgcnv77h_A_21_8"></a><a id="Tc_hTniCrx6s0q2tTzFN4j9UA_21_11"></a><a id="Tc_lpy5QJOXnU61Vv7f3Qz4Xg_21_14"></a><a id="Tc_MJmsuHWNxUKunjhedn_evg_21_17"></a><a id="Tc_4bLrAGKFzEq8F2GKLEWzhw_22_0"></a><a id="Tc_TDnL0fZWCkyn4A53sCyP3w_22_2"></a><a id="Tc_VGkulW_3LkCwOJo0gIGShw_22_5"></a><a id="Tc_LgOV_ZpKTEKq9ioqHHQwcg_22_11"></a><a id="Tc_ipBt9-q_3Ea06hAxjjc-DQ_22_14"></a><a id="Tc_LOE_XElzUkSsQLv2KKEf9g_23_0"></a><a id="Tc_2uR5yGDjGUymg0Jom3Z1VA_23_2"></a><a id="Tc_z9jZcFJGjkaZX-TifUWIkQ_23_5"></a><a id="Tc_IZJlz8hr3US4B0HnpWfe0Q_23_8"></a><a id="Tc_lc5FDJrz9kqLzYNusxRBjg_23_11"></a><a id="Tc_hdKN-DZSykyR8j2IL21utg_24_0"></a><a id="Tc_Sr13J_7akkOmiQijmv1ADA_24_4"></a><a id="Tc_IvdnqEMZjke07v45bs3syw_24_7"></a><a id="Tc_ImGfnGsT3keGtnwjvAcEug_24_10"></a><a id="Tc_AViK4yijCEq_jxbJ2xAy2g_24_13"></a><a id="Tc_KNKmH6jED0OOFUA7D73L4w_24_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Paid</b><b style="font-size:7.5pt;font-weight:bold;">&#8209;</b><b style="font-size:7.5pt;font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Income (Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2023</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Jl5WhaKOMEWbPOAHelRptA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_I8Sm07jT9UyJPQ-Co82e4w_5_2">75,979,495</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Jl5WhaKOMEWbPOAHelRptA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XQTCoIJAkUa-0tFirkGnWA_5_5">76</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2nNWjMEjVEeMAdYk2gMIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UXiTpwvrOE2ayoQSd2rDnA_5_8">901,471</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_nozla3sC4EiSz8NaIUpFgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_tQttyR4UT0aR7QqXLWQidA_5_11">92</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZjASu7KTjUmyEQ3U5sdd6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_evy-4C8qvEifEZP-CnTmMg_5_14">676,421</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xvTL7jJ4JkKv1CC-hQmqiA_5_17">225,218</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized loss on marketable securities</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rkA0oDL87kCoKZIqo1taMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_7p4z2Uahgk2UPdTvyJSGUQ_6_11">142</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_v4nSyTlCD0miY6K9nqZKTw_6_17">142</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4gsxBsTIOUKDdJU0qMOv6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_DB2-3iaiFU6kyHrAU3Ikvg_7_2">47,293</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dN42DahesES9T_h8Jy0MRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_OmTpPgz8hEGGG60eGQ_9Pw_7_8">280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_jh8GQmFlN0qqTOKDxKZSyw_7_17">280</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Issuance of common shares upon RSU vesting</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4gsxBsTIOUKDdJU0qMOv6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_EOitBaj-uk-NstHOwQyFxA_8_2">360,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of pre-funded and common warrants</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4gsxBsTIOUKDdJU0qMOv6Q" decimals="INF" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Tc_Q2FZB0HudUyrfs_hyN655w_9_2">3,357,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4gsxBsTIOUKDdJU0qMOv6Q" decimals="-3" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Tc__p0fwv0Cjk6NcvKyCst7Dg_9_5">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dN42DahesES9T_h8Jy0MRw" decimals="-3" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Tc_vLBwCXqpeE-WZAHDH4ujjw_9_8">6,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ" decimals="-3" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Tc_Vsa1lk5yM0uO69GjeHAilg_9_17">6,106</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Equity-based compensation expense</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dN42DahesES9T_h8Jy0MRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_w7VdnA2UoUOztiCfA9hgMg_10_8">8,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_9Ezw30vjOUifx0Qf5dW1UA_10_17">8,164</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__bNeEJWJfkecGakhaXbnYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_DyDfBZ_Wb0G4d9lurbltgA_11_14">56,853</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Myqua_NKOkat5KJ5V23tqw_11_17">56,853</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2024</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kviCKzjbT0OnEPOSUwBMvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_pIa5qLoPZk-XEOWHeCCJow_12_2">79,744,654</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kviCKzjbT0OnEPOSUwBMvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2Z4bTrgbAUCmwRzBCGSX_A_12_5">80</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_55LwgvBeAEWVjIhgYoVZ_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_v-U092OFek2KPP4vSEG9TA_12_8">916,017</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bEpiyEGiwkG49eAV_JtQTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_uqkOiLpDuUqiL1a5CemLBA_12_11">50</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ORLJCxuY40S9_SNp0cm9Hg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Sh9OhYPZ7EuH6L63owjQfw_12_14">733,274</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_3_31_2024_wqwnwDf4JkGc0MFSynknLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jEwrQHFwk02bd8V5yZOjbg_12_17">182,773</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized loss on marketable securities</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KI1BGZUe6kqHi_LI40MMew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_KPKjiSnWIUu9rSKkZ4UIMw_13_11">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2024_To_6_30_2024_n1BJNZBWIkiQKIcb1a5qjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_LbMGIQ1QfkiVxp-88EGd3g_13_17">4</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0wakrHVLCE2j3KU_Wo3X-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_1FkA3LbyW0uz0VCkUPOhbA_14_2">6,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5mmOYnBYhECqu2JZBuf-nQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_ls5JHo5WKkW15_dzToMkqA_14_8">47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2024_To_6_30_2024_n1BJNZBWIkiQKIcb1a5qjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_2UkDoUXSC06QamtQpshpxA_14_17">47</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Issuance of common shares upon RSU vesting</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0wakrHVLCE2j3KU_Wo3X-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_2YxYWomDf0ib-IcwCRtfGQ_15_2">240,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Equity-based compensation expense</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5mmOYnBYhECqu2JZBuf-nQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_9NEHqRwYTEqMyojpvcEb9g_16_8">9,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2024_To_6_30_2024_n1BJNZBWIkiQKIcb1a5qjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_ddhBkH9X7U-PimrQrDmRKQ_16_17">9,312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AvRWZZzhQUSBZgDTGob30Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_K6Skx1GFIEa6-DYItYpYCQ_17_14">58,508</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2024_To_6_30_2024_n1BJNZBWIkiQKIcb1a5qjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NZ3KehfXMECg4qY1QZtuug_17_17">58,508</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2024</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BUGwTFWlqE6W4huRO8juSA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_1X1wcYonJk6GIntWJyV6_w_18_2">79,992,068</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BUGwTFWlqE6W4huRO8juSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Gj2cjF-zQUuVw_XOlbVW2g_18_5">80</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cYBDTrhv5k6-VEbdQ5UWiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-d4xHnY29EmivLTujBRhDQ_18_8">925,376</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dKD3wJCHqEuE8Jri1puoRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_XForxAlwVUK9UORBZRT0QQ_18_11">54</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g5MOsQI7QkGSEfP3mEn_Fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_195-IepZtUSslCHX65Dh5A_18_14">791,782</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_6_30_2024_74qePC5v6kCjrygaeq4KKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LaPka7JuWk61ZoqeownZvg_18_17">133,620</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hohbrgalOEmxhqwnpMP8fA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_BoXy7LLbSUWHexemVbIObw_19_11">182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_OzdPsXEGDUaYpmfibHwKfQ_19_17">182</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pFHBf0hY5UW0FWY703uxbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_6uHi3cZ__02UZ1T7U5iJYg_20_2">41,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ERzFFMLhQkOjWn1JX4pSxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_7zrMMwN6E0iS2JXG1OJxmA_20_8">223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_EeuBBlZOLEy45EVYRb-CKQ_20_17">223</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Issuance of common shares upon RSU vesting</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pFHBf0hY5UW0FWY703uxbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_eacZuGUfTkSOaaWTJ9a48g_21_2">48,389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Equity-based compensation expense</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ERzFFMLhQkOjWn1JX4pSxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_bpT3_PvbO06xiZIrRfqMyQ_22_8">9,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_ZE0MjprQuEKUyEUfdLjTng_22_17">9,650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QKxAZY5g4UK604mpOKeFxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zRgcQ1fB7Uef6o7jG3e0Kg_23_14">64,479</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_9qLO-oUZD0Wip5b2JZj7tg_23_17">64,479</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2024</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UaO3_RTxqUKoz5-Yyidv_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_91O1ECKElkmvaecpKFs_mw_24_2">80,081,535</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UaO3_RTxqUKoz5-Yyidv_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_mHVek3WRdkSIeDttofKOoQ_24_5">80</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MuQ8eux8ckqYO9qz-3WyHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_IV6eTRiy0k68FhHjbA_qtQ_24_8">935,249</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9xzkVt4VMU2Z76J7CR-7zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__yhaZ0fCSEiF7FAQnZsJFg_24_11">128</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7Zh84n4-Ykq6WGOpfdZ02g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_NerynIMILkayURuTja21mg_24_14">856,261</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YAOPraTnwkmgo2Kq-x7YbQ_24_17">79,196</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Content</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_0rn2Up7qLk2cBvm_IqqkUw_41_0"></a><a id="Tc_O0Yske-3ikqAFxIuqLzxhQ_42_0"></a><a id="Tc_KWWjKZLo3Ei8gXriGxiveA_43_0"></a><a id="Tc_tX9gieKXB0eaHsXEQCo2Ug_44_0"></a><a id="Tc_nJOBOPlX00q-nTwlTGPWfg_46_10"></a><a id="Tc_enXt3SKZr0KTsHGrar6XOQ_47_7"></a><a id="Tc_nItlK-YL10iCphAVaiamiw_47_10"></a><a id="Tc_BLqZ8J9IiEO2ZdafKBXOXQ_47_16"></a><a id="Tc_NdpBC1eXRUKFQHrIbRCAAw_48_2"></a><a id="Tc_okmDQ8cKh0C5qm2_e25rYw_48_7"></a><a id="Tc_EIP1H_VLzUuaf_aZcGnS_Q_48_10"></a><a id="Tc_K6za6FoeOEiPNUFsa1NW_A_48_13"></a><a id="Tc_ckv_o-F08k-6ZFWh5NdsOg_48_16"></a><a id="Tc_ZE0-6qpyLE-zy-8eX2CqkA_49_2"></a><a id="Tc_RjwpgXvBfUmA-i1KepS7sQ_49_4"></a><a id="Tc_pQ8wgFnJU06tvrg-ZyTAOw_49_7"></a><a id="Tc_5H2j38w81EKW9DRm3HfaFg_49_10"></a><a id="Tc_yZV9B3Pv10WR39BN8KmS5g_49_13"></a><a id="Tc_WymRNN_kDUaGGA5izZe-3A_49_16"></a><a id="Tc_3Y_LWTYBikyP7p3VsMaK0w_50_0"></a><a id="Tc_W2wsYgkOh0yP-WChTat-Vw_50_4"></a><a id="Tc_zEQJfH_1w0-i4TeoPjYF3Q_50_7"></a><a id="Tc_Z0oxwWcwtkaI3NI0fIcERw_50_10"></a><a id="Tc_86fjjyQh_kueqL5B1xq1Zg_50_13"></a><a id="Tc_mJFz9lxJE0mI8L30i_zPKQ_50_16"></a><a id="Tc_C1gUEVdEnEiPEo2NLGjofw_51_0"></a><a id="Tc_DVfMYZ94NUKFctD_ExWRQQ_51_2"></a><a id="Tc_OSdPS40xxk6GR0rVdjP-wg_51_5"></a><a id="Tc_WRfA6Zy1OUaAPdU9n8Cb9g_51_8"></a><a id="Tc_NTWuPowvsEy7mu6wWlIbKw_51_14"></a><a id="Tc_pad8xARp1EecpvA7Yoqcnw_52_0"></a><a id="Tc_Ntol0X9x10KTjZtxYvBayw_52_5"></a><a id="Tc_Rc1zKoiHZk-mZNE9wf53zw_52_11"></a><a id="Tc_D49joiBF_0yPsJgg8AjI_Q_52_14"></a><a id="Tc_Vz-LByDTKkS0EksQszmNug_53_0"></a><a id="Tc_JAQUGynC6UGYbTi7SMRNhg_53_5"></a><a id="Tc_AFwLcOmxdECRqKp1Zf_2EA_53_11"></a><a id="Tc_CKEfiB46LkumiOYSuYVbAA_53_14"></a><a id="Tc_gGLictkbBk6WeYC3tuEtBw_54_0"></a><a id="Tc_rKpV-MJ5306Z8GGWYM9U7A_54_5"></a><a id="Tc_czGJrzcVaE-cOnJ9Pm98RQ_54_8"></a><a id="Tc_KDaCOtVfpEil-1NM6-lzNw_54_11"></a><a id="Tc_TBLaL8KwwkasuYlCvl0lzg_54_14"></a><a id="Tc_GC1OyoibIEC7LQlBJQ9wdA_54_17"></a><a id="Tc_YyMT1BZuEkuPoDwhDs-I2w_55_0"></a><a id="Tc_Mn0GwJlqKkC4zzuyEwMDOQ_55_2"></a><a id="Tc_txXAmg9b6E-pZIZcyBUWag_55_5"></a><a id="Tc_aay-SbXT90ik5Os4ar7E5A_55_11"></a><a id="Tc_MTJyngxNGEmj2wNhQP0UTQ_55_14"></a><a id="Tc_dOUC4jHfBECdc9MWtA4rcw_56_0"></a><a id="Tc_PgqZs2lyoUSceoBrStlmlg_56_2"></a><a id="Tc_l3Y3TH7kH027toDbmyt83g_56_5"></a><a id="Tc_vzShRfHLfkyrBF3eKO_-3g_56_11"></a><a id="Tc_XOR_-YvotkSgL3lSpGA4fA_56_14"></a><a id="Tc_R4tQFnp8vEKtwVyB6xkCFw_57_0"></a><a id="Tc_myA9bnsPz06gcxkBxcpmGQ_57_2"></a><a id="Tc_nExlkJX9T0K9sJBgL5RXTQ_57_5"></a><a id="Tc_o44WX5M-F0O4UXyKR9kUOQ_57_8"></a><a id="Tc_Gx0nOBss9UqPMj-VyOyJcQ_57_11"></a><a id="Tc__7o9YIYdg0-5M7e_3wFTTg_58_0"></a><a id="Tc_l5Dwt7xZtkqXZERnvOZXlw_58_4"></a><a id="Tc_xmbx2lgiyku3OiCrOyw_rw_58_7"></a><a id="Tc_l3rSuS51r0OPblhkjmLGrw_58_10"></a><a id="Tc_gsmD4CbNNkOBCorxIPfFpg_58_13"></a><a id="Tc_fNDllmkYwkajDVTPLTtsRA_58_16"></a><a id="Tc_MMmgmNKjF0W50rg2-iuLSw_59_0"></a><a id="Tc_E6Cf9oDJyE-Vr54v_eErzg_59_2"></a><a id="Tc_P_I5cUAR3ky-CF-dT9ESzg_59_5"></a><a id="Tc_d2pjUKq-jEyP64dPiC8RLg_59_8"></a><a id="Tc_P2QYS-0Tekm-87G_xa4QBg_59_14"></a><a id="Tc_um-K_yCcFkS6uxVmm60vyw_60_0"></a><a id="Tc_apmNCcBxQ0qMXOdtyXEKyg_60_11"></a><a id="Tc_JBLQYhKm9UW0LRTPOW0YrA_60_14"></a><a id="Tc_BeL8QXh1Z02noA_JMWFC9g_61_0"></a><a id="Tc_9AgLCSv4MUuGNiGuQvX0mA_61_5"></a><a id="Tc_E2p9O35mq0-aaNmcpqL_5g_61_11"></a><a id="Tc_wQJqjR5DAE6uJ6Zadd05Mw_61_14"></a><a id="Tc_7w2jeiN8sUyAPYWk8lBCuQ_62_0"></a><a id="Tc_ZFkbRB2v1E6R91zFKZehZw_62_5"></a><a id="Tc_GJSBr-2lRkGc93crr1Ue1Q_62_8"></a><a id="Tc_wSlF4yAHUkWKd5bbrsatTA_62_11"></a><a id="Tc_6usYKwJztkSGq73Zr8MW0Q_62_14"></a><a id="Tc_tgWKQyPP3kymdKfD1hoKMA_62_17"></a><a id="Tc_jRroX1ucakqsgE9rxWPl6w_63_0"></a><a id="Tc_F8YRO3-KCEyCAMA5sZ7-Vw_63_11"></a><a id="Tc_i8-NHZtLx0aq2oUVhLeP0A_63_14"></a><a id="Tc_8CefxUNdCEiPDkRtodPP-A_63_17"></a><a id="Tc_scf_poyzUUeWmLdE-Y-qMg_64_0"></a><a id="Tc_kUlFdUuiikylC0zMSnMgRg_64_2"></a><a id="Tc_8_wYgeVof0qVZCwStAV-8Q_64_5"></a><a id="Tc_AbCBNbKqgUq4wv0kOLDgcA_64_11"></a><a id="Tc_3b0NTAIZd0WHVPn1K80RoQ_64_14"></a><a id="Tc_j04U15sp90iR3rYgAUkRhg_65_0"></a><a id="Tc_slUfCpZh30uje50gR4PuqA_65_2"></a><a id="Tc_OoRjvIDnzUqZ9jeH_ZRvJA_65_5"></a><a id="Tc_n5GoiMcSvUKGidox1npz5g_65_11"></a><a id="Tc_nR8e2-cyDE2xcbIqVGfN3w_65_14"></a><a id="Tc_JT-1koqUT0KScZ-QJtCaYg_66_0"></a><a id="Tc_FYg_0Mm0bkShuCrKQ_IMNA_66_2"></a><a id="Tc_roIWjH_590aRTN1AbT2nNg_66_5"></a><a id="Tc_1YvEujVbs0a284ikPSVLzg_66_8"></a><a id="Tc_nX6SDapFUUGk4BTRk-2mjA_66_11"></a><a id="Tc_2oY0WCQc3E2mZJ-5xCp1pg_67_0"></a><a id="Tc_9-WYK3lehkunPElMWAQuEA_67_4"></a><a id="Tc_iF7y5tfGuUmIib5F5oIr0w_67_7"></a><a id="Tc_fNgpDRJ8r0yE53ed-DiVUQ_67_10"></a><a id="Tc_qwuexquCvk6v5XUu5Pb1fg_67_13"></a><a id="Tc_7am5-3B7i0mUPU315ZDX5w_67_16"></a><a id="Tc_d4v5mSnzs0qAGMvssDCafA_68_0"></a><a id="Tc_0QTh_OORF0q7vaorxKUv_A_68_2"></a><a id="Tc_2uXeXnysckmulc70ip4mgg_68_5"></a><a id="Tc_HVHljyd7sUGhO_i0ZFxRgA_68_8"></a><a id="Tc_ihTnER_U7kKP_wdcyq3iaQ_68_14"></a><a id="Tc_g35fCI6x80anG1tHCkhRcQ_69_0"></a><a id="Tc_pZVYoNxC5Eu3xgvnA0-wvQ_69_5"></a><a id="Tc_xRaLeMnFskK8myzTddz18Q_69_11"></a><a id="Tc_1rz7BcW_OkWtodDzMjb-iw_69_14"></a><a id="Tc__K2BwG74G02pahmrq8Xn6g_70_0"></a><a id="Tc_BxFpoiExf0ORBNiK5kZVJw_70_5"></a><a id="Tc_3qzymLju40WUbsIjcIemjg_70_8"></a><a id="Tc_YO9uuJSxXUS-KBF4x77bUA_70_11"></a><a id="Tc_7ABeHGf5LkCTvXr2YEo_ig_70_14"></a><a id="Tc_WEGe1RKfWEaKP6_0G4A94Q_70_17"></a><a id="Tc_KOtowVhWTUGIx_JWkfKrUA_71_0"></a><a id="Tc_3JRiJ-8QQ06R-IMdb2kffg_71_11"></a><a id="Tc_71ibYwMs3EGlT6RWyQt9yQ_71_14"></a><a id="Tc_8tGYBA-9NUW6zc0nRd_KHg_71_17"></a><a id="Tc_zKFo2rL9P0CBWvgb6JkcNQ_72_0"></a><a id="Tc_UhDPKneL-Eu-f83_SsWmgA_72_2"></a><a id="Tc_rrE7hJP5Dkm9glXRXNxJMA_72_5"></a><a id="Tc_reLHYwAtsEi0A9eYk7_mcQ_72_11"></a><a id="Tc_9IrICDaqm0SkQ9dMCHy3AA_72_14"></a><a id="Tc_iez7Ar8s3EGN3G9gUIGvLA_73_0"></a><a id="Tc_3AKx169I_kWHd4gTNg1d8g_73_2"></a><a id="Tc_22hrvfw910WU4tCE_mHi3Q_73_5"></a><a id="Tc_P_C_kZsl3UeFtEwlE2ABuA_73_8"></a><a id="Tc_41kjYA9GlUK3rs_ScHpFiw_73_11"></a><a id="Tc_n_tfcHKSKkqfoPPJY2ZnKw_74_0"></a><a id="Tc_UCPguI9L_0i0y-88EY2i5w_74_4"></a><a id="Tc_7eacTSWjQ0OonuiLrEQNww_74_7"></a><a id="Tc_o-AyyUwmD0uggqsMevPZgw_74_10"></a><a id="Tc_A1Xyg7vcnEaFBow68DQH2Q_74_13"></a><a id="Tc_Q5cUqy5whE-axMy50t36Sg_74_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="18" style="vertical-align:middle;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SCHOLAR ROCK HOLDING CORPORATION</b></p></td></tr><tr><td colspan="18" style="vertical-align:middle;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY </b></p></td></tr><tr><td colspan="18" style="vertical-align:middle;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td colspan="18" style="vertical-align:middle;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Paid</b><b style="font-size:7.5pt;font-weight:bold;">&#8209;</b><b style="font-size:7.5pt;font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q6t-2V68bkiFrfajlGSBeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_7_0TNiifMEKmsIlmJBNNYQ_50_2">51,672,579</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q6t-2V68bkiFrfajlGSBeg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7D3tqETabki87MLZtXsFwA_50_5">52</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fq5xFmnwbE6Bb4giq5tdsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Pk8m24yPjUWkVMr9QQ38Kw_50_8">771,699</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6oRTpQ0UIkSjNufZC8jLZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_cFoNa6smjkCAzYdwcW25JA_50_11">884</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j0Tq9iEgI0WxB3qMug6fdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_fKgEobYU6UmTHYgp5rvdqQ_50_14">510,632</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2022_xn5zGRExdEqV3w6EYHlpYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9Zd7jD7lkk6x7FblaWXzNg_50_17">260,235</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JwQxc0pT8kKm0ykun0RF7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_ZWpZrivzMUqxnFgxubH9ig_51_11">555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_MIFvJohWBEuvFZa3pe4_Bw_51_17">555</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Sale of common shares, net of issuance costs</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oFzCQeJoUUSgYwvWF5ktNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_aSXXd_2INU2pk8Z86AgQCQ_52_2">68,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rC1XfV1TjE6F-U0p2kSCCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_lV41BhpKHkGZzOco5OmKZg_52_8">827</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_E8KkHQReD0G4oXTrNZvzFg_52_17">827</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oFzCQeJoUUSgYwvWF5ktNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_AKilMrRRvUyp-GUIB7KvEQ_53_2">28,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rC1XfV1TjE6F-U0p2kSCCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_QzalDA_VUkavKyfODuzF4Q_53_8">243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_TcymuxOgdUuZ3D6tpbAnCA_53_17">243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Issuance of common shares upon RSU vesting</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oFzCQeJoUUSgYwvWF5ktNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_0Ukt032fXEqgY0-CQlUSNA_54_2">219,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Equity-based compensation expense</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rC1XfV1TjE6F-U0p2kSCCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_z7uU-RAPBUi4Ee9s5il2uA_55_8">6,170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_RxVzn-iDs0GK8DZ2TLzCNg_55_17">6,170</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rC1XfV1TjE6F-U0p2kSCCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="Tc_psvOZIOAykSy5ZnBdIdpLg_56_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="Tc_n5YFfWwQ-E6AfF6wS3mshw_56_17">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_19bHARrGm0mAeIg-yhN-Xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_BEBZlccSyUO0YdhZTClJTA_57_14">39,379</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XUfNYW-66Uahm4i07EGoaQ_57_17">39,379</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2023</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Upyc56e-ZUuXeiJ1EZGbkg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_IWs4yzfLZ06av-vw144YtQ_58_2">51,989,359</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Upyc56e-ZUuXeiJ1EZGbkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6GRijOG5lkWL0rNHvLPoPg_58_5">52</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CDkUieplhE6Jbi_MfC9KFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ABT-sLcgPESapXLc8vaNVQ_58_8">778,941</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DSycY3vZYkmsf4sXbaV2Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tkh2_CC8hEeEKTwpT88Plw_58_11">329</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8rb9ujm1066sXa5nb2vXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_b34Tw6EKqUK7BwZmy1B2ZQ_58_14">550,011</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_3_31_2023_Ck3LkULZgUu4IahGYkThNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bWr8Xg0EakWEuWxHraKYHw_58_17">228,653</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NipCJOW77ECvOR_obikyPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_9P2SnUCb-0-RYdYkGEnm-A_59_11">266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_WwhMLnijy0ykxfuKvtF4IA_59_17">266</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Sale of common shares, net of issuance costs</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_udZeHx07m0qowsveepiCbw_60_2">550,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_I6mb5gZ6EE6HYHUw91ncjw_60_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_XSlRvgZz1ESPbr2F1kwsgg_60_8">4,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_1Dsbb4pZHk21vTU3wald6Q_60_17">4,396</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_ixXf56HJsk-HUcPWVdWD3g_61_2">53,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_3miIyjXCgUuCVY_3g7ohhQ_61_8">292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_TZRL0zxX1kKLBVVWlneh-A_61_17">292</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Issuance of common shares upon RSU vesting</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_fKNDF7ofKkSeEmuj95iDKQ_62_2">273,035</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of pre-funded warrants</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw" decimals="INF" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Tc_tbd0aV0gj0WPGFbkQUM77Q_63_2">2,293,466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw" decimals="-3" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Tc_OU_Mxp7FBky9mCmY8VFYiA_63_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw" decimals="-3" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodValueExerciseOfWarrants" sign="-" scale="3" id="Tc_PlpQkLpO9ES3lxuTO2OzUA_63_8">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Equity-based compensation expense</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_T8hwbPqEi0qlUOd3PftX7Q_64_8">6,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_1SJxbdF1HkePPmTIckfg7A_64_17">6,818</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="Tc_BorACzKkVEatZ7MOYjJqhA_65_8">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="Tc_iE92JZ2FpEaOwgphE5vGfw_65_17">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fk_SSWQDLU6gbCA2Hoe86w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_KqNVkZYC_0Gbf0ETfkyLNA_66_14">37,925</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_gonNTqqG1ECJHc5TVgWlMA_66_17">37,925</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2023</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8SSCuIUnHEa3XtfgIHQmTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_qHlohO2yq0SkZG07-zBwrg_67_2">55,159,787</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8SSCuIUnHEa3XtfgIHQmTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_adve96EgMkOSkAn_mzA1ew_67_5">55</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sEwTkPlLLkSbqd_LCKEveg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jleq6rwr-kqofz8sI1I6UA_67_8">790,445</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iGIZ5dBRVkeElrLQcBXYfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Z28pqGkPo0mrf5TnFcG39Q_67_11">63</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mdZ4Vf_v90mj5UjPiNSTZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_S4gf01aPRU6s8yVLIo2uKA_67_14">587,936</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_6_30_2023_Fxn6BbkW0Um942NziX600Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_upGMe7sYjE6h_gvvBM3tEg_67_17">202,501</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uw72zZDY0ka7tF4uwvAQKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_QoNXwexzHEOE1T-nxNeYyA_68_11">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_833rFxlYm0mVDqbX7vyEdg_68_17">40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ePsDgOB7_0WDZ--l8zx3Lw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_rYpzxlirfUGsxWhibh5vNQ_69_2">49,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CE-n08KE9kym4zuTU2o9Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Cdnev64CsEKsmyylxk-gJg_69_8">280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_fXv9Az-0CUaVnAg2TmonXQ_69_17">280</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Issuance of common shares upon RSU vesting</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ePsDgOB7_0WDZ--l8zx3Lw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_v2ElyL1XzUq0rhGVn4Bjjw_70_2">24,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of pre-funded warrants</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ePsDgOB7_0WDZ--l8zx3Lw" decimals="INF" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Tc_p6LfJadPbEiwTQw0uYDHUg_71_2">1,026,893</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ePsDgOB7_0WDZ--l8zx3Lw" decimals="-3" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Tc_vU1GTWIEY0i-hCh9OQkd_Q_71_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CE-n08KE9kym4zuTU2o9Cg" decimals="-3" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodValueExerciseOfWarrants" sign="-" scale="3" id="Tc__JIHwDGshE-zRV-ax3BGhA_71_8">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Equity-based compensation expense</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CE-n08KE9kym4zuTU2o9Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_tonmNqgEgU2aV15gUjxkpw_72_8">7,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_oER-By5beEiRKiIQT_QftQ_72_17">7,203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tkrpxbJb_Eq1PgDgb69BVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XtV674fvyU6Zp3XpdFqmVQ_73_14">42,359</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_nn9Z8clQb0uZ-F4yqVUrDA_73_17">42,359</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2023</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JqYd9nXR30C5hBt7QuvWkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_jFVq0cTKh0ePZKiAS_nGnQ_74_2">56,260,574</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JqYd9nXR30C5hBt7QuvWkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__0Mok1slc0e_vUdnfPIurA_74_5">56</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LyOvZrAbr0mYiQTtryH6Zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uXsTfJAemE-Ha7omEWmuNg_74_8">797,927</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_WyRIrmBEzU25Yii5LaCicA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_cEfjcKdLME2AWz4BqEhrlQ_74_11">23</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rI2SWZIWcUGpK_a1C6sCUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_vZajRaogokKo91i_rYAccA_74_14">630,295</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7PvS2dJDIEWSiA7JkvlJcQ_74_17">167,665</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;font-weight:normal;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_66dfd671_e195_491f_80ac_1f31c933a838"></a><a id="Item1ConsolidatedStatementsofCashFlows"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">SCHOLAR ROCK HOLDING CORPORATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(In thousands)</p><a id="_9e8e6d0c_c957_4bde_a0df_bc0d47232399"></a><a id="Tc_sAVdthQOPUSD_dmRAQBk_g_1_2"></a><a id="Tc_SWYcTm3bMkmRnVZYVDnmPQ_2_2"></a><a id="Tc_y4aSkD78fUuF4xIyy3h9Zg_3_2"></a><a id="Tc_GIWgVGw3sEKZ9wyLPFaJ-w_3_5"></a><a id="Tc_6ZNt7W1q7EKT0Uf2zSCwqQ_4_0"></a><a id="Tc_1EmC0dNM_kmFKCEnIesBLA_5_0"></a><a id="Tc_hY9Zm_rSuUKMvzBE_mii5A_5_2"></a><a id="Tc_hn9DJe5SyEWlu65imPxVJA_5_5"></a><a id="Tc_nDTiDDrseUa4hk8VlHE3WQ_6_0"></a><a id="Tc_S713D6lhNUWs6TCKR-W6Iw_7_0"></a><a id="Tc_XinYB221PEe5RrCiTlYh4Q_8_0"></a><a id="Tc_QyMCpPD6cU6yn5QgdLZnGw_9_0"></a><a id="Tc_8TQpQOQi0UOg30rvVDaa3A_10_0"></a><a id="Tc_ff71jXEkgEmwj64W9cE_8g_11_0"></a><a id="Tc_Gzfwg1YTo0ysJBknlb_TmQ_12_0"></a><a id="Tc_VN6zlQwHaEm9DuLMQ4j2ZA_13_0"></a><a id="Tc_oLEtXIHwikq4AMEkRiEgmw_14_0"></a><a id="Tc_zOkBBwjrZkWxJzYSaIhWlA_15_0"></a><a id="Tc_-N_JKPzpL0W7s2o1bcUoyA_16_0"></a><a id="Tc_RJ5DVDo0CkWLK2RB014kRg_17_0"></a><a id="Tc_pVFSZunz0kyHY6x7qKlj_Q_18_0"></a><a id="Tc_8jodWK3DZEGnQ5ZR3dPwcQ_19_0"></a><a id="Tc_lty_CCnjOEyhGFq9JJyvWw_20_0"></a><a id="Tc_-kP7sGBtL02eBnwQBJFRDA_21_0"></a><a id="Tc_X5tK6vkqYkKCn1J6WswidA_22_0"></a><a id="Tc_kewOzRjKBk2VQ189I9E9Mg_22_3"></a><a id="Tc_kPbNW7TLIk2gStboa7xEGQ_23_0"></a><a id="Tc_1e9zEU7q-Eeq04kKNzIEYA_24_0"></a><a id="Tc_SrRwag_OCEaiRqAwqYprgA_25_0"></a><a id="Tc_3Ibsvf-cpkutyFwrbjZTSw_26_0"></a><a id="Tc_JWjZgPVdQECCb9KWvH-Orw_27_0"></a><a id="Tc_-KPcGclz00Cd6BfNPoEZzQ_27_3"></a><a id="Tc_v7ZhFBEJp0ya_tHmNCbGQw_28_0"></a><a id="Tc_XnHVJgCGoUulrfkAVdUZSQ_28_6"></a><a id="Tc_WLkzLC6HN0q8lR8H7wzqmg_29_0"></a><a id="Tc_7SZtufUDhEqXfXDn2Ko7qw_29_6"></a><a id="Tc_wu0e8Rfb-kqfKvEkS2bG9Q_30_0"></a><a id="Tc_rSv2qYJW70urDFNT6qhRjw_31_0"></a><a id="Tc_cmqD2uMPEEu4qAzhIFIZTQ_31_3"></a><a id="Tc_YCbYtNimOEiJ3xLoa4eI4A_32_0"></a><a id="Tc_r_a7DMrC9U6GT64WkWIl5A_33_0"></a><a id="Tc_7xgliFM2n0iA8qCmWFPO-g_34_0"></a><a id="Tc_ZtsVyeybVEOl6bvV1Hg1uQ_35_0"></a><a id="Tc_tShxD5GHlkS__buLAZTJ9g_35_2"></a><a id="Tc_LOPjkNUpDk6K_dl13NnzTg_35_5"></a><a id="Tc_5lRB003z9kO8bj5QH-WO_w_36_0"></a><a id="Tc_yWkWtg2D0k-ruoK1g_959g_37_0"></a><a id="Tc_br1Bu9rcR06G4kCaP0bJNg_37_2"></a><a id="Tc_eYl6-xnNWUu-aqQboXKWNg_37_5"></a><a id="Tc__ij8yLgwLkqM62ClSI3How_37_6"></a><a id="Tc_uACurqarsk6_tUXDWUlLew_38_0"></a><a id="Tc_gcsSoJ4vCU24jQHOSC_NFw_38_2"></a><a id="Tc_Ge2WukvNMEGIr9Mm_OHSuw_38_5"></a><a id="Tc_6r7Y71SBJ0y2Wssv4qnAkw_38_6"></a><a id="Tc_yBcbiq9YX0Kkkst2BJZPfA_39_0"></a><a id="Tc_Y6H6i0dmdUWmolcJGr61hA_40_0"></a><a id="Tc_bAZc-DNeNUyiPPrJKDoWnQ_40_2"></a><a id="Tc_1t46fMTxXU6H9eOlBuGb5g_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_XZG1TWo7I0K96n7n4jS8Bg_5_3">179,840</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_SG9PHpr1V0aTRKjyv6X9Tw_5_6">119,663</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_-7PMdtBJpUqlbPlrt1A-GA_7_3">1,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_9Cg45LcnRUuO4NUBs5aD5Q_7_6">2,172</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_bjdNIVmYA06eKKJmOqAWVg_8_3">206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_IPJcg_HBKkOmxFhS_0N0SA_8_6">215</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Equity-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_BNo8ZXKBQ067ddjB_m6Q2w_9_3">27,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_CkFJnHhoF0-xTqvdwlJ47A_9_6">20,191</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization/accretion of investment securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="Tc_NDZRNt374k29iA5UXD1v8A_10_3">3,945</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="Tc_YgvDv4dHvECAlHo82Zow1A_10_6">4,417</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_MqHA3hlngEmfvjuLhXFxpQ_11_3">4,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_HGE0-lqLpEivI9CfDdrnhg_11_6">5,546</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Change in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_gmpa6bWWN0aMjlppMR8RBA_13_3">5,734</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_MTGf5Ea9XEK7sGVrF8WIsg_13_6">2,817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_5ZNq_u94-UqLS58S9D5H0Q_14_3">608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_8dC0403VkEWK7P4x4qhb4Q_14_6">387</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_L-BfhhY-2kmjm51Y-6QgZg_15_3">606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_RvsmeJZJCUOa7vYX-SCLkw_15_6">2,026</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_OABdUTp1pEyYm5zwf_ZZpA_16_3">8,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_KhkXNATQnkO32nNGTi2Kdw_16_6">6,924</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_vLT2yL4YJE-Hc83aApQZKQ_17_3">4,744</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_eBnX5DHSkk6ZHTaYV0dg3g_17_6">6,117</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_Tt0HFniI90-aZ13nW8T4tw_18_3">116</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_aCdoZGsCjUCcqrYJWRtJsA_18_6">58</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 30pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_bEPf41rlr0-pTkUPdiFy3w_19_3">151,436</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_ttFoY9zSyEKwm4GLuVIyoQ_19_6">107,877</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_b2uUbnmAeE-GPOn3HLrcUA_21_3">76</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_oUdzNbQXSkahMkzTAgAAYw_21_6">71</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_sb6JTCzb9kqXver3cF9ncg_22_6">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchases of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_VIZvIi1o9kuMCcajeu2AzA_23_3">82,710</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_OIVEomkk4UOMKlL5lWU7TA_23_6">186,673</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Maturities of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_hSFls_GigE-DOmjeMR0WNA_24_3">202,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_5xOmMigVRkewBc9RbaOUuQ_24_6">253,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Net cash provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_52-VKRHzqk-Wp5Y4wHiT8Q_25_3">119,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_yvH6qE9di0uRZclWaGm9bw_25_6">66,269</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of common shares, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_zj27S4JurUqp5QDHfDZRHA_27_6">5,223</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from pre-funded and common warrant exercises</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_EDVWHMXSD0O2kvMrH8vD4g_28_3">6,106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Debt modification payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtRestructuringCosts" scale="3" id="Tc_S2XbaAd6l0WF0MhddoCzeQ_29_3">125</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from stock option exercises</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_1QDUqvZPpE6eVneBrE2iuw_30_3">677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_ICJMdUOKYUC6qTXrB0DLHw_30_6">819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="Tc_XNOWNWUOg0SgKx2V_tHQeA_31_6">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_vCGWBL2kSEeQeYpgnwJLgQ_32_3">6,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_mVQnv1qSdUiqZS14afh_fA_32_6">6,045</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_b_vhFVyb7023U3Ef5kxK4w_33_3">25,464</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_39HLeJDnjEiOnWGSFG6O2w_33_6">35,563</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_RH6ErUPGf0yy2htzPcWaeQ_34_3">104,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2022_xn5zGRExdEqV3w6EYHlpYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_5N6aVi6aW0CWoQTSI5153w_34_6">105,773</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_hBIULSr2wUWXcEt3dxCYrQ_35_3">78,798</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_6vINr28aUk6q7u_2Y0R9aw_35_6">70,210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosure for non-cash items:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment purchases in accounts payable &amp; accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_tZGPP39UhEi48Wch57Uhmg_37_3">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liability adjustment from rent modification</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="srrk:OperatingLeaseLiabilityAdjustmentFromRentModification" scale="3" id="Tc_m3jIbwNEP0anAqU3rWSdng_38_3">9,451</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_Uxa33QzlvkGnZsa8yRf7aA_40_3">5,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_cad9wiM7CE286UuBdd5Qzg_40_6">4,743</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bcf5ae19_836b_4d92_8523_08051b0d1595"></a><a id="Item1NotestoConsolidatedFinancialStatem"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">SCHOLAR ROCK HOLDING CORPORATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Notes&#160;to Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="Tb_PJj9iNmRyUGIe9cO1mNeNg" continuedAt="Tb_PJj9iNmRyUGIe9cO1mNeNg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1. Nature of the Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Scholar Rock Holding Corporation (the &#8220;Company&#8221;) is a late-stage biopharmaceutical company focused on the discovery, development, and delivery of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. As a global leader in transforming growth factor beta (&#8220;TGF&#946;&#8221;) superfamily biology, the Company&#8217;s novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, the Company believes that it may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s first product candidate, apitegromab, is a highly selective, fully human, monoclonal antibody, with a unique mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of spinal muscular atrophy (&#8220;SMA&#8221;). The Company is conducting SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with nonambulatory Type 2 and Type 3 SMA. The Company completed enrollment of SAPPHIRE in 2023. In October 2024, the Company announced positive top-line results that showed the study achieved its primary endpoint. Additionally, in 2024, the Company announced data from the Phase 2 TOPAZ trial extension period which showed patient outcomes at 48 months of treatment with apitegromab. The FDA granted Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation to apitegromab for the treatment of SMA in May 2021, August 2020 and March 2018, respectively. The European Medicines Agency (&#8220;EMA&#8221;) granted Priority Medicine (&#8220;PRIME&#8221;) designation in March 2021 and the EC granted Orphan Medicinal Product designation in December 2018 to apitegromab for the treatment of SMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In October 2023, the Company announced an expansion into cardiometabolic disorders by advancing its anti-myostatin program with SRK-439, a novel, fully human anti-myostatin monoclonal antibody, for evaluation in cardiometabolic disorders, including obesity, towards a potential investigational new drug (&#8220;IND&#8221;) submission in 2025. To inform the development of SRK-439, in May 2024 the Company initiated the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve muscle mass in individuals living with obesity and on background therapy of a GLP-1 receptor agonist (&#8220;GLP-1 RA&#8221;). In September 2024, the Company announced that it had completed enrollment in the Phase 2 EMRAZE proof-of-concept trial. Top-line results from this trial are expected in the second quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s second product candidate, SRK-181, a highly selective inhibitor of the activation of latent TGF&#946; is being developed for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies (referred to together as anti-PD-(L)1 antibody therapies). SRK-181 is being evaluated in the Company&#8217;s Phase 1 DRAGON proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors that exhibit resistance to anti-PD-(L)1 antibody therapies. The Phase 1 DRAGON trial completed enrollment in December 2023 and continues to treat patients who remain on study. This two-part clinical trial consists of a dose escalation portion (Part A) and a dose expansion evaluating SRK-181 in combination with an approved anti-PD- (L)1 antibody therapy (Part B). Part B includes the following active cohorts: urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma, and head and neck squamous cell carcinoma. Safety, efficacy and biomarker data were presented in November 2023 at the Society for Immunotherapy of Cancer 38th Annual Meeting and in June 2024 at the American Society of Clinical Oncology (&#8220;ASCO&#8221;) annual meeting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additionally, the Company continues to create a pipeline of product candidates to deliver novel therapies to underserved patients suffering from a wide range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. The Company was originally formed in May 2012. Its principal offices are in Cambridge, Massachusetts.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_PJj9iNmRyUGIe9cO1mNeNg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since its inception, the Company&#8217;s operations have focused on research and development of monoclonal antibodies that selectively inhibit activation of growth factors for therapeutic effect, as well as establishing the Company&#8217;s intellectual property portfolio and performing research and development activities. The Company has primarily financed its operations through various equity financings, including in October 2024 (Note 12), as well as research and development collaboration agreements and the Company&#8217;s debt facility (Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Revenue generation activities have been limited to two collaborations, both containing research services and the issuance of a license. The first agreement, executed in 2013, was with Janssen Biotech, Inc., a subsidiary of Johnson &amp; Johnson and was terminated in July 2022. The second agreement (the &#8220;Gilead Collaboration Agreement&#8221;), with Gilead Sciences, Inc. (&#8220;Gilead&#8221;), was in effect between December 2018 and January 2022. No revenues have been recorded from the sale of any commercial product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company&#8217;s product candidates. The Company has incurred recurring losses since its inception, including net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_FKXz7Z4ykUuX1o-4MWBJBA">179.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_bhfEwfAwuE2Orig8O4JBlQ">119.7</ix:nonFraction> million for the nine months ended September 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_F27oHkgYUUumxvNYBz3kSA">856.3</ix:nonFraction> million as of September 30, 2024. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company believes that its existing cash, cash equivalents, and marketable securities at September 30, 2024 together with the approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EKUEbTHr-Ea-uOCZ6iVjdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_hy4INaEFX0WedN_pqr-Bkg">324.4</ix:nonFraction> million in net proceeds from the follow-on offering completed in October 2024 will be sufficient to allow the Company to fund its current operations through at least a period of one year after the date these financial statements are issued.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b077c771_e9c5_4c84_b8f0_e629ced0f6c0"></a><a id="Tc_vEkbBVXr5ECR3F7DSKWIwA_1_2"></a><a id="Tc_oUuRv_nmRUKrreD8zZh_Jw_2_2"></a><a id="Tc_t11266UlqE26Zg5BQOOpLA_2_5"></a><a id="Tc_tfZlLEF9H06n2cFBuHVDYw_3_0"></a><a id="Tc_EwgYmBTa6EiWd8Gaf1zf6g_3_2"></a><a id="Tc_JOJPj7pgT0SF6TuOxE2IzA_3_5"></a><a id="Tc_dDFFcRT9gkCFT4L-h4zPvA_4_0"></a><a id="Tc_XryefYlcrE-O9Ri9Hc-X0w_5_2"></a><a id="Tc_LEvc-zs6YUGEMurlSYzQvw_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_X77N6dq6OUS5lSGvtS6Klw" continuedAt="Tb_X77N6dq6OUS5lSGvtS6Klw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The significant accounting policies used in preparation of the unaudited consolidated financial statements are described in the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K. There have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_4YaMHGh9y0GsQeFYd0wb3w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="Tb_-Js0v2Wy_kWLNev0n67lHw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_tCeRyyEYcEyNusdua4Z4iQ_3_3">76,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_6g7fsDaO60utNYqqH5917Q_3_6">67,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_CMGRe1dt1Uy1JXO7v-64_Q_4_3">2,407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_5ZfdX5cVh02kfhUQjASuWA_4_6">2,612</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_gmFqKBp__U6lijGdNiMh_g_5_3">78,798</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_C7JY0igZ20aA4FD_Jtx_nw_5_6">70,210</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="srrk:UnauditedInterimFinancialInformationPolicyTextBlock" id="Tb_3LBjYVVr_UC2bkBnxFqeYA" continuedAt="Tb_3LBjYVVr_UC2bkBnxFqeYA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Unaudited Interim Financial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The consolidated financial statements of the Company included herein have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). The unaudited consolidated financial statements include the accounts of Scholar Rock Holding Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of </p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_X77N6dq6OUS5lSGvtS6Klw_cont1" continuedAt="Tb_X77N6dq6OUS5lSGvtS6Klw_cont2"><ix:continuation id="Tb_3LBjYVVr_UC2bkBnxFqeYA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full&#160;year or any other interim period.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:UseOfEstimates" id="Tb_oYIUK5IHukWvkGbVi4WWuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_aTRcN05lUEmMuKVeGQktdw" continuedAt="Tb_aTRcN05lUEmMuKVeGQktdw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;)</i>. The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under previous GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. In November 2019, the FASB deferred the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. Therefore, the new standard was effective for the Company on January 1, 2023. The Company established processes and internal controls to comply with the new credit loss standard and related disclosure requirements. The Company&#8217;s investment policy has primary objectives of preservation of capital and maintenance of liquidity. As a result, the Company typically invests in money market funds, U.S. treasury obligations and government agency securities. The Company believes that such funds are subject to minimal credit risk. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these investments. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued Accounting Standards Update 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2017-07&#8221;). The standard requires disclosure of incremental segment information on an annual and interim basis and allows for multiple measures of a segment&#8217;s profit or loss provided that one of those measures is consistent with GAAP. The amendments in this update do not change how a public company identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments, but rather requires public entities to provide in interim periods all disclosures about a reporting segment&#8217;s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for interim periods starting on January 1, 2025. The option for early adoption is permitted, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures in future years as a result of the adoption of ASU 2023-07.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2023, the FASB issued Accounting Standards Update 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(&#8220;ASU 2023-09&#8221;), which enhances the transparency of income tax disclosures to provide information to investors to better assess how a company&#8217;s operations and related tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This requires public entities to disclose additional categories in the rate reconciliation regarding federal and state income taxes, and provide more details surrounding reconciling items if a quantitative threshold is met. The effective date for public companies is for annual periods starting on January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_X77N6dq6OUS5lSGvtS6Klw_cont2"><ix:continuation id="Tb_aTRcN05lUEmMuKVeGQktdw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">available for issuance, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures will be in future years as a result of the adoption of ASU 2023-09.</p></ix:continuation></ix:continuation><a id="_fa452aa1_311d_4752_b6f0_9bb567e71197"></a><a id="Tc_cHZ8n8btLUi6KtGgC-n7hg_1_2"></a><a id="Tc_bC4yLPJ_P0KZy9n8JJZNiw_2_2"></a><a id="Tc_TBEgpX3qf0WPpS2K8vSKDw_2_5"></a><a id="Tc_gl56QePM7EWDT3q1iczD3A_2_8"></a><a id="Tc_rfPb3oE-sk-uC22fPZKuqA_2_11"></a><a id="Tc_mBAlPEdHbEu6ViNAr-0ZPA_3_0"></a><a id="Tc_Ejpw26XXCkW5E8S6MtOSiQ_4_0"></a><a id="Tc_O5lo9TFD3k-tn4ccpUITEQ_4_2"></a><a id="Tc_Y70KntjxcUGsh9u7hFDZHg_4_5"></a><a id="Tc_AEvreUyvRUmEk6KJSSkEOg_4_8"></a><a id="Tc_pTcrAREyW0-3ylwmyVJYkw_4_9"></a><a id="Tc_G8Muh2GmDkaAAOs5UYp8CA_4_11"></a><a id="Tc_T0GdLavlkk-I38GWdunmvQ_4_12"></a><a id="Tc_q1N5NhVmiUeVZqkPbNp1Qw_5_0"></a><a id="Tc_JzgUs1XXwUGWGPxuwN08bw_5_3"></a><a id="Tc_PdL2HE3-S0md875t3oZxSw_5_6"></a><a id="Tc_cUCXMOpZ_k2MIP-YIZEFOg_5_9"></a><a id="Tc_P_LjE2qErkiyR4ue2Ne1eA_5_12"></a><a id="Tc_uYhcmnhEu02kKEojiFH03Q_6_0"></a><a id="Tc_TML5zZvx50WCGDpGup-pyA_7_0"></a><a id="Tc__n01wNi5d0yCmVA8QcaCzg_7_9"></a><a id="Tc_vRo2qbAn6Uub_WakMZs9_w_7_12"></a><a id="Tc_NPc1-5aG_0WONlkaURBL1A_8_0"></a><a id="Tc_RgbbsUOOvk-85JGkrQls9A_8_2"></a><a id="Tc_7sjCwfVpcEy3yMHPpJ08kQ_8_5"></a><a id="Tc_22M_nCIKGEm4G0MPz_W02g_8_8"></a><a id="Tc_zEsSOnUrWkuffhPdfizFlw_8_9"></a><a id="Tc_VTVUJ1P9SU2-IaDltqbRFQ_8_11"></a><a id="Tc_up2ysw7alEiVKH5FViM1Qw_8_12"></a><a id="_2ad706e3_5f4a_4555_b3ad_fbcbd48b84fb"></a><a id="Tc_96q7WO01BkWhJhMZamxL1Q_1_2"></a><a id="Tc_4XGgQu34VUeqf7h8-QbDHw_2_2"></a><a id="Tc_uvOsZ9ks6kmacgoHHm0SPg_2_5"></a><a id="Tc_C1pvWXTqlUS2QhImhZfK4A_2_8"></a><a id="Tc_tahMhoWqJU26eNWl9b2QnA_2_11"></a><a id="Tc_FYmaLf-_UU6C0CjNWWLAJg_3_0"></a><a id="Tc_oHIgsxAyOkSkCjaB3uD3FQ_4_0"></a><a id="Tc_-kSx_5NuZEymwuTzSdE8IA_4_2"></a><a id="Tc_td1ToBdqwkG2vCBw7xpI_Q_4_5"></a><a id="Tc_IGFGn8sC2UaP6vw05dhTYQ_4_8"></a><a id="Tc_vLwmEo-CZUK8Q0i1sWcg1Q_4_9"></a><a id="Tc_qU-XSsKzkkG_0Oemrq4mcQ_4_11"></a><a id="Tc_jXXSfesQ0EKjKj7QEeZdyQ_4_12"></a><a id="Tc_QMpD4WEOX0-EtW_Up2Agpw_5_0"></a><a id="Tc_WrQ3vdZcOkGDk82wUHmKFA_5_9"></a><a id="Tc_3ul9ofRAGUamSHoDNIK5zA_5_12"></a><a id="Tc_3WbrdmuAvki0VQkTXQYamw_6_0"></a><a id="Tc_Q21RIzkPvE-ux2Zag2cqgQ_7_0"></a><a id="Tc_I58w3Uq5dUmja2fFYaEEfA_7_9"></a><a id="Tc_ymR2Gd2-tEaib_rD2QLx1w_7_12"></a><a id="Tc_RGxPX9rVI0C_uZVH_aycLw_8_0"></a><a id="Tc_FevIwKAfW0y45PV7t3JFog_8_2"></a><a id="Tc_27-usT1xC0ypPpcYS5ARtA_8_5"></a><a id="Tc_CALDZxBvikmu1P_KVndaIQ_8_8"></a><a id="Tc_hB3cTnmfQ0-X842WeTQu1w_8_9"></a><a id="Tc_1a7AtE7IxU-hHDAAlE_cGA_8_11"></a><a id="Tc_bBsXDl17uk2j9Z6V4Bmvvw_8_12"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_Xgh4kvoC9UmGLdWKGr9bcw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3. Fair Value of Financial Assets and Liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_a1G8q32c4key0JtyZFT7aw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following tables summarize the assets and liabilities measured at fair value on a recurring basis at September 30, 2024 and December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EGRmdupzaUKG_rn7xck0fA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_xNweEOUWBkSDBVonOk-KTw_4_3">70,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hWuMG1NhkkW9bHAcUgbYxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_DDUgltefi0-lkcHJZW2T4Q_4_6">70,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. treasury obligations, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yUXtseVKLEmLijTO5Hn_0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_uHmo0FFmUkGmewPLjdXkPg_7_3">62,674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_UlyEzRV6tEm11MvO7uPFnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_FuDO9WOaI0ufBpNmsAdcPQ_7_6">62,674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yUXtseVKLEmLijTO5Hn_0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_bia7kvdPj0iNywIsMqW-UQ_8_3">133,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_UlyEzRV6tEm11MvO7uPFnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_JD3aLsrypU-Iuw4770urjw_8_6">133,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XZbR-apKpk2fl7Q5s_WQGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_yeUwVcTqdkiOv349kuf04w_4_3">61,764</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_GRQncXuqCk6pkM25ZxfA6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_MguCRfxrOUOyhkWq1uPJ4A_4_6">61,764</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. treasury obligations, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Q37l2topEU2AU5wm5NYCjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_zWfsLY64g0WzskOnrLsEhw_5_3">30,765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lH_pD1wqKE-js0Bu3cDiQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_YfTNxjJqdkORA6WN6A_1Jg_5_6">30,765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bwusGcH5nkSqDzdmdcCglA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_fvG2lfxP7kKqLGBfsTqUwA_7_3">178,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hZuVKm_vv0uSY2YRXuVk-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_o5extafPQEeAT_-uCTjvmQ_7_6">178,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bwusGcH5nkSqDzdmdcCglA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_u1WQccpCQ0unE_zDWYEUNw_8_3">270,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hZuVKm_vv0uSY2YRXuVk-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Z8BVcGVuIUS2-SkA_f_3Cg_8_6">270,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cash, cash equivalents and marketable securities are Level 1 assets and include investments in money market funds and U.S. treasury obligations and government agency securities that are valued using quoted market prices. Accordingly, money market funds and government funds are categorized as Level 1 as of September 30, 2024 and December 31, 2023. There were no transfers of assets between fair value measurement levels during the nine months ended September 30, 2024 or 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The carrying amounts reflected in the balance sheets for prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values at September 30, 2024 and December 31, 2023, due to their short-term nature. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company believes the terms of its debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company's debt approximates its fair value based on Level 3 of the fair value hierarchy.</p></ix:nonNumeric><a id="_e75806d0_cbaf_43c1_aec5_195c9da6ef45"></a><a id="Tc_ix6zeIhdMk6M0jkzHG8ykw_1_5"></a><a id="Tc_7KCvQAspxEatexbhGksteQ_2_2"></a><a id="Tc_lKkqg0l6QkWhsyTfEqGcAQ_2_5"></a><a id="Tc_dSlxSwpseUmW3OWHvvbrYg_2_11"></a><a id="Tc_591f9tjHA0Ki-3QSEJqbiw_3_2"></a><a id="Tc_YhOlath1HECHlSabtVKRAA_3_5"></a><a id="Tc_mp35OfXuo0CYgW6AZnJamg_3_8"></a><a id="Tc_Oy0JQCwPp0O2EtjLqMw1zg_3_11"></a><a id="Tc_NZEsRxnu6Uy8ALnyzdzmWQ_4_0"></a><a id="Tc_UgZvKfmY2UyFw0wU5OJ_zw_5_0"></a><a id="Tc_tY0qOfMv90-75z6QV7gjUw_5_2"></a><a id="Tc_W6U4ldvx40eTPVWxUPNWAw_5_5"></a><a id="Tc_FLVZNP1RWk2-rQ6KeMfong_5_8"></a><a id="Tc_bvhmCC1MKkCpImYqijfTfA_5_9"></a><a id="Tc_IXwYHDQ4BEWHiXp0OrCI6Q_5_11"></a><a id="Tc_7FSw1htz9U-Bd389ttJpdQ_6_0"></a><a id="Tc_C8OFyftHt0qbaEBmzcKzMQ_6_2"></a><a id="Tc_VHExl1la7E2zvZTlT-thPw_6_5"></a><a id="Tc_ypXdShAarUSn9GU5tWpapg_6_8"></a><a id="Tc_svg_HszyA0eh5Sd9KYzg2w_6_9"></a><a id="Tc_w_DBjf8NjECYSZ1Bbxj3Qg_6_11"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Tb_484aDjRuY0KF942UF-uWgw" continuedAt="Tb_484aDjRuY0KF942UF-uWgw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4. Marketable Securities</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:MarketableSecuritiesTextBlock" id="Tb_46xnc-PKAUSD3hA5_Pjo1g" continuedAt="Tb_46xnc-PKAUSD3hA5_Pjo1g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s investments as of September 30, 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities available-for-sale:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-T623QZuKkiWEpLOpPmaJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_U7xkhfuYeEqZG5Ws9Vt0vw_5_3">62,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-T623QZuKkiWEpLOpPmaJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_fwCagkIeZkSXfKUcIlZFOQ_5_6">128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-T623QZuKkiWEpLOpPmaJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_6k4ookz-2U6mtKP_HY5J_Q_5_12">62,674</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total available-for-sale securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_rbb427Nl2UiBsZWl3G_-1w_6_3">62,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_60zC2jATpE6jKxDulEmgsA_6_6">128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_3ng8GuWzZEqck9Syd8Y7-Q_6_12">62,674</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_aa4618fe_2958_4d83_93ca_82cd2ad3ab59"></a><a id="Tc_NlfzDcOKBkSwFGb37r-miA_1_5"></a><a id="Tc_yG-fj0s8i0ChoDr7gF1Ncw_2_2"></a><a id="Tc_gLMrjMu6UEScSRDJGCRDJQ_2_5"></a><a id="Tc_4lBfCsjP-0urV6f5-8s4rw_2_11"></a><a id="Tc_Tu_oH99_4keSBn1EIkv4WA_3_2"></a><a id="Tc_lXi825gubEaFF-OZ_4TVOQ_3_5"></a><a id="Tc_fMvPevoXq0G2QRo4Izb4KQ_3_8"></a><a id="Tc_iWBDU3tcG0CQgRhWMxEc4g_3_11"></a><a id="Tc_JwzxvsGI90yAOIu8Cr34fg_4_0"></a><a id="Tc_asudlGxZd02cjqibTzRGOw_5_0"></a><a id="Tc_b2nOBROzzUacFMXU0zdG8g_5_2"></a><a id="Tc_lXGZSOcLek-ZNb5J0Nb0tA_5_5"></a><a id="Tc_t9zc0uHh40yYaUHup6MzEQ_5_8"></a><a id="Tc_LqO_Lfr_MEOpXFM27vvP-A_5_11"></a><a id="Tc_5taN0NjQPU2Llj2obhwFgQ_6_0"></a><a id="Tc_U4p_xZ-HPEK78FK38x2jZg_6_2"></a><a id="Tc_dBYp6QMxY0220iY_QGkqcA_6_5"></a><a id="Tc_NmDLYshYr0K7aT6_qxgz2w_6_8"></a><a id="Tc_cEHTKR8zkUCJUGCN3cUt9Q_6_11"></a><ix:continuation id="Tb_484aDjRuY0KF942UF-uWgw_cont1"><ix:continuation id="Tb_46xnc-PKAUSD3hA5_Pjo1g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s investments as of December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities available-for-sale:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_kZda-3Zt-kGSsr8DQ7g3kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_rry9pTJ11EKkDTAya3nAcQ_5_3">177,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_kZda-3Zt-kGSsr8DQ7g3kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_VCNuq3iQXEiaH8RzvjNFXg_5_6">93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_kZda-3Zt-kGSsr8DQ7g3kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_KehFgBVKr0WKN0UlXQv32g_5_9">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_kZda-3Zt-kGSsr8DQ7g3kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_q-o9hbW8pkiVJNJiUaUwPA_5_12">178,083</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total available-for-sale securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_1Cri8kYwXkWoLQzLmd6OHg_6_3">177,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_yjG-KXxackGhO-BK89CrDA_6_6">93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_jTIGmqaxcka1YNCic3KyVA_6_9">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_TSjBZITJvUGK31PI0VyL8w_6_12">178,083</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The aggregate fair value of marketable securities with unrealized losses was $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="Narr_dDSkxqnyPUarEEozXhRpvw">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="Narr_ZCPONvPq_ES0zmfqdhIqvQ">11.9</ix:nonFraction>&#160;million at September 30, 2024 and December 31, 2023, respectively.<b style="font-weight:bold;">&#160;</b>At September 30, 2024 and December 31, 2023, <ix:nonFraction unitRef="Unit_Standard_security_rO9x9MuL10eAmA3nIFOJ7w" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="Narr_a3Kv-T5NbEmYjjNdj-V5aw">no</ix:nonFraction> investments and&#160;<ix:nonFraction unitRef="Unit_Standard_security_rO9x9MuL10eAmA3nIFOJ7w" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="Narr_VlPq76lFNEe_80apL_GB3A">three</ix:nonFraction>&#160;investments, respectively, were in an unrealized loss position. All such investments have been in an unrealized loss position for less than a&#160;year and these losses are considered temporary. The Company has the ability and intent to hold these investments until a recovery of their amortized cost, which may not occur until maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company believes that U.S. treasury obligations and government agency securities are subject to minimal credit risk. As a result, the Company did not record any charges for credit-related impairments for its available-for-sale securities for the nine months ended September 30, 2024.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dae0be15_03da_4114_bff2_04d0bb2d77db"></a><a id="Tc_pmxHJzcZm0GTZioeCXRkFg_1_2"></a><a id="Tc_H8GsifcYDE6TkVT-9tTmCw_2_2"></a><a id="Tc_P3kX_K_SwkOeXl3vU4co_Q_2_5"></a><a id="Tc_sFnFh7sE402mDn3rqXVkOA_3_2"></a><a id="Tc_wnFRfCaqykOQwUKnLuUmPA_3_5"></a><a id="Tc_J1M9M7v0XUSTfRPet-H1ag_4_0"></a><a id="Tc___IfrChs1UWcI47ZqRYBTw_4_2"></a><a id="Tc_W8FnE1tJZUaNzfxSHJO2fw_4_5"></a><a id="Tc_DDnv21ebe0S4Vg0xEPzwbw_5_0"></a><a id="Tc_rG5LRj_wlUCM2ST7SB1IvQ_6_0"></a><a id="Tc_XfKFUMJOpkGk2KtjuglXnw_7_0"></a><a id="Tc_BFoGFaBjL0e8Jwtql8uaZg_8_0"></a><a id="Tc_hwXwwj807UiXtqnFGVGotw_9_2"></a><a id="Tc_f_AUQjAO2kS6BvlotZI-IQ_9_5"></a><a id="_0e4bb7db_13e3_4e81_8ac9_14d17cf8158c"></a><a id="Tc_RlJDBinQYkuvfpcYN6tEBA_1_2"></a><a id="Tc_DdnTCwknakynDY3iHSxz6A_2_2"></a><a id="Tc_-WdGbui4Zk6A0WhrU1MzBw_2_5"></a><a id="Tc_htLPhq-mVk2XnOJrfwjVbw_3_2"></a><a id="Tc_ANYA7vsPiEupaDUQUJUVIA_3_5"></a><a id="Tc_sRn0qVgQB0qfBn4mYXZlCw_4_0"></a><a id="Tc_ukjv3CYBLUmhxmagWIouIg_4_2"></a><a id="Tc_RlQ5uKBBOkWnw5DZnuvNVA_4_5"></a><a id="Tc_LL_GQP-RFEaOK722HnjZOQ_5_0"></a><a id="Tc_kq3Abb6lokOiJnc7-l9ZHQ_6_0"></a><a id="Tc_6c2CwIZiSUK0MrLpusDSow_7_2"></a><a id="Tc_AasqSLnFhE2wWZPkArKkJQ_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:OtherAssetsDisclosureTextBlock" id="Tb_OypBWcDhLkKvRiwqZtizvg" continuedAt="Tb_OypBWcDhLkKvRiwqZtizvg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5. Prepaid Expenses and other Assets</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="Tb_-Q6X0GopKE6QqWAAXrvhaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024 and December 31, 2023, prepaid expenses and other assets consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="srrk:PrepaidExternalResearchAndDevelopmentExpenseCurrent" scale="3" id="Tc_jiRnK4nLXkqeMUpoheobIA_4_3">8,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="srrk:PrepaidExternalResearchAndDevelopmentExpenseCurrent" scale="3" id="Tc_liB0dIGSMk-SMnK0jgZI6g_4_6">4,059</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_fN6Fj2-IzkKqHTx7-ErCAg_5_3">2,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_RYFbpj2ex0y2wX7sO0Sa0w_5_6">2,281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NontradeReceivablesCurrent" scale="3" id="Tc_hAAjpFzGDUev4Q4SEGs5zQ_6_3">1,120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NontradeReceivablesCurrent" scale="3" id="Tc_i39e8CNmv06qDUm30hbq5g_6_6">1,076</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_PVDgQZEjdkOiWpJ6bHroFA_7_3">739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_vTnbbwTAZkG3boJ7No6N7w_7_6">635</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid professional and consulting expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="srrk:PrepaidProfessionalConsulting" scale="3" id="Tc_APpkCpnuoUyOKOMZBc7EOA_8_3">421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="srrk:PrepaidProfessionalConsulting" scale="3" id="Tc_ibhhuzc6DU6t6TFoA-B7YQ_8_6">205</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_zJrSbjTHQEKLw-NKIRZ0sA_9_3">13,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_zEYdBla9J0maVriByu2_RQ_9_6">8,256</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024 and December 31, 2023, other long-term assets consist of the following (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" id="Tb_ff4EBxiZd0SM2dfBgUpQ6g" continuedAt="Tb_ff4EBxiZd0SM2dfBgUpQ6g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="srrk:PrepaidExternalResearchAndDevelopmentExpenseNoncurrent" scale="3" id="Tc_kjKWIgfPoECa-isaUBkTow_4_3">3,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="srrk:PrepaidExternalResearchAndDevelopmentExpenseNoncurrent" scale="3" id="Tc_SDmAPbtWMkmHxUCtyC1v_g_4_6">4,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="3" id="Tc_HsKPVu8kTkqNSj40Rt1BJA_5_3">394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="3" id="Tc_Ke8C9-vIUEavLudjvllvOQ_5_6">312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="srrk:PrepaidInsuranceNoncurrent" scale="3" id="Tc_hecNQgYs_0-b1TmZ1Px2_Q_6_3">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="srrk:PrepaidInsuranceNoncurrent" scale="3" id="Tc_kw_ydhR4jEaYQKWxU7ClwA_6_6">31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_Lrl-uc9AaUCLjrsbUdpwAQ_7_3">3,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_vA3JBiH9IUiPcHv7Wfzj9w_7_6">4,417</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_OypBWcDhLkKvRiwqZtizvg_cont1"><ix:continuation id="Tb_ff4EBxiZd0SM2dfBgUpQ6g_cont1"></ix:continuation></ix:continuation><a id="_2c3265a2_923d_4efe_b32f_93c93d0f9f44"></a><a id="Tc_Q0NEswubwUuRbBIQgxachg_1_2"></a><a id="Tc_NWXK8xu_bEebWYjZcEi-Iw_2_2"></a><a id="Tc_LhFzRKImj0mwDAzjvNRM1g_2_5"></a><a id="Tc_FbhmkJYkIUmY2SOWKhMlDg_3_2"></a><a id="Tc_OK9CjMrteE23PGG4Fe7uTQ_3_5"></a><a id="Tc_ymoqTAGGNE6feogOGpstug_4_0"></a><a id="Tc_lPsb9kN-pEWEJVGAI8j8Xg_4_2"></a><a id="Tc_tY98jdOwlE63DYZIchlq_g_4_5"></a><a id="Tc_cwRsjgvnf0aNqEE9VfS5uw_5_0"></a><a id="Tc_sN5vKqdBEEC5_Fw0bD0ixw_6_0"></a><a id="Tc_ago_-kMZCkegi02IGW15Aw_7_0"></a><a id="Tc_9lgxz777jUmaC1EOU9sFmA_8_2"></a><a id="Tc_KsJytwkKt0epftQgnYD_ag_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_lH_ltnWjvUqC6ZE0Uy32YQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">6. Accrued Expenses</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_UL0zi7SQTk-L5SxY4VoQyw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024 and December 31, 2023, accrued expenses consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="srrk:AccruedExternalResearchAndDevelopmentExpense" scale="3" id="Tc_O44VDFXb1UqI_QXVNoqbMQ_4_3">15,040</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="srrk:AccruedExternalResearchAndDevelopmentExpense" scale="3" id="Tc_T7nlgwPMMUKNrOo5waRtEQ_4_6">6,825</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_mJBk3CwLO0GdUW6wi0M1Tw_5_3">9,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_4BZgX0uQzU6jNddOamJznQ_5_6">10,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and consulting expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_P2JO7OBtXUacxQtNlQdnWQ_6_3">3,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_OGpz7tYYrUabNIiYPKRJ_w_6_6">2,267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_G8dSV2zww06c4ufEcVCl-w_7_3">831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_4YaSXxzh4kCIGYVN8p4vug_7_6">766</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_ggdYedFo5UOeQJf0FcpTFg_8_3">29,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_qPW8gD7F1k610r9UuhHVWQ_8_6">20,449</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="srrk:CommonStockTextBlock" id="Tb_97XuC2aL30iSR0mJDVKgvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">7. Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">In June 2024, the stockholders approved an amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of common stock from </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_5_31_2024_5P3UGITXB0-czc9H0PmBtw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_IcX-COeQPkW6m8_gMyqrGg">150,000,000</ix:nonFraction></span><span style="background:#ffffff;"> to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_6_30_2024_74qePC5v6kCjrygaeq4KKQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_kRAMv-JZ5kW12HQg65Wkog">300,000,000</ix:nonFraction></span><span style="background:#ffffff;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The Company has had a sales agreement in place during various time periods with Jefferies LLC with respect to an at-the-market (&#8220;ATM&#8221;) offering program. Under this program, the Company is able to offer and sell, from time to time at its sole discretion, shares of its common stock through Jefferies as its sales agent. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. The current ATM agreement, established in November 2022, allows for the sale of shares of common stock having an aggregate offering price of up to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_11_30_2022_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_BxOz9tF8aU6Z0utpswOoRQ" decimals="-6" format="ixt:numdotdecimal" name="srrk:MaximumAggregateOfferingPrice" scale="6" id="Narr_--j9cESPJU-uRO6Jt1xocw">100</ix:nonFraction></span><span style="background:#ffffff;"> million. As of September 30, 2024, the Company has sold </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_srt_StatementScenarioAxis_srrk_AggregateMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_ya99nBLVs0yCCbyZ5u51EA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_t3SlQ21_0E-sbIONbb5qlQ">619,290</ix:nonFraction></span><span style="background:#ffffff;"> shares, generating net proceeds of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_srt_StatementScenarioAxis_srrk_AggregateMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_ya99nBLVs0yCCbyZ5u51EA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_OpAy6NaNWE28PDRniwagig">5.2</ix:nonFraction></span><span style="background:#ffffff;"> million, under the ATM program. </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_7FmVsKFVF0aJhLlDxLXyug" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_EfhD2G57b0OgxDjBZOZZqw">No</ix:nonFraction></span><span style="background:#ffffff;"> sales were made under the ATM program during the nine months ended September 30, 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">The Company has issued pre-funded warrants, as well as warrants as part of its financing activities. Both the pre-funded warrants and warrants meet the conditions for equity classification and are recorded as a component of stockholders&#8217; equity within additional paid-in capital. In June 2022 and November 2020, the Company issued </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_PTkW0Ae7q0-gfeY7Vb1FxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_CQBvO21h8kaaY2vqmjuBEw">25,510,205</ix:nonFraction></span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_11_30_2020_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_WrTjGUDWz0OGm3OPxFpVKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_69j8mpIZCEynOtIjpW7X3Q">2,179,487</ix:nonFraction></span><span style="background:#ffffff;"> pre-funded warrants, respectively. During the nine months ended September 30, 2024, </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_SZALhDjjmEyPmtlfB7lZaA" decimals="0" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Narr_PiOAB0HGK02EFJaJPYC44Q">2,526,833</ix:nonFraction></span><span style="background:#ffffff;"> of the Company&#8217;s pre-funded warrants were exercised. As of September 30, 2024, the Company has </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_n9DGS8M0kE24zj_oklD1kA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_kGmec1MG9kiATyH1jso99Q">17,008,164</ix:nonFraction></span><span style="background:#ffffff;"> pre-funded warrants outstanding. In June 2022, the Company also issued </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_-E3ijiIBr06-jKD1_9WN-w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_g4pmrNcI4ky_ZBDvZ_A_Sg">10,459,181</ix:nonFraction></span><span style="background:#ffffff;"> warrants with an exercise price of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_-E3ijiIBr06-jKD1_9WN-w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_j4nrpTcnHEuGR3Ppwp2L-A">7.35</ix:nonFraction></span><span style="background:#ffffff;">. During the nine months ended September 30, 2024, </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_UUZbJLH39kSS8xaTMnAraA" decimals="0" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Narr_UIehXepqUUuubt-8D4ZiMQ">830,660</ix:nonFraction></span><span style="background:#ffffff;"> of the Company&#8217;s warrants were exercised. As of September 30, 2024, the Company has </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_6NJQiQ1vPEGInMGw0DCVKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_t8EJ3cbTcUmMy2Jddv_P-Q">9,157,496</ix:nonFraction></span><span style="background:#ffffff;"> warrants outstanding.</span> <span style="background:#ffffff;">In October 2024, the Company issued pre-funded warrants to purchase up to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_iFj3QnQzOU-8kQacFHjl3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_9nDvZKRSaEqX3ueFky4m2w">353,983</ix:nonFraction></span><span style="background:#ffffff;"> shares of common stock (see Note 12).</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_571de1ae_36e3_409e_8eef_53bb00de5b47"></a><a id="Tc_YIDsXOzEJkagOupuTbxLlA_1_2"></a><a id="Tc_bfymF-WaOkCHYcFHIuBK1Q_1_8"></a><a id="Tc_hIHK2ekE202QWTrcRiOjWw_2_2"></a><a id="Tc_oWCQnh7_s0yz1NDtczvR8A_2_8"></a><a id="Tc__GWZ6DjaY0qfYcEAb4IH4A_3_2"></a><a id="Tc_Cy_Aip83Nk6rdf3rMnPJYA_3_5"></a><a id="Tc_902rRdXMOkmB2xUglFlWww_3_8"></a><a id="Tc_9XR9Kyg_bEyuITIMITMHMg_3_11"></a><a id="Tc_cXE-ZUJUm0e85pfBrusjlg_4_0"></a><a id="Tc_r2ePzTDDAE6SbFLS8lS_hQ_4_2"></a><a id="Tc_GubGdUeOeEu0ebA6s-sozQ_4_5"></a><a id="Tc_6AkXuynpREuUy85Pv5rr1Q_4_8"></a><a id="Tc_1j0cgjaoq0Kn-QAdW47A7w_4_11"></a><a id="Tc_tVZ8HoGrpUqS16RmjMyoyA_5_0"></a><a id="Tc_O-fdCLKAmE2mDFLbJ33Xew_6_2"></a><a id="Tc_mkXWIf7Ea0mxlxSxuSAWlg_6_5"></a><a id="Tc_NKerXAeruE-XoNX93CaVHw_6_8"></a><a id="Tc_EpdwITEyJkqBpjLTJvQMyQ_6_11"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_8FMqKwIHEku1QqhjVQ3ItA" continuedAt="Tb_8FMqKwIHEku1QqhjVQ3ItA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">8. Equity-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The Company recorded equity-based compensation expense related to all equity-based awards, which was allocated as follows in the consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023 (in thousands):</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_We1Ke25piEuM63WZaJ0VQg" continuedAt="Tb_We1Ke25piEuM63WZaJ0VQg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.38%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_sX3h_3P7vU628onpj2CP_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_EkR4EAIdSU2bVJDrbx-V9w_4_3">4,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WYPheoLxHESQikinAnOQbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_U-RnaNZbg0KpB0BfqVoWzw_4_6">2,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0rdTgvAQZ0SGGGDzlLKrng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Q4gruLtBSECtKywiD8Z6fg_4_9">11,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_EyntDTnzGkKhLJiLcViJlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Ndy_w0DgHkeBVs3ewyen7g_4_12">8,341</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_33ZytFP8IkiHsYntj3TCwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_gLtiCKZMuEuW-dSsyGgkzg_5_3">5,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZscaUP5tbkyTvjREC97cOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XC-NtBAwd0Gjjs8ILbLNvg_5_6">4,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ephi9PPE4Em6WeJ6Tatiiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4kDEx55wxUGR1OB8TzgPQg_5_9">15,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3cefOggcskeAM_epSw3VaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_YwYsSWvWeUiFiCHegZqQWA_5_12">11,850</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_RfEh8WWlcEyN0Nv3SYJJ8g_6_3">9,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ojkFqPQWiEOJeB0lSujwEQ_6_6">7,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_AM94MF5Qu0ikEHQ4cUwo8A_6_9">27,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_n--9zEllbkiNw6STsJJwEw_6_12">20,191</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_fK1UGQnWQUeaQdoAKGKeXQ_2_1"></a><a id="Tc_VSTCLf5q4Eev64y4GdSvMw_3_2"></a><a id="Tc_bl3sRnp2Bk6k0yCnI2IpnQ_3_4"></a><a id="Tc_wYXdap_PckSUOqzi6vTnUA_4_0"></a><a id="Tc_d1HGzisPfEGFRihXiUqyZA_4_1"></a><a id="Tc_qb2LTgr1a0axqNZINA3jyg_5_0"></a><a id="Tc_zwB-FWZ3PkW54K_V3jSNPw_6_1"></a><a id="Tc_ryAxgzmAckW0kV2fda9ZsA_1_4"></a><a id="Tc_u_qMhuUow0ad_zEIlUKvtQ_2_4"></a><a id="Tc_CpnL6MqMR06oCSA5NP0Maw_3_2"></a><a id="Tc_Yrc5D_NeJ0iL5E-agfDqaQ_3_4"></a><a id="Tc_qXWLS6Y8GEyKH2ZgNos1WQ_4_0"></a><a id="Tc_uUOWjEIA0EyT1YyFhMJdYQ_4_4"></a><a id="Tc_VM0spJoXv0yP7ERh59rfxA_5_0"></a><a id="Tc_bJ7hDyJmdUiwAzSfc2ApUw_5_4"></a><a id="Tc_UqOHksYBtk2PWvMXI4fHoQ_6_0"></a><a id="Tc_2UHUeJZUMUSWDLcNJ5fEaA_6_4"></a><a id="Tc_f22JBJ3iVk2d9XHcmSk_cw_7_0"></a><a id="Tc_nnd1PJ_y4ECl3pSS0fktVw_7_4"></a><a id="Tc_kH42Wlk74kO9o81NsrG_lw_8_0"></a><a id="Tc_QopyA4oVTkWzweHaQBPYng_8_4"></a><a id="Tc_AKx_j3Gs3E-ugnHzDqlteg_1_7"></a><a id="Tc_kWgJHm9Vjkm4vtpm6SNuiw_2_4"></a><a id="Tc_Qh2uWbB_S0CyhQqnsjm8-A_2_7"></a><a id="Tc_PAZReZ03t0mBNITDzm3qKQ_3_2"></a><a id="Tc_WZJSaskywEyBQB3p8Eg25A_3_4"></a><a id="Tc_e0lWSE7ewEe_rH3Ll2bFig_3_7"></a><a id="Tc_3n2cQToMh0SL0xKwHhwX1A_3_9"></a><a id="Tc_xFOAHDVDb0usn0JIBj2mpQ_4_2"></a><a id="Tc_sx7Il6NoYUmZ481I1c9Ypg_4_4"></a><a id="Tc_lTNeWOYOqk2F_zJAEmd5gA_4_7"></a><a id="Tc_uRF8alDF1E2_PoA2r6Y7rg_4_9"></a><a id="Tc_VdK5y-0rQEG6iXFpY_bLOQ_5_7"></a><a id="Tc_jjKNVxoB_06hYyl9wNr2bA_5_9"></a><a id="Tc_Oj6d6vTYI0iefAhB0ilkBA_6_0"></a><a id="Tc_Jjc3unJzvkemtD6bDxn7VQ_6_4"></a><a id="Tc_pD-M0-dyJ0moW9Pe5Vw68w_6_9"></a><a id="Tc_YFklZ3ruMEKH-JLAVxlaeA_7_0"></a><a id="Tc_HwbXCH_ZwUm7RdsYf0oMzA_7_4"></a><a id="Tc_zyKV9Jw5zUyxcvysFAIIzA_8_0"></a><a id="Tc_qrBMSua5tUCOKbHv9vJKNw_8_4"></a><a id="Tc_Hps5OxMLy0qkua2IRDImDg_9_0"></a><a id="Tc_JRv8g_hZC0ObkKMG7CG-vQ_9_4"></a><a id="Tc_MFv4r6k9H0aQOP6Y3X_DNQ_10_0"></a><a id="Tc_HrAoZcu4YkiulzA1JBT-sA_10_4"></a><a id="Tc_Kd4EjI3LdEurDllyNxY6Tw_10_9"></a><a id="Tc_pVFSjvFQbkWg-G85P76pcg_11_0"></a><a id="Tc_MBHqQRJI6EK8f_acHHmAfQ_11_4"></a><a id="Tc_C2bysDskhEy7LFYn43rQOQ_11_9"></a><a id="Tc_xu80-s0U0EqClV_pmJ__QQ_1_1"></a><a id="Tc_uMvUwX28ckWi7Lts6zlKnA_2_1"></a><a id="Tc_i7OtmLmoaEuiZER_0DGxUw_3_1"></a><a id="Tc_zsighGk4ZUetghXIcfVipQ_3_3"></a><a id="Tc_xVGoymqma0Ci_AvJwuhvRw_4_0"></a><a id="Tc_OeqhaOcPbECOnoMEK76LJw_4_2"></a><a id="Tc_ExCw0YI9N0m1OZmAGHxdrw_4_4"></a><a id="Tc_Y7Q5c9T_iEWjnLMBXCEaFA_5_0"></a><a id="Tc_21pJhS5UKUiLmNeG53igvA_5_2"></a><a id="Tc_Lhl5LI2MfkmZfCwOVviQfA_5_4"></a><a id="Tc_JCFjEBmXH0Cfn_MB-lHr5w_6_0"></a><a id="Tc_10DGlFirZU-aRcDtDe-agQ_7_0"></a><a id="Tc_iSG6VCQSNUi__k6eto6Fow_7_2"></a><a id="Tc_asHAQBWBxEuMYi53tftdZw_7_4"></a><ix:continuation id="Tb_8FMqKwIHEku1QqhjVQ3ItA_cont1"><ix:continuation id="Tb_We1Ke25piEuM63WZaJ0VQg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes the Company&#8217;s unrecognized equity-based compensation expense as of September 30, 2024:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="Tb_ylMI5x-fKEe8SBh4n0h7hw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrecognized Expense (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Remaining Period of Recognition (years)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted Stock Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_V7tZSLwfkEiSdTEO0LipJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Tc_Ov2PEa3PjkaMIbbHyU2Mxw_4_2">35,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Tc_xDdh9BgVDkiPrqwQG5gK8g_4_4"> 2.8</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Tc_-J68NFNd1EWLOB4C5SZYRA_5_2">40,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Tc__B3eaiHcpEevyEdfzf6pRA_5_4"> 2.6</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Tc_OZZa5HzSCkijTelfkc-YSw_6_2">75,457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s restricted stock unit activity for the current year:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="Tb_mnssrdJ_106I1fhKdo7zyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:9pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_btXk1iwRBEitcM4l_d0v9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_dR72-h9T2kSq9Cqnv8M6dQ_4_2">2,089,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_btXk1iwRBEitcM4l_d0v9g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_0_f32ZcESkeqRVLPcJuXWw_4_5">11.92</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_OUKePioE1kiqkW5UQ8kfQQ_5_2">2,126,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_LBrQFn4aakWN2m61l7Jm6w_5_5">13.52</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_5iXSsBFWo0WydzvKAVxOoA_6_2">649,559</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_kGR0SUhv7UGgdBGFq8A8tg_6_5">12.38</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_BBjQHp0XD0S1WT0Sa4nzwA_7_2">179,956</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_dSqApmCHVkqBXBCxHOVnow_7_5">12.42</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_V7tZSLwfkEiSdTEO0LipJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_AhbcYN06ekCzru-Q2_pD2Q_8_2">3,386,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_V7tZSLwfkEiSdTEO0LipJQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_8mqkbR1l_Ue-AHTRYIky_Q_8_5">12.82</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The total fair value of restricted stock units vested during the nine months ended September 30, 2024 was $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_fDU2QxHDqkOk5Xsmj5h43Q">8.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s stock option activity for the current year:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_76JIpywZ20asc4OK5_AI3A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q7G20lfZrEGGf9s5KiiN4w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_tvTaZxpWs0KL7DcVoOAHPA_6_2">7,300,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q7G20lfZrEGGf9s5KiiN4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_s1_m-gKqbkGtw-3jAm68Zg_6_5">15.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_75tkU34fOUy3WI_eCj09wA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_KzAmy434rUmhVueh2rFCYg_6_7"> 7.90</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q7G20lfZrEGGf9s5KiiN4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_XR3d6j7N1Uy6Aozh8blQfQ_6_10">52,299</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_vq9d6-R7nECwP_Q8TqpjbQ_7_2">2,835,756</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_x3R-P6iMqEyqwdzRwi0LQQ_7_5">13.52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_iQJ40d4mKEugE4NtmE65gw_8_2">94,988</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Kh-1A1c8oUi_snmtESWNrg_8_5">5.79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_01Y--vZbgkiaG4alw21wKg_9_2">371,557</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_wK4VeGPZaketeEHgDr9CRg_9_5">19.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_6u8hi8UyJUWZxMIvmeIL1A_10_2">9,670,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_goD3QvLa_EmMjcWkyU377A_10_5">14.47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_hdAAqzAbmUioX0bGYFx7Yw_10_7"> 7.80</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_gSkVy3J_zEecJWzod4Z_Yg_10_10">2,967</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_FLC38nxEUU-MOUHtDaHrIw_11_2">4,831,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_j6SeE0y78EmlMvoynI9enQ_11_5">16.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_0p3kwJWBj0WH_kTFt1M0FQ_11_7"> 6.72</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_qRxOma_dNEmwLCtn0-QfWw_11_10">2,310</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Using the Black-Scholes option pricing model, the weighted average fair value of options granted during the nine months ended September 30, 2024 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_rKrK1I6TmU-4qPnyeXjMWg">10.38</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following weighted average assumptions were used in determining the fair value of options granted in the nine months ended September 30, 2024 and 2023:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_jbtAfn5PSEO4xgb5j-V9Lg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_3a11hCy5F0SEKrau1Go-cg_4_1">4.09</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qeLfTKYhf0WUaB1ixSydRQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_mfzXkJ0JzkeXUr_xg1-r0w_4_3">3.87</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_IxEDJdxVX0mqJ4y39R1sjg_5_1">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qeLfTKYhf0WUaB1ixSydRQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_nEeGdh20IkOb7TcbTM7DLg_5_3">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years to liquidity)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_A8HHa5-K002plfwMgxLMfA_6_1">6.00 </ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qeLfTKYhf0WUaB1ixSydRQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_Y1oV8Rjkpk61rfi2h2U0aA_6_3">6.12 </ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_jt0oBDP9WUK8hNlt7hpQVQ_7_1">91.15</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qeLfTKYhf0WUaB1ixSydRQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_BnWURHomfEupBcFo8t-u0g_7_3">90.54</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3bdd4847_5bac_4552_a087_4c1f537e6a7d"></a><a id="Tc_Qqsg1xVKrEOiTdlHvoP5Nw_1_2"></a><a id="Tc_pKUr7kGUF027nMJSwmVvXw_1_5"></a><a id="Tc_QdKUfuK-TUuQwj2Y-c5lOQ_2_2"></a><a id="Tc_MyM-C7IASEuXQerqrrgiMg_2_5"></a><a id="Tc_gUACwJRQuEWJ6Yf582Mz5g_3_2"></a><a id="Tc_XQ-mGscRL0qnuWd1C58ipg_3_5"></a><a id="Tc_qAIJFsGNLEqkqe5Vj3bw9w_4_0"></a><a id="Tc_Vhj1lD4y-0GdTtnkzx_yVg_5_0"></a><a id="Tc_8vXj0zxpR0C-tnxKQOXeYQ_5_2"></a><a id="Tc_p7hJkfd6vU2T0UAQUW7qLg_5_5"></a><a id="Tc__mOd0gQmvEyc7vSvBrTtcw_6_0"></a><a id="Tc_YuvT7NeoXUOKZVw9U32H_A_7_0"></a><a id="Tc_JioWzjiRsUKwV-imd2uHIA_7_2"></a><a id="Tc_1IzsCAyIqEuIXeJ7rK5Wdw_7_5"></a><a id="_174bdfef_9f0a_472e_8d75_cf05c5fc4999"></a><a id="Tc_dxSiZ9nD3E2Sa_5TYby4CQ_1_1"></a><a id="Tc_TPG4l-cub06A74m5DNCsVA_2_1"></a><a id="Tc_BsJNjd1pFkevUuAIiCvwag_3_1"></a><a id="Tc_pejxefSvE06z-b4K5LxJcA_4_0"></a><a id="Tc_2JcM6bUHZUiAWDh_kgL89A_5_0"></a><a id="Tc_PJ0F6ogoLkSPflvd0CQG3w_5_1"></a><a id="Tc_ROk28tqL5UeqAwhOmsSobA_6_0"></a><a id="Tc_dVeLHyythUWBhJzT0qSafg_7_0"></a><a id="Tc_WSAo2trzpUyXgPpymrBFqA_7_3"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb__F0w8OIDgE2TsAEclWmhVQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">9. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Operating Lease </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In November 2019, the Company entered into a lease of office and laboratory space at 301 Binney Street in Cambridge, Massachusetts to be used as its new corporate headquarters (the &#8220;Lease&#8221;). The expiration date of the Lease was originally in August 2025 and included an <ix:nonNumeric contextRef="Duration_11_1_2019_To_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_CdJUVb4pFUiKpg6aL0QLLg" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_K4y5Qb3iZEyWmc3On18wWA">option to extend</ix:nonNumeric> the term by <ix:nonNumeric contextRef="As_Of_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_GTqAgMQoLEKmU-Yg4Ni_LQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_u3kPd_PdLU-SroBxefFZlQ">two years</ix:nonNumeric>. The base rent under the original Lease was $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_GTqAgMQoLEKmU-Yg4Ni_LQ" decimals="-5" format="ixt:numdotdecimal" name="srrk:LesseeOperatingLeaseBaseRent" scale="6" id="Narr_xrR-naAaDE2w7SKsFy3aoQ">6.9</ix:nonFraction> million per year, subject to an annual increase of <ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_11_1_2019_To_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_CdJUVb4pFUiKpg6aL0QLLg" decimals="3" format="ixt:numdotdecimal" name="srrk:AnnualLeaseAdjustmentPercent" scale="-2" id="Narr_a39zJxYhA0am6IWM_Q0GNQ">3.5</ix:nonFraction>%, and the Company was subject to a free-rent period through mid-August 2020. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The Lease included incentives of $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_GTqAgMQoLEKmU-Yg4Ni_LQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncentiveToLessee" scale="6" id="Narr_yJVrRJLM5k6EeQVjIs8UWg">14.1</ix:nonFraction> million in the form of an allowance for tenant improvements related to the design and build out of the space. In connection with the Lease, the Company has secured a letter of credit for $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_GTqAgMQoLEKmU-Yg4Ni_LQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="Narr_focmdHabFUqAnOeYBtsncg">2.3</ix:nonFraction><span style="white-space:pre-wrap;"> million which renews automatically each year. The Lease commencement date, for accounting purposes, was reached in September 2020.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In May 2024, the Company entered into the First Amendment (the &#8220;Lease Amendment&#8221;) to the Lease to extend the term for approximately <ix:nonNumeric contextRef="As_Of_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_M1v0aqRvFEaEli6XZP3iLA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_2hewEAF_ZECXqbjSmFAIpQ">two years</ix:nonNumeric>, commencing on August 19, 2025 (the &#8220;First Extension Term&#8221;) with the base rent to start at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_M1v0aqRvFEaEli6XZP3iLA" decimals="-5" format="ixt:numdotdecimal" name="srrk:LesseeOperatingLeaseBaseRent" scale="6" id="Narr_15sgvI5PX0GweVtruJ7qXw">6.2</ix:nonFraction> million per year, followed by a <ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_5_1_2024_To_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_gi0LiBrpuUGw7o_sZbKeZg" decimals="2" format="ixt:numdotdecimal" name="srrk:AnnualLeaseAdjustmentPercent" scale="-2" id="Narr_YSKD3q5rfUyLZCtBMCVS3g">3</ix:nonFraction>% annual increase. Pursuant to the Lease Amendment, the Company also has an <ix:nonNumeric contextRef="Duration_5_1_2024_To_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_gi0LiBrpuUGw7o_sZbKeZg" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_qgA_jGyL2U6FtzM4PtRXNw">option to extend</ix:nonNumeric> the term of the Lease by <ix:nonNumeric contextRef="As_Of_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_srt_StatementScenarioAxis_srrk_UponExpirationOfFirstExtensionTermMember_WYDXdjdOlEim9o-T7lrtyw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_QZ3gmpLc4Ua-TZ3x4M_6Vg">five years</ix:nonNumeric>, upon the expiration of the First Extension Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:LeaseCostTableTextBlock" id="Tb_Yi3HZfA_vUSP4n5m4nOOwQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other information related to the Lease is as follows (in thousands, except lease term and discount rate):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease Cost:</b></p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease cost</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_cYSdTR4t8EGflEdAvNvn8A_5_3">1,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_OoOgEhAk0EiVnczsq4snCw_5_6">5,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Variable lease cost</p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_Iv-iO8Mw9Ui4Z2xPkJzF0Q_6_3">363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_kVUD2AEgpka_IUshkVCufQ_6_6">1,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_MAbQxddXGkmLbeDKKWCkZg_7_3">2,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_MKLtUzJzgEK-v3oPy6EgdA_7_6">6,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows used for operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_SlEpQRpEvEWO_x8DAN-Ggg_5_2">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_QZEJ9Cdvv0Kj3nqAJNLiVA_6_2"> 2.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Weighted average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_39XCnr0E00i7_WgR0rkSpg_7_2">13.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company, from time to time, may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the nine months ended September 30, 2024 and 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:DebtDisclosureTextBlock" id="Tb_pnHk4XntQ0mj3-p2yS_32Q" continuedAt="Tb_pnHk4XntQ0mj3-p2yS_32Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;">10. Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On October 16, 2020 (the &#8220;Closing Date&#8221;) the Company entered into a Loan and Security Agreement with Oxford Finance LLC (&#8220;Oxford&#8221;) and Silicon Valley Bank (&#8220;SVB&#8221;) for $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_JtpKqHohmUCTdUXoThTIWQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_RtxfS-v3bUOvAlx850EaMQ">50.0</ix:nonFraction> million (the &#8220;Loan and Security Agreement&#8221;). Tranche 1 of $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_10_16_2020_To_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_gUd46vYiWE6S_1qXC2sVKg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="Narr_5KW96SdDAUyUdy4_OL5zfg">25.0</ix:nonFraction> million was funded on the Closing Date. The Company had an additional $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_0F_1Zc84bky0_5lT0wv1fw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="Narr_TMqoeO15Ska4-eyVz0Jhlg">25.0</ix:nonFraction> million in loan proceeds available under Tranche 2 which was funded in December 2021, in conjunction with the Company entering into the First Amendment to Loan and Security Agreement with Oxford and SVB. The Loan and Security Agreement was to mature on May 1, 2025 and required interest-only payments through November 2022, with principal payments to commence in December 2022. Pursuant to the Loan and Security Agreement, the Company was required to maintain cash in an SVB account equal to the lesser of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_10_16_2020_To_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_gUd46vYiWE6S_1qXC2sVKg" decimals="2" format="ixt:numdotdecimal" name="srrk:PercentageOfDollarValueOfConsolidatedCash" scale="-2" id="Narr_wr28QWaJWUOAqHpT99Z6-Q">100</ix:nonFraction>%&#160;of the Company&#8217;s consolidated cash or&#160;<ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_10_16_2020_To_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_gUd46vYiWE6S_1qXC2sVKg" decimals="2" format="ixt:numdotdecimal" name="srrk:PercentageOfOutstandingObligation" scale="-2" id="Narr_pFQeEs2MdEyLPxS7ELfpOA">105</ix:nonFraction>%&#160;of the dollar amount of the outstanding debt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_pnHk4XntQ0mj3-p2yS_32Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On November 10, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement ( &#8220;Amendment 2&#8221;) to increase the Company&#8217;s borrowing capacity under the Loan and Security Agreement to an amount up to $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_A2Z61BQQoEaOUGpduwOO4Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_hCBiJcpN0UiWea725t1XUA">100.0</ix:nonFraction> million, comprised of the original $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_JtpKqHohmUCTdUXoThTIWQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_j7ASAxLnnUOBjoK3I-DHlQ">50.0</ix:nonFraction> million loan which remains outstanding and two additional $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_11_10_2022_srt_StatementScenarioAxis_srrk_TrancheOneMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_1o4-ToeAa0Ws6_A2nhaIWg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_xjUZt1HMV0-xyxHErNSUOg">25.0</ix:nonFraction> million tranches. The first $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_11_10_2022_srt_StatementScenarioAxis_srrk_TrancheTwoMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_CDA1wcxtM0OOvFBfiQ1ZIw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_-8jUPlc9LkCzYWwE8AuRbQ">25.0</ix:nonFraction> million tranche available under Amendment 2, was available at the Company&#8217;s discretion through December 2023 upon achievement of certain development and business performance milestones. The Company did not exercise this tranche. The second $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_11_10_2022_srt_StatementScenarioAxis_srrk_TrancheTwoMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_CDA1wcxtM0OOvFBfiQ1ZIw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_o_sn_hB88U2gE5ltXMejiQ">25.0</ix:nonFraction> million tranche available under Amendment 2, may be available upon the Company&#8217;s request, at Oxford and SVB&#8217;s discretion. Amendment 2 also extended the interest-only payment period for an additional <ix:nonNumeric contextRef="Duration_11_10_2022_To_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_rTABVC0FK0WrPzEHVwYh_g" format="ixt-sec:durwordsen" name="srrk:InterestOnlyPeriod" id="Narr_ZCQsj89nDUmfVHOSTBsz9g">24 months</ix:nonNumeric> through November 2024, with principal payments to commence in December 2024. The maturity of the loan was extended to November 2027. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Effective upon Amendment 2, the interest rate on the unpaid principal is the greater of the Wall Street Journal <span style="-sec-ix-hidden:Hidden_VBPAhXNcSkCfo6QuLvnBlg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prime rate</span></span> plus <ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_11_10_2022_To_11_10_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_CK6FHGQq20Km9jMf98wKZQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_ith7KdZ6mUm9GEU3NmhnbQ">4.60</ix:nonFraction>% or <ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_11_10_2022_To_11_10_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_EPztZdder02zre_iKLe24Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_13FOfUmJY02-l6xFG02wxQ">9.35</ix:nonFraction>% per annum. Prepayment is permitted and may include a pre-payment fee ranging from <ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="As_Of_11_10_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_ijSq6JdiwE60YiJXwFSdRw" decimals="2" format="ixt:numdotdecimal" name="srrk:PrepaymentPenaltyPercent" scale="-2" id="Narr_cXfsfEmdJU-4klAEazHJ4g">0</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="As_Of_11_10_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_ZLcu95SjEEyxu4lbKeIrfg" decimals="2" format="ixt:numdotdecimal" name="srrk:PrepaymentPenaltyPercent" scale="-2" id="Narr_-J55DF987Uqm4o6v0vk83w">3</ix:nonFraction>% (of the principal amount being prepaid), depending on when the prepayment is made. The Company is also required to make a final payment equal to <ix:nonFraction unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw" contextRef="Duration_11_10_2022_To_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_rTABVC0FK0WrPzEHVwYh_g" decimals="2" format="ixt:numdotdecimal" name="srrk:DebtInstrumentFinalPaymentFee" scale="-2" id="Narr_psQBFKe-tUyg6uxKQJRHXg">2</ix:nonFraction>% of the original principal amount. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">In conjunction with Amendment 2, the Company was required to pay $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_11_10_2022_To_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_rTABVC0FK0WrPzEHVwYh_g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_15VuknUiIkyLsXZy9QxKJg">0.9</ix:nonFraction> million for the accrued portion of the final payment on the previous outstanding balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver. Afterward, the FDIC transferred all deposits of the former Silicon Valley Bank to Silicon Valley Bridge Bank, N.A., as operated by the FDIC. On March 27, 2023, Silicon Valley Bridge Bank was closed by the Office of the Comptroller of the Currency, and the FDIC was appointed as receiver. First Citizens Bank then entered into an agreement with the FDIC to purchase out of FDIC receivership substantially all loans and certain other assets and assume all customer deposits and certain other liabilities of Silicon Valley Bridge Bank. On March 27, 2023, Silicon Valley Bridge Bank and its U.S. branches began operating as Silicon Valley Bank, a division of First Citizens Bank.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On April 18, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement to amend certain provisions relating to the Company&#8217;s operating accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On May 17, 2024, the Company entered into the Fourth Amendment to the Loan and Security Agreement (&#8220;Loan Amendment No. 4&#8221;). The Company currently has $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_5_17_2024_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_Hgg07AAyG02T4Jv5fZE-FQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_zMroVZEdtE-GckPw3POPNQ">50.0</ix:nonFraction> million outstanding under the Loan and Security Agreement, which was drawn down in two equal tranches. The third $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_5_17_2024_srt_StatementScenarioAxis_srrk_TrancheThreeMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_u2DvbaL6ckmuYfubdLSQiw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_Qg-cFJ-DDEWvRDscxE3kGQ">25.0</ix:nonFraction> million tranche is available at the Company&#8217;s discretion through December 2024, upon achievement of certain clinical and business milestones, which were amended under Loan Amendment No. 4. The fourth $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="As_Of_5_17_2024_srt_StatementScenarioAxis_srrk_TrancheFourMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_NKmevx8gPUq3cZ8kssDJNw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_hYc3xUDbp0-TqMa4bfHjaQ">25.0</ix:nonFraction> million tranche may be available through June 1, 2025 (or through December 1, 2025 upon achievement of certain business milestones) upon the Company&#8217;s request, at Oxford and SVB&#8217;s discretion. Amendment No. 4 also extends the interest-only payment period for an additional <ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_qdKJj99R-UKWV1diKEhPMg" format="ixt-sec:durwordsen" name="srrk:LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod" id="Narr_pqeOo26NH0yMEMwxLfI9QA">six months</ix:nonNumeric> through May 2025, with principal payments to commence in June 2025. Additionally, upon achievement of certain business performance milestones, which were achieved in October 2024, the interest-only payment period was extended through November 2025, with principal payments to commence in December 2025.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_sXIoc-xzGUu0LLr4KwtAVQ" continuedAt="Tb_sXIoc-xzGUu0LLr4KwtAVQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">11. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company calculates basic net loss per share by dividing net loss by the weighted average number of common shares outstanding, excluding restricted common stock. The weighted average number of common shares used in the basic and diluted net loss per share calculation includes the pre-funded warrants issued in connection with the Company&#8217;s November 2020 and June 2022 follow-on offerings as the pre-funded warrants are exercisable at any time for nominal cash consideration. As of September 30, 2024, <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_srt_StatementScenarioAxis_srrk_AggregateMember_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_vHhfARkPrEeM6UAWteancQ" decimals="INF" format="ixt:numdotdecimal" name="srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Narr_ovUcEb67-0KzqGwzbqBzCw">10,681,528</ix:nonFraction> pre-funded warrants have been exercised and <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_n9DGS8M0kE24zj_oklD1kA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_oy0orkStaEq2s4CITm1poA">17,008,164</ix:nonFraction> pre-funded warrants remain outstanding. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_O07YNV01jk6iYDG8lYMBnQ_1_2"></a><a id="Tc_k5exAd2nPUmGgfQf7Wy6BA_2_2"></a><a id="Tc_WAyFdBCtN0CbVyDy-7s3fA_2_4"></a><a id="Tc_Su-JtCKK3UWeiF9-yB6flA_3_0"></a><a id="Tc_kLSkwP4eJUOChpDYphCiDA_4_0"></a><a id="Tc_0knimC-FC0WC4GrXOC6XFA_5_0"></a><ix:continuation id="Tb_sXIoc-xzGUu0LLr4KwtAVQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_JCBkaj_gtkCJyRWOMmRl1Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BRNbuA-xdUWVSanmpZGNKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_YIqvOSfxN0mcewJmDpX1EA_3_2">3,386,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_WcKh_paNQEO1eHbYGf_3nw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Exr-_qAmLEuRuWk1o5WLjw_3_4">2,081,607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_BYs8SrAKnkyWg65xLBo1ng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_FPuwLSBJEUKLROfLidyaSg_4_2">9,670,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_leFkp74BkEGzez-zOjF2mg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_m7Hp1t6itEmuhL4bfOS0tg_4_4">7,422,412</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_srrk_CommonWarrantMember_5ObJ1CZ65E21VrAjZyMJVA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_bMFN1qHUKkagIJcirr3odw_5_2">9,157,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_srrk_CommonWarrantMember_gCi3mjIZR0W0dKa1gLVEAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_TvBUhuLF7kO2CKAUo5R1CQ_5_4">10,459,181</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_LHn3HRXUAkqVFMaVcEn77A_6_2">22,214,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_urI283R14Eil_PikATpMug_6_4">19,963,200</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_qT2mKEl4mU2grRw95PyM4A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">12. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On October 8, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler &amp; Co., as representatives of the several underwriters named therein (the &#8220;Underwriters&#8221;), relating to the issuance and sale of an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_10_8_2024_To_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_tVRY0dVzb0i50FyP8rdL6A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Na8eTkMh4E-xS3Zln8sFpg">10,265,488</ix:nonFraction> shares of the Company&#8217;s common stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_iFj3QnQzOU-8kQacFHjl3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_f9EJVM-bRU-2BSQzjM9WkA">28.25</ix:nonFraction> per share and pre-funded warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="As_Of_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_iFj3QnQzOU-8kQacFHjl3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_gsHZ2rzWTECT6ND8D5vAdg">353,983</ix:nonFraction> shares of its common stock. The offering price per pre-funded warrant was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_10_8_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_kidvJgGpG0maEoeyfhtn0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_dxV_i9_SE0eWrNx_G5WF9Q">28.2499</ix:nonFraction>, which equals the per share public offering price for the common shares less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw" contextRef="As_Of_10_8_2024_us-gaap_StatementEquityComponentsAxis_srrk_PreFundedWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_5SGDYfs7OECckL2UaG60KA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Wa-6Ds6Q2kmCI6hHBG6CSw">0.0001</ix:nonFraction> exercise price for each such pre-funded warrant. The pre-funded warrants are exercisable at any time and only expire when exercised in full. The offering closed on October 10, 2024. Pursuant to the Underwriting Agreement, the Company also granted the Underwriters a 30-day option to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg" contextRef="Duration_10_10_2024_To_10_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DS-yvkHxka87ldWHUSkvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Wd9RMiBxC0eoJMcSAZbb9g">1,592,920</ix:nonFraction> additional shares (the &#8220;Option Shares&#8221;) of common stock, which was exercised in full on October 16, 2024. Total proceeds of the transaction, including the Option Shares were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ" contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EKUEbTHr-Ea-uOCZ6iVjdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_fUQTt_msBkSLqg9kM565mg">324.4</ix:nonFraction> million, net of underwriting discounts and estimated offering expenses. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2048b6ee_6235_413f_a89f_d84a692faa7a"></a><a id="Item2_MDA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item 2.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report, and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report, including those risks identified under Part&#160;II, Item&#160;1A. Risk Factors.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules&#160;of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">We are a late-stage biopharmaceutical company focused on the discovery, development, and delivery of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. As a global leader in TGF&#946; superfamily biology, our novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, we believe we may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Based on this proprietary and scalable technology platform, we are building a growing portfolio of novel product candidates with the aim of transforming the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis and iron-restricted anemia. We have discovered and progressed the development of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Apitegromab, an investigational, fully human monoclonal antibody that inhibits myostatin activation by selectively binding the pro- and latent forms of myostatin in skeletal muscle and is being developed for the treatment of SMA. We also believe apitegromab could have potential in the treatment of other neuromuscular disorders where the inhibition of myostatin may be beneficial. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SRK-439, a novel, preclinical, investigational myostatin inhibitor that has high in vitro affinity for pro- and latent myostatin and maintains myostatin specificity and is being developed for the treatment of cardiometabolic disorders.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SRK-181, an investigational inhibitor of the activation of latent TGF&#946;1, that is being developed for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potent and selective inhibitors of the activation of TGF&#946; for the treatment of fibrotic diseases. We are advancing multiple antibody profiles toward product candidate selection including antibodies that selectively inhibit the activation of latent TGF&#946;1 in the context of fibrotic extracellular matrix and that avoid perturbing TGF&#946;1 presented by cells of the immune system.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional discovery and early preclinical programs related to the selective modulation of growth factor signaling including bone morphogenic protein 6 and other growth factors.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our first product candidate, apitegromab, is a highly selective, fully human, monoclonal antibody with a unique mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. We are&#160;conducting SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with nonambulatory Type 2 and Type 3 SMA (which is estimated to represent the majority of the current prevalent SMA patient population in the U.S. and Europe).&#160;We completed enrollment of SAPPHIRE in 2023. In October 2024, the Company announced positive top-line results that showed the study achieved its primary endpoint (see <span style="font-style:italic;font-weight:bold;">Recent Developments</span>). We are planning to submit a U.S. Biologics License Application to the FDA and a European Union marketing authorization application to the EMA in Q1 2025. If apitegromab is approved, we expect to initiate a commercial product launch in 2025 in the United States, with a commercial launch of apitegromab in Europe to follow.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Apitegromab was evaluated in our Phase 2 TOPAZ proof-of-concept clinical trial for the treatment of patients with Type 2 and Type 3 SMA.&#160;Positive 12-month top-line results were initially announced in April 2021. We have subsequently presented data from the TOPAZ trial over 24-months (2022), 36-months (2023) and 48-months (2024). At 48-months over 90% of TOPAZ patients with nonambulatory Type 2 and 3 SMA receiving an SMN therapy remained on apitegromab treatment and showed sustained clinical benefit, a continued favorable safety profile with no new safety findings. Additionally, we have a long-term extension study, ONYX, for patients from both the TOPAZ and SAPPHIRE studies, who are receiving apitegromab in conjunction with an approved SMN therapy. The FDA granted Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation to apitegromab for the treatment of SMA in May 2021, August 2020 and March 2018, respectively. The EMA granted PRIME designation in March 2021 and the EC granted Orphan Medicinal Product designation in December 2018 to apitegromab for the treatment of SMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In October 2023, we announced an expansion of our therapeutic focus into cardiometabolic disorders by advancing our anti-myostatin program with SRK-439, a novel, fully human anti-myostatin monoclonal antibody, for evaluation in cardiometabolic disorders, including obesity. We are developing SRK-439 towards a potential IND submission in 2025. In 2024, we have presented preclinical data at scientific conferences which support the potential of SRK-439 to increase lean mass and contribute to a favorable body composition in conjunction with a GLP-1 RA treatment. To inform the development of SRK-439, in May 2024 we initiated the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve muscle mass in individuals living with obesity and on background therapy of a GLP-1 RA. In September 2024, we announced that we completed enrollment in the Phase 2 EMRAZE proof-of-concept trial<span style="font-size:12pt;">.</span> Top-line results from this trial are expected in the second quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We believe that apitegromab has the potential to be the first muscle-targeted therapy which is aimed at improving motor function in patients with SMA who are receiving an SMN therapy. We have identified multiple other diseases for which the selective inhibition of the activation of myostatin may offer therapeutic benefit, including additional patient populations in SMA (such as patients under the age of two with SMA and ambulatory patients with SMA) and indications for other neuromuscular disorders beyond SMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our second product candidate, SRK-181,<span style="background:#ffffff;"> a highly selective inhibitor of the activation of latent TGF&#946;,</span> is being developed for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies (referred to together as anti-PD-(L)1 antibody therapies). <span style="background:#ffffff;">SRK-181 is being evaluated in our Phase 1 DRAGON proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors that exhibit resistance to anti-PD-(L)1 antibody therapies. We completed enrollment of the DRAGON trial in December 2023 and continue to treat patients who remain on study</span>. This two-part clinical trial consists of a dose escalation portion (Part A) and a dose expansion portion evaluating SRK-181 in combination with an approved anti-PD-(L)1 antibody therapy (Part B).&#160;<span style="background:#ffffff;">Part B commenced in 2021 and includes the following active cohorts: urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma (&#8220;ccRCC&#8221;), and head and neck squamous cell carcinoma.</span> Safety, efficacy and biomarker data were presented in June 2024 at the ASCO annual meeting and in November 2024 at the Society for Immunotherapy of Cancer (&#8220;SITC&#8221;) 39<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;Annual Meeting. The data showed encouraging responses in heavily pretreated and anti-PD-(L)1 resistant patients across multiple tumor types. <span style="background:#ffffff;">We believe that the </span><span style="background:#ffffff;">DRAGON trial achieved its study objectives by showing objective, durable clinical responses in patients with ccRCC resistant to PD-1 </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">therapy above what is expected from continuing PD-1 alone. We anticipate that </span>emerging data from the DRAGON trial will be presented at medical meetings in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Using our innovative<span style="background:#ffffff;"> approach and proprietary platform, we are creating a pipeline of novel product candidates that selectively modulate the activation of growth factors implicated in a variety of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. </span><span style="background:#ffffff;">Our proprietary platform is designed to generate highly selective antibodies that target the growth factor&#8217;s latent precursor form prior to its activation within the disease microenvironment, or tissue where it is localized.</span><span style="background:#ffffff;">&#160;</span><span style="background:#ffffff;">Our structural insights and unique antibody discovery capabilities can also be applied to other protein classes beyond growth factors, with an aim of generating differentiated candidates targeting cell surface receptors such as immune cell receptors or G-protein coupled receptors, where selectivity remains challenging.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since inception, we have incurred significant operating losses. Our net losses were $179.8 million for the nine months ended September 30, 2024. As of September 30, 2024, we had an accumulated deficit of $856.3 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future in performing our ongoing activities, as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">develop our commercialization capabilities to support product sales, marketing and distribution activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">continue development activities for apitegromab, including the conduct and completion of our Phase 3 SAPPHIRE pivotal clinical trial in SMA, the conduct of ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies and the clinical trial drug supply;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue research and development activities for SRK-181, including the conduct of our Phase 1 DRAGON proof-of-concept clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">continue research and development activities for our cardiometabolic program, including EMBRAZE, our Phase 2 proof-of-concept trial with apitegromab and advancing SRK-439 towards a potential IND submission in 2025;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to discover, validate and develop additional product candidates through the use of our proprietary platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional research, development, commercial and other business personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to build the infrastructure to support our operations as a public company.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">To date, we have not generated any revenue from product sales. If we successfully complete clinical development and obtain regulatory approval for apitegromab, SRK-181, SRK-439 or any of our future product candidates, we may generate revenue in the future from product sales. In addition, if we obtain regulatory approval for apitegromab, SRK-181, SRK-439 or any of our future product candidates, we expect to incur significant expenses related to developing our commercialization capabilities to support product sales, marketing and distribution activities.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Developments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">Phase 3 SAPPHIRE Trial Top-line Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October 7, 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab, an investigational muscle-targeted therapy, in patients with SMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">SAPPHIRE was a randomized, double-blind, placebo-controlled, Phase 3 clinical trial that evaluated the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 SMA who are receiving current standard of care, either nusinersen or risdiplam. SAPPHIRE enrolled 156 patients ages 2&#8211;12 years old in the main efficacy population. These patients were randomized 1:1:1 to receive either apitegromab 10 mg/kg, apitegromab 20 mg/kg, or placebo by intravenous infusion every 4 weeks. An exploratory population that enrolled 32 patients ages 13&#8211;21 years old was also evaluated. These patients were randomized 2:1 to receive either apitegromab 20 mg/kg or placebo.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:172.92pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement for apitegromab compared to placebo in motor function as measured by the gold standard Hammersmith Functional Motor Scale Expanded (&#8220;HFMSE&#8221;) in SMA patients on chronic dosing of standard of care therapies (either nusinersen or risdiplam). Based upon the similar pharmacological profile of the 20 mg/kg and 10 mg/kg doses of apitegromab, the statistical analysis plan was prespecified to analyze both the combined dose (10 mg/kg and 20 mg/kg) and the 20 mg/kg dose, each compared to placebo. Statistical significance was achieved per the prespecified statistical analysis plan (Hochberg multiplicity adjustment) where the p-value (&#8804;0.025) is more rigorous if only one prespecified analysis crosses the statistical significance boundary of &#8804; 0.05.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the main efficacy population (ages 2&#8211;12), the mean difference in change from baseline in HFMSE was 1.8 points (p =0.0192) for all patients receiving apitegromab 10 mg/kg and 20 mg/kg (n=106) compared to placebo (n=50). Patients receiving 20 mg/kg of apitegromab (n=53) showed a 1.4 point mean difference compared to placebo (p=0.1149).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;The prespecified analysis of the 10 mg/kg dose showed that patients receiving 10 mg/kg of apitegromab (n=53) showed an improvement of 2.2 points (nominal p=0.0121) compared to placebo.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;Based upon PK/PD data from the SAPPHIRE trial, similar levels of target engagement were observed for the 10 mg/kg and 20 mg/kg dose groups.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">&#8203;Motor function outcomes were meaningful and consistent across the main efficacy population and in the ages 13&#8211;21 exploratory population, and favored apitegromab (n=22) compared to placebo (n=10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes the changes from baseline in HFMSE total score at month 12 across the various dose and age groups studied in SAPPHIRE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change from Baseline in HFMSE Total Score at Month 12*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="srrk-20240930x10q004.jpg" alt="Graphic" style="display:inline-block;height:172.92pt;width:471.6pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">Abbreviations: CI, Confidence Interval; HFMSE, Hammersmith Functional Motor Scale Expanded; LS, Least Squares;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">*n values at 12-month endpoint</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">30.4% of patients receiving apitegromab in the main efficacy population (ages 2-12) had &#8805;3 point improvement in HFMSE versus 12.5% of patients on placebo, as shown below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:285.01pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proportion of Patients With &#8805;3 Point Improvement in HFMSE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="srrk-20240930x10q005.jpg" alt="Graphic" style="display:inline-block;height:284.86pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Proportion of patients achieving &#8805;3 Point Improvement in HFMSE was higher for apitegromab vs. placebo in combined dose (odds ratio 3.0, p=0.0256)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">SOC = standard of care</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients receiving apitegromab in the main efficacy population (ages 2&#8211;12) demonstrated early motor function improvement compared to placebo from the first measured time point at 8 weeks, and clinical benefit expanded at 52 weeks as measured by HFMSE, as shown below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:237pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">HFMSE Improvement vs. Placebo in SAPPHIRE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="srrk-20240930x10q006.jpg" alt="Graphic" style="display:inline-block;height:237pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">Abbreviations: CI=Confidence Interval; HFMSE=Hammersmith Functional Motor Scale Expanded; LS=Least Squares; SOC=standard of care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Treatment with apitegromab was well-tolerated across all age groups. There were no clinically relevant differences in the adverse event profile by dose, 10 mg/kg versus 20 mg/kg. No new safety findings were observed in the SAPPHIRE clinical trial; the profile was consistent with that observed in the Phase 2 TOPAZ clinical trial, including an extension study which had over four years of treatment as of the cut-off date. Serious adverse events (&#8220;SAEs&#8221;) were consistent with the underlying disease and the current standard of care received by patients; no SAEs were assessed as related to apitegromab. There were no study drug discontinuations due to adverse events. The most common adverse events were pyrexia, nasopharyngitis and cough, observed in 29.2%, 24.5% and 24.5% of patients in the main efficacy population (10 mg/kg and 20 mg/kg combined), respectively. The table below summarizes the adverse events observed in the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Summary of Adverse Events in SAPPHIRE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="srrk-20240930x10q007.jpg" alt="Graphic" style="display:inline-block;height:143.2pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are also continuing our long-term extension study, ONYX, for patients from both the TOPAZ and SAPPHIRE studies, who are receiving apitegromab in conjunction with current standard of care. Following trial completion, 98% of SAPPHIRE patients (185/188) enrolled in the ONYX open-label expansion study.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations, and the EMA has granted PRIME designation and the EC has granted Orphan Medicinal Product designation to apitegromab for the treatment of SMA. We continue to evaluate the clinical, pharmacokinetic, and other data from SAPPHIRE to inform dose selection discussions with the FDA and EMA. We plan to submit a Biologics License Application to the FDA and a marketing authorization application to the EMA in the first quarter of 2025 and to request priority review and accelerated assessment, respectively. Assuming marketing approval is obtained, we plan to commercially launch apitegromab in the U.S. in the fourth quarter of 2025 with a commercial launch of apitegromab in Europe to follow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">Follow-on Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On October 8, 2024, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler &amp; Co., as representatives of the several underwriters named therein (the &#8220;Underwriters&#8221;), relating to the issuance and sale of an aggregate of 10,265,488 shares of our common stock at $28.25 per share and pre-funded warrants to purchase 353,983 shares of our common stock. The offering price per pre-funded warrant was $28.2499, which equals the per share public offering price for the common shares less the $0.0001 exercise price for each such pre-funded warrant. The pre-funded warrants are exercisable at any time and only expire when exercised in full. The offering closed on October 10, 2024. Pursuant to the Underwriting Agreement, we also granted the Underwriters a 30-day option to purchase up to 1,592,920 additional shares (the &#8220;Option Shares&#8221;) of common stock, which was exercised in full on October 16, 2024. Total proceeds of the transaction, including the Option Shares were approximately $324.4 million, net of underwriting discounts and estimated offering expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Financial Operations Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses consist primarily of costs incurred for our research and development activities, including our product candidate discovery efforts, preclinical studies, manufacturing, and clinical trials under our research programs, which include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, benefits and equity-based compensation expense for our research and development personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with third parties that conduct research and development and preclinical activities on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements related to our clinical trials, including the costs for investigative sites and contract research organizations (&#8220;CROs&#8221;), that conduct our clinical trials</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing process-development, manufacturing of clinical supplies and technology-transfer expenses</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consulting and professional fees related to research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of purchasing laboratory supplies and non-capital equipment used in our internal research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to compliance with clinical regulatory requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facility costs and other allocated expenses, which include expenses for rent and maintenance of facilities, insurance, depreciation and other supplies.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks. Nonrefundable advance payments for research and development goods and services to be received in the future from third parties are deferred and capitalized. The capitalized amounts are expensed as the related services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A significant portion of our research and development costs have been external costs, which we track on a program-by-program basis after a clinical product candidate has been identified. However, we do not allocate our internal research </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">and development expenses, consisting primarily of employee-related costs, depreciation and other indirect costs, on a program-by-program basis as they are deployed across multiple projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, as well as the associated clinical trial material requirements. We expect research and development costs for our product candidates to continue to be substantial for the foreseeable future as the development programs progress. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The successful development of apitegromab, SRK-181, SRK-439 and any future product candidates is uncertain. Accordingly, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of apitegromab, SRK-181, SRK-439 and any future product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of our product candidates, if approved. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing an appropriate safety profile;</span></td></tr></table><div style="margin-top:3pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in and completion of clinical trials;</span></td></tr></table><div style="margin-top:3pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether our product candidates show safety and efficacy in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant and changing government regulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercializing the product candidates, if and when approved, whether alone or in collaboration with others; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued acceptable safety profile of the products following any regulatory approval.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A change in the outcome of any of these variables with respect to the development of apitegromab, SRK-181, SRK-439 or any of our future product candidates could significantly change the costs and timing associated with the development of that product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">General and Administrative</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">General and administrative expenses consist primarily of employee-related expenses, including salaries, benefits and equity-based compensation expenses for personnel in executive, finance, business development, investor relations, legal, information technology, human resources and commercial functions. Other significant general and administrative expenses include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters and fees for accounting, consulting services, and corporate expenses. We expect general and administrative expense to increase as we continue to invest in building the infrastructure to support the commercialization of apitegromab.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Other income (expense), net consists primarily of interest income earned on our cash, cash equivalents and marketable securities, partially offset by interest expense incurred on our debt facility, including amortization of debt discount and debt issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Comparison of the Three Months Ended September 30, 2024 and 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes our results of operations for the three months ended September 30, 2024 and 2023 (in thousands, except&#160;percentages):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48,719</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 30,337</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,382</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 60.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,061</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,335</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,726</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 64,780</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 43,672</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21,108</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (64,780)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (43,672)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (21,108)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 301</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,313</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,012)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (77.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (64,479)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (42,359)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (22,120)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 52.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">Research and Development </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expense was $48.7 million and $30.3 million for the three months ended September 30, 2024 and 2023, respectively, an increase of $18.4 million or 60.6%. The following table summarizes our research and development expense for the three months ended September 30, 2024 and 2023 (in thousands, except&#160;percentages): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">External costs by program</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Apitegromab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,523</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,002</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,521</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 125.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">SRK-181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,064</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,239</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,175)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other early programs and unallocated costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,376</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,427</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,949</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 136.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total external costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,963</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,668</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,295</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 90.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Internal costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,552</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,389</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,163</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Facility and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,204</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,280</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (76)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1.8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total internal costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,756</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,669</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,087</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 48,719</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,337</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,382</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The increase in research and development expense was primarily attributable to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An increase in our external research and development costs of $13.3 million, which primarily consisted of:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$12.5 million increase in costs associated with apitegromab primarily due to clinical trial costs, particularly the conduct of ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies and EMBRAZE, our Phase 2 proof-of-concept study, as well as an increase in drug supply manufacturing, including to support lifecycle management initiatives; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.2 million decrease in costs associated with SRK-181; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.9 million increase in other early development candidates, including pre-clinical costs and manufacturing development for SRK-439 and unallocated costs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$5.1 million increase in internal research and development costs, which was primarily driven by an increase in employee compensation and benefits, including salaries, bonus, and non-cash equity-based compensation expense related to increased headcount, as well as an increase in temporary support expense.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Total research and development expenses are expected to continue to be substantial, driven by employee compensation costs and development costs associated with our clinical stage programs as we continue development activities for apitegromab in SMA, including the conduct and completion of our Phase 3 SAPPHIRE pivotal clinical trial in SMA, the conduct of ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies and the associated drug supply, as well as costs associated with supporting our cardiometabolic program, including EMBRAZE, our Phase 2 proof-of-concept trial of apitegromab and our preclinical program, SRK-439. Additionally, we will continue to invest in our pipeline. We expect costs of our SRK-181 program to continue to decrease, as we completed enrollment of the Phase 1 DRAGON clinical trial in December 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">General and Administrative</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">General and administrative expense was $16.1 million and $13.3 million for the three months ended September 30, 2024 and 2023, respectively, an increase of $2.7 million or 20.4%. The increase was primarily associated with employee-related costs including salaries, benefits and non-cash equity-based compensation expense related to increased headcount, in addition to an increase in consulting and professional services. We expect general and administrative expense to increase as we continue to invest in building the infrastructure to support the commercialization of apitegromab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Other Income (Expense), Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The change in other income (expense), net was primarily attributable to a decrease in interest income earned due to lower balances in our cash, cash equivalents and marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Comparison of the Nine Months Ended September 30, 2024 and 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes our results of operations for the nine months ended September 30, 2024 and 2023 (in thousands, except&#160;percentages):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 134,185</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 86,939</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 47,246</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 54.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48,512</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 36,324</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,188</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 33.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 182,697</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 123,263</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59,434</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (182,697)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (123,263)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (59,434)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,857</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,600</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (743)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (20.6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (179,840)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (119,663)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (60,177)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expense was $134.2 million and $86.9 million for the nine months ended September 30, 2024 and 2023, respectively, an increase of $47.2 million or 54.3%. The following table summarizes our research and development expense for the nine months ended September 30, 2024 and 2023 (in thousands, except&#160;percentages): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">External costs by program:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Apitegromab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 57,852</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,204</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29,648</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 105.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">SRK-181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,069</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,905</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,836)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (26.0)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other early programs and unallocated costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,319</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,492</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,827</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 138.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total external costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 74,240</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 42,601</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 31,639</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 74.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Internal costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 46,977</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 32,023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,954</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 46.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Facility and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,968</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,315</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 653</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total internal costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59,945</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 44,338</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,607</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 134,185</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 86,939</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 47,246</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 54.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The increase in research and development expense was primarily attributable to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An increase in our external research and development costs of $31.6 million, which primarily consisted of:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$29.6 million increase in costs associated with apitegromab primarily due to clinical trial costs, particularly the conduct of ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies and EMBRAZE, our Phase 2 proof-of-concept study (including purchases of GLP-1 drug), as well as an increase in drug supply manufacturing, including to support lifecycle management initiatives; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.8 million decrease in costs associated with SRK-181 mostly due to purchases of pembrolizumab in 2023 which were used in the Phase 1 DRAGON clinical trial; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$4.8 million increase in other early development candidates, including pre-clinical costs and manufacturing development for SRK-439 and unallocated costs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$15.6 million increase in internal research and development costs, which was primarily driven by an increase in employee compensation and benefits, including salaries, bonus, payroll taxes and non-cash equity-based compensation expense related to increased headcount, as well as an increase in temporary support expense.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Total research and development expenses are expected to continue to be substantial, driven by employee compensation costs and development costs associated with our clinical stage programs as we continue development activities for apitegromab in SMA, including the conduct and completion of our Phase 3 SAPPHIRE pivotal clinical trial in SMA, the conduct of ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies and the associated drug supply, as well as costs associated with supporting our cardiometabolic program, including EMBRAZE, our Phase 2 proof-of-concept trial of apitegromab and our preclinical program, SRK-439. Additionally, we will continue to invest in our pipeline. We expect costs of our SRK-181 program to continue to decrease, as we completed enrollment of the Phase 1 DRAGON clinical trial in December 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">General and Administrative</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expense was $48.5 million and $36.3 million for the nine months ended September 30, 2024 and 2023, respectively, an increase of $12.2 million or 33.6%. The increase was primarily associated with employee-related costs including salaries, benefits and non-cash equity-based compensation expense related to increased </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">headcount, in addition to an increase in consulting and professional services. We expect general and administrative expense to increase as we continue to invest in building the infrastructure to support the commercialization of apitegromab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Other Income (Expense), Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The change in other income (expense), net was primarily attributable to a decrease in interest income earned due to lower average balances in our cash, cash equivalents and marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Sources of Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since our inception, we have not generated any product revenue and have incurred significant operating losses and negative cash flows from our operations. We have funded our operations to date primarily with proceeds from the sale of our convertible preferred stock and units in private placements before our initial public offering (&#8220;IPO&#8221;), and issuance of our common stock through our IPO in 2018, to Gilead in an exempt private placement, through multiple secondary public offerings, including our recent follow-on offering in October 2024 (see Note 12) and through ATM sales, as well as payments from our research collaborations and the Loan and Security Agreement entered into in October 2020 and subsequently amended (see Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">The following table provides information regarding our total cash, cash equivalents and marketable securities at September 30, 2024 and December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 76,391</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 101,855</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 62,674</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 178,083</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 139,065</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 279,938</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the nine months ended September 30, 2024, our cash, cash equivalents and marketable securities balance decreased by $140.9 million. The change was primarily due to cash used to operate our business, including payments related to, among other things, research and development and general and administrative expenses as we continued to invest in our product candidates and supported our internal research and development efforts and made interest payments on our debt, partially offset by proceeds from the exercises of warrants and stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our current ATM program, established in November 2022, allows for the sale of shares of our common stock having an aggregate offering price of up to $100 million. As of September 30, 2024, the Company has sold 619,290 shares, generating net proceeds of $5.2 million, under the ATM program. No sales were made under the ATM program during the nine months ended September 30, 2024. <span style="background:#ffffff;">In October 2021, we sold 500,000 shares of our common stock through a sale in our prior ATM program (in place between March 2021 and June 2022)&#160;and received $13.1 million in net proceeds, after deducting commissions and fees.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">In October 2024, we entered into an underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler &amp; Co., as representatives of the several underwriters named therein, relating to the issuance and sale of an aggregate of 11,858,408 shares of our common stock and pre-funded warrants to purchase 353,983 shares of our common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,592,920 shares. The offering price per share was $28.25 and the offering price per pre-funded warrant was $28.2499, which equals the per share public offering price for the common shares less the $0.0001 exercise price for each such pre-funded warrant. The offering resulted in estimated proceeds of approximately $324.4 million, net of underwriting discounts and estimated offering expenses (see Note 12).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In October 2023, we entered into an underwriting agreement with J.P. Morgan Securities LLC and Piper Sandler &amp; Co., as representatives of the several underwriters named therein, relating to the issuance and sale of an aggregate of 14,270,074<span style="background:#ffffff;"> shares of our common stock, which includes the exercise in full by the underwriters of their option to </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">purchase an additional 1,861,314 shares. The offering price per share was </span>$6.85. <span style="background:#ffffff;">The offering resulted in proceeds of </span>approximately $92.4 million, net of underwriting discounts and offering expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In June&#160;2022, we entered into a securities purchase agreement relating to the issuance and sale of an aggregate of 16,326,530 shares of our common stock, pre-funded warrants to purchase 25,510,205 shares of our common stock and associated common warrants to purchase 10,459,181 shares of our common stock. Gross proceeds from the transaction were $205.0 million. Upon the offering closing, we received $195.3 million in net proceeds, after deducting placement agent fees and expenses and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In October 2020, we entered into an underwriting agreement relating to the issuance and sale of an aggregate of 3,717,948 shares of our common stock at $39.00 per share and pre-funded warrants to purchase 2,179,487 shares of our common stock. The offering closed in November 2020, and we received $215.9 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In October 2020, we entered into the Loan and Security Agreement with Oxford and SVB, which was amended in November 2022, for $100 million of which $25.0 million from Tranche 1 was received in October 2020 and $25.0 million from Tranche 2 was received in December 2021 (Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In June and July 2019, we sold 3,450,000 shares of our common stock through an underwritten public offering. As a result of the offering, we received aggregate net proceeds, after underwriting discounts and commissions and other offering expenses, of $48.3 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2018, we entered into the Gilead Collaboration Agreement pursuant to which we conducted research and preclinical development activities relating to the diagnosis, treatment, cure, mitigation or prevention of diseases, disorders or conditions, other than in the field of oncology in accordance with a pre-determined research plan. Pursuant to the Gilead Collaboration Agreement, Gilead made non-refundable payments of $80.0 million, including an upfront payment and an equity investment. In December 2019, we achieved a $25.0 million preclinical milestone for the successful demonstration of efficacy in preclinical in vivo proof-of-concept studies, and subsequently received the associated payment in January 2020. Revenue was recognized during the period January 2019 through December 2021, as research and development services were provided. All revenue related to the Gilead Collaboration Agreement had been fully recognized by January 31, 2022, upon the termination of Gilead&#8217;s option exercise period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">During the nine months ended September 30, 2024, 2,526,833 of the Company&#8217;s pre-funded warrants were exercised. As of September 30, 2024, the Company had 17,008,164 pre-funded warrants outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">During the nine months ended September 30, 2024, 830,660 of the Company&#8217;s common warrants were exercised. As of September 30, 2024, the Company had 9,157,496 common warrants outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table provides information regarding our cash flows for the nine months ended September 30, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (151,436)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (107,877)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 119,314</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 66,269</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,658</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,045</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (25,464)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (35,563)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">Net Cash Used in Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities was $151.4 million for the nine months ended September 30, 2024, and consisted of our net loss of $179.8 million and changes in our assets and liabilities of $0.6 million, partially offset by non-cash adjustments of $29.0 million. The non-cash adjustments are primarily from equity-based compensation. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Net cash used in operating activities was $107.9 million for the nine months ended September 30, 2023, and consisted of our net loss of $119.7 million, changes in our assets and liabilities of $11.9 million, partially offset by non-cash adjustments of $23.7 million. The changes in our assets and liabilities includes a $6.9 million change in accrued expenses, mostly related to external research and development expenses. The non-cash adjustments are primarily from equity-based compensation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">Net Cash Provided by Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by investing activities was $119.3 million for the nine months ended September 30, 2024 compared to net cash provided by investing activities of $66.3 million for the nine months ended September 30, 2023. Net cash provided by investing activities for both periods was primarily associated with transactions involving our marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">Net Cash Provided by Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by financing activities was $6.7 million for the nine months ended September 30, 2024 compared to $6.0 million for the nine months ended September 30, 2023. Net cash provided by financing activities for the nine months ended September 30, 2024 was primarily attributable to proceeds from the exercise of warrants. Net cash provided by financing activities for the nine months ended September 30, 2023 was primarily attributable to proceeds from the sale of common stock through our ATM. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">We expect our expenses to be substantial as we continue the research and development of apitegromab in SMA. In addition, we will seek marketing approval for apitegromab, and if we seek marketing approval for any of our future product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We expect to continue to incur costs related to SRK-181 as we continue to treat patients who remain on the Phase 1 DRAGON clinical trial. We expect to incur costs to support our cardiometabolic program, including EMBRAZE, our Phase 2 proof-of-concept trial of apitegromab and our preclinical program, SRK-439. Additionally, we will support the development of our pipeline and any other preclinical programs. Furthermore, we expect to continue to incur costs associated with operating as a public company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">We expect that our existing cash, cash equivalents, marketable securities, cash available to us, together with the approximately $324.4 million in net proceeds from the follow-on offering completed in October 2024 will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2026. However, we will require additional capital in order to complete clinical development and commercialization for each of our current programs. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the costs and timing of developing our product candidates and future product candidates, including costs associated with apitegromab in our Phase 3 SAPPHIRE clinical trial in SMA and ONYX, our&#160;long-term extension study&#160;in SMA for patients from both the TOPAZ and SAPPHIRE studies, our Phase 2 proof-of-concept trial for apitegromab in our cardiometabolic program, our Phase 1 DRAGON clinical trial for SRK-181, and the costs and timing of conducting future preclinical studies and clinical trials for SRK-439 or any other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the costs of future manufacturing of apitegromab, SRK-181, SRK-439 and any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of discovery, preclinical development, laboratory testing and clinical trials for other potential product candidates we may develop, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of identifying and developing, or in-licensing or acquiring, additional product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements, license agreements, or other agreements we might have at such time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of seeking marketing approvals for our product candidates that successfully complete clinical trials, including apitegromab in SMA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our headcount growth and associated costs as we expand our business operations and research and development activities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of supporting our infrastructure and facilities, including equipment and physical infrastructure to support our research and development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the impact of adverse global economic conditions on our business, which may exacerbate the magnitude of the factors discussed above.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 36pt;"><span style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, common stockholder ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect the rights of a common stockholder. Additional debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Market volatility or other factors could also adversely impact our ability to access capital as and when needed. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Critical Accounting Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This management&#8217;s discussion and analysis is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">consolidated financial statements prospectively from the date of change in estimates. Our actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There have been no material changes to our critical accounting estimates from those described in Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this Quarterly Report, they will not have a material impact on our financial statements or do not otherwise apply to our operations.</p><a id="_753c8b5c_56ea_47d7_8bad_26ee204de013"></a><a id="ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item 3.&#160;Quantitative and Qualitative Disclosures About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item. </p><a id="_c43aa15f_1c9c_4f3b_a5d7_2ffb90833834"></a><a id="ITEM4CONTROLSANDPROCEDURES_891868"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item 4.&#160;Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1)&#160;recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules&#160;and forms and (2)&#160;accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, with the participation of our chief executive officer (principal executive officer) and chief financial officer (principal financial and accounting officer) has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date. We continue to review and document our disclosure controls and procedures, including our internal controls and procedures for financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Changes in Internal Controls Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">No change in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the</span> <span style="font-weight:normal;">Exchange Act) occurred during the nine months ended September 30, 2024 that has materially affected, or is</span> <span style="font-weight:normal;">reasonably</span> <span style="font-weight:normal;">likely to materially affect, our internal control over financial reporting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9af0d964_4d48_472a_b4ab_2f61bc8938f2"></a><a id="PartII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Part&#160;II. OTHER INFORMATION</p><a id="PartIIOtherInformation_286525"></a><a id="_beb67fd3_b68c_47b9_b02d_f565941cd287"></a><a id="Item1LegalProceedings_714803"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1. Legal Proceedings </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Quarterly Report, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><a id="_83fa2196_dcb4_4643_aace_7c6e4fbda1e4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Item1ARiskFactors_725058"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;1A. Risk Factors</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Careful consideration should be given to the following risk factors, together with all other information set forth in this Quarterly Report, including our consolidated financial statements and related notes, and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and in other documents that we file with the Securities and Exchange Commission (the &#8220;SEC&#8221;), in evaluating Scholar Rock Holding Corporation and our subsidiaries (collectively, the &#8220;Company&#8221;, &#8220;we&#8221;, or &#8220;our&#8221;) and our business, before investing in our common stock. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The market price of our common stock could decline if one or more of these risks or uncertainties were to occur, which may cause you to lose all or part of the money you paid to buy our common stock. The risk factors described below disclose both material and other risks, and are not intended to be exhaustive and are not the only risks facing the Company. New risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations. Certain statements below are forward-looking statements. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; in this Quarterly Report.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Summary of the Material Risks Associated with Our Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">Our business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled &#8220;Risk Factors.&#8221; These risks include, but are not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Risks Related to Product Development, Regulatory Approval and Commercialization</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of apitegromab, SRK-181, SRK-439, or any future product candidates. Many of the factors that cause, or lead to, a delay in the initiation or completion of clinical trials may also ultimately lead to the denial of regulatory approval or limit market acceptance of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The results of preclinical studies and early-stage clinical trials may not be predictive of future results. Success of a product candidate in an early-stage clinical trial may not be replicated in later-stage clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Interim, initial and preliminary results from our clinical trials that we announce or publish from time to time may change (e.g. from positive safety or efficacy results to poor or negative safety or efficacy results) as more patient data become available and are subject to additional audit, validation and verification procedures that could result in material changes in the final data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our clinical trials and to conduct certain aspects of our preclinical studies. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with legal and regulatory requirements, we may be delayed or unable to receive regulatory approval of or commercialize apitegromab, SRK-181, SRK-439 or any future product candidates, and our business could be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have never commercialized a product and will need to build and scale our business for potential commercialization of apitegromab, including building our compliance, medical affairs and commercial organizations, which, if we are not able to do so successfully could negatively impact our business, including the potential for a successful commercialization of apitegromab.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval process for our product candidates in the U.S., EU and other jurisdictions will be lengthy, time-consuming and inherently unpredictable and we may fail to receive or be delayed in receiving regulatory approval of apitegromab, SRK-181, SRK-439 and future product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have received Orphan Drug designation from the FDA for apitegromab for the treatment of SMA and the EC granted Orphan Medicinal Product designation to apitegromab for the treatment of SMA. We may seek Orphan Drug designation from regulatory authorities in other jurisdictions for apitegromab and Orphan Drug </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designation from the FDA, EC or regulatory authorities in other jurisdictions for our other product candidates. In any of these instances, we may not receive the requested designation or we may be unable to realize the benefits associated with Orphan Drug designation, including the potential for market exclusivity. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical development is uncertain. Our preclinical programs, such as SRK-439, may experience delays or may never advance to clinical trials, which would adversely affect our ability to develop our product pipeline and receive regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Risks Related to Our Business and Operations</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because we rely on a limited number of third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials, and, if approved, commercial materials, may become limited or interrupted or may not be of satisfactory quantity or quality.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our reliance on third parties, such as manufacturers, may subject us to risks relating to manufacturing scale-up and may cause us to undertake substantial obligations, including financial obligations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need to continue to grow our organization in certain areas, including our personnel, systems and relationships with third parties, in order to develop our drug candidates and we may experience difficulties in managing this growth.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our executives and highly skilled technical and managerial personnel are critical to our business. If we have transition in management, lose key personnel, or if we fail to recruit additional highly skilled personnel, our ability to further develop apitegromab, SRK-181, SRK-439 and identify and develop new or next generation product candidates may be impaired.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to comply with health care privacy and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operation results and business.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Risks Related to Intellectual Property</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. Third-party claims of intellectual property infringement may prevent or delay our product discovery, development, and commercialization efforts.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Risks Related to Our Financial Condition and Capital Requirements</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require additional capital to fund our operations and if we fail to obtain necessary capital, we will not be able to complete the development and commercialization of apitegromab, SRK-181, SRK-439 and any future product candidates.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Risks Related to Our Common Stock</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The price of our stock is volatile, and you could lose all or part of your investment.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">Risks Related to Product Development, Regulatory Approval and Commercialization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Product development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of apitegromab, SRK-181, SRK-439, or any future product candidates. Many of the factors that cause, or lead to, a delay in the initiation or completion of clinical trials may also ultimately lead to the denial of regulatory approval or limit market acceptance of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Before obtaining regulatory approvals for the commercial sale of any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain, a clinical trial can fail at any stage of development. We may experience delays in initiating, progressing or completing our clinical trials. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful. Clinical trials may fail to meet their primary or secondary endpoints, raise safety concerns or generate mixed results. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Clinical data may not be sufficient to apply for and obtain regulatory approval on the timelines we expect or at all. Other decisions or actions of regulatory agencies may affect our plans, progress or results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We also may experience numerous unforeseen events during, or as a result of, any clinical trials in process or any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize apitegromab, SRK-181, SRK-439, or any future product candidates, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or inability to reach agreement with the FDA or comparable foreign regulatory authorities on acceptable clinical trial design, conduct or statistical analysis plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators, Institutional Review Boards (&#8220;IRBs&#8221;) or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by our collaborators to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may provide insufficient funding for a clinical trial program, delay or stop a clinical trial, abandon a product candidate or clinical trial program, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of any product candidates may fail to show safety and effectiveness, or produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower or more challenging than we anticipate or subjects may drop out of these clinical trials or fail to return for post treatment follow-up at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">challenges in identifying or recruiting sufficient study sites or investigators for clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical study sites or clinical investigators may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations on our or our CROs&#8217; ability to access and verify clinical trial data captured at clinical study sites through monitoring and source document verification;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of a product candidate may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate to initiate or complete a given clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate the trials, or reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates may have undesirable side effects or other unexpected characteristics when used in a new disease indication or with products in a different class which may raise safety, efficacy or other concerns about our product candidate as a potential therapy in that new disease indication or other indications or its use with products in a different class;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidate and/or data emerging from other molecules in the same class as our product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, EMA or other regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or change or impose other requirements before permitting us to initiate a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evolution in the standard of care or changes in applicable governmental regulations or policies during the development of a product candidate that require amendments to ongoing clinical trials and/or the conduct of additional preclinical studies or clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to complete a clinical trial.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">Many of the factors that cause, or lead to, a delay in the initiation or completion of clinical trials may also ultimately lead to the denial of regulatory approval or limit market acceptance of our product candidates. For example, we anticipate some of our future trials to, in part, utilize an open-label trial design, and our ongoing Phase 1 DRAGON clinical trial for SRK-181 in cancer immunotherapy and our ongoing ONYX long-term extension study for apitegromab in patients from both the TOPAZ and SAPPHIRE trials, utilize an open-label trial design. An open-label trial is one where both the patient and investigator know whether the patient is receiving the test article or either an existing approved drug or placebo. Open-label trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label studies are aware that they are receiving treatment. Open-label trials may be subject to a patient bias, for example, if patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Open-label trials also may be subject to an investigator bias where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The potential sources of bias in clinical trials as a result of open-label design may not be adequately mitigated and may cause any of our trials that utilize such design to fail and additional trials may be necessary to support future marketing applications. In addition, other types of trials (including randomized, double-blind, parallel arm studies), particularly if smaller in size or if limited to one study, are also subject to potential sources of bias and limitations that may exaggerate any therapeutic effect or falsely identify a positive efficacy signal</span>, <span style="font-weight:normal;">or conversely, fail to detect an efficacy signal when in fact there may actually be a positive therapeutic effect. Furthermore, we are conducting clinical trials with apitegromab in SMA, but by using apitegromab in a Phase 2 obesity clinical trial, we may become aware of safety information associated with apitegromab that we did not observe when we used apitegromab in our clinical trials in SMA. We, the FDA, the competent authorities and/or ethics committees of the EU Member States or other applicable regulatory authorities for their jurisdictions, or an </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">IRB for their site(s) may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our clinical development strategy depends on the continued use and availability of certain third-party approved drug therapies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Apitegromab and SRK-181 are our two clinical-stage product candidates. Patients in our Phase 3 SAPPHIRE clinical trial, and ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies, are receiving apitegromab in conjunction with an approved SMN therapy. These patients are reliant on the continued use and availability of such therapies. If access to an approved SMN therapy such as nusinersen or risdiplam becomes limited or is unavailable, we may be forced to pause or stop our SAPPHIRE or ONYX long-term extension trials, or the medical condition of patients may be affected which could negatively affect the efficacy and safety results for apitegromab in the trials or reduce the amount of data or confound the data from these trials. In May 2024, we initiated the Phase 2 EMBRAZE proof-of-concept trial of apitegromab in combination with approved GLP-1 RAs in obesity. This study will rely upon the continued availability of such GLP-1 RA. Access to approved GLP-1 RAs are limited for use in clinical trials and may continue to be limited for such use. If GLP-1 RAs become more limited or unavailable, we may be unable to enroll, or may be delayed in enrolling patients, or may be forced to stop our Phase 2 study. While we have obtained substantial supply of an approved GLP-1 RA for use in this Phase 2 study, we cannot assure you that we will be able to obtain adequate supply for future studies of our product candidate in obesity. Patients in Part B of our ongoing Phase 1 DRAGON clinical trial of SRK-181 in patients with locally advanced or metastatic solid tumors that exhibit resistance to anti-PD-(L)1 antibody therapies are receiving SRK-181 in conjunction with an approved anti-PD-(L)1 therapy such as pembrolizumab. If access to the approved anti-PD-(L)1 therapy becomes limited or is unavailable, we may be forced to pause or stop our Phase 1 DRAGON clinical trial, or the medical condition of patients may be affected which could negatively affect the efficacy and safety results for SRK-181 in the trial. Any delay or suspension of our clinical trials would significantly and delay our clinical development programs and harm our business, financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">The results or success of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of future results or replicated in later preclinical studies or clinical trials of our product candidates in the same indications or other indications.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The results or success of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of future results or replicated in later preclinical studies or later-stage clinical trials. Preclinical studies and early-stage clinical trials are primarily designed to study PK and PD, understand the side effects of product candidates, and evaluate various doses and dosing schedules. Our current or future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later-stages of clinical trials may fail to show desired pharmacological properties or produce positive safety and efficacy results despite having progressed through preclinical studies and early-stage clinical trials. We completed a Phase 1 clinical trial for apitegromab in healthy adult volunteers and we completed the treatment period of our Phase 2 TOPAZ clinical trial for the treatment of patients with Type 2 and Type 3 SMA. In 2024, we announced data from the Phase 2 TOPAZ trial extension period which showed patient outcomes at 48 months of treatment with apitegromab. These data show that continued treatment with apitegromab over the extended period was associated with sustained clinical benefit, a continued favorable safety profile with no new safety findings, and a retention rate of over 90% in patients with nonambulatory Types 2 and 3 SMA receiving SMN therapy. In January 2022, we initiated our Phase 3 SAPPHIRE clinical trial of apitegromab for the treatment of patients with Type 2 and Type 3 SMA and in September 2023, we announced completion of trial enrollment. In October 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the efficacy and safety of apitegromab. We also announced in October 2023 our plans to expand into cardiometabolic disorders based on preclinical data with SRK-439, and we initiated the Phase 2 EMBRAZE proof-of-concept trial of apitegromab in combination with a GLP-1 receptor agonist in obesity in May 2024 with top-line results expected in the second quarter of 2025. We cannot assure you that any future clinical trials of apitegromab, such as our Phase 2 clinical trial in obesity, or of SRK-439 will show positive results. Additionally, product candidates evaluated in one disease indication may interact in unforeseen or harmful ways in a patient population with a different disease indication than was previously studied. For example, we are evaluating apitegromab in SMA, and have initiated a Phase 2 clinical trial of apitegromab in obesity. Apitegromab may interact in unforeseen or different ways in the obesity population than in the SMA patient population. There can be no assurance that any of our current or planned clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There can also be no assurance that any of our future clinical trials will show similar results to our earlier clinical trials or support further development or registration of any of our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interim, initial, or preliminary results from our clinical trials that we announce or publish from time to time may change (e.g. from positive safety or efficacy results to poor or negative safety or efficacy results) as more patient data become available and are subject to additional audit, validation and verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">From time to time, we may publish interim, initial, or preliminary data, including interim top-line results or initial or preliminary results from our clinical trials. Any interim, initial or preliminary data and other results from our clinical trials may materially change as more patient data become available. Preliminary, initial, interim or top-line results also remain subject to audit, validation and verification procedures that may result in the final data being materially different from the interim, initial or preliminary data we previously published. As a result, interim, initial or preliminary data may not be predictive of final results and should be viewed with caution until the final data are available. We may also arrive at different conclusions, or considerations may qualify such results, once we have received and fully evaluated additional data. For example, clinical data from our Phase 1 DRAGON trial in cancer immunotherapy, including preliminary safety, efficacy and biomarker data were presented in June 2024 at the ASCO 2024 annual meeting and in November 2024 at the SITC 39th Annual Meeting, and we will continue to present data from our Phase 1 DRAGON trial while the trial is ongoing. Tumor response data is based on assessments by site investigators. Central reads for the tumor responses are also being conducted, with a comprehensive review of the central reads to be performed once completed within and/or across the cohorts. Differences between preliminary, initial or interim data and final data could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical development even after achieving promising results in earlier studies, and we cannot be certain that we will not face similar setbacks. Many drugs have failed to replicate efficacy and safety results in larger or more complex later stage trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory approval. If we fail to produce positive results in our ongoing and planned preclinical studies and clinical trials in apitegromab, SRK-181, SRK-439 or if a regulatory authority interprets and analyzes the results as not positive, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including:</span> </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility and exclusion criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness or availability of patients to participate in our trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and location of participating trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to trial sites and any limitations on travel or access to trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop-out of the trials before completion of their involvement in the study.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">For example, we are initially developing apitegromab for the treatment of SMA, a rare disease, affecting an estimated 20,000 patients in the U.S. and Europe. As a result, we may encounter difficulties enrolling patients in our clinical trials for apitegromab due, in part, to the small size of this patient population. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. Additionally, patients may opt out of participation in clinical trials in favor of treatment with FDA-approved therapies, or therapies approved in the EU or other foreign jurisdictions.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We rely on third parties to conduct our clinical trials and certain aspects of our preclinical studies. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with legal and regulatory requirements, we may be delayed or unable to receive regulatory approval of or commercialize apitegromab, SRK-181, SRK-439, or any future product candidates, and our business could be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We depend upon third parties to conduct certain aspects of our preclinical studies and to conduct our clinical trials, under agreements with universities, medical institutions, CROs, strategic partners and others. We often have to negotiate budgets and contracts with such third parties, and if we are unsuccessful or if the negotiations take longer than anticipated, this could result in delays to our development timelines and increased costs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">We rely especially heavily on third parties over the course of our clinical trials, and, as a result, have limited control over the clinical investigators and limited visibility into their day-to-day activities, including with respect to their individual employment policies or compliance with the approved clinical protocol. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with Good Clinical Practice (&#8220;GCP&#8221;) requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot be certain that, </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP requirements. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in civil monetary penalties, adverse publicity and civil and criminal sanctions. The FDA and National Institutes of Health have signaled the government&#8217;s willingness to begin enforcing these registration and reporting requirements against non-compliant clinical trial sponsors. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our failure or any failure by these third parties to comply with these regulations would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Any third parties conducting aspects of our preclinical studies or clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our preclinical studies and clinical trials. The third party CROs and clinical trial sites that conduct our clinical trials have experienced staffing shortages and the inability of a CRO or clinical trial site to maintain appropriate levels of competent staffing to support the demands of our clinical trials could negatively impact the execution of our clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines if they need to be replaced or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons, our development timelines, including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, receive regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We have never commercialized a product and will need to build and scale our business for potential commercialization of apitegromab, including building our compliance, medical affairs and commercial organizations, which, if we are not able to do so successfully could negatively impact our business, including the potential for a successful commercialization of apitegromab.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Although we are preparing our commercialization capabilities in anticipation of a potential approval and commercial launch of apitegromab, we have no prior sales or distribution experience and limited capabilities for marketing and market access. We expect to invest significant financial and management resources over time to establish compliance, medical affairs and commercial organizations for the marketing, sales and distribution of apitegromab, if approved, and other capabilities and infrastructure to support commercial operations. If we are unable to establish these commercial capabilities and infrastructure in a timely manner or to enter into agreements with third parties to market, sell, and/or distribute apitegromab if approved, we may be unable to complete a successful commercial launch. To the extent we enter into agreements with third parties, the revenue we receive may depend upon the efforts of such third parties, over which we may have limited or no control, and our revenue from product sales may be lower than if we had commercialized the products ourselves. We also face competition in our search for third parties to assist us with the distribution, sales and marketing of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Furthermore, we intend to commercialize apitegromab globally, if approved. In order to do so, we must build, on a territory-by-territory basis, marketing, sales, distribution, managerial and other capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">The regulatory approval process for our product candidates in the U.S., EU and other jurisdictions will be lengthy, time-consuming and inherently unpredictable and we may fail to receive or be delayed in receiving regulatory approval of apitegromab, SRK-181, SRK-439 and future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The research, testing, manufacturing, labeling, approval, sale, import, export, marketing, promotion and distribution of drug products, including biologics, are subject to extensive regulation by the FDA in the U.S. and other regulatory authorities outside the U.S. We are not permitted to market any biological product in the U.S. until we receive a biologics license from the FDA. We have not previously submitted a Biologics License Application (&#8220;BLA&#8221;) to the FDA or similar marketing application to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, pure and potent for each desired indication. FDA approval of a new biologic or drug generally requires dispositive data from two (and in some cases, one) adequate and well-controlled pivotal Phase 3 clinical trials of the biologic or drug in the relevant patient population. The FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials or our analysis or interpretation of data from preclinical studies or clinical trials, the results of our clinical trials may not meet the level of statistical significance or amount of data required for approval, or we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks. A BLA must also include significant information regarding the chemistry, manufacturing, and controls for the product, and the manufacturing facilities must complete a successful pre-license inspection as well as certain key clinical sites conducting our clinical trials. The FDA, EMA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The FDA may seek independent advice from a panel of experts, referred to as an Advisory Committee, on complex or novel issues that may be presented in an application, including issues related to the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to receive approval of any product candidates that we develop based on the completed clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions at which such trials are being conducted, or the FDA, the competent authorities and/or ethics committees of the EU Member States or other regulatory authorities, or recommended for suspension or termination by the DSMB for such trial, due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, competent authorities of the EU Member States or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the prospects for regulatory approval and commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing any clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We have received Orphan Drug designation from the FDA for apitegromab for the treatment of SMA and the EC granted Orphan Medicinal Product designation to apitegromab for the treatment of SMA. We may seek Orphan Drug designation from regulatory authorities in other jurisdictions for apitegromab and Orphan Drug designation from the FDA, EC or regulatory authorities in other jurisdictions for our other product candidates. In any of these instances, we may not receive the requested designation or we may be unable to realize the benefits associated with Orphan Drug designation, including the potential for market exclusivity. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">We have received Orphan Drug designation from the FDA for apitegromab for the treatment of SMA, and following the EMA&#8217;s Committee for Orphan Medicinal Products&#8217; positive opinion, the EC designated apitegromab as an orphan medicinal product for the treatment of SMA. Even if we receive orphan drug exclusivity, the benefit of that exclusivity may be limited if we seek approval for an indication broader than the orphan-designated indication or could be revoked under certain circumstances, for example if the FDA later determines that the request for designation was materially defective or that we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we receive orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition during the exclusivity period because different drugs with different active moieties can be approved for the same condition, and the same product can be approved for different uses. Also, </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">in the U.S., even after an orphan drug is approved and receives orphan drug exclusivity, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug, including because it has been shown to be clinically superior to the drug with exclusivity because it is safer, more effective or makes a major contribution to patient care. In the EU, a marketing authorization may be granted to a similar medicinal product to an authorized orphan product for the same orphan indication if:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">See the sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled, &#8220;Business &#8212; Government Regulation &#8212; US Biological Product Development  &#8212; Orphan Drug Designation&#8221; and &#8220;Business &#8211; Government Regulation &#8211; European Union Drug Development  &#8212; European Union Orphan Designation and Exclusivity.&#8221;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We have received Rare Pediatric Disease designation for apitegromab for the treatment of SMA. However, a marketing application for apitegromab, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have received Rare Pediatric Disease designation for apitegromab for the treatment of SMA. Designation of a biologic as a product for a rare pediatric disease does not guarantee that a BLA for such biologic will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the Federal Food, Drug, and Cosmetic Act, we will need to request a rare pediatric disease priority review voucher in our original BLA for apitegromab. The FDA may determine that a BLA for apitegromab, if approved, does not meet the eligibility criteria for a rare pediatric disease priority review voucher, including for the following reasons:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SMA no longer meets the definition of a rare pediatric disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">apitegromab contains an active ingredient (including any ester or salt of the active ingredient) that has been previously approved in an application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the BLA is not deemed eligible for priority review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the BLA does not rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the BLA seeks approval for a different adult indication than the rare pediatric disease for which apitegromab is designated.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The authority for the FDA to award rare pediatric disease priority review vouchers for biologics after September 30, 2024 is currently limited to biologics that receive Rare Pediatric Disease designation on or prior to December 30, 2024, and the FDA may only award rare pediatric disease priority review vouchers through September 30, 2026. If the BLA for apitegromab is not approved on or prior to September 30, 2026 for any reason, it will not be eligible for a priority review voucher. However, it is possible the authority for the FDA to award rare pediatric disease priority review vouchers will be further extended by Congress. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We have received Fast Track designation from the FDA and PRIME designation from the EMA for apitegromab for the treatment of SMA. We may seek Fast Track designation or Breakthrough Therapy designation from the FDA or PRIME designation from the EMA for certain of our current and future product candidates, and we may not be successful in receiving such designations, or if received, such designation may not actually lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We may seek Fast Track designation, Breakthrough Therapy designation or PRIME designation for certain of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">In May 2021, the FDA granted Fast Track designation for apitegromab for the treatment of SMA. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure that the FDA would decide to grant it. Although the FDA has granted Fast Track designation for apitegromab in SMA, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;white-space:pre-wrap;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the products no longer meet the conditions for qualification and rescind the breakthrough designation. See the sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled, &#8220;Business &#8212; Government Regulation &#8212; US Biological Product Development  &#8212; Expedited Development and Review Programs.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In March 2021, the EMA granted PRIME designation to apitegromab for the treatment of SMA. PRIME is a scheme provided by the EMA to enhance support for the development of medicines that target an unmet medical need. The receipt of PRIME designation for apitegromab for the treatment of SMA may not result in a faster development process, review or approval compared to products considered for approval under conventional regulatory agency procedures and does not assure ultimate approval by the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">See the section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled, &#8220;Business &#8211; Government Regulation &#8211; European Union Drug Development  &#8212; European Union Expedited Review and Development.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;white-space:pre-wrap;">We may seek priority review or accelerated assessment for certain of our product candidates at the time of submitting a marketing application to the FDA or EMA. Even if received, priority review designation may not result in a shorter timeline to approval, and such designation may be rescinded if a product no longer meets the qualifying criteria. An application for accelerated assessment may not be accepted by the EMA and, even if it is, there is no guarantee that a product will be granted a marketing authorization.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As appropriate, we may seek priority review at the time of submitting a marketing application for certain of our product candidates. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) goal date for taking action on a marketing application from ten months to six months from FDA&#8217;s acceptance of the application for review. However, priority review does not guarantee a faster review or approval process or assure ultimate approval by the FDA. In addition, priority review designation may be rescinded if the FDA determines that a product no longer meets the qualifying criteria.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, as appropriate, we may seek accelerated assessment of a marketing authorization application by the EMA for certain of our product candidates. The EMA may accept an application for accelerated assessment if the applicant can show that its product is of major interest for public health, particularly from the perspective of therapeutic innovation. Accelerated assessment reduces the timeframe for the EMA to review a marketing authorization application from 210 days (excluding &#8220;clock stops&#8221;, when applicants are required to provide additional information in response to questions from the EMA) to 150 days (excluding clock stops). There is no single definition of what constitutes major public health interest and the EMA may not accept an application for accelerated assessment. Even if an application for accelerated assessment is accepted, the evaluation of the marketing authorization application is subject to the same evidence requirements as evaluation under a standard timetable and there is no guarantee that a product will be granted a marketing authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Receiving and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in receiving or maintaining regulatory approval of our product candidates in other jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Receiving and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to receive or maintain regulatory approval in any other jurisdiction, but a failure or delay in receiving regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in other jurisdictions. Even if the FDA grants marketing approval of a product candidate, the EC, the competent authorities of EU Member States or comparable regulatory authorities in foreign jurisdictions may not approve the manufacturing, marketing and promotion of the product candidate in other countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the U.S. have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Receiving foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements, including requirements related to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, import, export, conduct of post-marketing studies and submission of safety, efficacy and other post-marketing information. In addition, we will be subject to continued compliance with current Good Manufacturing Practice (&#8220;cGMP&#8221;) and GCP requirements for any clinical trials that we conduct post-approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, EU and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to periodic review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA or other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved uses for which the product may be marketed or contain requirements for potentially costly post-market testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters, untitled letters or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention or refusal to permit the import or export of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permanent injunctions and consent decrees, including the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Products may be promoted only for their approved indications and in a manner consistent with their FDA-approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of unapproved uses and a company that is found to have improperly promoted unapproved uses may be subject to significant liability. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. In addition, the U.S. Supreme Court&#8217;s July 2024 decision to overturn established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may face enforcement action and our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">If apitegromab, SRK-181, SRK-439 or any future product candidate we develop receives marketing approval, whether as a single agent or in conjunction with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. For example, doctors may deem it sufficient to treat patients with SMA with an SMN therapy such as nusinersen or risdiplam, and therefore will not be willing to utilize apitegromab in conjunction with such SMN therapy. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount, scope and nature of the clinical data (and other forms of data) available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to offer our products, if approved, for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">convenience and ease of administration compared to alternative treatments;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain sufficient third-party coverage and adequate reimbursement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Competing therapies may exist or could emerge that adversely affect the amount of revenue we are able to generate from the sale of apitegromab, if approved, or any of our future product candidates, if successfully developed and approved. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The biopharmaceutical industry is highly competitive. There are many public and private companies, universities, governmental agencies and other research organizations actively engaged in the research and development of products that may be similar to our product candidates or address similar markets. If we are successful in developing apitegromab, it is probable that the number of companies seeking to develop products and therapies similar to our products candidates or targeting similar indications will increase. Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and human resources than we do, and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and the commercialization of those treatments. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. We expect competition in the indications we are pursuing will focus on efficacy, safety, convenience, availability, and price. The commercial opportunity for apitegromab, if approved, could be reduced or eliminated if our competitors develop and commercialize products that are perceived to be safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than apitegromab. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Preclinical development is uncertain. Our preclinical programs, such as SRK-439, may experience delays or may never advance to clinical trials, which would adversely affect our ability to develop our product pipeline and receive regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Before we can commence clinical trials for any product candidate, we must complete extensive preclinical studies that support our planned INDs in the U.S., or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our preclinical studies or of the timing of any planned IND submission to the FDA or similar applications in other jurisdictions, and cannot predict if the FDA, EMA or other regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical studies will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for the clinical development of our preclinical programs, such as our potential IND for SRK-439, on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA, the competent authorities and/or ethics committees in the EU Member States or other regulatory authorities allowing clinical trials to begin.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Conducting preclinical testing can be a lengthy, time-consuming and expensive process. The time required for such testing may vary substantially according to the type, complexity and novelty of the program, and can be several years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. We also may be affected by delays associated with the preclinical testing and studies of certain programs that are the responsibility of our collaborators or our potential future collaborators over which we have limited or no control. The commencement and rate of completion of preclinical studies for a product candidate may be delayed by many factors, including, for example, challenges in reaching consensus with regulatory agencies regarding the scope of the necessary preclinical study program and/or appropriate preclinical study designs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business and Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Because we rely on a limited number of third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials, and, if approved, commercial materials, may become limited or interrupted or may not be of satisfactory quantity or quality.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We rely on a limited number of third-party contract manufacturers to manufacture all of our clinical trial product supplies and, if approved, all of our commercial product supplies, including all of our drug substance, drug product, labeling, and packaging. We do not own our own manufacturing facilities for producing any clinical trial or commercial product supplies. There can be no assurance that our preclinical, clinical development, and, if approved, commercial product supplies will not be limited or interrupted due to impacts to our third-party contract manufacturers. For example, we rely on a single source supplier for the manufacture of apitegromab and SRK-181. Any replacement of our current drug substance contract manufacturer or drug product contract manufacturer would require significant resources, lead time and expertise because there may be a limited number of qualified replacements. In addition, our ability to procure sufficient supplies for the development of apitegromab, SRK-181, SRK-439 or future product candidates could be impacted by factors outside of our control such as current macroeconomic and geopolitical events and the changing rates of inflation and interest rates. We have no direct control over our contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our third-party contract manufacturers supply and/or manufacture materials or products for other companies, which exposes our third-party contract manufacturers to regulatory risks for the production of such materials and products. As a result, failure to satisfy the regulatory requirements for the production of those materials and products may affect the regulatory clearance of our contract manufacturers&#8217; facilities generally.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on the original manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we must change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We expect to continue to rely on third-party manufacturers for commercial supplies of drug substance, drug product, and packaged and labeled product for apitegromab, if we receive regulatory approval. We will also rely on our contract manufacturers to manufacture sufficient quantities of apitegromab to produce validation batches. We do not have long-term supply agreements in place with any of our contract manufacturers, and each batch of our product candidates is individually contracted through a purchase order governed by master service and quality agreements. If our existing contract manufacturers for our product candidates are not willing to enter into long-term supply agreements, or are not willing or are unable to supply product candidate supplies to us, we could be required to engage new contract manufacturers who would need to scale up the manufacturing process before we would be able to use the product candidate supplies they manufacture, which could result in delays to our clinical trials or future commercialization plans, if we are successful and gain approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">To the extent that we have existing, or in the future enter into, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third-party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to initiate or continue clinical trials for apitegromab, SRK-181, SRK-439 or of future product candidates under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay in submitting regulatory applications, or receiving regulatory approvals, for apitegromab, SRK-181, SRK-439 or future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of the cooperation of an existing or future collaborator;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to cease distribution or to recall batches of apitegromab, SRK-181, SRK-439 or future product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of approval to market and commercialize apitegromab, SRK-181, SRK-439 or a future product candidate, an inability to meet commercial demands for our products.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">In addition, we contract with fill and finishing providers which we believe have the appropriate expertise, facilities and scale to meet our needs. Failure to maintain compliance with cGMP can result in a contractor receiving FDA sanctions, which can impact our ability to operate or lead to delays in any clinical development programs. We believe that our current fill and finish contractors are operating in accordance with cGMP, but we can give no assurance that the FDA, EMA, competent authorities of the EU Member States or other regulatory agencies will not conclude that a lack of compliance exists. In addition, any delay in contracting for fill and finish services, or failure of the contract manufacturer to perform the services as needed, may delay any clinical trials, registration and commercial launches, which could negatively affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Our reliance on third parties, such as manufacturers, may subject us to risks relating to manufacturing scale-up and may cause us to undertake substantial obligations, including financial obligations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In order to continue to conduct later-stage clinical trials, or, if approved, produce commercial product, we will need to manufacture such product candidate in large quantities. In particular, we expect to rely on our contract manufacturers to scale our manufacturing processes for future clinical trials of apitegromab, and if our development efforts are successful and if apitegromab is approved, for commercial supply of apitegromab. We, or any manufacturing partners, may be unable to successfully increase the manufacturing capacity for apitegromab in a timely or cost-effective manner to meet our supply requirements. In addition, quality-control issues may arise during scale-up activities. If we, or any manufacturing partners, are unable to successfully scale-up the manufacture of our product candidates in sufficient quality and quantity, the development, testing, clinical trials, and if approved, commercial supply, of that product candidate may be delayed or infeasible, and regulatory approval, commercial launch or commercial supply of any resulting product may be delayed or not received, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We will need to continue to grow our organization in certain areas,</span> <span style="font-style:italic;">including our personnel, systems and relationships with third parties, in order to develop our product candidates, and we may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">As our clinical development plans and commercialization strategies continue to develop and expand, we expect we will need to hire additional managerial, clinical development, scientific, regulatory, commercial, and administrative personnel. Our ability to compete in the highly competitive biotechnology industry depends upon our ability to attract and retain highly qualified specialized personnel. As apitegromab approaches commercialization, we will also need to hire sales, marketing and other commercial personnel. Future growth would impose significant added responsibilities on members of management, including:</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing our development efforts effectively, including the clinical and regulatory review process for apitegromab, SRK-181, SRK-439, and any future product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improving our operational, financial and management controls, reporting systems and procedures.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our future financial performance and our ability to commercialize apitegromab, SRK-181, SRK-439 and future product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on third parties, advisors and consultants to provide certain services, including CROs, contract manufacturers and companies focused on antibody development and discovery activities. There can be no assurance that the services of third parties, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality, accuracy or quantity of the services provided is compromised for any reason, our preclinical studies and clinical trials may be extended, delayed or terminated, and we may not be able to receive, or may be substantially delayed in receiving, regulatory approval of apitegromab, SRK-181, SRK-439 or future product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for a limited number of qualified personnel in the biopharmaceutical space, especially those engaged in oncology and immuno-oncology</span> <span style="font-weight:normal;">and cardiometabolic fields. In this highly competitive market, there may be increased costs to attract and retain qualified personnel. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high quality candidates than what we have to offer. If we are not able to offer competitive compensation or appealing opportunities for high quality candidates, we may not be able to attract or retain qualified candidates and personnel.</span> <span style="font-weight:normal;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize apitegromab, SRK-181, SRK-439 or any future product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Our executives and highly skilled technical and managerial personnel are critical to our business. If we have transition in management, lose key personnel, or if we fail to recruit additional highly skilled personnel, our ability to further develop apitegromab, SRK-181 and SRK-439 and identify and develop new or next generation product candidates may be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our performance substantially depends on the performance of our management team. Any transition or loss of the services of any of our executives or highly skilled technical and managerial personnel could have a disruptive impact on our ability to implement our strategy and impede the achievement of our research, development and commercialization objectives. In addition, these transitions or departures could, cause us to incur increased operating expenses, divert senior management resources in searching for replacements, or otherwise have a material adverse effect on our business, internal controls, financial condition and results of operations. Management transition inherently causes some loss of institutional knowledge, which can negatively affect strategy and operational execution during this phase. If we have additional changes to our executives or highly skilled technical and managerial personnel, we may be unable to successfully manage and grow our business, and our results of operations, execution of corporate goals, internal controls and financial condition could suffer as a result. The unplanned loss of the services of our executives or other personnel also could harm our reputation.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Our internal computer systems, or those used by our contract research organizations, or other contractors or consultants, may fail or suffer security breaches, incidents or compromises.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We have outsourced significant parts of our IT and business infrastructure to third-party providers, and we currently use these providers to perform business critical IT and business services for us.</span> <span style="font-weight:normal;">Despite the implementation of security measures, our computer systems, whether they are managed by us directly or by the third parties with whom we contract, and those of our existing and future CROs, and other contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. Our increased reliance on personnel working from home may increase our cyber security risk, create data accessibility concerns, and make us more susceptible to workforce and communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other agencies and contractors. For example, the loss of preclinical or clinical data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of apitegromab, SRK-181 and SRK-439 and to conduct preclinical studies and clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of apitegromab, SRK-181, SRK-439 and future product candidates could be delayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">As a company that uses IT systems, our systems may be subject to cyber-attacks, incidents or compromises. Due to the nature of some of these attacks, there is a risk that they may remain undetected for a period of time. While we have invested in the protection of data and information technology, our efforts may not prevent service interruptions or security breaches (e.g., ransomware attacks). We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business, or reputational losses, including regulatory fines, that may result from an interruption or breach of our systems.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA and other similar foreign regulatory bodies; provide true, complete and accurate information to the FDA, EMA and other similar foreign regulatory bodies; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we receive FDA approval of apitegromab, SRK-181, SRK-439 or any future product candidates and begin commercializing those products in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of civil, criminal and administrative penalties, damages, monetary fines, individual imprisonment, disgorgement, possible exclusion from participation in government healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment of our operations, any of which could adversely affect our ability to operate our business, financial condition and results of operations.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Changes in statutes, regulations or the interpretation of existing statutes or regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; (iv) additional record-keeping requirements; or (v) changes to our pricing arrangements, or coverage of or reimbursement for our products. If any such changes were to be imposed, they could adversely affect the profitability and operation of our business. See the sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled, &#8220;Business &#8212; Government Regulation &#8212; Current and Future Healthcare Reform Legislation&#8221; and &#8220;Business &#8211; Government Regulation &#8211; Coverage and Reimbursement.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">It is possible that the ACA, as currently enacted or as it may be amended or otherwise modified in the future, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare or other healthcare funding, more rigorous coverage criteria, or new payment methodologies or otherwise affect the prices we may obtain for any of our product candidates for which we may receive regulatory approval. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from commercial payors. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be modified or invalidated. The continuing health care reform initiatives efforts of the government, insurance companies, managed care organizations and other payers of health care services to contain or reduce costs of health care may adversely affect the demand for any product candidates for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability; and the level of taxes that we are required to pay.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Healthcare providers, physicians and third-party payors in the U.S. and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information received in the course of patient recruitment for clinical trials.</span> <span style="font-weight:normal;">See the section in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled &#8220;Business &#8211; Government Regulation &#8211; Other Healthcare Laws.&#8221; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Failure to comply with health care privacy and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We, our CROs, and any potential collaborators may be subject to strict and changing federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security) and policies and contractual obligations related to data privacy and security. In the U.S., numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our CROs and collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009. Depending on the facts and circumstances, we could be subject to civil, criminal, and administrative penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We have conducted our Phase 2 TOPAZ clinical trial of apitegromab in the European Economic Area (&#8220;EEA&#8221;), are conducting our Phase 3 SAPPHIRE clinical trial and ONYX, our long-term extension clinical trial of apitegromab, in the EEA and the UK, and may conduct future clinical trials in the EEA or the UK and therefore may be subject to additional privacy laws. The EU General Data Protection Regulation (the &#8220;EU GDPR&#8221;) imposes a broad range of strict requirements on companies subject to the EU GDPR, including requirements relating to having legal bases and conditions for processing personal information relating to identifiable individuals and transferring such information outside the EEA or the UK, including to the U.S., providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#8217; requests to exercise their rights in respect of their personal information, where required reporting security breaches involving personal data to the competent national data protection authority and affected individuals, where required, appointing data protection officers, where required conducting data protection impact assessments, and record-keeping. The EU GDPR imposes penalties in the event of non-compliance, including fines of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious offenses. The EU GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the EU GDPR. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">The EU GDPR ceased to apply in the UK after the UK&#8217;s exit from the EU on January 31, 2020, but the UK incorporated the EU GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law (&#8220; the UK GDPR&#8221;). The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but currently still aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EU&#8217;s GDPR, the UK is recognized as providing adequate protection under the EU GDPR (&#8220;UK Adequacy Decision&#8221;) and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Likewise, personal data transfers from the UK to the EEA remain free flowing. The UK </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Government has introduced a Data Protection and Digital Information Bill (&#8220;UK Bill&#8221;) which failed in the UK legislative process but may be reintroduced at some point in the future. This may lead to additional compliance costs and could increase our overall risk. The respective provisions and enforcement of the EU GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Adequate safeguards must be implemented to enable the transfer of personal data outside of the EEA or the UK in compliance with European and UK data protection laws. The EC has issued forms of standard contractual clauses (&#8220;SCCs&#8221;) for data transfers from controllers or processors in the EEA (or otherwise subject to the EU GDPR) to controllers or processors established outside the EEA (and not subject to the EU GDPR). The UK is not subject to the EC&#8217;s SCCs but has published its own standard clauses, the International Data Transfer Agreement, which enables transfers from the UK. We will be required to implement these new safeguards when conducting restricted data transfers under the EU GDPR and UK GDPR and doing so will require significant effort and cost. Where relying on the SCCs or UK IDTA for data transfers, we may also be required to carry out transfer impact assessments to assess whether the recipient is subject to local laws which allow public authority access to personal data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In July 2023, the EC adopted its adequacy decision for the EU-U.S. Data Privacy Framework (&#8220;Framework&#8221;). On the basis of the new adequacy decision, personal data can flow safely from the EU to U.S. companies participating in the Framework, without having to put in place additional data protection safeguards. There has been an extension to the Framework to cover UK transfers to the United States. The long term validity of the Framework remains uncertain as the Framework could be challenged like its predecessor frameworks. This complexity and the additional contractual burden increases our overall risk exposure. There may be further divergence in the future, including with regard to administrative burdens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The EU GDPR and UK GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the EU GDPR and UK GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the EU GDPR and UK GDPR, including as implemented by individual countries. Given the new law, we face uncertainty as to the exact interpretation of the new requirements and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the law. Compliance with the EU GDPR and UK GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">EU Member States have adopted implementing national laws to implement the EU GDPR which may partially deviate from the EU GDPR and the competent authorities in the EU Member States may interpret EU GDPR obligations slightly differently from country to country, so that we do not expect to operate in a uniform legal landscape in the EU. Also, as it relates to processing and transfer of genetic data, the EU GDPR specifically allows national laws to impose additional and more specific requirements or restrictions, and European laws have historically differed quite substantially in this field, leading to additional uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect that we will continue to face uncertainty as to whether our efforts to comply with our obligations under European privacy laws will be sufficient. If we are investigated by a European or UK data protection authority, we may face fines and other penalties. Any such investigation or charges by European or UK data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or pharmaceutical partners. We may also experience hesitancy, reluctance, or refusal by European or multi-national clients or pharmaceutical partners to continue to use our products and solutions due to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on them by certain data protection authorities in interpretation of current law, including the EU GDPR and UK GDPR. Such clients or pharmaceutical partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain, or otherwise objectionable and therefore decide not to do business with us. Any of the foregoing could materially harm our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, many states in which we operate have laws that protect the privacy and security of sensitive and personal information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. Where state laws are more protective than HIPAA, we must comply </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">with the state laws we are subject to, in addition to HIPAA. In certain cases, it may be necessary to modify our planned operations and procedures to comply with these more stringent state laws. Further, in some cases where we process sensitive and personal information of individuals from numerous states, we may find it necessary to comply with the most stringent state laws applicable to any of the information. For example, California&#8217;s California Consumer Privacy Act (&#8220;CCPA&#8221;), creates comprehensive individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. While there are currently exceptions for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA, as amended by the California Privacy Rights Act, and other enacted or proposed comprehensive state consumer privacy legislation may impact our business activities. We continue to monitor the impact that the state consumer privacy and protection laws, like the CCPA, may have on our business activities. See the section in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled &#8220;Business &#8211; Government Regulation &#8211; European General Data Protection Regulation and &#8220;Business &#8211; Government Regulation &#8211; Other Healthcare and Privacy Laws.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The potential use of new and evolving technologies, such as artificial intelligence, in our offerings to employees may result in additional spending and present risks and challenges that can impact our business including by posing security and other risks to our confidential information, proprietary information and personal information, and as a result we may be exposed to reputational harm, legal liability, and regulatory investigations and fines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may build and integrate artificial intelligence into our offerings, and this innovation may present risks and challenges that could affect its adoption, and therefore our business. If we enable or offer solutions that draw controversy due to perceived or actual negative societal impact, we may experience brand or reputational harm, competitive harm or legal liability. The use of certain artificial intelligence technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement, <span style="background:#ffffff;">for example where third party data sources are used to train artificial intelligence models, or the output of artificial intelligence systems reproduce or incorporate third party intellectual property rights, in each case without the right to do so</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additionally, we expect to see increasing government and supranational regulation related to artificial intelligence use and ethics, which may also significantly increase the burden and cost of research, development and compliance in this area. For example, the EU&#8217;s Artificial Intelligence Act (&#8220;AI Act&#8221;) &#8212; the world&#8217;s first comprehensive AI law &#8212; is anticipated to enter into force in Summer 2024 and, with some exceptions, become effective 24 months thereafter. This legislation imposes tiered obligations on providers and deployers of artificial intelligence systems which are put onto the EU market, or where the output is intended for use in the EU market, depending on the risk classification of the AI system, and encourages providers and deployers of artificial intelligence systems to account for EU fundamental rights in their development and use of these systems. If we develop or use AI systems that are governed by the AI Act, it may necessitate ensuring higher standards of data quality, transparency, and human oversight, and if the AI systems are considered high risk, we would be required to implement substantive risk and quality management systems and post-market monitoring systems and adhere to specific and burdensome and costly ethical, accountability, and administrative requirements. Other jurisdictions, including the United States and UK, are also taking steps to regulate AI systems. The rapid evolution of artificial intelligence will require the application of significant resources to design, develop, test and maintain our service offerings to help ensure that artificial intelligence is implemented in accordance with applicable law and regulation and in a socially responsible, safe and ethical manner and to minimize any real or perceived unintended harmful impacts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our vendors may in turn incorporate artificial intelligence tools into their own offerings, and the providers of these artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business. <span style="background:#ffffff;">A risk of our proprietary intellectual property rights being compromised through the use of artificial intelligence could arise through third party vendors using our data to train their models and/or to generate output for </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">other users of their systems. There is also a risk (as with any hosted service) of security incidents occurring that could lead to unauthorized access to our data. In the event that personal data (including special category data relating to patients) were to be compromised, we may also face action from regulators and affected data subjects, and damage to our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional laws and regulations governing international operations, including certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, could negatively impact or restrict our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If we further expand our operations outside of the U.S., we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the U.S., or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the U.S., it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the U.S., which could limit our growth potential and increase our development costs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities, and as a result, may be subject to lengthy and expensive litigation and excessive damages and we may not have, or be able to obtain, sufficient capital to pay such amounts. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We face an inherent risk of product liability as a result of testing apitegromab, SRK-181, SRK-439 and any of our future product candidates in clinical trials and will face an even greater risk if we commercialize any products, if approved. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to bring a product candidate to the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants and inability to continue clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exhaustion of any available insurance and our capital resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any product candidate, if approved; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decline in our share price.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. We may be unable to obtain, or may obtain on unfavorable terms, additional clinical trial insurance in amounts adequate to cover any liabilities from any of our clinical trials. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies&#8217; operations, could prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Our current laboratory operations are concentrated in one location, and we or the third parties upon whom we depend, including our clinical trial sites and the manufacturing facilities of our third-party contract manufacturers, may experience business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster, including earthquakes, outbreak of disease or other natural disasters.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our office and laboratory facilities are located in Cambridge, Massachusetts. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, the facilities at any clinical trial site, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of apitegromab, SRK-181, SRK-439 and future product candidates or interruption of our business operations. If a natural disaster, outbreak of disease, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities, our clinical trial sites or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Global events, including global health concerns could also result in social, economic, and labor instability in the countries in which we operate or where the third parties with whom we engage, including our clinical trial sites and manufacturing facilities of our third-party contract manufacturers, operate. Unforeseen global events, such as </span><span style="font-weight:normal;">increasing rates of inflation and interest</span><span style="font-weight:normal;">, could adversely impact our business. For example, we are conducting SAPPHIRE, our Phase 3 clinical trial and, ONYX, our long-term extension clinical trial of apitegromab in the U.S. and EU, and regional instability caused by the 2022 Russian invasion of Ukraine could adversely affect the conduct of our clinical trials. Such conflicts could lead to sanctions, embargoes, supply shortages, regional instability, geopolitical shifts, cyberattacks, other retaliatory actions, and adverse effects on macroeconomic conditions, currency exchange rates, and financial markets, which could adversely impact our operations and financial results, as well as those of third parties with whom we conduct business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at our facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">any damages and losses. If our facilities, the manufacturing facilities of our third-party contract manufacturers, or the sites where we conduct clinical trials or preclinical studies, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The success of our product candidates, apitegromab and SRK-181, and future product candidates such as SRK-439, if approved, depends on the availability of coverage and adequate reimbursement from third-party payors. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, apitegromab, SRK-181, SRK-439 or future product candidates or assure that coverage and reimbursement will be available for any product that we may develop.</span> <span style="font-weight:normal;">See the sections in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled &#8220;Business&#8211; Government Regulation &#8211; Coverage and Reimbursement&#8221; and &#8220;Business&#8211;Government Regulation&#8211;Current and Future Healthcare Reform Legislation.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid or national payor bodies (such as in European countries), and commercial payors is critical to new product acceptance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a covered benefit under its health plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safe, effective and medically necessary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appropriate for the specific patient;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost-effective; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">neither experimental nor investigational.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">In the U.S., no uniform policy of coverage and reimbursement for products exists</span> <span style="font-weight:normal;">among third party payors, Coverage and reimbursement for products can differ significantly from payor to payor. One payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. Coverage and reimbursement for products may vary widely across national payors from country to country.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain and maintain coverage and reimbursement for any product, we may need to conduct expensive evidence generation studies in order to demonstrate the medical necessity and cost-effectiveness of such a product, in addition to the costs required to obtain regulatory approvals. If payors do not consider a product to be cost-effective compared to current standards of care, they may not cover the product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to cover its costs or make a profit. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. There is significant uncertainty related to insurance coverage and reimbursement of newly approved </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. Additional state and federal healthcare reform measures are expected to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Moreover, increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European Member States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We intend to seek approval to market our product candidates in both the U.S. and in selected foreign jurisdictions. If we receive approval in one or more foreign jurisdictions for apitegromab, SRK-181, SRK-439 or future product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of medicinal products is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after receiving marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future health care reform measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Much like the federal Anti-Kickback Statute prohibition in the U.S., the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-inducement, advertising and anti-bribery laws of EU Member States. Infringement of these laws could result in substantial fines and imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Payments made to physicians in certain EU Member States must be disclosed publicly. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, in most foreign countries, including several EU Member States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced Member States, can further reduce prices. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of any of our product candidates in those countries would be negatively affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We may seek to enter into collaborations in the future with third parties, including for apitegromab, SRK-181, SRK-439 or potential product candidates. If we are unable to enter into such collaborations, or if these collaborations are not successful, our business could be adversely affected. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">A part of our strategy is to evaluate and, as deemed appropriate, enter into additional collaborations or partnerships in the future when strategically attractive, including potentially with biotechnology or pharmaceutical companies. We have limited capabilities for product development and only recently have begun to build our capabilities to prepare for potential commercialization. Accordingly, we may enter into collaborations with other companies to provide us with important technologies, capabilities and funding for our programs and underlying technology. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Any future collaboration we enter into may pose a number of risks, including the following: </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may have significant discretion or decision-making authority in determining the efforts and resources that they will apply to the collaboration or that we are required to apply to the collaboration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected or in a manner satisfactory to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may commit to certain preclinical or clinical development or commercialization efforts as part of the collaboration that we are unable to meet or our collaborators may not be satisfied with our preclinical or clinical development or commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated by the collaborator, and, if terminated, we may be blocked to advance the program due to collaborator patents that are not licensed to us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">If our future collaborations do not result in the successful discovery, development and commercialization of product candidates or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Quarterly Report on Form 10-Q also apply to the activities of potential therapeutic collaborators. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the biotechnology or pharmaceutical industry, including within the business and financial communities, could be adversely affected. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">We face significant competition in seeking appropriate partners for our product candidates, and the negotiation process is time-consuming and complex. In order for us to successfully partner our product candidates, potential partners must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations or do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates, bring them to market and generate revenue from sales of drugs or continue to develop our technology, and our business may be materially and adversely affected. Even if we are successful in our efforts to establish new strategic collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic collaborations if, for example, development or approval of a product candidate is delayed or </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">sales of an approved product are disappointing. Any delay in entering into new strategic collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. Unforeseen global events, and sanctions or actions relating to such events, could affect our ability to file, prosecute, maintain, and/or defend patents and applications in those markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the U.S. and/or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. For example, Russia issued a decree in March of 2022, stating that patent owners who reside in a country &#8220;unfriendly&#8221; to Russia are not entitled to compensation in the event of patent infringement. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property and/or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, a competitor&#8217;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights, or will design around the claims of patents that we have had issued that cover our products. </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, periodic maintenance fees on any issued patent are due to be paid to the U.S. Patent Office (&#8220;USPTO&#8221;) and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Moreover, complications due to global pandemics may result in inadvertent lapse due to, for example, unexpected closures of the USPTO or foreign patent offices, delays in delivery of notifications relating to deadlines, or failure to timely and/or properly obtain signatures on necessary documents. Additionally, due to the ongoing conflict in Ukraine, there remain uncertainties as to any potential impact on patent protection and/or enforcement in the region, including, for example, payments to the Russian Patent Office and other entities. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents, as the case may be, or parts of our or their patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the laws of foreign countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make or use compounds or cells that are similar to the biological compositions of our product candidates but that are not covered by the claims of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that others may circumvent our owned or in-licensed patents;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the active biological ingredients in our current product candidates will eventually become commercially available in biosimilar drug products, and no patent protection may be available with regard to formulation or method of use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies for which we can obtain patent protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#8217; patents or other exclusive rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours; and/or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our current patents covering our proprietary technologies and our product candidates are expected to expire beginning in 2034, without taking into account any possible patent term adjustments or extensions. Our earliest patents may expire before, or soon after, our first product achieves marketing approval in the U.S. or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a material adverse effect on our business, results of operations, financial condition and prospects. We own pending patent applications covering our proprietary technologies or our product candidates that if issued as patents are expected to expire from 2034 through 2045, without taking into account any possible patent term adjustments or extensions. However, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of these patent applications.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We depend on intellectual property licensed from third parties. Failure to comply with our obligations under any of these licenses or termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We are dependent on patents, know-how and proprietary technology, including intellectual property rights licensed from others. We may be a party to license agreements pursuant to which we in-license key patents and patent applications for our product candidates. These licenses impose various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate the license. Any termination of licenses by third parties could result in our loss of significant intellectual property rights and could harm our ability to commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to sublicense patent and other rights to third parties under collaborative development relationships; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Because our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our product candidates may also require specific formulations to work effectively and efficiently, and these rights may be held by others. We may develop products containing our compounds and pre-existing pharmaceutical compounds. We may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent law in the U.S. and in ex-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act (the &#8220;America Invents Act&#8221;), enacted in 2013, the U.S. moved from a &#8220;first to invent&#8221; to a &#8220;first to file&#8221; system. Under a &#8220;first to file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act, and many of the substantive changes to patent law, including the &#8220;first to file&#8221; provisions, only became effective in March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Recent U.S. Supreme Court rulings have also narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. As a consequence, issued patents may be found to contain invalid claims according to the newly revised eligibility and validity standards. Additionally, some of our owned or in-licensed patents may be subject to challenge and subsequent invalidation or significant narrowing of claim scope in proceedings before the USPTO, or during litigation, under the revised criteria which could also make it more difficult to obtain patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents, or interpretation thereof, could change in unpredictable ways that would weaken our ability to obtain new patents, to maintain, or to enforce our existing patents and patents that we might obtain in the future. For example, in the case Amgen Inc. v. Sanofi, the Federal Circuit held that a well characterized antigen is insufficient to satisfy the written description requirement of certain claims directed to a genus of antibodies that are solely defined by function. While the validity of a subset of patents at issue was subsequently upheld by a district court jury, uncertainty remains as to the legal question pertaining to the written description requirement under 35 USC &#167;112 as it relates to functional antibodies. In the case of Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. We cannot predict how these decisions or any future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Similarly, any adverse changes in the patent laws of other jurisdictions could have a material adverse effect on our business and financial condition. For example, Russia issued a decree in March of 2022, stating that patent owners who reside in a country &#8220;unfriendly&#8221; to Russia are not entitled to compensation in the event of patent infringement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post-grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third-party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a license is available from a third-party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting clinical trials and other development activities in the U.S. is protected under the Safe Harbor exemption as set forth in 35 U.S.C. &#167; 271. If and when apitegromab, SRK-181, or another one of our product candidates is approved by the FDA, that certain third-party may then seek to enforce its patent by filing a patent infringement lawsuit against us. While we are not aware of any claims of such a patent that could otherwise materially adversely affect commercialization of our product candidates, we may be incorrect in this belief, or we may not be able to prove it in a litigation. In this regard, patents issued in the U.S. by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, and/or pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may also choose to challenge the patentability of claims in a third-party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-exam, inter partes review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge the grant of a third-party&#8217;s patent in opposition proceedings in the European Patent Office (&#8220;EPO&#8221;) or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office, then we may be exposed to litigation by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additionally, the Unitary Patent/Unified Patent Court system in Europe became fully operational in June 2023.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The new court may be associated with greater degrees of uncertainty in litigation, with respect to both planning and outcome. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The opt-out selection afforded during the transition may have a direct impact on future litigation and may result in loss of certain flexibility with regard to choice of forum and other litigation strategy considerations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">We may incur substantial costs as a result of litigation or other proceedings relating to our patents or the patents of our licensors, and we may be unable to protect our rights to our products and technology.</span><span style="font-family:'Arial','Helvetica','sans-serif';"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims against a third party(ies), which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. There is also the risk that, even if the validity of our patents or the patents of our licensors is upheld, the court will refuse to stop the third-party on the ground that such third-party&#8217;s activities do not infringe our owned or in-licensed patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In some situations, we or our licensor, may not be able to detect infringement against our owned or in-licensed patents, as the case may be, which may be especially difficult for manufacturing processes or formulation patents. Even if we or our licensors detect infringement by a third-party of our owned or in-licensed patents, we or our licensors, as the case may be, may choose not to pursue litigation against or settlement with the third-party. If we, or our licensors, later sue such third-party for patent infringement, the third-party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">brought. Such legal defenses may make it impossible for us or our licensors to enforce our owned or in-licensed patents, as the case may be, against such third-party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">If we or one of our licensing partners initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include inter parties review, ex parte re-examination, post-grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). For example, EP3368069, EP2981822 and EP3365368 are currently subject to opposition proceedings. Such proceedings are expensive and could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, because some patent applications in the U.S. may be maintained in secrecy until the patents are issued, because patent applications in PCT member jurisdictions are typically not published until 18 months after the earliest filing, and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products, compositions, methods of use, or technology similar to ours. Any such patent application may have priority over our owned and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the U.S. If we or one of our licensors is a party to an interference proceeding involving a U.S. patent application on inventions owned by or in-licensed to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For applications filed under pre-AIA, interference proceedings declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Indeed, Russia issued </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">a decree in March of 2022, stating that patent owners who reside in a country &#8220;unfriendly&#8221; to Russia are not entitled to compensation in the event of patent infringement. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the U.S. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products and/or methods of medical treatment, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As another example, in Europe, a new unitary patent system became effective in June 2023, which may significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unified Patent Court (&#8220;UPC&#8221;). As the UPC is a new court system, there is little precedent for the court, increasing the uncertainty of any litigation. Subject to current transitional provisions, European patents have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC are potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may result in inadequate protection for our product candidates, and we may be unable to obtain patent term extensions and data exclusivity for our product candidates, resulting in material harm to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, also known as the Hatch Waxman Amendments. The Hatch Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. The patent term restoration period is generally one-half of the time between the effective date of the IND or the date of patent grant (whichever is later) and the date of submission of the BLA, plus the time between the date of submission of the BLA and the date of FDA approval of the product. The patent holder must apply for restoration within 60 days of approval. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. We may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Given the amount of time required for the development, testing and regulatory review of new product candidates, the patents protecting our product candidates might expire before or shortly after such candidates are commercialized. If we </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours, which could materially harm our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to patent protection, we rely heavily upon know-how and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third-party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">In addition, courts outside the U.S. are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. We have also adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Third parties may assert that our employees or consultants have wrongfully used, disclosed, or misappropriated their confidential information or trade secrets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Financial Condition and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We are a biopharmaceutical company formed in 2012 and our operations to date have been focused on research and development of monoclonal antibodies that selectively inhibit activation of growth factors for therapeutic effect. We have not yet demonstrated the ability to progress any of our product candidates through clinical trials, we have no products approved for commercial sale and we have not generated any revenue from product sales to date. We continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. For the nine months ended September 30, 2024 and 2023, we reported a net loss of $179.8 million and $119.7 million, respectively. We have incurred losses since our inception, and as of September 30, 2024, we had an accumulated deficit of $856.3 million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, apitegromab, SRK-181, SRK-439, and any future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:normal;">To become and remain profitable, we or any current or potential future collaborators must develop and eventually commercialize products with significant market potential and favorable pricing. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, receiving marketing approval for product candidates, manufacturing, marketing and selling products for which we may receive marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:normal;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;">We will require additional capital to fund our operations and if we fail to obtain necessary capital, we will not be able to complete the development and commercialization of apitegromab, SRK-181, SRK-439 and any future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:normal;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts of cash to conduct further research and development, including clinical trials for apitegromab and SRK-181 and preclinical studies and clinical trials for SRK-439 and any future product candidates, to seek regulatory approvals for our product candidates and to launch and commercialize any products for which we receive regulatory approval. As of September 30, 2024, we had approximately $139.1 million in cash, cash equivalents and marketable securities. Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities as of September 30, 2024, cash available to us, together with the net proceeds from the follow-on offering completed in October 2024, will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2026. However, our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will in any event require additional capital in order to complete clinical development of any of our current programs. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. Additionally, any program setbacks or delays due to changes in federal or state laws or clinical site or clinical vendor policies as a result of the impacts of current macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates could impact our programs and increase our expenditures. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, progress, timing, completion, costs and results of clinical trials for apitegromab and SRK-181 and preclinical studies and clinical trials for SRK-439 and any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical development plans we establish for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we identify and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms of any collaboration, strategic alliance, or licensing agreements we are currently party to or may choose to enter into in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA, and other comparable foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of developing research cell lines and development and completion of commercial scale outsourced manufacturing activities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers, or other vendors resulting from pandemics or similar public health crisis or macroeconomic conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">We do not have any committed external source of funds or other support for our development efforts. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek collaborators for apitegromab, SRK-181, SRK-439 or any future product candidate at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of apitegromab, SRK-181, SRK-439 or one or more of our future product candidates or other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Changes in tax law could adversely affect our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. For example, under Section 174 of the Code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development in the U.S. will be capitalized and amortized, which may have an adverse effect on our cash flow. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. It cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our shareholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">As of December 31, 2023, we had net operating loss carryforwards for federal and state income tax purposes of $403.2 million and $402.8 million, respectively, which begin to expire in 2032, except for our post 2017 federal net operating loss carryforwards of $352.7 million which do not expire. As of December 31, 2023, we also had available tax credit carryforwards for federal and state income tax purposes of $40.8 million and $6.1 million, respectively, which begin to expire in 2034 and 2024, respectively. Additionally, for taxable years beginning after December 31, 2017 the deductibility of the indefinite lived federal net operating losses is limited to 80% of our taxable income in any future taxable year. Under Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), changes in our ownership may limit the amount of our net operating loss carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50% within a three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards before they expire. Private placements and other transactions that have occurred since our inception, as well as our IPO, may trigger such an ownership change pursuant to Section 382 of the Code. Any such limitation, whether as the result of our IPO, prior private placements, sales of our common stock by our existing stockholders or additional sales of our common stock by us, could have a material adverse effect on our results of operations in future years. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, SVB was closed by the California </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Department of Financial Protection and Innovation, which appointed the FDIC as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Since then, additional financial institutions have experienced similar failures and have been placed into receivership. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the Company, the financial institutions with which the Company has credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which the Company has financial or business relationships, but could also include factors involving financial markets or the financial services industry generally. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delayed or lost access to, or reductions in borrowings available under our existing debt facility; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential or actual breach of contractual obligations that require the Company to maintain certain financial accounts at specific financial institutions.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our suppliers, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on us, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any supplier bankruptcy or insolvency, or any breach or default by a supplier, or the loss of any significant supplier relationships, could result in material losses to us and may have a material adverse impact on our business.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our current investment policy focuses on preservation of capital. However, we could recognize losses on securities held in our investment portfolio, particularly if interest rates increase or economic and market conditions deteriorate. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024, the fair value of our cash equivalents and investments in our marketable debt securities portfolio was approximately $133.6 million and consisted primarily of investments in money market funds and U.S. treasury obligations and government agency securities. Factors beyond our control can significantly influence the fair value of securities in our portfolio and can cause potential adverse changes to the fair value of these securities. For example, fixed-rate securities acquired by us are generally subject to decreases in market value when interest rates rise. Additional factors include, but are not limited to, rating agency downgrades of the securities or our own analysis of the value of the security, defaults by the issuer with respect to the underlying securities, and continued instability in the credit markets. Any of the foregoing factors could cause other-than-temporary impairment in future periods and result in realized losses. The process for determining whether impairment is other-than-temporary usually requires difficult, subjective judgments about the future financial performance of the issuer and any collateral underlying the security in order to assess the probability of receiving all contractual principal and interest payments on the security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At September 30, 2024, we had $0 in net unrealized losses in our marketable securities available-for-sale portfolio, and unrealized losses in our securities portfolio may increase in the future due to the aforementioned economic factors. While our goal is to hold each security until maturity, that may not be possible in light of our policy to preserve capital and liquidity and because investment in securities with unrealized losses has a diminished utility as a source of liquidity prior to maturity. Selling securities with an unrealized loss would result in the realization of such losses, which could have an adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">The price of our stock is volatile, and you could lose all or part of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Similar to the trading prices of the common stock of other biopharmaceutical companies, the trading price of our common stock is subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Quarterly Report on Form 10-Q, these factors include:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic collaborations or partnerships, joint ventures or capital commitments by us, our collaborators or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated variations in quarterly operating results or our cash position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting practices; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or stockholder litigation.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, our ability to pay cash dividends is currently restricted by the terms of our debt facility with Oxford and SVB, and future debt or other </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Our Board members, management, and their affiliates, own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">As of September 30, 2024, our executive officers, directors and their affiliates beneficially hold, in the aggregate, approximately 12% of our outstanding voting stock. These stockholders, acting together, are able to significantly influence all matters requiring stockholder approval. For example, these stockholders are able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are and expect to continue to be a &#8220;smaller reporting company&#8221; as defined in the Exchange Act, and have elected and expect to continue to elect to take advantage of certain of the scaled disclosures available to smaller reporting companies, including reduced disclosure obligations regarding executive compensation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">While we are no longer an &#8220;emerging growth company&#8221;, we are and expect to continue to be a &#8220;smaller reporting company&#8221; as defined in the Exchange Act, and have elected and expect to continue to elect to take advantage of certain of the scaled disclosures available to smaller reporting companies, including reduced disclosure obligations regarding executive compensation. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to audit our internal control over financial reporting for so long as we report less than $100 million in annual revenues for the most recent fiscal year and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock price may be more volatile. We will remain a smaller reporting company until our public float exceeds $250 million or our annual revenues exceed $100 million with a public float greater than $700 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We expect to continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. These rules and regulations have significantly increased our legal and financial compliance costs and we anticipate that these activities will become more time-consuming and costly over time</span> <span style="font-weight:normal;">now that we no longer qualify as an </span><span style="font-weight:normal;">emerging growth company</span><span style="font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Pursuant to Section 404 of the Sarbanes-Oxley Act, we will be required to furnish a report by our management on our internal control over financial reporting. Our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act until the date we report at least $100 million in annual revenues and have a public float of at least $75 million for the most recent fiscal year or have a public float of at least $700 million for the most recent fiscal year. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction to the trading price of our common stock in the financial markets due to a loss of confidence in the reliability of our financial statements. </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are a &#8220;smaller reporting company&#8221;, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. We will qualify as a &#8220;smaller reporting company&#8221; if the market value of our common stock held by non-affiliates is below $250 million (or $700 million if our annual revenue is less than $100 million) as of June 30 in any given year. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">We have broad discretion in the use of our existing cash, cash equivalents and marketable securities and may not use them effectively. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our management has broad discretion in the application of our existing cash, cash equivalents and marketable securities. Because of the number and variability of factors that will determine our use of our existing cash and cash equivalents, their ultimate use may vary substantially from their currently intended use. Our management might not apply our existing cash and cash equivalents in ways that ultimately increase the value of your investment. The failure by our management to apply these funds effectively could harm our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement of approval of not less than two thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our amended and restated certificate of incorporation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to securities litigation, which is expensive and could divert management attention</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our amended and restated bylaws contain certain exclusive forum provisions requiring that substantially all disputes between us and our stockholders be resolved in certain judicial forums, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our bylaws, any action to interpret, apply, enforce, or determine the validity of our amended and restated certificate of incorporation or bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. In addition, our amended and restated bylaws contain a provision by virtue of which, unless we consent in writing to the selection of an alternative forum, the U.S. District Court for the District of Massachusetts will be the exclusive forum for any complaint asserting a cause of action arising under the Securities Act. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions, however, stockholders cannot and will not be deemed to have waived compliance with federal securities laws and the rules and regulations thereunder. We have chosen the U.S. District Court for the District of Massachusetts as the exclusive forum for such causes of action because our principal executive offices are located in Cambridge, Massachusetts. Some companies that have adopted similar federal district court forum selection provisions are currently subject to a suit in the Court of Chancery of the State of Delaware brought by stockholders who assert that the federal district court forum selection provision is not enforceable. While the Delaware Supreme Court ruled in March 2020 that federal forum </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our federal forum selection provision, and we may incur additional costs of litigation should such enforceability be challenged. If the federal forum selection provision is otherwise found inapplicable to, or unenforceable in respect of, one or more of the specified actions or proceedings, we may incur additional costs, which could have an adverse effect on our business, financial condition or results of operations. We recognize that the federal district court forum selection clause may impose additional litigation costs on stockholders who assert the provision is not enforceable and may impose more general additional litigation costs in pursuing any such claims, particularly if the stockholders do not reside in or near the Commonwealth of Massachusetts. Additionally, the choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have issued a substantial number of warrants and equity awards from our equity plans which are exercisable into shares of our common stock which could result in substantial dilution to the ownership interests of our existing stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024, approximately 9,157,496 shares of our common stock were reserved for issuance upon exercise or conversion of outstanding warrants. Additionally, 13,057,021 shares of our common stock were reserved for issuance upon exercise of outstanding stock options and vested restricted stock units. The exercise or conversion of these securities will result in a significant increase in the number of outstanding shares and substantially dilute the ownership interests of our existing stockholders. The shares underlying the equity awards from our equity plans are registered on a Form S-8 registration statement. As a result, upon vesting these shares can be freely exercised and sold in the public market upon issuance, subject to volume limitations applicable to affiliates. The exercise of options and the subsequent sale of the underlying common stock could cause a decline in our stock price. <span style="background:#ffffff;">As of September 30, 2024, we also have 17,008,164 shares of our common stock</span> <span style="background:#ffffff;">, which does not include the pre-funded warrants to purchase up to 353,983 shares of common stock issued in October 2024, reserved for issuance upon exercise of pre-funded warrants, which are already included in our calculation of our weighted average common shares outstanding.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The sales of a substantial number of the shares and/or the exercise and sale of a substantial number of the pre-funded warrants in the public market or the perception that these sales might occur could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. In addition, the sale of substantial amounts of our common stock could adversely impact the price of our common stock. The sale, or the availability for sale, of a large number of shares of our common stock in the public market could cause the price of our common stock to decline. <span style="background:#ffffff;">As of September 30, 2024, 10,681,528 of the 27,689,692 pre-funded warrants, which does not include the pre-funded warrants to purchase up to 353,983 shares of common stock issued in October 2024, have been exercised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The sale or issuance of our common stock to, or through, Jefferies may cause significant dilution and the sale of the shares of common stock acquired by Jefferies, or the perception that such sales may occur, could cause the price of our common stock to fall.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On November 14, 2022, we entered into a sales agreement with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which we may offer and sell our common stock, subject to certain limitations in the sales agreement and compliance with applicable law, at any time throughout the term of the sales agreement. The number of shares that are sold by Jefferies after delivering a placement notice will fluctuate based on the market price of the common stock during the sales period and limits we set with Jefferies. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued. Sales to, or through, Jefferies by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock, or the anticipation </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From January 1, 2024 through September 30, 2024, we did not sell any shares of common stock through the Jefferies sales agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_62f3465f_e87f_4dad_a044_bd76a1e058df"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2. Unregistered Sales of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Issuer Purchases of Equity Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_1915aa3b_bf6f_4798_881b_9d0ee8fd0594"></a><a id="Item3DefaultsUponSeniorSecurities_371711"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Item&#160;3. Defaults Upon Senior Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">None.</p><a id="_a8caa62f_8200_42a3_b7df_9e341c574436"></a><a id="Item4MineSafetyDisclosures_809103"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">None.</p><a id="_5107e666_9196_4670_b332_c34b3808b1ed"></a><a id="Item5OtherInformation_154003"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;5. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Trading Plans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the three months ended September 30, 2024, <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_k1PZdgKPEEyV9g7669vBvQ">none</ix:nonNumeric> of our <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_XSq-XwwMr0GhC4QQ2ZgrIQ">directors or officers</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_-VKUzVqihEOL3XnAOC_-_w">adopted</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_4bqYIeEOk0ew_hT1gXEIyw">contracts</ix:nonNumeric>, instructions or written plans for the purchase or sale of our securities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5a360238_d491_4877_a743_efa73490058e"></a><a id="Item6Exhibits_14170"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;6. Exhibits </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT&#160;INDEX</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:middle;width:9.38%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:48.03%;margin:0pt;padding:0pt;"/><td colspan="4" style="vertical-align:top;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference to:</b></p></td></tr><tr><td style="vertical-align:bottom;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:1.67%;border-bottom:1px solid transparent;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.03%;border-bottom:1px solid #000000;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;width:5.8%;border-bottom:1px solid #000000;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></td><td style="vertical-align:bottom;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1727196/000104746918003566/a2235535zex-3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of the Registrant</span></a></p></td><td style="vertical-align:bottom;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">333-224493</p></td><td style="vertical-align:bottom;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">May 8, 2018</p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1727196/000104746918003733/a2235690zex-3_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Amended and Restated Certificate of Incorporation of the Registrant</span></a></p></td><td style="vertical-align:bottom;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">333-224493</p></td><td style="vertical-align:bottom;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">3.1.1</p></td><td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">  May 14, 2018</span></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">3.3</p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1727196/000155837024009582/srrk-20240627xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Amended and Restated Certificate of Incorporation of the Registrant</span></a></p></td><td style="vertical-align:bottom;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">001-38501</p></td><td style="vertical-align:bottom;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">June 28, 2024</p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">3.4</p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1727196/000104746918003566/a2235535zex-3_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated By-laws of the Registrant</span></a></p></td><td style="vertical-align:bottom;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">333-224493</p></td><td style="vertical-align:bottom;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:bottom;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;margin:0pt;">May 8, 2018</p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">31.1*</p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="srrk-20240930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934</span></a></p></td><td style="vertical-align:top;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">31.2*</p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="srrk-20240930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934</span></a></p></td><td style="vertical-align:top;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">32.1**</p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="srrk-20240930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">Inline XBRL Instance Document</p></td><td style="vertical-align:top;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document </p></td><td style="vertical-align:top;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:top;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:top;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:top;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.03%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="color:#212529;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)</span></p></td><td style="vertical-align:top;width:5.8%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.96%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.25%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.87%;margin:0pt;padding:1.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:33.25pt;text-indent:-33.25pt;margin:0pt 0pt 0pt 2pt;"><span style="font-size:10pt;">*</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size:10pt;">Filed herewith</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:33.25pt;text-indent:-33.25pt;margin:0pt 0pt 0pt 2pt;"><span style="font-size:10pt;">**</span>&#160;&#160;&#160;&#160;&#160;<span style="font-size:10pt;">Furnished herewith</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:33.25pt;text-indent:-33.25pt;margin:0pt 0pt 0pt 2pt;"><span style="font-size:10pt;background:#ffffff;">&#8224;</span><span style="background:#ffffff;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt;background:#ffffff;">Portions of this exhibit (indicated by asterisks) were omitted in accordance with the rules of the Securities and Exchange Commission.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.25pt;text-indent:-33.25pt;margin:0pt 0pt 0pt 2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.25pt;text-indent:-33.25pt;margin:0pt 0pt 0pt 2pt;"><span style="display:inline-block;text-indent:0pt;width:33.25pt;"></span><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.25pt;text-indent:-33.25pt;margin:0pt 0pt 0pt 2pt;"><span style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_e545d28e_2c63_4bbe_86ca_180741d1daf8"></a><a id="SIGNATURES_251590"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="3" style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:middle;width:41.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:5.58%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:52.46%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:58.04%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SCHOLAR ROCK HOLDING CORPORATION</p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.58%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:52.46%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:41.95%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 12, 2024</p></td><td style="vertical-align:bottom;width:5.58%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:52.46%;border-bottom:1px solid #000000;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jay T. Backstrom</p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.58%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:52.46%;border-top:1px solid #000000;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jay T. Backstrom<br/>President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:41.95%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 12, 2024</p></td><td style="vertical-align:bottom;width:5.58%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:52.46%;border-bottom:1px solid #000000;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Edward H. Myles</p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.58%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:52.46%;border-top:1px solid #000000;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Edward H. Myles<br/>Chief Operating Officer &amp; Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>srrk-20240930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/11/2024 02:39:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Certifications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">I, Jay T. Backstrom, certify that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;font-size:11pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">I have reviewed this Quarterly Report on Form 10-Q of Scholar Rock Holding Corporation;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;font-size:11pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;font-size:11pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;font-size:11pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010000;font-size:11pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010000;font-size:11pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010000;font-size:11pt;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010000;font-size:11pt;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;font-size:11pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010000;font-size:11pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Date:   November 12, 2024</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Jay T. Backstrom</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Jay T. Backstrom</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">President and Chief Executive Officer</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">(Principal Executive Officer)</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>srrk-20240930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/11/2024 02:39:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Certifications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">I, Edward H. Myles, certify that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;font-size:11pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">I have reviewed this Quarterly Report on Form 10-Q of Scholar Rock Holding Corporation;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;font-size:11pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;font-size:11pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;font-size:11pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010000;font-size:11pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010000;font-size:11pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010000;font-size:11pt;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010000;font-size:11pt;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;font-size:11pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010000;font-size:11pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size:11pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Date:  November 12, 2024</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Edward H. Myles</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Edward H. Myles</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chief Operating Officer &amp; Chief Financial Officer</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">(Principal Financial and Accounting Officer)</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>srrk-20240930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/11/2024 02:39:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">18 U.S.C. SECTION 1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">In connection with the Quarterly Report on Form 10-Q of Scholar Rock Holding Corporation (the &#8220;Company&#8221;) for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to his or her knowledge, that:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">(1)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">(2)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be &#8220;filed&#8221; for any purpose whatsoever.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Date:  November 12, 2024</font></p></td><td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Jay T. Backstrom</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Jay T. Backstrom</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">President and Chief Executive Officer</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Date:  November 12, 2024</font></p></td><td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Edward H. Myles</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Edward H. Myles</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chief Operating Officer &amp; Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>srrk-20240930x10q004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 srrk-20240930x10q004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %; [ # 2(  A$! Q$!_\0
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M,(AE[G[G&<\'=WX^;GY8\-1VFF?"_P >^"O'7C30O"^K3ZW+'J.CZAX7DO\
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M2M1UG4I7AM;2VD+N[J<,IP/E.?7&>U=]XH\0VGA+PYJ6M7TBQV=A;O<RLQP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV#HNX#.!Z5XY_P +S\;?]$SU+\Y?_C5'_"\_&W_1,]2_.7_XU1_;V![R_P#
M)_\ R(?V)C.T?_ X_P"9[-;:99V=Q/<06D$%Q.09IHXPKR'MN(&3^-5=8\+:
M-XAD@?5=(L=2> [HFO+9)C&?52P.#]*\C_X7GXV_Z)GJ7YR__&J/^%Y^-O\
MHF>I?G+_ /&J/[>P/>7_ (!/_P"1#^Q,9VC_ .!Q_P SV2]T>PU&**.[LK>Y
MCA8/&DT2L$(Z%<C@_2K8P!@#BO$/^%Y^-O\ HF>I?G+_ /&J/^%Y^-O^B9ZE
M^<O_ ,:H_M[ ]Y?^ 3_^1#^Q,9VC_P"!Q_S/9;;2;&UO9KR&SMX;N?\ ULZ1
M*LDF.FY@,G\:FOK*WU*TEMKNWBNK:08>&9 Z,/0@\&O%/^%Y^-O^B9ZE^<O_
M ,:H_P"%Y^-O^B9ZE^<O_P :H_M[ ]Y?^ 3_ /D0_L3&=H_^!Q_S/6]1\*Z+
MK%M;V]]I%A?06Q#017-LDB1$="H((7\*LVVD65G<3W%O9V\%Q/CS9(HPK28Z
M;B!DX]Z\;_X7GXV_Z)GJ7YR__&J/^%Y^-O\ HF>I?G+_ /&J/[>P/>7_ (!/
M_P"1#^Q,9VC_ .!Q_P SUO2?">B:#<W%SIFCV&GW-P<S36MLD3R?[S* 3^-)
M=>$M#O\ 5X=5N=&T^XU2''EWLMJCSICIAR-P_.O)?^%Y^-O^B9ZE^<O_ ,:H
M_P"%Y^-O^B9ZE^<O_P :H_M[ ]Y?^ 3_ /D0_L3&=H_^!Q_S/8[K1K"^N&GN
M+*VFF:%K=I)(59C&WWD)(SM/<=*72=&T_0;)++3+&WTVT3)6"UA6*-<GG"J
M!7C?_"\_&W_1,]2_.7_XU1_PO/QM_P!$SU+\Y?\ XU1_;V![R_\  )__ "(?
MV)C.T?\ P./^9ZY9>%-%T[59M3M='L+74I\^;>0VR)-)GKN<#)_$UK5X;_PO
M/QM_T3/4OSE_^-4?\+S\;?\ 1,]2_.7_ .-4?V]@>\O_  "?_P B']B8SM'_
M ,#C_F>Y45X;_P +S\;?]$SU+\Y?_C5'_"\_&W_1,]2_.7_XU1_;V![R_P#
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M?]$SU+\Y?_C5'_"\_&W_ $3/4OSE_P#C5']O8'O+_P  G_\ (A_8F,[1_P#
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MC;_HF>I?G+_\:H_X7GXV_P"B9ZE^<O\ \:H_M[ ]Y?\ @$__ )$/[%QG:/\
MX''_ #,/X.?LO>(/#7Q5F^(_Q!\8V_BSQ&NG_P!EV5MI^G+9V=I;G&0J \DX
M'8=^M?06GZ79Z3#Y-C:06<&2WEP1K&N3U. !S7C/_"\_&W_1,]2_.7_XU1_P
MO/QM_P!$SU+\Y?\ XU1_;V![R_\  )__ "(?V+C.T?\ P./^9ZT/"FB+K/\
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M# $=",]ZM*,8XJ2BIY4G=+4=W:S"BBBJ$%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !12-TKP3]L3]I*]_9B\ :+XCLM$AUU]0U>
M/36AFN#$$5HI7W@A3D_N\8]Z /?**KV,YNK2"9EVF1%<@'.,C.*L4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36Z4ZB@"A<:7
M9W=Y;W=Q;137-ON$,KH"T>[&<'MG _*KJ]:=14J*5VNH[MZ!1115""BBB@ H
MHHH *:YP/2G51URZ>QT:^N(O]9#!)(OU"DB@#"U3XG^%-$L]9N]0\0:?96NC
M2K#?SW%P$CMI& (1F/ 8@CCKR/6EM_BAX1N_"#^*H_$NE-X:0;GU7[6@MDQU
MW29P/Q-?*?AOP_=ZI\"O@SXMMX+#7M6DUN3Q!>:+=W,=N^K7,QE+"(R$*TJ!
M@55B!B(>E87]@7_Q,U3XLZ!=W&B^ 6U3Q-HCPV&I2BX@68 NT+*C;&F<*FY%
M.#\H)H'8^MK#XZ_#S5- U/6K+QIH=]I.F &\N[6^CEC@S]T.5)P3C@=ZU(?B
M3X8N-!TS68-;M)]+U.9+>SN(Y0RSR,<*BXZMGC'8@U\[V_AGQ%XQUOQ7\*M0
MO]&N=8T(Z?XBL/$-EI(MK>9Q*62"Y@5B,@IV;H:XW0;NY^&_BZV/]GR>,Y=-
MUB\^RV]HR6]K<ZQ,AFNI$+\*D$(VKDY+-GK0%C[?QMY'2O/[[]H'X<:=XL'A
MBY\::-#KI?ROL3WB!PYZ(>>&/H>:B3QZWQ%^!=UXJ\,I-#-?Z3//:QRC;)'(
M%8%3@_># CCN*\U^$FD_#4_LC:<VO16#>&9=--SK,MR,.\V29GD8?/YF_//W
MLXH$>WZEX_\ #FC76HVM[K5G;W6G6JWMW THWP0$X$K+U"Y[]*V(=2M9;!;Y
M+A'LVB$PN P*%,9W9Z8QSFOFWX<V^CZU^U%XF@L%:XT*[\!Z?'")MVY[=G(4
M-N^;E3WYK:_9SU6XU#]G36K.=C)%I,VJ:7;N3G,,3.$Y]@<?A0,]:T/XH>$?
M$OA^^UW2_$6FWVC6!<75]!<*T,)7[VY@<#%;6A:YI_B32;74]*O(-0TZZC$L
M%U;.'CE4]&5AP17Q-<>)9%_9.^$G@G3M+O\ 6KKQ'M:^T_1[=9[F2PAE9YL(
M2 0V%7)(X)H\%_&;6OAG\,_'G@_2=%U/PE?:9JMO_8L&MVP$]AIUY,%65H\E
M2L9+ #..F: L?;^HZA;:7:M<7EQ%:VZD!I9G"J,G Y/N0*JZ7XCTO5[^_LK*
M_M[J\L&5+J&*0,T+,-RAAVR"#7R7^T%X2U70_AUK&@W/Q4U'Q"LD^F7D=M<"
MV^WP,;I4:3<J &%CRH*Y##&2*T];^)7B[PSK?C;4+34?.TWPCKVF+>I)#"AF
MT^2!%F,C*F6*LXDSGC![<4!8^M:*^+_%GQV\;:XEO?Z!>W\^@^+_ !/)I>D/
MHR0&>.PMXCN>#S@$WS,I(9V( Z#I7IGP5\=>-=+T_P <P>(-*U[6K31FCFTN
MVOGLI=9E1D!,,B6\FPL#G:QV[@10%CVWQ7XKT?P1H5SK.OZG:Z/I5L 9KR\E
M$<4>2 ,L>!R0*YGP?\=?A[\0-0EL/#GC+1=9OHT,K6UG>QO)L'5MH.<#UKQC
M]I#QU?\ C[]E[7M2D\(ZOX9NTU*QCCTSQ)''!)*PNX<$[&<;2>,_I5A?AYX^
M\>^,/!WB'Q)X3\+^#=-\*F:^6;3;\WEY=LUNT8B!\F,1QG<2V2<X7ZT ?1?A
M_7].\3Z3;:II-]!J.G7*;X;JV</'(OJ".#6C7PI\/_$^K2?#?X8^%]+UKQ5$
M7\/"]FT;P=8V_P!J!:5U2XFN[@^7'$-I 3JQ!).!BMSX4_%3QO\ '*W^&GAC
M4O%5YX>6^T*_U;4M9TF.%+J^>"Z%O'$K,K(F =[E5Y) &!0%C[.-9EQXCTRV
MUVUT26_MX]7NH7N8+)Y )9(D*J[JO4@%UR>VX5\B^(OB3XYOO&VA^ +;Q/K'
MBZUL=&GO[S6_ J6,-Y?3K>2P*K_:'\M?*$0#B/DN3D*O%5]!A\7?%+XE?"5?
M$GB:?PSXA_X1_7H+Z_THVIGNXHKVWC0*P\V*.5@$=PN<%74 =@+'VH/\\US_
M (E^(/AOPAJFC:;K>MV.EW^LS_9M.M[N=8WNY=RKLC!/S-ET&!_>'K7S!X5^
M(?C;X@ZWX8^'5YXQN-*0:IXAL[WQ/8PPQWFKQ:=/%%"L)96CC=A-N<A3_J3M
MQGBCK_BO6==\,VNA:[J:^(Y_"7Q@T+1K;76B5)+J'[5:3#S-HV^8GF[&*@ E
M.@.: L?9]%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB'_@K(C2_
MOPBJ*S-_PE,'"C/_ "[W%?;IZ52U+1[#684BO[.WO8D8.J7,2R ,.X!'!]Z
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MBB#\SRN[IU?Y50\#=GKP >X4444""BBB@ HHHH **** "BBB@ HHHH ****
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M<6K20W<]P+F%2H(D<L!SW&:]DHH$%%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX)UC7?"EOH_@[Q3'="WNEO/,N8'@MWG=I$QC8RQ28()/ R.:L:1^T=XUN/\
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M=%)>Q32/OF6"X;E%D;).5)&3BO?%39M'8<#Z4 2T444""BBB@ HHHH ****
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MT)WB_P#\%C4?\/*O!7_0G>+_ /P6-0!]?T5\@?\ #RKP5_T)WB__ ,%C4?\
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M5BPB0L>%5<  4 >^TE?*O[5OCG4/$WBGX1^!?#GB&XTK2/&>I.EYJND2@2O
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M7'KY8W_3FM[- "T4F>*H:MKEAH4=O)J-W#9QW%Q':Q-,VT/-(P5$'J6)  H
MT**3/O1F@!:*3-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 (:9)$DH&]5< YPPS@T\]*^-_\ @I_XRUWP
M3\&/"][X?U:[TB[D\20PO+9RF-G0P3DJ2.HRJG\* /L@>V,4M4]*8MIEH22Q
M,2$D]3\HJY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY-CXWG]U'C)"#N:]M\2?!7PGXJ\,:3H5[I[QVFDJ%L)+:9HIK; Q\C@Y''%
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M.2.JB@5SYPU#XV_%?5]3\4^)](@U;R]&\17.F6VGB*%=(,%O<>2R3R,0PD8
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M7;_>DD.2Q/15'4D^@KPKX8_\%$OA%\3O%L7AZUU&ZTN\N)/+MI-1@,4<S9P
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MMO<L"0S-G:ZD28R.,&O>_P!D>X;PY\2/C=X#@R-(T7Q$;RQB'W8([E3(8E]
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MXX7_ (UU18XK2QTU=(T:&-LD1LWF32,.@+-M4#T04 >G4444""BBB@ HHHH
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M<Q'_ &,]*]CHH :O!IU%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB!\>F1FK%4](/_$ILO\ KBG_ *"*MYH 6BDS1F@!:*3-&: %HI,T4 +1110
M44F11F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*2EH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BDI: "BBB@ HHI* %HI*6@
M HHHH **** "BBB@ HHHH \ ^(N@6FE_M._!BXL=.2W:[EUV>[F@BQYDALD
M:1@.N!@9KS;]I?QSHGC71]8TZRGU73/&OAS6 MCX-EMRT.N7*31O!*T0&)8G
MP#OSQR3@BOJ#3_&>E:YXWU;P[:HUQJ.APPR7<_EYCMWF!*1;O[Y0!B!T5ESU
M%;1TVQFO$O&M;>2[0;5N#&I<>P;J.] [GFND>(_&7A?PGXEUKXJQ:"NE6-H;
MC9HD<LA**K&565R=W   '6O*O@C\0?#WQR^*^E^+=:UNS36H+69/#?A.!7W:
M?#)'^]DE8J 9FC&".BC(%?3FNW]AI6D7M[JLD,.F6\+S7,MQCRTC499FSQ@
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MHR+I9!&.>>!@UZS^RC-K%Q^QGX/DL93-KCZ'.UK).Q;,V9/++$^^W-=?X_\
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M!*)XX+R]A=5D (# %NH!(_&O-3_P3M^!P'_(K2G_ +?9/\:^8_V_?V9/AQ\
M?A7X?UOPCH'V34+S78K*9YKAY 8C#,Q !/'*+^5 S]!(_BMX'B14'B[0550
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MJ4&FZ;:1F1Y9G"YP,[5!ZD]@*R?A#\4](^-'@'3_ !;H<<\>FWQ;REN%VO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\%QX4N])M_#MM976G:=. M_=1S1S.ID7=M1G\H;4)R,_-S6?H/Q=^(FA^,/
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MCE59HF0@^IKWG6/@UX(\0>)XO$6H^%M,O-;C97%[+;J9"R_=)/<CL379@;<
M# [ "@+GR7XW\(>-_C,T$R^!;SPB-!\*:MIP6ZN(2]_=7-N(D@C"$@QJ4SN8
MC[PXKN/"/PMUC3/B'\*=0N-&CBL=$\)W.G7D@*8M[AC;[4 ^B/R..OK7O]%
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MW@:>5'%U& ")EVG@')&#SQ6[110(**** "BBB@ HHHH **** "BBB@ HHHH
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MOCQ%_P!$ \=_^ [_ /QJC_AOCQ%_T0#QW_X#O_\ &J^P** /C_\ X;X\1?\
M1 /'?_@._P#\:H/[>WB)N/\ A0'CS_P'?_XU7V!2'..* /R*_;Q_:]\8?$^Q
MT3PVOA?7_AWI#*\]S:ZF&BDO6! &/E7*KZ>N*^8?@O\ %SQ+\(/B%H_B#P_>
M72W4%PF^VB=B+E"0&C*]]PXQBOVF_:=_94\,?M/^%[>PUF2;3M4L6+V.IVX!
M>$GJI!X93W'\J\(^ _\ P2X\-?"[QO:>)/$GB*3Q9)82":TLQ;>1") <AG&6
M+8ZXR![4#OH=%%^WOXB**W_"@?'9R >+=\?^BJ?_ ,-\>(O^B >._P#P'?\
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M[PH\-^V."995\I2?7"D_A7O-8NB^$M+T#4M6U"QM$AO=4F$]Y/U>9@-HR3V
MZ#M6U0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *^'_ /@K.1_PHOP@.Y\4V^!_V[7%
M?;YZ5GZKH>G:] L.I6-O?PH_F+'<QK(%8 @$ CKR>?>@"71R#I-D0<CR4_\
M015RF* , =!Z4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH ^Y**^&_P#AZAX=_P"B8^+O^_2U7'_!6'PDUX;0?#KQ0;M1N, $>\#UV]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]_9QZC97%K+
MN\J:-HVVL5.",'!'2OG6']E[4_@UI$3?!:\M(;^348+O4+/QC<2W=O=Q1AQY
M:2[7:!OG)W(N3^H^DJ* /#_V=?@QXB^'>O\ Q \4^+)]+&O^,-2BO)K'0VD:
MSM4B38@5I%1F8@DL2HR:]PHHH *1N0:6B@#YU^(O[#7P_P#B3KFNZS=ZAXFT
MO5-9)-U/IVKR*I! ! C<,F#CH5Q6-\$_V0]=^$OQ[U3QA-X]US7/#[:;%96D
M&H:CYMQ.5XV7"B%5,:#E IX-?4=% [A1110(0UY1\3?V:_"'Q8\8Z5XHUIM4
M35]+"_96L[^6&(%6W*612 W('7KTKUBB@#Y.\1? #XQ?$?Q1X63QCK'A";3-
M!UTZI'XBTY9HM6F@4YCA\H0K&G'RL1(<BOJ\?E3J* "D/2EHH X#XQ?!3PY\
M<?#L&B>)A??8H)Q<(+"[>V?> 1RR$''/2OG/QG^S%\5KWXD:#=Z7#X+U_P !
M^$[:.W\-:#XGU:_(A= ,7,ZI"1)-QP69@..X%?9=% &=H7]IG2+$ZO':1:GY
M*_:DL79H%DQ\P0L Q7/3(!K1HHH *QO&/A:R\;^%M5T#4O.^P:C;O;3_ &>4
MQR;&&#M8<@^XK9HH \(O?V7],\*_L]^.OAQX$DFMW\06UR(I-;OI9T2>2)8\
MLYW,J?*O ![\<UZ3\(O"=[X#^%G@_P -ZC)#+?Z/I%I87$ELQ:)Y(H51BA(!
M*Y4XR ?:NNHH **** $/2OG3XT_ SQUJGQIL/B3\/;CP^VJ-X>N/#E_:>(99
MH8S"S%XY(WBC<EE=CE2 "!UYKZ,HH \T_9P^$7_"BO@MX7\$O<K>W&F0,+BY
M08629W:23;GG;N=@,\X KTNBB@ HHHH I:S:27^D7MM%M$DT+QJ6. "5(&?;
MFO,?V6?A/K'P2^"^B>$-=GLKK4K)IFDET]W>$[Y&8;2R*>A_NBO6Z* "BBB@
M KFOB/;^)KSP/K%OX.DL(?$TMNR6,VJ.ZV\<A& SE%8X'7@&NEHH ^7OV4_@
M?\3_ (+ZG<KXILO!5\-3,EQK'B*QU"\N=6OK@\J6\V%$"]MH( QQ7U!WI:*
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M?X,^&?$Y\0W=A/K_ (G\0WGB*^@TC?\ 8;62<K^Z@W@,5 0<D \X["O9Z**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>srrk-20240930x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 srrk-20240930x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ([ ZH# 2(  A$! Q$!_\0
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M)_"FF6FL:ZI3R+.^N#;PR#< V7 .,+N(XZB@1T5%?/(^-GQ-\(^,_!NF>//
MVC:9I7B751HT-UI6K&XDCG:&2124*CY<1')KZ&H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAP0?O#/?'T%\9/VF]%^&W[.*?%&T7[6FI6$$^BV4W#7,]P@:&,@<_P 6YL=
MK>E 'MV:6N/^%&I^*-9^'6@ZAXRLK73?$EW;+/>65GN\NW9LL(_FYW*I4-[@
MXXKL* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4W<*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5@>-_!VG?$'PEJ_AK5Q*VEZK;/:W2
M02M$[1.,, RD$9!Q]*WZY/XHZ1XCUSX?:_8^$=670_$TMJPTZ_>-76*88*[@
MP(P<;3P>"30!^=_[;7@+P[\+_ ?ASX2>'OA[+H'A&TU"VFN?B7J5O)+#;/(S
ME@9(XR[M\WS')X&T+TQK_MFFS\2?$']E/P"FK?\ "1^#[I[(-=[@\>I1O-;0
M"5L$YW1ACU_Y:''6K'CS5?VF_B[\&IO@QXA^&4\^M7TL5O?>+9Y46VEA299%
M?@!0V44$CC R!D\=9^T#^QSXMT?X5?!2^\";=?\ %WPP\LM;DX^VX>.4E,_W
M9(SA>NUSZ4%&)\:]*L/A3_P4K^#EUX9LH='&LV$-O>PV<8CCF\R2XMV8J./N
M>6/^ *>H%9WQ1_9K^+ ;XU?#[1O!JZ]IOQ&\30:Y9>+'OX8X+*/[09G693\X
M*\+P.?F(!X!Z[X=_#KXD_M&?M=>'_BYX]\&S> O#WA6P6"RTV\?,T\P$A7 ]
MI)F8GT11WKZ2_:?\;>)O WP@U:7P9I=WJ_BW4BNF:7':1ES#/+D><W8*@!;)
MXR .] 'SO;^*/#WC/X]#Q)XLUZVL_A3\%((]&L]0U!PL.H:\R!9)!D?.T87
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M9<';ZFO5*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M42@V=T=P5CPWRCGZ^M?7U>"?M/?\CC\!AV_X3R#_ -(KNO>Z!A1110(****
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M%%%%([0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)L^&T(_Z>9OYBO4*P>Y]SA/X$/0****1V!1110 4444 %%%% !1110 4444
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MC?3?AMX*USQ5K#O'IFD6DEY<;!ERB*3M4=V., >IKHZAN4AD@D6<(T.T[Q(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S[XL_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV>%(Q_TV?^==A6;/H:/\.(4444C8**** "BBB@ HHHH **** "BBB@ HHHH
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M *;/#Z#_ *:-72UFSV:7P(****1J%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !29S1D5Y7\=OVE? O[.FG:==>,M2:V;4)3%;VUO
M&99GP,EMHYVCIGIDB@#U6DS5 ZY8IHW]K37"6]@(/M+3S':J1[=Q9B>@ YKY
MNU'_ (*0_ S3M?;3#XEGN-K;#>6]F[P9SC._'(]Z!V/J&BLGPKXKTCQOH%CK
M>A:A!JFDWL8EM[NW;<DB^H/UXJQK>M6?AW1K_5;^406-C!)<W$IZ)&BEF/X
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $]C_P ?UO\
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MBBB@ HHHH **** "BBB@ KY2_P""C_\ R0/3O^P_;_\ HFXKZMKY2_X*/_\
M) ]._P"P_;_^B;BMJ/QH\W,?]TJ>A^9U%%%>T?F@4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!/8_\?UO_ -=%_F*_=*V_X]XO]T?RK\+;
M'_C^M_\ KHO\Q7[I6W_'O%_NC^5>?B_L_,^NX?\ ^7OR_4EHHHKSSZ\*SM<_
MY!=Q]!_,5HUG:Y_R"[CZ#^8H)E\+.-HHHJSS@HHHH **** .M\-_\@P?[QK6
MK)\-_P#(,'^\:UJEG?3^%!1112- HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Y[Q=\/O#/CZ&WA\2:!INO16Y+0IJ-LDZQD\$@,
M#BNAHH Q/$'@S0_%FCC2=:TBQU;3 486=Y LL0*_=.U@1QVKE3^SI\+_ /HG
MOAG_ ,%4/_Q->BT4 <M9_"WPAIWAB[\.6OAG2K?P_=N9+C2X[.-;>5CMR6C
MP3\J]1V'I6GX?\*:/X4T>/2-'TNSTO2X]VRRM(%CB7<26PH&.223ZYK6HH \
M[MOV=_AG9>(/[<M_ F@1:KO\P7*V$>0_]X#& <\Y KT)4VTZB@#DM"^%7A;P
MSXRUOQ7IFC6]KXCUH*-0U(%FFG Q@$DG X' P.!Z"J'Q)^!?@/XP-:-XR\,6
M&O26F1!+<J1)&#U 92#CVSBN\HH R/"_A/2/!6AVFC:%IUMI.E6B;(+2UC"1
MH,Y. /4DDGN36O110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVGO^1R^ W_8^P?\ I%=U[W7@G[3W_(Y? ;_L?8/_ $BNZ][H&%%%% @HHHH
M**** "BBB@ HHHH **** "OE+_@H_P#\D#T[_L/V_P#Z)N*^K:^4O^"C_P#R
M0/3O^P_;_P#HFXK:C\:/-S'_ '2IZ'YG4445[1^:!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $UF=MY <9Q(O\Z_9"7XG:]:_$"'PU'\.
M]?N=),D<7_"2H]O]BVL@8O@R;\ G:?ESD5^.%C_Q_6__ %T7^=?NC;C-O'[J
M/Y5Y^+^S\SZWA_\ Y>_+]3RC2/C7XIU*WUF2?X1>*M/>QMC/!'<26A-X^]5\
MJ/;,?FPQ;G PIYS@%6^-?B@>$DU<?"/Q4;YKYK0Z1YEI]H6,1AA.3YVW822O
M7.5/&*]9\OWI=@S7GGV)Y5JOQD\3:?<Z'%#\*?$]\NH6L-Q<2026N+%W9@T4
MN91\R  G;D888)I9_B;XEU3Q1J?AX?#/Q#!91/.D6MRR6PM9Q'DJRXD+XDVX
M7*CEAG'./5-@R3ZT; !@<4">JL>!:=X[\7WOA[6-1E^%?B6SNK$P"'3II;3S
MKP.Q5C'B8K\@ )R1PPQFC4O'?B^Q\.Z/J,7PK\2WEU?&<3:=#+:>=9^6P5?,
MS-M^<$D8)X!SBO?-GO2A.>M.YC[*)X?<^+/%$'C&QT5/AUKLUC<& 2:RDEM]
MF@WJ"V[][O\ W9)#87JIQGC,&F>,_%M]>:[!-\,?$-DNG6T\\$TTMKLOWC8!
M8HL2D[G!R-V!@<D5[MY?/6@ID@YZ47#V43P,>._%Y\)MJ_\ PJOQ+]M%\+0:
M1YMI]H,?EEO/_P!=MV9^7KG/;%&K^.O%^FPZ,\'PL\1Z@U];K-.EO+:YLG+$
M>5)NF'S  -QD8(YKWW;SUHV\]:+A[*)Y=H_Q#\16/C23PS+\.]>_L]'EQX@$
MEO\ 8W C+J0/,W_,1L'R_>(SQS5;2_C5XIU#0=;OYOA'XJL;G3UA:"PFDM#+
M?%Y K"+$Q'R [CN(XZ9->M!,$\]:-N>](U225CR.[^-OBJW\-Z?J<?P@\5W%
MW<SS12::DEIYUNJ!=KOF;;A]QQ@D_*<XXS=N?B[XD@\2:-IJ_"[Q)-:7Z6KS
MZBDEMY-D90-ZR?O=Q,63NV@_=.W->G[:39SG-!1YA8_%[Q)=ZSKME)\+?$MM
M!IT%S-;WDDEMY=^T6=D<6)<[I/X=P YYQ5.#XV^*9?#%WJC?"'Q7%>074=NF
MEM):>?*C*Q:53YVW:I4 Y.<L,9YKUO8#2[>2?6@#R/5OC;XJT_2=&O(/A#XK
MOY[Z%Y)[."2T\RR99"H23,P&6 #C:3PPS@Y V7^*&OK\0O\ A'1\.=?;2MX3
M_A(@]O\ 8\>7OW8\S?C/R_=Z^U>A",#//6EV\=:!'D.E_&_Q5J&EZO=3?!_Q
M78S64*2P6L\MIYEXS2*A2/$Q&0&+G.!A3WP"2_&_Q5'X;M]3'P?\5R7<EW);
MOIBRVGGQHJ(RS']]MVL7*CG.4;/;/KVP9S0%Y)H&>6WWQB\2VFJZ):1_"KQ-
M<PW]O;S3W4<EKLL6D^_'+F7.Z/\ BVY'IFG0?%_Q)+XDUC3&^%OB6.TL5NF@
MU)I+7R;SR@QC$?[W<#+M 7<!]X;L<UZAL]Z39SG- 'D5G\;_ !5<^'M1U&3X
M/^*[>ZM9H8XM.DEM/.N5</N=,3;<)L&<D'YUQGG#M3^-GBJPT+1[^'X0^*KV
MXOEF,]C#+:>;9%'VJ),S ?./F&TGCKSQ7KFWG- 3&: /-I?BMXAC\>6V@#X:
M>(GTV1X4?7P]M]DB#HK,Q'F[\(25.%ZJ<9K,TGXV^*M1AUAYOA!XKL&L;5KB
M!)Y;0F\<.JB*/;,?F(8MS@80\YP#Z[MYS2;.<Y- CR0_&OQ2/"JZM_PJ+Q4;
MTWQM3I/F6GV@1^6&\_\ UVW9D[>N<]L4_5OC1XGTZ315@^$WBB_%_:Q7$[02
M6N+%V=E:*7=*/F4*&.W(PPKUC;0$P<T#/(]9^.>MZ%J^OPWGPS\16^CZ5'=2
M_P!N2RVPM9TA5F#+B0OA]HQE<_,,CK7FO_#>NC?]"I?_ /@0G^%>W_' 8^#W
MC3_L$77_ *+:OS!VTF5%)GV?_P -ZZ-_T*E__P"!"?X4?\-ZZ-_T*E__ .!"
M?X5\8;:-M*Y?*C[/_P"&]=&_Z%2__P# A/\ "C_AO71O^A4O_P#P(3_"OC#;
M1MHN'*C[/_X;UT;_ *%2_P#_  (3_"C_ (;UT;_H5+__ ,"$_P *^,-M&VBX
M<J/L_P#X;UT;_H5+_P#\"$_PH_X;UT;_ *%2_P#_  (3_"OC#;1MHN'*C[/_
M .&]=&_Z%2__ / A/\*/^&]=&_Z%2_\ _ A/\*^,-M&VBX<J/L__ (;UT;_H
M5+__ ,"$_P */^&]=&_Z%2__ / A/\*^,-M&VBX<J/L__AO71O\ H5+_ /\
M A/\*/\ AO71O^A4O_\ P(3_  KXPVT;:+ARH^S_ /AO71O^A4O_ /P(3_"C
M_AO71O\ H5+_ /\  A/\*^,-M&VBX<J/L_\ X;UT;_H5+_\ \"$_PH_X;UT;
M_H5+_P#\"$_PKXPVT;:+ARH^S_\ AO71O^A4O_\ P(3_  H_X;UT;_H5+_\
M\"$_PKXPVT;:+ARH_4_X:>.HOB1X(TOQ'#:/917ZNRP2,&9=KLO)'^[G\:ZB
MO*?V7/\ D@WA(Y_Y8R_^CY*]6JC$**** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110!PWQP_Y([XT_[!%U_P"BVK\PJ_3WXX?\D=\:?]@BZ_\
M1;5^85)FD HHHJ30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _2']ES_D@OA/_KC-_P"CY*]5KRK]ES_D@OA/_KC-_P"CY*]5JSG>X444
M4 %%%% !1110 4444 %%%% !1110 4444 %?G3<:S\:OVX?BAXUA\$^,/^%?
M_#[PQJ+:9$\+,LEPZD_,=OS$D+NZX 8#FOT6K\ZM0^$_QE^"'Q0\<>)?V<M7
MT?QGX3UO4))[[1(KRWF>RN2[;XV1V !5BP!#!L<$<9H&CHO@KX[^+/[-O[1G
MAWX0?%#7D\8Z%XJB=])U<L6>&10V!D\X)3:5.?OJ<U]Y8%?$/P"_9T^,'COX
M^:;\8?CK=6MO>Z);M%H^B6SHWENRLN2(\HJJ&9N"26.3C'/V_0#"BBB@1\5_
M\%8RJ_LS:9V/_"26N/\ OQ<U8_;Q\'W_ (O_ &&;-].@>ZDTF/3=2ECB&YO*
M5 CMCT42%C[*37U;XS\ ^'/B+I*:9XGT6RUW3TE$ZVU]")$$@! ;![@,>?>M
M4:;:BP6R%O&+-8Q"(-HV; ,!<=,8XQ0,_+']J?XO>'?C?^RS\!_ OA"]36/%
ML\UA'+I=N"TL$D5H;=D<=CYD@ ]0":_1O6OA3X.USPMI-KXMT32]:AT6T5$N
M-1@1Q$$0!F#'H,#)[56\)_LZ?#/P-XF?Q#H/@K1]+UIB3]LM[55=2>NTXXZ]
MJ['Q1X8T[QEX=U+0]6A-QIFHV[VUS"'*[XV&&7(Y&1QQ0%SX"NO%^L:UX-^+
MO[3&C6BVMKHM@?#?P_M_( CM+)9EBFO$3& 268CT 8'@5T_[.OCWQ7X9_:/\
M">#I/&]]XXT/Q;X%A\1:A]ND67[)>,'8LA4?*IV*-I_OCVK[)TGX>^'-$\#P
M>#[32+6/PS#:?8ETTQAH3#C!0@]0<G.>N37-_#/]GGX??!^_N[[PEX:M=)O;
MJ,0R7"9:3RP<B,,22%S_  CCB@#T:N>\>>#XO'GA>[T674=0TA+@H?M>ES^3
M<)M8-\KX.,XP?;-=#2 8H$?('Q2^"EM\,OB1\$=0@\4^)M=:?QM#;FWUK4#<
M0J#:73;@N!AN,9]":^P*\$_:>_Y''X#?]C[!_P"D5W7O= PHHHH$%%%% !11
M10 4444 %%%% !1110 5\I?\%'_^2!Z=_P!A^W_]$W%?5M?*7_!1_P#Y('IW
M_8?M_P#T3<5M1^-'FYC_ +I4]#\SJ***]H_- HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@">Q_X_K?_KHO\Q7[I6W_ ![Q?[H_E7X6V/\
MQ_6__71?YBOW2MO^/>+_ '1_*O/Q?V?F?7</_P#+WY?J2T445YY]>%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '#?'#_ )([XT_[!%U_Z+:OS"K]/?CA_P D=\:?]@BZ_P#1;5^85)FD HHH
MJ30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _2']ES_D@
MOA/_ *XS?^CY*]5KRK]ES_D@OA/_ *XS?^CY*]5JSG>X4444 %%%% !1110
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MR^ W_8^P?^D5W7O=>"?M/?\ (Y? ;_L?8/\ TBNZ][H&%%%% @HHHH ****
M"BBB@ HHHH **** "OE+_@H__P D#T[_ +#]O_Z)N*^K:^4O^"C_ /R0/3O^
MP_;_ /HFXK:C\:/-S'_=*GH?F=1117M'YH%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 3V/_'];_\ 71?YBOW2MO\ CWB_W1_*OPML?^/Z
MW_ZZ+_,5^Z5M_P >\7^Z/Y5Y^+^S\SZ[A_\ Y>_+]26BBBO//KPHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MX;XX?\D=\:?]@BZ_]%M7YA5^GOQP_P"2.^-/^P1=?^BVK\PJ3-(!1114F@44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^D/[+G_)!?"?\
MUQF_]'R5ZK7E7[+G_)!?"?\ UQF_]'R5ZK5G.]PHHHH **** "BBB@ HHHH
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M_P"NB_S%?NE;?\>\7^Z/Y5Y^+^S\SZ[A_P#Y>_+]26BBBO//KPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X
M;XX?\D=\:?\ 8(NO_1;5^85?I[\</^2.^-/^P1=?^BVK\PJ3-(!1114F@444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^D/[+G_ "07PG_U
MQF_]'R5ZK7E7[+G_ "07PG_UQF_]'R5ZK5G.]PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *P_&_B>#P5X-U[Q#<X-OI-A/?R G
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M;NI_"VDV>N:VI3R+&_O#:0R L VZ4(Y7"Y/W3D\4"/)?VGO^1R^ W_8^P?\
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M>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M85)FD HHHJ30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ$>;F/\ NE3T/S.HHS1FO:/S,**,T9H **,T9H **,T9H **,T9H **,T9H
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M .3M8=AD=Y^Q)X1URW\>?&KQM<>'M1\*>%O%>LPW&BZ5JEL;68*GFEY3"?\
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M_P#\!4_PH \V_P"&O/@[_P!#]IGY2?\ Q-'_  UY\'?^A^TS\I/_ (FO2?\
MA$="_P"@+I__ ("I_A1_PB.A?] 73_\ P%3_  H \V_X:\^#O_0_:9^4G_Q-
M'_#7GP=_Z'[3/RD_^)KTG_A$="_Z NG_ /@*G^%'_"(Z%_T!=/\ _ 5/\* /
M-O\ AKSX._\ 0_:9^4G_ ,37SM^W-\=O ?Q.^#MCI/A3Q':Z[J2:S#<-;6JN
M6$8BF!;E1P"P_.OM+_A$="_Z NG_ /@*G^%)_P (CHJG*Z/IZGVM4_PJHRY9
M*2.?$457I2I-VN?AUY=Q_P ^LW_?MO\ "CR[C_GUF_[]M_A7[D?\(MH__0)L
M/_ 9/\*/^$6T?_H$V'_@,G^%=?UN7\I\]_8%'_GY+\/\C\-_+N/^?6;_ +]M
M_A1Y=Q_SZS?]^V_PK]R/^$6T?_H$V'_@,G^%'_"+:/\ ] FP_P# 9/\ "CZW
M+^4/[ H_\_)?A_D?AOY=Q_SZS?\ ?MO\*/+N/^?6;_OVW^%?N1_PBVC_ /0)
ML/\ P&3_  H_X1;1_P#H$V'_ (#)_A1];E_*']@4?^?DOP_R/PW\NX_Y]9O^
M_;?X4>7<?\^LW_?MO\*_<C_A%M'_ .@38?\ @,G^%'_"+:/_ - FP_\  9/\
M*/K<OY0_L"C_ ,_)?A_D?AOY=Q_SZS?]^V_PH\NX_P"?6;_OVW^%?N1_PBVC
M_P#0)L/_  &3_"C_ (1;1_\ H$V'_@,G^%'UN7\H?V!1_P"?DOP_R/PW\NX_
MY]9O^_;?X4>7<?\ /K-_W[;_  K]R/\ A%M'_P"@38?^ R?X4?\ "+:/_P!
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M_GUF_P"_;?X4>7<?\^LW_?MO\*_<C_A%M'_Z!-A_X#)_A1_PBVC_ /0)L/\
MP&3_  H^MR_E#^P*/_/R7X?Y'X>6@FBNX6:VF"JP)/EGU'M7ZZ0_M=?!U8(U
M_P"$]TS[H'_+3_XFO3_^$6T?_H$V'_@,G^%-_P"$0T+_ * NG?\ @+'_ (5C
M5JNK:ZV/4P.7PP/-R2;O;>W3T]3S;_AKSX._]#]IGY2?_$T?\->?!W_H?M,_
M*3_XFO2?^$1T+_H"Z?\ ^ J?X4?\(CH7_0%T_P#\!4_PK ]4\V_X:\^#O_0_
M:9^4G_Q-'_#7GP=_Z'[3/RD_^)KTG_A$="_Z NG_ /@*G^%'_"(Z%_T!=/\
M_ 5/\* /-O\ AKSX._\ 0_:9^4G_ ,31_P ->?!W_H?M,_*3_P")KTG_ (1'
M0O\ H"Z?_P" J?X4?\(CH7_0%T__ ,!4_P * /-O^&O/@[_T/VF?E)_\31_P
MUY\'?^A^TS\I/_B:])_X1'0O^@+I_P#X"I_A1_PB.A?] 73_ /P%3_"@#S;_
M (:\^#O_ $/VF?E)_P#$T?\ #7GP=_Z'[3/RD_\ B:])_P"$1T+_ * NG_\
M@*G^%'_"(Z%_T!=/_P# 5/\ "@#S;_AKSX._]#]IGY2?_$T?\->?!W_H?M,_
M*3_XFO2?^$1T+_H"Z?\ ^ J?X4?\(CH7_0%T_P#\!4_PH \V_P"&O/@[_P!#
M]IGY2?\ Q->6?M1?M-_#/Q9^SUX_TC0/&=G?:U>:5-%9VUKYGFR2D?*J_+UK
MZ<_X1'0O^@+I_P#X"I_A2#PAH8;(T;3\^OV6/_"@1Y3HW[6_P@M]&L(Y/'NF
MB1((U8-YF<A1G/RU>_X:\^#O_0_:9^4G_P 37I'_  B&A_\ 0%T[_P !8_\
M"E_X1'0O^@+I_P#X"I_A0!YM_P ->?!W_H?M,_*3_P")H_X:\^#O_0_:9^4G
M_P 37I/_  B.A?\ 0%T__P !4_PH_P"$1T+_ * NG_\ @*G^% SS;_AKSX._
M]#]IGY2?_$T?\->?!W_H?M,_*3_XFO2?^$1T+_H"Z?\ ^ J?X4?\(CH7_0%T
M_P#\!4_PH \V_P"&O/@[_P!#]IGY2?\ Q-'_  UY\'?^A^TS\I/_ (FO2?\
MA$="_P"@+I__ ("I_A1_PB.A?] 73_\ P%3_  H \V_X:\^#O_0_:9^4G_Q-
M'_#7GP=_Z'[3/RD_^)KTG_A$="_Z NG_ /@*G^%'_"(Z%_T!=/\ _ 5/\* /
M-O\ AKSX._\ 0_:9^4G_ ,31_P ->?!W_H?M,_*3_P")KTG_ (1'0O\ H"Z?
M_P" J?X4?\(CH7_0%T__ ,!4_P * /-O^&O/@[_T/VF?E)_\31_PUY\'?^A^
MTS\I/_B:])_X1'0O^@+I_P#X"I_A1_PB.A?] 73_ /P%3_"@#PKXL?M3?"G7
MOAGXHTW3_&NGW=_>:;/!;P1B0M([1D*H^7J2:^!_[<LO^>Q_[]M_A7ZV#PAH
M8.?[&T_.<Y^RI_A4O_"+Z-_T";'_ ,!D_P *!IV/R._MRR_Y['_OVW^%']N6
M7_/8_P#?MO\ "OUQ_P"$7T;_ *!-C_X#)_A1_P (OHW_ $";'_P&3_"E8?,?
MD=_;EE_SV/\ W[;_  H_MRR_Y['_ +]M_A7ZX_\ "+Z-_P! FQ_\!D_PH_X1
M?1O^@38_^ R?X46#F/R._MRR_P">Q_[]M_A1_;EE_P ]C_W[;_"OUQ_X1?1O
M^@38_P#@,G^%'_"+Z-_T";'_ ,!D_P *+!S'Y'?VY9?\]C_W[;_"C^W++_GL
M?^_;?X5^N/\ PB^C?] FQ_\  9/\*/\ A%]&_P"@38_^ R?X46#F/R._MRR_
MY['_ +]M_A1_;EE_SV/_ '[;_"OUQ_X1?1O^@38_^ R?X4?\(OHW_0)L?_ 9
M/\*+!S'Y'?VY9?\ /8_]^V_PH_MRR_Y['_OVW^%?KC_PB^C?] FQ_P# 9/\
M"C_A%]&_Z!-C_P" R?X46#F/R._MRR_Y['_OVW^%']N67_/8_P#?MO\ "OUQ
M_P"$7T;_ *!-C_X#)_A1_P (OHW_ $";'_P&3_"BP<Q^1W]N67_/8_\ ?MO\
M*/[<LO\ GL?^_;?X5^N/_"+Z-_T";'_P&3_"C_A%]&_Z!-C_ . R?X46#F/R
M._MRR_Y['_OVW^%']N67_/8_]^V_PK]<?^$7T;_H$V/_ (#)_A1_PB^C?] F
MQ_\  9/\*+!S'Y'?VY9?\]C_ -^V_P */[<LO^>Q_P"_;?X5^N/_  B^C?\
M0)L?_ 9/\*/^$7T;_H$V/_@,G^%%@YCYO^ /[3/PP\(_"#P[I&L^,;#3]3M8
MI%FMI@X="9G(S\OH17H?_#7GP=_Z'[3/RD_^)KTAO"&ALVXZ-I^?>U3_  I?
M^$1T+_H"Z?\ ^ J?X4R3S;_AKSX._P#0_:9^4G_Q-'_#7GP=_P"A^TS\I/\
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M/%^A^--5\6:U>V%AX@N;"YO9YK>:*&<I)&TC%64XZ$$$5^^G_"(:%_T!=/\
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M;R00V=I"]Q-*>B(BEF/X &@"Y17*_#?XG>&_BYX7B\1>%-2CU;1Y97A2YC!
M+(<,.?0UU)( S0 FX4N:^(D_;;^)OQ=\2:_%\%/AG'XE\.:+<-;2:M?7'E^>
MXSC:O;<!D#KR/6O3OV4/VN!^T)>^(O#FN>'Y?"GC;P\V+[3')92 VQBI(S\K
M<$'U'K0.Q]'YHW U\8>.?V[/$?B3XI:IX#^"?@5O'E]I3&.]U*24I;HRDJVT
MCL&R,D\X.*L_#K]N;7=*^*6F_#SXS^"'\ ZUJ;+'87R2;[:5F(5 2>@).,@X
M!ZT!8^QMWM1D5\]_M1_M=:9^SS-HV@V&DS^*O'&MX_L_1+4\E2VT.Y'(!;(
M R<'TKQ;5?VZ?BO\&]2TF\^+_P )6T'POJ,RQ"^L9B[PL<G:1T)"ACC@G'%
M6/NZBJ6CZS9Z_I%EJ=A,MS8WL"7-O,G22-U#*P]B"#5V@04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*H=SU)).:YO]E&\@TW]JC]K&[N=271K>"YN9)-1; %JHN;@F4YXPH^;GTK]
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M+_V*/ W@#]GW6?A5>^?K=AKQ:;5[^3$<UQ/\NV1!R$V&-"@Y *Y.<G/CJ_\
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M!ZFO2OB9^P$UQ\3[WXA?";QYJ'PQ\17[M)>16B%K>5G.9"H5@5#'#%#N7(X
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MSV<UL08I(64,C)CC:5(Q[5IU!:64&GVL-K:Q);6T*+'%#$H5(T4855 X
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M5^V]\6_C!)X@UKX/?""/Q'X)T>9H?M^HW!CN+LJ-Q$<>]<N5(.Q0Y&0#R0*
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M?"LUT;RXMHYW\QOFP"Q5E4LH&1O;T-?HZ849PQ4%AT..13@H% [GYA?MG?M
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M_P#D:@=CW:BO"?[>_:/_ .A1^'/_ (/KW_Y&H_M[]H__ *%'X<_^#Z]_^1J
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MVC_^A1^'/_@^O?\ Y&H_M[]H_P#Z%'X<_P#@^O?_ )&H"Q[M17A/]O?M'_\
M0H_#G_P?7O\ \C4?V]^T?_T*/PY_\'U[_P#(U 6/=J*\)_M[]H__ *%'X<_^
M#Z]_^1J/[>_:/_Z%'X<_^#Z]_P#D:@+'NU%>$_V]^T?_ -"C\.?_  ?7O_R-
M1_;W[1__ $*/PY_\'U[_ /(U 6/=J*\)_M[]H_\ Z%'X<_\ @^O?_D:C^WOV
MC_\ H4?AS_X/KW_Y&H"Q[M17A/\ ;W[1_P#T*/PY_P#!]>__ "-1_;W[1_\
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M^'/_ (/KW_Y&H_M[]H__ *%'X<_^#Z]_^1J L>[45X3_ &]^T?\ ]"C\.?\
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M[]H__H4?AS_X/KW_ .1J L>[45X3_;W[1_\ T*/PY_\ !]>__(U']O?M'_\
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M_#G_ ,'U[_\ (U 6/=J*\)_M[]H__H4?AS_X/KW_ .1J/[>_:/\ ^A1^'/\
MX/KW_P"1J L>[45X3_;W[1__ $*/PY_\'U[_ /(U']O?M'_]"C\.?_!]>_\
MR-0%CW:BO"?[>_:/_P"A1^'/_@^O?_D:C^WOVC_^A1^'/_@^O?\ Y&H"Q[M1
M7A/]O?M'_P#0H_#G_P 'U[_\C4?V]^T?_P!"C\.?_!]>_P#R-0%CW:BO"?[>
M_:/_ .A1^'/_ (/KW_Y&H_M[]H__ *%'X<_^#Z]_^1J L>[45X3_ &]^T?\
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M)NHE)&?]EB/QK\B6_;6^.1+'_A9FNY)/250/_0:!I7/W@HK\'_\ AM7XY?\
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MS]X**_!__AM7XY?]%-U[_O\ #_"C_AM7XY?]%-U[_O\ #_"@.5G[P45^#_\
MPVK\<O\ HINO?]_A_A1_PVK\<O\ HINO?]_A_A0'*S]X**_!_P#X;5^.7_13
M=>_[_#_"C_AM7XY?]%-U[_O\/\* Y6?O!17X/_\ #:OQR_Z*;KW_ '^'^%'_
M  VK\<O^BFZ]_P!_A_A0'*S]X**_!_\ X;5^.7_13=>_[_#_  H_X;5^.7_1
M3=>_[_#_  H#E9^\%%?@_P#\-J_'+_HINO?]_A_A1_PVK\<O^BFZ]_W^'^%
M<K/W@HK\'_\ AM7XY?\ 13=>_P"_P_PH_P"&U?CE_P!%-U[_ +_#_"@.5G[P
M45^#_P#PVK\<O^BFZ]_W^'^%'_#:OQR_Z*;KW_?X?X4!RL_>"BOP?_X;5^.7
M_13=>_[_  _PH_X;5^.7_13=>_[_  _PH#E9^\%%?@__ ,-J_'+_ **;KW_?
MX?X4?\-J_'+_ **;KW_?X?X4!RL_=^C-?A O[:WQR!4_\+,UW((ZRJ1_Z#7K
<NF?M7_%V?3;21_'NK,[Q(S$R+R2!GM0)JQ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>srrk-20240930x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 srrk-20240930x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '* ZH# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME%%%2:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4E32<5?5+[S[)ZTM,1%C0*!A0, >U/J3<**** "BBB@ HHHH **** "BBB@
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M_(,2#6;C);H[(5J=3X9)_,ZVBBBI-@HHHH **** "BBB@ HHHH *^</V%O\
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M.E-=#:&/PT]I_>?6E?.'["W_ "2SQ-_V-NJ?^C%KRWXV_P#!2C2O!?B2PMO
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MZW\O_"8_8'/&R^L+B/\ \>V%?UKO=$_:0^%GB([=/^(7AR9S_P LWU**-_\
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M*ZG(([$&I:B]]SJC%15HJR"BBBD4%%%% !1110 4444 %%%% !1110 4444
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M?0U%%% @HHHH **** "BBB@ HHJGJ.IVFDV<MW?74-G:1#=)/<2+&B#U+$X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\X?L+?\DL\3?]C;JG_HQ:]K\>:9X@UCPEJ-GX7UB+P_K\BJ+74I[47*0-N!
M),;<-E01SZYKR3]FGX$^-_@?/JUGK7CBS\1Z#>R37@L8-+6W=;N5U9Y?,R3@
M@,-O3YN,8JU;E:.2?-[:#4=->W7YGO\ 1114'6%%%% !1110 4444 %%%% !
M1110 4444 %%%% !7FW[2/\ R;U\3/\ L6M1_P#2:2O2:\V_:1_Y-Z^)G_8M
M:C_Z3254?B1E5_AR]&1?LR_\F\?#3_L7;#_T0E>G5YC^S+_R;Q\-/^Q=L/\
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MC/M7?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5YM^TC_P F]?$S_L6M1_\
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M7KG7]3CT]V:WMVE((A1F +!>3GU;'(&2#Z'N,LJ01O)(XCC0%F=S@ #DDD]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=5OI;NZTN.:YE.YY"S L?7@XH Z6BD "C Z"EH **** "BBB@ HHHH ****
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M-4?\,_\ Q3_Z.)\2_P#@CT[_ .-4AV/H*BOGW_AG_P"*?_1Q/B7_ ,$>G?\
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M[_XU0%CZ"HKY]_X9_P#BG_T<3XE_\$>G?_&J/^&?_BG_ -'$^)?_  1Z=_\
M&J L?05%?/O_  S_ /%/_HXGQ+_X(]._^-4?\,__ !3_ .CB?$O_ ((]._\
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M ,:H_P"&?_BG_P!'$^)?_!'IW_QJ@+'T%17S[_PS_P#%/_HXGQ+_ ."/3O\
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M:H"Q]!45\^_\,_\ Q3_Z.)\2_P#@CT[_ .-4?\,__%/_ *.)\2_^"/3O_C5
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M#F-4^&_AO5\F?28$8]7@!B;_ ,=Q7(ZI\ -+GRUAJ%S:-V64"1?Z']:]5HI
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M\EK&4:\ACN)B7+;I&1<GD\?05UM !1110 4444 %%%% !1110 4444 %%%%
M'AO[9'P[UOXG_ C5='\/Z8-=O8[RSOGT5Y_)&HPPW"226^\G +*IQ[CUKYF\
M*_LZZS\/?VD?#EGX:^$JV,%GXN?Q##XS*+]D@T6XMCYVGLN2#+%([+&3\R[$
M*C!R?3_V[OVC/"WA?X?Z_P" [/Q\_AKQF6M'NK6Q29;PV;RQM,L,@78':(L0
M"PR/E[UY]\$(/V9S\3O"<GA7XS^,];\1F[C:PTO4=1NFBGEQ\L<BM;JO/=21
MZ4%(^_:***"0HHHH *^>?CC_ ,G4?LV?]?FO_P#IL:OH:OGGXX_\G4?LV?\
M7YK_ /Z;&H&CZ&HHHH$%%%% !1110 4444 %%%% !7$^'?\ DI_B[_KE:?\
MHNNU/((Z>]<5H?P^O-(U]M5;Q%=7<DI7[0CQJ!,%!"@D'M0!VU%%% !1110
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M$O0_^O*+_P! %;U8/@3_ )$O0_\ KRB_] %;U !1110 4444 %%%% !1110
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M+K<T9G\O4Q;QVQ:!ADHA#9XXY]:]3HHH **** "BBB@ HHHH **** "BBB@
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M8V,X'.*^DZ^>?CC_ ,G4?LV?]?FO_P#IL:@:/H:BBB@04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<3\)_^0!?_ /82N/\ T(5VU<3\)_\ D 7_ /V$KC_T(4Q';4444AA1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH HZO)?1:=,^FQ13WH \N.9RJ$Y&<GZ9KE/AUH^OZ"+JUU.UM8K
M2222X62&4NWF,P.W'IC-=S10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6'XX_P"1-U[_ *\9O_0&K<K#\<?\B;KW_7C-_P"@-0 WP)_R)>A_
M]>47_H K>K!\"?\ (EZ'_P!>47_H K>H **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5A^./^1-U[_KQF_P#0&K<K
M#\<?\B;KW_7C-_Z U #? G_(EZ'_ ->47_H K>K!\"?\B7H?_7E%_P"@"MZ@
M HHHH **** "BBB@ HHHH **** "BBB@#Y^^,G[2_BWX8>-I=#T?X)^,/'-D
MD,<JZQHT3-;LS#)0$1MRO0\UXOKGQ/\ 'WQ^^-'P:^T_!'QGX-L- \0_;[K4
M=4M7,"QF)D.YO+4+@G.2:^Z:*!W"BBB@04444 %?//QQ_P"3J/V;/^OS7_\
MTV-7T-7SS\<?^3J/V;/^OS7_ /TV-0-'T-1110(**** "BBB@ HHHH ****
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M% 'SW_PWW\"?^AVE_P#!)J/_ ,CT?\-]_ G_ *':7_P2:C_\CU]"44 ?/?\
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M_P"AVE_\$FH__(]'_#??P)_Z':7_ ,$FH_\ R/7T)10!\]_\-]_ G_H=I?\
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M ^>_^&^_@3_T.TO_ ()-1_\ D>C_ (;[^!/_ $.TO_@DU'_Y'KZ$HH ^>_\
MAOOX$_\ 0[2_^"34?_D>C_AOOX$_]#M+_P""34?_ )'KZ$HH ^>_^&^_@3_T
M.TO_ ()-1_\ D>C_ (;[^!/_ $.TO_@DU'_Y'KZ$HH ^>_\ AOOX$_\ 0[2_
M^"34?_D>C_AOOX$_]#M+_P""34?_ )'KZ$HH ^>_^&^_@3_T.TO_ ()-1_\
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M*$?>).<\UXC^SC^TM\8OCA8P>)+OP1X7TSP0LEY#=:BFJ.)HI(8WQ\C$_*9
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M4NBL2(\AG/"]:+!J<Y_PV]?_ /1 OBU_X(1_\<H_X;>O_P#H@7Q:_P#!"/\
MXY77?%KXB^(D^"Z>*?AQI\VJWEY]FEB+Z=)+<0VCLOF3):,4DED1"6$)*L3^
M5>.Z-^T?XSOO!&G:=IFNZ!XD\4:SXIA\-V6JW&E7&GOIX>!IGDOK"0@I*JQO
MM5'VN-ASU%%@N=I_PV]?_P#1 OBU_P""$?\ QRC_ (;>U$YQ^S]\8&QW3PYN
M'YA\5S7B;X^?$+X-KXU\+>(9M%\8>*-/LM,O-#U6&T>P@N!>WALU6ZB#OL\N
M3YOD;YEXX->Z?"73OB?HNIW]GXXUWP_XGT@P)-9ZCIMD]A=QS%B)(I("[H4
MP5<,&Z@B@:9YA_PV_J7_ $;W\8O_  FS_P#%T?\ #;^I?]&]_&+_ ,)L_P#Q
M=?45%(9\N_\ #;^I?]&]_&+_ ,)L_P#Q='_#;^I?]&]_&+_PFS_\76+:_M&>
M/M%T[7]0\0I/I>NW5O.^A>&-:\.O8P$F^2WC<77FEIA"DD3R(51F63<O'3VK
MX2^,-?NO%?C7P7XDO8=9U/PS+:.FL6]J+;[7!<P^8N^(%@KHRR+P<%=AQG-
M'E__  V_J7_1O?QB_P#";/\ \71_PV_J7_1O?QB_\)L__%U]144 ?+O_  V_
MJ7_1O?QB_P#";/\ \71_PV_J7_1O?QB_\)L__%U]144 ?+O_  V_J7_1O?QB
M_P#";/\ \71_PV_J7_1O?QB_\)L__%U]144 ?+O_  V_J7_1O?QB_P#";/\
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M-OZE_P!&]_&+_P )L_\ Q=?45% 'R[_PV_J7_1O?QB_\)L__ !='_#;^I?\
M1O?QB_\ ";/_ ,77U%10!\N_\-OZE_T;W\8O_";/_P 71_PV_J7_ $;W\8O_
M  FS_P#%U]144 ?+O_#;^I?]&]_&+_PFS_\ %T?\-OZE_P!&]_&+_P )L_\
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M .+H_P"&W]2_Z-[^,7_A-G_XNOJ*B@#Y=_X;?U+_ *-[^,7_ (39_P#BZ/\
MAM_4O^C>_C%_X39_^+KZBHH ^7?^&W]2_P"C>_C%_P"$V?\ XNC_ (;?U+_H
MWOXQ?^$V?_BZ^HJ* /EW_AM_4O\ HWOXQ?\ A-G_ .+H_P"&W]2_Z-[^,7_A
M-G_XNOJ*B@#Y=_X;?U+_ *-[^,7_ (39_P#BZ/\ AM_4O^C>_C%_X39_^+KZ
MBHH ^7?^&W]2_P"C>_C%_P"$V?\ XNC_ (;?U+_HWOXQ?^$V?_BZ^HJ* /EW
M_AM_4O\ HWOXQ?\ A-G_ .+H_P"&W]2_Z-[^,7_A-G_XNOJ*O$?VFOC=?_"S
MPK=VWAA]/E\7&S?4@NH2+Y5G91R(LMQ(NY2V2XC10<L[>BM@ XO_ (;?U+_H
MWOXQ?^$V?_BZ/^&W]2_Z-[^,7_A-G_XNK/B[X\>*M,^/2:'8W-H?#D&L:9I+
M0_8'DMI8[J(/))/?@[(+A"<1P$?/NBZ^<I7Z9H ^7?\ AM_4O^C>_C%_X39_
M^+H_X;?U+_HWOXQ?^$V?_BZ^HJ* /EW_ (;?U+_HWOXQ?^$V?_BZ>/VVM3(!
M_P"&?/C!_P"$Y_\ 9U]/T4 <I_;6G_\ /[#^?_UJ/[:T_P#Y_8?S_P#K5Y7\
M8?VDM,^$/C_PEX:NM*FU!-699-2OXG"QZ-:O/';0W$^0?D>>54'(Z/Z8/0>(
M?C]\/O"OBUO#&K>*+.PUQ9H()+64-^Z:8 Q;V"E8P^1AF(!)QG-49Z':?VUI
M_P#S^P_G_P#6KE_'_A7PS\2M.TNSU>_81:=J=KJT!MI=C>?;R"2/<2#E=PY%
M<-_PU3X=LO'VD>$M3@2+4=7\1WWA^SDL)_M4:FW53OG8(/*=G=4\OYMI.2VW
M)'4Z/^T+\.->M_$%Q9>+]-EM]!A:XU"9B42*$,RF568 21[E9=\>Y=PVYSQ0
M&AH^-?"WAGQ[<>'IM4O3NT+4TU6U\B;8#,(I(@&X.5V2OP,?6O*]%_9(^&&D
M:9>:=+JNIZII]QHS^'UM;V^79!9^>LZ+&$1<.DBAED.6S]XL:[1/VH?A:^A7
M>L'QA9Q:?:30V]Q)-#+&\,DJN\4;(R!E9EC8A2,\>XJ^G[0_PY?Q5I'AO_A*
M;%-;U6*"2UM)$=&/GKO@1B5"QNZ\K&Y5F[+0,X^Y_9S\(7^E6T=YXS\1:AK]
MKJ#:C!XFO;^.;4(I##Y#*I:(Q!#'\I41X/WOO?-47B3]F7P%XD-NS>)=?L'7
M08_#5Q)9ZLRO>Z>KN[13EE8OYAD;<WWL'Y2M=!>?M7_":PNKFUG\:627%MYH
M>(0S,Q:)BDJ* AWNA&65<LJ_,1MYK8N_V@OAY9ZQHFER>*+,W>LPVUQ8^4CO
M')'<'%NS2JI2/S#PF]EW?PYH Y#5_P!FWX=ZOXF?4O[4U*STN>6TN+[PU:W[
M)I5]+:J@MY)H,$DH(H^ RJWEIO#8KU#Q!9^&_%-O:0:JUM>Q6MW#?0K([#9/
M$X>*08QRKJ&'N*\_^&G[3_A'Q_XFO_#-Q=P:-XH@UC4-)BTJ:0N\[6LK(Q#;
M H<JN_R\[@O/(YKK?%WQ@\*>!O$NA:#K.KVUGJ&L3/#"DDT:B(I"\I:4DC8I
M6-@">K8'>@"+XE^#?"_Q6\-C1M8U":W6*XBO;2]T^Z:WN;.XC;='-#(!E74]
M#@_2N C_ &9?AW+X;U?3M2UG5];U;5-0M]4G\3WVI-_:RW=NNRWFCG15$;1)
ME5VJ  Q&"#6_\>_CQ'\%K'PX(M/L[V\U^\>SM9]5U)--TZ$K$TK-/=,K"/*K
MA5P=S<5AZA^T?K@T_P (:;IOP\N;GX@>(UN)8?#L^J0I;V\$!'FW#7B!T:([
MT\ME4E]XP!0!9TO]GCX>P^&?%&DZWJ>H^+[CQ-'%'JFKZ_?&:]G6$Y@574(L
M8C;YE\M5PW/6NF^$OPG\)_"_6-3U_P#X2;5_%'B348([.76?$>H_:;E;9&+)
M A"J%0,Q/"Y8\L2:X4?M47$VD0Z;%X(N3\2Y-<?PZWA%[Z(*ETL'VEI3<X(-
ML(?WGF!-Q' 3->Q?"/QCK_C+0+E_$W@^[\&:O97+6LMI<3I<PSX (E@F3'F1
MD' )56!!!6DQHZK_ (232_\ G_@_[[%'_"2:7_S_ ,'_ 'V*TJP_%OB,^$_#
MM[JW]FZAK+6Z@I8:5;&>YG8D!41<@9)/4D*!RQ !-(9Y,GP"\"7%G>66J^(M
M9\06#6%QIEA;ZKJIF_LJWF=7=;>3 DWAHXMLDC.ZB-%5@,Y[+P%X8\/^ O[7
MN(M=N=9U;5YUGU#5M5G1[FX9(UC0'8J*JHBA0JJHZGJ23QQ_:*O]8\->$+SP
MWX/;6=:USP\_BB?2VU)81:6B+'N02E"))6>41HH 4D,690.6:?\ M1V/B3Q=
MI>E>']+M;^TNTL&S?:Q;V=_-]JA2?_1K5SF;R89$>3YE^\53>RE:"CV7_A)-
M+_Y_X/\ OL4?\))I?_/_  ?]]BM*B@DS?^$DTO\ Y_X/^^Q1_P ))I?_ #_P
M?]]BM*B@#-_X232_^?\ @_[[%'_"2:7_ ,_\'_?8K2HH S?^$DTO_G_@_P"^
MQ7FOC'X7>%/&VO7=_?\ B/54L-0-L=2T.'4/]!OS VZ+S$924' #"-D#@ /N
M%>N5XE_PTI"^E^.KI/"6JQ3>'M0L],LK&\*VUQJ<]T42#"./W*/)(H#/SM^<
MJ.E T:/AWX5^#?#GC2+Q##K-Y<"UGO+K3M+N;M6L].GNV+7,D"!007+/@,S!
M1(X0*&(KTK_A)-+_ .?^#_OL5XAXD_:CF\'V4=EJWA[3=,\5)KDFBW5CJ.OQ
MVUC&$LA>?:%NVC.Z,Q/%@&-6W/M(&TU[3X6U6;7O#>EZE<PVUO->6Z3M':70
MNH1N /R3 *)%P>& &1S0#)O^$DTO_G_@_P"^Q1_PDFE_\_\ !_WV*TJ*!&;_
M ,))I?\ S_P?]]BC_A)-+_Y_X/\ OL5I44 9O_"2:7_S_P '_?8H_P"$DTO_
M )_X/^^Q6E10!Y_XZT'2/&\FEW">)]1\/ZEIDKR6U_H]XL;@.I1T9'5XY%([
M.C8(#+@C-<3/^SS\.WLK/3[;5M1L=)2S@L-0TZWU#]UJ\,4SSHMV6!9V,DDA
M9E9682.K$J<5V&K?%Z/2_C!HW@3^P[\_;[6XN7UJ9?*M$,:*_EQDC,K;6RVW
MA>,G)P.&MOVJ/L_AR]\1:SX4ETC0[GP_?>)="N'OT=K^UMB@*3+M MY'66%U
M4EUVR<L&5A0,]M_X232_^?\ @_[[%'_"2:7_ ,_\'_?8KD/@_P#$BZ^)VA7>
MHW-GHUJ(I_( T77$U5,A5+*[I&@1P6P5P?7H:]!H$9O_  DFE_\ /_!_WV*/
M^$DTO_G_ (/^^Q6E10!F_P#"2:7_ ,_\'_?8H_X232_^?^#_ +[%:5% &;_P
MDFE_\_\ !_WV*/\ A)-+_P"?^#_OL5I44 9O_"2:7_S_ ,'_ 'V*/^$DTO\
MY_X/^^Q6E10!F_\ "2:7_P _\'_?8H_X232_^?\ @_[[%:5% &;_ ,))I?\
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M_%^+4/BY:^";?1-1%M/I,NJ1Z_.@CM)]A@_=09YE(6=2S#"K]W);(4&SL_\
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MDFE_\_\ !_WV*/\ A)-+_P"?^#_OL5I44 9O_"2:7_S_ ,'_ 'V*/^$DTO\
MY_X/^^Q6E10!F_\ "2:7_P _\'_?8H_X232_^?\ @_[[%:5% &;_ ,))I?\
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M32_^?^#_ +[%'_"2:7_S_P '_?8K2HH S?\ A)-+_P"?^#_OL4?\))I?_/\
MP?\ ?8K2HH S?^$DTO\ Y_X/^^Q1_P ))I?_ #_P?]]BM*B@#-_X232_^?\
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MY?WCW4CQ(MO:V:D +;V\>YBJ*!U9F8DDD\U^"/D1_P#/-/\ OD5FWRA)V"@
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MI \JS@2WC:.(+O)9W(8EG;_94#"#/I?]M:?_ ,_UM_W]7_&OYO** Y3^D/\
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M0_[:T_\ Y_K;_OZO^-']M:?_ ,_UM_W]7_&OYO** Y3^D/\ MK3_ /G^MO\
MOZO^-']M:?\ \_UM_P!_5_QK^;RB@.4_I#_MK3_^?ZV_[^K_ (T?VUI__/\
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MUM_W]7_&C^VM/_Y_K;_OZO\ C7\WE% <I_2'_;6G_P#/];?]_5_QH_MK3_\
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G;?\ ?U?\:/[:T_\ Y_K;_OZO^-?S>5K001&&,F-"2HY*CTH#E/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>srrk-20240930x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 srrk-20240930x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $5 ZH# 2(  A$! Q$!_\0
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M6WE05V8P=V:W=)^->K+%!ING:3<^*O$6I:SJMM9V]U<0V<:6]K+M=FD6/"J
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M1TH\,_M"^/9-?TZ#7-'\/'3U\9/X(OFT]YQ-)<B-I%N8@Q(2,*!E6+,?446
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M23#P[!/H>E^)-*\;:3I%S<V8G^RWD5TBRQ(0275<G$F#DK]W%=QI?QV\3_\
M"YF\-:]IFF^']#FU6;3+%KN*YWWJJN8Y(;M0UN[NW6 [&4<9+<46 ]\HHHI
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MP9S\HX&:5Y=4#ITI)RA+I?YV>FOGI\_+7Q^&3Q%/HUYJT>H:JVGVD\5M-/\
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ML)?<>F,FF_$K]H'QM\6/#>BZ)XAUFYNK#3H561&D#?;9U=V6XD&!AP)-O'&
M*ZOP;\=O#7A3X;W&AC3?$3SSZ5/IUUX>%\DN@7\\BLHO723<\<@RK%(P 60$
M%>[;J6NEJ9TXX9SDG+W;:-Z:_+\/R9C6?[.6K7D6G:>/$FAQ^-]2L%U2R\&R
M&;[=+ R&1%,@0Q),R#<(F;=CWJAHWP-N=2T#2KS4/%?A_P -ZMK5D^I:1H>K
MRR137ELN[$C2[?*AWF-@@D8%L5UFD_'KPG:^)=&^(-[X>UFZ^)>D:?#91(+J
M+^R;BXAM_(BO),CS00@!,0X+#[P[XS?%+P/XET7P_=^-/#&JZ[XIT#2?[&MX
M(+M(M,U&--_D27&,2HT?F<A#\V!R.ZO4_JQJX83=-?>]M-7UYM]%IY=_(D.]
M0V&&>QX-:45LC1(3&I)4'-9J*0@#'>W<],UK0_ZF/_=%;GF1V/W)KA_B#\%_
M!7Q5DM)?%7A^VU::T!6&=G>.15/WDWH5)4]U)Q[5W%%?/GZZ>?Z[\!_ 'B.W
MTB"_\+64T&E6[6EG$@:-(X".8BJD!D/7:V1GGK5F3X-^"Y=-NK!] MFL[K3K
M?2)HLMA[2'_4Q'G.%[=Z[>B@#D+KX5>$[W6+C5)]#MI-0GNK.]EN#NW--:@B
MVD//6,$X_6G)\+/":2;ET.V5O[9/B+(W?\A';M-QU^]@X]/:NMHH \STW]G/
MX;Z/+<O9>$[.W-Q#<6SJKR;1#.K+-$J[L(C!F^10%&20 :J?$;X(1^/X_!FA
MK=VFG>"M N;>ZDT<67F23FW&(8EE+8C3;\K?*6(XR,UZO10!E>(?#NF>*]&O
M-)U>Q@U'3;M#'/;7*!HW7KR#[C(/8\BN5T;X&>!/#_A\Z)9>&[:+3FO(K]HV
M=W=YXV!CD9V8NQ4@8R3CITKOZ* ,/5?"&CZWK^C:S?6$=UJFC&5K"XDSFW,J
MA)"HSC)48Y'TK)\0_"+PAXKEUN75M!M;V36X(K;43)N'VE(CF+=@CYD/W6'S
M+V-=E10!P>E_!#P-HOAO5_#]IX<M(](U< 7]J2S"Y(  9RQ)+<9W9SGG.>:?
MXN^"W@KQUINEV&M^'[:ZMM,C\BS5&>$P1E0IC5D*G854 IG:1U%=S10!RL'P
MS\*VLNJ-%H-DHU.RBTV\C\L&.:UC0HD+)]W8JL0% Z5B:7\ /A]H^AZKI%OX
M9M7TW5(4M[N&X>2X\R)#E(PTC,513RJJ0%/(P:]%HH YKP1\/O#WPXTJ73O#
MFF)IEK+,UQ* [2/+(0 7=W)9V( &22:X_1OV7_A=X>U^SUO3?!]G9:I:3K<P
M7$<DH,<@.58+OQP?:O5:* .:MOAYX;M-0\0WL>BV8N/$01=69HP1>A5**LBG
M@C:Q&,<Y.>M<_HW[/WP^\/Z/>Z58^&;:&QO9H)KB-Y))#*T+!H069BVU"/E7
M.U>PKT6B@#A_$7P8\%^+4UA=7\/P79UB>&YOG+NCRRQ+LB?<K JRKP"I%,L?
M@GX'TWQ<?$]KX=MH=9,[77FJ7\L3L,-,(L^6)".L@7<?6N[HH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KQ#]L;_ )(5JG_7S;?^C17M]>(?
MMC?\D*U3_KYMO_1HH&MS\^****@W"M?PEH2>(=>BM)I&@M$CDN;J5?O+#$C2
M.5SQDA<#W-9%:_A+6X_#VO175Q&TMF\<EK=1KC<T,J,C[<\;@&W#W% '::3\
M*[#6K#P7?6]U.8]2,/\ ;-H&7S+*.:9TAEC;'*'9L)(^5\9^\*XC1/#TFO7-
MS#'=VUGY/.ZZ\S!&XC V(QS]16OX=^)NM>%-;T34].DMS-H]DVFPK+#NCN+<
MLQ*S*3ALE\^Q [BN>L-7O])EDDL+^[L'D^^]K.T989S@E2,C-,2-GPWX8M+[
MQM!H^IW\,%DK2&>Z6<0H52-GPKR !22H4$CJ>E;MSX*T;28;G5-4MK^+2-]E
M%:QV.HPW)G$^\M.LXC"LBK$V%V@[OE;&#7(Z;XAN+#6?[2FCAU69@ZS1ZFGG
MI.KJ58/D[LD'A@0RG!!!%;4?Q*NU*02:5I=QI44<"6^DRQN;>#R69XW4APQ;
M=(Y8ECNWD-Q2 C\3^#%\/V>J%)VGGTG6)-*NF/"R JS0R*/X<A'!'KBN7K?U
M+Q0^H^'[FUE=Y]0U+4WU34+A@ &8*P15Q[R2,?J!VK H&%%%% '8>#O^1*\=
M?]<;#_TJ6L6MKP=_R)7CK_KC8?\ I4M8M>EA_@/C<V_WGY+\V%%%%=)XQJ^&
M]'BU>[O'N2Z6-A937]R8^'*1J,(I/0L[(,^]=M_PJ>P>[T":WNYY]/N].$FH
M@;1+9WALGN47.,>7)L^5CZ.O45Q/AG5X=*N[Q+L.]A?V4UA<^4 7".H*NH/4
MJZHV/:M/3?B3K>EZG+?V[P)+/I:://#L)BE@6+RU)&?O <ANS?4UF^;H;TW2
M27.NID^&_#DWB:&1X[RSLS&$W"Z\P;BPS\NQ&Z>^*T/"GAVPO_$E]9ZM>0P6
MEI:W$SRBZ6V69T7Y4620':"Q[J3CM6-INK:AHD133]1O+!6 W?9;AHMV!@;M
MI&<>]3Z7KCV%Y=W$]O;:J+F)X;F+4 9 X8@EMP(97! (<$,/Q-4[F<7!<M]^
MO8['1_ >DW_C&3P]>0:A97D[H]NJ7T#I#:M%O6X$F +@L2NR- "R]#NKD[O1
MT3PMIVL0L_[RZFL+J.3^&9 KJ5!&0&1^5/1D-:\7Q*O4OTNYM)T>[EMIH)[!
M9;4[=/:% D(BPP)10JG:Y92PW'G-9>HZ\+OPY9::IEDE^V3ZE>SR#!EN)-JC
M&.P1>3W9S4J]S23IM.W]:JQCT445H8!57Q__ ,D1UG_L/:=_Z*N*M55\?_\
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ML_\ X5;\0/\ HG_B?_P6M5*I%=3*6$KM^[3?]?U8YRBNC_X5;\0/^B?^)_\
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M"YJ+!S(Y2BNK_P"%/?$7_H0/$W_@N:C_ (4]\1?^A \3?^"YJ+!S(\\^.?\
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MZ_XT?\)-I'_04L_^_P"O^- &G169_P )-I'_ $%+/_O^O^-'_"3:1_T%+/\
M[_K_ (T :=%9G_"3:1_T%+/_ +_K_C1_PDVD?]!2S_[_ *_XT :=%9G_  DV
MD?\ 04L_^_Z_XT?\)-I'_04L_P#O^O\ C0!IT5F?\)-I'_04L_\ O^O^-'_"
M3:1_T%+/_O\ K_C0!IT5F?\ "3:1_P!!2S_[_K_C1_PDVD?]!2S_ ._Z_P"-
M &G169_PDVD?]!2S_P"_Z_XT?\)-I'_04L_^_P"O^- &G169_P )-I'_ $%+
M/_O^O^-'_"3:1_T%+/\ [_K_ (T :=>'_'+XW7O@[6M-T'PU-IW]H0WVG2ZY
M<WDBXL;*XNTA5%4D9FFR^W/"HDCGHN?7?^$FTC_H*6?_ '_7_&N$^('PZ^&G
MQ-B)U^QT2[N3<6UPUYL@^T,89%D1&D(+%#L"E>ZDKWH YGQ-XU\;^#OC'X9M
M;_5K-_#_ (AU5K*"R&FO':06OD,4+7I_Y?'D3Y8ONLIV@9&ZM+XL?%/5_#'B
M36+'2)["SCT'PI=>([J75'"6\TI+Q6D3OUC0O',S,.?D0#J:=-\*_!EQXJ75
MYO$U]/8IJRZZF@2ZHK6"7Z@!9E4C> & <1A_+#_,$S4?Q \":#XY\9O>7E]I
M]YH6LZ'-X?UNT>]$;F'>9;>6)EY#H[2#J"/,##E:=T&IY!9?M'>-K71;W39[
MR\N-3N]4TC3[&[O_  V]IJL(N[>669O[/SAU'DE8G)"[C('R(6+>HZ-\9=2T
MO]G_ ,6>+KJ\C\0:SX?^VQ&.XL&L)A/%D)#=0Y(20$J'9#L8?.GRL*E;X,^#
M[N.\N-0\9ZKJNORRV<L/B"ZU*'[=9_96=K=8BB*@4&27<"AW^8^_=FM'3OAA
MX+L="GT>;Q%<ZA8:A]N;5X;J_C8:O)=J%EDN, $L ,)LV!1P!@#!=!J<CJ_C
M_P"('P]C\8Z7JNM67B34O#^AV?BU+Q+%;436XDF6[LV0$@ BW<QN/F&_#9VY
M/T!IU_#JMA:WMNV^WN8EFB;^\K $'\C7A^L?"G3;;P7XDTG3/%TVL:OXEMX-
M&O=;UZ_CEGM]-7<K1Q[553MCDFP,99Y-SL:]@L]:T*PM(+6WU"QB@A18XT$Z
MX55& !SV H VJ*S/^$FTC_H*6?\ W_7_ !H_X2;2/^@I9_\ ?]?\:0&G169_
MPDVD?]!2S_[_ *_XT?\ "3:1_P!!2S_[_K_C0!IT5F?\)-I'_04L_P#O^O\
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MC^Q[#_GQMO\ ORO^%7:* *7]CV'_ #XVW_?E?\*/['L/^?&V_P"_*_X5=HH
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ML>P_Y\;;_ORO^%']CV'_ #XVW_?E?\*NT4@*7]CV'_/C;?\ ?E?\*/['L/\
MGQMO^_*_X5=HH I?V/8?\^-M_P!^5_PH_L>P_P"?&V_[\K_A5VB@#QNW^)]Q
M#XZT;1]8\ C1-)UW4+O3=+O)KB)KN62WCEE:62U"Y2%TA<JX9C]S<J[Q6O\
M"OX@Z;\4KSQ5'#X5N=!30]16P":M;"&XG!@CE64Q$9C4B4;0WS$<D+G%<WX-
M^&7Q!TSXPWOB[Q%<>%]:CNI)H(KS_2A=V%@>8[6VC),48W*ID8#=(>6)VH%[
MCP)X#NO"7BWQ]J\]W#<1>(]4BU""*-"I@5+2" JQ)()+0ELCL:- .;UGXLZ5
MI6F^.-3MO"MQK-CX;N?[/1=+MQ-/?7:Q!YHU4+A$CW*K2.0H(?. O.'J/QRC
M-GH9T3P/%J]]=^%E\7WMM)>0VZVMFP7$:.4(EE+%@!A5^3+.N1G9\%^#M1LM
M+^*GA&:)[<ZCJ=_?66H/"?(FBOD+@@_Q-'(TB,.N$4_Q"N4\:_LWZUXB\%>"
M]#AD\,7\^C>'DT*>[U2RFWQ/Y4<;3PM&X+QG82;>3Y&(C)8;>7H!VGC/XIZ'
MX?\ ACH?C/2]&@U6RUQK%;%IMEM;QI=;#'-<3$$11!6!9L'G"@$D50\'?&'3
M/$]GX4O+GPU%IMEKNHWFC+=>9'+"M[ SA/+< ":&80RE)5QG"#&6X@\7?!77
MM8\'Z'X9L+K1I-&\+SZ=+I-EJ,,DD6H1V\#120WZJ0I4E@Z; 0K1H2IQBL'3
M_@YK.BP^!_#$KI,W_"62^+;U].@9--TJ&/>Z6EN&.54R21JJ]_WK[5'R@L@/
M?O['L/\ GQMO^_*_X4?V/8?\^-M_WY7_  J[12 I?V/8?\^-M_WY7_"LNSTJ
MR.OZBIM8"HCBPIC7 X;H,5T-9%C_ ,C%J?\ USB_DU %K^Q[#_GQMO\ ORO^
M%']CV'_/C;?]^5_PJ[10!2_L>P_Y\;;_ +\K_A7GOQ2^(VF?#/4/#-G_ ,(K
M=:Q+K>JVFFF>UM0MM9+/.D(EGF(VJ T@P@RS'H,9(]/KA_BMX"N?B%I&AVEM
M>0V;:?KVFZL[3(6#I;723,@P>&8)@'L: #X@^(M/\#V.F&/1X-0U'5M2@TNQ
MM-@022R$DDMM.%1$DD8X^ZA[UQVI?'7PUH_C+QKI%]X9N[.P\*Z&^N7.IW%H
ML8ND1W5UMXV ,B@QD!\A6;A<]:WOC#I-\;[P/XDL+26_/AW74NKBVA0N[6TT
M$UK*ZJ 2603^9QV1JS?'OP,D\?>-_%6I7>IQP:1KO@X^%S#'$3/%(9II#,&)
MP0!*,+CJM,"W\.?'#>*O$%]X?\1>#X/"^OP6%MJT=J)X[M)+28NJG>$7$B/&
MR.N, X*LP.:Y[P]\9T\1ZWIL5MX+BBT/7I]0L?#^JR7,>+NYM!(2LT83,*2"
M"4HP+G;'\RJ2HK2\*?#_ ,?6&OWGBO6]2\/WGBF2RL=&B2UAG2T%G%,TD\AR
M=WG2>:^!]U-D8^;YB<CPQ\&-=\&:UH;7VJV=SX(\'7>HZMI-M9V\KZA.UPDP
M6.;DJ1$MQ.J[ 2_[LX4@@F@'I'P]UW1_B'X,TKQ!9Z=#;I>Q$O;RPKO@D5BD
ML3<?>1U93[K71_V/8?\ /C;?]^5_PKA_@+X:U#PO\,=/AU:W:SU2^N;S5KFT
M))-N]U=2W)B.>A3SMI]UKT6D!2_L>P_Y\;;_ +\K_A1_8]A_SXVW_?E?\*NT
M4 4O['L/^?&V_P"_*_X4?V/8?\^-M_WY7_"KM% %+^Q[#_GQMO\ ORO^%']C
MV'_/C;?]^5_PJ[10!2_L>P_Y\;;_ +\K_A1_8]A_SXVW_?E?\*NT4 >5?$?Q
M\WA3Q!;:!X?\'0^*=<?3;G69K;SX[58K6%E4X9E;=([R!47 !.2S*!78>$-1
MT/QMX4T;Q#IMG"=.U:SBOK8RP!6\N5 ZY'8X;D5R'Q+^'7B?4?%EIXI\%:CI
MEEK1TFXT.Y368I)(?(E=9$F4(0?,C=/NGY75R"5P#7:> ?"4'@'P/H'AFUF>
MXM]'L(+".:4 /*L4:H&8#C)VY- &G_8]A_SXVW_?E?\ "C^Q[#_GQMO^_*_X
M5=HH I?V/8?\^-M_WY7_  H_L>P_Y\;;_ORO^%7:* *7]CV'_/C;?]^5_P *
M7^R+#_GRM_\ ORO^%7** //_ !W-H'PY\(ZQXGUW5M2M-'TJU>[NIA=.Q5%&
M2 HY)/0 =3Q7"^(_C3X#\.>#/!OB8W_B?5=/\7;/['BTB&XN[FX+1&4#RD!8
M,$!R,9&#2_M3^#O&OQ/M/!?@WPG:V\=A>ZS'J.LZIJ,*SV-O!:8N(X9X=ZM*
M)IEB7:O9&S@<U\\ZG\#?B7X?\*>&/#.J:#KVMVGA#QK>7UO>^!KJ/39Y=.NK
M6216M&:93%Y=Q,Z%"W"_*"1S3L.Y]66GB7PN?AJ_CK4]1UWPWX?B@DN)WUTS
MV4]NB,4)>)P'4DKP,9;(QG(K*^&'Q&\+?%:2]33%\8Z6+:*.X637K*[L$GA<
MD)+$\J@.I(XP<^U<YX_^&NO_ !:_9-;PUI>GZQIOB!/(N;73_&UVMU=SR6MX
MLRQW4RR.&\T18#%C@.N[&"*\@^)WA_XS_&VR^))'A'Q7H_AS5/#UO:KX6US4
M;1U_M3[;;%C:>6<B(012$NS#+.<#G@LA7/K[^P](/D_\3J[_ 'KF*/\ XF!^
M=QU5>>2,=!7,?$WQ'X<^%&E6=_K%_K,JW5_:Z>D-K=EY=\\RQ(Q4L/DW-R:^
M7OVL/V<=6/V/PM\-_A9;_P#"/6VBR-I&H:%:6S7-OJ1GWLC33SH;9,*K;XU9
MW8[<]J7X@?!#Q1J?Q5U2[U#X9WOBSQ!=>-]*UZP\<"2#RK+1HFM]UKAY0ZLG
MER@QA?FW[NPHL@U/LM/#.GO<R6RZK?-<1@,T0OV+J#T)&<@&N.B\<^ #X^O/
M!,_C">Q\56Q7.EWUY+;RS!E5E:'S-HF!##F,M@Y!Y!KYU^#7P(\9>&/VE(=;
M\0Z-KPU.#6]6O9_$ME;6*V-_9W ?RQ/<^=Y\JX\L+ 8_W;*", 5WWQH^$'BS
MXC_$&^;Q!X.G^(_@Z&>*73-%O/$L.FZ?"1&H+F&.#S)'WESF21AV Q18-3T?
MXK>,_#OP?LK6[UA?%^H17"RR$:):W5\88XE!DEE\L$1HH8'<V/;H:ZGPU8Z+
MXQ\/:=KFCZQ?WNDZC;I=6EREW(%EB<!E8 X(R#W%>;?M<6.M>(?A_%X;TOPQ
MXTUF/4(YPUQX+U6*R>"41%(XK@M(I>!_-;<,,O[OYATKT3X(:#K7A;X0^#=&
M\16UC9ZWI^EV]K=6^G(JV\3H@78@7C  QQQZ<4AW-C_A#;;_ )_M3_\  U_\
M:/\ A#;;_G^U/_P-?_&NBHH"YSO_  AMM_S_ &I_^!K_ .-'_"&VW_/]J?\
MX&O_ (UT5% 7.=_X0VV_Y_M3_P# U_\ &C_A#;;_ )_M3_\  U_\:Z*B@+G.
M_P#"&VW_ #_:G_X&O_C1_P (;;?\_P!J?_@:_P#C7144!<YW_A#;;_G^U/\
M\#7_ ,:/^$-MO^?[4_\ P-?_ !KHJ* N<[_PAMM_S_:G_P"!K_XT?\(;;?\
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MNBHH"YSO_"&VW_/]J?\ X&O_ (T?\(;;?\_VI_\ @:_^-=%10%SG?^$-MO\
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M:/\ A#;;_G^U/_P-?_&NBHH"YSO_  AMM_S_ &I_^!K_ .-'_"&VW_/]J?\
MX&O_ (UT5% 7. \9R^'?A_HO]J:YK&I6MJ9H[:()<32RSS.P6.**-06D=F.
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M,%(6:^3[0^<]V$,D6?0.E%@U/0_^$-MO^?[4_P#P-?\ QH_X0VV_Y_M3_P#
MU_\ &NBHI#N<[_PAMM_S_:G_ .!K_P"-'_"&VW_/]J?_ (&O_C7144!<YW_A
M#;;_ )_M3_\  U_\:/\ A#;;_G^U/_P-?_&NBHH"YSO_  AMM_S_ &I_^!K_
M .-<]#>^%9_',W@V+Q)=3>)X;+^T9M-COG:2*WWA!(^,A<LXP"03U Q7H=>2
MQ>")M._:5@U^QT5+;1[CPQ=Q7FH01HBRWCW=L5$A'S.YCC.&(/"8S0%S8\,7
MOA7QIJ.M6.A^)+K5;C1KD6E_]EOG=()B@?RRP^4L%89 )VG@X/%9?BCQ?X*\
M'75Y:ZIXBU*.ZM);>W>"&6::1[B<,88$1 3)*RH6"*"VWYB O-1?"+P1-X,^
M)/Q4:#14T;0;W4+!]+$$210R1I80I(8U7H!('!R!SFO/;CQ)XE\$Z9\1X?#_
M (8F\3>,G\;M(NV!+@Z?;W$$?DW[1EU:1(X!L5$8,S)LRHW$.PM3LKWXM_#;
M3M#T_5I?%6J&TO1<LJQ"[DFA6W8)=//$J;X5A8A9&D"A"<-BNH\47?AGP=X>
MCUO4M=U%=.F>*.W>WNI9VN9)& B2%4W-*SE@%502:\,T3PWJW@5(]<TSP;XM
M\0IJ^@ZCI5RFH6L,>HRZK-=&=[BX0.%CBG9V^8':@C1<!<5T?C?PIXBB^#/@
MWP9#H6L7;^$WT1=6O=*1!<RQ10?/)IKELF5)$CW'"MM+A<DT60:GH7ASQ/X-
M\62Z5'IGB'4IVU,7(MD>>:-C);L%GA96 9)8S]Z-@&&T\<&NO_X0VV_Y_M3_
M / U_P#&OG/PSX;UK1=&^'.D2V5UI^HW/Q N=7TZ/4&4:G)IOESR33WK*3NE
M99&5B3NQ)&&^;(KZNI#N<[_PAMM_S_:G_P"!K_XT?\(;;?\ /]J?_@:_^-=%
M10%SG?\ A#;;_G^U/_P-?_&C_A#;;_G^U/\ \#7_ ,:Z*B@+G._\(;;?\_VI
M_P#@:_\ C1_PAMM_S_:G_P"!K_XUT5% 7/(M.^('@'5?$\F@V_BG4#>K+<6Z
MRR33I;330!C/%'<,!'(\85BRJQ*['S]UL6O 'BSP9\3I+J+P]K^JW4MO%'<F
M.=[BW:2"7=Y5Q&) IDA?:VV1<HV#@UY/KNF>(_BUXKU[2=3\(Z_X;L+>WU73
MO"]L+!$TR&>:VFA.IW4RN27D669414PBRL6W,^5[+X-Z9KVL_$*R\0:CX6O?
M"UIHWA.#P[+%J(59)KL2J\@A"LP>% @ DSAB_P O0T[(6IV&JZWX1T-?$<FH
M^)+JPMO#L22ZI=7-Z\<-J'7>JLYXW;,':#G#I_>%8WB+XD?#_P +Z5HVI7_B
M751::O8G5;9H/M4S?8E5&>ZD5%+10JLB;G<*JY&>:P?"?AB/7?!_QAT.^TV'
M4=<C\1ZI>+:72K*Q>6,264BAN!^Z:(*W8IP?EKSKQ]\-?%%SX4\!6U_X?\3/
M;0> 5T1E\*/&E\NH/'$)+:\8O@VQ$:]R@97+G[M%D&I[]XKU/PMX+T"VUG5-
M>U 6-Y+'!:-:W$UR]W)+S''"D>YI68<@*#QST!-1:!XA\(>*)='CTSQ#J%P=
M7BN)+(FXF3S3"X6:,A@"LB,?FC8!A@\?*<<-XZTWQ#?_  ^\*12>'];T_P 6
M>$)]/N/MWA>TMW@AG:S>.=K6"1@L]NOFO$T?RL%?*\J*Y?PWX.U[0+?X>6MX
M;F#Q+K?Q#OO$_DWC(+J*Q>.Y:8S"/*(3&Z*R*=JM,J9)HL@U/HO_ (0VV_Y_
MM3_\#7_QH_X0VV_Y_M3_ / U_P#&NBHI#N<[_P (;;?\_P!J?_@:_P#C6?:^
M%+=]:OXC>7X5$C(873ACD'J<\UV59%C_ ,C%J?\ USB_DU 7*G_"&VW_ #_:
MG_X&O_C1_P (;;?\_P!J?_@:_P#C7144!<YW_A#;;_G^U/\ \#7_ ,:Y[Q=J
M'A/P&^D1^(/$MSIDVKWT6F:?#+?/ONKF1@B1QJ,EB689P,#J<"O0Z\G^/7@B
M?Q-:>$[W2]%34=8LO$ND3-<K&GG06B7T,LY#GE5"IN8 \[>AH"YT/B:UT7PC
MIHOM3U34H+<S16Z!;J1VDED=4C15&2S,S!0 *S&U[P8OB?5_#Q\5S?VMH]B-
M1U& 7[XLK<D@/*WW4^Z3ACG'.,<U3^-JB'7OA=J%VI;1K/Q3&;OCY4>2UN(;
M:1CT %Q+".?XF6N%^)WP9U3Q'\0/B1%H&C1Z?9>(/ $NGI?1A(H;C49+B=F6
M0CYBQ5DW,1T/6G86IZ%X"\1>$/B8EXWA[7=5NWM1$\L,[W%O((Y5)BD"2JK%
M'4$JX&UL'!X-9]EX^\":IX@U#0[/Q'JESJ5F+D^7$UP5N&MSBXC@<KLFDC)V
MLL99E/!&0:Q/!&I:YJ/Q#U#Q[=^"->T.Q&BZ=X>72YH8OM4D_P!JD>:0()"/
M(A$J_/GD>85!Q\W-_#OPCXDTG7OA]X9OO#EY80>!]7U?4[_Q#<[%LKJ&9+M(
M# X8EVD%VKN"!L*.&YQDL@U/;M#T?2?$FCV6JZ;JU_=Z?>PK<6]PEX^V2-@"
MK#OR#5W_ (0VV_Y_M3_\#7_QKB_V9()(_@[I<IC:*SNKW4;RPB92I6REOIY;
M88/;RG0CVQ7JU(=SG?\ A#;;_G^U/_P-?_&C_A#;;_G^U/\ \#7_ ,:Z*B@+
MG._\(;;?\_VI_P#@:_\ C1_PAMM_S_:G_P"!K_XUT5% 7.=_X0VV_P"?[4__
M  -?_&C_ (0VV_Y_M3_\#7_QKHJ* N<KJ'A[3-(L9[V^U>\L[.!3)+//?LD<
M:@<LS$@  =2:S?!H\/>/_#5AX@T#6M0U'1K]#):W274JK*F2-P#8."1Z5UNK
MZ/8:]8RV.I64&H64N/,MKJ-9(WP01N4@@X(!YKQ_X/>#_$VB?LIVGAV:TFTC
MQ6ND7L$<$K@/#.[3&/)!('+*>#0+4V[SQ=X(T[PA'XHNO$][!H,UVMA!>/<R
ME;B9IO(18@,E]TG (!!'S?=YK3\:W/AOX>:0FIZ[K&JVUK+/':1"*2>XDFFD
M;"1I'&&9V)Z  U\Y^*_AOXU^(7P:\$:MX/31M7TO3_#^EV>GZ/=1RK/9W*RP
MBZD&TA3(!'Y9) 9%24+R[5['\8X'\5:?I<&J^"_$FMVWA_6K6ZN7T&[:TD=O
MLSD3VP617GC5Y-C)N1ARPW;<%V0:G1:)JWAGQ!<Z1!;ZIK<,VJP3W-E%??:+
M62987"2C9*%8,I8':0#M.X<<UTW_  AMM_S_ &I_^!K_ .->":#I?B>U7X0Z
M9JTU^NN#Q;J&I:?%JLIN-0M=#6&Z"QW4N6+.(YH(V)9CN=%9F8;J^G:+#N<[
M_P (;;?\_P!J?_@:_P#C1_PAMM_S_:G_ .!K_P"-=%12"YSO_"&VW_/]J?\
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M^-=%10!SOV3Q)_T$+#_P';_&C[)XD_Z"%A_X#M_C7144 <[]D\2?]!"P_P#
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M;_&NBHH YW[)XD_Z"%A_X#M_C1]D\2?]!"P_\!V_QKHJ* .=^R>)/^@A8?\
M@.W^-'V3Q)_T$+#_ ,!V_P :Z*B@#DCIFKV-Q<Z@;K2;>:1%$]T;4JS(F2H9
MMW(&YL9/&XU96U\2,,C4; @\@BW;_P"*KSW]H@Z9]N^'$7B5X4\%R>(U&K?:
MR!;,?LMP;59\_+Y9N!%PWREMF:M?LQNC?#:Y6R<R>'H];U./0VR2G]GK=R"
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MKHJ* .1@TS5M(C*PW>DV4<LQ8A;4H&E=LL<;AEF8Y/<GWJY]D\2?]!"P_P#
M=O\ &O%/CZGA>?XK:?'\19+5/!R>$M3EL_[3<);_ &T20B1D)./M A/R8^<
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M6H_]"]>?]_(__BJ/^$BU'_H7KS_OY'_\57144 <[_P )%J/_ $+UY_W\C_\
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M._!^IZQ<Z_;Z!<6;V6H7^PW1BN( YCE9 JN5=6PV =K@'.,D [+_ (2+4?\
MH7KS_OY'_P#%4?\ "1:C_P!"]>?]_(__ (JNBHH YW_A(M1_Z%Z\_P"_D?\
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MNB?\^7_D5_\ XJBX6.?VFC::Z#_A!=$_Y\O_ "*__P 51_P@NB?\^7_D5_\
MXJBX6.?VFC::Z#_A!=$_Y\O_ "*__P 51_P@NB?\^7_D5_\ XJBX6.?VFC::
MZ#_A!=$_Y\O_ "*__P 51_P@NB?\^7_D5_\ XJBX6.?VFC::Z#_A!=$_Y\O_
M "*__P 51_P@NB?\^7_D5_\ XJBX6.?VFC::Z#_A!=$_Y\O_ "*__P 51_P@
MNB?\^7_D5_\ XJBX6.?VFC::Z#_A!=$_Y\O_ "*__P 51_P@NB?\^7_D5_\
MXJBX6.?VFC::Z#_A!=$_Y\O_ "*__P 51_P@NB?\^7_D5_\ XJBX6.?VFC::
MZ#_A!=$_Y\O_ "*__P 51_P@NB?\^7_D5_\ XJBX6.?VFC::Z#_A!=$_Y\O_
M "*__P 51_P@NB?\^7_D5_\ XJBX6.?VFC::Z#_A!=$_Y\O_ "*__P 57(>(
M-=^'OAGQMX>\(WLT8\2:](ZV6G122/*56-W9W /R)B-@&; )X&31<+%_::-I
MKG]%\9>!->\9'P_9Z7JLA:XGLHM6^Q7']G3W,.[SH$N/NETV2 YP"8W )*D5
M>\9Z_P" _ =Y/;:M%,DEOITFJSB!)IC%;JP0,54EBSNVU% +,P.!P:+L+(TM
MIHVFN-3XH?#]](:?^P]<36%OUTP^&S8S?VG]H,1G">2#T,(,N_.W:/O9XKH+
M'Q!\/+_X>7'C<N;7P[:Q3274UUYL;VQB9DFCDC)W+(CHR%<9R,#-%V%D:6TT
M;37+:-\0? &K64L\VEZKI$UMJ%MIU[9:K;RP7%B]QCR'F0M\L<A90'R5RV#@
MAL>D_P#""Z)_SY?^17_^*HN%CG]IHVFN@_X071/^?+_R*_\ \51_P@NB?\^7
M_D5__BJ+A8Y_::-IKH/^$%T3_GR_\BO_ /%4?\(+HG_/E_Y%?_XJBX6.?VFC
M::Z#_A!=$_Y\O_(K_P#Q5'_""Z)_SY?^17_^*HN%CG]IHVFLV]U[X?6/Q)TS
MP&TJ2>*;^"6Z73X9)':&)%#%Y2"1&"#\N[!;MT-97@OX@_#OQ[XE&BZ;:WR3
M3I<2Z?=7<$T-OJD<#B.=[5R<2+&[*#T^^",CFBX61T^TT;361XK\2^!/!]_J
M=E=V5Y<W6GV]O--#81RW#%[B4Q6\"JI):61P=J8Z?,<#FJ:^/?ANGPWUSQM>
M)<:7I&AF6+4XK])8KFTFC +0O$3GS#N7"C.[>FW.11<+(Z/::-IJ#7KOP5X9
M\"GQ;J,$D&D>1%.NT2O*WF%1$BQJ2S.S.JA0,EFQ6'H/C?P#KXT]?[.O].N;
MK4FT>2TU&*2WEM+P1>:L,ZEOD9TPR'D-E<'D47"R.CVFC::Z#_A!=$_Y\O\
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M6KG0[:?0=7T.[UHW(M+?5[>6WD9H,%T92WRL5RZ@_>5'(Z5V?_""Z)_SY?\
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M!=$_Y\O_ "*__P 51<+'/[31M-=!_P (+HG_ #Y?^17_ /BJ/^$%T3_GR_\
M(K__ !5%PL<_M-&TUT'_  @NB?\ /E_Y%?\ ^*H_X071/^?+_P BO_\ %47"
MQS^TT;370?\ ""Z)_P ^7_D5_P#XJC_A!=$_Y\O_ "*__P 51<+'/[31M-9_
MQ U;PA\.SID-YI&H:IJ.J2O%8:9I$4MS=7#(I>0J@( 55&2S$#MU(!ETC5?
M.M_#X>-[9P/#7V62]>\E,J&*./=YF]"=RLA1@RD9#*1C-%PLBWM-&TUQY^)_
MPZB\00Z3/IFK0./LD=[>2V<XM=-GN@AM[>ZESB*5_,C^0_=\Q-VW<,[WQ-\0
M_#SX0:$FK>*)%L+>69+>WB5Y'FN)&("I'&"2YYR<#Y1R<#FB["R-+::-IJ2V
MM?"MUXNOO#7V-XM5M+:*],<KNJRP.S*'C.[Y@&0JW]TXSU&=S_A!=$_Y\O\
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M;6O^A@/_ (!QT?V-K7_0P'_P#CH WJ*P?[&UK_H8#_X!QT?V-K7_ $,!_P#
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M.HP33,MI/!'!*LDH5MP1@2"P4-D#G&?>MG^QM:_Z& _^ <=(#>HK!_L;6O\
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M+3Q+QAF0'<H^9>2.XI=*NI=?>Z73/&5KJ)M)3#<+:1PRF&0=4;:3M8>AYIW
M\2MK[QWX>\.^,O#O@G16N?%#^,[Y]1O$FM_/L;&Y8W"7D4<[JDLAC=(T4G:&
M4[LA"IRO$'P>URU\*6$7A3P9XGT:^NO#]YH<YC\0V@N)7DF9P=19RX97>22<
MW$#&96DD7;\U>^W\HT9KZYO?%UE8FVCC:ZFN(H(_*0EA&9&)&U2VX+GOG%3B
M6Y_LI=4_X2^W_LQHUE%[Y,/DE#C#!\XVG/!S1<#SSQ$OQ%\#_##2/"?@CPT]
M[J&F1V&CC61/;?):K; 37<$,L@#NA38L<A4%F#'<@.<"R\-C3H_@UX8TS1=1
M\/:K:>(+C6KJ+5+B*ZO6@C@N!=75Q-&SJSSRW"9;/S--VZ#V;4TO-#L9;W4/
M%D-A90C,MS<P11QH,XRS,0!R>YJCI-Q'KLD%UIOC"QU)YXW\J>TB@E+QJP#8
M92<J&8 XZ$\T7 [>BL'^QM:_Z& _^ <=']C:U_T,!_\  ..D!O5D6/\ R,6I
M_P#7.+^35!_8VM?]# ?_  #CK-M-+U4ZU?(NM,DBI'ND^RH=PP<#'08H ["B
ML'^QM:_Z& _^ <=']C:U_P!# ?\ P#CH WJ\S^-/@G4/%T/A*72;&&XO+'Q+
MI=[=2LZHZVD-RLDOS'D@ 9VCJ:Z[^QM:_P"A@/\ X!QU!>VNI:?:RW-WXG2V
MM8@6DFFM8D5!W)8G 'UH X[XW(;+6?AKKERGF:/I7B:-[W/W(A-;7%M#,Q/
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M_@:/_B:/[4U[_H!P_P#@:/\ XF@+'0T5SW]J:]_T X?_  -'_P 31_:FO?\
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MP'7Y5.?IC^U->_Z </\ X&C_ .)H&I:X,D:%"">3_IHY_P#':=PL> ^/-?\
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M6EZW<^'8YK_34E2T9K\;83(%#N%VXW%5QNZA20.IHN%CN**Y[^U->_Z </\
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MC_\ /:;_ ,!W_P * .BHKG?^$]T?_GM-_P" [_X4?\)[H_\ SVF_\!W_ ,*
M.BHKG?\ A/='_P">TW_@._\ A1_PGNC_ //:;_P'?_"@#HJ*YW_A/='_ .>T
MW_@._P#A1_PGNC_\]IO_  '?_"@#HJ*YW_A/='_Y[3?^ [_X4?\ ">Z/_P ]
MIO\ P'?_  H Z*BN=_X3W1_^>TW_ (#O_A1_PGNC_P#/:;_P'?\ PH Z*BN=
M_P"$]T?_ )[3?^ [_P"%'_">Z/\ \]IO_ =_\* .BHKG?^$]T?\ Y[3?^ [_
M .%'_">Z/_SVF_\  =_\* .BHKG?^$]T?_GM-_X#O_A1_P )[H__ #VF_P#
M=_\ "@#HJ*YW_A/='_Y[3?\ @._^%'_">Z/_ ,]IO_ =_P#"@#HJ*YW_ (3W
M1_\ GM-_X#O_ (4?\)[H_P#SVF_\!W_PH Z*BN=_X3W1_P#GM-_X#O\ X4?\
M)[H__/:;_P !W_PH Z*BN=_X3W1_^>TW_@._^%'_  GNC_\ /:;_ ,!W_P *
M .BHKG?^$]T?_GM-_P" [_X4?\)[H_\ SVF_\!W_ ,* .BKQOXJ:EXHTGXO_
M  L^S>(#9^&;_5Y+*XT>VMP&NV^Q74F^68G.Q3&N(U !/S,3@ >A?\)[H_\
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MK2+S4K:^U=3!-<3:@D)0K$\LA+8/E1*22<("HQFO3O\ A/='_P">TW_@._\
MA2 Z*BN=_P"$]T?_ )[3?^ [_P"%'_">Z/\ \]IO_ =_\* .BHKG?^$]T?\
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M#VFBN=_X3W1_^>TW_@._^%'_  GNC_\ /:;_ ,!W_P *0'145SO_  GNC_\
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M--+BUJ^G:2;RY$C"GR'R2 <\8H [2BN=_P"$]T?_ )[3?^ [_P"%'_">Z/\
M\]IO_ =_\* .BKQG]H+4?$^CZA\/[O2/$3:3H\GBG3+.^L[: &:^66Y5#&TI
M)V1;<Y55W-TW 9SZ)_PGNC_\]IO_  '?_"LCQ!J?A+Q7'8QZK;F^CLKR'4+8
M2VTF(KB)@\4@X^\K#(H S?C#K.H)?^!_#>G7<NGOXCUU+6YNH6*.MM%#-=2H
MK @JSK;^7D=G..:\M^(WC_QQX!^(WQ4N#KRWT-AX"EUS2-.BM_+MK%UGG1&9
M26,KXC#,QP/X0H%>G?$&71_&MCI9AOYK#4](U.#5+&Z-K(ZI+&2"& QE7C>2
M,\]'SUJ_<R^";SQ!<ZY<:>DVJW6GC2I[F2T=C+:!V?R6&,%-SL<$?Q4[@<K\
M+CJ?A+XJZCX/D\2:GXITN3PY8ZT+K5[C[1-%<---#(5? PDHC5@GW597VX!P
M.&\(:]X@U>_\$^(KOQ1JTDGC+Q%K.AZAHOVG%M!;1K>B);=  89(?L:9<'<Q
M,N[.5V^B:%X(^&'AG2;C3-,T=[2TN)[:XD"_:3(YMRI@7>3NV1[1M3.T#(VX
M)S+#X=\!:3XCU'Q3HVFPV?BFY6=H[Z6WF=(YI54/(L6=JLY1-[(%9L?,:+H-
M36^ WB;4/%?PRT^?5IC<ZI97-WI5S<D8^T26MU+;&7ZOY6X^[5Z)7F_PYF\/
M_#GP7I?AZUO+JZ2RB(DN9;=]\\K,SRRL,<,[NSD?[5=-_P )[H__ #VF_P#
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MXCLQI6DZY>ZY_8.M#4(9KBVTVYC$Z7'R1LLC 20X7!Y5P?>N\^$?Q)U+Q)X
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M)_SU3_OL?XT .WO_ 'F_[ZHWO_>;_OJF^8G_ #U3_OL?XT>8G_/5/^^Q_C0
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MJF^8G_/5/^^Q_C1YB?\ /5/^^Q_C0 [>_P#>;_OJC>_]YO\ OJF^8G_/5/\
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M3_OL?XT>8G_/5/\ OL?XT .WO_>;_OJC>_\ >;_OJF^8G_/5/^^Q_C1YB?\
M/5/^^Q_C0 [>_P#>;_OJC>_]YO\ OJF^8G_/5/\ OL?XT>8G_/5/^^Q_C0 [
M>_\ >;_OJC>_]YO^^J;YB?\ /5/^^Q_C1YB?\]4_[['^- #M[_WF_P"^JK0L
M?MLYSSA>?SJ?S$_YZI_WV/\ &JL+I]MG^=.@[CWH N;W_O-_WU1O?^\W_?5-
M\Q/^>J?]]C_&CS$_YZI_WV/\: ';W_O-_P!]4;W_ +S?]]4WS$_YZI_WV/\
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M +XK;HH"YB?\(;HG_0,M_P#OBC_A#=$_Z!EO_P!\5MT4!<Q/^$-T3_H&6_\
MWQ1_PANB?] RW_[XK;HH"YB?\(;HG_0,M_\ OBC_ (0W1/\ H&6__?%;=% 7
M,3_A#=$_Z!EO_P!\4?\ "&Z)_P! RW_[XK;HH"YB?\(;HG_0,M_^^*/^$-T3
M_H&6_P#WQ6W10%S$_P"$-T3_ *!EO_WQ1_PANB?] RW_ .^*VZ* N8G_  AN
MB?\ 0,M_^^*/^$-T3_H&6_\ WQ6W10%S$_X0W1/^@9;_ /?%'_"&Z)_T#+?_
M +XK;HH"YB?\(;HG_0,M_P#OBC_A#=$_Z!EO_P!\5MT4!<Q/^$-T3_H&6_\
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M%_#OP]X'T'2;.[TZ#3&TR:>[E*QP!;9@DCQ@!I@\@ 8!E;YRV<UXC:_#O6/
MOA[Q;KEWX,TGP39_\(>WAI?#GAV?[1%K-\[!890JJ,*"WE1EP9"LS[\!119!
MJ?247A+09XDDCTZV>-@&5T7((/(((ZBI/^$-T3_H&6__ 'Q47@'0[CPQX&\.
MZ/=2"6ZT[3;:TED!R&>.)48@^Y6N@I 8G_"&Z)_T#+?_ +XH_P"$-T3_ *!E
MO_WQ6W10.YB?\(;HG_0,M_\ OBC_ (0W1/\ H&6__?%;=% 7,3_A#=$_Z!EO
M_P!\4?\ "&Z)_P! RW_[XK;HH"YS.I>&='L-/N;J/0EO9(HFD6VMU7S)2%)"
M)N(&XXP,D#WKA?A[XQT#Q]XKUKPZ? FK^']1T>"&>[.J00>7&9<E(MT4SC>5
M&[;V4@GJ,^P5YW\#O!6I>"O!<_\ ;Z0CQ-J^I7>KZL]O(9$>>:9BH#$#*I$(
MHQQPL:CM0+4Y_6O'_@W2;_4+&T\.76LWUOJB:+;V^GPHS7EZ83/)%&6=5"Q1
MC=([E57D9R,5L_V]X0M/AU=>--5T*ZT'3K2"26ZM-3L6CNX3&S*R&(9+,67"
M[-P?(*%@P)\=U#X4ZAX@FO;,:'9^(-0\+>.-0UJY\/W\_P!GBU>ROHY6C;S"
M"I($P.U@59K=T;'4=#_PI?Q=JOP U/X:7$5KIRZI:WMQ;SC4'EATAFNA-::>
M#CS'C1#Y?FJ1M"?*N-N'9!J=/!XZ\.16+76L^!M8\,QPW]K93G5;6-$B6X.V
M&;S$D:-DWE4;:Q9&.&4=:]*_X0W1/^@9;_\ ?%?,NO\ PWUW3OA_\0;,^&[/
MP>OC1]-T?2/"FGWGVI(KO<1+>%E4(C%6#-@?=M0S'<<5]:T@,3_A#=$_Z!EO
M_P!\4?\ "&Z)_P! RW_[XK;HH'<Q/^$-T3_H&6__ 'Q6;:>%-(?6]0B:PA,2
M)&53;P"0<X^M=;618_\ (Q:G_P!<XOY-0(C_ .$-T3_H&6__ 'Q1_P (;HG_
M $#+?_OBMNB@=S$_X0W1/^@9;_\ ?%'_  ANB?\ 0,M_^^*VZ* N8G_"&Z)_
MT#+?_OBN+^(.M^&O -UH]@/#%SX@US6))5L=)TJ&,SS+$F^:3=(Z(JHN,EF&
M6=%&217I]>7?%3P]XF7Q?X1\9>%]-M]>N]$CO;2?2)[I;5IXKE8_G25@0K(\
M*9!'*LW< $$;7@H>$?B#X3TOQ'HME%/I>I0+<0/)"4< ]593RK Y!4\@@BMS
M_A#=$_Z!EO\ ]\5@_!;P+>?#;X8Z%X=U&YAO-0M(G:YFME*Q&:21Y7" \[0S
MD#/..M=S0!B?\(;HG_0,M_\ OBC_ (0W1/\ H&6__?%;=% [F)_PANB?] RW
M_P"^*/\ A#=$_P"@9;_]\5MT4!<Q/^$-T3_H&6__ 'Q1_P (;HG_ $#+?_OB
MMNB@+F)_PANB?] RW_[XH_X0W1/^@9;_ /?%;=% 7,3_ (0W1/\ H&6__?%'
M_"&Z)_T#+?\ [XK;HH"YY/\ $3Q9X6^'FH6>FCPK?^(=5GM)]1-CHMLDDL-I
M"5$L[;G48!D50H)9V.%4\XZW0-*\+>*-"T_6-,M+6ZTW4+>.[MKA$P)8G4,C
M#ORI!KBOB=X4\76?CZT\9>#]*L]>NY=#N= GL+Z\^RB(O*DL-P'VMN161PZC
MYB'!7.,'N/ACX/;X?_#GPOX9>=;J31],MK!IT7:)&BB5"P'8$KG% M2[_P (
M;HG_ $#+?_OBC_A#=$_Z!EO_ -\5MT4#N8G_  ANB?\ 0,M_^^*/^$-T3_H&
M6_\ WQ6W10%S$_X0W1/^@9;_ /?%+_PA^B#_ )AMO_WQ6U10(Y[_ (1BY_Z#
MVI?]])_\31_PC%S_ -![4O\ OI/_ (FNAHH'<Y#6K*'PYI%[JNJ>*;ZQTVQA
M>YN;J>5$CAB12S.Q*X"A0237.^"/&_A3XDW,]OX8^(;:S<VZ+++;VMU&94C)
MP'*;=VTG@-C%6?VC-.NM7^ 'Q(L;*UEOKVY\.ZA%!:V\9DDF<V[A451RS$\
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M -![4O\ OI/_ (FC_A&+G_H/:E_WTG_Q-=#10%SGO^$8N?\ H/:E_P!])_\
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MIY9F^S2.NQG49QNV\ D9'.,9HHH W/\ AY/XK_Z%'1O^_P!+_C1_P\G\5_\
M0HZ-_P!_I?\ &BBBP!_P\G\5_P#0HZ-_W^E_QH_X>3^*_P#H4=&_[_2_XT44
M6 /^'D_BO_H4=&_[_2_XT?\ #R?Q7_T*.C?]_I?\:**+ '_#R?Q7_P!"CHW_
M '^E_P :/^'D_BO_ *%'1O\ O]+_ (T446 /^'D_BO\ Z%'1O^_TO^-'_#R?
MQ7_T*.C?]_I?\:**+ '_  \G\5_]"CHW_?Z7_&C_ (>3^*_^A1T;_O\ 2_XT
M446 /^'D_BO_ *%'1O\ O]+_ (T?\/)_%?\ T*.C?]_I?\:**+ '_#R?Q7_T
M*.C?]_I?\:/^'D_BO_H4=&_[_2_XT446 /\ AY/XK_Z%'1O^_P!+_C1_P\G\
M5_\ 0HZ-_P!_I?\ &BBBP!_P\G\5_P#0HZ-_W^E_QH_X>3^*_P#H4=&_[_2_
MXT446 /^'D_BO_H4=&_[_2_XT?\ #R?Q7_T*.C?]_I?\:**+ '_#R?Q7_P!"
MCHW_ '^E_P :/^'D_BO_ *%'1O\ O]+_ (T446 /^'D_BO\ Z%'1O^_TO^-'
M_#R?Q7_T*.C?]_I?\:**+ '_  \G\5_]"CHW_?Z7_&C_ (>3^*_^A1T;_O\
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M=PE[ )99B$F3.Q\9Y(R2,]#@]0#6A_P\G\5_]"CHW_?Z7_&BB@ _X>3^*_\
MH4=&_P"_TO\ C1_P\G\5_P#0HZ-_W^E_QHHHL ?\/)_%?_0HZ-_W^E_QJO'_
M ,%&_$\5S-<KX0T??*JALS2]MV.]%% %C_AY/XK_ .A1T;_O]+_C1_P\G\5_
M]"CHW_?Z7_&BBBP!_P /)_%?_0HZ-_W^E_QH_P"'D_BO_H4=&_[_ $O^-%%%
M@#_AY/XK_P"A1T;_ +_2_P"-'_#R?Q7_ -"CHW_?Z7_&BBBP!_P\G\5_]"CH
MW_?Z7_&C_AY/XK_Z%'1O^_TO^-%%%@#_ (>3^*_^A1T;_O\ 2_XT?\/)_%?_
M $*.C?\ ?Z7_ !HHHL ?\/)_%?\ T*.C?]_I?\:/^'D_BO\ Z%'1O^_TO^-%
M%%@#_AY/XK_Z%'1O^_TO^-'_  \G\5_]"CHW_?Z7_&BBBP!_P\G\5_\ 0HZ-
M_P!_I?\ &C_AY/XK_P"A1T;_ +_2_P"-%%%@#_AY/XK_ .A1T;_O]+_C1_P\
MG\5_]"CHW_?Z7_&BBBP!_P /)_%?_0HZ-_W^E_QH_P"'D_BO_H4=&_[_ $O^
M-%%%@#_AY/XK_P"A1T;_ +_2_P"-'_#R?Q7_ -"CHW_?Z7_&BBBP!_P\G\5_
M]"CHW_?Z7_&C_AY/XK_Z%'1O^_TO^-%%%@#_ (>3^*_^A1T;_O\ 2_XU97_@
3HUXK('_%*:-_W]E_QHHHL!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>srrk-20240930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/11/2024 2:39:38 PM-->
<!--Modified on: 11/11/2024 2:39:38 PM-->
<xsd:schema xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" targetNamespace="http://www.scholarrock.com/20240930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:srrk="http://www.scholarrock.com/20240930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashDetails">
        <link:definition>99940201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" id="DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails">
        <link:definition>99940301 - Disclosure - Fair Value of Financial Assets and Liabilities - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" id="DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails">
        <link:definition>99940401 - Disclosure - Marketable Securities - Summary of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" id="DisclosurePrepaidExpensesAndOtherAssetsDetails">
        <link:definition>99940501 - Disclosure - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>99940601 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99940901 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables" id="DisclosureEquityBasedCompensationTables">
        <link:definition>99930803 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>99930903 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails" id="DisclosureNatureOfBusinessDetails">
        <link:definition>99940101 - Disclosure - Nature of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureCommonStockDetails" id="DisclosureCommonStockDetails">
        <link:definition>99940701 - Disclosure - Common Stock - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails" id="DisclosureEquityBasedCompensationExpenseDetails">
        <link:definition>99940801 - Disclosure - Equity-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails" id="DisclosureEquityBasedCompensationUnrecognizedExpenseDetails">
        <link:definition>99940802 - Disclosure - Equity-Based Compensation - Unrecognized Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails" id="DisclosureEquityBasedCompensationRestrictedStockDetails">
        <link:definition>99940803 - Disclosure - Equity-Based Compensation - Restricted stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails" id="DisclosureEquityBasedCompensationStockOptionsDetails">
        <link:definition>99940804 - Disclosure - Equity-Based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails" id="DisclosureEquityBasedCompensationAssumptionsDetails">
        <link:definition>99940805 - Disclosure - Equity-Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureDebtDetails" id="DisclosureDebtDetails">
        <link:definition>99941001 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails" id="DisclosureNetLossPerShareAntidilutiveDetails">
        <link:definition>99941101 - Disclosure - Net Loss per Share - Antidilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941201 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>995210101 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995210201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" id="DisclosureFairValueOfFinancialAssetsAndLiabilities">
        <link:definition>995210301 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>995210401 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets" id="DisclosurePrepaidExpensesAndOtherAssets">
        <link:definition>995210501 - Disclosure - Prepaid Expenses and Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210601 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>995210701 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensation" id="DisclosureEquityBasedCompensation">
        <link:definition>995210801 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995210901 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>995211001 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995211101 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211201 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" id="DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables">
        <link:definition>99930303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>99930403 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables" id="DisclosurePrepaidExpensesAndOtherAssetsTables">
        <link:definition>99930503 - Disclosure - Prepaid Expenses and Other Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930603 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scholarrock.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99931103 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="srrk-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="srrk-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="srrk-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="srrk-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:element id="srrk_UnauditedInterimFinancialInformationPolicyTextBlock" name="UnauditedInterimFinancialInformationPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="srrk_AccruedExternalResearchAndDevelopmentExpense" name="AccruedExternalResearchAndDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="srrk_PercentageOfOutstandingObligation" name="PercentageOfOutstandingObligation" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="srrk_DebtInstrumentFinalPaymentFee" name="DebtInstrumentFinalPaymentFee" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="srrk_CommonStockTextBlock" name="CommonStockTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="srrk_BinneyStCambridgeMaMember" name="BinneyStCambridgeMaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="srrk_AnnualLeaseAdjustmentPercent" name="AnnualLeaseAdjustmentPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="srrk_LesseeOperatingLeaseBaseRent" name="LesseeOperatingLeaseBaseRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="srrk_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="srrk_TrancheOneMember" name="TrancheOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="srrk_TrancheTwoMember" name="TrancheTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="srrk_PrepaymentPenaltyPercent" name="PrepaymentPenaltyPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="srrk_InterestOnlyPeriod" name="InterestOnlyPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="AtMarketOfferingMember" id="srrk_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumAggregateOfferingPrice" id="srrk_MaximumAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentageOfDollarValueOfConsolidatedCash" id="srrk_PercentageOfDollarValueOfConsolidatedCash" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreFundedWarrantMember" id="srrk_PreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonWarrantMember" id="srrk_CommonWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnderwritingAgreementMember" id="srrk_UnderwritingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrepaidExternalResearchAndDevelopmentExpenseCurrent" id="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PrepaidExternalResearchAndDevelopmentExpenseNoncurrent" id="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PrepaidInsuranceNoncurrent" id="srrk_PrepaidInsuranceNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TedMylesMember" id="srrk_TedMylesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TraceySaccoMember" id="srrk_TraceySaccoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PurchaseOfStockArrangementMember" id="srrk_PurchaseOfStockArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AggregateMember" id="srrk_AggregateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheThreeMember" id="srrk_TrancheThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheFourMember" id="srrk_TrancheFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod" id="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="UponExpirationOfFirstExtensionTermMember" id="srrk_UponExpirationOfFirstExtensionTermMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="JingMarantzMember" id="srrk_JingMarantzMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OperatingLeaseLiabilityAdjustmentFromRentModification" id="srrk_OperatingLeaseLiabilityAdjustmentFromRentModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PrepaidProfessionalConsulting" id="srrk_PrepaidProfessionalConsulting" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>srrk-20240930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/11/2024 2:39:38 PM-->
<!--Modified on: 11/11/2024 2:39:38 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" roleURI="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" roleURI="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" roleURI="http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosurePrepaidExpensesAndOtherAssetsDetails" roleURI="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638669327767694816" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638669327767694816" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638669327767704818" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638669327767694816" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638669327767704818" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_638669327767704818" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638669327767694816" xlink:to="us-gaap_MarketableSecuritiesCurrent_638669327767704818" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638669327767704818" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638669327767694816" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638669327767704818" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638669327767704818" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638669327767704818" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638669327767704818" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638669327767704818" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638669327767844816" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638669327767844816" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638669327767844816" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638669327767844816" order="5" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638669327767844816" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638669327767844816" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638669327767844816" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638669327767844816" xlink:to="us-gaap_LiabilitiesCurrent_638669327767844816" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638669327767844816" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638669327767844816" xlink:to="us-gaap_AccountsPayableCurrent_638669327767844816" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638669327767844816" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638669327767844816" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638669327767844816" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638669327767854853" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638669327767844816" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638669327767854853" order="3" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_638669327767854853" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638669327767844816" xlink:to="us-gaap_ShortTermBorrowings_638669327767854853" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638669327767854853" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638669327767844816" xlink:to="us-gaap_OtherLiabilitiesCurrent_638669327767854853" order="5" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638669327767854853" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638669327767844816" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638669327767854853" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638669327767854853" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638669327767844816" xlink:to="us-gaap_LongTermDebtNoncurrent_638669327767854853" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638669327767854853" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638669327767854853" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638669327767864824" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638669327767864824" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638669327767864824" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638669327767864824" xlink:to="us-gaap_PreferredStockValue_638669327767864824" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638669327767864824" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638669327767864824" xlink:to="us-gaap_CommonStockValue_638669327767864824" order="2" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638669327767864824" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638669327767864824" xlink:to="us-gaap_AdditionalPaidInCapital_638669327767864824" order="3" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638669327767864824" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638669327767864824" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638669327767864824" order="4" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638669327767864824" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638669327767864824" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638669327767864824" order="5" use="optional" weight="1" priority="3" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638669327767874858" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638669327767874858" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638669327767874858" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638669327767874858" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638669327767874858" order="1" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638669327767874858" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638669327767874858" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638669327767874858" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638669327767874858" xlink:to="us-gaap_OperatingIncomeLoss_638669327767874858" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638669327767874858" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638669327767874858" xlink:to="us-gaap_OperatingExpenses_638669327767874858" order="1" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638669327767874858" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638669327767874858" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638669327767874858" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638669327767874858" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638669327767874858" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638669327767874858" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638669327767884837" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638669327767874858" xlink:to="us-gaap_NonoperatingIncomeExpense_638669327767884837" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" order="1" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638669327767884837" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_ProfitLoss_638669327767884837" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_638669327767884837" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_AmortizationOfFinancingCosts_638669327767884837" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638669327767884837" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_DepreciationAndAmortization_638669327767884837" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638669327767884837" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_ShareBasedCompensation_638669327767884837" order="4" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638669327767884837" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638669327767884837" order="5" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638669327767894827" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638669327767894827" order="6" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638669327767894827" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638669327767894827" order="7" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638669327767894827" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638669327767894827" order="8" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638669327767894827" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638669327767894827" order="9" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638669327767894827" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638669327767894827" order="10" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638669327767894827" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638669327767894827" order="11" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638669327767894827" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327767884837" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638669327767894827" order="12" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638669327767904822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638669327767904822" order="2" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638669327767904822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638669327767904822" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638669327767904822" order="1" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638669327767904822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638669327767904822" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638669327767904822" order="2" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638669327767904822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638669327767904822" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638669327767904822" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638669327767904822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638669327767904822" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638669327767904822" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638669327767904822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638669327767904822" order="3" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638669327767904822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638669327767904822" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638669327767904822" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638669327767914822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638669327767904822" xlink:to="us-gaap_ProceedsFromWarrantExercises_638669327767914822" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638669327767914822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638669327767904822" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638669327767914822" order="3" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638669327767914822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638669327767904822" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638669327767914822" order="4" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_638669327767914822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638669327767904822" xlink:to="us-gaap_PaymentsOfDebtRestructuringCosts_638669327767914822" order="5" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638669327767914822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638669327767914822" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638669327767924822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent_638669327767924822" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Fair Value of Financial Assets and Liabilities - (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638669327767924822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638669327767924822" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638669327767924822" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638669327767924822" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Marketable Securities - Summary of Investments (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638669327767934839" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638669327767934839" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638669327767934839" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638669327767934839" order="2" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638669327767944823" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638669327767944823" order="3" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Prepaid Expenses and Other Assets (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent_638669327767944823" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent_638669327767944823" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_638669327767954828" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_638669327767954828" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidInsuranceNoncurrent" xlink:label="srrk_PrepaidInsuranceNoncurrent_638669327767954828" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="srrk_PrepaidInsuranceNoncurrent_638669327767954828" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent_638669327767954828" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent_638669327767954828" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638669327767954828" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638669327767954828" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent_638669327767954828" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_NontradeReceivablesCurrent_638669327767954828" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638669327767954828" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_638669327767954828" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidProfessionalConsulting" xlink:label="srrk_PrepaidProfessionalConsulting_638669327767954828" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="srrk_PrepaidProfessionalConsulting_638669327767954828" order="5" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Accrued Expenses (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638669327767964874" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638669327767964874" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638669327767964874" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638669327767964874" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AccruedExternalResearchAndDevelopmentExpense" xlink:label="srrk_AccruedExternalResearchAndDevelopmentExpense_638669327767964874" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="srrk_AccruedExternalResearchAndDevelopmentExpense_638669327767964874" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638669327767964874" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638669327767964874" order="4" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Commitments and Contingencies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638669327767964874" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_638669327767964874" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638669327767964874" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638669327767964874" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>srrk-20240930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/11/2024 2:39:38 PM-->
<!--Modified on: 11/11/2024 2:39:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" roleURI="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" roleURI="http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureCommonStockDetails" roleURI="http://www.scholarrock.com/role/DisclosureCommonStockDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationExpenseDetails" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationUnrecognizedExpenseDetails" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationRestrictedStockDetails" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationStockOptionsDetails" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationAssumptionsDetails" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureDebtDetails" roleURI="http://www.scholarrock.com/role/DisclosureDebtDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureNetLossPerShareAntidilutiveDetails" roleURI="http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.scholarrock.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="srrk-20240930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OperatingLeaseLiabilityCurrent_2" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OperatingLeaseLiabilityNoncurrent_2" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_1" xlink:title="us-gaap_ResearchAndDevelopmentExpense_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_ResearchAndDevelopmentExpense_1" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" xlink:title="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" xlink:title="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1 To srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember" xlink:title="ecd_AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TraceySaccoMember" xlink:label="srrk_TraceySaccoMember" xlink:title="srrk_TraceySaccoMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="srrk_TraceySaccoMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To srrk_TraceySaccoMember" order="3" priority="0" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TedMylesMember" xlink:label="srrk_TedMylesMember" xlink:title="srrk_TedMylesMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="srrk_TedMylesMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To srrk_TedMylesMember" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_JingMarantzMember" xlink:label="srrk_JingMarantzMember" xlink:title="srrk_JingMarantzMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="srrk_JingMarantzMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To srrk_JingMarantzMember" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended" xlink:title="Trading Arrangements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="ecd_AllTradingArrangementsMember" xlink:title="ecd_AllTradingArrangementsMember" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PurchaseOfStockArrangementMember" xlink:label="srrk_PurchaseOfStockArrangementMember" xlink:title="srrk_PurchaseOfStockArrangementMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllTradingArrangementsMember" xlink:to="srrk_PurchaseOfStockArrangementMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllTradingArrangementsMember To srrk_PurchaseOfStockArrangementMember" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of the Business (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Fair Value of Financial Assets and Liabilities - (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Marketable Securities - Summary of Investments (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Common Stock - (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AtMarketOfferingMember" xlink:label="srrk_AtMarketOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="srrk_AtMarketOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_UnderwritingAgreementMember" xlink:label="srrk_UnderwritingAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="srrk_UnderwritingAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PreFundedWarrantMember" xlink:label="srrk_PreFundedWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="srrk_PreFundedWarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_CommonWarrantMember" xlink:label="srrk_CommonWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantMember" xlink:to="srrk_CommonWarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AggregateMember" xlink:label="srrk_AggregateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srrk_AggregateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_MaximumAggregateOfferingPrice" xlink:label="srrk_MaximumAggregateOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="srrk_MaximumAggregateOfferingPrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Equity-Based Compensation - Expense (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Equity-Based Compensation - Unrecognized Expense (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Equity-Based Compensation - Restricted stock (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Equity-Based Compensation - Stock Options (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - Equity-Based Compensation - Assumptions (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Commitments and Contingencies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_BinneyStCambridgeMaMember" xlink:label="srrk_BinneyStCambridgeMaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="srrk_BinneyStCambridgeMaMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_UponExpirationOfFirstExtensionTermMember" xlink:label="srrk_UponExpirationOfFirstExtensionTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srrk_UponExpirationOfFirstExtensionTermMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_LesseeOperatingLeaseBaseRent" xlink:label="srrk_LesseeOperatingLeaseBaseRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="srrk_LesseeOperatingLeaseBaseRent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AnnualLeaseAdjustmentPercent" xlink:label="srrk_AnnualLeaseAdjustmentPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="srrk_AnnualLeaseAdjustmentPercent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncentiveToLessee" xlink:label="us-gaap_IncentiveToLessee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_IncentiveToLessee" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeaseCostAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Debt (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_LoanAndSecurityAgreementMember" xlink:label="srrk_LoanAndSecurityAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="srrk_LoanAndSecurityAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheOneMember" xlink:label="srrk_TrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srrk_TrancheOneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheTwoMember" xlink:label="srrk_TrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srrk_TrancheTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheThreeMember" xlink:label="srrk_TrancheThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srrk_TrancheThreeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheFourMember" xlink:label="srrk_TrancheFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srrk_TrancheFourMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_InterestOnlyPeriod" xlink:label="srrk_InterestOnlyPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="srrk_InterestOnlyPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaymentPenaltyPercent" xlink:label="srrk_PrepaymentPenaltyPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="srrk_PrepaymentPenaltyPercent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_DebtInstrumentFinalPaymentFee" xlink:label="srrk_DebtInstrumentFinalPaymentFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="srrk_DebtInstrumentFinalPaymentFee" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PercentageOfDollarValueOfConsolidatedCash" xlink:label="srrk_PercentageOfDollarValueOfConsolidatedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="srrk_PercentageOfDollarValueOfConsolidatedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PercentageOfOutstandingObligation" xlink:label="srrk_PercentageOfOutstandingObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="srrk_PercentageOfOutstandingObligation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod" xlink:label="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Net Loss per Share - Antidilutive (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_CommonWarrantMember" xlink:label="srrk_CommonWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="srrk_CommonWarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PreFundedWarrantMember" xlink:label="srrk_PreFundedWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="srrk_PreFundedWarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AggregateMember" xlink:label="srrk_AggregateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srrk_AggregateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Subsequent Events (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_UnderwritingAgreementMember" xlink:label="srrk_UnderwritingAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="srrk_UnderwritingAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PreFundedWarrantMember" xlink:label="srrk_PreFundedWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="srrk_PreFundedWarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>srrk-20240930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/11/2024 2:39:38 PM-->
<!--Modified on: 11/11/2024 2:39:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Securities Act File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other long-term assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total other long-term assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-Term Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term portion of operating lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 300,000,000 shares authorized; 80,081,535 and 75,979,495 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance at end</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance at beginning</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Unrealized (loss) gain on marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Total other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (decrease) in Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance at end (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance at beginning (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common shares, net of issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common shares, net of issuance costs (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common shares, net of issuance costs (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common shares upon RSU vesting</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common shares upon RSU vesting (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Equity impact of shares issued during period on exercise of warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Stock Issued During Period, Value, Exercise Of Warrants</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of pre-funded and common warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Number of shares issued during period on exercise of warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of pre-funded and common warrants (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENT OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Equity-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Amortization/accretion of investment securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common shares, net of issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from pre-funded and common warrant exercises</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtRestructuringCosts" xlink:to="us-gaap_PaymentsOfDebtRestructuringCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_lbl" xml:lang="en-US">Payments of Debt Restructuring Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_lbl" xml:lang="en-US">Debt modification payment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash items:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Property and equipment purchases in accounts payable &amp; accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_OperatingLeaseLiabilityAdjustmentFromRentModification" xlink:label="srrk_OperatingLeaseLiabilityAdjustmentFromRentModification" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_OperatingLeaseLiabilityAdjustmentFromRentModification" xlink:to="srrk_OperatingLeaseLiabilityAdjustmentFromRentModification_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_OperatingLeaseLiabilityAdjustmentFromRentModification_lbl" xml:lang="en-US">Effect on cash flow during the period of non-cash operating lease liability, adjustment from rent modification.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_OperatingLeaseLiabilityAdjustmentFromRentModification_lbl" xml:lang="en-US">Operating Lease Liability, Adjustment From Rent Modification</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_OperatingLeaseLiabilityAdjustmentFromRentModification_lbl" xml:lang="en-US">Operating lease liability, adjustment from rent modification</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of the Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Nature of the Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Common Stock.</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_CommonStockTextBlock" xlink:label="srrk_CommonStockTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_CommonStockTextBlock" xlink:to="srrk_CommonStockTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_CommonStockTextBlock_lbl" xml:lang="en-US">The entire disclosure of common stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_CommonStockTextBlock_lbl" xml:lang="en-US">Common Stock [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_CommonStockTextBlock_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="srrk_UnauditedInterimFinancialInformationPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="srrk_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for unaudited interim financial information.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xml:lang="en-US">Unaudited Interim Financial Information [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xml:lang="en-US">Unaudited Interim Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted and Recently Issued Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of summary of the assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Summary of investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US">Schedule of Other Assets, Noncurrent [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US">Schedule of other long-term assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Summary of accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Summary of allocation of equity-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xml:lang="en-US">Summary of unrecognized equity-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of stock activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions in fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Leased assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Summary of lease costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Summary of anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent event</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money market funds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">U.S. Treasury obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Financial assets and financial liabilities measured at fair value on a recurring basis:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US">Assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US">Marketable Securities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US">Marketable securities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">U.S. Treasury obligations and government agency securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xml:lang="en-US">Marketable securities available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US">Fair value of marketable securities with unrealized loss, less than a year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xml:lang="en-US">Number of investments with unrealized loss, less than a year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent" xlink:to="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US">The amount of prepaid external research and development expense as of the balance sheet date. Used to reflect the current portion of the asset (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US">Prepaid External Research And Development Expense, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US">Prepaid external research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NontradeReceivablesCurrent" xlink:to="us-gaap_NontradeReceivablesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xml:lang="en-US">Nontrade Receivables, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xml:lang="en-US">Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidProfessionalConsulting" xlink:label="srrk_PrepaidProfessionalConsulting" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_PrepaidProfessionalConsulting" xlink:to="srrk_PrepaidProfessionalConsulting_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_PrepaidProfessionalConsulting_lbl" xml:lang="en-US">Amount of asset related to consideration paid in advance for professional and / or consulting within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_PrepaidProfessionalConsulting_lbl" xml:lang="en-US">Prepaid Professional Consulting</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_PrepaidProfessionalConsulting_lbl" xml:lang="en-US">Prepaid professional and consulting expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl" xml:lang="en-US">Other Assets, Noncurrent Disclosure [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl" xml:lang="en-US">Other long-term assets</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent" xlink:to="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent_lbl" xml:lang="en-US">The amount of prepaid external research and development expense as of the balance sheet date. Used to reflect the noncurrent portion of the asset (due after one year or outside the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid External Research And Development Expense, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid external research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xml:lang="en-US">Prepaid Expense Other, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xml:lang="en-US">Prepaid other</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidInsuranceNoncurrent" xlink:label="srrk_PrepaidInsuranceNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_PrepaidInsuranceNoncurrent" xlink:to="srrk_PrepaidInsuranceNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_PrepaidInsuranceNoncurrent_lbl" xml:lang="en-US">Amount of asset related to consideration paid in advance for insurance that provides economic benefits after a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_PrepaidInsuranceNoncurrent_lbl" xml:lang="en-US">Prepaid Insurance, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_PrepaidInsuranceNoncurrent_lbl" xml:lang="en-US">Prepaid insurance</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AccruedExternalResearchAndDevelopmentExpense" xlink:label="srrk_AccruedExternalResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_AccruedExternalResearchAndDevelopmentExpense" xlink:to="srrk_AccruedExternalResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_AccruedExternalResearchAndDevelopmentExpense_lbl" xml:lang="en-US">The amount of accrued external research and development expense as of the balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_AccruedExternalResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Accrued External Research And Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_AccruedExternalResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Accrued external research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional and consulting expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AtMarketOfferingMember" xlink:label="srrk_AtMarketOfferingMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_AtMarketOfferingMember" xlink:to="srrk_AtMarketOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_AtMarketOfferingMember_lbl" xml:lang="en-US">Represents information relating to At the market offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_AtMarketOfferingMember_lbl" xml:lang="en-US">At Market Offering [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_AtMarketOfferingMember_lbl" xml:lang="en-US">ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_UnderwritingAgreementMember" xlink:label="srrk_UnderwritingAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_UnderwritingAgreementMember" xlink:to="srrk_UnderwritingAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_UnderwritingAgreementMember_lbl" xml:lang="en-US">An underwriting agreement relating to the issuance and sale of the entity's common stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PreFundedWarrantMember" xlink:label="srrk_PreFundedWarrantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_PreFundedWarrantMember" xlink:to="srrk_PreFundedWarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_PreFundedWarrantMember_lbl" xml:lang="en-US">Represents the information pertaining to the pre-funded warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre-funded warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_CommonWarrantMember" xlink:label="srrk_CommonWarrantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_CommonWarrantMember" xlink:to="srrk_CommonWarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_CommonWarrantMember_lbl" xml:lang="en-US">Represents the information pertaining to the common warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_CommonWarrantMember_lbl" xml:lang="en-US">Common Warrant [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_CommonWarrantMember_lbl" xml:lang="en-US">Warrants, non pre-funded</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AggregateMember" xlink:label="srrk_AggregateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_AggregateMember" xlink:to="srrk_AggregateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_AggregateMember_lbl" xml:lang="en-US">Information reported for the aggregate, since inception.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_AggregateMember_lbl" xml:lang="en-US">Aggregate [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_AggregateMember_lbl" xml:lang="en-US">Aggregate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_MaximumAggregateOfferingPrice" xlink:label="srrk_MaximumAggregateOfferingPrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_MaximumAggregateOfferingPrice" xlink:to="srrk_MaximumAggregateOfferingPrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US">Maximum aggregate offering price.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Sale of shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrant to purchase preferred stock converted into warrant to purchase common stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrant to purchase (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding warrants (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Sale of stock price (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Equity-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted Average Remaining Period of Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Number of Shares/Units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding, end (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding, beginning (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Outstanding, end (in dollars per share)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Outstanding, beginning (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of non-option awards vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of Units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, end (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, beginning (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable, end (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding, end (in dollars per share)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding, beginning (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable, end (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, end</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Assumptions used in determining the fair value of options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years to liquidity)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_BinneyStCambridgeMaMember" xlink:label="srrk_BinneyStCambridgeMaMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_BinneyStCambridgeMaMember" xlink:to="srrk_BinneyStCambridgeMaMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_BinneyStCambridgeMaMember_lbl" xml:lang="en-US">Related to property located on Binney Street in Cambridge, Massachusetts.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_BinneyStCambridgeMaMember_lbl" xml:lang="en-US">Binney St Cambridge MA [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_BinneyStCambridgeMaMember_lbl" xml:lang="en-US">301 Binney St, Cambridge MA</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_UponExpirationOfFirstExtensionTermMember" xlink:label="srrk_UponExpirationOfFirstExtensionTermMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_UponExpirationOfFirstExtensionTermMember" xlink:to="srrk_UponExpirationOfFirstExtensionTermMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_UponExpirationOfFirstExtensionTermMember_lbl" xml:lang="en-US">Represents information pertaining to the scenario after expiration of first extension term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_UponExpirationOfFirstExtensionTermMember_lbl" xml:lang="en-US">Upon Expiration Of First Extension Term [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_UponExpirationOfFirstExtensionTermMember_lbl" xml:lang="en-US">First extension</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US">Option to extend the term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Renewal term</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_LesseeOperatingLeaseBaseRent" xlink:label="srrk_LesseeOperatingLeaseBaseRent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_LesseeOperatingLeaseBaseRent" xlink:to="srrk_LesseeOperatingLeaseBaseRent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_LesseeOperatingLeaseBaseRent_lbl" xml:lang="en-US">Amount of base rent for initial period under the lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_LesseeOperatingLeaseBaseRent_lbl" xml:lang="en-US">Lessee Operating Lease Base Rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_LesseeOperatingLeaseBaseRent_lbl" xml:lang="en-US">Base rent</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AnnualLeaseAdjustmentPercent" xlink:label="srrk_AnnualLeaseAdjustmentPercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_AnnualLeaseAdjustmentPercent" xlink:to="srrk_AnnualLeaseAdjustmentPercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_AnnualLeaseAdjustmentPercent_lbl" xml:lang="en-US">The annual upward lease adjustment percentage.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_AnnualLeaseAdjustmentPercent_lbl" xml:lang="en-US">Annual Lease Adjustment Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_AnnualLeaseAdjustmentPercent_lbl" xml:lang="en-US">Annual upward adjustment (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncentiveToLessee" xlink:label="us-gaap_IncentiveToLessee" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveToLessee" xlink:to="us-gaap_IncentiveToLessee_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncentiveToLessee_lbl" xml:lang="en-US">Incentive to Lessee</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncentiveToLessee_lbl" xml:lang="en-US">Incentive to lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US">Letter of credit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease Cost:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows used for operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_LoanAndSecurityAgreementMember" xlink:label="srrk_LoanAndSecurityAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_LoanAndSecurityAgreementMember" xlink:to="srrk_LoanAndSecurityAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Represents the Loan and Security Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Loan and Security Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Loan and Security Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheOneMember" xlink:label="srrk_TrancheOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_TrancheOneMember" xlink:to="srrk_TrancheOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_TrancheOneMember_lbl" xml:lang="en-US">Tranche one of the debt agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_TrancheOneMember_lbl" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_TrancheOneMember_lbl" xml:lang="en-US">Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheTwoMember" xlink:label="srrk_TrancheTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_TrancheTwoMember" xlink:to="srrk_TrancheTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_TrancheTwoMember_lbl" xml:lang="en-US">Tranche two of the debt agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_TrancheTwoMember_lbl" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_TrancheTwoMember_lbl" xml:lang="en-US">Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheThreeMember" xlink:label="srrk_TrancheThreeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_TrancheThreeMember" xlink:to="srrk_TrancheThreeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_TrancheThreeMember_lbl" xml:lang="en-US">Represents information pertaining to tranche three.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_TrancheThreeMember_lbl" xml:lang="en-US">Tranche Three [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_TrancheThreeMember_lbl" xml:lang="en-US">Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheFourMember" xlink:label="srrk_TrancheFourMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_TrancheFourMember" xlink:to="srrk_TrancheFourMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_TrancheFourMember_lbl" xml:lang="en-US">Represents information pertaining to tranche four.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_TrancheFourMember_lbl" xml:lang="en-US">Tranche Four [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_TrancheFourMember_lbl" xml:lang="en-US">Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of credit maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from credit facility</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_InterestOnlyPeriod" xlink:label="srrk_InterestOnlyPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_InterestOnlyPeriod" xlink:to="srrk_InterestOnlyPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_InterestOnlyPeriod_lbl" xml:lang="en-US">The interest only period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_InterestOnlyPeriod_lbl" xml:lang="en-US">Interest Only, Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_InterestOnlyPeriod_lbl" xml:lang="en-US">Interest only period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Variable rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xml:lang="en-US">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaymentPenaltyPercent" xlink:label="srrk_PrepaymentPenaltyPercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_PrepaymentPenaltyPercent" xlink:to="srrk_PrepaymentPenaltyPercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_PrepaymentPenaltyPercent_lbl" xml:lang="en-US">Prepayment penalty as a percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_PrepaymentPenaltyPercent_lbl" xml:lang="en-US">Prepayment Penalty, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_PrepaymentPenaltyPercent_lbl" xml:lang="en-US">Prepayment penalty (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_DebtInstrumentFinalPaymentFee" xlink:label="srrk_DebtInstrumentFinalPaymentFee" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_DebtInstrumentFinalPaymentFee" xlink:to="srrk_DebtInstrumentFinalPaymentFee_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_DebtInstrumentFinalPaymentFee_lbl" xml:lang="en-US">Represents the final payment fee, as a percent of the aggregate advances on the debt.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_DebtInstrumentFinalPaymentFee_lbl" xml:lang="en-US">Debt Instrument, Final Payment Fee</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_DebtInstrumentFinalPaymentFee_lbl" xml:lang="en-US">Final payment fee (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PercentageOfDollarValueOfConsolidatedCash" xlink:label="srrk_PercentageOfDollarValueOfConsolidatedCash" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_PercentageOfDollarValueOfConsolidatedCash" xlink:to="srrk_PercentageOfDollarValueOfConsolidatedCash_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_PercentageOfDollarValueOfConsolidatedCash_lbl" xml:lang="en-US">Dollar value of company's consolidated cash as a percent, as required by the agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_PercentageOfDollarValueOfConsolidatedCash_lbl" xml:lang="en-US">Percentage Of Dollar Value of Consolidated Cash</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_PercentageOfDollarValueOfConsolidatedCash_lbl" xml:lang="en-US">Percentage of dollar value of company's consolidated cash</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PercentageOfOutstandingObligation" xlink:label="srrk_PercentageOfOutstandingObligation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_PercentageOfOutstandingObligation" xlink:to="srrk_PercentageOfOutstandingObligation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_PercentageOfOutstandingObligation_lbl" xml:lang="en-US">The amount of cash required in a lender's account as a percentage of outstanding obligation requirement as per the agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_PercentageOfOutstandingObligation_lbl" xml:lang="en-US">Percentage of Outstanding Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_PercentageOfOutstandingObligation_lbl" xml:lang="en-US">Amount of cash required in a lender's account as a percentage of outstanding obligation (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term portion of loan</link:label>
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod" xlink:label="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod" xlink:to="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod_lbl" xml:lang="en-US">Additional period of only interest payments  in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod_lbl" xml:lang="en-US">Line of Credit Facility, Interest Only Payments, Additional Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod_lbl" xml:lang="en-US">Interest additional period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities excluded from the calculation of net loss per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>srrk-20240930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/11/2024 2:39:38 PM-->
<!--Modified on: 11/11/2024 2:39:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureNatureOfBusiness" roleURI="http://www.scholarrock.com/role/DisclosureNatureOfBusiness" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureFairValueOfFinancialAssetsAndLiabilities" roleURI="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureMarketableSecurities" roleURI="http://www.scholarrock.com/role/DisclosureMarketableSecurities" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosurePrepaidExpensesAndOtherAssets" roleURI="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureAccruedExpenses" roleURI="http://www.scholarrock.com/role/DisclosureAccruedExpenses" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureCommonStock" roleURI="http://www.scholarrock.com/role/DisclosureCommonStock" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensation" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensation" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureDebt" roleURI="http://www.scholarrock.com/role/DisclosureDebt" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureNetLossPerShare" roleURI="http://www.scholarrock.com/role/DisclosureNetLossPerShare" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureSubsequentEvents" roleURI="http://www.scholarrock.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" roleURI="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureMarketableSecuritiesTables" roleURI="http://www.scholarrock.com/role/DisclosureMarketableSecuritiesTables" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosurePrepaidExpensesAndOtherAssetsTables" roleURI="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.scholarrock.com/role/DisclosureAccruedExpensesTables" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationTables" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.scholarrock.com/role/DisclosureNetLossPerShareTables" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" roleURI="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" roleURI="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" roleURI="http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosurePrepaidExpensesAndOtherAssetsDetails" roleURI="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureCommonStockDetails" roleURI="http://www.scholarrock.com/role/DisclosureCommonStockDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationExpenseDetails" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationUnrecognizedExpenseDetails" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationRestrictedStockDetails" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationStockOptionsDetails" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureEquityBasedCompensationAssumptionsDetails" roleURI="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureDebtDetails" roleURI="http://www.scholarrock.com/role/DisclosureDebtDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureNetLossPerShareAntidilutiveDetails" roleURI="http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails" />
  <link:roleRef xlink:type="simple" xlink:href="srrk-20240930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638669327768394832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638669327768394832" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638669327768394832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638669327768394832" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638669327768394832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638669327768394832" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638669327768394832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638669327768394832" order="4" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638669327768394832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638669327768394832" order="5" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638669327768394832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638669327768394832" order="6" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638669327768394832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638669327768394832" order="7" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638669327768404871" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638669327768404871" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638669327768404871" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638669327768404871" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638669327768404871" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638669327768404871" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638669327768524864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638669327768524864" order="11" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638669327768524864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638669327768524864" order="12" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638669327768524864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638669327768524864" order="13" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638669327768524864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638669327768524864" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638669327768524864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638669327768524864" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638669327768534847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638669327768534847" order="16" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638669327768534847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638669327768534847" order="17" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638669327768534847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638669327768534847" order="18" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638669327768534847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638669327768534847" order="19" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638669327768534847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638669327768534847" order="20" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638669327768534847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638669327768534847" order="21" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638669327768534847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638669327768534847" order="22" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638669327768534847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638669327768534847" order="23" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638669327768544834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638669327768544834" order="24" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638669327768544834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638669327768544834" order="25" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638669327768544834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638669327768544834" order="26" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638669327768544834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638669327768544834" order="27" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638669327768544834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638669327768544834" order="28" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638669327768544834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638669327768544834" order="29" use="optional" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638669327768554828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638669327768554828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638669327768554828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638669327768554828" xlink:to="us-gaap_AssetsCurrentAbstract_638669327768554828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638669327768554828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638669327768554828" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638669327768554828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_638669327768564855" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638669327768554828" xlink:to="us-gaap_MarketableSecuritiesCurrent_638669327768564855" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638669327768564855" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638669327768554828" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638669327768564855" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638669327768564855" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638669327768554828" xlink:to="us-gaap_AssetsCurrent_638669327768564855" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638669327768574935" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638669327768554828" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638669327768574935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638669327768574935" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638669327768554828" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638669327768574935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638669327768574935" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638669327768554828" xlink:to="us-gaap_RestrictedCashNoncurrent_638669327768574935" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638669327768574935" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638669327768554828" xlink:to="us-gaap_OtherAssetsNoncurrent_638669327768574935" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638669327768574935" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638669327768554828" xlink:to="us-gaap_Assets_638669327768574935" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638669327768574935" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638669327768574935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638669327768574935" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638669327768574935" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638669327768574935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638669327768584837" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638669327768574935" xlink:to="us-gaap_AccountsPayableCurrent_638669327768584837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638669327768584837" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638669327768574935" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638669327768584837" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638669327768584837" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638669327768574935" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638669327768584837" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_638669327768584837" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638669327768574935" xlink:to="us-gaap_ShortTermBorrowings_638669327768584837" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638669327768584837" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638669327768574935" xlink:to="us-gaap_OtherLiabilitiesCurrent_638669327768584837" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638669327768584837" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638669327768574935" xlink:to="us-gaap_LiabilitiesCurrent_638669327768584837" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638669327768584837" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638669327768574935" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638669327768584837" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638669327768584837" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638669327768574935" xlink:to="us-gaap_LongTermDebtNoncurrent_638669327768584837" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638669327768594831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638669327768574935" xlink:to="us-gaap_Liabilities_638669327768594831" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638669327768594831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638669327768574935" xlink:to="us-gaap_CommitmentsAndContingencies_638669327768594831" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638669327768594831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638669327768574935" xlink:to="us-gaap_StockholdersEquityAbstract_638669327768594831" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638669327768594831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638669327768594831" xlink:to="us-gaap_PreferredStockValue_638669327768594831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638669327768594831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638669327768594831" xlink:to="us-gaap_CommonStockValue_638669327768594831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638669327768594831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638669327768594831" xlink:to="us-gaap_AdditionalPaidInCapital_638669327768594831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638669327768594831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638669327768594831" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638669327768594831" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638669327768604845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638669327768594831" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638669327768604845" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638669327768604845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638669327768594831" xlink:to="us-gaap_StockholdersEquity_638669327768604845" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638669327768604845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638669327768574935" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638669327768604845" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638669327768604845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638669327768604845" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638669327768604845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638669327768604845" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638669327768604845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638669327768604845" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638669327768604845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638669327768604845" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638669327768614903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638669327768614903" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638669327768614903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638669327768614903" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638669327768614903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638669327768614903" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638669327768614903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638669327768614903" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638669327768614903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638669327768614903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638669327768614903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638669327768614903" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638669327768614903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638669327768614903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638669327768614903" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638669327768614903" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638669327768614903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638669327768614903" xlink:to="us-gaap_OperatingExpenses_638669327768614903" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638669327768614903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638669327768614903" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638669327768614903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense_638669327768614903" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638669327768624834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638669327768624834" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638669327768624834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638669327768624834" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638669327768624834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638669327768624834" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638669327768624834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638669327768624834" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638669327768624834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638669327768624834" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638669327768624834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638669327768624834" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_6386693277686248341" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638669327768624834" xlink:to="us-gaap_NetIncomeLoss_6386693277686248341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638669327768624834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638669327768624834" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638669327768624834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638669327768624834" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638669327768624834" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638669327768624834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638669327768624834" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638669327768624834" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638669327768634883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638669327768624834" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638669327768634883" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638669327768634883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638669327768634883" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638669327768634883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638669327768634883" xlink:to="us-gaap_StatementEquityComponentsAxis_638669327768634883" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638669327768634883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638669327768634883" xlink:to="us-gaap_CommonStockMember_638669327768634883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638669327768634883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638669327768634883" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638669327768634883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638669327768634883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638669327768634883" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638669327768634883" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638669327768634883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638669327768634883" xlink:to="us-gaap_RetainedEarningsMember_638669327768634883" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638669327768634883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638669327768634883" xlink:to="us-gaap_EquityComponentDomain_638669327768634883" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638669327768634883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638669327768634883" xlink:to="us-gaap_StatementLineItems_638669327768634883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638669327768634883" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638669327768644856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_StockholdersEquity_638669327768644856" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638669327768644856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_SharesOutstanding_638669327768644856" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638669327768644856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638669327768644856" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638669327768644856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638669327768644856" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638669327768644856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638669327768644856" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638669327768644856" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638669327768644856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638669327768644856" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638669327768644856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638669327768644856" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638669327768644856" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638669327768644856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638669327768644856" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638669327768644856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638669327768644856" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638669327768644856" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants_638669327768654895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants_638669327768654895" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants_638669327768654895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srrk_StockIssuedDuringPeriodValueExerciseOfWarrants_638669327768654895" xlink:to="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants_638669327768654895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638669327768654895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638669327768654895" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_638669327768654895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_638669327768654895" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638669327768654895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_NetIncomeLoss_638669327768654895" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638669327768654895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_StockholdersEquity_638669327768654895" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638669327768654895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638669327768644856" xlink:to="us-gaap_SharesOutstanding_638669327768654895" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638669327768664849" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" xlink:to="us-gaap_ProfitLoss_638669327768664849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638669327768664849" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" xlink:to="us-gaap_DepreciationAndAmortization_638669327768664849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_638669327768664849" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" xlink:to="us-gaap_AmortizationOfFinancingCosts_638669327768664849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638669327768664849" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" xlink:to="us-gaap_ShareBasedCompensation_638669327768664849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638669327768664849" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638669327768664849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638669327768664849" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638669327768664849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638669327768664849" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638669327768664849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638669327768674850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638669327768664849" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638669327768674850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638669327768674850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638669327768664849" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638669327768674850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638669327768674850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638669327768664849" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638669327768674850" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638669327768674850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638669327768664849" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638669327768674850" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638669327768674850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638669327768664849" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638669327768674850" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638669327768674850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638669327768664849" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638669327768674850" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327768674850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638669327768664849" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638669327768674850" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638669327768674850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638669327768674850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638669327768674850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638669327768674850" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638669327768674850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638669327768674850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638669327768674850" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638669327768674850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638669327768684833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638669327768674850" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638669327768684833" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638669327768684833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638669327768674850" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638669327768684833" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638669327768684833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638669327768674850" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638669327768684833" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638669327768684833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638669327768684833" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638669327768684833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638669327768684833" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638669327768684833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638669327768684833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638669327768684833" xlink:to="us-gaap_ProceedsFromWarrantExercises_638669327768684833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_638669327768684833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638669327768684833" xlink:to="us-gaap_PaymentsOfDebtRestructuringCosts_638669327768684833" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638669327768684833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638669327768684833" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638669327768684833" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638669327768694864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638669327768684833" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638669327768694864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638669327768694864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638669327768684833" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638669327768694864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638669327768694864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638669327768694864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638669327768694864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638669327768694864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6386693277686948641" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6386693277686948641" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638669327768694864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638669327768694864" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638669327768694864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638669327768694864" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638669327768694864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_OperatingLeaseLiabilityAdjustmentFromRentModification" xlink:label="srrk_OperatingLeaseLiabilityAdjustmentFromRentModification_638669327768704839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638669327768694864" xlink:to="srrk_OperatingLeaseLiabilityAdjustmentFromRentModification_638669327768704839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638669327768704839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638669327768704839" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638669327768704839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638669327768704839" xlink:to="us-gaap_InterestPaidNet_638669327768704839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="995210101 - Disclosure - Nature of the Business">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638669327768704839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638669327768704839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210201 - Disclosure - Summary of Significant Accounting Policies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638669327768714832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638669327768714832" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" xlink:type="extended" xlink:title="995210301 - Disclosure - Fair Value of Financial Assets and Liabilities">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638669327768714832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638669327768714832" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureMarketableSecurities" xlink:type="extended" xlink:title="995210401 - Disclosure - Marketable Securities">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638669327768714832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638669327768714832" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets" xlink:type="extended" xlink:title="995210501 - Disclosure - Prepaid Expenses and Other Assets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_638669327768724916" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_638669327768724916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210601 - Disclosure - Accrued Expenses">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638669327768724916" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638669327768724916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureCommonStock" xlink:type="extended" xlink:title="995210701 - Disclosure - Common Stock">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_CommonStockTextBlock" xlink:label="srrk_CommonStockTextBlock_638669327768724916" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="srrk_CommonStockTextBlock_638669327768724916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensation" xlink:type="extended" xlink:title="995210801 - Disclosure - Equity-Based Compensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638669327768734870" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638669327768734870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995210901 - Disclosure - Commitments and Contingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638669327768734870" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638669327768734870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureDebt" xlink:type="extended" xlink:title="995211001 - Disclosure - Debt">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638669327768734870" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638669327768734870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995211101 - Disclosure - Net Loss per Share">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638669327768734870" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638669327768734870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211201 - Disclosure - Subsequent Events">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638669327768744835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638669327768744835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638669327768744835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638669327768744835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="srrk_UnauditedInterimFinancialInformationPolicyTextBlock_638669327768744835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srrk_UnauditedInterimFinancialInformationPolicyTextBlock_638669327768744835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638669327768744835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638669327768744835" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638669327768744835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638669327768744835" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_638669327768744835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_638669327768744835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638669327768754852" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638669327768754852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureMarketableSecuritiesTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Marketable Securities (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock_638669327768754852" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock_638669327768754852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Prepaid Expenses and Other Assets (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_638669327768754852" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_1" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_638669327768754852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_638669327768754852" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_1" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_638669327768754852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Accrued Expenses (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638669327768764839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638669327768764839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Equity-Based Compensation (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638669327768764839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638669327768764839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_638669327768764839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_638669327768764839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_638669327768764839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_638669327768764839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638669327768764839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638669327768764839" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638669327768764839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638669327768764839" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Commitments and Contingencies (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638669327768764839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638669327768764839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Net Loss per Share (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638669327768774847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638669327768774847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of the Business (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638669327768774847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable_638669327768774847" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638669327768774847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638669327768774847" xlink:to="us-gaap_SubsequentEventTypeAxis_638669327768774847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638669327768774847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638669327768774847" xlink:to="us-gaap_SubsequentEventTypeDomain_638669327768774847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638669327768774847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638669327768774847" xlink:to="us-gaap_SubsequentEventMember_638669327768774847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638669327768774847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638669327768774847" xlink:to="us-gaap_StatementLineItems_638669327768774847" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638669327768774847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638669327768774847" xlink:to="us-gaap_NetIncomeLoss_638669327768774847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638669327768774847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638669327768774847" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638669327768774847" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638669327768784831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638669327768774847" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638669327768784831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_638669327768784831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_638669327768784831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638669327768784831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract_638669327768784831" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638669327768784831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638669327768784831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract_638669327768784831" xlink:to="us-gaap_RestrictedCashNoncurrent_638669327768784831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638669327768784831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract_638669327768784831" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638669327768784831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Fair Value of Financial Assets and Liabilities - (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638669327768784831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638669327768784831" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638669327768784831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638669327768784831" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638669327768784831" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638669327768784831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638669327768784831" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638669327768784831" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638669327768784831" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638669327768794835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638669327768784831" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638669327768794835" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638669327768794835" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638669327768794835" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638669327768794835" xlink:to="us-gaap_FairValueInputsLevel1Member_638669327768794835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638669327768784831" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638669327768794835" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638669327768794835" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638669327768794835" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638669327768794835" xlink:to="us-gaap_MoneyMarketFundsMember_638669327768794835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638669327768794835" xlink:to="us-gaap_USTreasurySecuritiesMember_638669327768794835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638669327768784831" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638669327768794835" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638669327768794835" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_638669327768794835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638669327768794835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638669327768794835" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638669327768794835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract_638669327768804833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638669327768794835" xlink:to="us-gaap_MarketableSecuritiesAbstract_638669327768804833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638669327768804833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_638669327768804833" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638669327768804833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638669327768804833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_638669327768804833" xlink:to="us-gaap_AssetsFairValueDisclosure_638669327768804833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Marketable Securities - Summary of Investments (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_638669327768804833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_638669327768804833" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638669327768804833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_638669327768804833" xlink:to="us-gaap_FinancialInstrumentAxis_638669327768804833" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638669327768804833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638669327768804833" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638669327768804833" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638669327768804833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638669327768804833" xlink:to="us-gaap_USTreasurySecuritiesMember_638669327768804833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638669327768804833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_638669327768804833" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638669327768804833" order="2" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638669327768804833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638669327768804833" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638669327768804833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638669327768814850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638669327768804833" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638669327768814850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638669327768814850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638669327768804833" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638669327768814850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638669327768814850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638669327768804833" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638669327768814850" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638669327768814850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638669327768804833" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638669327768814850" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638669327768814850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638669327768804833" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638669327768814850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_638669327768814850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638669327768804833" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_638669327768814850" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Prepaid Expenses and Other Assets (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638669327768814850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_2" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638669327768814850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent_638669327768814850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638669327768814850" xlink:to="srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent_638669327768814850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638669327768814850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638669327768814850" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638669327768814850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent_638669327768824889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638669327768814850" xlink:to="us-gaap_NontradeReceivablesCurrent_638669327768824889" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638669327768824889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638669327768814850" xlink:to="us-gaap_PrepaidInsurance_638669327768824889" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidProfessionalConsulting" xlink:label="srrk_PrepaidProfessionalConsulting_638669327768824889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638669327768814850" xlink:to="srrk_PrepaidProfessionalConsulting_638669327768824889" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638669327768824889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638669327768814850" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638669327768824889" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_638669327768824889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_2" xlink:to="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_638669327768824889" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent" xlink:label="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent_638669327768824889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_638669327768824889" xlink:to="srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent_638669327768824889" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_638669327768824889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_638669327768824889" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_638669327768824889" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaidInsuranceNoncurrent" xlink:label="srrk_PrepaidInsuranceNoncurrent_638669327768824889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_638669327768824889" xlink:to="srrk_PrepaidInsuranceNoncurrent_638669327768824889" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638669327768824889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_638669327768824889" xlink:to="us-gaap_OtherAssetsNoncurrent_638669327768824889" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Accrued Expenses (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AccruedExternalResearchAndDevelopmentExpense" xlink:label="srrk_AccruedExternalResearchAndDevelopmentExpense_638669327768834847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="srrk_AccruedExternalResearchAndDevelopmentExpense_638669327768834847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638669327768834847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638669327768834847" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638669327768834847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638669327768834847" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638669327768834847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638669327768834847" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638669327768834847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638669327768834847" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Common Stock - (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638669327768834847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638669327768834847" order="1" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638669327768834847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638669327768834847" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638669327768834847" order="1" use="optional" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638669327768834847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638669327768834847" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638669327768834847" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AtMarketOfferingMember" xlink:label="srrk_AtMarketOfferingMember_638669327768834847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638669327768834847" xlink:to="srrk_AtMarketOfferingMember_638669327768834847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638669327768834847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638669327768834847" xlink:to="us-gaap_OverAllotmentOptionMember_638669327768834847" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_UnderwritingAgreementMember" xlink:label="srrk_UnderwritingAgreementMember_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638669327768834847" xlink:to="srrk_UnderwritingAgreementMember_638669327768844833" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638669327768834847" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638669327768844833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638669327768844833" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638669327768844833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638669327768844833" xlink:to="us-gaap_WarrantMember_638669327768844833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PreFundedWarrantMember" xlink:label="srrk_PreFundedWarrantMember_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638669327768844833" xlink:to="srrk_PreFundedWarrantMember_638669327768844833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_CommonWarrantMember" xlink:label="srrk_CommonWarrantMember_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638669327768844833" xlink:to="srrk_CommonWarrantMember_638669327768844833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638669327768834847" xlink:to="srt_StatementScenarioAxis_638669327768844833" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638669327768844833" xlink:to="srt_ScenarioUnspecifiedDomain_638669327768844833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AggregateMember" xlink:label="srrk_AggregateMember_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638669327768844833" xlink:to="srrk_AggregateMember_638669327768844833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638669327768834847" xlink:to="us-gaap_SubsequentEventTypeAxis_638669327768844833" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638669327768844833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638669327768844833" xlink:to="us-gaap_SubsequentEventTypeDomain_638669327768844833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638669327768854863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638669327768844833" xlink:to="us-gaap_SubsequentEventMember_638669327768854863" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638669327768834847" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_MaximumAggregateOfferingPrice" xlink:label="srrk_MaximumAggregateOfferingPrice_638669327768854863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" xlink:to="srrk_MaximumAggregateOfferingPrice_638669327768854863" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638669327768854863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638669327768854863" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638669327768854863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638669327768854863" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638669327768854863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638669327768854863" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants_638669327768854863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" xlink:to="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants_638669327768854863" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638669327768854863" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638669327768854863" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638669327768864861" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" xlink:to="us-gaap_SharesIssuedPricePerShare_638669327768864861" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638669327768864861" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638669327768864861" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638669327768864861" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638669327768854863" xlink:to="us-gaap_CommonStockSharesAuthorized_638669327768864861" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Equity-Based Compensation - Expense (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638669327768874844" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638669327768874844" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638669327768874844" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638669327768874844" xlink:to="us-gaap_IncomeStatementLocationAxis_638669327768874844" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638669327768874844" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638669327768874844" xlink:to="us-gaap_IncomeStatementLocationDomain_638669327768874844" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638669327768874844" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638669327768874844" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638669327768874844" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638669327768874844" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638669327768874844" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638669327768874844" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638669327768874844" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638669327768874844" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638669327768874844" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638669327768874844" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638669327768874844" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638669327768874844" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Equity-Based Compensation - Unrecognized Expense (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637559019383473642" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638669327768884894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637559019383473642" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638669327768884894" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638669327768884894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638669327768884894" xlink:to="us-gaap_AwardTypeAxis_638669327768884894" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768884894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638669327768884894" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768884894" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638669327768884894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768884894" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638669327768884894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638669327768884894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768884894" xlink:to="us-gaap_EmployeeStockOptionMember_638669327768884894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638669327768884894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638669327768884894" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638669327768884894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638669327768884894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638669327768884894" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638669327768884894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638669327768884894" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638669327768884894" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638669327768884894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Equity-Based Compensation - Restricted stock (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636782504207429833" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636782504207429833" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768894858" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768894858" xlink:to="us-gaap_AwardTypeAxis_638669327768894858" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768894858" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768894858" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638669327768894858" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768894858" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638669327768894858" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638669327768894858" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638669327768894858" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638669327768894858" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638669327768894858" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6386693277688948581" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6386693277688948581" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638669327768894858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638669327768894858" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638669327768904839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638669327768904839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638669327768904839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638669327768904839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638669327768904839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638669327768904839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638669327768904839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638669327768904839" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6386693277689048391" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6386693277689048391" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638669327768904839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768894858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638669327768904839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Equity-Based Compensation - Stock Options (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768904839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768904839" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638669327768914840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768904839" xlink:to="us-gaap_AwardTypeAxis_638669327768914840" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768914840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638669327768914840" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768914840" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638669327768914840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768914840" xlink:to="us-gaap_EmployeeStockOptionMember_638669327768914840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768914840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768904839" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768914840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638669327768914840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768914840" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638669327768914840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638669327768914840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638669327768914840" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638669327768914840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638669327768914840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638669327768914840" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638669327768914840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638669327768914840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638669327768914840" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638669327768914840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638669327768914840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638669327768914840" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638669327768914840" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6386693277689148401" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638669327768914840" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6386693277689148401" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638669327768914840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638669327768914840" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638669327768914840" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638669327768924841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768914840" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638669327768924841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638669327768924841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638669327768924841" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638669327768924841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638669327768924841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638669327768924841" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638669327768924841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638669327768924841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638669327768924841" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638669327768924841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638669327768924841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638669327768924841" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638669327768924841" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6386693277689248411" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638669327768924841" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6386693277689248411" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638669327768924841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638669327768924841" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638669327768924841" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638669327768924841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768914840" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638669327768924841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638669327768924841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638669327768924841" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638669327768924841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638669327768934858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638669327768924841" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638669327768934858" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638669327768934858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638669327768924841" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638669327768934858" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6386693277689348581" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638669327768924841" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6386693277689348581" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638669327768934858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638669327768924841" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638669327768934858" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638669327768934858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638669327768924841" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638669327768934858" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - Equity-Based Compensation - Assumptions (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636683891440743022" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768934858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636683891440743022" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768934858" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638669327768944842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768934858" xlink:to="us-gaap_AwardTypeAxis_638669327768944842" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768944842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638669327768944842" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768944842" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638669327768944842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638669327768944842" xlink:to="us-gaap_EmployeeStockOptionMember_638669327768944842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768944842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638669327768934858" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768944842" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638669327768944842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638669327768944842" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638669327768944842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638669327768944842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638669327768944842" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638669327768944842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638669327768944842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638669327768944842" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638669327768944842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638669327768944842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638669327768944842" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638669327768944842" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638669327768944842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638669327768944842" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638669327768944842" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Commitments and Contingencies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638669327768954839" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638669327768954839" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638669327768954839" order="1" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638669327768954839" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638669327768954839" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_BinneyStCambridgeMaMember" xlink:label="srrk_BinneyStCambridgeMaMember_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638669327768954839" xlink:to="srrk_BinneyStCambridgeMaMember_638669327768954839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638669327768954839" xlink:to="srt_StatementScenarioAxis_638669327768954839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638669327768954839" xlink:to="srt_ScenarioUnspecifiedDomain_638669327768954839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_UponExpirationOfFirstExtensionTermMember" xlink:label="srrk_UponExpirationOfFirstExtensionTermMember_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638669327768954839" xlink:to="srrk_UponExpirationOfFirstExtensionTermMember_638669327768954839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638669327768954839" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638669327768954839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638669327768954839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_LesseeOperatingLeaseBaseRent" xlink:label="srrk_LesseeOperatingLeaseBaseRent_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" xlink:to="srrk_LesseeOperatingLeaseBaseRent_638669327768954839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AnnualLeaseAdjustmentPercent" xlink:label="srrk_AnnualLeaseAdjustmentPercent_638669327768954839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" xlink:to="srrk_AnnualLeaseAdjustmentPercent_638669327768954839" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncentiveToLessee" xlink:label="us-gaap_IncentiveToLessee_638669327768964836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" xlink:to="us-gaap_IncentiveToLessee_638669327768964836" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_638669327768964836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_638669327768964836" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638669327768964836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" xlink:to="us-gaap_LeaseCostAbstract_638669327768964836" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638669327768964836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638669327768964836" xlink:to="us-gaap_OperatingLeaseCost_638669327768964836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638669327768964836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638669327768964836" xlink:to="us-gaap_VariableLeaseCost_638669327768964836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638669327768964836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638669327768964836" xlink:to="us-gaap_LeaseCost_638669327768964836" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638669327768964836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" xlink:to="us-gaap_OperatingLeasePayments_638669327768964836" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638669327768964836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638669327768964836" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638669327768974913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638669327768954839" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638669327768974913" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Debt (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638669327768974913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638669327768974913" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638669327768974913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638669327768974913" xlink:to="us-gaap_DebtInstrumentAxis_638669327768974913" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638669327768974913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638669327768974913" xlink:to="us-gaap_DebtInstrumentNameDomain_638669327768974913" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_LoanAndSecurityAgreementMember" xlink:label="srrk_LoanAndSecurityAgreementMember_638669327768974913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638669327768974913" xlink:to="srrk_LoanAndSecurityAgreementMember_638669327768974913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638669327768974913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638669327768974913" xlink:to="srt_StatementScenarioAxis_638669327768974913" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638669327768974913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638669327768974913" xlink:to="srt_ScenarioUnspecifiedDomain_638669327768974913" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheOneMember" xlink:label="srrk_TrancheOneMember_638669327768974913" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638669327768974913" xlink:to="srrk_TrancheOneMember_638669327768974913" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheTwoMember" xlink:label="srrk_TrancheTwoMember_638669327768984899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638669327768974913" xlink:to="srrk_TrancheTwoMember_638669327768984899" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheThreeMember" xlink:label="srrk_TrancheThreeMember_638669327768984899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638669327768974913" xlink:to="srrk_TrancheThreeMember_638669327768984899" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_TrancheFourMember" xlink:label="srrk_TrancheFourMember_638669327768984899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638669327768974913" xlink:to="srrk_TrancheFourMember_638669327768984899" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638669327768984899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638669327768974913" xlink:to="srt_RangeAxis_638669327768984899" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638669327768984899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638669327768984899" xlink:to="srt_RangeMember_638669327768984899" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638669327768984899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638669327768984899" xlink:to="srt_MinimumMember_638669327768984899" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638669327768984899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638669327768984899" xlink:to="srt_MaximumMember_638669327768984899" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638669327768984899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638669327768974913" xlink:to="us-gaap_DebtInstrumentLineItems_638669327768984899" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638669327768984899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638669327768984899" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638669327768984899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638669327768984899" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_InterestOnlyPeriod" xlink:label="srrk_InterestOnlyPeriod_638669327768994860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="srrk_InterestOnlyPeriod_638669327768994860" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638669327768994860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638669327768994860" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_638669327768994860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638669327768994860" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_638669327768994860" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PrepaymentPenaltyPercent" xlink:label="srrk_PrepaymentPenaltyPercent_638669327768994860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="srrk_PrepaymentPenaltyPercent_638669327768994860" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_DebtInstrumentFinalPaymentFee" xlink:label="srrk_DebtInstrumentFinalPaymentFee_638669327768994860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="srrk_DebtInstrumentFinalPaymentFee_638669327768994860" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638669327768994860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="us-gaap_RepaymentsOfDebt_638669327768994860" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PercentageOfDollarValueOfConsolidatedCash" xlink:label="srrk_PercentageOfDollarValueOfConsolidatedCash_638669327768994860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="srrk_PercentageOfDollarValueOfConsolidatedCash_638669327768994860" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PercentageOfOutstandingObligation" xlink:label="srrk_PercentageOfOutstandingObligation_638669327768994860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="srrk_PercentageOfOutstandingObligation_638669327768994860" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638669327768994860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="us-gaap_LongTermDebt_638669327768994860" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod" xlink:label="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod_638669327769004876" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638669327768984899" xlink:to="srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod_638669327769004876" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Net Loss per Share - Antidilutive (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638669327769004876" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638669327769004876" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638669327769004876" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638669327769004876" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638669327769004876" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638669327769004876" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638669327769004876" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638669327769004876" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638669327769004876" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638669327769004876" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638669327769004876" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638669327769004876" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638669327769004876" xlink:to="us-gaap_EmployeeStockOptionMember_638669327769004876" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_CommonWarrantMember" xlink:label="srrk_CommonWarrantMember_638669327769004876" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638669327769004876" xlink:to="srrk_CommonWarrantMember_638669327769004876" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638669327769004876" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638669327769004876" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638669327769004876" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638669327769014858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638669327769004876" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638669327769014858" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PreFundedWarrantMember" xlink:label="srrk_PreFundedWarrantMember_638669327769014858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638669327769014858" xlink:to="srrk_PreFundedWarrantMember_638669327769014858" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638669327769014858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638669327769004876" xlink:to="srt_StatementScenarioAxis_638669327769014858" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638669327769014858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638669327769014858" xlink:to="srt_ScenarioUnspecifiedDomain_638669327769014858" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_AggregateMember" xlink:label="srrk_AggregateMember_638669327769014858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638669327769014858" xlink:to="srrk_AggregateMember_638669327769014858" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638669327769014858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638669327769004876" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638669327769014858" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants_638669327769014858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638669327769014858" xlink:to="srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants_638669327769014858" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638669327769014858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638669327769014858" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638669327769014858" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638669327769014858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638669327769014858" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638669327769014858" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Subsequent Events (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638669327769024865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_StatementTable_638669327769024865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638669327769024865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638669327769024865" xlink:to="us-gaap_SubsequentEventTypeAxis_638669327769024865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638669327769024865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638669327769024865" xlink:to="us-gaap_SubsequentEventTypeDomain_638669327769024865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638669327769024865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638669327769024865" xlink:to="us-gaap_SubsequentEventMember_638669327769024865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638669327769024865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638669327769024865" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638669327769024865" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638669327769024865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638669327769024865" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638669327769024865" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_UnderwritingAgreementMember" xlink:label="srrk_UnderwritingAgreementMember_638669327769024865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638669327769024865" xlink:to="srrk_UnderwritingAgreementMember_638669327769024865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638669327769024865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638669327769024865" xlink:to="us-gaap_OverAllotmentOptionMember_638669327769024865" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638669327769024865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638669327769024865" xlink:to="us-gaap_StatementEquityComponentsAxis_638669327769024865" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638669327769034851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638669327769024865" xlink:to="us-gaap_EquityComponentDomain_638669327769034851" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638669327769034851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638669327769034851" xlink:to="us-gaap_CommonStockMember_638669327769034851" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="srrk-20240930.xsd#srrk_PreFundedWarrantMember" xlink:label="srrk_PreFundedWarrantMember_638669327769034851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638669327769034851" xlink:to="srrk_PreFundedWarrantMember_638669327769034851" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638669327769034851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638669327769024865" xlink:to="us-gaap_SubsequentEventLineItems_638669327769034851" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638669327769034851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638669327769034851" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638669327769034851" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638669327769034851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638669327769034851" xlink:to="us-gaap_SharesIssuedPricePerShare_638669327769034851" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638669327769034851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638669327769034851" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638669327769034851" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638669327769034851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638669327769034851" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638669327769034851" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035807399936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-38501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SCHOLAR ROCK HOLDING CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3750435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">301 Binney Street, 3rd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">259 3860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SRRK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,614,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001727196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035807545360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 76,391<span></span>
</td>
<td class="nump">$ 101,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">62,674<span></span>
</td>
<td class="nump">178,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">13,862<span></span>
</td>
<td class="nump">8,256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">152,927<span></span>
</td>
<td class="nump">288,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,156<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">16,834<span></span>
</td>
<td class="nump">11,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="nump">2,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">3,809<span></span>
</td>
<td class="nump">4,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">179,133<span></span>
</td>
<td class="nump">311,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,071<span></span>
</td>
<td class="nump">3,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">29,260<span></span>
</td>
<td class="nump">20,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">6,041<span></span>
</td>
<td class="nump">7,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">39,372<span></span>
</td>
<td class="nump">32,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liability</a></td>
<td class="nump">10,466<span></span>
</td>
<td class="nump">4,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">50,099<span></span>
</td>
<td class="nump">48,684<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">99,937<span></span>
</td>
<td class="nump">85,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 300,000,000 shares authorized; 80,081,535 and 75,979,495 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">935,249<span></span>
</td>
<td class="nump">901,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(856,261)<span></span>
</td>
<td class="num">(676,421)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">79,196<span></span>
</td>
<td class="nump">225,218<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 179,133<span></span>
</td>
<td class="nump">$ 311,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035810683824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">80,081,535<span></span>
</td>
<td class="nump">75,979,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">80,081,535<span></span>
</td>
<td class="nump">75,979,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035807840128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 48,719<span></span>
</td>
<td class="nump">$ 30,337<span></span>
</td>
<td class="nump">$ 134,185<span></span>
</td>
<td class="nump">$ 86,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,061<span></span>
</td>
<td class="nump">13,335<span></span>
</td>
<td class="nump">48,512<span></span>
</td>
<td class="nump">36,324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">64,780<span></span>
</td>
<td class="nump">43,672<span></span>
</td>
<td class="nump">182,697<span></span>
</td>
<td class="nump">123,263<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(64,780)<span></span>
</td>
<td class="num">(43,672)<span></span>
</td>
<td class="num">(182,697)<span></span>
</td>
<td class="num">(123,263)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">2,857<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (64,479)<span></span>
</td>
<td class="num">$ (42,359)<span></span>
</td>
<td class="num">$ (179,840)<span></span>
</td>
<td class="num">$ (119,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (1.86)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (1.86)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">97,050,637<span></span>
</td>
<td class="nump">80,606,438<span></span>
</td>
<td class="nump">96,587,149<span></span>
</td>
<td class="nump">80,115,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">97,050,637<span></span>
</td>
<td class="nump">80,606,438<span></span>
</td>
<td class="nump">96,587,149<span></span>
</td>
<td class="nump">80,115,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (64,479)<span></span>
</td>
<td class="num">$ (42,359)<span></span>
</td>
<td class="num">$ (179,840)<span></span>
</td>
<td class="num">$ (119,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (64,297)<span></span>
</td>
<td class="num">$ (42,319)<span></span>
</td>
<td class="num">$ (179,804)<span></span>
</td>
<td class="num">$ (118,802)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035803347296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning at Dec. 31, 2022</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 771,699<span></span>
</td>
<td class="num">$ (884)<span></span>
</td>
<td class="num">$ (510,632)<span></span>
</td>
<td class="nump">$ 260,235<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning (in shares) at Dec. 31, 2022</a></td>
<td class="nump">51,672,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares, net of issuance costs (in shares)</a></td>
<td class="nump">68,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">28,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common shares upon RSU vesting (in shares)</a></td>
<td class="nump">219,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,379)<span></span>
</td>
<td class="num">(39,379)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Mar. 31, 2023</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">778,941<span></span>
</td>
<td class="num">(329)<span></span>
</td>
<td class="num">(550,011)<span></span>
</td>
<td class="nump">228,653<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (in shares) at Mar. 31, 2023</a></td>
<td class="nump">51,989,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning at Dec. 31, 2022</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">771,699<span></span>
</td>
<td class="num">(884)<span></span>
</td>
<td class="num">(510,632)<span></span>
</td>
<td class="nump">260,235<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning (in shares) at Dec. 31, 2022</a></td>
<td class="nump">51,672,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,663)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Sep. 30, 2023</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">797,927<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(630,295)<span></span>
</td>
<td class="nump">167,665<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (in shares) at Sep. 30, 2023</a></td>
<td class="nump">56,260,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning at Mar. 31, 2023</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">778,941<span></span>
</td>
<td class="num">(329)<span></span>
</td>
<td class="num">(550,011)<span></span>
</td>
<td class="nump">228,653<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning (in shares) at Mar. 31, 2023</a></td>
<td class="nump">51,989,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common shares, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares, net of issuance costs (in shares)</a></td>
<td class="nump">550,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">53,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common shares upon RSU vesting (in shares)</a></td>
<td class="nump">273,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of pre-funded and common warrants</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of pre-funded and common warrants (in shares)</a></td>
<td class="nump">2,293,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,925)<span></span>
</td>
<td class="num">(37,925)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Jun. 30, 2023</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">790,445<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(587,936)<span></span>
</td>
<td class="nump">202,501<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (in shares) at Jun. 30, 2023</a></td>
<td class="nump">55,159,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">49,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common shares upon RSU vesting (in shares)</a></td>
<td class="nump">24,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of pre-funded and common warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of pre-funded and common warrants (in shares)</a></td>
<td class="nump">1,026,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,359)<span></span>
</td>
<td class="num">(42,359)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Sep. 30, 2023</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">797,927<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(630,295)<span></span>
</td>
<td class="nump">167,665<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (in shares) at Sep. 30, 2023</a></td>
<td class="nump">56,260,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning at Dec. 31, 2023</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">901,471<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="num">(676,421)<span></span>
</td>
<td class="nump">225,218<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning (in shares) at Dec. 31, 2023</a></td>
<td class="nump">75,979,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">47,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common shares upon RSU vesting (in shares)</a></td>
<td class="nump">360,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of pre-funded and common warrants</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">6,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of pre-funded and common warrants (in shares)</a></td>
<td class="nump">3,357,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,853)<span></span>
</td>
<td class="num">(56,853)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Mar. 31, 2024</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">916,017<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(733,274)<span></span>
</td>
<td class="nump">182,773<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (in shares) at Mar. 31, 2024</a></td>
<td class="nump">79,744,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning at Dec. 31, 2023</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">901,471<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="num">(676,421)<span></span>
</td>
<td class="nump">225,218<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning (in shares) at Dec. 31, 2023</a></td>
<td class="nump">75,979,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,840)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Sep. 30, 2024</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">935,249<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="num">(856,261)<span></span>
</td>
<td class="nump">79,196<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (in shares) at Sep. 30, 2024</a></td>
<td class="nump">80,081,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning at Mar. 31, 2024</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">916,017<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(733,274)<span></span>
</td>
<td class="nump">182,773<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning (in shares) at Mar. 31, 2024</a></td>
<td class="nump">79,744,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">6,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common shares upon RSU vesting (in shares)</a></td>
<td class="nump">240,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,508)<span></span>
</td>
<td class="num">(58,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Jun. 30, 2024</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">925,376<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(791,782)<span></span>
</td>
<td class="nump">133,620<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (in shares) at Jun. 30, 2024</a></td>
<td class="nump">79,992,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">41,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common shares upon RSU vesting (in shares)</a></td>
<td class="nump">48,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,479)<span></span>
</td>
<td class="num">(64,479)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Sep. 30, 2024</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 935,249<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="num">$ (856,261)<span></span>
</td>
<td class="nump">$ 79,196<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (in shares) at Sep. 30, 2024</a></td>
<td class="nump">80,081,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period on exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of shares issued during period on exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035807492592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (179,840)<span></span>
</td>
<td class="num">$ (119,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">2,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">27,126<span></span>
</td>
<td class="nump">20,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/accretion of investment securities</a></td>
<td class="num">(3,945)<span></span>
</td>
<td class="num">(4,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">4,034<span></span>
</td>
<td class="nump">5,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(5,734)<span></span>
</td>
<td class="nump">2,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">606<span></span>
</td>
<td class="num">(2,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">8,821<span></span>
</td>
<td class="num">(6,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(4,744)<span></span>
</td>
<td class="num">(6,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(151,436)<span></span>
</td>
<td class="num">(107,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(82,710)<span></span>
</td>
<td class="num">(186,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">202,100<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">119,314<span></span>
</td>
<td class="nump">66,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from pre-funded and common warrant exercises</a></td>
<td class="nump">6,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtRestructuringCosts', window );">Debt modification payment</a></td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">677<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,658<span></span>
</td>
<td class="nump">6,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(25,464)<span></span>
</td>
<td class="num">(35,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">104,262<span></span>
</td>
<td class="nump">105,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">78,798<span></span>
</td>
<td class="nump">70,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases in accounts payable &amp; accrued expenses</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_OperatingLeaseLiabilityAdjustmentFromRentModification', window );">Operating lease liability, adjustment from rent modification</a></td>
<td class="nump">9,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 5,003<span></span>
</td>
<td class="nump">$ 4,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_OperatingLeaseLiabilityAdjustmentFromRentModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect on cash flow during the period of non-cash operating lease liability, adjustment from rent modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_OperatingLeaseLiabilityAdjustmentFromRentModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035808463056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1. Nature of the Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Scholar Rock Holding Corporation (the &#8220;Company&#8221;) is a late-stage biopharmaceutical company focused on the discovery, development, and delivery of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. As a global leader in transforming growth factor beta (&#8220;TGF&#946;&#8221;) superfamily biology, the Company&#8217;s novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, the Company believes that it may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s first product candidate, apitegromab, is a highly selective, fully human, monoclonal antibody, with a unique mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of spinal muscular atrophy (&#8220;SMA&#8221;). The Company is conducting SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with nonambulatory Type 2 and Type 3 SMA. The Company completed enrollment of SAPPHIRE in 2023. In October 2024, the Company announced positive top-line results that showed the study achieved its primary endpoint. Additionally, in 2024, the Company announced data from the Phase 2 TOPAZ trial extension period which showed patient outcomes at 48 months of treatment with apitegromab. The FDA granted Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation to apitegromab for the treatment of SMA in May 2021, August 2020 and March 2018, respectively. The European Medicines Agency (&#8220;EMA&#8221;) granted Priority Medicine (&#8220;PRIME&#8221;) designation in March 2021 and the EC granted Orphan Medicinal Product designation in December 2018 to apitegromab for the treatment of SMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In October 2023, the Company announced an expansion into cardiometabolic disorders by advancing its anti-myostatin program with SRK-439, a novel, fully human anti-myostatin monoclonal antibody, for evaluation in cardiometabolic disorders, including obesity, towards a potential investigational new drug (&#8220;IND&#8221;) submission in 2025. To inform the development of SRK-439, in May 2024 the Company initiated the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve muscle mass in individuals living with obesity and on background therapy of a GLP-1 receptor agonist (&#8220;GLP-1 RA&#8221;). In September 2024, the Company announced that it had completed enrollment in the Phase 2 EMRAZE proof-of-concept trial. Top-line results from this trial are expected in the second quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s second product candidate, SRK-181, a highly selective inhibitor of the activation of latent TGF&#946; is being developed for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies (referred to together as anti-PD-(L)1 antibody therapies). SRK-181 is being evaluated in the Company&#8217;s Phase 1 DRAGON proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors that exhibit resistance to anti-PD-(L)1 antibody therapies. The Phase 1 DRAGON trial completed enrollment in December 2023 and continues to treat patients who remain on study. This two-part clinical trial consists of a dose escalation portion (Part A) and a dose expansion evaluating SRK-181 in combination with an approved anti-PD- (L)1 antibody therapy (Part B). Part B includes the following active cohorts: urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma, and head and neck squamous cell carcinoma. Safety, efficacy and biomarker data were presented in November 2023 at the Society for Immunotherapy of Cancer 38th Annual Meeting and in June 2024 at the American Society of Clinical Oncology (&#8220;ASCO&#8221;) annual meeting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additionally, the Company continues to create a pipeline of product candidates to deliver novel therapies to underserved patients suffering from a wide range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. The Company was originally formed in May 2012. Its principal offices are in Cambridge, Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since its inception, the Company&#8217;s operations have focused on research and development of monoclonal antibodies that selectively inhibit activation of growth factors for therapeutic effect, as well as establishing the Company&#8217;s intellectual property portfolio and performing research and development activities. The Company has primarily financed its operations through various equity financings, including in October 2024 (Note 12), as well as research and development collaboration agreements and the Company&#8217;s debt facility (Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Revenue generation activities have been limited to two collaborations, both containing research services and the issuance of a license. The first agreement, executed in 2013, was with Janssen Biotech, Inc., a subsidiary of Johnson &amp; Johnson and was terminated in July 2022. The second agreement (the &#8220;Gilead Collaboration Agreement&#8221;), with Gilead Sciences, Inc. (&#8220;Gilead&#8221;), was in effect between December 2018 and January 2022. No revenues have been recorded from the sale of any commercial product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company&#8217;s product candidates. The Company has incurred recurring losses since its inception, including net losses of $179.8 million and $119.7 million for the nine months ended September 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of $856.3 million as of September 30, 2024. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company believes that its existing cash, cash equivalents, and marketable securities at September 30, 2024 together with the approximately $324.4 million in net proceeds from the follow-on offering completed in October 2024 will be sufficient to allow the Company to fund its current operations through at least a period of one year after the date these financial statements are issued.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805588768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The significant accounting policies used in preparation of the unaudited consolidated financial statements are described in the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K. There have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,598</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,407</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,612</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,210</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Unaudited Interim Financial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The consolidated financial statements of the Company included herein have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). The unaudited consolidated financial statements include the accounts of Scholar Rock Holding Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full&#160;year or any other interim period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;)</i>. The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under previous GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. In November 2019, the FASB deferred the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. Therefore, the new standard was effective for the Company on January 1, 2023. The Company established processes and internal controls to comply with the new credit loss standard and related disclosure requirements. The Company&#8217;s investment policy has primary objectives of preservation of capital and maintenance of liquidity. As a result, the Company typically invests in money market funds, U.S. treasury obligations and government agency securities. The Company believes that such funds are subject to minimal credit risk. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these investments. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued Accounting Standards Update 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2017-07&#8221;). The standard requires disclosure of incremental segment information on an annual and interim basis and allows for multiple measures of a segment&#8217;s profit or loss provided that one of those measures is consistent with GAAP. The amendments in this update do not change how a public company identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments, but rather requires public entities to provide in interim periods all disclosures about a reporting segment&#8217;s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for interim periods starting on January 1, 2025. The option for early adoption is permitted, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures in future years as a result of the adoption of ASU 2023-07.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2023, the FASB issued Accounting Standards Update 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(&#8220;ASU 2023-09&#8221;), which enhances the transparency of income tax disclosures to provide information to investors to better assess how a company&#8217;s operations and related tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This requires public entities to disclose additional categories in the rate reconciliation regarding federal and state income taxes, and provide more details surrounding reconciling items if a quantitative threshold is met. The effective date for public companies is for annual periods starting on January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">available for issuance, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures will be in future years as a result of the adoption of ASU 2023-09.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035898762240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3. Fair Value of Financial Assets and Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following tables summarize the assets and liabilities measured at fair value on a recurring basis at September 30, 2024 and December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. treasury obligations, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. treasury obligations, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cash, cash equivalents and marketable securities are Level 1 assets and include investments in money market funds and U.S. treasury obligations and government agency securities that are valued using quoted market prices. Accordingly, money market funds and government funds are categorized as Level 1 as of September 30, 2024 and December 31, 2023. There were no transfers of assets between fair value measurement levels during the nine months ended September 30, 2024 or 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The carrying amounts reflected in the balance sheets for prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values at September 30, 2024 and December 31, 2023, due to their short-term nature. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company believes the terms of its debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company's debt approximates its fair value based on Level 3 of the fair value hierarchy.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805196176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4. Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s investments as of September 30, 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities available-for-sale:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,674</p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total available-for-sale securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,674</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s investments as of December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities available-for-sale:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total available-for-sale securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The aggregate fair value of marketable securities with unrealized losses was $0 and $11.9&#160;million at September 30, 2024 and December 31, 2023, respectively.<b style="font-weight:bold;">&#160;</b>At September 30, 2024 and December 31, 2023, no investments and&#160;three&#160;investments, respectively, were in an unrealized loss position. All such investments have been in an unrealized loss position for less than a&#160;year and these losses are considered temporary. The Company has the ability and intent to hold these investments until a recovery of their amortized cost, which may not occur until maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company believes that U.S. treasury obligations and government agency securities are subject to minimal credit risk. As a result, the Company did not record any charges for credit-related impairments for its available-for-sale securities for the nine months ended September 30, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035808585744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5. Prepaid Expenses and other Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024 and December 31, 2023, prepaid expenses and other assets consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,059</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,281</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,076</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 635</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid professional and consulting expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,256</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024 and December 31, 2023, other long-term assets consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,074</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 312</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,417</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805491248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">6. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024 and December 31, 2023, accrued expenses consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,825</p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,591</p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and consulting expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,267</p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 766</p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,449</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035888252480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">7. Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">In June 2024, the stockholders approved an amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of common stock from </span><span style="background:#ffffff;">150,000,000</span><span style="background:#ffffff;"> to </span><span style="background:#ffffff;">300,000,000</span><span style="background:#ffffff;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The Company has had a sales agreement in place during various time periods with Jefferies LLC with respect to an at-the-market (&#8220;ATM&#8221;) offering program. Under this program, the Company is able to offer and sell, from time to time at its sole discretion, shares of its common stock through Jefferies as its sales agent. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. The current ATM agreement, established in November 2022, allows for the sale of shares of common stock having an aggregate offering price of up to </span><span style="background:#ffffff;">$100</span><span style="background:#ffffff;"> million. As of September 30, 2024, the Company has sold </span><span style="background:#ffffff;">619,290</span><span style="background:#ffffff;"> shares, generating net proceeds of </span><span style="background:#ffffff;">$5.2</span><span style="background:#ffffff;"> million, under the ATM program. </span><span style="background:#ffffff;">No</span><span style="background:#ffffff;"> sales were made under the ATM program during the nine months ended September 30, 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">The Company has issued pre-funded warrants, as well as warrants as part of its financing activities. Both the pre-funded warrants and warrants meet the conditions for equity classification and are recorded as a component of stockholders&#8217; equity within additional paid-in capital. In June 2022 and November 2020, the Company issued </span><span style="background:#ffffff;">25,510,205</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">2,179,487</span><span style="background:#ffffff;"> pre-funded warrants, respectively. During the nine months ended September 30, 2024, </span><span style="background:#ffffff;">2,526,833</span><span style="background:#ffffff;"> of the Company&#8217;s pre-funded warrants were exercised. As of September 30, 2024, the Company has </span><span style="background:#ffffff;">17,008,164</span><span style="background:#ffffff;"> pre-funded warrants outstanding. In June 2022, the Company also issued </span><span style="background:#ffffff;">10,459,181</span><span style="background:#ffffff;"> warrants with an exercise price of </span><span style="background:#ffffff;">$7.35</span><span style="background:#ffffff;">. During the nine months ended September 30, 2024, </span><span style="background:#ffffff;">830,660</span><span style="background:#ffffff;"> of the Company&#8217;s warrants were exercised. As of September 30, 2024, the Company has </span><span style="background:#ffffff;">9,157,496</span><span style="background:#ffffff;"> warrants outstanding.</span> <span style="background:#ffffff;">In October 2024, the Company issued pre-funded warrants to purchase up to </span><span style="background:#ffffff;">353,983</span><span style="background:#ffffff;"> shares of common stock (see Note 12).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805466192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">8. Equity-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The Company recorded equity-based compensation expense related to all equity-based awards, which was allocated as follows in the consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023 (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.38%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,341</p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,850</p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,191</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes the Company&#8217;s unrecognized equity-based compensation expense as of September 30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrecognized Expense (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Remaining Period of Recognition (years)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted Stock Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.6</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s restricted stock unit activity for the current year:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:9pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,089,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.92</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,126,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.52</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (649,559)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.38</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,956)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.42</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,386,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.82</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The total fair value of restricted stock units vested during the nine months ended September 30, 2024 was $8.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s stock option activity for the current year:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,300,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,299</p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,835,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (94,988)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (371,557)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,670,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,967</p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,831,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,310</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Using the Black-Scholes option pricing model, the weighted average fair value of options granted during the nine months ended September 30, 2024 was $10.38. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following weighted average assumptions were used in determining the fair value of options granted in the nine months ended September 30, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.09 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.87 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years to liquidity)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.00 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.12 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">91.15 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90.54 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805161712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">9. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Operating Lease </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In November 2019, the Company entered into a lease of office and laboratory space at 301 Binney Street in Cambridge, Massachusetts to be used as its new corporate headquarters (the &#8220;Lease&#8221;). The expiration date of the Lease was originally in August 2025 and included an option to extend the term by two years. The base rent under the original Lease was $6.9 million per year, subject to an annual increase of 3.5%, and the Company was subject to a free-rent period through mid-August 2020. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The Lease included incentives of $14.1 million in the form of an allowance for tenant improvements related to the design and build out of the space. In connection with the Lease, the Company has secured a letter of credit for $2.3<span style="white-space:pre-wrap;"> million which renews automatically each year. The Lease commencement date, for accounting purposes, was reached in September 2020.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In May 2024, the Company entered into the First Amendment (the &#8220;Lease Amendment&#8221;) to the Lease to extend the term for approximately two years, commencing on August 19, 2025 (the &#8220;First Extension Term&#8221;) with the base rent to start at approximately $6.2 million per year, followed by a 3% annual increase. Pursuant to the Lease Amendment, the Company also has an option to extend the term of the Lease by five years, upon the expiration of the First Extension Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other information related to the Lease is as follows (in thousands, except lease term and discount rate):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease Cost:</b></p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease cost</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Variable lease cost</p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows used for operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Weighted average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company, from time to time, may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the nine months ended September 30, 2024 and 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035888254688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;">10. Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On October 16, 2020 (the &#8220;Closing Date&#8221;) the Company entered into a Loan and Security Agreement with Oxford Finance LLC (&#8220;Oxford&#8221;) and Silicon Valley Bank (&#8220;SVB&#8221;) for $50.0 million (the &#8220;Loan and Security Agreement&#8221;). Tranche 1 of $25.0 million was funded on the Closing Date. The Company had an additional $25.0 million in loan proceeds available under Tranche 2 which was funded in December 2021, in conjunction with the Company entering into the First Amendment to Loan and Security Agreement with Oxford and SVB. The Loan and Security Agreement was to mature on May 1, 2025 and required interest-only payments through November 2022, with principal payments to commence in December 2022. Pursuant to the Loan and Security Agreement, the Company was required to maintain cash in an SVB account equal to the lesser of&#160;100%&#160;of the Company&#8217;s consolidated cash or&#160;105%&#160;of the dollar amount of the outstanding debt. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On November 10, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement ( &#8220;Amendment 2&#8221;) to increase the Company&#8217;s borrowing capacity under the Loan and Security Agreement to an amount up to $100.0 million, comprised of the original $50.0 million loan which remains outstanding and two additional $25.0 million tranches. The first $25.0 million tranche available under Amendment 2, was available at the Company&#8217;s discretion through December 2023 upon achievement of certain development and business performance milestones. The Company did not exercise this tranche. The second $25.0 million tranche available under Amendment 2, may be available upon the Company&#8217;s request, at Oxford and SVB&#8217;s discretion. Amendment 2 also extended the interest-only payment period for an additional 24 months through November 2024, with principal payments to commence in December 2024. The maturity of the loan was extended to November 2027. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Effective upon Amendment 2, the interest rate on the unpaid principal is the greater of the Wall Street Journal <span style="-sec-ix-hidden:Hidden_VBPAhXNcSkCfo6QuLvnBlg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prime rate</span></span> plus 4.60% or 9.35% per annum. Prepayment is permitted and may include a pre-payment fee ranging from 0% - 3% (of the principal amount being prepaid), depending on when the prepayment is made. The Company is also required to make a final payment equal to 2% of the original principal amount. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">In conjunction with Amendment 2, the Company was required to pay $0.9 million for the accrued portion of the final payment on the previous outstanding balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver. Afterward, the FDIC transferred all deposits of the former Silicon Valley Bank to Silicon Valley Bridge Bank, N.A., as operated by the FDIC. On March 27, 2023, Silicon Valley Bridge Bank was closed by the Office of the Comptroller of the Currency, and the FDIC was appointed as receiver. First Citizens Bank then entered into an agreement with the FDIC to purchase out of FDIC receivership substantially all loans and certain other assets and assume all customer deposits and certain other liabilities of Silicon Valley Bridge Bank. On March 27, 2023, Silicon Valley Bridge Bank and its U.S. branches began operating as Silicon Valley Bank, a division of First Citizens Bank.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On April 18, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement to amend certain provisions relating to the Company&#8217;s operating accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On May 17, 2024, the Company entered into the Fourth Amendment to the Loan and Security Agreement (&#8220;Loan Amendment No. 4&#8221;). The Company currently has $50.0 million outstanding under the Loan and Security Agreement, which was drawn down in two equal tranches. The third $25.0 million tranche is available at the Company&#8217;s discretion through December 2024, upon achievement of certain clinical and business milestones, which were amended under Loan Amendment No. 4. The fourth $25.0 million tranche may be available through June 1, 2025 (or through December 1, 2025 upon achievement of certain business milestones) upon the Company&#8217;s request, at Oxford and SVB&#8217;s discretion. Amendment No. 4 also extends the interest-only payment period for an additional six months through May 2025, with principal payments to commence in June 2025. Additionally, upon achievement of certain business performance milestones, which were achieved in October 2024, the interest-only payment period was extended through November 2025, with principal payments to commence in December 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805623472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">11. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company calculates basic net loss per share by dividing net loss by the weighted average number of common shares outstanding, excluding restricted common stock. The weighted average number of common shares used in the basic and diluted net loss per share calculation includes the pre-funded warrants issued in connection with the Company&#8217;s November 2020 and June 2022 follow-on offerings as the pre-funded warrants are exercisable at any time for nominal cash consideration. As of September 30, 2024, 10,681,528 pre-funded warrants have been exercised and 17,008,164 pre-funded warrants remain outstanding. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,386,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,081,607</p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,670,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,422,412</p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,157,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,459,181</p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,214,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,963,200</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035808620736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">12. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On October 8, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler &amp; Co., as representatives of the several underwriters named therein (the &#8220;Underwriters&#8221;), relating to the issuance and sale of an aggregate of 10,265,488 shares of the Company&#8217;s common stock at $28.25 per share and pre-funded warrants to purchase 353,983 shares of its common stock. The offering price per pre-funded warrant was $28.2499, which equals the per share public offering price for the common shares less the $0.0001 exercise price for each such pre-funded warrant. The pre-funded warrants are exercisable at any time and only expire when exercised in full. The offering closed on October 10, 2024. Pursuant to the Underwriting Agreement, the Company also granted the Underwriters a 30-day option to purchase up to 1,592,920 additional shares (the &#8220;Option Shares&#8221;) of common stock, which was exercised in full on October 16, 2024. Total proceeds of the transaction, including the Option Shares were approximately $324.4 million, net of underwriting discounts and estimated offering expenses. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035807295312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (64,479)<span></span>
</td>
<td class="num">$ (58,508)<span></span>
</td>
<td class="num">$ (56,853)<span></span>
</td>
<td class="num">$ (42,359)<span></span>
</td>
<td class="num">$ (37,925)<span></span>
</td>
<td class="num">$ (39,379)<span></span>
</td>
<td class="num">$ (179,840)<span></span>
</td>
<td class="num">$ (119,663)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035888255040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035888187792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,598</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,407</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,612</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,210</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Unaudited Interim Financial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The consolidated financial statements of the Company included herein have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). The unaudited consolidated financial statements include the accounts of Scholar Rock Holding Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full&#160;year or any other interim period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;)</i>. The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under previous GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. In November 2019, the FASB deferred the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. Therefore, the new standard was effective for the Company on January 1, 2023. The Company established processes and internal controls to comply with the new credit loss standard and related disclosure requirements. The Company&#8217;s investment policy has primary objectives of preservation of capital and maintenance of liquidity. As a result, the Company typically invests in money market funds, U.S. treasury obligations and government agency securities. The Company believes that such funds are subject to minimal credit risk. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these investments. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued Accounting Standards Update 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2017-07&#8221;). The standard requires disclosure of incremental segment information on an annual and interim basis and allows for multiple measures of a segment&#8217;s profit or loss provided that one of those measures is consistent with GAAP. The amendments in this update do not change how a public company identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments, but rather requires public entities to provide in interim periods all disclosures about a reporting segment&#8217;s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for interim periods starting on January 1, 2025. The option for early adoption is permitted, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures in future years as a result of the adoption of ASU 2023-07.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2023, the FASB issued Accounting Standards Update 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </i>(&#8220;ASU 2023-09&#8221;), which enhances the transparency of income tax disclosures to provide information to investors to better assess how a company&#8217;s operations and related tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This requires public entities to disclose additional categories in the rate reconciliation regarding federal and state income taxes, and provide more details surrounding reconciling items if a quantitative threshold is met. The effective date for public companies is for annual periods starting on January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">available for issuance, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures will be in future years as a result of the adoption of ASU 2023-09.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for unaudited interim financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035888236032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,598</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,407</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,612</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,210</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035898761984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of summary of the assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following tables summarize the assets and liabilities measured at fair value on a recurring basis at September 30, 2024 and December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. treasury obligations, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. treasury obligations, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035898930144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s investments as of September 30, 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities available-for-sale:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,674</p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total available-for-sale securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,674</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s investments as of December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities available-for-sale:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total available-for-sale securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035904403936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024 and December 31, 2023, prepaid expenses and other assets consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,059</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,281</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,076</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 635</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid professional and consulting expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,256</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of other long-term assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,074</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 312</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,417</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035888245680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024 and December 31, 2023, accrued expenses consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,825</p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,591</p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and consulting expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,267</p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 766</p></td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,449</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805199888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of allocation of equity-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.38%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,341</p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,850</p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,191</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Summary of unrecognized equity-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrecognized Expense (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Remaining Period of Recognition (years)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted Stock Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.6</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of stock activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:9pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,089,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.92</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,126,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.52</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (649,559)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.38</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,956)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.42</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,386,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.82</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,300,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,299</p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,835,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (94,988)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (371,557)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,670,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,967</p></td></tr><tr><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,831,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,310</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions in fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.09 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.87 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years to liquidity)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.00 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.12 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">91.15 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90.54 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (i)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035888193984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of lease costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other information related to the Lease is as follows (in thousands, except lease term and discount rate):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease Cost:</b></p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease cost</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Variable lease cost</p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ffffff;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows used for operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Weighted average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035895989936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of anti-dilutive securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,386,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,081,607</p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,670,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,422,412</p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,157,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,459,181</p></td></tr><tr><td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,214,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,963,200</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035807534288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64,479)<span></span>
</td>
<td class="num">$ (58,508)<span></span>
</td>
<td class="num">$ (56,853)<span></span>
</td>
<td class="num">$ (42,359)<span></span>
</td>
<td class="num">$ (37,925)<span></span>
</td>
<td class="num">$ (39,379)<span></span>
</td>
<td class="num">$ (179,840)<span></span>
</td>
<td class="num">$ (119,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (856,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (856,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (676,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">$ 827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common shares, net of issuance costs</a></td>
<td class="nump">$ 324,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805833408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 76,391<span></span>
</td>
<td class="nump">$ 101,855<span></span>
</td>
<td class="nump">$ 67,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="nump">2,407<span></span>
</td>
<td class="nump">2,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">$ 78,798<span></span>
</td>
<td class="nump">$ 104,262<span></span>
</td>
<td class="nump">$ 70,210<span></span>
</td>
<td class="nump">$ 105,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805848768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">U.S. Treasury obligations and government agency securities</a></td>
<td class="nump">$ 62,674<span></span>
</td>
<td class="nump">$ 178,083<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">133,634<span></span>
</td>
<td class="nump">270,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">70,960<span></span>
</td>
<td class="nump">61,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">U.S. Treasury obligations and government agency securities</a></td>
<td class="nump">62,674<span></span>
</td>
<td class="nump">178,083<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">133,634<span></span>
</td>
<td class="nump">270,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 70,960<span></span>
</td>
<td class="nump">61,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Treasury obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,765<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035807604928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 62,546<span></span>
</td>
<td class="nump">$ 177,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">62,674<span></span>
</td>
<td class="nump">178,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value of marketable securities with unrealized loss, less than a year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of investments with unrealized loss, less than a year | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 62,546<span></span>
</td>
<td class="nump">$ 177,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 62,674<span></span>
</td>
<td class="nump">$ 178,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035807356320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent', window );">Prepaid external research and development expense</a></td>
<td class="nump">$ 8,876<span></span>
</td>
<td class="nump">$ 4,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">2,706<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Receivables</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_PrepaidProfessionalConsulting', window );">Prepaid professional and consulting expense</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">13,862<span></span>
</td>
<td class="nump">8,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Other long-term assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent', window );">Prepaid external research and development expense</a></td>
<td class="nump">3,397<span></span>
</td>
<td class="nump">4,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Prepaid other</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_PrepaidInsuranceNoncurrent', window );">Prepaid insurance</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other long-term assets</a></td>
<td class="nump">$ 3,809<span></span>
</td>
<td class="nump">$ 4,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid external research and development expense as of the balance sheet date. Used to reflect the current portion of the asset (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid external research and development expense as of the balance sheet date. Used to reflect the noncurrent portion of the asset (due after one year or outside the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_PrepaidInsuranceNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits after a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_PrepaidInsuranceNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_PrepaidProfessionalConsulting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for professional and / or consulting within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_PrepaidProfessionalConsulting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035888191312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_AccruedExternalResearchAndDevelopmentExpense', window );">Accrued external research and development expense</a></td>
<td class="nump">$ 15,040<span></span>
</td>
<td class="nump">$ 6,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">9,969<span></span>
</td>
<td class="nump">10,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting expense</a></td>
<td class="nump">3,420<span></span>
</td>
<td class="nump">2,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 29,260<span></span>
</td>
<td class="nump">$ 20,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_AccruedExternalResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued external research and development expense as of the balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_AccruedExternalResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035800887184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 10, 2024</div></th>
<th class="th"><div>Oct. 08, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srrk_PreFundedWarrantMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,510,205<span></span>
</td>
<td class="nump">2,179,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of pre-funded and common warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,526,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,008,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srrk_PreFundedWarrantMember', window );">Pre-funded warrants | Aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of pre-funded and common warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,681,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srrk_CommonWarrantMember', window );">Warrants, non pre-funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,459,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of pre-funded and common warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">830,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,157,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=srrk_AtMarketOfferingMember', window );">ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=srrk_AtMarketOfferingMember', window );">ATM Offering | Aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares, net of issuance costs (in shares)</a></td>
<td class="nump">1,592,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=srrk_UnderwritingAgreementMember', window );">Underwriting agreement | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,265,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period on exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=srrk_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=srrk_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srrk_AggregateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srrk_AggregateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=srrk_CommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=srrk_CommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=srrk_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=srrk_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=srrk_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=srrk_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035807603552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 9,650<span></span>
</td>
<td class="nump">$ 7,203<span></span>
</td>
<td class="nump">$ 27,126<span></span>
</td>
<td class="nump">$ 20,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">4,398<span></span>
</td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">11,980<span></span>
</td>
<td class="nump">8,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 5,252<span></span>
</td>
<td class="nump">$ 4,345<span></span>
</td>
<td class="nump">$ 15,146<span></span>
</td>
<td class="nump">$ 11,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805592688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Unrecognized Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 75,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 35,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Remaining Period of Recognition</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 40,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Remaining Period of Recognition</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805753616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Restricted stock (Details) - Restricted stock units<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares/Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning (in shares) | shares</a></td>
<td class="nump">2,089,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,126,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(649,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(179,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, end (in shares) | shares</a></td>
<td class="nump">3,386,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">13.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">12.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">12.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, end (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of non-option awards vested | $</a></td>
<td class="nump">$ 8.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805811984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Stock Options (Details) - Employee Stock Option<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning (in shares) | shares</a></td>
<td class="nump">7,300,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,835,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(94,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(371,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end (in shares) | shares</a></td>
<td class="nump">9,670,164<span></span>
</td>
<td class="nump">7,300,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, end (in shares) | shares</a></td>
<td class="nump">4,831,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">13.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">5.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">19.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end (in dollars per share)</a></td>
<td class="nump">14.47<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, end (in dollars per share)</a></td>
<td class="nump">$ 16.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">6 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning | $</a></td>
<td class="nump">$ 52,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, end | $</a></td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">$ 52,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable | $</a></td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035888177376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Assumptions (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used in determining the fair value of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.09%<span></span>
</td>
<td class="nump">3.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years to liquidity)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">91.15%<span></span>
</td>
<td class="nump">90.54%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035800892064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="nump">$ 5,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,077<span></span>
</td>
<td class="nump">6,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=srrk_BinneyStCambridgeMaMember', window );">301 Binney St, Cambridge MA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Leased assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend the term</a></td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_LesseeOperatingLeaseBaseRent', window );">Base rent</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_AnnualLeaseAdjustmentPercent', window );">Annual upward adjustment (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveToLessee', window );">Incentive to lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=srrk_BinneyStCambridgeMaMember', window );">301 Binney St, Cambridge MA | First extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Leased assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_AnnualLeaseAdjustmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The annual upward lease adjustment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_AnnualLeaseAdjustmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_LesseeOperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent for initial period under the lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_LesseeOperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveToLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive granted by lessor to lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-7<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479924/842-10-30-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveToLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=srrk_BinneyStCambridgeMaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=srrk_BinneyStCambridgeMaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srrk_UponExpirationOfFirstExtensionTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srrk_UponExpirationOfFirstExtensionTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035805091536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - Loan and Security Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 17, 2024</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Oct. 16, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_InterestOnlyPeriod', window );">Interest only period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:PrimeRateMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_DebtInstrumentFinalPaymentFee', window );">Final payment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_PercentageOfDollarValueOfConsolidatedCash', window );">Percentage of dollar value of company's consolidated cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_PercentageOfOutstandingObligation', window );">Amount of cash required in a lender's account as a percentage of outstanding obligation (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term portion of loan</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod', window );">Interest additional period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=srrk_LoanAndSecurityAgreementMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_PrepaymentPenaltyPercent', window );">Prepayment penalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=srrk_LoanAndSecurityAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_PrepaymentPenaltyPercent', window );">Prepayment penalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=srrk_LoanAndSecurityAgreementMember', window );">Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=srrk_LoanAndSecurityAgreementMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=srrk_LoanAndSecurityAgreementMember', window );">Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit maximum</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=srrk_LoanAndSecurityAgreementMember', window );">Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit maximum</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_DebtInstrumentFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the final payment fee, as a percent of the aggregate advances on the debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_DebtInstrumentFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_InterestOnlyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest only period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_InterestOnlyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional period of only interest payments  in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_PercentageOfDollarValueOfConsolidatedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dollar value of company's consolidated cash as a percent, as required by the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_PercentageOfDollarValueOfConsolidatedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_PercentageOfOutstandingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash required in a lender's account as a percentage of outstanding obligation requirement as per the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_PercentageOfOutstandingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_PrepaymentPenaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment penalty as a percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_PrepaymentPenaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=srrk_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=srrk_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srrk_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srrk_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srrk_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srrk_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srrk_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srrk_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srrk_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srrk_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035810026224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Antidilutive (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of net loss per share</a></td>
<td class="nump">22,214,517<span></span>
</td>
<td class="nump">19,963,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srrk_PreFundedWarrantMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of pre-funded and common warrants (in shares)</a></td>
<td class="nump">2,526,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants (in shares)</a></td>
<td class="nump">17,008,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srrk_PreFundedWarrantMember', window );">Pre-funded warrants | Aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of pre-funded and common warrants (in shares)</a></td>
<td class="nump">10,681,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of net loss per share</a></td>
<td class="nump">3,386,857<span></span>
</td>
<td class="nump">2,081,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of net loss per share</a></td>
<td class="nump">9,670,164<span></span>
</td>
<td class="nump">7,422,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srrk_CommonWarrantMember', window );">Warrants, non pre-funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of net loss per share</a></td>
<td class="nump">9,157,496<span></span>
</td>
<td class="nump">10,459,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period on exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=srrk_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=srrk_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srrk_AggregateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srrk_AggregateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srrk_CommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srrk_CommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46035807498064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 10, 2024</div></th>
<th class="th"><div>Oct. 08, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">$ 827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,594<span></span>
</td>
<td class="nump">68,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Underwriting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,265,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase preferred stock converted into warrant to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Underwriting agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.2499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Underwriting agreement | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares, net of issuance costs (in shares)</a></td>
<td class="nump">1,592,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=srrk_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=srrk_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=srrk_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=srrk_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1S!@:!O/[%0\AI7/H5'?D+-?</;/[)F"PER3C6'5[6CV6M$PT3:D4=80<%
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M]LW3+&Q*6"8A<E82<E,AU+M+_L*2-27,&JEV\:7&\:MVR<8UJYIRE@F(G)6
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M'/#E0:-OVMJZX"9V::.$]&>MPPH%*'8#3K> 4R_@[TPJD6>*K9N "UUJCV@
M^\/^A-$>-@0[ H+^<K:KI^#5S8%BHO3,SDV@O2%/8-I#Z; *!DN(=G@2/6,)
M>< A1\-)$2%]>+8=00B2@>Z).DY#SR.U(J?7>=%V3R>SH5>EMM>*MI]T1V[(
MSVZG6<8;36:@I@^&.IP)$WM"P+A/:@XK$D1#H]*1&O*SF@8H&M81AA.@S56Z
MZ4:PC]!A!H,@'8#841KR<UJ_GSU.H <G5IN>(AA8Q;2MX@ F T@[%D-^&INO
MN%#K+K%@U\XVZX_PXMGM($1"!G@.=42'_$QWL2<8=A:L,R-OK!=G9#-B,C3)
M.T)$?D;<EQ=/Y6-S'$E)W)=!+C,<[\RT?:P=%R(_&7[9$DVM)Y/92?(EX"]:
M C8/(AA$?>GA, M(BMWX<4>7V$^7'?ZA)8!M @PA3/L\Z3 +DB@9F-RX(TK\
M'*)\8A)@FP735,^"/D;;+ F3(3+'._L_+RU-9[PL<V7DY5K!9[PRH\^J3.,%
M;[]QQ4#ZS@G\?_ =<.X)?S_0?O(=9V+B%0ISQ;/;%2\63,B_6J&M'MQ[8"_W
MOG@3_$K1]K/NB!C[B5COW)9,-Z@%D";_,7@##R%$6C@(H'?$#7L/$!Q#V/X!
MN:+"[.X:I2DG_Y<MWH.*/S[-I324WF[]&B65OC"M@RHP9[5BY;5N[H^'':W5
M&<LV3YUG&)MJ>_&_9&;]?J#]&G=* ON5A%E6NJ$.%IA ;X43_4V"QB$)VZK%
MX3B-TW&0AD\57IH>_MS:CX$.5;/V^+!P-GCLV(+WQ9C#)A[8I.-.WV"_OCE=
M+')#2;I_FE.&@[S2&[8ZU_W4"=,6)RD)<6 U>H<=1$$\0*6XDS'8+V.TMFW*
MIJ!F8[DY ^&EGE,K<\I[QT!>Z7NG),>V"D$XZ>.VC0;ILY,JV"]5=C$OV#+/
M<C>'VNKC( DC'/65KLLPBJ, #U6W$RK8+U36/"H=S=H)V%8;>O>9]D6)PPSC
M$*,!:4XZ64+\LL1B_7;Q/1?])OC>D:)K\^RP<VZ>)SL'XN;7B*]4W.25U.IN
MJ1WA8:P+(-8'_.L;Q>OVC/R:*\7+]G+%J(9M#/3W2ZXEP>;&'+MO?V:9_@=0
M2P,$%     @ BSIL655Z_AC0 @  T@D  !@   !X;"]W;W)K<VAE971S+W-H
M965T,RYX;6RMEO]SFC 8QO^5'-OMMKM. HAHI]Q9==?>=:U7N^WG%%XE5R L
MB=KMKU\"R*3BM][\09/P/D\^#P:2_IKQ9Q$!2/22Q*D8&)&4V:5IBB""A(@6
MRR!55^:,)T2J+E^8(N- PER4Q*:-<<=,"$T-OY^/3;G?9TL9TQ2F'(EEDA#^
M^PIBMAX8EK$9>*"+2.H!T^]G9 $SD-^S*5<]LW():0*IH"Q%'.8#8VA=CBRL
M!7G%#PIKL=5&.LH38\^Z<Q,.#*R)((9 :@NB?E8P@CC63HKC5VEJ5'-JX79[
MX_XU#Z_"/!$!(Q;_I*&,!D;70"',R3*6#VQ]#64@5_L%+!;Y-UH7M:YGH& I
M)$M*L2)(:%K\DI?R1FP)K/8>@5T*[%,%3BEP\J %61YK3"3Q^YRM$=?5RDTW
M\GN3JU4:FNJ_<2:YNDJ53OJC^[O9_>W->/@X&:.KX>WP;C1!L^O)Y'&&/DX)
MAU1&(&E XD_H,WJ/3"0B-2KZIE2S:P\S*&>Z*F:R]\PT@ZR%''R!;&RW&^2C
MP_(Q!$INY7*G+C=5YBJX706W<S_G_.!-V0JS=K.9?M8N148"&!CJ81+ 5V#X
M']Y9'?RE*>E_,JOE=JK<SB%W?ZH>$^ <0J365O!\@3+"T8K$2VB*77AYN9=^
M(ZQ\W,+8ZINK[3S'JFJ@[0JT?1YHL? 06<J(<?H'PB;@PM/=0K%P\7G%?$)A
M#=NML-TW85,AELW([@[):]9#%37(3@79>1.D>L\+2=*0IHLFTLY1TD,5-5*O
M(O4.DHY8DJBW_2EKU3MIK1ZKJE%V*\KN&90G+=3NSIUR</-*/:6R1MVKJ'OG
M4^]?I[T=CB[&7<MUW%? NX6>V_-Z[9[;S&OA?YL5/I_XR*(M+4_@;JC< VYN
M;;CZM/.-\ 5-!8IAKJ2XY2D/7AP@BHYD6;X'/S&I=O2\&:E#%W!=H*[/&9.;
MCM[6JV.<_Q=02P,$%     @ BSIL6=1(;Y5L!0  '1@  !@   !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6RM66M3VS@4_2N:;&>GS%!L6;;CL"$S$+LM,X4P
MA+:?12P23VTK*RF!W5^_\H,\I!LO[.8+\>/<(YVK:^E(#)^Y^"47C"GT4N2E
MO.@ME%J>.XZ<+5A!Y1E?LE*_>>*BH$K?BKDCEX+1M XJ<L=SW= I:%;V1L/Z
MV9T8#?E*Y5G)[@22JZ*@XJ\KEO/GBQ[NO3ZXS^8+53UP1L,EG;,I4]^7=T+?
M.1N6-"M8*3->(L&>+GJ7^#S!@RJ@1OS(V+/<N4:5E$?.?U4WU^E%SZUZQ'(V
M4Q4%U3]K-F9Y7C'I?OS9DO8V;5:!N]>O[)]K\5K,(Y5LS/.?6:H6%[VHAU+V
M1%>YNN?/7UDK**CX9CR7]5_TW&+='IJMI.)%&ZQ[4&1E\TM?VD3L!&@>.,!K
M SPSP#\00-H \M86_#; ?VL+01M02W<:[77B8JKH:"CX,Q(56K-5%W7VZVB=
MKZRL"F6JA'Z;Z3@U&D]NIY-OU_'E0Q*CZ8/^N4EN'Z9H\AE-[I+[RX=K#4"7
MMS$:3V[N[I.OR>WT^D>"ODVF4_0)?9_&Z..'$_0!925Z6/"5I&4JAX[27:L:
M<&9M-ZZ:;G@'ND'0#2_50J*D3%D*Q,?=\8..>$>G9),7[S4O5UXGX90MSQ!Q
M3Y'G>C[0G_';PPDDY_^UGOSGUO>2039%0FH^<H!OLF2"JJR<(_:B9RC)Y#DT
MQ V)#Y-4,]ZY7-(9N^CI*4TRL6:]T>^_X=#] \KO,<GB8Y(E1R+;&PE_,Q)^
M%_OH7C-2,5L@_9GI^7"M)_JEGK85-!P-4U@S5>O%>N1'?3P8.NO=/-LHXA+2
MWT?%-@H3'T?!/BRQ85$X(-LF]S0'&\U!I^8OK-3EE]>2::KGP$RJJAS7#%+=
M< 6[/0W=$!NJ 10AQ) 3VR@_"K!GB+91)"359PN)#C>BPT[1#UQIR=SZ\"#)
MH=6!T.]'KB'91ODD[!MB8AN%(R\<&/60 #"/>"&!1?<WHON=HK]Q*=&3X,6K
M<%Z"@OM6ZY\@Q0 ,D@S 0,T0KD-TM!$==8J>J 43>OF<\8*AC^TXGYRBDH%?
M=617FVM6MXW!!!-#M@WRHL#4#+06NBXL>+ 1/.@4?*OM;ZY'&E(WL"80/;)^
MWYRT )COD<" Q0 ,]P>1;Q1* N'P(#PTLMC=FBOW35*1+F<D%U2PT\K69C/T
M4?NEE.<Y%3LO3T#CU#01[?;./0M#(R4P+#!''8+AL\A@2V"8?V FQSMN$[\[
M(6F6KQ1+WY,2_+:4@# [)0 ,2@D(.Y@2;YL2KS,E/^N]C-9/UWK.FS.D)X)"
M;Z%J^1+IS9U4>NG3B\!N[31OX>QXUD<[Z+N!&YJK^AA 1JY>+7T2F3D".,-
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M^7!IUHOH73V?':NVG-<W\[Y>>+0F(UK3Z>WR=E'WS2QZVU\WZTBU38W3ZV$
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M8ZV]F0\V-W:TCH;59AIG2NA?F1ZGIN=77V97GS]=G'U[?P%FW_2_R_=?OLW
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MI*#"&.C?YYRKS1=S@^W[&]/_ %!+ P04    " "+.FQ9GEA6S1(-  !U(
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M7-Q(I+L"+"'S^&1U((>+51U!*0Y/WGVVZR"D:H!"9%;>;7$T&$+XX"S(:GI
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M>LP93\N&Z;D42TZG]HO-Z%Z[6[U6?N6IH6QFEG+1I^S3O._URWNQU"LPBK*
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M9!!*+C(&]SBK6:BITKC8,&J;?&B\!R%.06F-6_(-)4OHUZ+44'AV &5I]+W
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MXD\%65Z ]RL#I/V -]C]33G["U!+ P04    " "+.FQ9N@] 3@L&   I$P
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M0H+#2:0Y9*]L@L -4X+=UPR8H?&3S,GBR3V:*-BO[R,)$#IABNI8N#&<TL$
M#1#%%1:LF7;+RK@%F3V* DE6K15%(PR></.3#B-]0!ZDB.>*E25BWKV7 <^
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M'4R+(V&;7*9Y=W/(OA*I6).WX*GIF$9 S]]5$:J19_B>=PBH=P_-7$EC';N
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M];'R;K_WH?0@(Q_=]GC:2 +P6LUJ>]CM7^E1^UX/*OS=N'G(V"7O08O[K=9
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M5%^$W4C*5N&:7)/>9!2!;:XIS8<WVW U6!E/%XWP6M+-#BT;T/S:T!)J/SC
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MG SPQGVY8\<;7^"=*_,&[5_1FA-ZH*3&[%S5+71R'FJ_FX6J< JQ9SX,!?(
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M:7#\*)8+G/= 60'<GTMI-H0U4$V0X]]02P,$%     @ BSIL6>K7Q-XL P
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M#%&?\_5 \=*<K2NN\*0VGRE>C4!H!_R?<*YV YV@O6S-?@%02P,$%     @
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M#6IC2F*(PMCQ/'^+8S?K"3ZMM "YA8SG1'%B$=J!3F/<3!^Z-!+P9 AX\M2
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M[K\4]-N^?(T^\;][BP#:4(9J%E2SH9H#U5RHYD$U'ZH%*$TLE;;KK)F7[C!
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M9L!K&BD[TG+ <"%;KB5FO(&3MS'OXA$1 OSY&F-V& @#]?\"T[]02P,$%
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MP9J6J;KCN\_0$)H8O(2GLOI%NWIN%#DH*:7B61.L*\A87O_3IV8A#@(TSG
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MZ@)XO5Z]WI%L7:VO?F92LKS:7%&BOK:7#=3Y!6-RMU,F:/\U,/T?4$L#!!0
M   ( (LZ;%D3U1EB1P,  / 4   -    >&PO<W1Y;&5S+GAM;-U876_:,!3]
M*Y&[3JTT-4#:0%9 VI J3=JF2NW#WBI#'+#DV)EC.MBOGV\<PD=]$>O#"@NB
ML>_).??8ODE<^J59"O8P8\P$BUS(<D!FQA0?P["<S%A.RRM5,&F13.F<&MO5
MT[ L-*-I":1<A)U6*PYSRB49]N4\O\M-&4S47)H!Z3:AP)V^I /2CJ])X.1&
M*F4#\G3Q_N=<F=MW@3N??3@[:SU=WN[&+RK@DH1>T9L#1*]:+5P80$P\/DQ\
MGS8FW3U(>H\R)MS;%E[Y.+=2C:ESC)QXR&LF1NNV#ER$_:O@AA36Q33L9TJN
M:RHB+F#STYP%SU0,R(@*/M8<6!G-N5BZ< <"$R64#HPM9FNH#9'RMX/;K@=U
M7NOD7"I=Y789W-]Q??D.L.J!02Y$8[!#7&#8+Z@Q3,L[VZDNKH(OH*!N/RX+
MZW"JZ;+=N2%K0G6R2<9*ITPW:=ID%1KV!<O CN;3&9R-*D( C5&Y;:2<3I6D
ME8<5HVY8V0D3X@$> C^R+>U%MK&RU;K*IFD-U4TGXSJ@OZGFM#=EKU^E&Q3\
M69G/<SL<6?6A7-B]9AE?5/U%UAC U-NX.BT*L?PD^%3FS W^X(3#/EWQ@IG2
M_+?-!J4RL0&F2?#,M.&3S<@O38M'MC"K<EIDN.?."7K^M_,\99)I*C9-V]H_
MYEE^M>.H^U:6JZ?*KF&OQ_K-?NPF;T[!9'P*)D^@)J/D^#W6>[5C-WD*,]E]
MLR?[7I-AO1/:V&YM;;::: ";V@'Y#IMHL4X:C.=<&"[KWHRG*9,O]EQ6WM"Q
M_7=N2]]>G[*,SH5Y;, !6;>_L93/\Z2YZAXFHKYJW?X*PVO'S8[:YN(R90N6
MCNJNGHZK9F ;-FM] &$7N:L./X)Q'.9' ,/R8 XPCF-A>?ZG\?30\3@,\];S
M(CV4TT,YCN5#1M4'R^/G)/;PCS1)HBB.L1D=C;P.1MB\Q3%\_6J8-V!@>2#3
MW\TUOMIXA>RO VQ-]U4(-E*\$K&1XG,-B'_>@)$D_M7&\@ #6P6L=B"_/P_4
ME)\31;"JF#?L#L:1),$0J$5_C<8Q,CLQ?/SK@]TE490D?@0POX,HPA"X&W$$
M<P >,"2*JO?@SOLH7+VGPO5OG,,_4$L#!!0    ( (LZ;%F7BKL<P    !,"
M   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8
M$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*N
MU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I
M2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3
MZ:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ BSIL604:
M:N83!   .!X   \   !X;"]W;W)K8F]O:RYX;6S%F5UOVCP4@/^*E:N^%QWD
MH]U6C4D4TA6I ]3P]G8RB2E6$YO93KONU^\D&9HSV-%NSK@*<1SSY#CV<V)_
M>-'F::WU$_M6E<J.@JUSNZO!P.9;47'[1N^$@BL;;2KNX-0\#NS."%[8K1"N
M*@?1<'@YJ+A4P<</^[:69N"?:"=R)[6"PJ;@08H7^^MZ<\J>I95K64KW.@K:
MWZ4(6"65K.1W48R"8<#L5K_<:B._:^5XF>5&E^4H"+L+#\(XF1\49PWDBJ]M
M6^+X^IX#R"BX'$*#&VFL:VNT[7-@?!90N3NKG;Z1I1-FRIWX9'2]D^JQ:0:>
M8N ]1AN'_;$+XI7YFS#JS4;F8JKSNA+*=7$THFP E=W*G0V8XI48!?LJC*N"
MI<I!D-A,=4U!W>9)X:]G1??4#G"]&)HK"1?,K&C!Z2 GBWFVN)M-QZMTRJ['
M=^/Y)&79;9JN,@\P0@"CDP&RLR7W(&,$,OZ'D-D*#I_3.0 N;MABF=Y[D D"
MF9P,,ELM)A[D!0)Y<3+(R3B[]2 O$<A+6L@Y=[413&^8VPIV75NIA+4>VUN$
M[2TM6U97%3>O#5PF'Y6$VSC,0>,\US7,01[D.P3R'2WD#9>&/?"R;H-X(Q57
MN>0E&UL+DS+S(-\CD.]I(3]S\R3 /:5@F<AK(YT4?B>'0VS:'M+"+8W8<0E>
M^0:-6&%;R2S@=31M$'U,U"[$>H'7SM3B%Z;/A4DEI+:*KBJM6.9T_N0S80X)
MB262?JTA13B_YA8"!H!-Q XR!<P?(;5 (&C2-96ZUVT"&1TD5P+&;K]G,7^$
MQ *9BK7S63!-A-2>@';OM+5L!\,RVW+3&Y>8)$)R2ZRM^%HWV6GZW'2H#X:)
M(20VPY*_LF?+EL*TMZM<L*FT>:EMW8\>)H:0V PS964!7;HRO( !P,;&<!@'
MU6^!C#!!1,2"0/. +Y&/B0DB(A8$CAG[F.A'"+$OT(2E'TU,(1&Q0HZF+.QL
MU938_WQ*S",1L4?0W*4?3,PD$;%)?L]=CL81TTM$K)<_)@P=J8^)N28B=@V:
M-K S'Q,S3T1LGD-9'^UPS#L1L7>.?W>RLRF,>5GZZHDQ]<0G54_B8V+JB8G5
M@\_IOGIB3#TQL7J.S^GG[&>4?4QT!8Q8/?BDWHLFYIZ8V#V'D_K/P>,/\AC3
M3DR] N9]FD(W'^7#K!.?S#KG351]3,PZ,;%U,,S_E?$Q,>O$Q-;!,.][7]4Q
M9IZ8V#P8)KRI_@(W9IZ$V#P8YKBW0IM@YDFH-UVPC*B7 ">8>1)B\S1+*4?G
MGP0334(LFB-Y&G0N!+"09=U;X$[0S19BT1RLL!R/)&::I#7-8+]368@-Y'O%
M')JW4)[S,E\:UARZY=3DHED4V=1E.8&RA;K3O-AO?.XW;3_^ %!+ P04
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M_'=2G6[WAN?C[\O'R<X+=<?9P>^QQ2]02P,$%     @ BSIL65/9*RFR 0
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MD?5E_Q%/CD'ZZO-1.^V,LE]ZA^O]T';5S<.Q;KG^CK_.^*1_80X!DD."Y$A
M<MR Y)B Y+@%R7$'DN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'
M(:M (:M (:M (:M (:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$
M(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:P)"ED3%+(F*&1-_I.L[UJO_OHW3[O&
MM2J;HS_K_J7-/P%02P$"% ,4    " "+.FQ9!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (LZ;%F9
MDPWJ[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( (LZ;%F97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ BSIL66OV8SC0!0
MZ1X  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( (LZ;%FW64 M&@8  '(9   8              " @1,.
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "+.FQ957K^
M&- "  #2"0  &               @(%C%   >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ BSIL6=1(;Y5L!0  '1@  !@
M ("!:1<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( (LZ
M;%GBQ6OCG0X  *"5   8              " @0L=  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " "+.FQ9:FUU[5,'  #+(0  &
M        @('>*P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ BSIL69Y85LT2#0  =2   !@              ("!9S,  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( (LZ;%F_C30L>0<  !P3   8
M              " @:]   !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " "+.FQ9>5<[6;<$   W$   &               @(%>2   >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ BSIL60YOB8&D P
M*0P  !D              ("!2TT  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " "+.FQ90V"7UQ #  !B"0  &0              @($F
M40  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( (LZ;%DH
M3?*NO0(  /,&   9              " @6U4  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ BSIL6:V-OHQ+!0  L@P  !D
M     ("!85<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (LZ;%F$M8Y"&@0  ',)   9              "
M@7%U  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ BSIL
M6:TUOO7K @  50L  !D              ("!PGD  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " "+.FQ9]5F_0T,"  "*!@  &0
M        @('D?   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( (LZ;%E4";=#*@<  ) 2   9              " @5Y_  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ BSIL69U/>UNO @  ;08
M !D              ("!OX8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " "+.FQ9 '%*>54#  !D#   &0              @(&EB0
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( (LZ;%F4;D P
M  ,  $T*   9              " @3&-  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ BSIL6>K7Q-XL P  > D  !D
M ("!:)   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "+
M.FQ90Q]#<,<"  #S!@  &0              @('+DP  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( (LZ;%F!_G&W404  &<1   9
M          " @<F6  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#
M%     @ BSIL68ZGR!H) P  3 @  !D              ("!49P  'AL+W=O
M<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "+.FQ9ZJ P@HP"  #@
M!0  &0              @(&1GP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM
M;%!+ 0(4 Q0    ( (LZ;%FPFF+"]0,  /<6   9              " @52B
M  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ BSIL6:>S
ME86Y @  $0D  !D              ("!@*8  'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6Q02P$"% ,4    " "+.FQ9RGTKY\L#  "M$P  &0
M    @(%PJ0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M (LZ;%F]<?9LA0,  *8-   9              " @7*M  !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ BSIL6;]K%'A8 P  $PP  !D
M             ("!+K$  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " "+.FQ9Z8B]=ZD"  "M!P  &0              @(&]M   >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( (LZ;%E9;Q5PC @
M ,-G   9              " @9VW  !X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ BSIL6344WAMA P  (Q   !D              ("!
M8,   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "+.FQ9
MKBRV*>T"  #:"0  &0              @('XPP  >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( (LZ;%EL%%'W?@,  )$+   9
M      " @1S'  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ BSIL67LZ['+G!   %A<  !D              ("!T<H  'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "+.FQ9#?)(R>D"   '"
M&0              @('OSP  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( (LZ;%D']?*Q(P4  /<>   9              " @0_3  !X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ BSIL6</(F=U_
M!@  LS(  !D              ("!:=@  'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " "+.FQ9FY3A91($  #K%   &0
M@($?WP  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( (LZ
M;%G1&<;-G@4  $$P   9              " @6CC  !X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ BSIL61/5&6)' P  \!0   T
M         ( !/>D  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "+.FQ9EXJ[
M',     3 @  "P              @ &O[   7W)E;',O+G)E;'-02P$"% ,4
M    " "+.FQ9!1IJYA,$   X'@  #P              @ &8[0  >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ BSIL6;@VQ-RI 0  +AL  !H
M     ( !V/$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ BSIL65/9*RFR 0  4QL  !,              ( !N?,  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #4 -0!J#@  G/4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>145</ContextCount>
  <ElementCount>230</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Prepaid Expenses and Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets</Role>
      <ShortName>Prepaid Expenses and Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureEquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureMarketableSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Prepaid Expenses and Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureEquityBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Nature of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails</Role>
      <ShortName>Nature of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureNatureOfBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Fair Value of Financial Assets and Liabilities - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Marketable Securities - Summary of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails</Role>
      <ShortName>Marketable Securities - Summary of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Common Stock - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureCommonStockDetails</Role>
      <ShortName>Common Stock - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureCommonStock</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Equity-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - Equity-Based Compensation - Unrecognized Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Unrecognized Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - Equity-Based Compensation - Restricted stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails</Role>
      <ShortName>Equity-Based Compensation - Restricted stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940804 - Disclosure - Equity-Based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940805 - Disclosure - Equity-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureDebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureDebt</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Net Loss per Share - Antidilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails</Role>
      <ShortName>Net Loss per Share - Antidilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="srrk-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scholarrock.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>srrk-20240930.xsd</File>
    <File>srrk-20240930_cal.xml</File>
    <File>srrk-20240930_def.xml</File>
    <File>srrk-20240930_lab.xml</File>
    <File>srrk-20240930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="srrk-20240930x10q.htm">srrk-20240930x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>srrk-20240930x10q004.jpg</File>
    <File>srrk-20240930x10q005.jpg</File>
    <File>srrk-20240930x10q006.jpg</File>
    <File>srrk-20240930x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="496">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "srrk-20240930x10q.htm": {
   "nsprefix": "srrk",
   "nsuri": "http://www.scholarrock.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "srrk-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "srrk-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "srrk-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "srrk-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "srrk-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "srrk-20240930x10q.htm"
     ]
    }
   },
   "keyStandard": 211,
   "keyCustom": 19,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 16,
   "memberCustom": 12,
   "hidden": {
    "total": 14,
    "http://fasb.org/us-gaap/2024": 9,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 145,
   "entityCount": 1,
   "segmentCount": 33,
   "elementCount": 456,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 496,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q6t-2V68bkiFrfajlGSBeg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JwQxc0pT8kKm0ykun0RF7w",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.scholarrock.com/role/DisclosureNatureOfBusiness",
     "longName": "995210101 - Disclosure - Nature of the Business",
     "shortName": "Nature of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities",
     "longName": "995210301 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.scholarrock.com/role/DisclosureMarketableSecurities",
     "longName": "995210401 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets",
     "longName": "995210501 - Disclosure - Prepaid Expenses and Other Assets",
     "shortName": "Prepaid Expenses and Other Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.scholarrock.com/role/DisclosureAccruedExpenses",
     "longName": "995210601 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.scholarrock.com/role/DisclosureCommonStock",
     "longName": "995210701 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "srrk:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "srrk:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.scholarrock.com/role/DisclosureEquityBasedCompensation",
     "longName": "995210801 - Disclosure - Equity-Based Compensation",
     "shortName": "Equity-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995210901 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.scholarrock.com/role/DisclosureDebt",
     "longName": "995211001 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.scholarrock.com/role/DisclosureNetLossPerShare",
     "longName": "995211101 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.scholarrock.com/role/DisclosureSubsequentEvents",
     "longName": "995211201 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables",
     "longName": "99930303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesTables",
     "longName": "99930403 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables",
     "longName": "99930503 - Disclosure - Prepaid Expenses and Other Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.scholarrock.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930603 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables",
     "longName": "99930803 - Disclosure - Equity-Based Compensation (Tables)",
     "shortName": "Equity-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "99930903 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.scholarrock.com/role/DisclosureNetLossPerShareTables",
     "longName": "99931103 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails",
     "longName": "99940101 - Disclosure - Nature of the Business (Details)",
     "shortName": "Nature of the Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails",
     "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)",
     "shortName": "Summary of Significant Accounting Policies - Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails",
     "longName": "99940301 - Disclosure - Fair Value of Financial Assets and Liabilities - (Details)",
     "shortName": "Fair Value of Financial Assets and Liabilities - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yUXtseVKLEmLijTO5Hn_0g",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yUXtseVKLEmLijTO5Hn_0g",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails",
     "longName": "99940401 - Disclosure - Marketable Securities - Summary of Investments (Details)",
     "shortName": "Marketable Securities - Summary of Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails",
     "longName": "99940501 - Disclosure - Prepaid Expenses and Other Assets (Details)",
     "shortName": "Prepaid Expenses and Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "srrk:PrepaidExternalResearchAndDevelopmentExpenseCurrent",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "srrk:PrepaidExternalResearchAndDevelopmentExpenseCurrent",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails",
     "longName": "99940601 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "srrk:AccruedExternalResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "srrk:AccruedExternalResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
     "longName": "99940701 - Disclosure - Common Stock - (Details)",
     "shortName": "Common Stock - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_74qePC5v6kCjrygaeq4KKQ",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "srrk:CommonStockTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails",
     "longName": "99940801 - Disclosure - Equity-Based Compensation - Expense (Details)",
     "shortName": "Equity-Based Compensation - Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails",
     "longName": "99940802 - Disclosure - Equity-Based Compensation - Unrecognized Expense (Details)",
     "shortName": "Equity-Based Compensation - Unrecognized Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails",
     "longName": "99940803 - Disclosure - Equity-Based Compensation - Restricted stock (Details)",
     "shortName": "Equity-Based Compensation - Restricted stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_btXk1iwRBEitcM4l_d0v9g",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_btXk1iwRBEitcM4l_d0v9g",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails",
     "longName": "99940804 - Disclosure - Equity-Based Compensation - Stock Options (Details)",
     "shortName": "Equity-Based Compensation - Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q7G20lfZrEGGf9s5KiiN4w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails",
     "longName": "99940805 - Disclosure - Equity-Based Compensation - Assumptions (Details)",
     "shortName": "Equity-Based Compensation - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99940901 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.scholarrock.com/role/DisclosureDebtDetails",
     "longName": "99941001 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_A2Z61BQQoEaOUGpduwOO4Q",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_A2Z61BQQoEaOUGpduwOO4Q",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
     "longName": "99941101 - Disclosure - Net Loss per Share - Antidilutive (Details)",
     "shortName": "Net Loss per Share - Antidilutive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941201 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_8_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_kidvJgGpG0maEoeyfhtn0Q",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "srrk-20240930x10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r38",
      "r42",
      "r714"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r556"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization/accretion of investment securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "srrk_AccruedExternalResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "AccruedExternalResearchAndDevelopmentExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued external research and development expense as of the balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued External Research And Development Expense",
        "terseLabel": "Accrued external research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional and consulting expense",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r52",
      "r102",
      "r429",
      "r448",
      "r449"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r15",
      "r327",
      "r330",
      "r380",
      "r444",
      "r445",
      "r673",
      "r674",
      "r675",
      "r685",
      "r686",
      "r687",
      "r689"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r556",
      "r746"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r685",
      "r686",
      "r687",
      "r689",
      "r715",
      "r747"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Equity-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_AggregateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "AggregateMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for the aggregate, since inception.",
        "label": "Aggregate [Member]",
        "terseLabel": "Aggregate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r588",
      "r598",
      "r630"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r581",
      "r591",
      "r601",
      "r633"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r592",
      "r602",
      "r626",
      "r634",
      "r638",
      "r646"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Equity-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r307"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt discount and debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r253",
      "r681",
      "r726"
     ]
    },
    "srrk_AnnualLeaseAdjustmentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "AnnualLeaseAdjustmentPercent",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The annual upward lease adjustment percentage.",
        "label": "Annual Lease Adjustment Percent",
        "terseLabel": "Annual upward adjustment (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from the calculation of net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r84",
      "r100",
      "r125",
      "r154",
      "r156",
      "r157",
      "r158",
      "r192",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r320",
      "r324",
      "r358",
      "r425",
      "r479",
      "r526",
      "r527",
      "r556",
      "r569",
      "r710",
      "r711",
      "r730"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r103",
      "r125",
      "r192",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r320",
      "r324",
      "r358",
      "r556",
      "r710",
      "r711",
      "r730"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r544"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to At the market offering.",
        "label": "At Market Offering [Member]",
        "terseLabel": "ATM Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r200",
      "r424"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r200",
      "r337",
      "r418",
      "r544",
      "r547",
      "r695",
      "r719",
      "r720",
      "r721"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Marketable securities available-for-sale"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "srrk_BinneyStCambridgeMaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "BinneyStCambridgeMaMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to property located on Binney Street in Cambridge, Massachusetts.",
        "label": "Binney St Cambridge MA [Member]",
        "terseLabel": "301 Binney St, Cambridge MA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of the Business",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r62",
      "r63"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases in accounts payable &amp; accrued expenses",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r98",
      "r520"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r75"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r59",
      "r122"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r59"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrant to purchase preferred stock converted into warrant to purchase common stock",
        "verboseLabel": "Warrant to purchase (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Outstanding warrants (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r79",
      "r426",
      "r466"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r214",
      "r215",
      "r514",
      "r704",
      "r709"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r685",
      "r686",
      "r689",
      "r715",
      "r745",
      "r747"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r467"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r467",
      "r485",
      "r747",
      "r748"
     ]
    },
    "srrk_CommonStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "CommonStockTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of common stock.",
        "label": "Common Stock [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 300,000,000 shares authorized; 80,081,535 and 75,979,495 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r428",
      "r556"
     ]
    },
    "srrk_CommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "CommonWarrantMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the common warrants.",
        "label": "Common Warrant [Member]",
        "terseLabel": "Warrants, non pre-funded"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r109",
      "r111",
      "r115",
      "r419",
      "r437",
      "r438"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r124",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r220",
      "r221",
      "r231",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r247",
      "r254",
      "r255",
      "r257",
      "r366"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r37",
      "r38",
      "r77",
      "r78",
      "r126",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r554",
      "r683",
      "r705",
      "r706",
      "r707",
      "r725",
      "r727"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percent)",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "srrk_DebtInstrumentFinalPaymentFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "DebtInstrumentFinalPaymentFee",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the final payment fee, as a percent of the aggregate advances on the debt.",
        "label": "Debt Instrument, Final Payment Fee",
        "terseLabel": "Final payment fee (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r554",
      "r683",
      "r725",
      "r727"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r126",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r554",
      "r683",
      "r705",
      "r706",
      "r707",
      "r725",
      "r727"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r28",
      "r29",
      "r33",
      "r67",
      "r68",
      "r126",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r554",
      "r683",
      "r725",
      "r727"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair value of marketable securities with unrealized loss, less than a year",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r202",
      "r529"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of investments with unrealized loss, less than a year",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r275",
      "r303",
      "r304",
      "r306",
      "r541"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r143",
      "r145",
      "r147",
      "r148",
      "r149",
      "r153",
      "r315",
      "r318",
      "r334",
      "r335",
      "r420",
      "r439",
      "r523"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r145",
      "r147",
      "r148",
      "r149",
      "r153",
      "r315",
      "r318",
      "r334",
      "r335",
      "r420",
      "r439",
      "r523"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r150",
      "r151",
      "r152"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Equity-based compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted Average Remaining Period of Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r94",
      "r112",
      "r113",
      "r114",
      "r127",
      "r128",
      "r129",
      "r131",
      "r136",
      "r138",
      "r140",
      "r155",
      "r193",
      "r194",
      "r205",
      "r262",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r368",
      "r380",
      "r435",
      "r444",
      "r445",
      "r446",
      "r455",
      "r505"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r588",
      "r598",
      "r630"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r585",
      "r595",
      "r627"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial assets and financial liabilities measured at fair value on a recurring basis:",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r348",
      "r544"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r348",
      "r544"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r347",
      "r348",
      "r350",
      "r387",
      "r388",
      "r389",
      "r532",
      "r533",
      "r537",
      "r538",
      "r539",
      "r544",
      "r547"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r341",
      "r544",
      "r720",
      "r723"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets and Liabilities",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r417",
      "r544",
      "r548"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r264",
      "r269",
      "r338",
      "r348",
      "r387",
      "r537",
      "r538",
      "r539",
      "r544"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r341",
      "r544",
      "r720",
      "r723"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r347",
      "r348",
      "r350",
      "r387",
      "r388",
      "r389",
      "r532",
      "r533",
      "r537",
      "r538",
      "r539",
      "r544",
      "r547"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r723"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r203",
      "r204",
      "r256",
      "r260",
      "r332",
      "r355",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r436",
      "r529",
      "r544",
      "r545",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r557",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r697",
      "r698",
      "r699",
      "r700",
      "r716",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r592",
      "r602",
      "r634"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r592",
      "r602",
      "r634"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r592",
      "r602",
      "r634"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r592",
      "r602",
      "r634"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r592",
      "r602",
      "r634"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r489"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_IncentiveToLessee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncentiveToLessee",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive to Lessee",
        "terseLabel": "Incentive to lease",
        "documentation": "Amount of incentive granted by lessor to lessee."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r658"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r212",
      "r213",
      "r342",
      "r344",
      "r349",
      "r441",
      "r443",
      "r490",
      "r519",
      "r546",
      "r744"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r342",
      "r344",
      "r349",
      "r441",
      "r443",
      "r490",
      "r519",
      "r546",
      "r744"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r680"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r592",
      "r602",
      "r626",
      "r634",
      "r638",
      "r646"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r650"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r650"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r650"
     ]
    },
    "srrk_InterestOnlyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "InterestOnlyPeriod",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest only period.",
        "label": "Interest Only, Period",
        "terseLabel": "Interest only period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r120",
      "r121"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "U.S. Treasury obligations and government agency securities",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r722"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r160",
      "r161",
      "r356",
      "r357",
      "r739"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r555"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of lease costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "srrk_LesseeOperatingLeaseBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "LesseeOperatingLeaseBaseRent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of base rent for initial period under the lease.",
        "label": "Lessee Operating Lease Base Rent",
        "terseLabel": "Base rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Option to extend the term",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r37",
      "r38",
      "r39",
      "r41",
      "r42",
      "r43",
      "r44",
      "r125",
      "r192",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r321",
      "r324",
      "r325",
      "r358",
      "r465",
      "r524",
      "r569",
      "r710",
      "r730",
      "r731"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r80",
      "r431",
      "r556",
      "r684",
      "r701",
      "r724"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r97",
      "r125",
      "r192",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r321",
      "r324",
      "r325",
      "r358",
      "r556",
      "r710",
      "r730",
      "r731"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional period of only interest payments  in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Interest Only Payments, Additional Period",
        "terseLabel": "Interest additional period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit maximum",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r40"
     ]
    },
    "srrk_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Loan and Security Agreement.",
        "label": "Loan and Security Agreement [Member]",
        "terseLabel": "Loan and Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "terseLabel": "Long-term portion of loan",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r78",
      "r244",
      "r258",
      "r532",
      "r533",
      "r554",
      "r742"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]",
        "terseLabel": "Marketable securities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of investments",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srrk_MaximumAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "MaximumAggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r270",
      "r308",
      "r341",
      "r415",
      "r440",
      "r442",
      "r450",
      "r457",
      "r458",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r517",
      "r518",
      "r528",
      "r536",
      "r540",
      "r547",
      "r548",
      "r552",
      "r553",
      "r558",
      "r712",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r270",
      "r308",
      "r341",
      "r415",
      "r440",
      "r442",
      "r450",
      "r457",
      "r458",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r517",
      "r518",
      "r528",
      "r536",
      "r540",
      "r547",
      "r548",
      "r552",
      "r558",
      "r712",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r61",
      "r81",
      "r95",
      "r107",
      "r110",
      "r114",
      "r125",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r146",
      "r192",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r315",
      "r318",
      "r335",
      "r358",
      "r434",
      "r487",
      "r503",
      "r504",
      "r567",
      "r710"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r592",
      "r602",
      "r626",
      "r634"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash items:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NontradeReceivablesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontrade Receivables, Current",
        "terseLabel": "Receivables",
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r525",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r555"
     ]
    },
    "srrk_OperatingLeaseLiabilityAdjustmentFromRentModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "OperatingLeaseLiabilityAdjustmentFromRentModification",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect on cash flow during the period of non-cash operating lease liability, adjustment from rent modification.",
        "label": "Operating Lease Liability, Adjustment From Rent Modification",
        "terseLabel": "Operating lease liability, adjustment from rent modification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r376"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "verboseLabel": "Non-cash operating lease expense",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average incremental borrowing rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r555"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r555"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Assets",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets",
        "totalLabel": "Total other long-term assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_OtherAssetsNoncurrentDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrentDisclosureAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent Disclosure [Abstract]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized (loss) gain on marketable securities",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r435"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive income",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r7",
      "r74",
      "r108",
      "r111",
      "r136"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r556"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r703"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r590",
      "r600",
      "r632"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r593",
      "r603",
      "r635"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r593",
      "r603",
      "r635"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtRestructuringCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Restructuring Costs",
        "negatedLabel": "Debt modification payment",
        "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "srrk_PercentageOfDollarValueOfConsolidatedCash": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "PercentageOfDollarValueOfConsolidatedCash",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dollar value of company's consolidated cash as a percent, as required by the agreement.",
        "label": "Percentage Of Dollar Value of Consolidated Cash",
        "terseLabel": "Percentage of dollar value of company's consolidated cash"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_PercentageOfOutstandingObligation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "PercentageOfOutstandingObligation",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash required in a lender's account as a percentage of outstanding obligation requirement as per the agreement.",
        "label": "Percentage of Outstanding Obligation",
        "terseLabel": "Amount of cash required in a lender's account as a percentage of outstanding obligation (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "srrk_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the pre-funded warrants.",
        "label": "Pre Funded Warrant [Member]",
        "terseLabel": "Pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r259"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r467"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r259"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r467",
      "r485",
      "r747",
      "r748"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r427",
      "r556"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseOtherNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseOtherNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense Other, Noncurrent",
        "terseLabel": "Prepaid other",
        "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "PrepaidExternalResearchAndDevelopmentExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepaid external research and development expense as of the balance sheet date. Used to reflect the current portion of the asset (due within one year or within the normal operating cycle if longer).",
        "label": "Prepaid External Research And Development Expense, Current",
        "terseLabel": "Prepaid external research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "PrepaidExternalResearchAndDevelopmentExpenseNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepaid external research and development expense as of the balance sheet date. Used to reflect the noncurrent portion of the asset (due after one year or outside the normal operating cycle if longer).",
        "label": "Prepaid External Research And Development Expense, Noncurrent",
        "terseLabel": "Prepaid external research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r530",
      "r703"
     ]
    },
    "srrk_PrepaidInsuranceNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "PrepaidInsuranceNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits after a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance, Noncurrent",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_PrepaidProfessionalConsulting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "PrepaidProfessionalConsulting",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for professional and / or consulting within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Professional Consulting",
        "terseLabel": "Prepaid professional and consulting expense"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_PrepaymentPenaltyPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "PrepaymentPenaltyPercent",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment penalty as a percent",
        "label": "Prepayment Penalty, Percent",
        "terseLabel": "Prepayment penalty (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of common shares, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "verboseLabel": "Proceeds from credit facility",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Sale of shares",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r676"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from stock option exercises",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from pre-funded and common warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r107",
      "r110",
      "r118",
      "r125",
      "r130",
      "r136",
      "r139",
      "r140",
      "r192",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r315",
      "r318",
      "r319",
      "r322",
      "r323",
      "r335",
      "r358",
      "r421",
      "r433",
      "r454",
      "r487",
      "r503",
      "r504",
      "r542",
      "r543",
      "r568",
      "r675",
      "r710"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "verboseLabel": "Leased assets",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r379",
      "r422",
      "r432",
      "r556"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r263",
      "r270",
      "r298",
      "r299",
      "r300",
      "r308",
      "r341",
      "r390",
      "r399",
      "r415",
      "r440",
      "r442",
      "r450",
      "r457",
      "r458",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r517",
      "r518",
      "r528",
      "r536",
      "r540",
      "r547",
      "r548",
      "r552",
      "r553",
      "r558",
      "r561",
      "r708",
      "r712",
      "r720",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r263",
      "r270",
      "r298",
      "r299",
      "r300",
      "r308",
      "r341",
      "r390",
      "r399",
      "r415",
      "r440",
      "r442",
      "r450",
      "r457",
      "r458",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r517",
      "r518",
      "r528",
      "r536",
      "r540",
      "r547",
      "r548",
      "r552",
      "r553",
      "r558",
      "r561",
      "r708",
      "r712",
      "r720",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r585",
      "r595",
      "r627"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r519",
      "r526",
      "r738"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r586",
      "r596",
      "r628"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r587",
      "r597",
      "r629"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r594",
      "r604",
      "r636"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents and restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r668",
      "r682"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r69",
      "r430",
      "r447",
      "r449",
      "r453",
      "r468",
      "r556"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r127",
      "r128",
      "r129",
      "r131",
      "r136",
      "r138",
      "r140",
      "r193",
      "r194",
      "r205",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r326",
      "r328",
      "r329",
      "r331",
      "r333",
      "r367",
      "r368",
      "r444",
      "r446",
      "r455",
      "r747"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureDebtDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r271",
      "r656",
      "r688"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of anti-dilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Summary of allocation of equity-based compensation",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of summary of the assets and liabilities measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of other long-term assets",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r379"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r743"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions in fair value",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of stock activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Summary of unrecognized equity-based compensation expense",
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, end (in shares)",
        "periodStartLabel": "Outstanding, beginning (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares/Units",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, end (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of non-option awards vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions used in determining the fair value of options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Equity-Based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, end (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, end (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, end",
        "periodStartLabel": "Aggregate intrinsic value, beginning",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end (in shares)",
        "periodStartLabel": "Outstanding, beginning (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Units",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails",
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years to liquidity)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Sale of stock price (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end (in shares)",
        "periodStartLabel": "Balance at beginning (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt",
        "terseLabel": "Short-term debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r77",
      "r556",
      "r741"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r123"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r49",
      "r50",
      "r94",
      "r112",
      "r113",
      "r114",
      "r127",
      "r128",
      "r129",
      "r131",
      "r136",
      "r138",
      "r140",
      "r155",
      "r193",
      "r194",
      "r205",
      "r262",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r368",
      "r380",
      "r435",
      "r444",
      "r445",
      "r446",
      "r455",
      "r505"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "verboseLabel": "Disclosure",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r155",
      "r368",
      "r416",
      "r451",
      "r456",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r467",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r562"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENT OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureDebtDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r271",
      "r656",
      "r657",
      "r688"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r155",
      "r159",
      "r368",
      "r416",
      "r451",
      "r456",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r467",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r562"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r589",
      "r599",
      "r631"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period on exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "terseLabel": "Exercise of pre-funded and common warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of common shares, net of issuance costs (in shares)",
        "verboseLabel": "Sale of common shares, net of issuance costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r45",
      "r46",
      "r69",
      "r452",
      "r505",
      "r513"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common shares upon RSU vesting (in shares)",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r45",
      "r46",
      "r69",
      "r284"
     ]
    },
    "srrk_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of shares issued during period on exercise of warrants.",
        "label": "Stock Issued During Period, Value, Exercise Of Warrants",
        "terseLabel": "Exercise of pre-funded and common warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common shares, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r45",
      "r46",
      "r69",
      "r455",
      "r505",
      "r513",
      "r568"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common shares upon RSU vesting",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r45",
      "r46",
      "r69"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r49",
      "r50",
      "r69"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets",
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance at end",
        "periodStartLabel": "Balance at beginning",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r49",
      "r50",
      "r64",
      "r469",
      "r485",
      "r506",
      "r507",
      "r556",
      "r569",
      "r684",
      "r701",
      "r724",
      "r747"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r382"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r382"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r382"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r382"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r383"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Equity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "srrk_TrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "TrancheFourMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to tranche four.",
        "label": "Tranche Four [Member]",
        "terseLabel": "Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche one of the debt agreement",
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_TrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "TrancheThreeMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to tranche three.",
        "label": "Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche two of the debt agreement",
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r256",
      "r260",
      "r332",
      "r355",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r436",
      "r544",
      "r545",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r557",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r697",
      "r698",
      "r699",
      "r700",
      "r716",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails",
      "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury obligations",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r537",
      "r539",
      "r544",
      "r740"
     ]
    },
    "srrk_UnauditedInterimFinancialInformationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "UnauditedInterimFinancialInformationPolicyTextBlock",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for unaudited interim financial information.",
        "label": "Unaudited Interim Financial Information [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Information"
       }
      }
     },
     "auth_ref": []
    },
    "srrk_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
      "http://www.scholarrock.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An underwriting agreement relating to the issuance and sale of the entity's common stock.",
        "label": "Underwriting Agreement [Member]",
        "terseLabel": "Underwriting agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "srrk_UponExpirationOfFirstExtensionTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.scholarrock.com/20240930",
     "localname": "UponExpirationOfFirstExtensionTermMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the scenario after expiration of first extension term",
        "label": "Upon Expiration Of First Extension Term [Member]",
        "terseLabel": "First extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r89",
      "r90",
      "r91",
      "r92"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r555"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.scholarrock.com/role/DisclosureCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r560",
      "r563",
      "r564",
      "r565",
      "r566"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r149"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r149"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-6"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-7"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479924/842-10-30-5"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001558370-24-015155-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-015155-xbrl.zip
M4$L#!!0    ( (LZ;%E^26D^G P  .][   1    <W)R:RTR,#(T,#DS,"YX
M<V3M76USV[@1_GXS_0^HOC2=J=XL.XT]<6YD6V[<RI9K*7?IIQN(A"0T)*@
MH&W=K^\"?!/%%Y!2/*.;<B;CR,3N8A</L%@LH?7'GU]=!ST3+JC'+EO]3J^%
M"+,\F[+E9<N7B_:'UL^?_O33QS^WVU^OGL;(]BS?)4PBBQ,LB8U>J%RAF;=>
M8X;N">?4<= 5I_:2(-3O=3YT>IWS,]1N?](RKK  'H\A+>RDTX\:KD-Q'KM
M_7X7_IWT3D[1R<7@_&+P 3W>1X3WH-N"&BE?A7TAK!5Q,0(+F;AP*/MVV5I)
MN;[H=E]>7CJO<^YT/+X$]MZ@JYKGH%PK)%>MMHP9MHG/ND%C3)H1_3+0M/WS
M\_.N;MV62DNTH$Q(S"S00F*^)/(!NT2LL452/&"7YV#./>M;Q_)<;7_O?*"@
M<X@"Y];C[@U98-\!"[[[V-$C%BDAN&S+S9J(6.@"B[E6(F[2,F.MA9UG'FC<
M[WZ]'T_U,$?$MN0[TE-F0G-7-:L.3MJ]07O03_3BWRK:&3 0YKLG>1"=]+KD
M51(FZ-PA;45&.)8PPT7[I!.S6S[G,-<W:0F"6)VE]]R-6E,CX8LV]YR\D8M:
M4N2<+ K!?M^%UF0*E4R*K^.M&22HE:\O-.RJ6@!RU)(B5\@7F!8WI1GDFA=H
M BUI520O-.^\"ZU;.B\Q7N>JK!I24LFKM<I70+6D2!FFELBGU4TI8LOSF>1%
MLR)H3$LG2^6Z2DQ4H]<-R2(N+"6G<U^2U&+U66:YO@IJ7GWMQ'/$>.8BF=+<
M)FM.K"K*)Y2)U=)LL4QZHOD#"@UIE4KGBIW,%>V#::Z#?A\X:+HSK=ID7CRU
M5&-Z>EEVP>RR[%W"MO#GA<2J,6#X]!-">F/"C'E2.R3U*'JX7E.V\((G\$SM
M&Q=J'&>P6)'Z\.7IKM0_ZD&_H<)R/.%S,H4)86-N#YE][0OIN<-7*FX\%U,6
MSC?10A2LK,<2*1BI:),%950; _M=KX?:*!$(OT0R$0A%@52DQ*) +HH$?^SN
MBMOIR(?08<(^Z<\P&P5L='H,E7L,F4.2$D8+.Y;OU.=+U"ID"Q]&D!T*)(R;
MU+OY->Q;GD-MM?JNL*-6^71%2(1>!;I2R,Z4)]&PQ9+@\_7D83H9W]T,9Z,;
M=#4<#Q^N1VCZ>32:31N@*@ 5/Q23Q60=A1]J77DNC,E*!2?/9.R),A1K"#%"
M?%(.\70&_]V/'F93-+E%D\?1TW!V!P1H^' #E/>/3Z//HX?IW2\C-)Y,FSE0
M=PY<8[&Z=;R7JG G]$9D3^L@>SV<?D:WX\FO#83%&Z?ONIAO)HLI73*(Q2S,
MY-#2H1\<BQ\!+HL2H1"Z(1)3)[N-UA90OJF>PNKM9_;5H!/D+=!6-RCI!T4=
MJ1D!?:%W86]_;: O@OX64_X+=GPR6=Q2!ELHQ<Y0"-A$P>N.*9Y3!S0CH@#X
MNNPFV =9V%472/>AD(][04$W"&(MM-41,#2H&U&_Q_P;#-+<(5,"YWX]<O$:
MOF//1$CME@M0K\MN0OTTBWK2!4KZ2#N!K8X:S,V8/W*RQM0>O:XABB)J?4[D
MBO!@&14 78G'A.Y9%MU0+HH$ZU6L14?+N@'4""AL?-PG,3@%$!90F4![GP4M
ME)2 UF!DQ C.+2X-?)0^Q>@XA3"K>$>MP&'"[CR+W994O=92<AL@]T])/&(.
MS2LB(1AUJN8GTDP5DA5GU9,5Z%U*>@-IW8/K5 (],-J$B]%WG\I-Q1-L#J,1
MVD&=H^QT-KG^U^?)^&;T-/T+&OW[R]WL/PV\1:XW@$"_?U79(]BRM/XS%5-F
MO&XY<;G#'?0^] :[#C<0&+[^W1:)W@5"FX6YSZ:9CYZ9P83@>19!PY;9H&A
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MINY>D=8C]Q9$"+WZU"G6=Y3)V6"KB.[XXJW@PD[POOG3_P!02P,$%     @
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M<I#'VK +2NTZ]HSQ#I!?K.@G!PZA/2>BKI7E;]T72#WA3[M@U*YCSQ@'!,X
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M:^;B[GQ";]K,Y_!;UN7SUP5D3S*>!<^!#R-_*%WFC[OUCM<A7>9SV$5=;K(
M+:.XEWU=C0&W?MNK ^WMB;4NJFW7AOH;"FDW(:5R:"=<'7GK]\,<=,-5'CNQ
M74#IFP=QFJA2]K 2B8"2&'D!--\G.#XXK.X3%+H?@8AM%10&<&1WX!:C!<3Q
MDBT"Q90);&]CP5#66_Q7->_*.1$<%^BB?^4TT3^^WT$0GI.8:A;%8>QYR3RA
MZD8G?[C T M2!3Z#Q,-!JF0YWISU_P[Z<W6O0$_8S!=TP(2>IJD.-($M=N;8
M<K<#VG7EP')_9U9AH@U\;K16!(+QCU3*!\>?#E:2QC^^GP11!)?W\2F8/^+
MG\%KP%W05P';7D'H0FTS*<GIM&.0]XPHYF/N/1@!.NL+7*X SI(K%27&#5VI
M@#A+$EGA\"TB-#8+I@%5,Y$/E, ZXN2D^K7AOYB,OKS3MP6*:/ ;8)#YUHL
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M/!DY@]1CKN]FF43ADONXN!#*=IQOP&TA#8Y90YF4$T "<K_ $/B3:%T.PK;
M1+O%^LU=J9MM/*W)B'-:J&M<BW<BL8L35\>6Z"_G$07,CC1IR=FP1]L1>5-=
M%^N"(0,&<:NW&"ZRVI1;2'N.EY(2=S&L*[73NBY63,D@3"^C>1'0WE<%0A>U
MBG6=!JY40.NR7T&.8W[Q;JTK1!KPU<%<*7<VF+SJ1 SCA3+S S,64Z(P!-E]
M.C1;0!%!8>"S.P%. 7GBNB7]QJZ4%&K[*7W2!I=3X:3"Y#$,9KQ 0+>1,\6
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M[UL<>'"]&"X2H1C>E9TI(ZF)R7%,4-P]L9N$,81F#IO-CE/JMJ!_LEQOC*X
MC<I*37IU95O)1.BMB79,-02N)SUFW= E5]NZ<H=-!QZY2EK3W;[5U^Q_CX#
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M+V*L9<O\Q$O3YS!^^,V+MKH@VA$7SAH&"=>T#B=$$&L9P%E?\1B2*%\F_M%
M7Q O)R4%(D@ V],D8OK\'[1&A[6T#U[Z.\WYQJ@N%**^3NB$ 6=5#H(T;<D
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M3BE!5","7^!9^CZO^Y]=>\_\2-=RX*$!!@R7C.RWPB<E)$PX96"E'UX5P*2
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M&! :V6_%>4I(F/#-P(JRR0DF%;'N+G306)3$O!M0@R)0$YN/$3>K</K0X8+
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MX;J<0B\G*S[C3[)H7DP\YL[**;WG',"ZL[J64%U*R.:>+#AP[L9)F*;[,"*
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MD1%8DI-XFD#"@ D=2UA9,]@3J7!D;+O\#6U4D?7E'!Q?&&@@T,\APEI=OHX
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MS"OF+*WFS&_,66Z:LX/PT_H(7C=E[V;Z>*,X.5P_O</$3^FG1[!QD'YZM)R
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M^T:<_Z!3Y^',/E27+[(M=TS/AGSK<:S+\MJNGIWSTD%3D,QMBG3SXLO\^@.
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MX0N(DH\[W\GRV.$2^X(V\K> ;"C(7:IL.QF?'AH#"F'3($BEA8M)7KD_6-X
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M=*?>X&P  >3(68YO&"%"DK]B)!IU;G&&X*^%;]/F' 'S=H:UEWD5ZVPD5(>
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MQ^!FJRK=I^/)\=ZV"EF$0J5Y>B;<LIXYL1<_0&J<^2PH@HM1^ TI=(ZWNT6
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MT%$^ZJ@Z+"0I)PC]Y\F)P=_^/U!+ P04    " ",.FQ9[/5\XH/N @ LS!T
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MZ1__)G$\2= 4?3/D/7O&'-]IM.6:2^)K1VMQR311$QQ(VP2=2J3BJ6=G_+*
M@1+&HQ>)1,S>IV!X0@Y(3@E:\I8G^](KU1:09R%43=& AA0'9->"*C(]L@!
M+6I@*@%+L#KI3#>+YRMXSVH^LL7NLC\61L=S/^R\*UJJ*.F@!,<)U\%I0\75
M@68YNX(6NJW"7U@#S<4;^<'2=#/-]/BA+G-:=F@R+;>Z,#+ZZ,>_+SG5_VE:
MZA2@=_A#?B+[?AX:Z1X70H,1V/_^C7RA7[;GYL#EQ#S?Z!?R(/[Y8:O3F8Y\
M'N^[L>>&H@6+;=RM^Y6M(*OEYU&?WD?;="WOD^>5_@I(YDUU1S)\3RG #U3P
M:4,QSI5LZ-S !647\#]H!3VR/?-[0#"VPK-2IVC%6#'F-K(#1NU.%,A/P4B
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MC0 ,\9&]RMB=4H.OY)0RC\]KC45X:Y>>:=D\F69($!%"#^DI(D#3SHT:F82
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MU6?+%P#B<PN4="(T2T?^%.$H/.EE0D=MB8(_GIQ_0W+/QY3 08[]GEWDG8E
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MMN7.@AW$[?MLT?#SVOQ$C.W7NKE4S*7/)Y:WN;CAFID+?449&P-11R88? S
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MK2RJ+K#'%A:2D5Y*]*O5(+PM##^GSLN0.Y#-]Y]2*Z07H/()_C9I)%M'Z>[
M\]X=H=Q;+"1Y(,J,C?NR<;W]PYE!KOI./.Y)]KMM=N'^IEN 6(0(X%=RV"G^
MG0-W9+]N=_&\_3UO3?=VXK;OV3R/A*2,CA#)( @O@(6H>Q_1F>U@!%,DLD14
M#,[PE:0GJ783]_@)DDX2/> ;^\N&8KK0AW0.5_!N$TG;'G1#.1$JI*\(.0O
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M!2"F5VT/OL1+V=[@"[3T96-06<.+> MS*XOLSK>M/1>$5,5(:(GX\!D'E6Z
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ME"L#?[DE+!(:\C--).21>>'K>"$-W]7="<KPCKEM#Z)5N;^LB"FCI#73*/&
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M.]>'!.@017$;@!$(+> V ",06D#BNQVW 1C=76@!B:\8;@,PNK/0 A(?D/B
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MFJ3J"F$&.@3\%/XL0?/9<Q294,W7;&=L--RQT7 VR_ VS.'/WW7,_%^#^6_
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M!\> I[M(IK>D W\*I.& SX-/CF@*WKRQH#6F@DF !S@:F""4;\-S)"3A^Y7
MA8P5N"T!I\/VSG!M<PMR)SR>?8+XWXW[#.D+%MBRS2O0-%?-X'V(*T472-QL
MLP.)SD-F"P_?B8--@+,!AQ2D/)Q2)]-LELIM/@;GHRXMN(8F3,0F&$("<H X
MT;7A)(%VH2Q%W0,[A:8#N C\50K$T6=/2.+#E<,^EJZ*;G6C70&'OFB,P80!
M#3=$=S-7"!I]'_W($&#6Q[.%4*\C:B@FP$Y]N_SMO.$KH+?D.U$VB0;8FC'
M4J@I'$N=""#?,R7P&%]#!= /K D@7::RXP/$%,[,6@68YKB>#+XIS:"\RD!4
M :+;J@$133'EN05,=[#/0 6&7 )Q*19,YM5W R87_7P[^'>?S#31;30SHX#&
M0!U13 ?U_T07W;>GC3^K@):$Y;F +@J"ID0*"H$[0_"VYQ!?!O9;X5.UD,\
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MX$>=+ [V4(7Q+!B VM=,WY[4N\Z:!^?,P89<IBN(CYM'[1P_@IOI7^&FWZ6
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M!7+ZX>R,\KZCZ/M2,KR289&%@M'3BH:R:M:>Y$>M"?L>,-]^LG2,Y1*72\G
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ME!I00'A-[V3QX]5LD<UBM8J6M4J+X5*=3[H3%HQ,/Q]9&OC#8JY%9KA^41T
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M$G)E6R1&[#]D\X7[@*3N76#FGULW_J#O72;BN4%VPQ#;SUMW&%:+5KWJ.PD
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MBZ,ZMX_JW%T[[I:"<_>51P 7KA[I>1<P+)M]9II+Y3&-QE [S7NS8J_? L
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M['(_D+]4 W%GIN>(ANS\?:&RS6^9O5<OV_PJ'5ZNZ?RAQ1_;EM]'2/K!;T!
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M_0/,#!T81Y#P2% U!\J#9#KAESS;#C8<&6Y> #O#IFW(0@3/ F@)'Z>#O^H
M??9%4LQ0K$TC^!K8\\4PQKG?[L:>JD.',\2/$"(.6QOX 0P%'F=0]C=&C6=P
M7MJ3IVN&&'(6+3;EGMTN5VN41G-*JS<O.0P?%.HAD]C+<+%C'YP+I#T$"EA6
M!W:IA1^"'=( ^S6B+BP;VF2!6 7Q 9@ 8P;?E15'G89\#[B,F-Z![8']E42
M20<X8B@A/WW5G3W:0$_-NQG4 @5((!1 (,\NV*(#V00?J&XPI5@^3K9[2"6G
M,<D&1#JJ+LXN3.^%S65B2@NY*([S_)(U&LHPXSJ&!,0%3Q*GF6;'$;+C(P!
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MML"OX<T'^M>/K^].F_U_/EOG5WM=K_HE.KIVWSF]J>5V2T@+F6?9PP$'3.3
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M-S#FW&>N^%J:H@9F9RS? #XD534;4KU"$NN2NTI^.XZCKI]UKDB;?0"8LSO
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MX1=]V[]G+!SQ&)^/\6;H>QPR2! .!Z-89]PCFX(SS^\+<K#%$F*D:)R.R@N
M=N!%?D9GNDL&0SK'//GF9Z^HE%/)Y:G76L0$0P>3FH,5!4PJ/[2:*"9\G(;U
MH=<KU9K-T?N2?E'^>%WI?F\5#AX1]?;<'M9-S]2N?A_[WM?OK4[8*KRWKDYO
MC-.3T\\+H]II#>E.*2!J*E^YXYLWKM+Q;BC?&:/?PJ;+A%A#(NA50^N.T:T^
M'&,YMGZD[U^WS:.J=36(_NU&[<[1^1=[@_&M+[V"=?"QL+_?^G9]MA]8MRWC
MZOV=XUOVXZ.HP"/FA5$MQW:QB#4;0TWBIC%B 6?A[!P8#$?):1Q"A.\YW]D.
MY$(FN!S<^OQIP*YOZ[W3RU^&];U^%03['S]O$+?Z_UK&[>5^>U@J7/PZ-LOM
M[H>?YIUQ:R(\*K'G8^2RN&#@%1EZ8V@E_S@/L:;@TNL51& )Z])1V&!50=@$
M[\#D7YH\^M7Y]/%GHW%6N/ST[:O6L3^U^J?'=P_!3L.A3%A6V/_-^*P3@=KA
M+W;BZ=7/'TJCX];QS>U1][#QI?GB[\"^712I154$$>'.05I"+?P&@##>D3.:
MSZ(69'9D.11?@JIU9'UEHBC-Q8IL8'A*+/KNQTSSWTHQ3EA/)\=N<ZGQBDN+
M6Z://6<"P,3SOCFMN#CXY]"S"K>_WU]&I:,CO_SI)FQ^G5)<//VY]187CV61
M:ZGT?JT("X<@)SGN*G3:-53H*YCO'8&!A6:S&0 ,7=B&([<1X#;0Q8&&,JF8
M\9^%W^-FO \,R+$V]WH@F@.ITAH93YX*Q(-!.VH0 S0&J$.%/N+Y$.#+E8,[
M+T[=_$37 'X,% D=&UOM=Z8=21Z;5_I1!#&0GL>"J.*[ 99G(LG:01#Q]0%=
M7#:]A"\6/FD^4*)]2%:F ZMV<)( .1RZ5/ 7H'=BUHMQIR+O3*IU"#/JIX"2
MR?4&Y#VE$BDLFK([C%,=,$WN:IEH8Z#>-5K#K_;'R6'AXL@H8.7Q^]O;3O7,
M-7\->O=JH[= ^6KV0-#UX,]CJM>>8P;!2?<;OXT3_PR1(?G:J<\.Z+[$ ^+;
MUQ_ZW>;9U:G?8L?5R^:WD($0R%AMAY\/[AK<.4=</"3P[U.W""X2B3J#EL@(
MC+>8M/(KI=/6KB^M5KM:*Y0^_?[U_N9W^]>[WWLWF"ZN5NN:6M'KDPK8-&3H
M Q& %H;^/_%BKO@L'YP337D>!1"WL?_^O'Y<NFKIY=\_?WA7SKYVU;P_0*1,
MF+J+5#W<="",2IY_!9?1^J4'Y;W#BX$V]#!GOZ:62G55JY;O!@2>.)YF9N.U
MVH'28Z[P,)L)Z\$J5,<1"D2 :P?H@^FH2N#=G6WA__'AP,1.*J948(%_!:F0
MRM##,B+NT*7%,#TKX%HENF!OO,CID$(/3Q7D$\OTFN5%>R35ZWG17EZTMSM%
M>Z;LB792JOW[^6M)^WE5M?_=?U]W_CU^YWY!V?^"7T#\Y%6%W38[NGMZ.7C?
MZW[IUKZ-JN^:/_3))[\U1P>==WOAY])>^^MH?U2H!487GRR//WD>%3Z&>Y\^
M&9??F'W0*(S>5;M.\X?QHS3Q]J/SJYO3,OMX>;+7'^[_.^SOV?O-'^7))TM7
MKCW8*QSLE;[ME=_[_YSL5?\Y:(+M+I^<4; XUZQ8$2*G[ ;N04.=D@(D?"HA
M!NE F@KU-.T?3FO8Z.FUKT%0 NZJB3Q".<2;DO#\DK$:J5!A8#=+.Q@,8+26
MX=.T<D+:=$>T_NIG=6T@F#GB3:8*2"EIPULM'JMEEAGQ6DC;3TD\+LJ2MV<D
MVIMUF*CG5I]U(@>TP":\6[[Z/):V+7$?V*P$M80HI'>>=!?;MA_WWEV9/W_T
MPJN]CZ.S;R?'@S-'^[(B:S7%E-,,:9H,3[YY#T_!-H[,;)2+E?HR1F9JQ;J6
M3YJ;BRJ;&IF93P#<1KCHQ7(U!\SV 48O5BLY7+8/+II6-'()LSVS3!<)_(W.
MCEM/>_*-]ZA>W@W$P_*,AP[+TZO%LK%+P_(F![O>;2YE3DA;1TCU11?PD,F!
MRYJ5QQ7!W:&;I0Z9G*^+[39B<(5GIQ##6 :KW+*9-V=)_)Z[%3'\N*0A>CLT
MX>?1#'++IU2M/ZE !J4?Z75]-YJ^ (6UY3L2)*>$ #Q2<'9^*0+<[\X^MZ-F
MX;9S^>WKN>D.AM_??_YT\_  ]R-/U"2__7@4_,+Z\>_AK^N3\^[MY]+ 8C<?
M!_O#?[06QDWT%W\;JE&OJO5*;37C;%"0Y:0L1%I.RD::E(TM(N5OUJ?^CZ'Y
M^4OK1&,?VO^^[_XPW"TDY=:M7_CQJSDX:D5GT;<KS:M\._IY Z1<!D5#+=4U
MM5J:1\I/STHC:"G>$ ^R//7BF3&@15[WW>0V&U0<6H.AXXT8(^P](>252L._
M0?W<;WYRKT;?>M7*[=$[3W-[V\=I#DZCFZ/S=Q];EY^.SDZZ1W9G9)[W?I11
M:6BHU5II:N[<4[!^MY% %WGY=Y- -Z@.S"90AQU<#6OE=U>M][_9[\+ODY\'
M^F +"710^S#4PJH=M@91_ZC<[IZ<ET(D4% %:FI9U]6R-ME89L>\$#(!._<[
MK-[OL$&7W%9RKPVH%Y1NOT?)?-E<^\I)^Z.V][U::>G:5[_Y\_OH^./71^3:
MKXIIM8\//FN_/EQ^NC)[AQ\MV_<-KW/SH\*U"JT"C*M1S5T1&W!%Y-2]<=UD
M)G7W]FQC\//P^UGI6ZGSR=1Z1U];S0>4-JV:NB^NWUWVHZ.#VM6)OO>I>>E5
MSK2]+T#=9:IZ*E> Q.OS!F<_/??$!DCX^3HPLCS* ![5\2+,+GZN3.J.B>O;
MQB>./KC&A[-_+IM7O[X>')M?K99;JS5_5%$+ +M%U\IJ15MA1.*9$<^TB'I.
M/.,2WMQKM ?^@?'SZM?/BF':'\N-6[:%*G3D'^IUXTPKMVSGQZE]U;P8'D<]
M(!X4L@VU4354?<K@S3$A^R>59:R^[#.;I;F\T?9YKXRD$"EJ!]@:QPU;UUC4
M-5E/].M"'WQJ.>7!I=[SSVX:E=/1<;FYJGJBS W.RXP!J:XDFU?X[N-4F2TI
M2%[!-DZ2OC/UA3WZ3)>WTKI!_H&5>$D7OM2T]\OT(Q.#WGG/BH_%TZ)R[/G8
M(S-A2,K1T9ZJ?&34EH+_2L7HIS:U(X$?L9?I?\W!\"ULD'=2]9DH&Z2,\;A'
M:\"NJ3]LO%_F!X2KU/;49[8[?<_PF-RI.M'UT19SOFE3@<EK;ZGWJ6@>@;^O
M4EB4?M1CTDQ^D?;@&/%=C(8LXV<>^_M8IPO\*P@)TQ^=FUA)2-[HQ!9,0W6\
M*53X]>S?4N?K[W;)KI0.1J=UOW-4?82XFMOQ A"=_C2]T<5GL\XNKH[[Y5;A
M]MSX[KCUX&#8(Y-/KU;4<GU*HPO9'&;6'.A4O:JY<,K;/C:I8=0C3H#XX-V>
M_<G[U.]?_7IWV#K_]/EK_7 X?<3 ]H#4/OAI?'&__#ZY+-2OOIC6P8>?CO$8
MD-)=<)B>@NAA4K>8"L5NH_7QZW&A?799T-^=?_G]\[CQ[:H)"GF]J$^.ZDCW
MIG [4UMFI+L0KZI7R0Y#;VJ[D\_4!PGV%?/O/6QLW'DWDI$0\>!T2NT%'[[K
M_N]O%ZV]B^KG_?I^Y;K9 4HU*H;:J$^.G$B1*79;GFS4)+L98<,SB^JWIZ "
MM4U;+PG+ID.M7Q$(>&0OGDL][M*HP%UM!.(I:+ 1)+JR.]<?>^^'[TL#L^6Q
M4;<?NJ5'6/#W8P&=VZ\_[,:/\U:)??,_W_YX7_EVT/C"64"Y,=GJ7[;5H]ZQ
M@:S@%VQA",8EJ+MC&"(K_;-MO!QLW8<?;Q&6S&MMM'$\J9R_W_^W&]1.6GO6
MU9%^:;ZOECZM351\,PO5_:#Z1;\:[!U6^Q_>O:_NG=_@.(A2J33IWTU&:"8X
M0-TD@@A;2DSP"\Y:[ML7#<40]6QDMT,;GJ.Q-TG'+% ^NY'CC+$MT<O?2S1R
M,5:A7%1.(Q]5S[@C]G0=.ZNZ4Y/1'FY6S$Q(*[F*J1BE0L<<B72VC(3D([E7
MJ\AJI;0FJY76(SGE$R=@'30=QZ-!%)F4B\;^>6%T??7A]LJLUYS.MP^7YU?7
MF]%EOW4:9\?VN]N]$O,^'EOGS>_M-HZDU-1*0U<;^I2FN:D>L8*=I:T<?E#>
MUS$V<]*-#'&OZ=;<$RB;P<ZJQ,X++Z2I0)[%6"=6I&F,!M^8*OH;DBV%@RK2
M&Q&=4(?P_5NXP9 YJYR$4TIY-^ 70UL&XK4^7;;:%Q_\0LLL1"=[WZOVUY^=
MYH,[+<_ F:^F$[%)E$FW6.Y>?KD(?PR"=U?G1[]ZC:OC2K4R0*4*P#2ENUP\
M%A[[X #8,M8]-C#FW7>0G;$@).!T$H8%S(VY 39HG^H6VUVGR8/\YD^R>5PC
M;QZ7-X^;C:M/LWD<</QRO5UE[$=5-RH_RIK1_6'6&]T?G7K9K#;TKFG6S$QS
MMD/0S?4?Q_M-\>G:>S/C!A2]R*M;CTT7*$DZ5<E)M0^\.@H".3VK"0K *+"#
M[(@M #37#NB9,Q9$#A]J=3(4'7N#E7#,\</\GST%56U0(6QKHIU<)WLP,W4P
M+_)I<!L_G)4YG)\<SHL/!RJ1;#J*,V-%+^7LO#Y<-')-4%5X-VB7,H]([B7O
M"J2Q%HB7.?2 ZV$':U!D@$Q(/CH!NT%G,^\*#;O^$ID^,#Y0<,X8CJ!+YG#)
M-R8OL5VN+\@CX5/\#>3 !@5=](RF@^"^FZZ+<U/XTJBI'< "</&%3[&I.X*M
M*;QE?-STW>#C$0P4X_9J9.;],. $S@(:"IY%PI$NP![0%-&DTSZC* U-ANC8
MJ)7@"'78"C6=C5O_R34$*F&[6U U?S*+.M]BLS[LCD^_>'ZJW1]VRP4S"JX.
MY\,5',^[PO<GP"\JW["Q8$0@&GD1[T(X^WDR&0&$2@_0 ,TR[LWJ1F'DL\RT
M  YO6,R;O(H,2JLS*<"Q?T5@ X6I66\=N"_'&\IY!;QM;R<*0A\G&,=C">1P
MND7W.N>@J'H#@&0_]"F87U0.DXD6*D%2L3E-K_^@U(P=.Y<'86: W:-.2,;X
MB"X18=XF+P+@%C5"AEW%Q_33^PVXI24Q CM0%K>$++.,>9P]S2>5%.N5+>+Y
MU3DH_8@* ,T]/T6E=V*?:;/2"X#6[> *KK"#K:>[=CSZYQ2^QV7GX:&JH##E
MOVG-HG(&7U$.^-NWY:I3? 4E%<4N/7+^#!T3^ .<*D+&YMC$+O@T$@  .;%F
M0T&:]@%(J"ONH#)C<QV%'$=9) <^D1GV@?!P3'M ZWMM@)>8RLEN+0;'@05@
M.0MNVR+V$,^T;8\4Q[R):=*/'/0YX*V+%YZW]E3N=D+G+'PU&M(>/&0!U^BB
MBX^40J009T)W'>#>]&>KCW.XI01$B]0*A;0G9BYDA)HP#?J#9?M6-,"6LA8R
M8<D3IKU0S!VBEK0D(8@QXZ<FL$:+#[ER["L 1M_S!-\>X]DW-HX1Y:Q4\$_$
MUH"%HDFN&!LQ1]8L&3,G=$^I3:=S2K*9 M?,O[;9S1(W,>V=BR8*?N/LVE10
MYP*ZP8D<;=L;]DW@1A:+*!L-'5I#SI&L2#A5"<?1I0'G&*EIGLL%1P< B'^B
M ).8/@N<>H \&^?YQ#I4""09#[#%@^&,8%B9 88$B7P)P,(&<L:9P2-4.$+,
M.8"3W0"X);,#:AZA*Q9]RSBL#-UHON<PFIQA*CW':\,G#K$ 7/GB_<%__],H
M5]\"EJ*^0/>.QW>\'IP)20 VSD3:0]PQ61#< %;&)L@@SAG2C1T,B/HSFT+4
MM?GD75 4T48$)DID)VX,]@6G&?HV"TVX+3A"B)(@OI[XCL6M9D3QP',]RR'_
M)"I>;:]CDT)K8AMFSD HMX(A@</UP^_PEAX+Y7@2*_(#SR<Z1 1 X.';)\\!
MVMD[^67I=DQ (N 1R"%U%G,<NAD']\L%FA5R.2=/A?!5!K;E>\R]MGW/%8,,
ML>NS@U.<\$?B"]>>S9D>""W8"F%D!PB^X( *2ZL&9I>%Q+T<AP$#PPDL@0?:
M#2J>I'_8;M]N\X?'D$9<M&\."=L51FR(F+7<")E&B/J(^!P]!'N^-J4Y,[8J
M;KS+)W*12@2@P@ '3A2V$7AI0(*VW%_;?--QR?G.C G:#C*H2)@#Q^33X0#%
M7:*+&$4)5C1+*+(=WDJ<;H$0 M@P*#>VAXC$:0B6[D3 WRVDH@Y-)XHU0Q2(
M2%4T*1J6EACFR!PDN"*;*SZ1=)<2XS=AC0Y(0Y):4_A'6J5Q601?B0).L_ $
M^<90EH&,L+T!G!I8-V! YD\@T7S4EMN^AX8R32<&9"VDAAR9+AO8)F$,=2V7
M)"N&N<#!>_!TP*9ITV_NVTC[<;J3E W5Y!/TPY$C$_=0  [J1>&;KGW+.FEO
MCW0D<FTK6\<A'L/F6B_^3/_A41L>2X4F/ROL=4XR='TBO1FX>[76>#N>93V6
M SWA[7N4%K#85=@<P@F 4@9F&V4EH.@UA@.X)F@Z*H6&1DH_@G=.8?$CSN %
M1P-6,_)0L4'[.I$U("337+]MNW&T"/"QP$T]XO@)PT\6@O\%H($Q%*!(,0ZW
MH6V<PTUN)([#K#-=BI\?-XD:*&0JF:B9G!KTB;C%?SS81HJ&S$I\UO@,RE6X
M.</M4<[>^3B"Y"!2VV0N0\YK.NB5$7[9B83IG J?$Q6>GWTJE(T&CHPG 44#
M,^0\7'6<*#/$0;@F31<<#]6'I1%_K^W0]]"0@55",N GJ"U%K? A3IY"QT>:
MBJ7]ARO<A^IFBK%BCO(YRDN4U^K:-*&3PFIAWJ2$"7PBL#>VF#0Q).;NR(F*
ME+!-4&D$C<A&BXK<,#3BY72_\.KHM986<ZB5@T63(W".P(3 IZ0L9&W:!'.#
MZ:B;6/E3,9-4^Y#S2[(9N.J"3I'.-;K( ;D'D1/:0X<EN ELO8LSB %[T<4T
M:=W(#<;#2,E &C/2TRJ:.,9=:$^J2B(E)W,*^-TW8_M[8(*1<IL$0+@M/00$
MB?PV[BBU:&I>U(@L^/@^[<$ QYT&HR!D@SG$^"23,C#O*T_*R),R=B4I8^T2
ML91+Q WZ$I(,U:RG&- 8A]PG)@WW0YF#($ZP$,G/B20=@ Q+AOIE_=B)LS<1
M9VW/Q2_YP[[78_"2V"]?Y2G;9+R/N9%G2X_IW*C*[Y43ZN;B)">4'>,'X:2D
M5].N#14U8I,,0B?E@LGX=-2I3AURAIJ8F?LK8DE(@6HBN1Y!$ES&P!)#-#4E
M.*LWX">9VU<3*U.=XN,I*BG/U#3-WL2C)0X;?A_\NP4>&A#UH.9PM, SY#,>
MO,0X8L1# ^?-T],/AV<MM,B']C4E09]2 KVAQ$@<8MH$8BZ[-IU(Q%BY7]VT
MA,^:!P/PWM+'<1,G,EVU"]<_:".^>T RF)FLZ/1]^M' K2JO>.P)KB+)UZ6(
MJ="5>!S(_.GY-G\C:661[Y-;WV=\%B<M)5X.US=,AM3S.H+B>9%>W(I\N.;7
M(BWM&U72@-*)+V6N#YP[OD5Q4[@"3S4Z3/+()XN.3=<%Q+9@&2X[@-*!L@H.
MCH.1Z,35T;YW([S401@!3II6'WUW'2H1&_IP S[6,'>&GHU5R@%CRBRQ+(+O
M4VK#SQCJ9,I^*DM#,(77L>H]=&#3HE0XB-H#T(M-?E'O1/@E4(YL"_.E 6F'
M#N88B;(+W/W!?I,'G<2=P@XO7?P['."*![#,*.P#V'Z+E(O)-5H -+C?+QK>
M: 6N> R? IYC?XUA[!LF8N4*Y9'!'?.@#Q8"8,J_F80_'!- T1>0J\0XX%*Z
M&I4M85X!YP6IKXNO32(U/R"^ER>3%.7(CLV$D](<A$H>!)G&676<HG7EXN2T
M^1UOQ>L6X'_ !RC_88S0IS*1+!U/I5QQ"Z<2WS6] #P7HTWCB'_#,V)L,5L]
MH178;Q-0WD$X:4EP)X@K%KAX%283" (SR>7BA^-'0)&LZ&7^_D!Y!<OIKU7%
MJ*8_,5[3 <KU](=EH(=FF/J0EFJ  HE6+;^_N[$TSLU %V#V-;=#X8//,:OV
MV8 G7Q$E) !,;IWX*N<.012(5*T85MR]CH%_133N0#<0V)H^UT4Y0Q8FL]RJ
MX@(&BC]U>7@"3.]$GW%&1%=TZ:8"PK)7 'MJ@ 8ND+U-]37 HU3EY/.__ZC<
MURIO@P"!2GP*&GB$F''B5VVBM+XGW%'QW63I:R*EU71CPD]?(J\^0\8C:\0.
M3)".%V",7X$()?6)9_J<X?M.6<=&V]S"7&,*A:>>H;V>@%H%[]KWHU[F;^@N
M2VUQEIC%O1^;(\)>56E&/0 ;_E*BQ8]-'[B)7M+JV)8!/<[<"\%/@:Q/GN+T
M[/"XE=D +<R_KFMQ0E)K+_Z*V/DQ3_5 *2YXW]@J<<HL[N.NYUIFH#RCX65%
MJ,&CVS$W,+'@$&14('0K9&7IK &>'D!M/6;ZX=&ODOB4*!<5_9Z)YU]HZ!S/
M)N,3Z;#@V#>G*)2<) 3_%3<^)]*=:/5P!< U1[$L%OH?J6A\3\+IE=4&#S_O
M<U'-T\N%@"/5A*LDDI@3IIFV3HB!H@Y"^1$8_T#2ZP)WIIPRD004#2D9F\*8
M\9L1,>*-X4%\(B@'Q?[ #'C0'AF3;[>CD&2EF6)/I'VCJB4,Z^E4K[P_.BUH
MREDSP4BLU!.)F]/R9&, )I18QDN0^@&G&RD/6\?OSIK?6Y,2D:2(*FB'ZY]P
M)EE5+1@H67Q2"1Y3$C G$*_<1PN/!W/I5LB"Z&#9-95X.YS]\;1]C@*B\%9)
M-(!89. [XBLA(,>S!!-P)^1#ZN7-#(U6Z$#)3<RYB%D=J'2B86E= F#&Q+P0
MS:"U<:G,RXV'E+4N-Q PM$:47SPM%H](&+PDAJ/?M9G6I(>EDO6P5.[>GVH%
M?#*5%\5=RBE4PUAHEC9#3 #@R9ASK<78T#)M;"J$D:4!"EGROGOH@.A*>IRP
MY%#:39'C;E8\2P4NE<T<N_6YIR)..D3&R3>4]8\L,KBS>0=4V)D1$K&>E(H(
M)/Z;20N1:)3L4,JBA<N-#\X3L6D+//,IO/&2VR#;)]$$)ZZ+:YNB-H->A$>>
MGVS19B.DCB6*X%VA"/0-"=XQQ3DD@ZZ9PTVQJ5[\/<5O=-^PK"H9X'+BLE:?
M65?<V$]G/8BPK*I(M)3Q6PT32>4O1]-"N<HKGP%9^,+]Z $70*1+K3$C!@RV
MT.(;%'>=G'Z&^:DI^V?-]R>?%]J?$[PF3JLE/0Y-)DS_#4VB>TLTU@ZC@2?O
ME-WRL)Z\5XO=)>"MS/'^( S%]N--IE1IW8CU'33$Z)H1XJF#]#UA\BG2BA)H
M@^H_BL@;KS $(3A^&Z*H)^#2'U-PJ<^@<&>A9H;_?H7E(8K@,?*Q6'>63TG%
M5&B5!#74NP9M6U@($];6O$L;B=>^D^ZSQ<C"G^=.%FGQQR:-* 8,1!V!+-,Q
M.55:7A^.$;Q1@%7" PY=#MA$M@O<0U6L" #-, ]UP!R3?P:V>2$8 .Y0:%5Q
M(FQ1(K)+*>C$/P=UUQ2/Q LJKT3#"<LZV]M+^NGA/OM8>8D_N$"I2@"ZRP#?
MFUT@5HO.25M4L_[2-E@$Z!;SN0Y.#I%$1X=+^8C!7])>17IW\WSO!)4[K,D8
M,.%/HTM3/@.D8B50/G_N@5(O\J$.,9;LI=3(/;J$^(SGAQ?Q$16C\7^@\D]*
MA%H1.3XJ>#)$28$E&7X:#_=X0P!WV(=;B(9BR*TH[CSFN^=F+QU?>#D (X!=
MF#T\&AK(GBNJ$>#"KVWN^B&R$DF^&=Q,>&A,<Z;E>Z!SQQH'L0@E' VIW\-"
M7!U7NO!6I51;^.4,L\BX=+F7UVO_Y-*&+%2\ &X&_I2QBT[$+:68'61N),L@
M"4>S4H0$PY-OWJ!K>9Y GB>P.WD"JV[D,I452;YOMCTL\!$9A+$A3E:ZT%R0
M!Q'G,!W/Y<6327$YYX("2FS ?&+462=\ANU1R6 [+=BPZA ]E(D,"^*Z02H8
MSLV<[+8O ^FV3.KY[F+4H/IF4C5H9VJI6UQ'A'X[KDLH0WO(R'\SKWQH(H5.
MY"^P*8;26'F6/>#Q/M&70+DV?5L$C5==0J3.K2&ZLU!'HW-JX2#04]I7V&,N
MK\J?,"W'DQ%3E8&9VXJ[H@AC,RX;I,H1# NC)N.10I&Z=-0&%E;[X3>Q#303
MM1PV\0,RL@ ).\4[7X>,>M[C]N#N :$BGRRH@#JK$FA$!D9L8"1Y-98Y-(GV
M\,XL-$UX@0L/'_/[YDX4F0AC.>2KE<Z3+!:JB8G#Z]\$K'BCEB[YOH6G.(WU
M<0TF*?E!Y'>QAAT=7T/";6F4BZQ-85;(O\*-OR_$V_.B(5:DQG]6!1PDEJ 3
MF)N*05Q=B?KR<EG-JCGD#(Q9.=,<#XZ?VVC^V^1IH%"@#(G 1Q'Y1)!NJ?8?
M3?VA1 ;'"R@O&;$66\OQW[FE]E(#9;$N6\_%3A[7IM0L"AOS!C6)?]Z(^V V
MR92?_(O8&86]3,N*!A'/&.M0%15Y(5[6*]6B(=]+XCE)@4@['^ALF8/)1G<\
MO#!VRO@$\&\0U8PT,]'! XT-WM9%2B+/[7FQ74YT25WL;]B&ZBJ-/!=R4[F0
M4XE<%MDCKB39-#+K)\//*=.(AQ>EKH$S"0"A4DE#6()O!SR02('Z&._>;E&-
M2HZ%VX6%,3M,1X@3U"&6E\TAS;1W%3F2PJU+3N%4%H),D8QS6V3NY*0K^_RX
MJ696Q&9UE#V#"\U,L7E8;DV<&3*VCPXFM""E.:.<9G*:(?]+3" H\BFW:+S9
MR1BUQ)6,TRDE0QIW#?;DV)ACXT(.?E<$)85CS"D@TKO22"NR?M1,:NSTS!=A
M+*:R+2CN$.>3W3\W*T?X'.&S[!?;4@EOAQKW-DJC>B9?99I'#@BGQS6#*&"2
M#T_S4^7(ER,?(9]L@:'R)(&X9U*(O@3N;0Z9@^ZHB",=5B^/D@Y3.2+EB$2(
MU+>I9C_F3U)4CS4G3!75)$6*[2C IH0!^I<"SW69\Q;_ND6HE5?9;HF I&YW
MHNE4US=E%(&E'4CDFDP:I?.Z23XT2[32O'<=K#%<>AWL^"QK#*M7)R\X'=\N
M;2X".='R=V&0Y\)3> JF=+-3LW 1#^,MEGWL9PMP):=&QNU'!7\W6.]E6< 8
M>.V%3,E++,>,"8#LI$VMU'W6D\FW/'U-U+)EO#RQ$2M5=TJ>',7-^$7;Z@DU
M2Y6=,>/8GCQ&)GX]_5#I-N$VG7!M6TZ72,Z,":2*TU.%)ZOWW\8Y<LON"CR_
M''8V?D\MDUU=P^)I&Q'<8,+#>$'V:%QCL6^&YEI(/C5=N:9.*S.9K&].4D*F
M^DK'?).II-2[E95/;:4UH\9!G5JYL)IZMHG(HSSP#<DB'P[D#3#"#LJ1%Z$:
M <+)Q5$.V!"][16H7,K#^:/JS")\2F^.$ZSO6(T$=Y M4YVLY@TR5:N3E1VR
MP#X08\M$\SM@],SF)0RDS?D!<ZG[N1UT;#C7H)C G6=4PZZU2C65I(F=@W7*
M=]#>:CJ-]P@4H [)6"EG.CY94JA!^:,X!#$^"X9FDUM6M#?P7]XZ $_!Y$[3
M-Z.5E$'OSZM>II\$8+G\%)WP'#J8I@E6D0\RS?6H[+ ;!3RI&M,4L,J,76$Q
M+14M.IXO;CII/<!A)R_!T,?N0#/$)>A:ZA((=S#C(0;ZPG/K"T\MSY<Z7O$)
M)XGJ>9)HGB2ZH231U"5K-;W8X#616Y\X.BZK+N[6?@3-^@%85Z$ODP:I!B<(
M16OVM'9)D5,AO3!/D)G87 1T>E%E2$,AQK5=;JJ)2B7)>:G6.E..:&*5AQE$
M8D@'I<\AMXRETP<3]=9@@.+M0'P+2P]HF7,<.JFTR/,%"\@JB \'Q^>MN Q"
M5 '&7!95W[[O8<>ECA>(D03CTC!=<S5?+KXN*KP+/ T^X9W] :@F,&0^!D(V
MO(];.(@JI)AWX_U*\44%/\&$GL2;RL0 2D:/8:L7$BU#WHB EV92C10\\9LE
ML69>'(1I2%A2]$I+OUUNY74<=M;3^U'Y5.(I$"U2TQ6YJP1I+,;EG43!H2BW
MS.QR]H%>??"L/BBJ<>](T<^W\S,*J/CN=:I[];"  I41].NE\EN@9[WR&C,A
M:6H T*;GDYSO\BDSV'8KLX_XW51E(JJ6@EGG:J, ,OEH#O%&!5XI*IUSI^ES
M\FP=SE=LE5=C.O%K3LG(0>,<5<IIE*.#>'H(L!,RO^!S8F5$2UJQKA#K!HXT
M5/X"E-,:^FO.=ATG86_3>[%,)7?EE?N75JJ^GLJKX6^5$C"WT\F%$ZTS:YW@
M5XS7L@C,A"V7^98G3CSUA4,XE*:5&Z^WJ6-Q3E\;I"_A&+T8EQSIR9M(4!GI
MF31B2Y?M)MBKW0U[W8QV@^TLBGI,@"Y8:!3%)3K4M:DDM$UHG = -H_&*37Q
M]-.?I_MC%5>Q>T7TK)%J)$V!XJC.:TR8VQ,C=[G'P&M3>YJD1\%T9D^T@?;S
M\/Y]1%<?/TF9,.*ZCK.6 F IT)A,W$\9(:)>7P[,%+7"<^6R*+<6#4"R'IOI
M/A]>=T1MCY Y9-F&KL\4H5KI]7I\E,@C.5=I,\>[48)H  _#%_E5</TBF*5@
MA)3S&EBH,&-I'Y8^*)J>ODPL\J+*+B_@22W8.H6CDTA:I3N56+S,4\_T(4T+
M;+4SKTP[Z6F9#K,\'ED<<R*-_Q4OZ TUBL&?)O[,J9XZ5L!;]U+JV[N)V[V@
MVSV7MWLL;O?__=^?[65&^^YU3?:@IP2^]=>+P/>O"A@-*#6,TJU6^E4JE8L_
MA[T7H%:&?[UX#_RV;ULOY X[=H"# M_8+C40:#N>=?5VW&_"^7.YQMU7*".6
M<LKZ7 IHMMLXJI-'C=\H>X<J^IJZV+$(-,Y#O! P%-]RF*CW<2R\58[.5>6(
M84O"<VQP104+JS_1_W,5,FUI,F#<A%.Z<-;"5HQ2L?Q'IFWHS%Z/=[&$"F #
M46D46<Z5MX:P#]*J5DPVH! $P' TO5C);@$;H7 62_5*J+&YG.UMC.M,J!3S
M&,\]6,M:TP7R$^<GWJ83/\T@EI$'L?(@UN:#6'J]4BQIVQS$VGZU_M3W9,<U
M 'KL"?V&.F.LP9R2!G,X18/95OV^\D#]7J^7BW6D99[-^,?X+)!24:M,Q1[I
M<A)V 6"FL3Z[X Z][#)@3G4=P^@5:KIW@#7YZ+%+"/,G0J'703$= AV+Q'F=
M#FC5B'Z*42RIW*>H5ZJOERK\'WM'YR=[RE\38=)UIJQ."40\P ))8C&I"#B3
M$W_&F^6F #W-P1/[[D1[7AG)#N&(PK(!RZW.,XK43"!=MK,5=1N\I5)%YX^.
MA\6%R9K;.OF)\Q/G)\Y/G)\X/W%^XOS$N5_J[GZI<NZ7ROU26^"7,FJY4^HQ
M3BGN;DC[(-"_<)KX%V0(?EO=3]6'NI\(<V;YGK;/\301D/YK=CSZKWN&H__*
M1J.5\Y.]O\:=,VM*/(D'HDRTV+FA9I*. ^S6D67#/*$$,U:3_!$JA/(9S^QQ
MO72Q 4"276,10I(\&C>:-CL8(698MT6-=7EV?7LD<M;C+"@11Y:)4$7E\]3Q
MB6/)5.(E,XH=WXIT=C&4$0Z:2D&BBZ#TP_'5LO,[LTMF!ANY$VWD^$@EC)W3
M(,LN5F2*ZK)N>M9DG!1I16'!ZW:IBKNHG(O&S)E+"Y+!$<U6$%=,T$5,GH?Q
MN4G.B+?8Y5V)XSYU,\H*9?4:^;&D:_4M0AE?R5_%)[+Q$<FI"N84*HUC"+\2
M:H9'+7>HP8#H%]#AG0:R!^4S*@9>0(Z\ >: 92^"#^X8^>S6QGDC9N!A^<;(
M[0%'D3/PHEY?S8!4;Q3U/U1%+V.& B7;E<=S%1:Z):<GZTD?\>MI$R;GY'F-
MG6H<_PC1GE=JUCE=$)5K-,7EM*XE:+9=5-8>FHE5-HKZE@G+!7)$S,ND$MG4
M$(.YO377/KYV%I<K*@?QE",Y[4FV&E651OV/S.#Q>*NOM'KE3ZU>?YU4$PM"
MQ7-A$Q1 =A,(/34"B@[^E(M\*[D=FMNA&[)#M];LG)_8C8.Q<3KHY'!L-3/I
M&MG<X@'9(A(9BEG5Z84GYU6G)E2G'[S3E.J[#J7F\_J2)E&R0T*F ;(:U]->
M@;@+;4M-=2!+*BF2*HIXNC O"N(S&3R7%,:(6GD&B6:+-XS+M<1VJ R5FN*T
MP2133.6=S>MX ^7(MK#9CM(<\BDHXJ3I5<QTUYPH['N^;+IC3GZIQ<>-)V'D
ML1&Z' 38!N)7Q(*0CPSAHR6N;4 P>J%EL=C$(FV:MVO+ZH[- +1%F@F;[$XV
M*\)BJC8?34]M8>0%)'V#P!IS3)"&_6EA]\OB>3$^!<ALN-;Q8XA)T*D.<F*Y
MR1XGK0@;%>+K^?# 96JL$[KGG-X]7*@7 %8G:'W"A6U)<ZY4+Y]ZJI</R5Y2
M(J@"G-MK-X L!.J>S[B_Z!5"21A^E^E'FO*1Q!1$H'TLGA:58\_OX51@'%_#
M>T8='>VIRD=&-\-_)5P\M;':^QQ^!(Q4_FL.AF]!'A15;MV)$5(FGY@G3-4
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M,[J--+VHQV^ %QA&L?I'4<DX-\<<EV-$(ME80<H'CEY3I9"044N1/-P537*
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MV.\]2.X^NM][YB=:ZB-91!-*O3DJ)_4X/L/RB,\&\OH!T($61_-#T-*_/V#
MVP>1%KY=B)LK6&W-?;LO@@%U&/MD6I<OM2[W[D_K<GSK\NCTP4%^Z&E=OA2H
MX-U[T[H<W[J 'IO6Y0C79=)CGW1=;MY!>=@\_F*3\/ &D_!)#=&O:08\XM*]
M#T5<NGWOJ/&6!B;O$/S2+^@9OV#/^&GL&1]$-)QVT='MHH=73, X>./'120[
M.[W]9;$&/O(6^:CH=8=-X6])!HX;EN[F,O"'4>IH1KX\$(/]YE]<8UHPL8_*
M,Q2%7/%'TWU']O%?HM<<(T='-@T?I[,<798C P$[O.!CO>,_G-T[2^[>N?_C
MQX160*U_9,O^1:3_^*9ADOZ.]-]ZD#Q\\* O_5^?P>\/-ZT8P>(.+M+Y1 ?<
M=[>?#^9!/OTW?T0(L<,AM\^$<G+C[7IV]@C[;3[V4?7=R?$7_N;O7H[OWT]N
MWW_TD<Z<([,P!H^A95ZDQ6+RLSZSG_6E02(_HQ(XPJ__!'HCN7^O#_,U.6J?
MR%'[T@(T;9^/O7UNW?T8B.=?SM,32%D\8Q6'#L.8!\#L$%VMRJEG!G^??+\_
M<L)^:=S(SQ39^=*?^0GB/+?O)7?OW_WH0<[O;A?TB@&F7? 5[8([]Y)[]^^,
M!#L_%U!LC))$%W_^EI"K&D#NW/<'+76!_"H)PY<^87@>.[*?8-:NE:UDW+BS
M>V<![>5&;2")-#,7=5XS[!HUE6 S] 81/+!%].S!H].'_NET/6'<U@I%F=:U
M$WMCDZ>TDCEW</_'K=/[H;MT",\5>U/I*],,VZQ"8^KM1Q86!)MC!B\E2#R/
MLTNM]]R@>C(GE-Y%N<5.;.J<D=;KKQ/)Z_:$Y#4A>8W+ZH3D=2SX!U?#>MU$
ML]]Z8&!G;J#9[UQ+LY^!L1/T\_75^ME9&-5-]?J=\$J+F'[5:SV@8SK[C_MF
M3@1OG2$5*H0O#]@;V[+F7G_?+0\:]RJ0<H]_]G'.G&\6J/2##*E7)BOPW">G
M/[$QU>VTO7:J7/8@[)(['V1=D22D%8M><>VWXC:Y?__#WGGG=';]S\/GXB$B
MV UUA[7 P&(01HD!;\/]>%%N+K0+>3M$FO Q&\K_L+0]\SFH8Y"VH8P82]O]
MH!X_7-;@*;<^IO0,#O=&H^M(5M-4^;QE@6G* ZP.EM3A$PWNSHT'I_!V@^!4
MN!W.W[[XJ#A/QI"\.8[!LY;@'6:O\9"J"!+F\TC^U9;0;\Q"LFAHUCP6(TSZ
MW!%>3P/KGB-]24110HLP>H(3#GG>.'C;-IVC9?#FQ3F!%"EZ*^$37<+V &7E
MWHOR(@%"$-4+>!^*CWD(&U/YDN#*#MU2[-706K9-R_@]'>H4QL/BKR:F%5"7
MLQJ<P!S!C6#\*%4H_+#._TX%8T<FQE@R^F"BM$C"@/ _BW8)6X'12&AVD/0%
M19ILKM_LZ\.4ZE 68#1%;WKS^N\GB/?978.2L;/ _(,=1_@DZQ+NVZ9HR#&"
MT"O&#)T]>7W^UY>_S#Q@$XPFW71&8M\._Q1R&<&XJ+*\W.(!4R+0F^<V"7A5
M3U_\_/K\?YXRNP^_]G8?#XK>VQ40@F\C1HV *.7?@!]_]\ZCT]FY1_[=[(W\
MR"@)5"R607IDOG.;7%#O2#@('6S@3:#<GK45_KHM$87L\CJ+U#V@C1^!=K+
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M0R@FOIVU@7,L4\&"1G8_J?F8736P*IGV=1+[2>R#'O< 80+%BUT#H*??PW;
MO8!,/]XXX59V*C;R\DT)6@^_+6B%H?6>R7*86JA*"XZD><D40#AJ)'KO]G;7
MH+5"]YK45=7FC:V>Z@S6WAV[;\NVXM8]9:2Y,IF5"[&?M=A /5QR==COC?*D
M2856-[\G(1=,1",XXC%MN6G'?<$=]PR$63B*;;72VJ4;Q.X@S(TJO\ Z0Q(\
M+"D$\6JD<6>37M:VJ,GT)VKE^@I!M0IR&YA9WGE.;KSX!PXG+ 2"@_G:%OE%
M3A7ML(^WE";;.?C_>(C\F/" &F>@,L@-^7-9^3@$T^3B9N/*CDX]AHFI^&8W
M7W:)=TR1B\.1"RRBI9[>EE.8,(G-?HI9?+=JY"5%%[BL/W,[HI1" MBT\L%
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MFX[>"5-%A41;_";TVNMX.S" 9.V1[I&8TS9=RC9%">U@Y^"CR;424$D&RR$
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M)RDU9P3IN!&)OB4\A.E^IHWPW6Z$KCB-Q8FC<&"]+B\UQ!?%<AFYL=3HKPO
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M\R\(Q/.EEFQSG&7HS3[=6- .A0.0HK;D&X"VWHH/57L?&3UF! B5ETL,52(
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M$WSY"2.@F"+R%-_<7Q%&BB"2'ZD@L-53&PP#^<.""0']"PV5)L>Y03ZS>OR
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M6,EA*4VC1??Y5$G(\E-IUWK5RS0$)L8TFU=EFFG^%=_ KS\Q'VJN)L]5ZOY
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M-(3Y;025D:L3VO'H'WCF3R8UQZ]O]0]<OH.'!L5ZJ3*!IBY'+A$3IHSEL C
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M ^[7(1-M]B2DRXI4-U$=93/\4SB=E).7C*D8S<WO9TP]C_64U-'8,.ND4"C
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MC$-Z8N5"N<+J;G'8$D9^(6QI-FGFA['2=&Y"I47<OR0O!+@%F9=\"S%1@4<
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MBVKJ0N>=),I=Y9]DSU5+!.WI= GYNIJ;=]I3]<3D\=@3%A,KV23<@IAA".]
MO!3L/273D:>[P6'0#P!Q:?2&?_:GJG'4$6KFNDJ?G)^%R2L3C)+-;RS6!!MJ
M% 5U:"2D>4]*==-6=*7G:%^NPN.!TF=[Z/<RILADL!R35$+8OJ[LZ!HY(24S
MU^5+ZB821_MHQ:I'LL!CA4!)&)ZS%??]@4GDMCW7/)B)*"D.+C;,I:^&^^KY
M\]ZL=J6L0-D!K-0F%5,>B^4Z;#Z]S"?)*-EX/>53TT\=O9IC2AH4,CZA96 $
MXNB5[?R7%DS^8\\MD*)7QJZC14/)$C>DJ0KB;(G+QDO%,=>/2>,#/N*U?NHK
M+5-H6,OVT(_',1@STQ$5/ZJ3Z.*$):2A/6=[4-ES^7@,I/)O-HSV_!Y%$1MC
M["&]Q'-H;\;#X'B$3%Q'OR<60BX,L$ZN-/:PE.$;AFO_^.WKJQ$#LNXKLMGL
MC1=EUQTY:]"U'%85X-WP1T^D3.%OO0/JNDZJ=\PERT1/^!C!G;2W4IKV=1.
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MQP9(+8!#4!+\%6R:[\%S<N8<@=U;#++R65LW#HTM9R%V/I\_Y%G%D 3 ,@+
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M0>7UNE-+$A* :J.2[Q NIZXKS4Y,_((*A$:-7<P/1Q8L_U!3B\HUG/!8***
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MRSI;U5['E0FA219$=Q)E>FI?*NYI'-UH/=D;^89T"WDD1[(7[P7BGWY_(<3
MDAXBJG,_4B[7HB,2)Y_ 5J"=%G,CE)J3*P*S2,*=,LHTDNC/2G:44$/DG:8$
M42;]IB(J1.[+-RQ$4^U$VAW.U*^OP+'+7<TQ^$&->\I&$QPGX&)1H!QM#0?M
M)'I&/D@QU4__9,XTF$0(,64$7 CHH74LTM!)1+^N-CL%*(FA3L2!*12)#NP%
M#8E&.(XK2Y&W3(DT),H@GE":9:16E:&[R*43+C >,,SR2(PLB I;FN6LM^%L
M1+4K.,6-<+)(8'=HS/E0% 9D$N*Y]P5M$<Y[KZ5,7N/0-4FD,1GFM2VF[]FW
M!D\#H<D\P/8$&%&8_.0EE;)V6U7[V!:GV)7LD#:-9H,N)T%XQ/35T=&,8 >M
ME37)\.4JJO,2BK.@64><&,]:.1PT3*$)P79'"!!TI9:B;C+8DN)])Q-6G,.J
M9YW),=?)Q#9 _NMJ)9ND[N72XZG@5%HY'3C[9JT)@RF4@4=K!=^H"47ADFF4
M0ML>W_RFW!RPH[)HW3\>6%(/PDN/<#7=B2/49^PA5;YC)/^^O$>T?V6:V()'
MN"//D-.5F^DQ2R'#Z&RP\O1'UOR14R+[M1C.ZX8\],K 84/YRGE?=Y)2**>.
M5_*0:(9B@X]_!O&K<S_SW,\\]S-_595ZU.-QS3&X*#N0@S/QX9X >BE"%%0O
MM;DX.@HGPKH%"8 $8I\R5D5JFB0+OF0($\FY=WQ.6<E,9P0S17>=?U%/9YR8
MJGI-D)FD#>9($1%C$Q8H>+YK"@3P Y[$1H7(/_7Z?LYUIY-!@ 8J^S?U/RW&
MZ%.*DX3K0D#2?"K*J\2#\8/6T7]%GR(6OD?9XSCEXR&:!,WC*-]=Z4Z9'Y2J
M3PE:H7<4PLKN8,72\!?$>$"P3^!!H=E!M>ENK]-YA=<NBC7S/9A"QP.# 9.<
MQ@81QYOQ>G[0#\2IMHZ]A+?%6V4\H^F,)A,D*4AI"26Z?'#5Y5*^"V_M^]%/
MJ[5!GT8F"#:"*SA4-^>#W\L7?<X?<_;"U"9\M>I[UW,WW98>/@2VX?KMK6N:
MB)3!$;:@Z41A3);HB8N"8!L+^HBWFF,(H_B_*>8$,6P7MN=&TP/Y4Z&0 S5-
MT [5E(83L6^$7!Y9 D/$>JS#NCMT@)"S+DNX4<.2I*P; *I/G99S8$>Z4:3K
M1)0A(X4A:Q#HP^B*T$^#XD;3H$K_$"-=?):PX.S$I) F$ <>A[O%Y(:XZEJJ
MUQMF=/'*5IG]6+%_H:HZ?B3;%&AM*($6@7)=3=KG;?M&[8Y2;2TET?D0GG##
MR0")WB&;7E'$C0D<E(24D5(AOI*4PGU$EY.Z)2KKU,NZ[(P@".6%FUJJO_9H
MD"30V6H<@/Q%<;&-?V/Q10R?F'*"OV7WZ[V2J.[55NH^(ULDX"4AIDEDQ,#3
M/*]@@UK1/41?+A- D0@FF$B([;89_['=V#K@\2Z^RR;FF&&@HSK5O$*^B-8&
MH+?V< 6%)SLZZMB^Q6U9M=(K4/+\\<).=I&MD=_WA*%IC3%W&GT$XIJP)Q6E
M[$%&9IAR#L-X?PQL1F'.)0UT+R5H,5$H?Q_7'[$GX@HJ0,?\RUCU$:K7ATZ!
M^;]+)B9C'(T_N5!F>QN\&4JC\*82M-H9KZDX6W;?5]NZ2<D)D^-5G#LQM%J]
M2+T?L<'!.^J^IUY>JLJE#0#I'41WI,&QG!KC$FW)) 0:J#"/03#+\W>)C#4W
MSS2(X*VUJ,;?L=ZG%=J#U%[?(:#8.P4<*?'U#GP>[L]\P0<YRJ6@*W)L3H4<
M*TY*>SYJ3-9A1'AU/#!R=,61/#=D/K?A>2.FA*M.;C[2MT; 4/+0MP.=\JMQ
M]F=\@*E(?4(7+);KW'B:*%PP/THN<2$MV'XG$^X(=>;!31MKFG-'.AYNI%BO
MB%R MBC=G*\"3$*X ).&&$%%QP-Q+EII):.HWJI:>Z+-9"&"1ITLBS06M#RT
MCYS)GDAZ$+YR_HFKYJ;N6I&'*Q2\B2]2KJK]<4H=-G+;Y[):0F79>;HYP QD
M>#@!O,CXFL[I&-ER'&.#^^2Y:JVH_G.XEN]+KYR)(5BN]"M7VI?ZR4W'[6C<
MX4>/]-8.B8)]12J IDC+:]#<5>7>&K?A" OG!],GK\N_E]V2'E4_ATRXESW(
M(UC+6.0BN,'LNL!Y.Z'R5>MY#7C=0ASFU)T4EA+_'?=V1U-87Y/ -%\PQI^K
M:95_04&]C[Y<5$>O-G!0^RKVX1DAO2_C64\&'?+;2!?B+YP>'B+6)@-]&MR*
M*4>==A$ECV/PDTNMP[#< -;Y>U<W22Q-"TB1L!2A(QK%5/IL+@Z[F2>0H-7C
M0=H[NB7.%.53.S,SK'EN96,?07K:U7+PO8U;TNF91[@T[QMG_"%PVR!7F/-@
MA)<V3K6*R3Y&GC%R/B</Z6TN'4:(^ -18)Y;8C AG,#.DVV-"%_""5G92U$S
MF9E6@*PB;,^H.89#"$51(4RYKV4B=V* :\.5T,(!.-?51JGS3:<^FHV7;^31
M.F,<497P125\\C'0PT\#N4%4,"+)$Y45G7*YFW[%-!ZK0^)R&48P,9[/-'M&
MU2B!RKHT6MNO6U!]IAMDU+9+Y26IWA;*9;$"HS: 7)8+27,=N11.PG2HQCL6
M(L71%$*KARM1B9;P P$2_S35D^5]Q5<H5;UEWN-*0*+ZZ(,OG+J^/G1:N/7^
M)]7'WPK\^MP*/+<"SZW ]YA?)OK,KW$>#5W.I$X[.<JZTT-E!!S;&N.#BYY^
MC9Z1)9'C&:S(*2=)C<R=:R_IH26!^9?PP905K*DV& (B%8U(".]K4V4SDKD#
MATZ1>]7$A)/C1R8,$(K4E75B8_TSX\]WN<)8<F!K34]KJGMZ]4)G+O1I%>PE
M*+%8D<<[4#2L(N"QD./"W\&02S'"/45EY?WZZ-: :H:1?$K^ <C5FRJ)GF[C
M$U(,P8)'X9ED;E4EWB)338@)N'Z,SK/*FV^I#,&IBQ F,>6D(41=UL5Q-6+>
M-+6*BZ9K4ZA)I+8@<Y(&M0KQZ2'L!/Z#Q,<)"9U>UV0M>0I4E;_T2WA1!1OZ
M 9#)C,.]Q\@;&'U+VZ6Q\$/;CL.:C-8BX[*19SJ@H]G1? WMUGVB6#\9Y/GT
MC3M2 U(^+F,.4\X(5,LJHP]M!4>J+0RM(%>U!L.894C#M<WI?2K&@":J4:]>
M_NGBZ5=/^3^^^/QK]@2,670Q^$@1>2"0*7N=*N/ZD- K4V84/"B+E_E/PDA>
MS8 +^@DP\-R0ID R[.$I\2K@V,>_HE0@**&C1S=L,#AJ&7&*A%%^@!74N#D4
M.7J(W+#>PT4M&8"?O>V@$,^ =FDOD_J[H\ :?IP%Z\N);<-%E$"J6B&6)-H6
MG,=D=W+_HHCOTI>T;\NNX?& D&2!UUEL17N"_#0%P3L,-"O]GOB$M#R*(R5U
MC.!K2R;N5G$\P6 *%S#1^G9[8+"7QDXSIF);NJ:+)'^12!*\?="F"Q^WKS8W
MM+WU\)I8Q7MZ"3YU_C$',?N.3-KQ7N)A>QV3&"-?CE1+[*9L),**!I<TN!U\
M_$9JOB!]"-Z$6:Q0M@"<X;!?@&-JU(HLBON#=V)LP9K=(16[@ SCKJ_^H/_Q
MS6^0TVB6RQDIW?5B4Q[#(_]A5;^MECYLUXR0G=Z^"_];ZB/*CWU%__:9_X=_
MZ!'#T8OVMV3)2)A#\O?-[3JXPHNP6@O*K&Z[<O>->P!)1^1!_\>_?_WE[[_^
MYO_];+_TSY7^T-"%_T/GQMTY7["MR&HWAY\JAW:K1'#LHKXQ Z%7^8P^P&?X
M8F=S^5<WEV6E1"K+:BNXPH1$\&P;C]8V)"H: &_/)O%H38)*2$2FP)VLC+C(
MI &4&3PYBXP"* N;S];T:*TIV,&^=AQI"?_)_.B&!,Y&\FB-1! SIE".)K#4
M/V.Q\6P@C]9 ('&B8P$QFS:X&HD[S!3(:2GVV6 >K<'X<I!)PX:8!F,4[4@P
M<[:51VLK6CGI*A*@$.YNCH!1B]N4!,H:5'MI"K*-F&]3N3A;TJ.U).5M$"GI
MLR4\6DNHWJ[+0V^</S3?>%/6&WSUV#76B$4[W^?(Y6PY/,Z:%%4F^J:QU)\T
M4+\ALSK;SV.UGV5%Q;=*"7QI* ]:*8OJ<MHHWA-!5F+'C/CQ@)]A:]>YQCVF
MC!=$E0B+!7LD,YI" F8(;IKLMW/+>M<Q*P:@U!BIU]'K82/8ANDBM5\Q*S<A
MD0#](1#%M%5D-B4J1$$A,<<XD?!3>=0%"'<X-*OR)OPJ?J[JJ)GMQ4'3DFM<
M$YJ\9CQ4!'L99HT<@V]\ U3D0!U9298G748 3,;G >3WC8R15F\7FT,?N21&
ME0K+J4^ CI,Q(^#"36OH*%L\QIHS^@M'IKXLY6TJ60:M2%K2IKINJ;18*;-<
MM=^;2&"Y]TA]PV&A]Z]HBRYR,P)71C\4IRIL:>R%/UX ^)=/S@#P,P#\#  _
M^5D<*.^W!*X".R2PM5)EYATKE V\*&MD<K"HWH3,F]?-LMHVD2Q7#T%*/(W6
M/_\A?1MZ"4M"".AE%!YKQG0UZJ[!L/=@6#ER2&EC#T[LO0#0RASD]]]>,5<&
MYJ6-&<(381/P#>CG.'*:3U_WZ\-^MFQOFSY*^-'DG$PUJHHRS3O*U117[N<3
MTZ"#Y!A2S49F 9-SFED1)=)@JOHD[)<CCLK<FZ.2HR;R@GHCGI_5!Q-.H*HC
MM@6Z!;L-QQET:)0H1LE)0.NL+Y)/(POJ#-3C;OQSA#+J_8XPGU;#,#3C2LV"
M67I%^G&IN5+Z68ARG_:(\I0AW*  J.)+K9C0U)N.LYKY87E=\;RQFN6&OF><
M#CS0%',1.Y["58S(ZZC3<9>S*XE5Y''W6!D9!L5WE4!I18*C!XU_NHJB &C7
M]!X$G(W/N0?6IZ0OS'.*:C1F"AFW5OSV^;PV BFZX'UFIXL1Y77''L6B6VI?
M=42RDJ[RYE"S=,6AD4E#\F8/QE7EA_./*PZ*0^9P';Y3YF26X/T=>ACF &11
M--Y?&<&^*BI-6;KX"6?P*F7&_3'C_@U?85OW$M?[#7TW94'*%_L]GV+Z5OVX
MXW3881$!F730IE C[GR@.3 F&T-*\R%B.#+#,5Y>4;V'>=AELU6]88IE,;L0
M0S.?^6*MOQ ,SH39"JO0>1EAH5T$G1FNRFV!!S=(D)V;E.]%<5UC5?!R>DS7
M1(ZD4[]"*>^F73A=G-M*"7]2,H+##GXCG#=(FHFBQ#N*80X:K%K9U1FGZO#N
MY&P-PKT:C+D;*4(R[UX,M%LB$5QD)>CMH]H_"VY)Q86"R=+030=>KF"91Y#Y
M17IMC3\V1ZM&*&</I:&<,>M%_!H$S[A?AU]]0TZP/>R11 &T'XYP&87G'=&$
MXX)FC?0J#\ZX<D_W$VL$U5+5=@;FOB2(\]J%VM;S<COOZB5-8_VE#!MNL3Y0
M$B]JQ\'#B^*CS/"K1UAMVG9):L:8<G^["\$OC#.N+OWUGOC^@RF66$\3/ XV
M LZFS:S:U2%.AIS)KKVEX85UV^V9/J3:T)S[]M!H#*V#%H,/A-I.LR5.3:4K
M4"H8^0/.QCAN>5 .[%@GX@D(H77@"1Q;,XYG_1KN)5 ?;"4CXOJM=M+@$(B\
MX=E!X,M\.^723E2H/2D>)2ZS95C1XVQ>]K64E' W/T-A*DTT3P)2@@4')UBA
M9,!"G!@3#O*'#E;T9VG'1:)<#MO=BJ2CL%%R$HBD@D\3H]5+)G)7]YBIFAZD
M\GP.8V&V9W5 $)$[A%'_H98<_@DD\VJL4O@$LS 8UR&EC;^ET1WQ7<R:3@R2
MF +RGX)X9=UCKJMR&39:MX>IL/P6IAO!?*6D@ZLN/&EW@$G%W>N'G!,[GSP@
M?D.KUII?S)LD/$ET9;T:K1$[AM\%;6*N6TM"/*)BP<HW"1 V^:@K7E<'3:&3
MJETB>@NN^J'[^#]NVCDY3K*;- WB?Q .#80071KNN7'SEOEB@X-MVN!^BWA>
M4,UU'UL!4IX?L&<Z>?A$BR@-1U!@T7"D@C+$O<.1W\34E/?W9Z(Z# 9/4Y'I
M NJ6T,]^YP=PXEX=NQ'FT4T%*0B,<N]+:J'B#CV(?"930D4P$H2G>77UXL4/
M/[[\CG?QBS7%,I_GZUM20/C37__O_^&?HISH@KH?'(7W3 69_$;J9!.R77K9
M[WXV@<5:A#NB_6#JT^A+GSUY]FSV\A!V*L9H;TH%$_[\AI0AJL$J2'[")HCW
MG&RDO *Y31N^0QUU/I2QW7%P5]MYV'PMU^EVQ-:@$0<S= [>(:3K51LSXWY=
MK\AL%L<YF=:^7)#TGRAADHIAS0%7Z4F_T_,:Q^>V7'2M;C]W8!:2'BR.QA7(
M9E;HS+J<N)+OI!GCJ %E6MWQ$NP/4D9/+B4@DYW<R/HM'C [WFLF9,LRB(3'
MS.4;G%EH5XQX/$G]6@A!6_R5E3MK3^Y/>V.0;& *N0[O7<JA;[VUX92L<5KD
M(^-KZ9.%W8.HHU++?\>W^L<J"E?,<:SWQB"YFZ/EJEF1L'P,:1XH6I8J',Y]
M1[ &,:\=Z]8H17GZ!#^$6.I&Y.'3=6\LUO>A/MTL#][CM'-(<&@IC^TA<KMI
M@Q-N7)\=P_1HK%J# 7YD7_>KX\=/1O7ETW,O\MR+//<BWV.<3O4!SS;#W4$D
MDF/%A=\LL:HDA.:0W)W6.6<(T-.5_6V_#S$YPHPN@<](D"^D]:<\+W%L"9>C
MQD-ECYH0=5\E[Z)@*\NXBC0=S7L6X72X[DKA6IBSQC,QE%!Y:K2V^(YEDU@?
MB9&1JU1)D(3OD 92X<$@Q_?@RH)9S?FYG<,(T^OMG/@]L+:RI!II4.K<>(RL
M(\*$9FA?77/G/)M>=U65! :91A_;\DU%67U,YV.RWB/^',-50FQV!4:8XT-;
MZ;&P,Z.0'ELAGT_11[&ZU>EZE::J4MW*5IJK_;TR6<MGM,[4PEN!1;.I.0A!
M6O0TN_*HP+I(%AJ%2A?3EJ4!5+2F%=5N(/]NVBDTAKI5PMF((13D/AZGN*/"
MUYYB2J*[];_^<1-[U-"5MHRX)[7&V=V&\:KBE^RKA4D7D75<-0T1S+RL(!H5
M/EW(\;?!YB[^9'B*5=V3?Z:F\HPI8+^M%B&-#0[V\[ 0(:G^7 $JRYF(%_V7
M^#1@(IY^,_MC[.V]C'JP^J^)@WCIUT4$D/ /XY<>O;+\VW-I=-%O2V_R!U2G
M%G3&O*P(#S'[<Q34OI3;/?!-_D(4V2@?9J(K)O];6E<C,I_+1ZQ=\\-S/%,C
MGS=LON<8*R&?0NO!FHMQ002\B#U*>>2\E76R[N+]+]-O>VK;Q_:O%1$7\G(X
M?F.E["]XRXXOR7^H<7:88 ->839O*:"8?:*_%TS^NP,1^Y5.C^=3=GH1:*/O
M7_>QC$WD]A$DHH#D9O'PB[6NI^Y8IR,J:OCAXSI#XG=?:447R:DJKLO?(>NN
M&J2L;7==-@*?1M>$PC(Y?Y?=X5J:O&H::)X?V?$I>'GI$F(>H7)FDME2:D*
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MA16MH4/W7;Q:Z2ZF7UT_-63)E#BL;2X,P"K4V6'%K^L;[T^4>+IDH6;/7),
M50:ME2:*""4"5EZ8"@JKRZ2WN@\.7EI>?7B&197$ 4YRLJMVFU*(N6.Y[J$?
M*BFM>5@5D@#=XXEBSJB-P$4)'GCJJ8>O<+"#A;[%AF6(V'M6IM]FBJ7H3$6K
MX[3T-CAJTI)SH +7<_>WP0?4WIJH'PQ_:H2O+O@@U41JJNM6VH%>*#2Z('\M
MTXYR$@.Q"#N2 "5#,)>SE^@RH>5&W7K://PDXV'XV+.)' #LF\]T4018=63N
MH-9 XX'\8!Q\\:%GZ\ -J= T1G"*_*WQ8)#0OK/IB>V,TZM(5)T@_:0[UDO5
MB_YO## G%+!]0B+^(MXQ[M8[??"(IJR%'Z=]*&=F]J$8W-&J.D0JO"O?5E[)
M\E<[ B'0, +08T@&R6Q7W7MP$M,^X752Z(=B<EA2/O5X']PS5"!5XY0,,IS-
MJE@FRI+^C CV3B*>LQ NE0(]1^,<RWL-5<G.>UGJ3T,2KX@Q+JG1D!U! &Q/
M'N=: CT7Y&O<=.\WT0@',_>J;):$..5^W\EX)TCT1?KL7N@9J&SXMW;"FQ'4
M/$ZKR56$0^\$)^INUD-B,WC!M5LO6G==17._WE3SI)X+-8MRQYNTKDPR453]
M&J_TETA6._Z69+N:3 OVA/HTJQ\Y#<+XC:J,A&ZJ*=^A+:/R.?=(1^6#:L@E
M=_PM-25^=45B<(3_VW\^7Y?@.8WS9)OR-M<QIC]7;R_PQP3L;-*NV_#A>U;T
MN2DWARI3A[ZNF@HB1QI=<:5IS%T[>D%3D?N0?NI*%&R%O9!S,R0S\[H=21_%
MW]#SBDW2[Z^K\J;>'%,LY:B)%9SP+$(B2<HP)OGXD]6'(J I8JB]YG;V4'6S
M//0DE:PE%.HSN2!U(5K;0G7+&MQ0CL:7%C%K"+I3Y$[Q&1W^%^2A#EM]H+JA
MGP(QC1/E_HAE_KX^-VC/#=I_G0;M!Y7Y"XF7=!"T."V4PN1&MN1IZE[('91N
MGCHV,O.2Z5,A7*"*07[V9M#9.%,_T(WFH-LI5CE\HOQF2CQ^.?O9L%154Z+;
M\.>J7!\O7FWI +@*T4NX04@&6<7M*IQ0G] /BP;AR+^K(F%A%\3LT]//BWBT
M;ML;!<&7>JE,/-O)VP]_A 1*] ?Z8[^OMOHB]_G9 F'65I=7^KF<Z'!2O+*I
M3#VA*6?:DKI6%$I1:D=33"E'/HM& $"W<R0'N:\-%T"BT%TSBWRO#%?S^6S$
M+"FV3>Y-@-)M*;0+\;=Y(JSCZ:BQCRA4EGVBRLC7]M68A41)X5'QX6*HY&<>
MG#PC9\51Y/JV/(X;:Q?MFO*2D&)6(6WS^MTX_C6*I^<,NS?L_OT%SP)UU4T=
M_D8_/\; 1+[;"ISZ^'0W:>#QN4UN3BF791"I@4+R(N&<"Q^)[NK1UP8'6T)*
M OCMIE%9>U5W'%ER+4[&ZD=_F/=4QJ4,Q"WT^!J[33=JVO$;%/PNI'5FXLJ2
M2/T%I2':C*CO1$?&!94#B5@@/3I6C,==+CMN 26#5_%SJ\]1S+K)EPL_#Q/C
M9$M(A57MF6A41_(<AY[JAQ1>U0T_!I<Y*RH!\!!'Q3!WKCAKD1=%13*&:NFF
MSR8^ P=Q>XRW;+#='[)_+JC.'I7L%[]"U&^J(B)!Z_L^+U_R$0GO\>JP(P\;
MPA$2?>\.(6N^%H-#M<&D+!+P[X@THR=ELB(ER/MH0VEV?AO"T*J1RZE(GUV/
M@1?^"E%V-=D=?";!+NB+1ZLXYF1.64J7T)58XL*1 MEG36GD=NY&DT0K=1T\
M$Y =P#H/;H<A4TW?\ZR3=C^IW,Z9/>!R=L5EHV!B_WW@\:T1[1'J);#Z>:M-
M1:,4%FH!%K%U,@IA6\-E!E\0KE:%=$/5X%DR./PN_8&^R)*T'7)-3ZI\WXO6
M7![0@6=-IT3E5OGE]E'.1S Q_BQCZT+JO>*7$ANK&S?2T<O$=#P:>-J$98>I
M;G,MVKD1A:YKL.AJ;,EDM\*RP;I+K1>Z\K*F'C#-[@R,Y,-42[ZM=# 9U=6%
M.'-I^V*KAHSANL,0-&PVG,X=G <=$=:WUO79KR=&E5B+PV7O!7_C!)B/M+M=
M%;)>?!+.H-^Z(S:W!=?6*8^40A-^CG?WQ)Y#K*"W=%7I0JK4XH/QV[%'/IA
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MGL[RQM/>Q1]<IF 4O2]P"@^ ZTTFFD.%L/(,V;@]^:ECNW9@,X;V#&G>)_?
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MO9B7U)1QR!1_0-)@4[U*RLE*_Z:>VT,/!D49RF]0CPX[II187:LI+YZ/$K2
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MV<#<1'WRM?__]KZUN6WK6ONO8-R>3G*&HGC3S6X[(\MVHS:Q'<MM\YXO&I
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MN;*1FX+/V7A_L79QK>/<%'#"L'1FC/IERO/T'3^%<U)Q:\2EJ7DCQG*N"5S
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MW/P;R0CY8_OPNVW]BS\T0BCCA7/ KB%ZB<;C>6%$9!EOF<6:@#MQD8>+%VH
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M"Q-+2DA= G9Y#I4"I-"H?A92W%882,6") )JBKVAT;Q,9M*Q;NMI5>F&;!3
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MCJI=W.K*VF!66+?MY,72BM5O0&?M\NM(-)/_6%>Q^0P)0_BZCUBET/&.%OA
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MW?KY1?T0E@7U"G"TJ7#!A8Z<#T@M_KJ,SK@:V>85A:#&FK!>;>M4;X$0>6!
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MY3)7$1%27HGK8-6VCW=F*\^2; '8&^$D7A+MFBT1Z:P^K+9=*"FT+8/] ,9
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M%8/]8:=GQM ;]&]G#/Y;.6&HF!2@DSR.- T??08(J0DA><V$*(&A7'[&N[>
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MYW2''%6="[ICR3#<737&M),-W[M7YO1FE\>/4_5O,++'&0/;:6-@;0SL*\7
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MXK:P?W:$\+4]N:I1G0%PAAV_96:WOZ"/,R\FV5W(LD'GDTDL#",/0JQ1)6G
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MJ+R4VQB3YJC_,'6-JG,V7[JK)U=BYD*(Z(PS[T6P+&R%L>&OIS06V\L:_XG
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M]JT$3_-WHW!&+Y:?(6\,T0^FB(\*UOGM-M5RRYQ+-K:?2$U-=1ER<(Q2.Z6
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MH>+9_NKF8C,<R#M\O],^SD9,B*=,I97!:'".Y6@!&6:S8J-,;FN90(IN7\E
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ME00P.R_1N*J540%T>^363 %ZT^M]O0I18@K1J/DQ_\(U+?;ET@*@2153 7M
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ML=?6+X#/:<G.(^I/^!==/X91QT!<0QE:1?&,MRY9S32[3-G\6FNTS#W:LD[
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M#8GR=;MW UZ_/(\#JN\F)1)M9-M_/U7N9IGK[GGC)LPSH;A,#W]E[YJ9,;\
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M0[1'VB/;9\\B5B2".EQ-[3_E_:J0_B4)+5I<2E%ELM*^38A*4N+SDOXU<_6
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M%*:M?8FGP86>(.AQS\?F%G;>FD<FPK5"X;_BN7\])@WYZ$A%+8=8R.L1]2K
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MVQZ$]#:YEO#PYJ;,^,XAK6X<#(%DR-3S[AU:%U3XT55AP;WE%KURG2%ZXZ=
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MZ;%+TNY+ENI0^F>+*L/<)$^Y"B(!MP%CN4F*)__DL)]-C/VW2S'].R%B>YW
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M8=$-3R0GWF9Z7YK"RD/]UM^1(I,;31.Y H*$K@CC1MW0DU"NR')K"V444VC
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MG!/2+'\L1I<9SXT.,IQ*5']9+:IXLL@'Z["X9UFRV?5EO/3E>'^\L#B2\'&
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MY)SFY8%@9CX-VML:?)+VNJQLW"$$==9'CI3$F"R.O0F""=5N=*B\E@N2D!2
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M,>!46M@D +V&(^K" ]AJ/X@44/\WST5=A$#B_\@R0+ YCB6%X>0<'YEQ;"8
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M$[[9RGAJST"05PASR^/KWT<O:I?_%CTMJ0MP93* ]I #!GRG>=@F_^#1[(-
MIGIT5W23/9'9S\Z>]TL?K^9UEU=#0H,L*E8^U*W5.2)$O9(PYTN9WJZ&M91.
M#@B=7O5:/],\WTVYCCV7N_FZ6:H->5_*CVL!7%A?APQ48F]@)Q'&>OV*:>Q+
M:XGC4DMLK.ST/ :*@OBB31/H"$0S%3^1+K;O_XW)$E#?_SV]:=P]SND.9_,
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MRQ9VR_[Z-Z8'=A9'=!\_ YB>J+!W\(I!J$=VWAO9<;AZ2]QM>7(<FFI6#C+
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M5HH=6,^>N;'HX4\K ^/QZC$XZ.M3" >2!G)4X8.(.X??V(^&$F:?U(K\TXK
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M'FMD['C2$AOBQVRY!V>F$O+\7BD3(71\HPP6_701OPL5S=2UVN_(.'7^5./
M$D3.9ZE+Z^QX*HL7FLV@S72:B?@)G]D.X_&#XIJA[/BG=90XK8))J9J$U\10
M>09$'8L4Y]>K3]4.CL%%R<?J*"7'L*7AV6""> CW<Z%%ZG>KV^6\&]N9C[['
M?B63+G ]:^S(^HO=VU>G@\DA+#R*"#TYYDZV]\I'Z'RO5_<(T-:T?^W2NY*3
MJKNMOJ<18YL1GJ='U[WME1Y)\N>-H_W59HVNG\Z9;G%?A%]". YMJ6T]G[LP
MK+KF4#^BY"U"<G'Q(]3>M9D=/1J8J,N/17]V:$7QD;4H*:X(S=*)&="VC7'U
M5X+B0Q9#XYHSIX>;U]*$6;^#=9CE,.A)\-HX%AY/-B!!V['3@?V6KI8'N#9G
MVXPYT?I$-ENILQW;[<&:G4+M@7LQJBZF4UY$..B.+7UN(QPV!V$'4Q4>NK-)
MYE[,C7PW$&*T[\N+"=$X9)UQN-W\*YA#N@4:MV2HXEDCJ<*S"-WQI\?4JE*P
M_1I2/A[MLNN]\HY\!8L=V%P'SI@C>_,3.0MB-&!]&2_;V6K9-MA;8CUK_-'Y
M,)-;G%#ND?=J.L3W$E)/KGED5'"6+RV-D'WQYM"S"(-:/ ETZ(#SJQGK'&N!
M"JI(5<L]N9R?08):%P1-_CJN,0O7I0Y094 SO*3^=RC'M-^XX;N.\SGV&^AT
M4F_AGN:;Y)_U789'KFTRXJ(Z\>ZAO^)CT94EE;BMHS\M4E$OM)E$'.<$JM A
M[P5]Z4 )4?]4Q*++]+#ZDO87KEOC/;YP%FT?*G\*1@,O7J7M30..<4<(ME\:
MH+!-/IXFQE<>+*<%H"K; 63!F&"LMD<V0@N_.(;&FEP3DS2HE)6N_]IEN*=L
M_HUA]0YW1[6ST,;#VHAV52=YNQ^YT5\#=K.2?@Q$PR%0<;(E&(N'F>##HU4I
MJ.M5A KU<]-3*@*&H7E#*9I,P7<-L')KJ?L[Q%?#Q8_)#GB)9E=F^3F=YPJB
M]R'@=MTF;("Q\?E_Y8V,7Q!7U1TM;$<-=OB+[]:NS.;.<#\@MY^3QI?W(_M0
MM8ZDL]2?Q:929C^B<OH6SU'_]B.F5[V_3W+6.TD?*K43#!)EN&Y^PCNO#UY'
M58TVW*$*FJ3>B"=.5<G>_7D3O$Y?I;'_;*Z< \U+ QQ1+3J?4'8;U!&2/-IN
M?OC;E(_#M(\<88TX!1["Q8?;',=WQD)/^U7!C_D-MPDF79:7,;::;$LH9+X4
MD%9]G^5L.[(W5(< ST#A[SR&,)/5Q6!86U]Z?R>&% ]\UGZ*[^&.03%^P+M^
MRWN:,^U\X%K/.SMY]-2MEK-F&<I-KI*#L8@&PO "W8_>FI0FZHS5GRV<OKMZ
M,)?MXL62[NM[)*AV^U?O\45FCA"!'U(QP%&N7*;=Y3;WZ%IX$SHXR6_:0C]U
M_.JPA%VU?JOUE9Z/HE?\%]-?.53;C.[?78#%9C"!_814&H!5WQ JA:\RCOUQ
MP2%,_G&&U8T:^:,+Y,\?6+M'NT_%SW%Q0OSI33B'D"[QLR#>'89;W7U@8FKV
M=<0;M.\ZXXSA5^;6[8O#C6CHK-50:A!WJ%R45]03LY?@&X*6_L,Y/,^,U+G*
MU$V)]^(QQEG(<137K_@081K0S@DAZ:/8P !4F;6!6$J*LL<BYT>1H\K:N[MB
M07*"':C*B%&8_3+8O,#-.N-7;G+L7/\'9X.NUQ)&EF=.G6!^>Z2'BQ6?>$W9
MD0=OT(R*0/+0<<"]-<5&A9*AB##(J2AQUX;[,S&_Z99SG;CB.B7H')-AN-8?
MI$ZZZZ?8B7-8#U\PL5UH3*PM#?,NME2P5!"\%LUQG_W<E6=G,].E/(7T_6=C
M]I:AJL@Y-$?C&6KG04=B] ^_8<OA<5.H4-SL]'HU<_"].R7S"C[)-[C\F!B^
ML#:@FK6A8FLH.F&SWV <:#MJ[!!48&WZ\51:4V$S7S&I4K+JEGLG/#/#\4QY
M.X(5&QC/CQQKE*=DE6IK%OEI83K#R?*#UC,NR8_&7"(%3AT24.D5_]J!Q,;E
M'MF$V6JIC5BUPRL$V[3J3"#6A(U!$X6G(B\B+'\6>/ Y6L<W5'BO%N37?$!.
M"!</=**BJ!R4-#),J],U2-;%1K&V6H,$S12:*>/5X&AC::8J29=;I".NX_-?
M((Q(@>T+Z(ANSNK6!DASL[?.A4U,<1&.G7?[C80=<B_SX!&L]A C[/+]VJBE
MXTMA>LEG^,X9QASY*BGQ3$-2=*22D$GF;;4<>^H^V7.@<,UITWM-(0 [;YR\
MD(@<6&QIMX"UB&42I(<:^[)>_K,[8SO13E:9T<(.+^2WJ#P&^38N3ZQ#O/)7
MS[H=:VD5NOSUP:L%TC.7!>[)Z?;,2FAZ$('%E&7E=FU:^=I0N@7IJN"=DN?*
MWM%>,3)2NUU8M$74$OH,]!AR+!G]);[#-/K"%3]W:X)-R$<7SV[^MC[;KZ&X
M9%W<<7O[7G%]E9"+AK]H0%@F!\R).Y(&5'2&D+T(%\8&=(<0JE(#$VDG>T*M
M?DP<WY2W$M)A<=E:W>=>J";S7;X(#A*T+N/OY3][VJ"(,_?G<5=\>]5C(W)^
MB2%PO9,.X#W,Y-\IJ,M7?MS )D<!;O,=L16K,@SO-/(FOP4.%_RO^,\+_\?S
M_6_CL!^"'KN0OMNQ#BZ9V^Q?#[B79$[#V36F9-X7[?R[3ES5K:AM#LB6\%A1
M)KTGNI11]2Z6>>F[5+[?J=9_)ACUUR?^ ]OGN>M5<"NN&,+ID ]K@U:)WS_D
M/$XJLL,;<G#)9;\//JM]<:&?NSU58^AI\<G.V\,,^@*^+^7+&-'>&_<-Q I?
MP\KS6VC @73C[S#F+1C9)$"!CZ'W+ED!'Y:.B49S68(.5ZKQE.FWBJI?UW%6
M_G<VNAV;FF&RO\3"\YQ 5$LJ+%35;S<68EP^M/MU[_&7BA#;2%]>JR,LFE))
M:ZEC[X.U-Z>)OJ"#/99[HQ?%Z,CC7$=N]JSB^0';"^Y@&-!D;#A\T_5"%/"C
M0BG41@ _$%.)YO^9JM90&O$K*^?Z2,BCU"=G@XVDF4*:FA8"CF03I!?@P51E
MM1R_WE8!X=WDMT>-/7.-CNOHVDO@IC5*MJ. +CSZQ6[\(4>?U/.A^59.%\S?
M/WXV-*:<D/7M&O!+*C$PR7+WOQ]I^<]XHA!!FE@+5A*TL.&1VD(DF-^YX=L5
M^/6E\>OC[@]X6=[>??TLQ3[6PO.SR)<[9R3Y]]*1SDY093"4SGRI8!Z.<@'%
M:./7VM0H-0JY538BSQ/]K.WUH6#MC1-WSFO>,+!DB8=3TM NIF+6B/O/,4H=
M VS3H&V'^DO5 W-*D;Y&"3'L8:Z;O=0GJ!C7X1M?685(Y] ZC3S]N*UI5F(1
MG=YS>K6HBW/BX<_OO[14&#IG['&"L]*S2>#4Q+$. !Y .9SUI[&J_\/#7'?3
MJU^*.O J[91.'D9*NXRACY[ C]#M*2E=JEL4CD_,F:9$NT@\!,^Y-TD[[7LE
MP.,$_B,".[X9^[6_'KGZ[UN$JO]MBY!VCB$XCDV_,G\W$?7"1G9XKF-B@-F7
MU_*8'VD444#L0SX^Z_9$.3]M@=\]%BDCSFMBC9 DF#6Z+%5<,'CK1 R-T3]^
MS32]^H%4J?6BZ?'2N]N4GSX<XQE!D8N6I1VFQYSV+HA>)Y\AZ&RO"GR>L39B
M3OY:YON(DZ_F%:(+D';3/WX_]2[U-)ARBZ"?C\'@!]J4[_ZQDVLY\\6*_6Z;
MOVQO)#O6Y*MUP6*8QS>=F_>[H16/@?L>NAF?.D.<YK0(05OAE;'Z\%#DJ?+:
M,F4V[Y]Y%3NE3&6WSV(?HB6 M(16CD>QQIU(I3+\9GQ!.[ZTK3K%HL/C?#I'
M5<;3S.1FB[Z^:>03H^/2P5Y1>_T9N]F::]>6H#W2X3-@>?M1OXY./=-PR_4Q
M=1:&TU\2K8)2.5?9W2B;-& V\?*#@(\=?GW"#C%DJR#_DF;U5LC12<5T5VV\
MB6I5G=+<>8:'T;Q)-<U=LR$AW?R;<W =QS.)7 %F3XAFVAQ^6^W++:Z%-*"E
MD* TK8>O$#9XYT1\#DFV&J /5?4CI$W-P&.S0G"M_>#Q!95F?'E;P'.X5=%P
M7GU5S1?/-O\;;F\03<",W?TXEWF?G;'8^E_O,>OO_7WB"=QMMZ&J2:WGR%KC
MZ/+!Q<X(YF2Z-7DBJ9C+K8+JTV_>IF!5.M6LC,%1;/KEBV-;2Z !ME D7>>!
MH_SIQ.^]"!O=HI-M;8C@3:T(W >3@.]7CPU8GE]ND+R5>%L[;@OG'E5,5L]?
M]2!+$.ZUS_;MZ)U.3;3T'UL-\:E;<OT:U'E<BIRO@5-W0RJ"B=R\CE/.9$6"
MU%C*3^>=U3.GJI/L[)D"NDFS;>U)=8XP[XW^ .242=JR*I]_:'S[%N^]M0L;
MKS+9$<:N+.F'^L;V$HU<%^<K[DZ*WDG1RJ6*-7'YM]]\3F^"/;Y]KF">#6'!
M_T/0;/I#\I"E_W:.G,!K^B1T?@W\6)8_F^$R1F0RKDX,<F3J^N4>VR@[O)LN
MO,W] BJ'SC@03 S4D*K8D7]K)\M[M8_E#H!STE;^QJ4[B8H2/B!?H@$OO!&:
MX]-7YHY1>27H:]BV,P7MH]T/#O3N!9 LLMF:!G2<? AC(>*7\\CNA-O9>:M[
M-Q$0PKV8L>NYGRT'%/+?^O6?S#8DG!5BB$Y;>&"*8#0FH-O-0+?YFQ!6LL6I
MF11/J\8W7Z;\">_?G^M#!56[",IJ?C,KGX8V?'90/?0CE<7?=:]#B7?*N?94
M+NI(O8D7)Z6A?GC6X%1)KT#25J>B_;<5&A#M9O#!Z3L"3I!JE!I3[0"ML'<V
MY&__S!I)-8:?WNGAL.6A[CTYM\'@R[ 7MNYEDUT^E^2@V0_X\V=VT !^:S#0
M;,0.A&'K @OO9L<I7#!RU5Y[_824?O;\S.GFM)?(IQW^K95T#T'V\_>*0!!Y
M%/Q$Q.X_4IEH5<A_9V=&+$A28=B)?^,J'5=/L*FI3OM^3"B+^WP*MCK"EK!8
M%0P5]HO<G13G"T+H5$^>Y(KJ:_.OP[]XK6'SR2.U;PAY'BPT"[_CWWC4KZ2Y
MR-42RYQA=<E=]$)!E$XYY$V8PC>6HSMI3&MU_OVGOWDEZ<9+P83)-[1E:ZO)
MLDK\(L,(UVM)2Y9!60:+83MT/N(ZF51=XC7-1['"&43N_E0U?XY1CU)JIQ19
M'*O@M<2V3TY:GO&] K4_<GRCJ_7(K]@*YN9^)NWXN^!R\8IE(YISN17&8[5R
M<,N73I_<C!4^5Z:?N'V?CCH88HR]UPY'7.42&C]7JTXYDD(#P*.9&)MY0I/M
MPEXL;)WG*9UC3:&5?8;L]4X'9=( SK4<U/>/*!H0<IC*AVH-6)G?E873@(5+
MJ%#$@ZK8BA*X+)2^P,-^#:)7;J%I0-.+OSRQW>#M?L"O1 /P)V MC<K3^E.*
MH@4D&%5D7)\&9--;10,8CY%E_KX>V.HJXOC5,V>=WBSW>R+44&.ZW6$SQ>?\
M744Y'&>%ZWM,3WPY#?B;KXK_FVJE,><'JZ+#_^]I(,44=,(5-$KY21H31,_'
MV_,?U,GS*C^Z5]+;#=E<)I2\K\\G6M. 1$Z,9.:^K1(U/K'!LJ#M_S5ALI-O
M 7:3_D".P8\B[MGB0XL0*@N9W/#N_* O^*)'3OP1O9JW'_[@G+[UX"*P[8G2
M*]RY:51-*8!RD.^!X1\1.J"3JV"8VL9#E_(\$Y[DT6E_B&.,?TB.(B#%5)T!
M,.BRQ.TMQ'?"8U&L5!T_7PRL8\)5S1AU3)+N3KH(!%JY!!NVRHBDR-X* Y[U
M!#PE5:OM^SZ!N;A:X10S"4I6H*U+B4NJ2>&4T_GJZZX5P\\I^Y*Q]LPUS,_Z
M^NCNN[T'<7D=C8-%457Q)65>!)?6\QG'QTXT;&\HK./L[DI,Y'L<FDYOBVLH
M8(EW^IU=F1W)6IY"G_V]Z6A*#IL?A=#\U)FUDIH2TBB^4OMSR'XLMO6BUZ=9
M2<-/DE,7M\M$JEB\0A(O6(S *[D[^N$+J/7@1NG!Y4FLW#L1.1&YCTB?.*?7
MEXUVGMK?6U?)T.W2D1':S4)DC+A#7^_;XMC^G_;> ZRI;<T;WX#2(2B]2$14
M5 2D5PG($414L !*"XIT$1'I(:%(;P(*"D)0FDB3$I!B(KV)5*67 %*$2")M
M0T+RQ7-GYA[/O3/_,W?FF>^;^S_/P\[#7LG:ZUV_]:[?6_9:>U.ED!TX")47
M<1?*JZ4W$U"ZKXMIN5:VT'O-\GQ%TV8PC]DM[9G:E*^B>\^OEYKLYE.,H'$X
M9\TXCA:D]"<MQ6DCXXBUY32Y88Q@F>%JU!'[SL1Y-0!_"?4I7EV=L6V*O,B%
M_HC=.X!4!]>:H67P)BA[[I?NMA;WR!Z5B)M^BHGW4F*THHXL5T^*VK*K+JC;
M;BMO5C>A]]Q *!-5(O!Q&H9YE?T$R2K#;V+U24^@2O&&7YY^2:A18EUZ]3+-
MDH]A>NKW3N)R \SY0W6L-E-F4UL5A0:,_:_=(B1##Q+]-O!_8*7ZWRS.Y"(U
M4<^M_H8K"]>W9B,HB5,BJ.%#RS3@+ 9Y\XK#HQ_+P?_0<LI=B=U4V%P(:$Q]
MVTT#LN=*34M/_+ZD4'WR/Y05GJ$JTM-:.A8Q$Q%WDV@<"\/#*=K$UI>CMXTY
M%#KN?37^X$UI?E17.\W,E+8K4/JQ6(\^$^$A4#XMCQGX2)=Y'\41?]K=)"F
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MS1818SDWD!V^#</E_- 3&=$JZ-4$%[*4(1B [^9]3_35'CB'26@Z-1H8]6!
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ML9N'O((B*:&:;! ':, +\@5*#@V8<>U'X??UXA8Y\NF]/O%#1R(7X>M[!V@
MD1_6&*0U]C,C&?S<MA1UWP$.:E MBLJ8_ROP/Y$5T__OVR;GH>;HO\?Q:\%?
M@ .F) =,P,V;,QSI'.DC\]5IQQR/'W:3Y+=76]3=8[Z:3SDD\J_\E$ YL>+O
M5G3N54KORV,,IB8 BRWSL3TK%K]-SUWU1M^MR;^LPR6=&,WND'$64'0P5M/.
M'/2S4\_O^V-YZZ-X(QL4:6H&\^/Q=0^QATG%WXL*<BV>'0I.=T<K\I09H#<S
M'@>8L" M^3#?IU8LR0ZJ!'WJD8$-:Q$(Q'54)]RK,MK,0[DN1#7NO;@0)PW
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MHT1WK_Y$0V*&1^;T9FD\#7#M"5.-F,E?>4=<;;:1J!F4?6B8?;%DN'1D09+
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MK888\M1PT^R'*>:-Y6>W0?N9D<RM!O_<KB0963;1E6<)!0>]R&.BPH]G<VE
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M,Z%^L*I6BN!QTY4?4[S5%./J=.WP/3W[$SDNS(RO($& $&.0=IDI:Q9#)3?
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M2K#I3C;:3BKO-8D+%8R*?KB65&HQ*Y^U"PMK&9Z'"LP$CWM[1\-TIMZ9+G.
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M+Z;*"$+(T9R^-%3%<I@[,,2,.[YTMEO@D:_2K_$=$4[:#E P/Q>?J_:SU9X
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M6++T5SRE!$\MB;>KF\5+6IXM$'M\UF\)CGI^!/(6B/)B<\T:[#PNML=I2K5
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M+J[\<9QXR7][FFGFY)6E (V)M+G9.^)5!7;K66YR ^C$:XL;J]4!NT<@K<_
M#O41O)'D57L$XM3K7.>[.-"[T_^IM2$)4Q?\YP'UTY=S!2>6M[S+'%.]4JA:
MC#0VV##2WIU5!$H^K1L,(+[6'2.ZN_(_Y/UQ_AUF"JQ4?7"@/J^W,3B/GMJR
MH$)B-]J'RB\_N[>3_4EF:7Y/"O,L9$B,94(I:^?[PX]IBS$O!][P#7A-".WG
MW7NYG[([/!2Z#N:BZ5*-HROU*4NO7LASYU?[[-MQV!FX#!]OOI,3U3+M9GJO
M'ZOM6)Z^(^LRF->P1XM'\:$V&/GZGJ%E?.FB?PW*T'/V"PQQ8CHNFE>VXG:O
M7C#%860SF&1\=4GT%?(*G[_CA:SVY6Q87FU*UYS@PAI8 *%GF/OY[#N18$:5
M58DZF&"KHG>"675:T^>W/ED?4J6H+X] E)E%U.4#R?AB?;5WB1^O9O:P[8%E
M8"CR%8'HK.=+V.L4F;3#YY[F*DA["4C5?;<YFE!\_V@.F*C0K3:E7E?_@'%I
M^01:Q39S?+TSK*S_#+ND._8O1#,8-?\6(QRJI 5'];J=&"A5Z75/L#Q8=,3D
MN$"GT+M-9%VHQ<0.K XZ/T*SSY [_";O@%(Y-"FLF+8IR]P-$B4WM$GL/S<*
MH_K#!1[DXKH;:_+W7V1=T5M/V4O3A:060Z?W2$>@J&R9D^2<U_'OSXW6N2?X
MTBY_?K;OLKJI_?&.;&+4J"1RS)@8O:.2"JA:(Y66=>..0&P>8\0[GE#"9M+P
M'DS-F@!YZC^W/Q%1R$B :PB!^PZ!N<<F*K5&\:UZ(.3=%Q,3DC@LB@N(#=]%
M1V\'V8=#ZR?-SZ*VBG4Z89#/ IU)(8K+A/$$F2>'R<)!C"H1/\SH(2\C3MQ%
M2I8=%#T;0LT7H=ATKCXG.8]N/Y_[2RVQ>K"CL24ZNW($8G"NSIQPL"\05V3A
MGM^:495"-^?Q.%YS!&(E :?+TH*V<^RME>B(G=/\)KF^!_/U:$ A^-EO&VG5
M7H/#F"<\'PE-+'^N0:H@O]HK]6LH5 V_GV 15( Z)\!"B/E"DE:]-F+DICU)
M>G"K)/!^[0\W\PLLS).]M&TC_@QR:1QF/O]1^TF ,#_W4JY3^$(NN*:E-LAH
M[5;B4EC'3;K#=,J5$Z,0,&H^-QS%UBZUGJL5U4M>/^YVN[<?=O;]S=2H[ZF)
MYU)C3!';Z)2*PISS.B6EZ8D]1&\%B;->;> ?AS<!)\:M/@8\)@7SKS7GQ<^J
M,_??T<1)?]A3>ZSV/6-@^UJB'JOW;[I.%$D=4!'#MHF%(J5_UJ.%+AM8GRI^
MKT1G[<D^ IU 9T%N8Z;DL'EUC_*(?/;=!KW%=]C30T1.3=C]&?TA8>/3PHZ;
MP;%0T,VM8E0!A#CY<I'9?%^0,^&QUKJFSI32C,=KVIM/6<5<KEL%3E)>6:_=
MK'=,+HX=@1AA$6N7G=%)>=8JYWU+[GZ97\#9HE!C#9H2'2B'DBLPL,%D/X/^
MI2\EKI<?KG^<J\[F(#&+WCL"_4*/>()-1Q#&_FJA_283MO72LG71MTV/0$P.
M;/Y7=\L0&GH'B<NTP*H#?V0H'$+GNE$^8S!($I!V=W^SG\MW:JST-@Z]Y:.:
M4HWUHLQC "6_3@S7_D.OU7"Z4I,]:0PM%6#2<FJR=,447;KR,<Q/;:K-B%\F
M=XBZHQ_,2=,B9SXM$ 1"L 9V,?G>NL<?=./6KC&CA#UM19PM ^/C/S.8Y/-_
MOWFIPO,RU_VQD#ZOW??K/BP*=N?/F[QF^EOZ'[@F)F;N\T0BC8MB1^J=0(FK
MU_?EF!?0)QO2+6).?OQ@=57>5TCZ*<N8>>1I%T.H62;_A\+]C/K(YI9MQD_F
MK_V'[9A_+(#I&:N/#*?VFC)+' 72F<<$_ZFWNQ6EK>8XN? MI+1[V$\Z/.@K
M).FQ$@.7\WDH-B/+S!2LT\IP'FE$?3$1R?WC.T3EP"*^^+3:NQ<K5_-Z1.B6
M),AF.EGXXF%.NY(K/ )[$'UXF#'[-NN9092<M93VYY*?UZ^)=GO7PXV1?^!%
MA/ H1$@DW_++5M4B6.-]W**E2?$M46RAGZ%IF#SO>V+[W<,DI "<A\'9^!%F
M895P=>Q!\0^3TZ,WD]W;="4\O6^(W6;N>U7T:47UL\[$V=)!YSZI*G_MUVCO
MY2"YW;##"II:L=LL/-AS[-Z9XF<*\<:&W?F*74P.0M8B]P6N7$\EI4R;=40D
M[B(5VI(X?H O/S]\0/]CL?Q'YR!,Q#I8R%*2DW1!]+H%2/JIJ)KW9O:,W/"-
M)RF=5VV6D+?4-_>I%^ Z\4!LUZ.'*O>Q3D/WU+(I*E\Y%CWY$QC0\AP_I:*#
MBFW04Z59#%Z%V\]+ZM'##K2O:;ZR,%WC"\G"8%.X@"@(OEU\J-YX!CEQ2^3+
M$:C]]?!RK&OLV ,- !:YLB]FSJ#09?!3\_EC1M)H5V:D;WV:U%.([I6)QPRZ
MU&EIPKW6PM9;5A[ AEG^>^45:7UQ"VTZ#O%1CS+XC1PAKU]*,4;BN!J.0$/F
ML.?CJ/GW&#:=B[;MZ66KEY;I1O7Z]M"#%:^<E?9$_0<4O*/?XR+Z))@]; ;S
M3\FS;"F=5H %'TH>;^D'$Z$OC,Q2-M"B_EFY3R+3'6*@AVQ)B/0J5*<J@N^^
M]7#K+2(/[[:8-5\'.*W@$/9LG)$NKY_4F2>G4+B_+SQRG]$I@"2<2:&5/1R.
ML#)NT(6(RA]*')RK%&?F-UT0'!$YH'6ET[D.*7N='QIC$3=NKAB@?&%ZQP=0
M[.8L?S^@F)!3=!;B++6[D2)+*!S+QWA$J'[M/W#:=8RP%EBOEZ,,I='L1]94
M_W+2A^;J!Y]V>'J;CE633/>V:)H2&K\IO5]H:Q'JP.G![DVF8? Q0.O2.YSC
MHH?;%]I,[*K-9%\^*L 1*@0; Y>,NBS_COTG>G7W*RIHAEF*]--GPJX_2+GC
MC_M;O6?&"$<^30USH?' ,DZ[]+?;^&D'I*HBZG+F95A!Y0,@(!+S@WH\?I]D
M?MANPK&.4J<I0FZ&]/:M\_S3Q3>C46Y;H?9X,X+?R^09"%$L5C'D"'1F[FJ\
M'B/R-YX=JIR0;[2\ AO.Q,K3_8I=_GLF_%N[/^+*>#HR[R,>6JW5C ][A0RT
M1411'9'3N6S#=:@X"*_"2-CR1+9=RS!;EWNW6NNJK(]34U^+_UG-1R,OW--J
MQ.,_E=I^,?1:_@FI5:=EX[#V5+&[D.V++J4N#(35JF_VSRN2][#V,7E3S7]@
MJ#LU0R9#N_"D1CSSA\>_Y&<^-4:V&;I,B]B=U1P]-W;K:M9"^.=_N+;TO_J3
M L=K^G#>,0$L)EIL[SYP;ZYG[R"CIR'E3L%LT#&O7YY7/A7:- G6JJ=Q+I=*
M]".JR!B<&P<6BM?\;<]%4R"7Q,XK45)HJG.;ZZ[O _O*ZLX,UKU1D9V-OOS1
MZ]Q#V&H*GN1 OI=-5O)*Q^D:Q)06MDSCI$N2K=K35G[D^5$-F76_RN--=[=^
MTG+(6CUS M5T69HR0VB2TW'XB)4#>G%PP&.BU,?AR;4S7UIS5TA[$^<J77DZ
M'7,UV=CDMF\S"O.K?[:'_M5CJL#]95(*+<=R8^H(!,TZ M&S)9\5_<OM3-YP
MP8)'YZ^SIF]ZJ<W/38,)8MT"(@%TZ9\(5_7ZR(MFHO68R;-.$3??W_/O2F9:
M@TVK+J%?//I4NIE-&7,6'[6\4_"ZBZDNV^L!3J(BWM;P_=B=\]^YC3TQ[$<@
MLU4W9;0JL$RU@&OM(G^V3Q.#S/1&+-P&K1NP,S."N.^8KB_SM;<LJ^%EUHT^
M0?J]/%EV7[<C[:_5#H52$S8OKDE)J89JVH8\D+4B.FC>>$L&[>B0E39/,E)?
MZ,OH[V)R2N?D8N[C]].0ET;/AZUP3QM24]^G/6B+036W2;86=<L8 -\8QS)3
MLOVSU"I6VX5C'/KO2+W^]!F,5?C1] /]B]>/^E$?W8CQW9HD,73$S >];^(3
M-(_5N)WLIEZ'W KF]_NP:?TS$0WGJY-=1\:?M.->K3OWFKC);!CTT5(8U,+/
M'E J*2;"5FC>E+2(-X\7J%8_O1Y%9#__];LY4[[:GLR"H?YHK4(^73E0BXT-
M[0O2LZF-LAO9]!;LA,'$D\^_#KWN<([-W]%UX-Z]C6WE6V4$DK^ZR]B_/4$&
MJ]*GAN&#W6(FO#\9+9OJ2M%I>%?I"L0'7?[VTYR:^5JG0>#D5]GE$H$G!W(=
M=-DVBGVT]HS3U:%[",/(L./[H2V]?#I?ONV[)FOUPO(+RUH^5-Z2M-,*:3]D
MM/0RO7_9:_^+G:-Y$J2E<.W2;3^-3$NQY:MB\14/ LXKG&#G_=(Y..M@V81.
M:0VA:B'.C4 "!V.08O7DL!=N_*4?UIQF;\2FW_UL\<Y"'T%^XC)=_S>XV[HP
M<[<9\*NV/&-;M.KF51P<"9>_^N:/ 4'P_V+OO>.:ZK;T\:.HB%*D=X+T(D6E
M20NH="%@ :6*=!$BU0"!T 2I41!0%*(@381([TV:BD@'Z20@O21("9#RC?=^
MWIFYK^^]\T[[_6;F,W^L/PCG[+//WFNM_3QKK;U/8F 2HJ,\,KTQ3T#LI7/R
M][K:@^(@VE949,@I@I'# Q<,P[&1BY5UCXU5K3PUW<-";Y:(AVW8I.BPE4RT
ME>JNB'C22!=\%"XYEI/?L*N:S<[N6BB8%2O)]A\MRF#_)4+QEZ3LWR:&W&<0
MPJF(CNAL$E/VXA\E9:5R=EZX%>A\G[)L?<!-ILMF! M)3;*=].G9;@I%,,!U
MP5BG&1##E/+NM&&H,FF+\R<K&EF5P5VR9IB'\9S44]\HK:N. (5_I%VR/="Y
M^C3U2\=U22-L[ 'RB1^:(*;WP<;8:M7"5JB?:^M 8U,5^4'_&[F"RB=PAAH"
MIIWZA(?!=Q$/H;Z#ST)$;< IP1LZEH6*@PNI- PR,\@O)",RG=?LI&2ZQ\F.
M,=&VPL_/4X/,P;'1G0MVPG (+K%L1@ZTD@G",_3;NEOZM6K[J?LH% J'7J!O
M/G\_*):TA$YJ<ML8I<$4YV# ,6!FL0$T B-F([5[G27GQR-R[^/STO>^GJW1
M%LZ!FM0UU0=4OZL\P9D]4 =6;W)FVE-IBFK:D;^%6/R.GI#:8]IQ(B60N<7#
MR3S$BS;GM@C)!YJ=%C\$]B^!QJZX'E2Z<#%\Y)=>^?RU?# S@[&^CDF5;5K9
MYF*L1+'/\!\IKSKM#GJXD<^=S%-&)0Y,CY2FCHU4O(@+:A!:U%<_"'J4:Q%U
M3X!=.7?RZPV(H+PZD@:7D=>*B$%4A+NI,G54U)65XKGP5S(9H@W/M@<5M7@*
MI\+DF!CS'.J$DIAZJH3G^3;6U&9!QP@..RF$#YG*.-+7\K&\\%?]OGHV$I/O
MSM>;>+]###W^;K(]![HHG4: X,5;R-*#34[0$XL\["1D#/%L@=#=*J8<+M:%
MT!@OB0/,2\?DD8)7;T*R?J:]_JI_/9V@/57D:!FY29$"D)04@QGLU(E4BIR<
M3WH!7OEA1P$&'$P5@AG^>@+#OTS&Y^4O^Z<;OZQZ,&(Z.G99V4"C+8Y'</N,
M";#?*Q-+70ABMA G+7.^5KP==5/Z.F5I''S_L;"RBNG-4!-:P[UD#+3-[H1E
MR B"MT*2:)9]*6]R=+$0ZB?V^D3[6:M[2AV342TSLSFP:"*;SVQ5F*8H#-J:
M*8"K>E14,6ED,FB+75@]_>8A:Y<3UE2IY-/BFY$/[*,F2 7/+<T@SF?>-\S"
MC?5LB,@!\!B4?.+T&\*928(/)GM\97\SF6UL -@Q[WR]B6\KU@B9H0#N3VS-
M<.=W3N.KU@X5(SX\P >9#;Y36.E@?58\D7&1!!$\-;WLT'DE?O:AJ?S04A,.
M@AI%M5B &'TA,?LY:3L],7*BU1PK,/:9DLU<6*ONR_"%+H;Z37 TUZ>#S*QK
MUTG?^-G>_V@?JSR]U"\-?=X#DVL>HVU%,XZ[VO+V%Y5[B'V[HV9U?:QFO6WS
M%M)?)'EBY)(.^Y<@28F?'D:"ZV=>=0',H>#[>$DY:WZ9SJD^ZE,J]^BICO88
M%5#[ALW7M%R]-TNXT;;-3WS"KFXORY@SY[:+K; H8L06^(#>"K$Z-&[Z6TM_
MF[&](><G;:RJL?O ="QO-_>Q(,G8NS:O@XG>[?EAXI0*F?=F%V*VDV;[%>-P
M++[[VDZ$K85)_\U]C<%G%*#3 OR52OPQRH0(;%F"YI1KEN=.ZH$%^>#>[(^\
MVQI3!E>/=WW$*O#?2@2(QC[IJ#84PQ(WZW*O&G(F]+D5!>#O#G"THU.WQXJS
MW!TI/*6.JK N1^_1(X=K-:1G&%_0,>3?5>;TF+0WXR'7*+@*1<<W*HU.+W'Z
MJZHK&RET?8\KD \[%G('N/!5U1?-C\X[T\A)N-/!D:#PS.Z^E.6]C]\T[ANH
M$*7G0#$H3G4&' 68584IN?FAWNO,%Y$VETH_>HB<.*'[EG.WY4=":UZ#]8V=
M<P57%5+F5X-I<9".X51S91[=[)#'S!+N-YZ_EY^\SMJ\\#)HI+3P\"%:P5VT
MU!"99BG-G)E?:M/=*D6[N_-K$LJ<CUU\?+/86+8>BBOX\%' 6,,$N-=U3Z]D
M&458TYVO VGWV4(QR(1T370I_V5^J1E\[:5:(<34&@'9T<#(G5V=X)@PK/_-
MR49?$&FJ<SJI[]]?6/47L?@*>E]%3.IA17P;?XM8;$>[X^>?8QD</E@FH!YN
M/ZH'HS^^E?&37-/YK#4>)M(QH72=N:?8_1/8&16FJ4P :1:Y%,&P/6V!#*O)
MMB>Y%"JJ_.I2AC+MSHO,A+9"(2_B[Q19I60GP:?&&/2,@_SV,BG 3^!K_T>[
M<W\36X\#?2IX;(!?H0 E[F84H-]-NM^]N\D-M*>,CD'MR-P%[QN+7@\1<;(@
M>&\YVOT>DC\C?VG:A((8P*LV[ZD4CLXVXW+5G6RBRCY5NZ6,_Z@"Z@3/UZH\
MPH,K-8-^[BL>YR&5D'/N=36I$EEFQ"NK6F;;BJVN=N5V'Z;9W#D"S9%XIE;+
MW(( P=BISSTWH@R<[SE*Y=\QF*T(Z%PC\4=2^8!N:=KPKG*_(AFUHZ$Y=5ZP
ML>;@NK/: U-MB86(B">#CJ%,Z7#^JAN$,$P4]!MVNGDS.%>=$*M<(0Y1F3=[
ME%*]'T'H50-Y_!:/_K?N>XX,/1=H>KC/]CQ>;:>>< V'ZHZVP-^HF'\-HC7I
M;^I?F"0-TSV.)FU6;-JU00A2''5%$_QJF)Z(X;[O:D)U0SY>]Q? K4<<@9!W
MTX;]"M]EGK1;<%]$MLO *\ ZXNEJ-RUOV=R).>3\X/0-/6^#1>F6$/&0"=!Q
M,E>,/:K-#;U\=BXX^N+AI1^+ULP\J$+GQG/1,P_6P =7/Z<)2-</^DX*F#."
MJQ:4S)>9+EA=![:6#IHZ&J8QT416VA9;@4U/N%N1+:%X*4 I=7K1OV9+14QW
M?\,NQ^W3<2)D_4)(64P1D<??YCM9+X4P2SYA,3O-1UUY'(F*N*>!CLG\[S^)
M>.3;?OK&%@^$+E0*O"^G *-J._&D-W)"@^K!A39NYF>\>=LL/&K/CNSZQV1$
M9T:*AB02>#'(2#+/MV#DARF!@7()>?;&]GOY_8=(.Z#S*&]CO^M!-T!A3,M7
M"XN%LD.,+H<$P]+(=#9\MNRET:UD^0.]1Y$'Q>O;$O'^'3)YWQ,5Z"]Y=HHB
MV;&9/*2P^AM8:&SC.=P93=&^K$'UL^PO1SAEDP-\3C[:S?TB"^/C([/O8^R4
MB:+4=;27\(,"V*J"R$D#";=&EYVLY%H++O9-CN.@6VH]H]D8F8WFC0A+4(0?
M[TJPX0^(>W02=NBF;H=!IA;G W7:3L7EIV;6:Y.3F6V"!>VZ:C]1)\=OZ-$+
MS$8!YD"O*<"W.^,4P+EXK!H5B]ADZJ4 JV<]J!IKX:$5'BN9N,*2>H==[RKL
M<!@RJZ8;0F7:OO%Q&9;CL.4GRL^FD^9K^"&S\T\\4DI*:^KM^UXP%Y!=MEXQ
MF675"\W.@F,5:^@M35!\>N^C.-(A(\);^0@,%R$!VT0@ILX??Y%?\_(R:K=Y
M88OJ]E'7\+I/LFEV)@W'OB$Q269UY+VO[D\&R2HP[TZAB8EE1M4 LS6[[A)B
M8?H V&74.FJPPD^@P(/;@0($GP5]KEV3FQF)4IC,-;HE9XU@_Q*)_'@[Y*FK
MC(FT*6&WP*8I+=?-M,TJU$E&.@2X4Q"<AX7$D6<:JAY2@-JL4:]M%;&&5DC?
M/86GXTY.4->FK0YYU,<;8\=@3LCF#'>SY.XA/WU[YX/Q!U3W0UTZB_PL79I1
M3*,SDY]\0DBMC6W$--IMM$%67&R'[/.9-2;=EK+^(GO[/N+['FKO^%##E?E9
MC_^2OZL.]M(F%&*RM#Y65+=0@% 4OAA;G>%#-LR+H@ KPPL40#LW=.VMLD[*
M"17Z=_+7X\,UE@TE#RU,21 4L]SKYLOL5@O+OBY:G$U>?\G4Q;XPX)JI1+ 2
M-G83[K[-:*3]_+0PZ0WXP0JRHS$\*Z-Y$TT/]R]I&&6L.#0PKQZ =\H2G_"V
MV$9?*6FJ'"Q*Q?;#UNT1=2)7N"%8Z:=X\(>BDVTMW]T1[R>K-(.+.<5).8L(
M5$- T48HW ZW^1VMX!XCZ]%Y9N>Y2!AI\:O/?J_P=#Y: -?9^?!CU4C1E7LJ
MRDJS\12@//H)(>3&LJI)E4/Q^,D$S77IZKIR%Y4=X7RPY26%W_,/JH;Q<(B?
M.&:PD]?/7!?1'WIAA0D$"[I6%SL\<B,J*,9D,-Y%9-];.JN8IE4U^"W\"E[?
MRM54A[\@_GCS-W^^E-GX PO$/ZY\^K,24+4F3 '$MO'GR>U%>A3 X W: ,U,
M0JL_<, PA9'%WM>6#4)EZ[5SI]R4#/+&%!9ZDJ:TZG9(0SW7;O [QDLK%'QJ
M_+((_GUNE8F$)'HX89O"0K@'UM84>=6*:" 5_6B'01D>ING.PYZCJ/J:1?<)
MB=0D>^T\0QG_OZ1<'_Y!!P7 !Q8PJRMX1#."U6U_(2ZM>4Q"OUA.L:/J%O'1
M; HH4H2_/>7BFEJ5 [0[=L]BYPY^3D"-4/5J:7BZO#/>[Q,F>4U^44"PCR'+
M_516TN<DA81J]B,OB=^.S(;K]5. 2F@8""O>;.Q@$'&CO[P0X^/FY^I7,\RK
M]CP[@U]FSEGPSL4Z+7";3H  *@=N3\K2E"0J5.,??*BSB^+A#-M6'"KVXQQT
MJ*FN26%.\5C[ )B+J4Q<X"++ J?U#S2IRI_\'3U6V"$@,1QR'GZ:H(-I8EG6
M9*K".XY46>:BW[PW:F&H%]/F,]$>?:E$7>M=*K4'2+%D(=B+=A[Q-J83L+(;
M+]IXT.'J9@]>Y9;<!](WIY3:/$[SVT5]VNH(^*34Y :-T)3#RR62^8A7""&U
M?@MQ<$Z-C^3/0V*N]DU5U5J)X5J,G30J/: +"Z&,R-4,G)$-X1(&S39-J,7V
M0SEA=;8U(]LJ6[O.555N^D)LSL![6Y-@*[ZP)*;7Z^<^/];=U,>J]'*X^(0"
M<TD0+>EYII@0=5Q/ N)NT^@07 ,K(V[K[MX0D,?CM&HA)N_;.6;EP/_JR50C
MJCI<+=\QRG7XYINK2-[0&T_C3^G=UX$7S?8\G&(@>!S<".EAP(#I%ANY@[HR
M F1Y]0:P%>>EEA*O@U.S[Q^9<\D!D(4KFRX[+TAYFI(PE]F1Q'(;WD[+2E3.
MZ%T(]&A%><M5=L#^ND-%2)G%G-W:I0,-HN%(HR;AX&8_G :]S.,TE?NCU<_E
M]J;>N<?53K?E?;:+T_GJ>Y[A?2!NJ[.K&T%;35#AQ[B%M>?X%SK#]SP[$[8U
MKH]_?G=F ]4=&Q(RFP^\UY!G=!^D G8VTENP.VN3:; %I%=6\[8<ZD"J%7KO
M,N"FUSBR/_*2R$]ZJ7GF%MP,Y_]:O)4",-]L@1:TJEE/W*PW8"ETK%,#.+F6
MC4,>NTYS4>GB26M2=)L2TI<UZH=>FBK2>I:!BF8K"D0YUT7NW\8-G64.&?,V
M/'!'3\'T6D$$473T5H_42F>(6,UP+I>,_9N\T5<4P/?CJ#](*ZJQC."',VIN
MHEMKLV7%-69DO^<U;C.-RN@\N%IIT\1J2>;%[\1@WX#LZ^S4MZO2YAXCFB%V
MK8I](R)YDIX]@:D<":!PI7_.[.R5843ZJM90^&F6T]VIT6%/DLEQXR,YP2 I
MSIBG_#EAP+Y%9],QA.,:M+D)5*$1 HU)CRJ2>5Z9M"/I2P4@O7:2X<*G.CTG
M.Q]+ZX]]79!Q$I?P[MAYL#2*'L%I=F3%2I__IR",E&2N%<PQ]5*DSIG.WD/)
MU@]B-<\L:O).L_207OO7!W"\D:<EY2Z"KZW9N@7-0CB)ANE&&K*3F')H2E8%
MYCZBZ73G#YJQC-!6/+(MPZ+]P0%QN+(TUEZFH?;V/>F,=Y"K4Q0@!;J(X%>T
M43.!R7DD7ZVFW7W >'!<(![8:S+\#M>;X7?_,-!1E9K3KWL]\6:(H[/PPR/T
MZSOM@18?P%$C/#9M8[EE=X4?YWZ4R37]4B.8)KA &\](<ELTE(>TV0G "J5S
M+=7-JH+4KNJ"IZCT[74()VRD[2OZ[52 80#X7LTYYBVS)[8[;]F 8T!.CC=2
ME.IF7%8D/GI<NI8^LZM_2I#XU=AOS.+#-/V2VI5 ZVLJ"\$=CA?V!<"&*Q)9
MV!*&AG*E)X\P,:?C?6\.2A ?&NNP1?UA)*QM!;5Y0UV9BI6JP/L,_D-_^[<"
MK8<.V]5_VBKS'*_<VL#4;I^^V:MW'_%]GBGIRD%F B'"UJ:0*(H'17H:[T:O
MS]5=G^-B_!2Z)?U2&;-G4==GK'8(:\M/F W.[=JQ8[ZED,,XG"XR*D4!ZO,
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M_]3=[EADV+YY8:.'S+A1M?H>(D0H)#J%R(2QO@KB@TO#[QB4;Z]]&9Y#*%"
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MF>VE8;]Z'UM<9WY\K%/8BXOD_JYT4,;O.+'+ZIFG WG+A"OD]N!3RW]DP^_
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MWS]T&=5X+J2?+$.PGW7SU0#-H.+5?1P?=TJM\"A<&5[]<LZ4F=>[@4D1N[]
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M P]HV[RP9GU&5^^ABFX.E\M(,Y_ZSF40,CY, &K:/OIU8H<.1'^]^G* X]4
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M&_E9)>E5[;&=#H,1\3I/1:AC*!*X%BW-"V=64&Y%*LX=SNO0&^]HSFUEK[K
M-C[+,JA(L"9M=RF8W.;ZRR'515;DX+3AY?T%RP?/JL"1_=X4Q)G,S7M.SIGC
MC*:/Z#<86WGZO>[#.X,&C=.^54)2=+JF/EHC+A.E?UUFZ'H(]T%E8S+_) ^W
MR98D\.2-7Z9OVIC.Q-S^.JGQ#NRHZ@!=-U_%^&M6U?P(8->J=LC7@8\5"A+O
MM7Q^;L'FLO+=>B'C#R1LH#WUMBBUN:="9GSV)]Z;Z\*1HI70TN<F $$EU3W3
MB9B>S1 PZZ782M >'LVV/E4_. @L,U[H&]ZHPYF\.'H8_2$DQ'[Q2VA>\) \
MGE=IO7/6]].MB!JK%9&34!;@E+1= 42#-<:K/3&*W[.U4\;;HN7J\LQP1>*'
M>PH^.!?/8IS<9F__6;(_'5+]8CXCFQ55Y0AW=,RA6((8[V^/7FE],C33&+0\
MH]75WGW3;"1F13.]&C@G2]\L2PEB)*-SU(>*15<VH?*1,F@QS8)>'*Y*)YO>
MI-33<F.EF](P%Y]*_=L*6Z3(6KBK/YB@HGJ?A09I[-AN,ZH1]KM>,#)Y&@8Q
M^$!]?VO(X/@6NG-UPY()<0XX&?P;9+[I)LN/2(R3)H2I!3B:(L/G/ETMN/>6
M@,E*EV_K+^^O)-6\VKQ_-/:,Z+>\QY4\TWQZQ%V./!N4(R.+94/&-<<*TUT9
M>Z5XE)O$5KTAYM+O3*84#%9B+*A/ZUWZKK?&&#BM@U9NB=5&\GUO7XAKS')P
MO*73G07"6L,.!>N\:CL^!7/&TV\!_AHD3<X7Q]^H[T7#Z+& 1K3P%*KC;=-\
MY7G$E%7$S!N*?:UR%9M/#TM2(VT,AQB#.*TRKHY:-JVS",5..D 3USTVNQ;+
M_IRH3+LB?]GV'+/.A(UAR?1+EW0+$9]L^]C[,:JB"[ST-M_HGTF%GKZL)(N^
MENU!] ^4O$X97GATL>RP9N\LNX^A<-D?]!+\79>L(4A_K_"C"%\X4J-?!<'?
MOX)SZ"F#H4?BK]:Y>9:L!22#"[Z]Q[%(E;<O-.=_7#=?B;9"-=ELE/HSOL_/
M<H&O]2$TF237HKF-/$'-:1[BE(+)>>SBNB;9.W'KVMK=Q>ZI?$KPBYF*TQZK
MK_-;R))(X$?'*C7]>>?<>:>( HL=[=3. _<C^D"FH[\%;HWK2-.+B;X[M@#W
MD-T5/U0.<E06TR<B0*Z+,1+**^W.^.,JW!=_751.I3<:X20W$V^MX76!/)BI
M;BG43]@X\6LD2Y.']_MBT% BX\].,XVJQZ R'%Q*YW0[)@NBN]+E1AYBWK=&
M7"-\_[R&LFEP/EXVW1-6TU*XRMS9EO0F7C[9>5J1C5-"I2]^A"B52=M_WMA!
M7%+#7<-E?JH;"^ _& GM7T^,KX%/G\.0+/<[O<OW#BH,45P74A,M8[A*-HJ"
M@/>JV0)=[^T>*O?0*+]&@>!9:OWM,I=%R%<3?==#'5;<)07VDO-UG@^OYBM:
M'SQ<[B?[:N5&G[3@1M-0$#BY2MJ$5 I'TFDAYEO\D,J*,^_K0X4[HNRO#%Z
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M"-?VTC_]5$O,?@;EK/$81B"<MVCRXKX(T/3"C3,D_XNP=\@G.X_O U:$^%8
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MG_N:(*5T+YW..>AY"\''#+#7X:LCIAA.PR$OWGOE)M^M9QST)W]3YA=G&H-
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M=-ML8"=J]'RDU+KD_]% -0\W":REX>*!%7RR"COXD5.TLJ)G1XASS!I^B1=
MB!!T$0SM*B=61^!N2 *O1/:,F> Z :>B%G>L_Q()B9=+/WI;E0I6WU"D4<=3
M6&VV-F5=5H\-C4RD\?)&6P"-PM)#H+> 8''ZR-,6:GSM(4,@6:5MG8%!;Y+!
M U?#5\^(7Y#Y6W5LX:*Q:!%B@4TG)=6MH2I#&?CR^?/ QJC-2(BQA4LGY+O
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MP'#*GM:O5GKQO>Z"ES43([H&R7X7Y];]=#Q&PU]75X1*TNHHM?);@/<FVRT
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M?SO'%%Z\\:N50>'[(<K#P^]M2=P"L.TAJ%N G1^2^A:PIHABK%LYN;XKHZO
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M'Z%^#<A\>X1"*5P#>F_^OD.6?0V0.=F\0L;<B-E?XAD$89P&_3"Z$??M<=<
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M= 4P*;%2X9X1=5,X>\<K.<^95VC^ "P FD%YGXJQMFC2.R1_SK:+M3$L?H?
MQJT07$0)#>#4W:<TY<+6=L$I,,4?5Z)9C:#'\%$N]@SI$GU/M;1YFIB=#12^
MX-_&H^J; SHXPG/*BH1"V,G= =35_J(:%;2\?UE0+_^CV/EL4V[,T^BW]K3)
MTCR2HCM/.S# Z\"P]$\/ JG^XZ&MJ?+B5,5VHE20X,Z0K^TZ6<"Z'",Q-D."
M66  'V=I.3NBN&!'+Z.'  /!KS+'XR-F4=)=8+2\8@/!G"<;(D^ZI\)85<#[
MV%),B5&BE6(<"_AWZ,W@YDAH3&GK)X60@XRXZ'A:S.0'09N2E]P5!.*>P07"
MV[LH^IL=[+Z5R_R70VK\-*^^3OCC@Q8VEF.GP6I& VQ#+3D1;<"'8*S,;8Z5
MW^Q;-J'!V5 I0A^U:IA?%%2__,[" L+]P BXP [U8FE0,@N_Y?!(AR*VFI\=
MPV/@#H;(OA\QHFJG/P/7YSY4[-LD]9*Q4FU[^N,J0B7F9[OD4MV):V!_GG]6
MVTA"$=/*HOS)?[Z"EP6' X[&[ND@R/M$ST).#$T5>?=K*'/3.Y[MFD8K,3WB
MK_*=>QW9089E[RQ2IMW3CMU&[)EWH-/8'&;W?::,ZX GN>L4:+"H%U#Q+%V?
MIU_SC;T!&<6HXX-V,I\;MW$6.IK2&_$"MI/#W]1/':_*"'Y?+*N4QDFE(8^;
M<8D6G4OQ##R-:9YJP_4$]1%NZ5D$EWL7*61M"^F-;-773>ZW](=#+#_=YZC\
M2HW^;6M$C(_'VZ%[CZG3&(_;X?7$B??\RT/-1-G"[23A80J>VU/\C]3?C;_6
MO@\I?W<-P&YA_?[&O 5X.QJ*-;E?&]&X2R<RD_@*:!7;]RJ,.J"%)&Y$':$"
MY]GI:Z.:.?%]<=15#YM_/L "BRX IS[AN&WA?C@=0GGYA>[1RR'X-0""%')P
M!B,EG_UP1$3&.3"1F'#:1:NA$SNOL*L?6=%SDYF &(^-;TO>RP^Q%W!OG>:Y
M[YVBWU!F[];<:/]FO5:D]N&S2;*(P;&AFAB?J0V$""Q97TS?U68O>4&C80;:
M'*C9J)S;D/:D4=(3]+"DPP^N;%+]8<1I[%)6=^OGFWXBWN9)+K;@DXV86Q?.
MRHSZ)43!=.YF-Y!BYVC4Q/*R*YJQ@I#OW<E$*JAPOFA^D.^9?"%62-9KDI#I
M=&N$)H)F]QVS.9HR1[RVKX2"JYL2S&'UV(B.BL8]3B$79#H&F:G7;_0GXQMF
M]7RWE&Z 3BT6\L0VIM<A6)((GA<&U9HHKQE2)03&ZN@O&M@&V.Q]CYZ87S4L
M9J3XY.!;U:>9$&KO%-X%U]Z[D^V)!16J_^(9RYJ1JV.3F+13H'"WNHXU46<^
MYY4,4Y1X+<NWH/.KHJNQOCWJ[KET9L.W&[/L;P1#72,>NR(V&AO3;;@G+4)[
M*M<'9./))-8<AA4W;V>UQQ7#R#M%5;NBZ'N&"G?>VBV=A=:R3?/8[?JL.0 >
M,2M3U0Q/*C[K;TP;U4T]IB@:@U&O7GHZ*$Z8)AY.3BD)WS$3+*MTP^MM(<E8
MT6<>A""#:;QTP6)H!LOEE\J>S@O:L.:MJ*O"+]M5MEI'2YU _D4%B:S,1PJ
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MP&X53=./S@<#/A:\%LRMH%#/*UF993L[*5<0)A^1U^EN+LJ8*&*]1QJ17;#
M]FD-PW9SF^#?C0</UJ@Q)HH$,=9]@T8D?[EM^KV0;MB"OFW=1?DWR:^D%8D>
MT4\/A]],+6::6QY9V2VD[#_@-M:<>V3C4&#\.:@^G*GAD,7:XK T"\3=QQ<5
MX-@M'CBBB^J;;?_Q6@J!10MP4->1^@:>N[J+=0T K&7_,6G^RUF-WJ&\>_;<
M)AF]1+*"0Y]6HY4]/PYV*A-^2:W$R5EUI\Q:YMPI;BS] G^E8= 5P5R1V_)\
MH#PM]R.-OWLJR=QM?]'P_Q$._(4+2NC_?0@L9U6 *FO++R@(4&C]"J="M=<
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MS"X0I3VF9!8P>[@Q"Q7V%L2<CPN7Z\[XP-5RTO\ 6HX/](#M:,^!#9K(6M=
M%#\F;43?Q/<+]N9H@:QXQ8/Y!JF'ZCX/O%S0?LWF07H@K 5."$JM]Z!C4^0V
ME>7Z,&1'G,5 R:7$ ,!B3LX&LL]$I[DY0'<XQVJQA/A[;Q%[=?A> QZ\$ZO
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M$@0]?G0(-^B\(-O,\7]K[[NCFM[6;8,H19I*!P$5!"04D5X$ 6FRD2:]B]0
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MS\R*X+T]YOBCKH&L70P9+V"Z3%'/RQI;H_MWF62_J#BPWVH(#^Z^L; -)(T
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MIWR@/%O-VX.![.FOIN=D /H#2S-+O,]LF/5O=KU[,W(KD_^5I]6E6#L_\#F
MR!%7QAY\A)R@8C!R;FK'!(;G  1UD3V=X</K]DXY+BNBHHM6!;D2;S+0H:L9
M^Z0X>;1R_E'HAF[JM/S22+)AZ55Z')ZOQA\QZU8S>9]"WC-F0S[?0V Q.=@K
MLY38P,1SP%&WP_ #HZY_WS$!C>'_'KEZ>3Q7RC\@L?S.#.@8<0%7L'\'^@,Q
MG5FJ2Y_4?L>A^IU761,GR?]7"P2R=GND4Z)-0]U5(3K5]74C^]/6S8U)'[EU
M!#4- 2Z/"0$N:M23NO0[D>TCIRH8<Y0IR?1,7MY@P3-TIV3Q([8T]7?7$V8(
MG*<"Z4P $S"AA>99+37(9827J_ZH#GVY8(O5Y#5GTHZH>]#H=>TZ4615:70I
MWO?G\7]C5,Z(+ ]&-6\S88)[TGE&[$_ON_N86^<9VGK4!WTM?C"JM"L8^(1I
M2.QRYC.N9[M.]S4#_ED.//_U"8(M=*9+HA/;%A@A%'U(595')S[&^4E^A9-$
M66.JU7C2B<U1$00N^0\?;.SQ*@A\U9Z?$@DX=2[V=1Z&:9?:-#V.%'[-NUE1
M.RM\MFALU9<0TM(T?9>=FS]"D0W]&:D"=")"[+1%P2CGE0\:*@3U'<\!E6Z5
M)29G$7@WH4S]<E<N1GT$ C=-#XG9G VE*(TENJ;NC^]C"5L^YP9.:HZJTVQR
MSW-*Q'8#BRZ^)7VW#-OH\2=M&?<%[6C).5 \VKG8REXU<B#!2.8F6M46,?G"
M=;JY4$+_40EYIN"'[D=;U/5HGPX35C09MKZ0+]2^1E6@*Z7+%9<M(4O_UL>1
MEZ?MX]VG IF6XH6LHN^6[(7V.4QZR!0]&D+5A^6/'<R*[R'K7[J5#- J8Z=;
MHM>G)E]XG/0'-MV9(:9C*RUTTC?W]1@JMIV[CEXN,7?PL[:T=;5U91@@'8XJ
M?=E.;>831"[O9$ >XXIN:T=<A6F@7BXTC!_X*9P#GC2HN%A9O_!?'IQ]C/?T
M1O1%DAC80'0M_)0>/;X=[$_I)2TW%BX>FI8[-35S0<X^[I9Z/]$Z'AW+(YFB
MZG_?6_C_ N/I-D<HEUE&WTF9T]4LX@IX=-WL+F%P-.PSK>2*X@Y+X,%VN#@B
MR)Z;9D%[^"NJN27.G,5:C3_YH4SUGI+P4@"=^L=7Z?A"LYX/1H723)5')5F]
M4<:*RO7U#<UU(PLOFKRW= 0)E*_03D4M6H< S@%7RE60+.VF5+YW,<7N=TZ?
M" V1Y0=Q>ZI:4NE2SJ066<4M<M[33Y%CE=:U%EOEFFF"O'1#T/B"1O:%(O@H
M-Q*=UINHQ[8TKJ<*U1H/XO4F"(JQTN-]/BIXQJ-Z#@A-9T.W=;50Z(R;H\N6
MPT'Y)D/F_./FX7)]Q%T#C(JL)=D-S[C)15BCQX.S3Q^CX97S'Q$T;0%":2*=
M=?!A!,G&!X</B9-O'!-TQ-("](;>R%UR:*GN=C_V#.:%T:*W.^<(/[NE2K2(
MD_'7]!4TORYUNE1G%B]I1O!&,H  +Z'597+ "UK1V6+1WLJ\X]CH.3_ T2$,
M08?5AR9UIC-E;%X%B0QVF+_F*GP?-/?$LB.V=*@-3YY&IFC_M<FUS];A;#&/
MZ[R^$.C*?[BQ2\1:6/2')#TQP?N\)<D_#R9?/=(D=JS9%)X:T<?[8!U]6^'&
M24)Y4"S=/VD _QOMSU4\*=3-ATQJ>?T^,?A9!'N<0]FX;Y^2IBP[BF ABC3V
M_D8(QF>!";]W#@B'B?L2EV @&L/SH3[5Q3*$2?1)MV_-4@V*)##6'6H2KPM\
MI5Z!X,.HB[R '3A[@G-9NZ9:\SQ+UH? -^.8O?.?9O+C<\41Y5QWJBS<?% K
M=@;JQ9*-@ ](&-7(C4$B\.-LF[K#8U_. >_GY@)]5)9I3[@UH",2"=J+UJS4
MU6<M2!*U,%T3P7$W8!GAXYH@9<<R(0F:Z"U*QGM5=*$J_);OO\ZPW,@R:\]@
M&I.B6F>^D7+XR<;#_\:8),\"5,Z@$7UV>@ZPCM2M:HW6@<+>7XZ_V+YIIITR
M.UPYYB:-SCLU+CX%C&$9C.1!!;Q%(!]GL.@8LYY;*"A+*#^=7+(7>N6;OUU<
M#4=_PW38,X8T269Q]*(.CWLIAE$/_<D),37YV-U0;_B687 =/:PK+N?9G#8C
MB$9!U)()--+V>P)T/S6= SK]/!]C(#L$GS".0QT;"XJC;GZL[U/\5J;B@2U=
M*E[Z3V[QZY!^8?$8$V#JI3XHN_$?[BTZ#@4A@F'P Z*4]Y37V"RUP(!8UY@R
M]]H?OI)^\/(<\-_0J\KY4.3UR K K,TA?B>MU(T)H?#;ADP<CT(%)#]> Z>H
MCHC?*N:]IQ^J/ZR@3+UVL(2@EKR/LOS^"T!+I)\PPJ1YF+6E)D,I?<W!P*M<
M1SKMMIELE>2=6$6N@1F #*/)9>:KF&#D?;ZNYSROM=:>OR9QQN\C5@0<Z&CU
MOQ.[I'8C".CZAU)H=DJ#YEGI!(>*TX:Y,[X!"Y$HI95;U6E6TN?&+3D%[-4(
MQ H,BD^X/O@7V>B_VL,7SP%7)?61X+"4D/0422 $Q:3CHWQ :9$]S1;?:4NL
MP;W9.&9&3RT;I/\%^60ONO[!"(P'!251@PM^5#$L$U&OC]Z:0E)>T$N38R4_
M+2)HJ B?H]IQSX@ID[2</^,:,FE.DFO\S/&N%7;"^1)6Q"V"=UBWJ*-(GK-\
ML\-H@; !8S%_B(&@5]YCZ;WAZZHLO]2]LQWV"&?@3"#!^W*ML?O"6/-_2Z?B
M.[UY?.,<\,;A>RR?J+.FXV+R= 4;/)5TMI]QJLJ"CC(Z!WSVT<3%_=4Y(+P\
M-(+0-19>FH5>CO,I7D^_TUHY:F_NDYI:M/0PFBY.1: 2&) EPS8A,1_#B-%"
MJ7XZQ-)A0J<&!IJXJZ:G9A4LE?K:75(]'3@"OG3KG^4(;I29SA-V13("]<$5
MCKX2A?*7RF!6RNRNCDB-)RZ?U #DM0OI@G!W2+A!3(@[./28IM17'NE J/UZ
M?>+X"9SK=GQ'=M" _^?PY>H9N@R;_HI7C96[2U\46^T.W]GP3RL78HIW^W@=
M66M"\I.I)$?N/H&ZP*KYVZE]L%<C,XXI[$R/1B [0KO,P=F8@I[G3_55"C>.
M4@S76YGV?!N$V-+AJZ:4KO>&O%1Z.5\^U8ZZ&!-Z22]E]6!6%T7X?I-1?=PM
MM<SEF$FZ6V2.?G1_]K'NVZ%+Z^V)E.#76PGFS99XX19+?5R+J$B\?9UJ6S#R
MY&'3V*F6MX7]J+QCU<RCE_GZS_06?DE8'US/].2@AOQ :8\PW(U'DX)6'KGY
M?*]G:K#1' 4F4\RE,@POY7,KS*L2F!FJH=-+UEE7-E!+TU.,XIWI=:<(%QPB
M\M)QT#XU=?9#\5AH^CW:.@=HCET;&;=(>5(3JK09F*8=E]2OUP^DFOG::W,[
MX%A /[ZS\Z. G?^]AJK=1!'W%*_Q!!,9!GY&UZ!%3M&-;A!N*\>/:Q@RFRK8
M8S4L>ZLT>K,@2KO&&*)9MV/O?[<5'9ID+33SSH@X.0M>Z4X9<+DTB(!4YEM$
M=;TT?UGDK%;/:GUV_W9/!KKRXO$>"#YO))QQ*39T^ZO#A7>[89^X3X,I!GO]
MOV+W+@4<Y_PQ (*0'^:%=<[W!)=CM'JU](Q,O2(U1AQ/>?)-57D;77D^8(?Y
MQ!]K+P[V<E4F0IUR@JAT&S29!GW^"5H3 R?)VZ-35EKI?>:QMNW<[X\#_2A[
M-T%U6K%MC (O9/5^$02A_/V!(IRCNH?."&OY3M:D,2FK-K@.C?C)'3\L0>@S
MKL2LM"'I&G$5YC#O'.#'\?TAQA^F!67A*LW0C^QB?IAV0@YGV#\WY865^S_R
MD_YI7F,RJDM_!>5/@R)$UA-X._>:FO3+"F3H;=Y=Y5M<Q8'QRL  P#JHH$+\
M+,M7HMBK?CX&Z@9EX&@<JQ#LRXF8$@C-6/KX4*#'6$8C8UN=E@WM49;C*SNZ
MV(I&0)?A9;=>]<<; M\L7OY"BO=^)^%&C+K,=8;5G[F8.*/C#Q'="&J8,:J%
M]A?8J*28<^Y:BDN?]]-#J_5E]D;K:<80\"Q;98\RW6P"B]M$S7^L6/]?T@XH
M&7?^1VZZ=M.V7A^%^4XT;69:"+V@U1 LJ0F8P>O3?& FM79#&#B\L<P7FI(?
MLQ 3E?)X@.:DXU@DI-R=#;T5=A;BZC@AT,_D""YXTW4+>EVP1S1X"3;$CWU:
MG!EC 2\7'*)X;#$N:2V<O@&ZO<%8\B:'^*+/P_A*K@O%V^IZ.WL:2(D6D5YQ
MV?7G%%'E[J!K RQI#O?NDK=Y*TTGL#:E@P8/IE,-I7$MDGKK5 ;9G$'3"<Y;
MK7#(E;-+NC?PC"TY+2M\:%OX%V8%C3[^3$#=L/HI/7S+#;3-8F=BDE=AX!5F
M]')-?&DK]79I4^[R@(RB//2A4_=BJ8K K3L]Q$]%!-XQA<1$G]XLSG]WF'%U
M9,W-$?Q)UUFTWKA;I(W%3?1&_>PEI2&"9CZ,@J,:J^E8)?;X>R,J:+]_4<^N
MR69\LQ:8QM[;(=+DV.Q08FO50T&*+^A2^X)7P_< G*;,+E<%%T&$?6N-.,MX
M-I:'89E7'#]B>K!:%RK[;4;Q=;/RD$3$@MB*H)"9.-\_]VNNQ,^>9Z9O9-EC
M'HLY)?Z[H<UP/4#@>[)G?[.B(V15XN^(\ ,JH@Z<Q*QP$FOZ36(S.(EY_IO$
MRM9E[_$_N!Z:P91?4;CN06/"W=S4,LJF5&$6ZI6V.?M9O"2@#4AE]N#^2\%>
M&HUUVD,'U,?73:/S*JD-4UZ!]>%'#IZWG8I]ZR3/ 1X-+ %S@'J,SP['PJ70
MY!R5G-5[ZW!*?2OAJX./,_!2Y#WZ8I-)MNQ?-8N)E5:0>LEV]C+0]LP"NZ9<
MUB=<O=*7RKG+\=AM1J8(JG347=:6B)2T=M.]-AY\?5[VVB,E.I"@$83:2*ZQ
M+>M>?!ZD=C4P$PA[Q.(HG+#BX1P-(I3=J0^1U,J7*UQCN1*:8\&SZ$'L#':G
MY)AB.3-Z%H+,8'7T/USJ<1%HG[09!K%4483YXI?I;<"GTK/F.4=45*55/1OD
MJ'-E%CKQ6%+H ZXTW_'797)>;BJ$2\K/MT%;^>$<RJ6.DOSF^5],]&U&U]1G
MUH4WG=""=S_]4MK'G;@!VW==*O=M(O#[_J^@ [@LNO^;7>F_VW7KW^QJD.(Y
MY=_A<#@0M/W15)1C%A'8S#Q9\N3:GR82+\"7WP6R+(U[QQ;WSBCD'^L WI_5
M9?S&@3YDXX+L-HI,65M!A?8!8>,W$/Y[\>6PA7$8F!RS>9!7$RO/7]D8H0[M
MTW1J<PN,[0S]JNH^QT8T=WT<?PU:=K/VM7!*EHHQ61@_H(O7M("-W+N"',.^
M8H 9+M]H,LDH@KR_+QU6^K73+D5C-%4^_HY1?L(U^P?KD:S53M.,^-ZD@(N>
M4SC924H@E0Z(A2#,*@61A*$2&5*HN\.PS#>QT$;N]FM4OET>923T;IMJG7&8
MT-&>5T8V:GA-QH\E"E7;7N.QJPDXSF;BOTH'=N;N^/H3H!$O#ZS077-L.TFG
M',=O/>*'+(3&#)Y]+8TS'EAB58J[G1Q%%NP*?&'D^*&Q>$U8'?MQ:N6%I)!E
M$694<]QM>E,67&MS1&.UJUQ!#$LPYPH2N:;*%C>]*'!)O=$T)2W@@(>RVY]A
MASD55&B;+N6S(9':/8I* ;[\($)*K!?S,<&%0/:M-2N3O+OI3\6[(D&(!-2&
MT3&]?N#6-%:+]&]Z-J4;<2"!;^Y>:,=?K$BJ0A3-7T>?4W]Y/;(QUUWL3LH)
M^_UI6@\1B[06Z<LRKH3_O*;_M(L22@4AIT,GA(AZJOU+B^CO$1@/Q'I)>FP:
MI_UXQ?VMBC_91?Q#S?G3?0:<(Q)<TX:W)CWE?V,G83#.8IDH$504AR_6=YE@
MIK*= _\=1V;Y+@RTP)I!X:N"L4:=G*@DGXKE2.61+777PI((!O4WQ\T3<J#Z
M=6E5O0WXP7>9& *9EA*CW"5$'3<EE?U<0>+$3]/I+9XE$%V\]\[HBLR'6Z4_
MQJ.1;[*MLQY+B[F#+)/0',T;WM)@3W!;>\<,O\,1KY1M1DY5+,Z+0/;,C:^-
MD?^_M!O;0]"!#%@Z,3Q6.QS1"+F(=5,NVM:FB)NL%AST3(#%] @Q4>H6EC".
M!/R"ET(T"O07Q:\H/B6?VLV(<I5'@B.%I=C@^SZS%IU'4E1C@DHZ@QW;2LWQ
M>J8?. ,CDH>%@Q3@_)MLSZR'I4AL#))"6BDPK KPJSGC;F<T@_ U^J.$A)O:
MEARM1#TVU .F?[(:S__B>F..R==-CZ;^OM[3$S#FCG3$V+R7HL(YH&WD' !E
M0>]"J'&C<G(@B#5(3P17*>Y('/8*4X$-86+$G@-4L(*0SKY3W7. ;#3T' #!
MI9&!,[O]IV'O#C*F>W"T4N!A)789%/N,FW+RB<K[:P6)5B>"T<WT8]:,=6AB
M^NL+]-D1@)G_P@0Q&&_IB'/ JL9PV_9^VX(\E1X^EED-U79,Y08^.>/#X.)!
MP;%C>G997.0,FW1JDQT)^ =4:>0B%G@.R/IM[50:9A0_XBJ>2F9T0_8Y5Q%'
MQZ8[V1'<>#_A_DQ=0S[@'V!_#BGG.\(?8'-^9"Y/ _@K('\%Y/] 0$B_2<]G
M,<P<S[9680D^#Q9=I  Q?4DT0W&X<R</<3VZT[$%E/MI9H#Z!&0^2WPEW"UU
M@$\+K1#N73!3D'0?]DJU[J%H_UMFF2'6MD<-&6A-4VJNXAC"U?X6P+6/O1OR
M5#C&_[G V1F:8CBW(WF7M)FIAG,(/?4MI>$1G!>V3R6!W8A][M6VHS'$]WN2
MT!6TD,_5V>< A!9DY\G?HHLTX<5%UUH>5_?R?[W/,"S$JQD;DD:+/4[]?IW2
MKY-=WO$\(Q'G.SL0P9U\GO"T.9:Y#.FUP6^@K0)I"KPJ95Q=0LU&V7Q@[Q B
M$IYU%&TCN.G/ 3_.;VV'J-=I1(F698_!F+),%!W<J6>467_1MH(&*V 0?3J=
MI$> 0RJ-!PS2/Q&%=+Z'&>,2-AB)ZX.JWR]H^36K/Q#%Y9T:M7U,XV9ZL@[&
M<N%T0<T'F<_&\E0F4,-XLOOI9>B\DY@@4V*%_ZA4]?\>(=(?FJ+5_4!JXT),
MFM/M4]=IC\.2#AOC]0/?]ES.<O2^Z3643V@.I?A96W@9)9 .6:$6MTF(C1>C
M7#.-)[$/(%'_I?(K"1;ZQ:AX@<_S!P!XV$\: /RGG5&\<P[H4#A5H_XT 422
ML?@69U4+MM1;M%"I7XKYGV/4_\&52\@2,I]C KP!Z;Z#@YC\&P3+^>3_ E!+
M P04    " ",.FQ9G:D,]'((   N*   &    '-R<FLM,C R-# Y,S!X97@S
M,60Q+FAT;>U:\6_;MA+^5_A<O#4!+,MVDG:3LP!MFF%]6+NL<_'P?J1$*B(B
MB1I)V?'^^O<=*3MVXK;.EG0)T*%S+/)('N\^?G<G^OA?4716%[S.I& _3]_]
MPH3.VDK6CF5&<H?6N7(%F^JFX35[)XU19<E>&R4N)&.CX>#%8#0^&@RCZ.08
M<YUV@W2=L-$HQK_Q<'S(AN/DX(=D/&+G[]C>Q^GIOA=_\^OI]'_G9V'=\X^O
M?WE[RGI1'/_WX#2.WTS?A([#P7#$IH;75CFE:U[&\=G['NL5SC5)',_G\\'\
M8*#-13S]$!>N*@_C4FLK!\*)WLDQM>!3<G%R7$G'659P8Z7[L?=Q^E/T/22<
M<J4\.8Z7?X-LJL7BY%BH&;-N4<H?>Q4W%ZJ.G&Z2@V'C)A@9H_N&S%4T5\(5
MR6@X_/>DX4*H^B(J9>Z2P\'AR^LFHRZ*59L.6TN,++E3,TESK\V:E9*;)-6N
MF-Q<8-O(9CDNU[6+<EZI<I$\GZI*6O9>SMD'7?'Z>3^TX*^51N7/)U[:JC\E
MIL;VG+QR$2_5!28G72=A_PGZ&/T_&H<OM&*ZL6*88X0N_SB7?JNI+@5DSZX*
ME2K'#D:#T7&<PH;- VB< <#2W)/*I](XE:N,DZ7M/2O]&15)\A-:]D[>]ME_
M^()-!^PUSRZM,[KJL\QKNF"NX"XYCFG0?>JZ >>#%TN3JUK W$GD6W;<3Z9+
M;9)G0Z!X.)S<VMUH\-VST8OAY*]]+G?^>0.R@L\D,W*FY!R,Y0IEV6\M-P!.
MN6 ?9*.- X^QG[2I0'31;TSG[/>LT"4W,%AVR7X&/F /=JH-A#T\)D_9ZN.'
MM_IK;GUT8-6"7=9Z7DK$D7XPO@DF%QKFJ34"$ 9S53->+UA;.]-*3(OHXJ,3
M?,%9A2>C>,ERGJ'),%V!6IP.<K<$:IE):[E9D$C%+R7679O3HDU &2Q9TOFG
M-4@@4P8A$6((DA::"&G8O%!9P6Q+']?CY]+(;A+:0*4LF-M#Q =1(VTC,Z\@
MS=M -2VPS1F&"98NULWPI(%T\ \"2;)<U7 5>?W:-7V@".+H-FO]JLYQN/W!
MQ?>L; 7FA/O7_- '=!010@/O$? (D,B 5LCJG&IO+ WP"A^:^R31EA  G#1\
M'L*(UR?CMF!YJ>=VB34C+Q3(G&,A3HU!;VC97X.,72IS2]LGC9K#AT?-=,/$
MWSW[?CQZ.;$=+KKH2<=5YXCW:"+COV7<2.]FN$VEI21W, ELI:6R!8F36 6J
M(KJB9Z%L5FK;8AR1F-%E\'=C-/)L-%NV!_<*";P$'YY=(2VMD5*_ C]\:$M(
MC YX-#K:D_M^Z.A(A*?PJ"B_J0/.:'Y&)+(&OP 'TF7GA?*-A7(L1/N\"4I(
M4-Q\1-F%[[@;TOC^@R/MC;1(1&%S'R.^#(@^A:^,MW;W(11'4@GG=BN%R*1;
M@PE %#-E/?U 2M9^'DH+KXEKG?Q"^0"T=*'IVN/]CABI4X'$H(O5I1*^RK-M
M:I50W"C:@ H!U--Q33.UEH*:/US61T!/5BC-H!"*+3^H0<*ELA8Y%3@6V_)*
M7 ='C BA=CU#P+=4DB!H$..E>$2T]Q?0F'YM-.Y,'K= N3OM[(Q-X'FF!$&.
M6U3WQ*_< JZ4;1$.N1%+3 "EBJ>J5&Y!\7+;LG1"/'P\,@*X-T37LC5/XU?=
MAIH6.;P%1"B^9YDVPBO@\[8+62-LEP H>F1#R"<1Y*0!A#@AJ@&3/FT89@\/
MP[,9+UO/'.0CF>=(G-0,UK5;$J!5=-Z!"</C]IS(HPX#P6(V9%ZI;MVG-=B%
MJ_E*6E):F7\YGV?I,F'U!TD&2U#%2),_:>"(K\!?P2>W?4NU89?0^)ZM +H#
M:U&$U%G6&O+@6CC:,FNEK4,[O6K"7#;#1'^$UP=L[Q-#<D 1?')#NE,<Q8#T
M92U5O'6[TFL_:%5PNXK=Q$0>NE)XBO;VZ.AS@>+U4I9=C7M#OO^W3?3(X'KW
M*N/HL589_G646 *]?TT8Q%_K8+OF#H++'8+YK>1NI1I'@N>TL:OXZ1LP954I
MYZ3\##NG&A&:^H6"?GZ2/4 29&B);/&7TLSE.9)_M KJ^S/3UIDOA?>_%1-?
M -2K$HD+$BG_%AIR5,]E2L+!7>Q;)?5SR2\IF(5$QH<SGX+YEV/+EP]W@DV7
M?X<:> O'<(&!5JXHYI,0ZQ(W# %.D%_U0T2U"*>VK> ,;-AOIJ/VK:]I'AG]
M;(/+/>?WKQ#A<H/SV(<GI*<0^-*_7NR<W@\!0M4S7<XD18F:7W1O24W'.K)J
M2KV0Z)T7.E -WX 4(' O(72P[AQ_/>9\3M\9)X7CI8EPI$K>6)DLOZP[A&Q:
MA!L8NNZB%;&7SO[!1;QU>MD0;M)\RX8;AX.C-<\&J="V=H'68_[""(?<WQC1
M;:!9ZMKI$)QX[,2R?48,C@#>W34YW70S'F'":Y0LEPZ(H879ZMN-"[ZUE<BN
M]$8P*90 ^%;/T=SP)DEQ!"^C.8SXQ4O#53]/4;"W3D[HYG)X8_OW?XWUF>.
M3BK\ A$L-]@[(9 -#S:*IW"QVGTZ\<WZ_ZSU8V?H8#R &QZ OE\.QC?Y.S3M
M9"4R$R*>DY%M>"835)7>^52$@&\3QMA[H*)*07^C<9_1SQLV;'<'M'9DF&KG
M= 4'73'_:HT]&_K_OKH9=S90[R2V\:W[YUMF>.RP^?1^=STH=W<VT<"3\O0W
M+S], /KJCCPWJ 2(#WV2?5HHF;.S*YFU%+[8KZ$6O?_4^@X:[IV'5ZG()V\I
MMK\==['/+I?!ZK$ 9BU^%JMT,L4)NC"ZK46TK"C#X5_[>==F1Y>84.PJ52VC
M[GFXD0J'GY!MY,(;3:O?JS4H"J*0PO <N6["9UJ)#KL_C ;#%RN2"FU#_Q.W
M\#LX_\.ZD_\#4$L#!!0    ( (PZ;%F<$7LP7P@  /XG   8    <W)R:RTR
M,#(T,#DS,'AE>#,Q9#(N:'1M[5IM;]LX$OXK/!?7)H!E^27I[LII@#9-L06V
M+]MU<;B/E$191"112U)V?+_^GB%E6T[<-ME-N@G0(K4M<D@.9QX^,R1U\J\@
M.*]R7B4B9;_.WOW&4I4TI:@L2[3@%J5+:7,V4W7-*_9.:"V+@KW2,IT+QD;#
MP?/!:'P\& ;!Z0GZ.FL;J2IBHU&(O_%P?,2&XVCR2S0>L8_OV,'GV=FA$W_]
MX6SVWX_G?MR/GU_]]O:,]8(P_,_D+ Q?SU[[BJ/!<,1FFE=&6JDJ7H3A^?L>
MZ^76UE$8+I?+P7(R4'H>SCZ%N2V+H[!0RHA!:M/>Z0F5X%/P]/2D%):S).?:
M"/NB]WGV)O@9$E;:0IR>A.MO+QNK='5ZDLH%,W95B!>]DNNYK *KZF@RK.T4
M+4-47Y&Y#)8RM7DT&@[_/:UYFLIJ'A0BL]'1X.BG;9&6\WQ3IOS4(BT*;N5"
M4-^=7I-"<!W%RN;3JP/L:UFOVV6JLD'&2UFLHF<S60K#WHLE^Z1*7CWK^Q)\
M&Z%E]FSJI(W\GT#7F)X5ES;@A9RC<])UZN<?H8[1_]'8_Z 1XYT1?1\C5+G'
MI7!3C5610O;\,I>QM&PR&HQ/PA@VK.]!XP0 %OJ.5#X3VLI,)IPL;>Y8Z:^H
M2))?T+)W^K;/SM,EUUBU _8.,J;/$J?HBMF<V^@DI#9WJ>H.FB?/UQ:750IK
M1X$KN>%T$E4H'3T9 L3#X?3:Y$:#IT]&SX?3O_:YGOG7[<=ROA!,BX442Q"6
MS:5AOS=< S?%BGT2M=(6-,;>*%V"YX+?F<K8'TFN"JYAL.2"_0IXP![L3&D(
M.W1,'[/5Q_=O]5?<N.# RA6[J-2R$ @C?6]\[4V>*IBG4H@_:,QEQ7BU8DUE
M=2/0+8*+"T[P!6<EGK3D!<MX@B+-5 EFL<K+71.H1"*,X7I%(B6_$!BWTZ=!
M60IE,&1!RY_&((%$:D1$B"%&&FB2"LV6N4QR9AKZV+9?"BW:3F@"I30@;@<1
M%T.U,+5(G(+4;PW55(II+M L9?&J:X9'#:3)/P@DP3)9P57D]:UK^D 1Q%&M
M._6RRK"XW<+%[Z1H4O0)]W?\T =T)!%"#>\1\ B02( VR&J=:JX,#?"F+C+W
M2:(I(  X*?C<1Q&G3\)-SK)"+<T::UK,I;'(=2SC5.CUAI;]#F3,6IEKVCYJ
MU!S=/VIF.R9^^N3G\>BGJ6EQT49/6JXJ0[A'$1G_+>-:.#?#;3(N!+F#"6 K
M+J3)29S$2E 5T14]I](DA3(-VA&):55X?]=:(<U&L6$'<&\J@!?OP_-+9*45
M,NJ7X(=/#:(Y&TUX,#H^$(>NZ>@X]4_^45)Z4WF<4?^,2*0#/P\'TN7& V4[
M V48B.9Y%920H+CY@+(+5W$[I/'#>T?::V&0A\+F+D9\&Q!]"E\);\S-FU <
MB06<VX[D(Y-J-#H 42RD<?0#*5&Y?B@MW!)7E_S\[@%H:4/3UN/]EABI4H+$
MH(M1A4S=)L\TL9&IY%K2!*0/H(Z.*^JI,134W.(R+@(ZLL+.# IAK^4:U4BX
M9-(@IP+'8EI.B6UP1 L?:KL9 G[%@@1!@V@OT@=$>W\!C?'W1N.-R>,:*&].
M.S?&)O"\D"E!CAML[HE?N0%<*=LB'&*'L\8$4"IY+ MI5Q0O]PU+*\3!QR'#
M@WM'M).M.1J_;"=4-\CA#2!"\3U)E$Z= BYOFXL*8;L 0%$C:D(^B2 G]2#$
M"I$UF/1QPS"Y?QB>+WC1..8@'XDL0^(D%["NV9, ;:+S#9C0/^[/B1SJT! L
M9GSF%:O&?EF#FW UWT@+2BNS;^?S+%XGK&XA"6\)VC%2YX\:..EWX"_OD^N^
MI;UAF]"XFKT N@5K48142=)H\F G'.WIM53&HIQ.FM"72=#1G_[X@!U\H4D&
M*()/KDBWBF,S(-RVEG:\5;/1Z]!KE7.SB=W$1 ZZ(G44[>S1TN<*F]<+4;1[
MW"OR_;]MH@<&U]OO,HX?ZB[#'4>E:Z#WMX1!_-4%VY8[""ZW".;7DKN-:AP)
MGE7:;.*G*T"792FM%>(K[!PK.H-$?2JAG^OD ) $&1HB6WQ3FKE>1^+/1D)]
MMV::*G%;X<,?FXEO .IE@<0%B90[A(8<[><2*>#@-O9MDOJEX!<4S'PBX\*9
M2\'<X=CZ\.%6L&GS;[\'WL,Q/$5#(S84\T6(M8D;F@ GR*_Z/J(:A%/3E' &
M)NPFTU+[WF.:!T8_^^!RQ_G]2T2X3&,]]N$)X2@$OG3'BZW3^SY R&JABH6@
M*%'Q>7M*JEO6$65=J)5 [3)7GFKX#J0 @3L)H8.N<^@*R]W'O.B19>FJS27X
MK:5BH$#H .NKX+41T?I'USMDX-S?QM#5%PV/B>TZ;#@X[OC07ZSYLLY-&0VN
MUR.W/7K_G-AT7;X@<D9L;F^1K*K;+H[1PQ8 Z[$\&&@DMOEUY>JN,Q*9C [[
MHERFP-7F.5AJ7D<Q5M=%L(1)OGD=N*GG,?;BC153NI,<7IOO75]0?07IJ*0]
MG5_CZPGV3@D_P\G.OLA?F;:?-OUA_7_6^J'5M##NP0W?<?YD (0I*P)3\T1$
MV HZM]+. 209,?8>[BYC4-9HW&?T1L*.46X!PY:S8F6M*F'Y2^:.P]B3H?OW
M<.W3.PU->/7*^)H5'B\<;KH ;N]K6MZ/RM$_G'PO<>6[^_$LER)C'WS:CDS\
M0[M??,K+>LI\[9M-"M;6WGUR? N-#S[ZPU"HLU6,<OJ7V_/25L_#_; ,78:X
M#E$/!4^=J)EODLB8)Q=SC6FEP7J+Z*FA\[K6;D6;CF#G,"UD)8+V>4TFW=?$
MVI+N6V)7WS^KD>4'/G'A&=+SB"^43%MH_S(:#)]O*,R7#=TK:_Z]-O>BW.G_
M 5!+ P04    " ",.FQ9]A_4'_$%  #.'0  &    '-R<FLM,C R-# Y,S!X
M97@S,F0Q+FAT;>U9;5,B.1#^*WUL[:Y6,6^@6SJP5"%BZ=4JKHQU=Q_#)# I
M,Y.Y3!"Y7W^=9$!P]SP_[%;AG18"DW22[L[3_:1)]Q?/&Q89*5)&X3RY_ )4
MIO.<%1I2Q8C&U@77&22R+$D!ETPI+@2<*$YG#" *_4]^U#KT0\_K=7&N03U(
M%C%$48"O5M@Z@+ 5MX_C5@37E[!WFPSVK?CI:)#\<3UTZU[?GGRY&$##"X+?
MVH,@.$U.7<>!'T:0*%)47'-9$!$$PZL&-#*MRS@(%HN%OVC[4LV"Y";(="X.
M B%EQ7RJ::/7-2WXS@CM=7.F":094173GQNWR9EWA!*::\%ZW6#UZ60GDBY[
M7<KOH=)+P3XW<J)FO/"T+.-V6.H.C@RP^XG,@[?@5&=Q%(;O.R6AE!<S3["I
MC@_]HZ/')L5GV;I-.M-BQ031_)Z9N3=F304C*IY(G76>+O"]D>5JW%06VIN2
MG(ME_#'A.:O@BBW@1N:D^-AT+?A9,<6G'SM6NN)_,9P:S=/L07M$\!E.;G3M
M./MC[ /S'[7<%[/B9&M%-T>$7?9QP:RI$RDHR@X?,C[A&MHM/^H&$_1A^1,T
M3A' 3/T@E0?#F^3B[&+03RY&5XC3F_%M_RJ!9/1*](^.X-8?^P,?QL.!M2%J
M'X:O1/G^&/JGH^MD>/H*/;_R]W'X"49GD)P/8=R_.>E?#<?>Z/<OPS^@/TA,
M3RL,6S_#)EY0M"=N?RJ?C5\S]!^L:O0N"DAE4;#4)!K'!CIC\'5.%'I*+.&&
ME5)I3/EP)E6.G.!]!3F%<9I)012JF][!.3H$TQX,I$)A8J?:,]-\>'?4:H6=
M@<R17Y;V*>KLPU0JNTJ)MDD*#.V@,&:E9OF$*6B'3;#$0BJ8<K%B*3-BS-*Y
MPJ2(SB(%A>$#YOL"N0I7R'E5F87Q920I,A5D3#%4=E,79\]*E28PDF;&(",R
M1T54A4 Q'#>=\A2?5GVU#8!MFD]1@2:4<U7-"3I72]@(P]J7)@R;Q@1"96E8
M<U-\)62P4R\P)FI""E9YHP?!EM!/M>DQV&F:$1E'592Q".X*N4"OS!AV9$3'
MW<!LJX.7)A/!8"(56O*Y$3907R%J6EH_5R5)ZV<<H?"?K@!R;\Q+B:@#QN(,
M2;&SR+AFGAG(8EQ>$6RR3&715R\0UXC[,1BO*1F94<L\-HCN;+#T2\"]%^UO
M^B;0=-/4'57:8*$.NNE<8 2FB#QA$+^. L7^G'/%S$'.XO,1<GMDWZ D.MRC
M^PY\)8Y-#2B::Z ]QM Z?FJT1<?M S<LMT'9,5'VC0L# YG (NT-<-N :[U2
MP/$"<W+N,C?R@2;<Y$#N4ND*C80;0B@5JPSPFJ:;8+F PU S(A"658E(K)IV
MU)076'B8=IR0VH.LS=DH-1<.MQ()P*[Y-,OZSV-NQS@T,;FYYH74^1 ;)LQ0
M8JGD/:=/LO\C61B2L%[! 86TG1/D+H:Q38% 291>N<;M0A/%E)'F3X3=0TUR
MEC5KCK-L:Y@+-<"*@L$".:.2# -OR\VVVG'17!OJ@MI+I1"DK%B\^K+I2..W
MS!V+3/5BL(/^7$'0ED9DKN6JP15&MF6K? H?8[J6,2T;M5 #;'[ <LD>X?XM
MC;APJ"<X./:/#]YO;._/3!\O"+G-U(;1Y-GDUNB=8AS% %?RWAV#HI8[!CV3
M49ZS^C#TP\/WG7H35_FA?(!*"D[A76C_=L<KC5Y0!? K64+BPPE)[RJM9/[]
M1/"*]OZ>5U@2"ZZ7<<8I)AL4,)$9MCL_9&--EM_I77W;T9?NZ YMVC6R-#?,
M:,EID'$VQ<,B'AS-SU P<K71IK6[Y/0W0.T:H/[+N_=&[B\F]R%=$$7AW(=+
M%*I>_=;_[[G];4-?6R9N]!R9CUSIC15J3>;P@>1EIZ;ZLW7M_AVJ_[8>=S=E
MN[(Y5AGWGJEU+8O'SYF2\X*:>E:J>!5-&]=OVQUU56M^4!&\8%[]'&[5MNZ*
M;ZNXW6I:WR>69,:\B6+DSB-3+&!C<B\YK4%R=.2W#M91[]I">P7I[BGMQ6?O
M;U!+ 0(4 Q0    ( (LZ;%E^26D^G P  .][   1              "  0
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M+3(P,C0P.3,P7W!R92YX;6Q02P$"% ,4    " ",.FQ9[/5\XH/N @ LS!T
M%0              @ &(Q@  <W)R:RTR,#(T,#DS,'@Q,'$N:'1M4$L! A0#
M%     @ C#IL6>T&^WJOO@  :=$  !@              ( !/K4# '-R<FLM
M,C R-# Y,S!X,3!Q,# T+FIP9U!+ 0(4 Q0    ( (PZ;%D_KQ/)EH,  )J]
M   8              "  2-T! !S<G)K+3(P,C0P.3,P>#$P<3 P-2YJ<&=0
M2P$"% ,4    " ",.FQ9A'["G".:   $R   &               @ 'O]P0
M<W)R:RTR,#(T,#DS,'@Q,'$P,#8N:G!G4$L! A0#%     @ C#IL6?IP%4UG
MZ0  ,RH! !@              ( !2)(% '-R<FLM,C R-# Y,S!X,3!Q,# W
M+FIP9U!+ 0(4 Q0    ( (PZ;%F=J0ST<@@  "XH   8              "
M >5[!@!S<G)K+3(P,C0P.3,P>&5X,S%D,2YH=&U02P$"% ,4    " ",.FQ9
MG!%[,%\(  #^)P  &               @ &-A 8 <W)R:RTR,#(T,#DS,'AE
M>#,Q9#(N:'1M4$L! A0#%     @ C#IL6?8?U!_Q!0  SAT  !@
M     ( !(HT& '-R<FLM,C R-# Y,S!X97@S,F0Q+FAT;5!+!08     #0 -
+ '@#  !)DP8    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>srrk-20240930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srrk="http://www.scholarrock.com/20240930"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="srrk-20240930.xsd" xlink:type="simple"/>
    <context id="Duration_10_1_2024_To_10_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EKUEbTHr-Ea-uOCZ6iVjdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pFHBf0hY5UW0FWY703uxbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0wakrHVLCE2j3KU_Wo3X-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_10_2024_To_10_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DS-yvkHxka87ldWHUSkvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-10</startDate>
            <endDate>2024-10-10</endDate>
        </period>
    </context>
    <context id="Duration_10_8_2024_To_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_tVRY0dVzb0i50FyP8rdL6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_7FmVsKFVF0aJhLlDxLXyug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oFzCQeJoUUSgYwvWF5ktNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7Zh84n4-Ykq6WGOpfdZ02g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MuQ8eux8ckqYO9qz-3WyHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9xzkVt4VMU2Z76J7CR-7zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g5MOsQI7QkGSEfP3mEn_Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cYBDTrhv5k6-VEbdQ5UWiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dKD3wJCHqEuE8Jri1puoRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ORLJCxuY40S9_SNp0cm9Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_55LwgvBeAEWVjIhgYoVZ_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bEpiyEGiwkG49eAV_JtQTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_wqwnwDf4JkGc0MFSynknLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZjASu7KTjUmyEQ3U5sdd6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2nNWjMEjVEeMAdYk2gMIZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_nozla3sC4EiSz8NaIUpFgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rI2SWZIWcUGpK_a1C6sCUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LyOvZrAbr0mYiQTtryH6Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_WyRIrmBEzU25Yii5LaCicA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mdZ4Vf_v90mj5UjPiNSTZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sEwTkPlLLkSbqd_LCKEveg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iGIZ5dBRVkeElrLQcBXYfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_Fxn6BbkW0Um942NziX600Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8rb9ujm1066sXa5nb2vXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CDkUieplhE6Jbi_MfC9KFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DSycY3vZYkmsf4sXbaV2Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_Ck3LkULZgUu4IahGYkThNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j0Tq9iEgI0WxB3qMug6fdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fq5xFmnwbE6Bb4giq5tdsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6oRTpQ0UIkSjNufZC8jLZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UaO3_RTxqUKoz5-Yyidv_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BUGwTFWlqE6W4huRO8juSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kviCKzjbT0OnEPOSUwBMvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Jl5WhaKOMEWbPOAHelRptA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JqYd9nXR30C5hBt7QuvWkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8SSCuIUnHEa3XtfgIHQmTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Upyc56e-ZUuXeiJ1EZGbkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q6t-2V68bkiFrfajlGSBeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_8_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_kidvJgGpG0maEoeyfhtn0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="As_Of_10_8_2024_us-gaap_StatementEquityComponentsAxis_srrk_PreFundedWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_5SGDYfs7OECckL2UaG60KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_75tkU34fOUy3WI_eCj09wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q7G20lfZrEGGf9s5KiiN4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qeLfTKYhf0WUaB1ixSydRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_btXk1iwRBEitcM4l_d0v9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_StatementScenarioAxis_srrk_AggregateMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_ya99nBLVs0yCCbyZ5u51EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:AggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_0F_1Zc84bky0_5lT0wv1fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hohbrgalOEmxhqwnpMP8fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KI1BGZUe6kqHi_LI40MMew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rkA0oDL87kCoKZIqo1taMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uw72zZDY0ka7tF4uwvAQKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NipCJOW77ECvOR_obikyPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JwQxc0pT8kKm0ykun0RF7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QKxAZY5g4UK604mpOKeFxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AvRWZZzhQUSBZgDTGob30Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__bNeEJWJfkecGakhaXbnYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tkrpxbJb_Eq1PgDgb69BVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fk_SSWQDLU6gbCA2Hoe86w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_19bHARrGm0mAeIg-yhN-Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_17_2024_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_Hgg07AAyG02T4Jv5fZE-FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-17</instant>
        </period>
    </context>
    <context id="As_Of_5_17_2024_srt_StatementScenarioAxis_srrk_TrancheThreeMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_u2DvbaL6ckmuYfubdLSQiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-17</instant>
        </period>
    </context>
    <context id="As_Of_5_17_2024_srt_StatementScenarioAxis_srrk_TrancheFourMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_NKmevx8gPUq3cZ8kssDJNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-17</instant>
        </period>
    </context>
    <context id="As_Of_11_10_2022_srt_StatementScenarioAxis_srrk_TrancheTwoMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_CDA1wcxtM0OOvFBfiQ1ZIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="As_Of_11_10_2022_srt_StatementScenarioAxis_srrk_TrancheOneMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_1o4-ToeAa0Ws6_A2nhaIWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="As_Of_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_A2Z61BQQoEaOUGpduwOO4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="As_Of_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_JtpKqHohmUCTdUXoThTIWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-16</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_srt_StatementScenarioAxis_srrk_UponExpirationOfFirstExtensionTermMember_WYDXdjdOlEim9o-T7lrtyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">srrk:BinneyStCambridgeMaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:UponExpirationOfFirstExtensionTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_V7tZSLwfkEiSdTEO0LipJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_11_10_2022_To_11_10_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_CK6FHGQq20Km9jMf98wKZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="Duration_11_10_2022_To_11_10_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_EPztZdder02zre_iKLe24Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_74qePC5v6kCjrygaeq4KKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2024_5P3UGITXB0-czc9H0PmBtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_n9DGS8M0kE24zj_oklD1kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_6NJQiQ1vPEGInMGw0DCVKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:CommonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_iFj3QnQzOU-8kQacFHjl3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_PTkW0Ae7q0-gfeY7Vb1FxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2020_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_WrTjGUDWz0OGm3OPxFpVKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_-E3ijiIBr06-jKD1_9WN-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:CommonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_xn5zGRExdEqV3w6EYHlpYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hWuMG1NhkkW9bHAcUgbYxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EGRmdupzaUKG_rn7xck0fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lH_pD1wqKE-js0Bu3cDiQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_GRQncXuqCk6pkM25ZxfA6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Q37l2topEU2AU5wm5NYCjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XZbR-apKpk2fl7Q5s_WQGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-T623QZuKkiWEpLOpPmaJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_kZda-3Zt-kGSsr8DQ7g3kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_UlyEzRV6tEm11MvO7uPFnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yUXtseVKLEmLijTO5Hn_0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hZuVKm_vv0uSY2YRXuVk-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bwusGcH5nkSqDzdmdcCglA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BRNbuA-xdUWVSanmpZGNKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_BYs8SrAKnkyWg65xLBo1ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_srrk_CommonWarrantMember_5ObJ1CZ65E21VrAjZyMJVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">srrk:CommonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_WcKh_paNQEO1eHbYGf_3nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_leFkp74BkEGzez-zOjF2mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_srrk_CommonWarrantMember_gCi3mjIZR0W0dKa1gLVEAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">srrk:CommonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_sX3h_3P7vU628onpj2CP_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_33ZytFP8IkiHsYntj3TCwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0rdTgvAQZ0SGGGDzlLKrng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ephi9PPE4Em6WeJ6Tatiiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WYPheoLxHESQikinAnOQbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZscaUP5tbkyTvjREC97cOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_EyntDTnzGkKhLJiLcViJlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3cefOggcskeAM_epSw3VaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ERzFFMLhQkOjWn1JX4pSxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5mmOYnBYhECqu2JZBuf-nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_n1BJNZBWIkiQKIcb1a5qjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rC1XfV1TjE6F-U0p2kSCCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dN42DahesES9T_h8Jy0MRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CE-n08KE9kym4zuTU2o9Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_StatementScenarioAxis_srrk_AggregateMember_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_vHhfARkPrEeM6UAWteancQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srrk:AggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_SZALhDjjmEyPmtlfB7lZaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_UUZbJLH39kSS8xaTMnAraA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srrk:CommonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4gsxBsTIOUKDdJU0qMOv6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ePsDgOB7_0WDZ--l8zx3Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_10_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_ijSq6JdiwE60YiJXwFSdRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="As_Of_11_10_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_ZLcu95SjEEyxu4lbKeIrfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="Duration_10_16_2020_To_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_gUd46vYiWE6S_1qXC2sVKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-16</startDate>
            <endDate>2020-10-16</endDate>
        </period>
    </context>
    <context id="As_Of_11_30_2022_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_BxOz9tF8aU6Z0utpswOoRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srrk:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="Duration_5_17_2024_To_5_17_2024_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_qdKJj99R-UKWV1diKEhPMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-17</startDate>
            <endDate>2024-05-17</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_M1v0aqRvFEaEli6XZP3iLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">srrk:BinneyStCambridgeMaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_GTqAgMQoLEKmU-Yg4Ni_LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">srrk:BinneyStCambridgeMaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="Duration_11_10_2022_To_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_rTABVC0FK0WrPzEHVwYh_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">srrk:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2024_To_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_gi0LiBrpuUGw7o_sZbKeZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">srrk:BinneyStCambridgeMaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2019_To_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_CdJUVb4pFUiKpg6aL0QLLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">srrk:BinneyStCambridgeMaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_7_2024_7kr9rNMD5kGfUtrmu_jUDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001727196</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_security_rO9x9MuL10eAmA3nIFOJ7w">
        <measure>srrk:security</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      id="Hidden_DwG3LGD1-kC2bTEkgK0sLg"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      id="Hidden_vL2eRir2PkqR1Vd-7r0w4A"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      id="Hidden_fK1O5Hk2KUGhAObC0ROnWw"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      id="Hidden_K0-1HCmOakWX3iXS5vAj_A"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_pkRxhkUuDU-AvpoQMW6jKg_1_1">0001727196</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_Yfe7Iq_0rk6X8BjkKOdNHg_2_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_lb3IwqGri0CWIzYrVwe2ng_3_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_MnSQMR3yXkSAf9hSWVR0IA_4_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_yWYjNBPfG0yrxk6VBiEv6Q_5_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="INF"
      id="Hidden_5YCHwVa3eUWYGBrG00S36Q"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="INF"
      id="Hidden_yNMlVyLhgkev8fVrqOwLKQ"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="INF"
      id="Hidden_LyQTJMKS5kuj9s5A7zJITA"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">80081535</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="INF"
      id="Hidden_SUTORcMu20ytkQS8A1M_tQ"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">75979495</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="Duration_11_10_2022_To_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_rTABVC0FK0WrPzEHVwYh_g"
      id="Hidden_VBPAhXNcSkCfo6QuLvnBlg">http://fasb.org/us-gaap/2024#PrimeRateMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_KaBU4eUJ2ESlJjtfwllaXQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_4n5iJhh-q0af6uw7R2b_3g_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_6dbZRkvnY0SM4CKM46s0Xw">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_GP6Ws5VysEeU6eiwg_GbRA">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_79rHxA1tIUC9PQPSlDbIrQ_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_Plf6lOESSU6laklVpJJ7-g">001-38501</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_OjXa02mo_0aJGXx_Skj2BQ">SCHOLAR ROCK HOLDING CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_fgSXGQbqUEurY71KAASCuA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_MMFvoa8TSkSv0TcpLYm7kQ_1_1">82-3750435</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_rSnbSFlNuE2UV1eAo4pg4w">301 Binney Street, 3rd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr__7sw6nl1vEyST50X_dWNiw">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_3Ws3sOuZXUeZ8btKpro1wA">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_9sxlIlimQESwr_V25AFpcA_4_1">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_WxrYVpDZNk-NQeJphGiOgQ">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_uzqlmKGaW0yM18l_Zjh-QA">259 3860</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_-FoeURyHk0a_hP6_4hoNjg">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_eHnpg9FLjUOia-RTG2ACug_2_1">SRRK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_1XMTYNSSdEmbh2seFA2l0Q">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_zO9wnqtHZU23nazKZfkHNg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_b-jM4lv3Y0OKnMH5EWvldg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_Jyyg30schU-90TFZvhn4FQ_3_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_MmxYrdAIYU6jd731DIiQhA_3_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tc_i7w4hUTT6E2h8a6z4uPQ1g_5_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_46xfoJ8SIUiAl0tiXJAxgA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_7_2024_7kr9rNMD5kGfUtrmu_jUDQ"
      decimals="INF"
      id="Narr_9LCSwsrZE0yKqw2Rvi5-KA"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">93614951</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_aCcRkB5vDUWxLLtU--jI-w_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">76391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_qJYKIZKqZEioRC2PD45SGg_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">101855000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_ItEMBhr5AUiafXdyHJ-UeA_6_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">62674000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_FBg-zPTC8E6tb16N4U4-kw_6_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">178083000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_NhOnfY8lEke8Wf3Hw5Zocg_7_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">13862000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_gm6_7XrfyEabNA5MIupDxg_7_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">8256000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_1w45VSSJsUqi7PHUeCF9rw_8_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">152927000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_30q_kjUamkSQyZCbS_MP5Q_8_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">288194000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_eMTDVg-7F0Cq9A43cTDQmA_9_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">3156000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_aChqpk5HdU6vS9aq2XXf7w_9_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_sKQFWPde7kSCtPsO2X62ZA_10_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">16834000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_9epHfdBN2kyQsY_EYwOLVQ_10_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">11417000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_pnLub_GHqEWg3LHDTep5uw_11_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2407000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_WKlyP3FTkU-zMYoSWZmSWA_11_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2407000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_K305BkPpxEGODdUOFYw7Lg_12_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">3809000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_YGlbk3j_KU-3f0X615AmNA_12_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4417000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_-61ooKn3mk6L0r4hDSoMXA_13_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">179133000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_KwEwEyeBl0O81mtBsTntTw_13_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">311035000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_VuZU-VByOk2G-Dx90LHnyA_16_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4071000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_PoUJYNKlLkK7JbqVQscjtw_16_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">3465000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_GHjeBYprt02LKZokCc1qow_17_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">29260000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_HCSsmY11UkOt8WSLH68g9w_17_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">20449000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_AJWIV8kwAEGzf8SebLq9Tg_18_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6041000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_CivlNMgDsUiKZ82qgLmvqg_18_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">7408000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_PKbpphgNlk2yWo64RY_yGg_19_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1334000</us-gaap:ShortTermBorrowings>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_5JqAsEOTiU21aOSR-L88_A_20_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">85000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_QcKdvixKiEyNoTnMdbpCWw_21_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">39372000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_gkRsz8KGzk2uh2VkALsHBw_21_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">32741000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_3biJYh1LV0S-rDKSkejdMg_22_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">10466000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_3hwCvLFPr0OJI-bJyqpxfQ_22_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4392000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_ci2slnzOfECLqUg0LjAhBg_23_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">50099000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_CCy7x68ytEyY8wtY4itwiQ_23_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">48684000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_R5kGVsaAZk-FhDO07qLkfQ_24_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">99937000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_8f1ROaW-2EyAHp5AN8CQgQ_24_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">85817000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="INF"
      id="Narr_cfqCJ8XAjECqVh0_TBYfpQ"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="INF"
      id="Narr_Si5IlHBX_Emz67vmQv2ZMA"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="INF"
      id="Narr_5LuIdYHy8ECuk_cdTdRn8Q"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="INF"
      id="Narr_L1SCZHYbYEqo0yl05zQPWg"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="INF"
      id="Narr_yTr11GPocU-25bykpYG3sA"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="INF"
      id="Narr_qWIoQsDjX0KD7_2F8ewXoA"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="INF"
      id="Narr_K66krIiX70CfPUQHZ7dmYA"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="INF"
      id="Narr_ueId3rW2MkCJEqXUrKjPSg"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="INF"
      id="Narr_rF3QnXEUM0uHP0qOxtG-CQ"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="INF"
      id="Narr_5ZTVfV7gSUu_z6ES7Y-UNQ"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="INF"
      id="Narr_ahRA9xdO3U2DsDvkxquW6w"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">80081535</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="INF"
      id="Narr_T1GMwkcs-Eqe_cjoqaGYQw"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">75979495</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_NVwC5RziF0CPl0si4HiL-w_28_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">80000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_6kB10_KVIUm4vYGyoLcBQQ_28_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">76000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_3BebXkDa5USohV3DPwQeSg_29_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">935249000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_e1quhkHPuEKQrxQKxbn_8g_29_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">901471000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_A5F7zkTx_kSEn213nFJdWA_30_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">128000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_B7fUyjLvjUKs0s9P64k0vA_30_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">92000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_MWr2fL-tQUCrJ_RLwC7ntw_31_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-856261000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_JqQl6v4pxkydVUh9yPoUqg_31_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-676421000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_i3HrZfkumka0Q-GD9__X2Q_32_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">79196000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_6GfUINMvRUOmSS_WiA9YKA_32_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">225218000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_3FWUM7ARLU6uRP4WzFF5gg_33_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">179133000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_PwWB44u_4Eqh0D62URAWFw_33_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">311035000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_PuP0elZT1kKBWvD_cXxr-A_4_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">48719000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_UO_YJyOAjEqGU6WVS8g00Q_4_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">30337000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_IE5ZnwP6_EG4X18eeP6Nxg_4_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">134185000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_v085U3mqzUqy0p64_FgMoQ_4_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">86939000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_j2ha1kBd6ESIAnFykGZ4EA_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">16061000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_vKEf7ekhaUuh1LEpJSFvZg_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">13335000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_K6_EfJHvw0ai4roDqci6KA_5_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">48512000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_SIEwQJJVC0ui1dqyEuGO6Q_5_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">36324000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_LlR4TC2tr0OiuhSVLOKgiA_6_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">64780000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_8QyeonHO0EGJMOINTt5egg_6_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">43672000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_IyBQ3TcSQEKge9YC0h8wmQ_6_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">182697000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_PKjp6Ksa90mJgWavmN807g_6_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">123263000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_boUs8BJelE6fqzogxlHOdg_7_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-64780000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_7oEGdhl4s0mRb7S3ZQGlRg_7_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-43672000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_k2IbCQYshUiSh7PTkHq0aw_7_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-182697000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_yl_QiCvhaUOahPaBH-XOkA_7_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-123263000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_kMVR0KkdQkCiFF-JOikNHw_8_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">301000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_SxUirkKVAEex8l88RTol5w_8_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1313000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_FHxhFe7QfkKgK5SJ9IQFmA_8_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2857000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_KtMksrprjkakxgXpRmi85A_8_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">3600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_cG0DfJOoy0aZmzgzpdMF9w_9_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-64479000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_GBg8h5tOl0CWyzgOIc_KOA_9_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-42359000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_PBeZzRj0u0yvfS02NVSXgw_9_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-179840000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_1esIPTnOL0mQpOGFzOqmnA_9_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-119663000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="2"
      id="Tc_zRuNCfFjvEOE-9JFQ1atFg_10_3"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="2"
      id="Tc_zRuNCfFjvEOE-9JFQ1atFg_10_3_2"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="2"
      id="Tc_C4PpbHm5_UqLPdC8GI0sSw_10_6"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="2"
      id="Tc_C4PpbHm5_UqLPdC8GI0sSw_10_6_2"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="2"
      id="Tc_4XVAnMhOSkS-YSsg5OK9uQ_10_9"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">-1.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="2"
      id="Tc_4XVAnMhOSkS-YSsg5OK9uQ_10_9_2"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">-1.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="2"
      id="Tc_Pyjy4KvkiUip3OZ7mZtL_A_10_12"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">-1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="2"
      id="Tc_Pyjy4KvkiUip3OZ7mZtL_A_10_12_2"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">-1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="0"
      id="Tc_MYOhjT0ktUiEAOPUO9CDIg_11_3"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">97050637</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="0"
      id="Tc_MYOhjT0ktUiEAOPUO9CDIg_11_3_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">97050637</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="0"
      id="Tc_t9mKdCnxvUyCRpS-rTgO9w_11_6"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">80606438</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="0"
      id="Tc_t9mKdCnxvUyCRpS-rTgO9w_11_6_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">80606438</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="0"
      id="Tc_nhJPy4U_dkaMdmPokXTj2g_11_9"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">96587149</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="0"
      id="Tc_nhJPy4U_dkaMdmPokXTj2g_11_9_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">96587149</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="0"
      id="Tc_w1-2YDG7KkyW-GIlxWFPfg_11_12"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">80115143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="0"
      id="Tc_w1-2YDG7KkyW-GIlxWFPfg_11_12_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">80115143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_3aI9iCN0306n128T6EuAEw_14_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-64479000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_ziBK0-qg-EqJ-U5sMPtDpA_14_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-42359000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_u8fi5OSgMUittCAMiBNtNA_14_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-179840000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_UFQpK7ghK0Gk-tqe-0-a8A_14_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-119663000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_h2SZRqVNZEeTbhm9XeGHjw_16_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">182000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_xXf19hrjhEeHGHopBOWZgQ_16_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">40000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_0tNpsyFYbUeSRTgXnCqM4Q_16_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">36000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_H62FkandYEGKWHZO_kDIXw_16_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">861000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_12SAWdlPO0eBBLirlP6Vsg_17_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">182000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_GS4MC20DqkuX--i9Alzg6Q_17_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">40000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_xBfIHMizCkuJBOykjNp4tA_17_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">36000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_AMRd_nkA3EqNvsqYqzummw_17_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">861000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_3z1GBnB9x0uMJPUaHkI3Gw_18_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-64297000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc__k_3LNa-I0yHS8dN3idJUw_18_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-42319000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_l4fRPLGYvE6VLuULvAUCIQ_18_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-179804000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_KhqCsUv2E0qvqrinllflgQ_18_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-118802000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Jl5WhaKOMEWbPOAHelRptA"
      decimals="INF"
      id="Tc_I8Sm07jT9UyJPQ-Co82e4w_5_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">75979495</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Jl5WhaKOMEWbPOAHelRptA"
      decimals="-3"
      id="Tc_XQTCoIJAkUa-0tFirkGnWA_5_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2nNWjMEjVEeMAdYk2gMIZA"
      decimals="-3"
      id="Tc_UXiTpwvrOE2ayoQSd2rDnA_5_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">901471000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_nozla3sC4EiSz8NaIUpFgA"
      decimals="-3"
      id="Tc_tQttyR4UT0aR7QqXLWQidA_5_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">92000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZjASu7KTjUmyEQ3U5sdd6w"
      decimals="-3"
      id="Tc_evy-4C8qvEifEZP-CnTmMg_5_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-676421000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_xvTL7jJ4JkKv1CC-hQmqiA_5_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">225218000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_rkA0oDL87kCoKZIqo1taMg"
      decimals="-3"
      id="Tc_7p4z2Uahgk2UPdTvyJSGUQ_6_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-142000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ"
      decimals="-3"
      id="Tc_v4nSyTlCD0miY6K9nqZKTw_6_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-142000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4gsxBsTIOUKDdJU0qMOv6Q"
      decimals="INF"
      id="Tc_DB2-3iaiFU6kyHrAU3Ikvg_7_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">47293</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dN42DahesES9T_h8Jy0MRw"
      decimals="-3"
      id="Tc_OmTpPgz8hEGGG60eGQ_9Pw_7_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">280000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ"
      decimals="-3"
      id="Tc_jh8GQmFlN0qqTOKDxKZSyw_7_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">280000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4gsxBsTIOUKDdJU0qMOv6Q"
      decimals="INF"
      id="Tc_EOitBaj-uk-NstHOwQyFxA_8_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">360373</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4gsxBsTIOUKDdJU0qMOv6Q"
      decimals="INF"
      id="Tc_Q2FZB0HudUyrfs_hyN655w_9_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">3357493</srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <srrk:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4gsxBsTIOUKDdJU0qMOv6Q"
      decimals="-3"
      id="Tc__p0fwv0Cjk6NcvKyCst7Dg_9_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4000</srrk:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <srrk:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dN42DahesES9T_h8Jy0MRw"
      decimals="-3"
      id="Tc_vLBwCXqpeE-WZAHDH4ujjw_9_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6102000</srrk:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <srrk:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ"
      decimals="-3"
      id="Tc_Vsa1lk5yM0uO69GjeHAilg_9_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6106000</srrk:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dN42DahesES9T_h8Jy0MRw"
      decimals="-3"
      id="Tc_w7VdnA2UoUOztiCfA9hgMg_10_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">8164000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ"
      decimals="-3"
      id="Tc_9Ezw30vjOUifx0Qf5dW1UA_10_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">8164000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__bNeEJWJfkecGakhaXbnYw"
      decimals="-3"
      id="Tc_DyDfBZ_Wb0G4d9lurbltgA_11_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-56853000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_o0jlD5TgBEy9mGwaVcB0aQ"
      decimals="-3"
      id="Tc_Myqua_NKOkat5KJ5V23tqw_11_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-56853000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kviCKzjbT0OnEPOSUwBMvA"
      decimals="INF"
      id="Tc_pIa5qLoPZk-XEOWHeCCJow_12_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">79744654</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kviCKzjbT0OnEPOSUwBMvA"
      decimals="-3"
      id="Tc_2Z4bTrgbAUCmwRzBCGSX_A_12_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_55LwgvBeAEWVjIhgYoVZ_g"
      decimals="-3"
      id="Tc_v-U092OFek2KPP4vSEG9TA_12_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">916017000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bEpiyEGiwkG49eAV_JtQTQ"
      decimals="-3"
      id="Tc_uqkOiLpDuUqiL1a5CemLBA_12_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ORLJCxuY40S9_SNp0cm9Hg"
      decimals="-3"
      id="Tc_Sh9OhYPZ7EuH6L63owjQfw_12_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-733274000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_wqwnwDf4JkGc0MFSynknLw"
      decimals="-3"
      id="Tc_jEwrQHFwk02bd8V5yZOjbg_12_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">182773000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KI1BGZUe6kqHi_LI40MMew"
      decimals="-3"
      id="Tc_KPKjiSnWIUu9rSKkZ4UIMw_13_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_4_1_2024_To_6_30_2024_n1BJNZBWIkiQKIcb1a5qjw"
      decimals="-3"
      id="Tc_LbMGIQ1QfkiVxp-88EGd3g_13_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0wakrHVLCE2j3KU_Wo3X-Q"
      decimals="INF"
      id="Tc_1FkA3LbyW0uz0VCkUPOhbA_14_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">6617</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5mmOYnBYhECqu2JZBuf-nQ"
      decimals="-3"
      id="Tc_ls5JHo5WKkW15_dzToMkqA_14_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2024_To_6_30_2024_n1BJNZBWIkiQKIcb1a5qjw"
      decimals="-3"
      id="Tc_2UkDoUXSC06QamtQpshpxA_14_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0wakrHVLCE2j3KU_Wo3X-Q"
      decimals="INF"
      id="Tc_2YxYWomDf0ib-IcwCRtfGQ_15_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">240797</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5mmOYnBYhECqu2JZBuf-nQ"
      decimals="-3"
      id="Tc_9NEHqRwYTEqMyojpvcEb9g_16_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">9312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2024_To_6_30_2024_n1BJNZBWIkiQKIcb1a5qjw"
      decimals="-3"
      id="Tc_ddhBkH9X7U-PimrQrDmRKQ_16_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">9312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AvRWZZzhQUSBZgDTGob30Q"
      decimals="-3"
      id="Tc_K6Skx1GFIEa6-DYItYpYCQ_17_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-58508000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_n1BJNZBWIkiQKIcb1a5qjw"
      decimals="-3"
      id="Tc_NZ3KehfXMECg4qY1QZtuug_17_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-58508000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BUGwTFWlqE6W4huRO8juSA"
      decimals="INF"
      id="Tc_1X1wcYonJk6GIntWJyV6_w_18_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">79992068</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BUGwTFWlqE6W4huRO8juSA"
      decimals="-3"
      id="Tc_Gj2cjF-zQUuVw_XOlbVW2g_18_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cYBDTrhv5k6-VEbdQ5UWiw"
      decimals="-3"
      id="Tc_-d4xHnY29EmivLTujBRhDQ_18_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">925376000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dKD3wJCHqEuE8Jri1puoRQ"
      decimals="-3"
      id="Tc_XForxAlwVUK9UORBZRT0QQ_18_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_g5MOsQI7QkGSEfP3mEn_Fg"
      decimals="-3"
      id="Tc_195-IepZtUSslCHX65Dh5A_18_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-791782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_74qePC5v6kCjrygaeq4KKQ"
      decimals="-3"
      id="Tc_LaPka7JuWk61ZoqeownZvg_18_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">133620000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hohbrgalOEmxhqwnpMP8fA"
      decimals="-3"
      id="Tc_BoXy7LLbSUWHexemVbIObw_19_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">182000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_OzdPsXEGDUaYpmfibHwKfQ_19_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">182000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pFHBf0hY5UW0FWY703uxbQ"
      decimals="INF"
      id="Tc_6uHi3cZ__02UZ1T7U5iJYg_20_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">41078</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ERzFFMLhQkOjWn1JX4pSxQ"
      decimals="-3"
      id="Tc_7zrMMwN6E0iS2JXG1OJxmA_20_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">223000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_EeuBBlZOLEy45EVYRb-CKQ_20_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">223000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pFHBf0hY5UW0FWY703uxbQ"
      decimals="INF"
      id="Tc_eacZuGUfTkSOaaWTJ9a48g_21_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">48389</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ERzFFMLhQkOjWn1JX4pSxQ"
      decimals="-3"
      id="Tc_bpT3_PvbO06xiZIrRfqMyQ_22_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">9650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_ZE0MjprQuEKUyEUfdLjTng_22_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">9650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QKxAZY5g4UK604mpOKeFxQ"
      decimals="-3"
      id="Tc_zRgcQ1fB7Uef6o7jG3e0Kg_23_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-64479000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_9qLO-oUZD0Wip5b2JZj7tg_23_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-64479000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UaO3_RTxqUKoz5-Yyidv_g"
      decimals="INF"
      id="Tc_91O1ECKElkmvaecpKFs_mw_24_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">80081535</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UaO3_RTxqUKoz5-Yyidv_g"
      decimals="-3"
      id="Tc_mHVek3WRdkSIeDttofKOoQ_24_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MuQ8eux8ckqYO9qz-3WyHw"
      decimals="-3"
      id="Tc_IV6eTRiy0k68FhHjbA_qtQ_24_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">935249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9xzkVt4VMU2Z76J7CR-7zg"
      decimals="-3"
      id="Tc__yhaZ0fCSEiF7FAQnZsJFg_24_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">128000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7Zh84n4-Ykq6WGOpfdZ02g"
      decimals="-3"
      id="Tc_NerynIMILkayURuTja21mg_24_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-856261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_YAOPraTnwkmgo2Kq-x7YbQ_24_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">79196000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q6t-2V68bkiFrfajlGSBeg"
      decimals="INF"
      id="Tc_7_0TNiifMEKmsIlmJBNNYQ_50_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">51672579</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q6t-2V68bkiFrfajlGSBeg"
      decimals="-3"
      id="Tc_7D3tqETabki87MLZtXsFwA_50_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fq5xFmnwbE6Bb4giq5tdsw"
      decimals="-3"
      id="Tc_Pk8m24yPjUWkVMr9QQ38Kw_50_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">771699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6oRTpQ0UIkSjNufZC8jLZg"
      decimals="-3"
      id="Tc_cFoNa6smjkCAzYdwcW25JA_50_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-884000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j0Tq9iEgI0WxB3qMug6fdA"
      decimals="-3"
      id="Tc_fKgEobYU6UmTHYgp5rvdqQ_50_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-510632000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_xn5zGRExdEqV3w6EYHlpYA"
      decimals="-3"
      id="Tc_9Zd7jD7lkk6x7FblaWXzNg_50_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">260235000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JwQxc0pT8kKm0ykun0RF7w"
      decimals="-3"
      id="Tc_ZWpZrivzMUqxnFgxubH9ig_51_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">555000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q"
      decimals="-3"
      id="Tc_MIFvJohWBEuvFZa3pe4_Bw_51_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">555000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oFzCQeJoUUSgYwvWF5ktNQ"
      decimals="INF"
      id="Tc_aSXXd_2INU2pk8Z86AgQCQ_52_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">68696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rC1XfV1TjE6F-U0p2kSCCA"
      decimals="-3"
      id="Tc_lV41BhpKHkGZzOco5OmKZg_52_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">827000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q"
      decimals="-3"
      id="Tc_E8KkHQReD0G4oXTrNZvzFg_52_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">827000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oFzCQeJoUUSgYwvWF5ktNQ"
      decimals="INF"
      id="Tc_AKilMrRRvUyp-GUIB7KvEQ_53_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">28706</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rC1XfV1TjE6F-U0p2kSCCA"
      decimals="-3"
      id="Tc_QzalDA_VUkavKyfODuzF4Q_53_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">243000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q"
      decimals="-3"
      id="Tc_TcymuxOgdUuZ3D6tpbAnCA_53_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">243000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_oFzCQeJoUUSgYwvWF5ktNQ"
      decimals="INF"
      id="Tc_0Ukt032fXEqgY0-CQlUSNA_54_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">219378</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rC1XfV1TjE6F-U0p2kSCCA"
      decimals="-3"
      id="Tc_z7uU-RAPBUi4Ee9s5il2uA_55_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q"
      decimals="-3"
      id="Tc_RxVzn-iDs0GK8DZ2TLzCNg_55_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rC1XfV1TjE6F-U0p2kSCCA"
      decimals="-3"
      id="Tc_psvOZIOAykSy5ZnBdIdpLg_56_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q"
      decimals="-3"
      id="Tc_n5YFfWwQ-E6AfF6wS3mshw_56_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_19bHARrGm0mAeIg-yhN-Xg"
      decimals="-3"
      id="Tc_BEBZlccSyUO0YdhZTClJTA_57_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-39379000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_WOLZYQY_qE2EC-0PhD9H0Q"
      decimals="-3"
      id="Tc_XUfNYW-66Uahm4i07EGoaQ_57_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-39379000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Upyc56e-ZUuXeiJ1EZGbkg"
      decimals="INF"
      id="Tc_IWs4yzfLZ06av-vw144YtQ_58_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">51989359</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Upyc56e-ZUuXeiJ1EZGbkg"
      decimals="-3"
      id="Tc_6GRijOG5lkWL0rNHvLPoPg_58_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CDkUieplhE6Jbi_MfC9KFA"
      decimals="-3"
      id="Tc_ABT-sLcgPESapXLc8vaNVQ_58_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">778941000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DSycY3vZYkmsf4sXbaV2Lg"
      decimals="-3"
      id="Tc_tkh2_CC8hEeEKTwpT88Plw_58_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-329000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8rb9ujm1066sXa5nb2vXg"
      decimals="-3"
      id="Tc_b34Tw6EKqUK7BwZmy1B2ZQ_58_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-550011000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_Ck3LkULZgUu4IahGYkThNA"
      decimals="-3"
      id="Tc_bWr8Xg0EakWEuWxHraKYHw_58_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">228653000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NipCJOW77ECvOR_obikyPg"
      decimals="-3"
      id="Tc_9P2SnUCb-0-RYdYkGEnm-A_59_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">266000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg"
      decimals="-3"
      id="Tc_WwhMLnijy0ykxfuKvtF4IA_59_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">266000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw"
      decimals="INF"
      id="Tc_udZeHx07m0qowsveepiCbw_60_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">550594</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw"
      decimals="-3"
      id="Tc_I6mb5gZ6EE6HYHUw91ncjw_60_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw"
      decimals="-3"
      id="Tc_XSlRvgZz1ESPbr2F1kwsgg_60_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4395000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg"
      decimals="-3"
      id="Tc_1Dsbb4pZHk21vTU3wald6Q_60_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4396000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw"
      decimals="INF"
      id="Tc_ixXf56HJsk-HUcPWVdWD3g_61_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">53333</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw"
      decimals="-3"
      id="Tc_3miIyjXCgUuCVY_3g7ohhQ_61_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">292000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg"
      decimals="-3"
      id="Tc_TZRL0zxX1kKLBVVWlneh-A_61_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">292000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw"
      decimals="INF"
      id="Tc_fKNDF7ofKkSeEmuj95iDKQ_62_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">273035</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw"
      decimals="INF"
      id="Tc_tbd0aV0gj0WPGFbkQUM77Q_63_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">2293466</srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <srrk:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DOmipPBTNEizFCvcF0liJw"
      decimals="-3"
      id="Tc_OU_Mxp7FBky9mCmY8VFYiA_63_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2000</srrk:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <srrk:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw"
      decimals="-3"
      id="Tc_PlpQkLpO9ES3lxuTO2OzUA_63_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-2000</srrk:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw"
      decimals="-3"
      id="Tc_T8hwbPqEi0qlUOd3PftX7Q_64_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6818000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg"
      decimals="-3"
      id="Tc_1SJxbdF1HkePPmTIckfg7A_64_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6818000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_muxERKbK3kS3BStju5ORVw"
      decimals="-3"
      id="Tc_BorACzKkVEatZ7MOYjJqhA_65_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg"
      decimals="-3"
      id="Tc_iE92JZ2FpEaOwgphE5vGfw_65_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fk_SSWQDLU6gbCA2Hoe86w"
      decimals="-3"
      id="Tc_KqNVkZYC_0Gbf0ETfkyLNA_66_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-37925000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_rkTl4FzSGEuUTXoEnPplPg"
      decimals="-3"
      id="Tc_gonNTqqG1ECJHc5TVgWlMA_66_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-37925000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8SSCuIUnHEa3XtfgIHQmTg"
      decimals="INF"
      id="Tc_qHlohO2yq0SkZG07-zBwrg_67_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">55159787</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8SSCuIUnHEa3XtfgIHQmTg"
      decimals="-3"
      id="Tc_adve96EgMkOSkAn_mzA1ew_67_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">55000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sEwTkPlLLkSbqd_LCKEveg"
      decimals="-3"
      id="Tc_jleq6rwr-kqofz8sI1I6UA_67_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">790445000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iGIZ5dBRVkeElrLQcBXYfg"
      decimals="-3"
      id="Tc_Z28pqGkPo0mrf5TnFcG39Q_67_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-63000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mdZ4Vf_v90mj5UjPiNSTZg"
      decimals="-3"
      id="Tc_S4gf01aPRU6s8yVLIo2uKA_67_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-587936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_Fxn6BbkW0Um942NziX600Q"
      decimals="-3"
      id="Tc_upGMe7sYjE6h_gvvBM3tEg_67_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">202501000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uw72zZDY0ka7tF4uwvAQKg"
      decimals="-3"
      id="Tc_QoNXwexzHEOE1T-nxNeYyA_68_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">40000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_833rFxlYm0mVDqbX7vyEdg_68_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">40000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ePsDgOB7_0WDZ--l8zx3Lw"
      decimals="INF"
      id="Tc_rYpzxlirfUGsxWhibh5vNQ_69_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">49604</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CE-n08KE9kym4zuTU2o9Cg"
      decimals="-3"
      id="Tc_Cdnev64CsEKsmyylxk-gJg_69_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">280000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_fXv9Az-0CUaVnAg2TmonXQ_69_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">280000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ePsDgOB7_0WDZ--l8zx3Lw"
      decimals="INF"
      id="Tc_v2ElyL1XzUq0rhGVn4Bjjw_70_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">24290</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ePsDgOB7_0WDZ--l8zx3Lw"
      decimals="INF"
      id="Tc_p6LfJadPbEiwTQw0uYDHUg_71_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">1026893</srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <srrk:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ePsDgOB7_0WDZ--l8zx3Lw"
      decimals="-3"
      id="Tc_vU1GTWIEY0i-hCh9OQkd_Q_71_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1000</srrk:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <srrk:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CE-n08KE9kym4zuTU2o9Cg"
      decimals="-3"
      id="Tc__JIHwDGshE-zRV-ax3BGhA_71_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-1000</srrk:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CE-n08KE9kym4zuTU2o9Cg"
      decimals="-3"
      id="Tc_tonmNqgEgU2aV15gUjxkpw_72_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">7203000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_oER-By5beEiRKiIQT_QftQ_72_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">7203000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tkrpxbJb_Eq1PgDgb69BVg"
      decimals="-3"
      id="Tc_XtV674fvyU6Zp3XpdFqmVQ_73_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-42359000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_nn9Z8clQb0uZ-F4yqVUrDA_73_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-42359000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JqYd9nXR30C5hBt7QuvWkA"
      decimals="INF"
      id="Tc_jFVq0cTKh0ePZKiAS_nGnQ_74_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">56260574</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JqYd9nXR30C5hBt7QuvWkA"
      decimals="-3"
      id="Tc__0Mok1slc0e_vUdnfPIurA_74_5"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">56000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LyOvZrAbr0mYiQTtryH6Zw"
      decimals="-3"
      id="Tc_uXsTfJAemE-Ha7omEWmuNg_74_8"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">797927000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_WyRIrmBEzU25Yii5LaCicA"
      decimals="-3"
      id="Tc_cEfjcKdLME2AWz4BqEhrlQ_74_11"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rI2SWZIWcUGpK_a1C6sCUg"
      decimals="-3"
      id="Tc_vZajRaogokKo91i_rYAccA_74_14"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-630295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ"
      decimals="-3"
      id="Tc_7PvS2dJDIEWSiA7JkvlJcQ_74_17"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">167665000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_XZG1TWo7I0K96n7n4jS8Bg_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-179840000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_SG9PHpr1V0aTRKjyv6X9Tw_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-119663000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_-7PMdtBJpUqlbPlrt1A-GA_7_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1542000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_9Cg45LcnRUuO4NUBs5aD5Q_7_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2172000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_bjdNIVmYA06eKKJmOqAWVg_8_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">206000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_IPJcg_HBKkOmxFhS_0N0SA_8_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">215000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_BNo8ZXKBQ067ddjB_m6Q2w_9_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">27126000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_CkFJnHhoF0-xTqvdwlJ47A_9_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">20191000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_NDZRNt374k29iA5UXD1v8A_10_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">3945000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_YgvDv4dHvECAlHo82Zow1A_10_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4417000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_MqHA3hlngEmfvjuLhXFxpQ_11_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4034000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_HGE0-lqLpEivI9CfDdrnhg_11_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">5546000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_gmpa6bWWN0aMjlppMR8RBA_13_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">5734000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_MTGf5Ea9XEK7sGVrF8WIsg_13_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-2817000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_5ZNq_u94-UqLS58S9D5H0Q_14_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-608000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_8dC0403VkEWK7P4x4qhb4Q_14_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-387000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_L-BfhhY-2kmjm51Y-6QgZg_15_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">606000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_RvsmeJZJCUOa7vYX-SCLkw_15_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-2026000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_OABdUTp1pEyYm5zwf_ZZpA_16_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">8821000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_KhkXNATQnkO32nNGTi2Kdw_16_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-6924000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_vLT2yL4YJE-Hc83aApQZKQ_17_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-4744000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_eBnX5DHSkk6ZHTaYV0dg3g_17_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-6117000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_Tt0HFniI90-aZ13nW8T4tw_18_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-116000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_aCdoZGsCjUCcqrYJWRtJsA_18_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-58000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_bEPf41rlr0-pTkUPdiFy3w_19_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-151436000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_ttFoY9zSyEKwm4GLuVIyoQ_19_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-107877000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_b2uUbnmAeE-GPOn3HLrcUA_21_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">76000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_oUdzNbQXSkahMkzTAgAAYw_21_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">71000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_sb6JTCzb9kqXver3cF9ncg_22_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">13000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_VIZvIi1o9kuMCcajeu2AzA_23_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">82710000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_OIVEomkk4UOMKlL5lWU7TA_23_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">186673000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_hSFls_GigE-DOmjeMR0WNA_24_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">202100000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_5xOmMigVRkewBc9RbaOUuQ_24_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">253000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_52-VKRHzqk-Wp5Y4wHiT8Q_25_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">119314000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_yvH6qE9di0uRZclWaGm9bw_25_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">66269000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_zj27S4JurUqp5QDHfDZRHA_27_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">5223000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_EDVWHMXSD0O2kvMrH8vD4g_28_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6106000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_S2XbaAd6l0WF0MhddoCzeQ_29_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">125000</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_1QDUqvZPpE6eVneBrE2iuw_30_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">677000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_ICJMdUOKYUC6qTXrB0DLHw_30_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">819000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_XNOWNWUOg0SgKx2V_tHQeA_31_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">3000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_vCGWBL2kSEeQeYpgnwJLgQ_32_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6658000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_mVQnv1qSdUiqZS14afh_fA_32_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6045000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_b_vhFVyb7023U3Ef5kxK4w_33_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-25464000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_39HLeJDnjEiOnWGSFG6O2w_33_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-35563000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_RH6ErUPGf0yy2htzPcWaeQ_34_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">104262000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_xn5zGRExdEqV3w6EYHlpYA"
      decimals="-3"
      id="Tc_5N6aVi6aW0CWoQTSI5153w_34_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">105773000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_hBIULSr2wUWXcEt3dxCYrQ_35_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">78798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ"
      decimals="-3"
      id="Tc_6vINr28aUk6q7u_2Y0R9aw_35_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">70210000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_tZGPP39UhEi48Wch57Uhmg_37_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">22000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <srrk:OperatingLeaseLiabilityAdjustmentFromRentModification
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_m3jIbwNEP0anAqU3rWSdng_38_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">9451000</srrk:OperatingLeaseLiabilityAdjustmentFromRentModification>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_Uxa33QzlvkGnZsa8yRf7aA_40_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">5003000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_cad9wiM7CE286UuBdd5Qzg_40_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4743000</us-gaap:InterestPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_PJj9iNmRyUGIe9cO1mNeNg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;1. Nature of the Business &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;Scholar Rock Holding Corporation (the &#x201c;Company&#x201d;) is a late-stage biopharmaceutical company focused on the discovery, development, and delivery of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. As a global leader in transforming growth factor beta (&#x201c;TGF&#x3b2;&#x201d;) superfamily biology, the Company&#x2019;s novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, the Company believes that it may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s first product candidate, apitegromab, is a highly selective, fully human, monoclonal antibody, with a unique mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of spinal muscular atrophy (&#x201c;SMA&#x201d;). The Company is conducting SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with nonambulatory Type 2 and Type 3 SMA. The Company completed enrollment of SAPPHIRE in 2023. In October 2024, the Company announced positive top-line results that showed the study achieved its primary endpoint. Additionally, in 2024, the Company announced data from the Phase 2 TOPAZ trial extension period which showed patient outcomes at 48 months of treatment with apitegromab. The FDA granted Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation to apitegromab for the treatment of SMA in May 2021, August 2020 and March 2018, respectively. The European Medicines Agency (&#x201c;EMA&#x201d;) granted Priority Medicine (&#x201c;PRIME&#x201d;) designation in March 2021 and the EC granted Orphan Medicinal Product designation in December 2018 to apitegromab for the treatment of SMA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;In October 2023, the Company announced an expansion into cardiometabolic disorders by advancing its anti-myostatin program with SRK-439, a novel, fully human anti-myostatin monoclonal antibody, for evaluation in cardiometabolic disorders, including obesity, towards a potential investigational new drug (&#x201c;IND&#x201d;) submission in 2025. To inform the development of SRK-439, in May 2024 the Company initiated the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve muscle mass in individuals living with obesity and on background therapy of a GLP-1 receptor agonist (&#x201c;GLP-1 RA&#x201d;). In September 2024, the Company announced that it had completed enrollment in the Phase 2 EMRAZE proof-of-concept trial. Top-line results from this trial are expected in the second quarter of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s second product candidate, SRK-181, a highly selective inhibitor of the activation of latent TGF&#x3b2; is being developed for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies (referred to together as anti-PD-(L)1 antibody therapies). SRK-181 is being evaluated in the Company&#x2019;s Phase 1 DRAGON proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors that exhibit resistance to anti-PD-(L)1 antibody therapies. The Phase 1 DRAGON trial completed enrollment in December 2023 and continues to treat patients who remain on study. This two-part clinical trial consists of a dose escalation portion (Part A) and a dose expansion evaluating SRK-181 in combination with an approved anti-PD- (L)1 antibody therapy (Part B). Part B includes the following active cohorts: urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma, and head and neck squamous cell carcinoma. Safety, efficacy and biomarker data were presented in November 2023 at the Society for Immunotherapy of Cancer 38th Annual Meeting and in June 2024 at the American Society of Clinical Oncology (&#x201c;ASCO&#x201d;) annual meeting. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;Additionally, the Company continues to create a pipeline of product candidates to deliver novel therapies to underserved patients suffering from a wide range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. The Company was originally formed in May 2012. Its principal offices are in Cambridge, Massachusetts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;Since its inception, the Company&#x2019;s operations have focused on research and development of monoclonal antibodies that selectively inhibit activation of growth factors for therapeutic effect, as well as establishing the Company&#x2019;s intellectual property portfolio and performing research and development activities. The Company has primarily financed its operations through various equity financings, including in October 2024 (Note 12), as well as research and development collaboration agreements and the Company&#x2019;s debt facility (Note 10).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;Revenue generation activities have been limited to two collaborations, both containing research services and the issuance of a license. The first agreement, executed in 2013, was with Janssen Biotech, Inc., a subsidiary of Johnson &amp;amp; Johnson and was terminated in July 2022. The second agreement (the &#x201c;Gilead Collaboration Agreement&#x201d;), with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;), was in effect between December 2018 and January 2022. No revenues have been recorded from the sale of any commercial product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company&#x2019;s product candidates. The Company has incurred recurring losses since its inception, including net losses of $179.8 million and $119.7 million for the nine months ended September 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of $856.3 million as of September 30, 2024. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company believes that its existing cash, cash equivalents, and marketable securities at September 30, 2024 together with the approximately $324.4 million in net proceeds from the follow-on offering completed in October 2024 will be sufficient to allow the Company to fund its current operations through at least a period of one year after the date these financial statements are issued.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-5"
      id="Narr_FKXz7Z4ykUuX1o-4MWBJBA"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-179800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-5"
      id="Narr_bhfEwfAwuE2Orig8O4JBlQ"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-119700000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-5"
      id="Narr_F27oHkgYUUumxvNYBz3kSA"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">-856300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EKUEbTHr-Ea-uOCZ6iVjdA"
      decimals="-5"
      id="Narr_hy4INaEFX0WedN_pqr-Bkg"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">324400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_X77N6dq6OUS5lSGvtS6Klw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;2. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The significant accounting policies used in preparation of the unaudited consolidated financial statements are described in the Company&#x2019;s audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K. There have been no material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,407&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78,798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Unaudited Interim Financial Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The consolidated financial statements of the Company included herein have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). The unaudited consolidated financial statements include the accounts of Scholar Rock Holding Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full&#160;year or any other interim period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;)&lt;/i&gt;. The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under previous GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. In November 2019, the FASB deferred the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. Therefore, the new standard was effective for the Company on January 1, 2023. The Company established processes and internal controls to comply with the new credit loss standard and related disclosure requirements. The Company&#x2019;s investment policy has primary objectives of preservation of capital and maintenance of liquidity. As a result, the Company typically invests in money market funds, U.S. treasury obligations and government agency securities. The Company believes that such funds are subject to minimal credit risk. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these investments. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial position and results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;In November 2023, the FASB issued Accounting Standards Update 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU 2017-07&#x201d;). The standard requires disclosure of incremental segment information on an annual and interim basis and allows for multiple measures of a segment&#x2019;s profit or loss provided that one of those measures is consistent with GAAP. The amendments in this update do not change how a public company identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments, but rather requires public entities to provide in interim periods all disclosures about a reporting segment&#x2019;s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for interim periods starting on January 1, 2025. The option for early adoption is permitted, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures in future years as a result of the adoption of ASU 2023-07.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In December 2023, the FASB issued Accounting Standards Update 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/i&gt;(&#x201c;ASU 2023-09&#x201d;), which enhances the transparency of income tax disclosures to provide information to investors to better assess how a company&#x2019;s operations and related tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This requires public entities to disclose additional categories in the rate reconciliation regarding federal and state income taxes, and provide more details surrounding reconciling items if a quantitative threshold is met. The effective date for public companies is for annual periods starting on January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;available for issuance, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures will be in future years as a result of the adoption of ASU 2023-09.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_4YaMHGh9y0GsQeFYd0wb3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,407&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78,798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_-Js0v2Wy_kWLNev0n67lHw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,407&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78,798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_tCeRyyEYcEyNusdua4Z4iQ_3_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">76391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ"
      decimals="-3"
      id="Tc_6g7fsDaO60utNYqqH5917Q_3_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">67598000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_CMGRe1dt1Uy1JXO7v-64_Q_4_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2407000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ"
      decimals="-3"
      id="Tc_5ZfdX5cVh02kfhUQjASuWA_4_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2612000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_gmFqKBp__U6lijGdNiMh_g_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">78798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_XRuQrcmRdEmc-jokHxORtQ"
      decimals="-3"
      id="Tc_C7JY0igZ20aA4FD_Jtx_nw_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">70210000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <srrk:UnauditedInterimFinancialInformationPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_3LBjYVVr_UC2bkBnxFqeYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Unaudited Interim Financial Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The consolidated financial statements of the Company included herein have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). The unaudited consolidated financial statements include the accounts of Scholar Rock Holding Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full&#160;year or any other interim period.&lt;/p&gt;</srrk:UnauditedInterimFinancialInformationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_oYIUK5IHukWvkGbVi4WWuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_aTRcN05lUEmMuKVeGQktdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;)&lt;/i&gt;. The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under previous GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. In November 2019, the FASB deferred the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. Therefore, the new standard was effective for the Company on January 1, 2023. The Company established processes and internal controls to comply with the new credit loss standard and related disclosure requirements. The Company&#x2019;s investment policy has primary objectives of preservation of capital and maintenance of liquidity. As a result, the Company typically invests in money market funds, U.S. treasury obligations and government agency securities. The Company believes that such funds are subject to minimal credit risk. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these investments. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial position and results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;In November 2023, the FASB issued Accounting Standards Update 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU 2017-07&#x201d;). The standard requires disclosure of incremental segment information on an annual and interim basis and allows for multiple measures of a segment&#x2019;s profit or loss provided that one of those measures is consistent with GAAP. The amendments in this update do not change how a public company identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments, but rather requires public entities to provide in interim periods all disclosures about a reporting segment&#x2019;s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for interim periods starting on January 1, 2025. The option for early adoption is permitted, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures in future years as a result of the adoption of ASU 2023-07.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In December 2023, the FASB issued Accounting Standards Update 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/i&gt;(&#x201c;ASU 2023-09&#x201d;), which enhances the transparency of income tax disclosures to provide information to investors to better assess how a company&#x2019;s operations and related tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This requires public entities to disclose additional categories in the rate reconciliation regarding federal and state income taxes, and provide more details surrounding reconciling items if a quantitative threshold is met. The effective date for public companies is for annual periods starting on January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;available for issuance, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures will be in future years as a result of the adoption of ASU 2023-09.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_Xgh4kvoC9UmGLdWKGr9bcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;3. Fair Value of Financial Assets and Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following tables summarize the assets and liabilities measured at fair value on a recurring basis at September 30, 2024 and December 31, 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds, included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. treasury obligations, included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;U.S. treasury obligations and government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,674&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,674&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,634&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,634&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds, included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. treasury obligations, included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;U.S. treasury obligations and government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 270,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 270,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;Cash, cash equivalents and marketable securities are Level 1 assets and include investments in money market funds and U.S. treasury obligations and government agency securities that are valued using quoted market prices. Accordingly, money market funds and government funds are categorized as Level 1 as of September 30, 2024 and December 31, 2023. There were no transfers of assets between fair value measurement levels during the nine months ended September 30, 2024 or 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The carrying amounts reflected in the balance sheets for prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values at September 30, 2024 and December 31, 2023, due to their short-term nature. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company believes the terms of its debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company's debt approximates its fair value based on Level 3 of the fair value hierarchy.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_a1G8q32c4key0JtyZFT7aw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following tables summarize the assets and liabilities measured at fair value on a recurring basis at September 30, 2024 and December 31, 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds, included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. treasury obligations, included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;U.S. treasury obligations and government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,674&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,674&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,634&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,634&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds, included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. treasury obligations, included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;U.S. treasury obligations and government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 270,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 270,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EGRmdupzaUKG_rn7xck0fA"
      decimals="-3"
      id="Tc_xNweEOUWBkSDBVonOk-KTw_4_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">70960000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hWuMG1NhkkW9bHAcUgbYxQ"
      decimals="-3"
      id="Tc_DDUgltefi0-lkcHJZW2T4Q_4_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">70960000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yUXtseVKLEmLijTO5Hn_0g"
      decimals="-3"
      id="Tc_uHmo0FFmUkGmewPLjdXkPg_7_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">62674000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_UlyEzRV6tEm11MvO7uPFnQ"
      decimals="-3"
      id="Tc_FuDO9WOaI0ufBpNmsAdcPQ_7_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">62674000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yUXtseVKLEmLijTO5Hn_0g"
      decimals="-3"
      id="Tc_bia7kvdPj0iNywIsMqW-UQ_8_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">133634000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_UlyEzRV6tEm11MvO7uPFnQ"
      decimals="-3"
      id="Tc_JD3aLsrypU-Iuw4770urjw_8_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">133634000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XZbR-apKpk2fl7Q5s_WQGA"
      decimals="-3"
      id="Tc_yeUwVcTqdkiOv349kuf04w_4_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">61764000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_GRQncXuqCk6pkM25ZxfA6Q"
      decimals="-3"
      id="Tc_MguCRfxrOUOyhkWq1uPJ4A_4_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">61764000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Q37l2topEU2AU5wm5NYCjg"
      decimals="-3"
      id="Tc_zWfsLY64g0WzskOnrLsEhw_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">30765000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lH_pD1wqKE-js0Bu3cDiQw"
      decimals="-3"
      id="Tc_YfTNxjJqdkORA6WN6A_1Jg_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">30765000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bwusGcH5nkSqDzdmdcCglA"
      decimals="-3"
      id="Tc_fvG2lfxP7kKqLGBfsTqUwA_7_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">178083000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hZuVKm_vv0uSY2YRXuVk-w"
      decimals="-3"
      id="Tc_o5extafPQEeAT_-uCTjvmQ_7_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">178083000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bwusGcH5nkSqDzdmdcCglA"
      decimals="-3"
      id="Tc_u1WQccpCQ0unE_zDWYEUNw_8_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">270612000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hZuVKm_vv0uSY2YRXuVk-w"
      decimals="-3"
      id="Tc_Z8BVcGVuIUS2-SkA_f_3Cg_8_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">270612000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_484aDjRuY0KF942UF-uWgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;4. Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the Company&#x2019;s investments as of September 30, 2024 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Marketable securities available-for-sale:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;U.S. treasury obligations and government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,674&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,674&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the Company&#x2019;s investments as of December 31, 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities available-for-sale:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;U.S. treasury obligations and government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 177,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 177,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The aggregate fair value of marketable securities with unrealized losses was $0 and $11.9&#160;million at September 30, 2024 and December 31, 2023, respectively.&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;At September 30, 2024 and December 31, 2023, no investments and&#160;three&#160;investments, respectively, were in an unrealized loss position. All such investments have been in an unrealized loss position for less than a&#160;year and these losses are considered temporary. The Company has the ability and intent to hold these investments until a recovery of their amortized cost, which may not occur until maturity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company believes that U.S. treasury obligations and government agency securities are subject to minimal credit risk. As a result, the Company did not record any charges for credit-related impairments for its available-for-sale securities for the nine months ended September 30, 2024.&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_46xnc-PKAUSD3hA5_Pjo1g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the Company&#x2019;s investments as of September 30, 2024 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Marketable securities available-for-sale:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;U.S. treasury obligations and government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,674&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,674&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the Company&#x2019;s investments as of December 31, 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities available-for-sale:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;U.S. treasury obligations and government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 177,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 177,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-T623QZuKkiWEpLOpPmaJw"
      decimals="-3"
      id="Tc_U7xkhfuYeEqZG5Ws9Vt0vw_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">62546000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-T623QZuKkiWEpLOpPmaJw"
      decimals="-3"
      id="Tc_fwCagkIeZkSXfKUcIlZFOQ_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">128000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_-T623QZuKkiWEpLOpPmaJw"
      decimals="-3"
      id="Tc_6k4ookz-2U6mtKP_HY5J_Q_5_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">62674000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_rbb427Nl2UiBsZWl3G_-1w_6_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">62546000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_60zC2jATpE6jKxDulEmgsA_6_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">128000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_3ng8GuWzZEqck9Syd8Y7-Q_6_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">62674000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_kZda-3Zt-kGSsr8DQ7g3kg"
      decimals="-3"
      id="Tc_rry9pTJ11EKkDTAya3nAcQ_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">177991000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_kZda-3Zt-kGSsr8DQ7g3kg"
      decimals="-3"
      id="Tc_VCNuq3iQXEiaH8RzvjNFXg_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">93000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_kZda-3Zt-kGSsr8DQ7g3kg"
      decimals="-3"
      id="Tc_KehFgBVKr0WKN0UlXQv32g_5_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_kZda-3Zt-kGSsr8DQ7g3kg"
      decimals="-3"
      id="Tc_q-o9hbW8pkiVJNJiUaUwPA_5_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">178083000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_1Cri8kYwXkWoLQzLmd6OHg_6_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">177991000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_yjG-KXxackGhO-BK89CrDA_6_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">93000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_jTIGmqaxcka1YNCic3KyVA_6_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_TSjBZITJvUGK31PI0VyL8w_6_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">178083000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-5"
      id="Narr_dDSkxqnyPUarEEozXhRpvw"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-5"
      id="Narr_ZCPONvPq_ES0zmfqdhIqvQ"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">11900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="INF"
      id="Narr_a3Kv-T5NbEmYjjNdj-V5aw"
      unitRef="Unit_Standard_security_rO9x9MuL10eAmA3nIFOJ7w">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="INF"
      id="Narr_VlPq76lFNEe_80apL_GB3A"
      unitRef="Unit_Standard_security_rO9x9MuL10eAmA3nIFOJ7w">3</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:OtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_OypBWcDhLkKvRiwqZtizvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;5. Prepaid Expenses and other Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;As of September 30, 2024 and December 31, 2023, prepaid expenses and other assets consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid external research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,059&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,076&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid professional and consulting expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;As of September 30, 2024 and December 31, 2023, other long-term assets consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid external research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 312&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,417&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_-Q6X0GopKE6QqWAAXrvhaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;As of September 30, 2024 and December 31, 2023, prepaid expenses and other assets consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid external research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,059&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,076&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid professional and consulting expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <srrk:PrepaidExternalResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_jiRnK4nLXkqeMUpoheobIA_4_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">8876000</srrk:PrepaidExternalResearchAndDevelopmentExpenseCurrent>
    <srrk:PrepaidExternalResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_liB0dIGSMk-SMnK0jgZI6g_4_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4059000</srrk:PrepaidExternalResearchAndDevelopmentExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_fN6Fj2-IzkKqHTx7-ErCAg_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2706000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_RYFbpj2ex0y2wX7sO0Sa0w_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2281000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_hAAjpFzGDUev4Q4SEGs5zQ_6_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1120000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_i39e8CNmv06qDUm30hbq5g_6_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1076000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_PVDgQZEjdkOiWpJ6bHroFA_7_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">739000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_vTnbbwTAZkG3boJ7No6N7w_7_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">635000</us-gaap:PrepaidInsurance>
    <srrk:PrepaidProfessionalConsulting
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_APpkCpnuoUyOKOMZBc7EOA_8_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">421000</srrk:PrepaidProfessionalConsulting>
    <srrk:PrepaidProfessionalConsulting
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_ibhhuzc6DU6t6TFoA-B7YQ_8_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">205000</srrk:PrepaidProfessionalConsulting>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_zJrSbjTHQEKLw-NKIRZ0sA_9_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">13862000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_zEYdBla9J0maVriByu2_RQ_9_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">8256000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_ff4EBxiZd0SM2dfBgUpQ6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid external research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 312&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,417&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <srrk:PrepaidExternalResearchAndDevelopmentExpenseNoncurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_kjKWIgfPoECa-isaUBkTow_4_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">3397000</srrk:PrepaidExternalResearchAndDevelopmentExpenseNoncurrent>
    <srrk:PrepaidExternalResearchAndDevelopmentExpenseNoncurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_SDmAPbtWMkmHxUCtyC1v_g_4_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4074000</srrk:PrepaidExternalResearchAndDevelopmentExpenseNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_HsKPVu8kTkqNSj40Rt1BJA_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">394000</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_Ke8C9-vIUEavLudjvllvOQ_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">312000</us-gaap:PrepaidExpenseOtherNoncurrent>
    <srrk:PrepaidInsuranceNoncurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_hecNQgYs_0-b1TmZ1Px2_Q_6_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">18000</srrk:PrepaidInsuranceNoncurrent>
    <srrk:PrepaidInsuranceNoncurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_kw_ydhR4jEaYQKWxU7ClwA_6_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">31000</srrk:PrepaidInsuranceNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_Lrl-uc9AaUCLjrsbUdpwAQ_7_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">3809000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_vA3JBiH9IUiPcHv7Wfzj9w_7_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4417000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_lH_ltnWjvUqC6ZE0Uy32YQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;6. Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;As of September 30, 2024 and December 31, 2023, accrued expenses consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.43%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,040&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,825&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional and consulting expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 766&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_UL0zi7SQTk-L5SxY4VoQyw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;As of September 30, 2024 and December 31, 2023, accrued expenses consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.43%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,040&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,825&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional and consulting expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 766&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <srrk:AccruedExternalResearchAndDevelopmentExpense
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_O44VDFXb1UqI_QXVNoqbMQ_4_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">15040000</srrk:AccruedExternalResearchAndDevelopmentExpense>
    <srrk:AccruedExternalResearchAndDevelopmentExpense
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_T7nlgwPMMUKNrOo5waRtEQ_4_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6825000</srrk:AccruedExternalResearchAndDevelopmentExpense>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_mJBk3CwLO0GdUW6wi0M1Tw_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">9969000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_4BZgX0uQzU6jNddOamJznQ_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">10591000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_P2JO7OBtXUacxQtNlQdnWQ_6_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">3420000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_OGpz7tYYrUabNIiYPKRJ_w_6_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2267000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_G8dSV2zww06c4ufEcVCl-w_7_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">831000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_4YaSXxzh4kCIGYVN8p4vug_7_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">766000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_ggdYedFo5UOeQJf0FcpTFg_8_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">29260000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_908cMWE-PUq0XdyxbT7Ouw"
      decimals="-3"
      id="Tc_qPW8gD7F1k610r9UuhHVWQ_8_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">20449000</us-gaap:AccruedLiabilitiesCurrent>
    <srrk:CommonStockTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_97XuC2aL30iSR0mJDVKgvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In June 2024, the stockholders approved an amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of common stock from &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;150,000,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;300,000,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company has had a sales agreement in place during various time periods with Jefferies LLC with respect to an at-the-market (&#x201c;ATM&#x201d;) offering program. Under this program, the Company is able to offer and sell, from time to time at its sole discretion, shares of its common stock through Jefferies as its sales agent. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. The current ATM agreement, established in November 2022, allows for the sale of shares of common stock having an aggregate offering price of up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$100&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million. As of September 30, 2024, the Company has sold &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;619,290&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares, generating net proceeds of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$5.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, under the ATM program. &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;No&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; sales were made under the ATM program during the nine months ended September 30, 2024. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company has issued pre-funded warrants, as well as warrants as part of its financing activities. Both the pre-funded warrants and warrants meet the conditions for equity classification and are recorded as a component of stockholders&#x2019; equity within additional paid-in capital. In June 2022 and November 2020, the Company issued &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;25,510,205&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;2,179,487&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; pre-funded warrants, respectively. During the nine months ended September 30, 2024, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;2,526,833&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the Company&#x2019;s pre-funded warrants were exercised. As of September 30, 2024, the Company has &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;17,008,164&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; pre-funded warrants outstanding. In June 2022, the Company also issued &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;10,459,181&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; warrants with an exercise price of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$7.35&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;. During the nine months ended September 30, 2024, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;830,660&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the Company&#x2019;s warrants were exercised. As of September 30, 2024, the Company has &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;9,157,496&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; warrants outstanding.&lt;/span&gt; &lt;span style="background:#ffffff;"&gt;In October 2024, the Company issued pre-funded warrants to purchase up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;353,983&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of common stock (see Note 12).&lt;/span&gt;&lt;/p&gt;</srrk:CommonStockTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_5_31_2024_5P3UGITXB0-czc9H0PmBtw"
      decimals="INF"
      id="Narr_IcX-COeQPkW6m8_gMyqrGg"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2024_74qePC5v6kCjrygaeq4KKQ"
      decimals="INF"
      id="Narr_kRAMv-JZ5kW12HQg65Wkog"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">300000000</us-gaap:CommonStockSharesAuthorized>
    <srrk:MaximumAggregateOfferingPrice
      contextRef="As_Of_11_30_2022_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_BxOz9tF8aU6Z0utpswOoRQ"
      decimals="-6"
      id="Narr_--j9cESPJU-uRO6Jt1xocw"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">100000000</srrk:MaximumAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_StatementScenarioAxis_srrk_AggregateMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_ya99nBLVs0yCCbyZ5u51EA"
      decimals="0"
      id="Narr_t3SlQ21_0E-sbIONbb5qlQ"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">619290</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_StatementScenarioAxis_srrk_AggregateMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_ya99nBLVs0yCCbyZ5u51EA"
      decimals="-5"
      id="Narr_OpAy6NaNWE28PDRniwagig"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">5200000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_srrk_AtMarketOfferingMember_7FmVsKFVF0aJhLlDxLXyug"
      decimals="0"
      id="Narr_EfhD2G57b0OgxDjBZOZZqw"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_PTkW0Ae7q0-gfeY7Vb1FxQ"
      decimals="0"
      id="Narr_CQBvO21h8kaaY2vqmjuBEw"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">25510205</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_30_2020_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_WrTjGUDWz0OGm3OPxFpVKA"
      decimals="0"
      id="Narr_69j8mpIZCEynOtIjpW7X3Q"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">2179487</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_SZALhDjjmEyPmtlfB7lZaA"
      decimals="0"
      id="Narr_PiOAB0HGK02EFJaJPYC44Q"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">2526833</srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_n9DGS8M0kE24zj_oklD1kA"
      decimals="0"
      id="Narr_kGmec1MG9kiATyH1jso99Q"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">17008164</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_-E3ijiIBr06-jKD1_9WN-w"
      decimals="0"
      id="Narr_g4pmrNcI4ky_ZBDvZ_A_Sg"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">10459181</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_-E3ijiIBr06-jKD1_9WN-w"
      decimals="2"
      id="Narr_j4nrpTcnHEuGR3Ppwp2L-A"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">7.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_UUZbJLH39kSS8xaTMnAraA"
      decimals="0"
      id="Narr_UIehXepqUUuubt-8D4ZiMQ"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">830660</srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_CommonWarrantMember_6NJQiQ1vPEGInMGw0DCVKA"
      decimals="0"
      id="Narr_t8EJ3cbTcUmMy2Jddv_P-Q"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">9157496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_iFj3QnQzOU-8kQacFHjl3A"
      decimals="INF"
      id="Narr_9nDvZKRSaEqX3ueFky4m2w"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">353983</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_8FMqKwIHEku1QqhjVQ3ItA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;8. Equity-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The Company recorded equity-based compensation expense related to all equity-based awards, which was allocated as follows in the consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.38%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,341&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,650&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,191&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s unrecognized equity-based compensation expense as of September 30, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.44%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrecognized Expense (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average Remaining Period of Recognition (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted Stock Units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the Company&#x2019;s restricted stock unit activity for the current year:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:9pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.27%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,089,552&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.92&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,126,820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (649,559)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (179,956)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,386,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.82&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The total fair value of restricted stock units vested during the nine months ended September 30, 2024 was $8.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the current year:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,300,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,299&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,835,756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (94,988)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (371,557)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,670,164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,967&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercisable as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,831,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,310&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;Using the Black-Scholes option pricing model, the weighted average fair value of options granted during the nine months ended September 30, 2024 was $10.38. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following weighted average assumptions were used in determining the fair value of options granted in the nine months ended September 30, 2024 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.09 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.87 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years to liquidity)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.12 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;91.15 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;90.54 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_We1Ke25piEuM63WZaJ0VQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.38%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,341&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,650&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,191&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_sX3h_3P7vU628onpj2CP_w"
      decimals="-3"
      id="Tc_EkR4EAIdSU2bVJDrbx-V9w_4_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WYPheoLxHESQikinAnOQbw"
      decimals="-3"
      id="Tc_U-RnaNZbg0KpB0BfqVoWzw_4_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2858000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0rdTgvAQZ0SGGGDzlLKrng"
      decimals="-3"
      id="Tc_Q4gruLtBSECtKywiD8Z6fg_4_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">11980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_EyntDTnzGkKhLJiLcViJlg"
      decimals="-3"
      id="Tc_Ndy_w0DgHkeBVs3ewyen7g_4_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">8341000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_33ZytFP8IkiHsYntj3TCwg"
      decimals="-3"
      id="Tc_gLtiCKZMuEuW-dSsyGgkzg_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">5252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ZscaUP5tbkyTvjREC97cOw"
      decimals="-3"
      id="Tc_XC-NtBAwd0Gjjs8ILbLNvg_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">4345000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ephi9PPE4Em6WeJ6Tatiiw"
      decimals="-3"
      id="Tc_4kDEx55wxUGR1OB8TzgPQg_5_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">15146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3cefOggcskeAM_epSw3VaA"
      decimals="-3"
      id="Tc_YwYsSWvWeUiFiCHegZqQWA_5_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">11850000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_RfEh8WWlcEyN0Nv3SYJJ8g_6_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">9650000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_cywY-WY3Z0a7WPpyMpmkTg"
      decimals="-3"
      id="Tc_ojkFqPQWiEOJeB0lSujwEQ_6_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">7203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_AM94MF5Qu0ikEHQ4cUwo8A_6_9"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">27126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="-3"
      id="Tc_n--9zEllbkiNw6STsJJwEw_6_12"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">20191000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_ylMI5x-fKEe8SBh4n0h7hw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.44%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrecognized Expense (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average Remaining Period of Recognition (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted Stock Units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_V7tZSLwfkEiSdTEO0LipJQ"
      decimals="-3"
      id="Tc_Ov2PEa3PjkaMIbbHyU2Mxw_4_2"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">35001000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA"
      id="Tc_xDdh9BgVDkiPrqwQG5gK8g_4_4">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ"
      decimals="-3"
      id="Tc_-J68NFNd1EWLOB4C5SZYRA_5_2"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">40456000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      id="Tc__B3eaiHcpEevyEdfzf6pRA_5_4">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="-3"
      id="Tc_OZZa5HzSCkijTelfkc-YSw_6_2"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">75457000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_mnssrdJ_106I1fhKdo7zyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:9pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.27%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,089,552&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.92&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,126,820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (649,559)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (179,956)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,386,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.82&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_btXk1iwRBEitcM4l_d0v9g"
      decimals="INF"
      id="Tc_dR72-h9T2kSq9Cqnv8M6dQ_4_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">2089552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_btXk1iwRBEitcM4l_d0v9g"
      decimals="2"
      id="Tc_0_f32ZcESkeqRVLPcJuXWw_4_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">11.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA"
      decimals="INF"
      id="Tc_OUKePioE1kiqkW5UQ8kfQQ_5_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">2126820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA"
      decimals="2"
      id="Tc_LBrQFn4aakWN2m61l7Jm6w_5_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">13.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA"
      decimals="INF"
      id="Tc_5iXSsBFWo0WydzvKAVxOoA_6_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">649559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA"
      decimals="2"
      id="Tc_kGR0SUhv7UGgdBGFq8A8tg_6_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">12.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA"
      decimals="INF"
      id="Tc_BBjQHp0XD0S1WT0Sa4nzwA_7_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">179956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA"
      decimals="2"
      id="Tc_dSqApmCHVkqBXBCxHOVnow_7_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">12.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_V7tZSLwfkEiSdTEO0LipJQ"
      decimals="INF"
      id="Tc_AhbcYN06ekCzru-Q2_pD2Q_8_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">3386857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_V7tZSLwfkEiSdTEO0LipJQ"
      decimals="2"
      id="Tc_8mqkbR1l_Ue-AHTRYIky_Q_8_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">12.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sKXJvVuOaU6kyU1bMiwiMA"
      decimals="-5"
      id="Narr_fDU2QxHDqkOk5Xsmj5h43Q"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">8600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_76JIpywZ20asc4OK5_AI3A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,300,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,299&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,835,756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (94,988)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (371,557)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,670,164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,967&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercisable as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,831,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,310&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q7G20lfZrEGGf9s5KiiN4w"
      decimals="INF"
      id="Tc_tvTaZxpWs0KL7DcVoOAHPA_6_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">7300953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q7G20lfZrEGGf9s5KiiN4w"
      decimals="2"
      id="Tc_s1_m-gKqbkGtw-3jAm68Zg_6_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">15.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_75tkU34fOUy3WI_eCj09wA"
      id="Tc_KzAmy434rUmhVueh2rFCYg_6_7">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_q7G20lfZrEGGf9s5KiiN4w"
      decimals="-3"
      id="Tc_XR3d6j7N1Uy6Aozh8blQfQ_6_10"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">52299000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      decimals="INF"
      id="Tc_vq9d6-R7nECwP_Q8TqpjbQ_7_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">2835756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      decimals="2"
      id="Tc_x3R-P6iMqEyqwdzRwi0LQQ_7_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">13.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      decimals="INF"
      id="Tc_iQJ40d4mKEugE4NtmE65gw_8_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">94988</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      decimals="2"
      id="Tc_Kh-1A1c8oUi_snmtESWNrg_8_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">5.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      decimals="INF"
      id="Tc_01Y--vZbgkiaG4alw21wKg_9_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">371557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      decimals="2"
      id="Tc_wK4VeGPZaketeEHgDr9CRg_9_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">19.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ"
      decimals="INF"
      id="Tc_6u8hi8UyJUWZxMIvmeIL1A_10_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">9670164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ"
      decimals="2"
      id="Tc_goD3QvLa_EmMjcWkyU377A_10_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">14.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      id="Tc_hdAAqzAbmUioX0bGYFx7Yw_10_7">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ"
      decimals="-3"
      id="Tc_gSkVy3J_zEecJWzod4Z_Yg_10_10"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2967000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ"
      decimals="INF"
      id="Tc_FLC38nxEUU-MOUHtDaHrIw_11_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">4831989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ"
      decimals="2"
      id="Tc_j6SeE0y78EmlMvoynI9enQ_11_5"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">16.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      id="Tc_0p3kwJWBj0WH_kTFt1M0FQ_11_7">P6Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_39kv1gmwnkiyKN-zqRRYqQ"
      decimals="-3"
      id="Tc_qRxOma_dNEmwLCtn0-QfWw_11_10"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2310000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      decimals="2"
      id="Narr_rKrK1I6TmU-4qPnyeXjMWg"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">10.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_jbtAfn5PSEO4xgb5j-V9Lg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.09 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.87 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years to liquidity)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.12 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;91.15 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;90.54 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      decimals="4"
      id="Tc_3a11hCy5F0SEKrau1Go-cg_4_1"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.0409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qeLfTKYhf0WUaB1ixSydRQ"
      decimals="4"
      id="Tc_mfzXkJ0JzkeXUr_xg1-r0w_4_3"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.0387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      decimals="3"
      id="Tc_IxEDJdxVX0mqJ4y39R1sjg_5_1"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qeLfTKYhf0WUaB1ixSydRQ"
      decimals="3"
      id="Tc_nEeGdh20IkOb7TcbTM7DLg_5_3"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      id="Tc_A8HHa5-K002plfwMgxLMfA_6_1">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qeLfTKYhf0WUaB1ixSydRQ"
      id="Tc_Y1oV8Rjkpk61rfi2h2U0aA_6_3">P6Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qmloHgCtqUmuNQENwlRtAg"
      decimals="4"
      id="Tc_jt0oBDP9WUK8hNlt7hpQVQ_7_1"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.9115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qeLfTKYhf0WUaB1ixSydRQ"
      decimals="4"
      id="Tc_BnWURHomfEupBcFo8t-u0g_7_3"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.9054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb__F0w8OIDgE2TsAEclWmhVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;9. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Operating Lease &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In November 2019, the Company entered into a lease of office and laboratory space at 301 Binney Street in Cambridge, Massachusetts to be used as its new corporate headquarters (the &#x201c;Lease&#x201d;). The expiration date of the Lease was originally in August 2025 and included an option to extend the term by two years. The base rent under the original Lease was $6.9 million per year, subject to an annual increase of 3.5%, and the Company was subject to a free-rent period through mid-August 2020. Variable lease payments include the Company&#x2019;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The Lease included incentives of $14.1 million in the form of an allowance for tenant improvements related to the design and build out of the space. In connection with the Lease, the Company has secured a letter of credit for $2.3&lt;span style="white-space:pre-wrap;"&gt; million which renews automatically each year. The Lease commencement date, for accounting purposes, was reached in September 2020.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In May 2024, the Company entered into the First Amendment (the &#x201c;Lease Amendment&#x201d;) to the Lease to extend the term for approximately two years, commencing on August 19, 2025 (the &#x201c;First Extension Term&#x201d;) with the base rent to start at approximately $6.2 million per year, followed by a 3% annual increase. Pursuant to the Lease Amendment, the Company also has an option to extend the term of the Lease by five years, upon the expiration of the First Extension Term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other information related to the Lease is as follows (in thousands, except lease term and discount rate):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Cost:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other information:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating cash flows used for operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Weighted average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Weighted average incremental borrowing rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;Legal Proceedings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company, from time to time, may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the nine months ended September 30, 2024 and 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_11_1_2019_To_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_CdJUVb4pFUiKpg6aL0QLLg"
      id="Narr_K4y5Qb3iZEyWmc3On18wWA">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_GTqAgMQoLEKmU-Yg4Ni_LQ"
      id="Narr_u3kPd_PdLU-SroBxefFZlQ">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <srrk:LesseeOperatingLeaseBaseRent
      contextRef="As_Of_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_GTqAgMQoLEKmU-Yg4Ni_LQ"
      decimals="-5"
      id="Narr_xrR-naAaDE2w7SKsFy3aoQ"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6900000</srrk:LesseeOperatingLeaseBaseRent>
    <srrk:AnnualLeaseAdjustmentPercent
      contextRef="Duration_11_1_2019_To_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_CdJUVb4pFUiKpg6aL0QLLg"
      decimals="3"
      id="Narr_a39zJxYhA0am6IWM_Q0GNQ"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.035</srrk:AnnualLeaseAdjustmentPercent>
    <us-gaap:IncentiveToLessee
      contextRef="As_Of_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_GTqAgMQoLEKmU-Yg4Ni_LQ"
      decimals="-5"
      id="Narr_yJVrRJLM5k6EeQVjIs8UWg"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">14100000</us-gaap:IncentiveToLessee>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="As_Of_11_30_2019_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_GTqAgMQoLEKmU-Yg4Ni_LQ"
      decimals="-5"
      id="Narr_focmdHabFUqAnOeYBtsncg"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2300000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_M1v0aqRvFEaEli6XZP3iLA"
      id="Narr_2hewEAF_ZECXqbjSmFAIpQ">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <srrk:LesseeOperatingLeaseBaseRent
      contextRef="As_Of_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_M1v0aqRvFEaEli6XZP3iLA"
      decimals="-5"
      id="Narr_15sgvI5PX0GweVtruJ7qXw"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6200000</srrk:LesseeOperatingLeaseBaseRent>
    <srrk:AnnualLeaseAdjustmentPercent
      contextRef="Duration_5_1_2024_To_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_gi0LiBrpuUGw7o_sZbKeZg"
      decimals="2"
      id="Narr_YSKD3q5rfUyLZCtBMCVS3g"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.03</srrk:AnnualLeaseAdjustmentPercent>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_5_1_2024_To_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_gi0LiBrpuUGw7o_sZbKeZg"
      id="Narr_qgA_jGyL2U6FtzM4PtRXNw">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_5_31_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_srrk_BinneyStCambridgeMaMember_srt_StatementScenarioAxis_srrk_UponExpirationOfFirstExtensionTermMember_WYDXdjdOlEim9o-T7lrtyw"
      id="Narr_QZ3gmpLc4Ua-TZ3x4M_6Vg">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_Yi3HZfA_vUSP4n5m4nOOwQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other information related to the Lease is as follows (in thousands, except lease term and discount rate):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease Cost:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ffffff;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other information:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating cash flows used for operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Weighted average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Weighted average incremental borrowing rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_cYSdTR4t8EGflEdAvNvn8A_5_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1714000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_OoOgEhAk0EiVnczsq4snCw_5_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">5290000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_Iv-iO8Mw9Ui4Z2xPkJzF0Q_6_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">363000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_kVUD2AEgpka_IUshkVCufQ_6_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">1086000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2024_To_9_30_2024_lhQO9AVQAUqhVDQ0pE_BHg"
      decimals="-3"
      id="Tc_MAbQxddXGkmLbeDKKWCkZg_7_3"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">2077000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_MKLtUzJzgEK-v3oPy6EgdA_7_6"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6376000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="-3"
      id="Tc_SlEpQRpEvEWO_x8DAN-Ggg_5_2"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">6000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      id="Tc_QZEJ9Cdvv0Kj3nqAJNLiVA_6_2">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2024_uKGzgPT3_UC_qj_uuGc3bw"
      decimals="3"
      id="Tc_39XCnr0E00i7_WgR0rkSpg_7_2"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.131</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_pnHk4XntQ0mj3-p2yS_32Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;"&gt;10. Debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;On October 16, 2020 (the &#x201c;Closing Date&#x201d;) the Company entered into a Loan and Security Agreement with Oxford Finance LLC (&#x201c;Oxford&#x201d;) and Silicon Valley Bank (&#x201c;SVB&#x201d;) for $50.0 million (the &#x201c;Loan and Security Agreement&#x201d;). Tranche 1 of $25.0 million was funded on the Closing Date. The Company had an additional $25.0 million in loan proceeds available under Tranche 2 which was funded in December 2021, in conjunction with the Company entering into the First Amendment to Loan and Security Agreement with Oxford and SVB. The Loan and Security Agreement was to mature on May 1, 2025 and required interest-only payments through November 2022, with principal payments to commence in December 2022. Pursuant to the Loan and Security Agreement, the Company was required to maintain cash in an SVB account equal to the lesser of&#160;100%&#160;of the Company&#x2019;s consolidated cash or&#160;105%&#160;of the dollar amount of the outstanding debt. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;On November 10, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement ( &#x201c;Amendment 2&#x201d;) to increase the Company&#x2019;s borrowing capacity under the Loan and Security Agreement to an amount up to $100.0 million, comprised of the original $50.0 million loan which remains outstanding and two additional $25.0 million tranches. The first $25.0 million tranche available under Amendment 2, was available at the Company&#x2019;s discretion through December 2023 upon achievement of certain development and business performance milestones. The Company did not exercise this tranche. The second $25.0 million tranche available under Amendment 2, may be available upon the Company&#x2019;s request, at Oxford and SVB&#x2019;s discretion. Amendment 2 also extended the interest-only payment period for an additional 24 months through November 2024, with principal payments to commence in December 2024. The maturity of the loan was extended to November 2027. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;Effective upon Amendment 2, the interest rate on the unpaid principal is the greater of the Wall Street Journal &lt;span style="-sec-ix-hidden:Hidden_VBPAhXNcSkCfo6QuLvnBlg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;prime rate&lt;/span&gt;&lt;/span&gt; plus 4.60% or 9.35% per annum. Prepayment is permitted and may include a pre-payment fee ranging from 0% - 3% (of the principal amount being prepaid), depending on when the prepayment is made. The Company is also required to make a final payment equal to 2% of the original principal amount. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;In conjunction with Amendment 2, the Company was required to pay $0.9 million for the accrued portion of the final payment on the previous outstanding balance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) as receiver. Afterward, the FDIC transferred all deposits of the former Silicon Valley Bank to Silicon Valley Bridge Bank, N.A., as operated by the FDIC. On March 27, 2023, Silicon Valley Bridge Bank was closed by the Office of the Comptroller of the Currency, and the FDIC was appointed as receiver. First Citizens Bank then entered into an agreement with the FDIC to purchase out of FDIC receivership substantially all loans and certain other assets and assume all customer deposits and certain other liabilities of Silicon Valley Bridge Bank. On March 27, 2023, Silicon Valley Bridge Bank and its U.S. branches began operating as Silicon Valley Bank, a division of First Citizens Bank.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;On April 18, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement to amend certain provisions relating to the Company&#x2019;s operating accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;On May 17, 2024, the Company entered into the Fourth Amendment to the Loan and Security Agreement (&#x201c;Loan Amendment No. 4&#x201d;). The Company currently has $50.0 million outstanding under the Loan and Security Agreement, which was drawn down in two equal tranches. The third $25.0 million tranche is available at the Company&#x2019;s discretion through December 2024, upon achievement of certain clinical and business milestones, which were amended under Loan Amendment No. 4. The fourth $25.0 million tranche may be available through June 1, 2025 (or through December 1, 2025 upon achievement of certain business milestones) upon the Company&#x2019;s request, at Oxford and SVB&#x2019;s discretion. Amendment No. 4 also extends the interest-only payment period for an additional six months through May 2025, with principal payments to commence in June 2025. Additionally, upon achievement of certain business performance milestones, which were achieved in October 2024, the interest-only payment period was extended through November 2025, with principal payments to commence in December 2025.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_JtpKqHohmUCTdUXoThTIWQ"
      decimals="-5"
      id="Narr_RtxfS-v3bUOvAlx850EaMQ"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_10_16_2020_To_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_gUd46vYiWE6S_1qXC2sVKg"
      decimals="-5"
      id="Narr_5KW96SdDAUyUdy4_OL5zfg"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">25000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_0F_1Zc84bky0_5lT0wv1fw"
      decimals="-5"
      id="Narr_TMqoeO15Ska4-eyVz0Jhlg"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">25000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <srrk:PercentageOfDollarValueOfConsolidatedCash
      contextRef="Duration_10_16_2020_To_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_gUd46vYiWE6S_1qXC2sVKg"
      decimals="2"
      id="Narr_wr28QWaJWUOAqHpT99Z6-Q"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">1</srrk:PercentageOfDollarValueOfConsolidatedCash>
    <srrk:PercentageOfOutstandingObligation
      contextRef="Duration_10_16_2020_To_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_gUd46vYiWE6S_1qXC2sVKg"
      decimals="2"
      id="Narr_pFQeEs2MdEyLPxS7ELfpOA"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">1.05</srrk:PercentageOfOutstandingObligation>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_A2Z61BQQoEaOUGpduwOO4Q"
      decimals="-5"
      id="Narr_hCBiJcpN0UiWea725t1XUA"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">100000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_10_16_2020_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_JtpKqHohmUCTdUXoThTIWQ"
      decimals="-5"
      id="Narr_j7ASAxLnnUOBjoK3I-DHlQ"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_11_10_2022_srt_StatementScenarioAxis_srrk_TrancheOneMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_1o4-ToeAa0Ws6_A2nhaIWg"
      decimals="-5"
      id="Narr_xjUZt1HMV0-xyxHErNSUOg"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_11_10_2022_srt_StatementScenarioAxis_srrk_TrancheTwoMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_CDA1wcxtM0OOvFBfiQ1ZIw"
      decimals="-5"
      id="Narr_-8jUPlc9LkCzYWwE8AuRbQ"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_11_10_2022_srt_StatementScenarioAxis_srrk_TrancheTwoMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_CDA1wcxtM0OOvFBfiQ1ZIw"
      decimals="-5"
      id="Narr_o_sn_hB88U2gE5ltXMejiQ"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <srrk:InterestOnlyPeriod
      contextRef="Duration_11_10_2022_To_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_rTABVC0FK0WrPzEHVwYh_g"
      id="Narr_ZCQsj89nDUmfVHOSTBsz9g">P24M</srrk:InterestOnlyPeriod>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_11_10_2022_To_11_10_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_CK6FHGQq20Km9jMf98wKZQ"
      decimals="4"
      id="Narr_ith7KdZ6mUm9GEU3NmhnbQ"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.0460</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_11_10_2022_To_11_10_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_EPztZdder02zre_iKLe24Q"
      decimals="4"
      id="Narr_13FOfUmJY02-l6xFG02wxQ"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.0935</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <srrk:PrepaymentPenaltyPercent
      contextRef="As_Of_11_10_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_ijSq6JdiwE60YiJXwFSdRw"
      decimals="2"
      id="Narr_cXfsfEmdJU-4klAEazHJ4g"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0</srrk:PrepaymentPenaltyPercent>
    <srrk:PrepaymentPenaltyPercent
      contextRef="As_Of_11_10_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_ZLcu95SjEEyxu4lbKeIrfg"
      decimals="2"
      id="Narr_-J55DF987Uqm4o6v0vk83w"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.03</srrk:PrepaymentPenaltyPercent>
    <srrk:DebtInstrumentFinalPaymentFee
      contextRef="Duration_11_10_2022_To_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_rTABVC0FK0WrPzEHVwYh_g"
      decimals="2"
      id="Narr_psQBFKe-tUyg6uxKQJRHXg"
      unitRef="Unit_Standard_pure_7SuINeIuaU6P8UzUajC8sw">0.02</srrk:DebtInstrumentFinalPaymentFee>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_11_10_2022_To_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_rTABVC0FK0WrPzEHVwYh_g"
      decimals="-5"
      id="Narr_15VuknUiIkyLsXZy9QxKJg"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">900000</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_5_17_2024_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_Hgg07AAyG02T4Jv5fZE-FQ"
      decimals="-5"
      id="Narr_zMroVZEdtE-GckPw3POPNQ"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">50000000.0</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_5_17_2024_srt_StatementScenarioAxis_srrk_TrancheThreeMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_u2DvbaL6ckmuYfubdLSQiw"
      decimals="-5"
      id="Narr_Qg-cFJ-DDEWvRDscxE3kGQ"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_5_17_2024_srt_StatementScenarioAxis_srrk_TrancheFourMember_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_NKmevx8gPUq3cZ8kssDJNw"
      decimals="-5"
      id="Narr_hYc3xUDbp0-TqMa4bfHjaQ"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <srrk:LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod
      contextRef="Duration_5_17_2024_To_5_17_2024_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_qdKJj99R-UKWV1diKEhPMg"
      id="Narr_pqeOo26NH0yMEMwxLfI9QA">P6M</srrk:LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_sXIoc-xzGUu0LLr4KwtAVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;11. Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company calculates basic net loss per share by dividing net loss by the weighted average number of common shares outstanding, excluding restricted common stock. The weighted average number of common shares used in the basic and diluted net loss per share calculation includes the pre-funded warrants issued in connection with the Company&#x2019;s November 2020 and June 2022 follow-on offerings as the pre-funded warrants are exercisable at any time for nominal cash consideration. As of September 30, 2024, 10,681,528 pre-funded warrants have been exercised and 17,008,164 pre-funded warrants remain outstanding. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,386,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,081,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,670,164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,422,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,157,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,459,181&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,214,517&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,963,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_StatementScenarioAxis_srrk_AggregateMember_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_vHhfARkPrEeM6UAWteancQ"
      decimals="INF"
      id="Narr_ovUcEb67-0KzqGwzbqBzCw"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">10681528</srrk:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_srrk_PreFundedWarrantMember_n9DGS8M0kE24zj_oklD1kA"
      decimals="INF"
      id="Narr_oy0orkStaEq2s4CITm1poA"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">17008164</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_JCBkaj_gtkCJyRWOMmRl1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,386,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,081,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,670,164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,422,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,157,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,459,181&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,214,517&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,963,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BRNbuA-xdUWVSanmpZGNKw"
      decimals="INF"
      id="Tc_YIqvOSfxN0mcewJmDpX1EA_3_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">3386857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_WcKh_paNQEO1eHbYGf_3nw"
      decimals="INF"
      id="Tc_Exr-_qAmLEuRuWk1o5WLjw_3_4"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">2081607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_BYs8SrAKnkyWg65xLBo1ng"
      decimals="INF"
      id="Tc_FPuwLSBJEUKLROfLidyaSg_4_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">9670164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_leFkp74BkEGzez-zOjF2mg"
      decimals="INF"
      id="Tc_m7Hp1t6itEmuhL4bfOS0tg_4_4"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">7422412</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_srrk_CommonWarrantMember_5ObJ1CZ65E21VrAjZyMJVA"
      decimals="INF"
      id="Tc_bMFN1qHUKkagIJcirr3odw_5_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">9157496</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_srrk_CommonWarrantMember_gCi3mjIZR0W0dKa1gLVEAQ"
      decimals="INF"
      id="Tc_TvBUhuLF7kO2CKAUo5R1CQ_5_4"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">10459181</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      decimals="INF"
      id="Tc_LHn3HRXUAkqVFMaVcEn77A_6_2"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">22214517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_aC9bmrF3jkqj53aiJ49xeA"
      decimals="INF"
      id="Tc_urI283R14Eil_PikATpMug_6_4"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">19963200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Tb_qT2mKEl4mU2grRw95PyM4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On October 8, 2024, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler &amp;amp; Co., as representatives of the several underwriters named therein (the &#x201c;Underwriters&#x201d;), relating to the issuance and sale of an aggregate of 10,265,488 shares of the Company&#x2019;s common stock at $28.25 per share and pre-funded warrants to purchase 353,983 shares of its common stock. The offering price per pre-funded warrant was $28.2499, which equals the per share public offering price for the common shares less the $0.0001 exercise price for each such pre-funded warrant. The pre-funded warrants are exercisable at any time and only expire when exercised in full. The offering closed on October 10, 2024. Pursuant to the Underwriting Agreement, the Company also granted the Underwriters a 30-day option to purchase up to 1,592,920 additional shares (the &#x201c;Option Shares&#x201d;) of common stock, which was exercised in full on October 16, 2024. Total proceeds of the transaction, including the Option Shares were approximately $324.4 million, net of underwriting discounts and estimated offering expenses. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_8_2024_To_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_tVRY0dVzb0i50FyP8rdL6A"
      decimals="INF"
      id="Narr_Na8eTkMh4E-xS3Zln8sFpg"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">10265488</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_iFj3QnQzOU-8kQacFHjl3A"
      decimals="INF"
      id="Narr_f9EJVM-bRU-2BSQzjM9WkA"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">28.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_iFj3QnQzOU-8kQacFHjl3A"
      decimals="INF"
      id="Narr_gsHZ2rzWTECT6ND8D5vAdg"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">353983</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_8_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_kidvJgGpG0maEoeyfhtn0Q"
      decimals="INF"
      id="Narr_dxV_i9_SE0eWrNx_G5WF9Q"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">28.2499</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_8_2024_us-gaap_StatementEquityComponentsAxis_srrk_PreFundedWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_srrk_UnderwritingAgreementMember_5SGDYfs7OECckL2UaG60KA"
      decimals="INF"
      id="Narr_Wa-6Ds6Q2kmCI6hHBG6CSw"
      unitRef="Unit_Divide_USD_shares_FBCiKoKhhkqBIESKNV8Ipw">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_10_2024_To_10_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DS-yvkHxka87ldWHUSkvA"
      decimals="INF"
      id="Narr_Wd9RMiBxC0eoJMcSAZbb9g"
      unitRef="Unit_Standard_shares_OI-TL3-50EaGxxd6Rnaqmg">1592920</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2024_To_10_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EKUEbTHr-Ea-uOCZ6iVjdA"
      decimals="-5"
      id="Narr_fUQTt_msBkSLqg9kM565mg"
      unitRef="Unit_Standard_USD_9dlkwGJhnECOJHfeUJlSmQ">324400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_k1PZdgKPEEyV9g7669vBvQ">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_XSq-XwwMr0GhC4QQ2ZgrIQ">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_-VKUzVqihEOL3XnAOC_-_w">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2024_To_9_30_2024_IRCwptPkLEGpFaSWRk-bfQ"
      id="Narr_4bqYIeEOk0ew_hT1gXEIyw">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
